[
{
  "model": "admin.logentry",
  "pk": 1,
  "fields": {
    "action_time": "2024-11-19T09:29:33.170Z",
    "user": 1,
    "content_type": 7,
    "object_id": "1",
    "object_repr": "chronobiotic",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2,
  "fields": {
    "action_time": "2024-11-19T09:29:43.670Z",
    "user": 1,
    "content_type": 7,
    "object_id": "2",
    "object_repr": "radioprotector",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 3,
  "fields": {
    "action_time": "2024-11-19T09:30:10.792Z",
    "user": 1,
    "content_type": 9,
    "object_id": "1",
    "object_repr": "protect",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 4,
  "fields": {
    "action_time": "2024-11-19T09:30:34.990Z",
    "user": 1,
    "content_type": 8,
    "object_id": "1",
    "object_repr": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6317057/",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 5,
  "fields": {
    "action_time": "2024-11-19T09:30:42.468Z",
    "user": 1,
    "content_type": 10,
    "object_id": "1",
    "object_repr": "Resveratrol",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 6,
  "fields": {
    "action_time": "2024-11-27T06:15:40.566Z",
    "user": 1,
    "content_type": 12,
    "object_id": "2",
    "object_repr": "NAD-dependent deacetylase sirtuin-1 (SIRT1)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 7,
  "fields": {
    "action_time": "2024-11-27T06:16:10.091Z",
    "user": 1,
    "content_type": 12,
    "object_id": "3",
    "object_repr": "Prostaglandin G/H synthase 1 (COX-1)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 8,
  "fields": {
    "action_time": "2024-11-27T06:17:08.871Z",
    "user": 1,
    "content_type": 10,
    "object_id": "1",
    "object_repr": "Resveratrol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Linkslists\", \"Target\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 9,
  "fields": {
    "action_time": "2024-11-27T07:04:16.055Z",
    "user": 1,
    "content_type": 12,
    "object_id": "3",
    "object_repr": "T60529",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Targetsname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 10,
  "fields": {
    "action_time": "2024-11-27T07:08:05.685Z",
    "user": 1,
    "content_type": 12,
    "object_id": "3",
    "object_repr": "T60529",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Targetsfullname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 11,
  "fields": {
    "action_time": "2024-11-27T07:08:23.638Z",
    "user": 1,
    "content_type": 12,
    "object_id": "2",
    "object_repr": "T14731",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Targetsname\", \"Targetsfullname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 12,
  "fields": {
    "action_time": "2024-11-28T05:08:09.500Z",
    "user": 1,
    "content_type": 9,
    "object_id": "2",
    "object_repr": "activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 13,
  "fields": {
    "action_time": "2024-11-28T05:10:55.540Z",
    "user": 1,
    "content_type": 12,
    "object_id": "4",
    "object_repr": "T58921",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 14,
  "fields": {
    "action_time": "2024-11-28T05:10:59.062Z",
    "user": 1,
    "content_type": 10,
    "object_id": "2",
    "object_repr": "Rosiglitazone",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 15,
  "fields": {
    "action_time": "2025-03-10T22:37:46.415Z",
    "user": 1,
    "content_type": 10,
    "object_id": "2",
    "object_repr": "Rosiglitazone",
    "action_flag": 3,
    "change_message": ""
  }
},
{
  "model": "admin.logentry",
  "pk": 16,
  "fields": {
    "action_time": "2025-03-10T22:38:06.541Z",
    "user": 1,
    "content_type": 10,
    "object_id": "1",
    "object_repr": "Resveratrol",
    "action_flag": 3,
    "change_message": ""
  }
},
{
  "model": "admin.logentry",
  "pk": 17,
  "fields": {
    "action_time": "2025-03-10T22:38:36.801Z",
    "user": 1,
    "content_type": 12,
    "object_id": "4",
    "object_repr": "T58921",
    "action_flag": 3,
    "change_message": ""
  }
},
{
  "model": "admin.logentry",
  "pk": 18,
  "fields": {
    "action_time": "2025-03-10T22:38:36.801Z",
    "user": 1,
    "content_type": 12,
    "object_id": "3",
    "object_repr": "T60529",
    "action_flag": 3,
    "change_message": ""
  }
},
{
  "model": "admin.logentry",
  "pk": 19,
  "fields": {
    "action_time": "2025-03-10T22:38:36.801Z",
    "user": 1,
    "content_type": 12,
    "object_id": "2",
    "object_repr": "T14731",
    "action_flag": 3,
    "change_message": ""
  }
},
{
  "model": "admin.logentry",
  "pk": 20,
  "fields": {
    "action_time": "2025-03-10T22:38:47.293Z",
    "user": 1,
    "content_type": 9,
    "object_id": "2",
    "object_repr": "activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ.",
    "action_flag": 3,
    "change_message": ""
  }
},
{
  "model": "admin.logentry",
  "pk": 21,
  "fields": {
    "action_time": "2025-03-10T22:38:47.293Z",
    "user": 1,
    "content_type": 9,
    "object_id": "1",
    "object_repr": "protect",
    "action_flag": 3,
    "change_message": ""
  }
},
{
  "model": "admin.logentry",
  "pk": 22,
  "fields": {
    "action_time": "2025-03-10T22:38:57.619Z",
    "user": 1,
    "content_type": 7,
    "object_id": "2",
    "object_repr": "radioprotector",
    "action_flag": 3,
    "change_message": ""
  }
},
{
  "model": "admin.logentry",
  "pk": 23,
  "fields": {
    "action_time": "2025-03-10T22:38:57.619Z",
    "user": 1,
    "content_type": 7,
    "object_id": "1",
    "object_repr": "chronobiotic",
    "action_flag": 3,
    "change_message": ""
  }
},
{
  "model": "admin.logentry",
  "pk": 24,
  "fields": {
    "action_time": "2025-03-10T23:12:34.383Z",
    "user": 1,
    "content_type": 7,
    "object_id": "3",
    "object_repr": "radioprotector",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 25,
  "fields": {
    "action_time": "2025-03-10T23:12:38.833Z",
    "user": 1,
    "content_type": 7,
    "object_id": "4",
    "object_repr": "chronobiotic",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 26,
  "fields": {
    "action_time": "2025-03-10T23:13:04.708Z",
    "user": 1,
    "content_type": 9,
    "object_id": "3",
    "object_repr": "protect",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 27,
  "fields": {
    "action_time": "2025-03-10T23:13:31.139Z",
    "user": 1,
    "content_type": 12,
    "object_id": "5",
    "object_repr": "T60529",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 28,
  "fields": {
    "action_time": "2025-03-10T23:13:34.039Z",
    "user": 1,
    "content_type": 10,
    "object_id": "3",
    "object_repr": "Resveratrol",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 29,
  "fields": {
    "action_time": "2025-03-10T23:15:56.348Z",
    "user": 1,
    "content_type": 10,
    "object_id": "3",
    "object_repr": "Resveratrol",
    "action_flag": 3,
    "change_message": ""
  }
},
{
  "model": "admin.logentry",
  "pk": 30,
  "fields": {
    "action_time": "2025-03-10T23:17:00.395Z",
    "user": 1,
    "content_type": 10,
    "object_id": "4",
    "object_repr": "test",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 31,
  "fields": {
    "action_time": "2025-03-11T14:21:32.876Z",
    "user": 1,
    "content_type": 12,
    "object_id": "6",
    "object_repr": "T58921",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 32,
  "fields": {
    "action_time": "2025-03-11T14:21:38.108Z",
    "user": 1,
    "content_type": 10,
    "object_id": "5",
    "object_repr": "abc",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 33,
  "fields": {
    "action_time": "2025-03-11T22:03:33.209Z",
    "user": 1,
    "content_type": 10,
    "object_id": "5",
    "object_repr": "abc",
    "action_flag": 3,
    "change_message": ""
  }
},
{
  "model": "admin.logentry",
  "pk": 34,
  "fields": {
    "action_time": "2025-03-11T22:03:33.209Z",
    "user": 1,
    "content_type": 10,
    "object_id": "4",
    "object_repr": "test",
    "action_flag": 3,
    "change_message": ""
  }
},
{
  "model": "admin.logentry",
  "pk": 35,
  "fields": {
    "action_time": "2025-03-11T22:04:07.173Z",
    "user": 1,
    "content_type": 12,
    "object_id": "6",
    "object_repr": "T58921",
    "action_flag": 3,
    "change_message": ""
  }
},
{
  "model": "admin.logentry",
  "pk": 36,
  "fields": {
    "action_time": "2025-03-11T22:04:07.173Z",
    "user": 1,
    "content_type": 12,
    "object_id": "5",
    "object_repr": "T60529",
    "action_flag": 3,
    "change_message": ""
  }
},
{
  "model": "admin.logentry",
  "pk": 37,
  "fields": {
    "action_time": "2025-03-11T22:11:13.496Z",
    "user": 1,
    "content_type": 12,
    "object_id": "7",
    "object_repr": "T60529",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 38,
  "fields": {
    "action_time": "2025-03-11T22:11:15.680Z",
    "user": 1,
    "content_type": 10,
    "object_id": "6",
    "object_repr": "Resveratrol",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 39,
  "fields": {
    "action_time": "2025-03-11T22:12:27.902Z",
    "user": 1,
    "content_type": 12,
    "object_id": "8",
    "object_repr": "T58921",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 40,
  "fields": {
    "action_time": "2025-03-11T22:12:29.990Z",
    "user": 1,
    "content_type": 10,
    "object_id": "7",
    "object_repr": "Rosiglitazone",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 41,
  "fields": {
    "action_time": "2025-03-14T12:19:24.011Z",
    "user": 2,
    "content_type": 10,
    "object_id": "6",
    "object_repr": "Resveratrol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Uniprot\", \"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 42,
  "fields": {
    "action_time": "2025-03-14T12:21:34.162Z",
    "user": 2,
    "content_type": 9,
    "object_id": "4",
    "object_repr": "SIRT1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 43,
  "fields": {
    "action_time": "2025-03-14T12:22:26.425Z",
    "user": 2,
    "content_type": 10,
    "object_id": "6",
    "object_repr": "Resveratrol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Mechanisms\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 44,
  "fields": {
    "action_time": "2025-03-14T12:32:24.211Z",
    "user": 2,
    "content_type": 12,
    "object_id": "9",
    "object_repr": "Melatonin receptor",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 45,
  "fields": {
    "action_time": "2025-03-14T12:33:09.972Z",
    "user": 2,
    "content_type": 10,
    "object_id": "8",
    "object_repr": "Melatonin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 46,
  "fields": {
    "action_time": "2025-03-14T12:36:44.313Z",
    "user": 2,
    "content_type": 10,
    "object_id": "8",
    "object_repr": "Melatonin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Linkslists\", \"Uniprot\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 47,
  "fields": {
    "action_time": "2025-03-14T12:36:45.230Z",
    "user": 2,
    "content_type": 10,
    "object_id": "8",
    "object_repr": "Melatonin",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 48,
  "fields": {
    "action_time": "2025-03-14T12:37:46.938Z",
    "user": 2,
    "content_type": 10,
    "object_id": "8",
    "object_repr": "Melatonin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Kegg\", \"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 49,
  "fields": {
    "action_time": "2025-03-14T12:38:44.346Z",
    "user": 2,
    "content_type": 10,
    "object_id": "8",
    "object_repr": "Melatonin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 50,
  "fields": {
    "action_time": "2025-03-14T12:49:22.659Z",
    "user": 2,
    "content_type": 9,
    "object_id": "5",
    "object_repr": "Melatonin receptor binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 51,
  "fields": {
    "action_time": "2025-03-14T12:49:47.340Z",
    "user": 2,
    "content_type": 10,
    "object_id": "9",
    "object_repr": "Indole",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 52,
  "fields": {
    "action_time": "2025-03-14T12:54:47.763Z",
    "user": 2,
    "content_type": 10,
    "object_id": "9",
    "object_repr": "Indole",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Article\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 53,
  "fields": {
    "action_time": "2025-03-14T12:55:19.811Z",
    "user": 2,
    "content_type": 10,
    "object_id": "9",
    "object_repr": "Indole",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 54,
  "fields": {
    "action_time": "2025-03-14T12:57:40.073Z",
    "user": 2,
    "content_type": 10,
    "object_id": "9",
    "object_repr": "Indole",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 55,
  "fields": {
    "action_time": "2025-03-15T06:37:35.853Z",
    "user": 2,
    "content_type": 10,
    "object_id": "10",
    "object_repr": "Ramelteon",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 56,
  "fields": {
    "action_time": "2025-03-15T06:42:40.297Z",
    "user": 2,
    "content_type": 9,
    "object_id": "6",
    "object_repr": "antagonist of melatonin receptors",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 57,
  "fields": {
    "action_time": "2025-03-15T06:42:47.792Z",
    "user": 2,
    "content_type": 10,
    "object_id": "11",
    "object_repr": "Luzindole",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 58,
  "fields": {
    "action_time": "2025-03-15T06:43:56.122Z",
    "user": 2,
    "content_type": 9,
    "object_id": "7",
    "object_repr": "MT2 receptor antagonist",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 59,
  "fields": {
    "action_time": "2025-03-15T06:49:49.964Z",
    "user": 2,
    "content_type": 10,
    "object_id": "12",
    "object_repr": "4-P-PDOT (N-(4-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 60,
  "fields": {
    "action_time": "2025-03-15T06:54:23.583Z",
    "user": 2,
    "content_type": 10,
    "object_id": "13",
    "object_repr": "Agomelatine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 61,
  "fields": {
    "action_time": "2025-03-15T07:00:09.879Z",
    "user": 2,
    "content_type": 10,
    "object_id": "14",
    "object_repr": "N-[(6-Methoxy-9-tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaenyl)methyl]acetamide (UCM 549)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 62,
  "fields": {
    "action_time": "2025-03-15T07:05:14.844Z",
    "user": 2,
    "content_type": 9,
    "object_id": "8",
    "object_repr": "MT3 receptor ligand",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 63,
  "fields": {
    "action_time": "2025-03-15T07:06:26.327Z",
    "user": 2,
    "content_type": 12,
    "object_id": "10",
    "object_repr": "MT3",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 64,
  "fields": {
    "action_time": "2025-03-15T07:06:49.638Z",
    "user": 2,
    "content_type": 10,
    "object_id": "15",
    "object_repr": "5-MCA-NAT",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 65,
  "fields": {
    "action_time": "2025-03-15T07:11:08.479Z",
    "user": 2,
    "content_type": 9,
    "object_id": "9",
    "object_repr": "MT1 receptor binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 66,
  "fields": {
    "action_time": "2025-03-15T07:12:09.759Z",
    "user": 2,
    "content_type": 12,
    "object_id": "11",
    "object_repr": "MT1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 67,
  "fields": {
    "action_time": "2025-03-15T07:13:05.819Z",
    "user": 2,
    "content_type": 12,
    "object_id": "12",
    "object_repr": "MT2",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 68,
  "fields": {
    "action_time": "2025-03-15T07:13:25.374Z",
    "user": 2,
    "content_type": 10,
    "object_id": "16",
    "object_repr": "S26131",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 69,
  "fields": {
    "action_time": "2025-03-15T07:17:50.506Z",
    "user": 2,
    "content_type": 10,
    "object_id": "17",
    "object_repr": "Melatonin-d4",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 70,
  "fields": {
    "action_time": "2025-03-15T07:38:50.182Z",
    "user": 2,
    "content_type": 10,
    "object_id": "18",
    "object_repr": "2-Iodomelatonin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 71,
  "fields": {
    "action_time": "2025-03-15T07:45:17.049Z",
    "user": 2,
    "content_type": 10,
    "object_id": "19",
    "object_repr": "8-M-PDOT",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 72,
  "fields": {
    "action_time": "2025-03-15T07:45:40.402Z",
    "user": 2,
    "content_type": 9,
    "object_id": "10",
    "object_repr": "MT2 receptor ligand",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 73,
  "fields": {
    "action_time": "2025-03-15T07:45:57.334Z",
    "user": 2,
    "content_type": 10,
    "object_id": "19",
    "object_repr": "8-M-PDOT",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Mechanisms\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 74,
  "fields": {
    "action_time": "2025-03-15T07:49:21.943Z",
    "user": 2,
    "content_type": 10,
    "object_id": "20",
    "object_repr": "Tasimelteon",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 75,
  "fields": {
    "action_time": "2025-03-15T07:52:25.333Z",
    "user": 2,
    "content_type": 10,
    "object_id": "21",
    "object_repr": "Agomelatine hydrochloride",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 76,
  "fields": {
    "action_time": "2025-03-15T07:56:38.467Z",
    "user": 2,
    "content_type": 10,
    "object_id": "22",
    "object_repr": "ACH-000143",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 77,
  "fields": {
    "action_time": "2025-03-15T08:03:14.257Z",
    "user": 2,
    "content_type": 10,
    "object_id": "23",
    "object_repr": "Piromelatine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 78,
  "fields": {
    "action_time": "2025-03-15T08:10:40.390Z",
    "user": 2,
    "content_type": 9,
    "object_id": "11",
    "object_repr": "Melatonin agonist",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 79,
  "fields": {
    "action_time": "2025-03-15T08:10:48.290Z",
    "user": 2,
    "content_type": 10,
    "object_id": "24",
    "object_repr": "UCM 608 (N-[2-(5-methoxy-2-phenyl-1H-indol-3-yl)ethyl]acetamide)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 80,
  "fields": {
    "action_time": "2025-03-15T09:18:41.124Z",
    "user": 2,
    "content_type": 10,
    "object_id": "25",
    "object_repr": "Ramelteon metabolite M-II-d3",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 81,
  "fields": {
    "action_time": "2025-03-15T09:25:03.305Z",
    "user": 2,
    "content_type": 10,
    "object_id": "26",
    "object_repr": "N-Acetyltryptamine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 82,
  "fields": {
    "action_time": "2025-03-15T09:32:22.479Z",
    "user": 2,
    "content_type": 10,
    "object_id": "27",
    "object_repr": "Ramelteon metabolite M-II (DES(1-oxopropyl)-2-hydroxy-1-oxopropyl-ramelteon)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 83,
  "fields": {
    "action_time": "2025-03-15T09:35:59.911Z",
    "user": 2,
    "content_type": 10,
    "object_id": "28",
    "object_repr": "Melatonin-d3",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 84,
  "fields": {
    "action_time": "2025-03-15T09:40:07.211Z",
    "user": 2,
    "content_type": 10,
    "object_id": "29",
    "object_repr": "Agomelatine-d4",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 85,
  "fields": {
    "action_time": "2025-03-15T09:45:48.081Z",
    "user": 2,
    "content_type": 10,
    "object_id": "30",
    "object_repr": "Melatonin receptor agonist 1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 86,
  "fields": {
    "action_time": "2025-03-15T09:54:16.426Z",
    "user": 2,
    "content_type": 10,
    "object_id": "31",
    "object_repr": "Melatonin-d7",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 87,
  "fields": {
    "action_time": "2025-03-15T09:58:32.734Z",
    "user": 2,
    "content_type": 10,
    "object_id": "32",
    "object_repr": "Ramelteon-d5",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 88,
  "fields": {
    "action_time": "2025-03-15T10:02:15.883Z",
    "user": 2,
    "content_type": 10,
    "object_id": "33",
    "object_repr": "7-Desmethyl-3-hydroxyagomelatine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 89,
  "fields": {
    "action_time": "2025-03-15T10:27:56.963Z",
    "user": 2,
    "content_type": 10,
    "object_id": "34",
    "object_repr": "Agomelatin-d3",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 90,
  "fields": {
    "action_time": "2025-03-15T10:33:26.436Z",
    "user": 2,
    "content_type": 10,
    "object_id": "35",
    "object_repr": "TIK-301",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 91,
  "fields": {
    "action_time": "2025-03-15T10:36:31.344Z",
    "user": 2,
    "content_type": 10,
    "object_id": "36",
    "object_repr": "S-20928",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 92,
  "fields": {
    "action_time": "2025-03-15T10:40:19.740Z",
    "user": 2,
    "content_type": 10,
    "object_id": "37",
    "object_repr": "DH97",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 93,
  "fields": {
    "action_time": "2025-03-15T10:43:41.595Z",
    "user": 2,
    "content_type": 10,
    "object_id": "38",
    "object_repr": "Ramelteon-d3",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 94,
  "fields": {
    "action_time": "2025-03-15T10:46:50.788Z",
    "user": 2,
    "content_type": 10,
    "object_id": "39",
    "object_repr": "6-Chloromelatonin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 95,
  "fields": {
    "action_time": "2025-03-15T10:50:51.071Z",
    "user": 2,
    "content_type": 10,
    "object_id": "40",
    "object_repr": "GR 196429",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 96,
  "fields": {
    "action_time": "2025-03-15T10:54:38.045Z",
    "user": 2,
    "content_type": 10,
    "object_id": "41",
    "object_repr": "Agomelatine (L(+)-Tartaric acid)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 97,
  "fields": {
    "action_time": "2025-03-15T10:58:06.772Z",
    "user": 2,
    "content_type": 10,
    "object_id": "42",
    "object_repr": "Tasimelteon-d5",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 98,
  "fields": {
    "action_time": "2025-03-15T11:01:00.220Z",
    "user": 2,
    "content_type": 9,
    "object_id": "12",
    "object_repr": "Melatonin receptor antagonist",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 99,
  "fields": {
    "action_time": "2025-03-15T11:01:08.651Z",
    "user": 2,
    "content_type": 10,
    "object_id": "43",
    "object_repr": "GR 128107",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 100,
  "fields": {
    "action_time": "2025-03-15T11:11:04.784Z",
    "user": 2,
    "content_type": 10,
    "object_id": "44",
    "object_repr": "ACH 000143",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 101,
  "fields": {
    "action_time": "2025-03-15T11:11:53.911Z",
    "user": 2,
    "content_type": 10,
    "object_id": "44",
    "object_repr": "ACH 000143",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 102,
  "fields": {
    "action_time": "2025-03-15T11:16:18.545Z",
    "user": 2,
    "content_type": 10,
    "object_id": "45",
    "object_repr": "S24014",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 103,
  "fields": {
    "action_time": "2025-03-15T11:21:25.106Z",
    "user": 2,
    "content_type": 12,
    "object_id": "13",
    "object_repr": "JNK",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 104,
  "fields": {
    "action_time": "2025-03-15T11:21:46.799Z",
    "user": 2,
    "content_type": 9,
    "object_id": "13",
    "object_repr": "JNK kinase mediated circadian rhythm modulation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 105,
  "fields": {
    "action_time": "2025-03-15T11:22:04.447Z",
    "user": 2,
    "content_type": 7,
    "object_id": "5",
    "object_repr": "circadian rhythm modulator",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 106,
  "fields": {
    "action_time": "2025-03-15T11:22:20.584Z",
    "user": 2,
    "content_type": 10,
    "object_id": "46",
    "object_repr": "SP600125",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 107,
  "fields": {
    "action_time": "2025-03-16T04:47:08.997Z",
    "user": 2,
    "content_type": 7,
    "object_id": "6",
    "object_repr": "Chronodisruptor",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 108,
  "fields": {
    "action_time": "2025-03-16T04:47:50.741Z",
    "user": 2,
    "content_type": 9,
    "object_id": "14",
    "object_repr": "Disruption of circadian clock",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 109,
  "fields": {
    "action_time": "2025-03-16T04:49:29.941Z",
    "user": 2,
    "content_type": 12,
    "object_id": "14",
    "object_repr": "RORA",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 110,
  "fields": {
    "action_time": "2025-03-16T04:51:09.489Z",
    "user": 2,
    "content_type": 12,
    "object_id": "15",
    "object_repr": "NR1D1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 111,
  "fields": {
    "action_time": "2025-03-16T04:52:24.333Z",
    "user": 2,
    "content_type": 12,
    "object_id": "16",
    "object_repr": "RORB",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 112,
  "fields": {
    "action_time": "2025-03-16T04:56:46.969Z",
    "user": 2,
    "content_type": 9,
    "object_id": "15",
    "object_repr": "Core clock modulation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 113,
  "fields": {
    "action_time": "2025-03-16T04:56:53.077Z",
    "user": 2,
    "content_type": 10,
    "object_id": "47",
    "object_repr": "Cannabidiol",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 114,
  "fields": {
    "action_time": "2025-03-16T05:03:47.676Z",
    "user": 2,
    "content_type": 9,
    "object_id": "16",
    "object_repr": "Unknown",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 115,
  "fields": {
    "action_time": "2025-03-16T05:05:02.972Z",
    "user": 2,
    "content_type": 12,
    "object_id": "17",
    "object_repr": "Cannabinoid receptor",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 116,
  "fields": {
    "action_time": "2025-03-16T05:05:41.991Z",
    "user": 2,
    "content_type": 10,
    "object_id": "48",
    "object_repr": "Cannabigerol",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 117,
  "fields": {
    "action_time": "2025-03-16T05:10:07.547Z",
    "user": 2,
    "content_type": 7,
    "object_id": "7",
    "object_repr": "Potential chronodisruptor",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 118,
  "fields": {
    "action_time": "2025-03-16T05:12:09.036Z",
    "user": 2,
    "content_type": 10,
    "object_id": "49",
    "object_repr": "Cannabichromenes",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 119,
  "fields": {
    "action_time": "2025-03-16T05:22:11.266Z",
    "user": 2,
    "content_type": 10,
    "object_id": "50",
    "object_repr": "Dronabinol",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 120,
  "fields": {
    "action_time": "2025-03-16T05:36:04.719Z",
    "user": 2,
    "content_type": 9,
    "object_id": "17",
    "object_repr": "Cannabinoid receptor stimulation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 121,
  "fields": {
    "action_time": "2025-03-16T05:37:29.515Z",
    "user": 2,
    "content_type": 12,
    "object_id": "18",
    "object_repr": "CB2",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 122,
  "fields": {
    "action_time": "2025-03-16T05:38:25.701Z",
    "user": 2,
    "content_type": 10,
    "object_id": "51",
    "object_repr": "Cannabinol (CBN)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 123,
  "fields": {
    "action_time": "2025-03-16T05:44:21.711Z",
    "user": 2,
    "content_type": 10,
    "object_id": "52",
    "object_repr": "Cannabinodiol",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 124,
  "fields": {
    "action_time": "2025-03-16T05:52:49.483Z",
    "user": 2,
    "content_type": 10,
    "object_id": "53",
    "object_repr": "Nabilone",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 125,
  "fields": {
    "action_time": "2025-03-17T06:39:44.517Z",
    "user": 2,
    "content_type": 10,
    "object_id": "54",
    "object_repr": "Nabiximols",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 126,
  "fields": {
    "action_time": "2025-03-17T06:47:03.366Z",
    "user": 2,
    "content_type": 9,
    "object_id": "18",
    "object_repr": "Mu opioid receptor binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 127,
  "fields": {
    "action_time": "2025-03-17T06:47:32.400Z",
    "user": 2,
    "content_type": 12,
    "object_id": "19",
    "object_repr": "Mu opioid receptor",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 128,
  "fields": {
    "action_time": "2025-03-17T06:49:14.339Z",
    "user": 2,
    "content_type": 12,
    "object_id": "20",
    "object_repr": "OPRK1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 129,
  "fields": {
    "action_time": "2025-03-17T06:49:20.049Z",
    "user": 2,
    "content_type": 10,
    "object_id": "55",
    "object_repr": "Oxycodone",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 130,
  "fields": {
    "action_time": "2025-03-17T06:53:15.290Z",
    "user": 2,
    "content_type": 9,
    "object_id": "19",
    "object_repr": "Kappa opioid receptor binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 131,
  "fields": {
    "action_time": "2025-03-17T06:53:50.855Z",
    "user": 2,
    "content_type": 9,
    "object_id": "20",
    "object_repr": "delta opioid receptor binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 132,
  "fields": {
    "action_time": "2025-03-17T06:55:21.801Z",
    "user": 2,
    "content_type": 12,
    "object_id": "21",
    "object_repr": "OPRD1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 133,
  "fields": {
    "action_time": "2025-03-17T07:01:06.745Z",
    "user": 2,
    "content_type": 10,
    "object_id": "56",
    "object_repr": "Oxymorphone",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 134,
  "fields": {
    "action_time": "2025-03-17T07:04:40.615Z",
    "user": 2,
    "content_type": 10,
    "object_id": "57",
    "object_repr": "Hydrocodone",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 135,
  "fields": {
    "action_time": "2025-03-17T07:07:34.854Z",
    "user": 2,
    "content_type": 10,
    "object_id": "58",
    "object_repr": "Hydromorphone",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 136,
  "fields": {
    "action_time": "2025-03-17T07:15:15.401Z",
    "user": 2,
    "content_type": 10,
    "object_id": "59",
    "object_repr": "Fentanyl",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 137,
  "fields": {
    "action_time": "2025-03-17T07:21:09.718Z",
    "user": 2,
    "content_type": 9,
    "object_id": "21",
    "object_repr": "opioid receptors binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 138,
  "fields": {
    "action_time": "2025-03-17T07:24:14.893Z",
    "user": 2,
    "content_type": 10,
    "object_id": "60",
    "object_repr": "Codeine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 139,
  "fields": {
    "action_time": "2025-03-17T07:31:26.435Z",
    "user": 2,
    "content_type": 12,
    "object_id": "22",
    "object_repr": "NMDA receptor",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 140,
  "fields": {
    "action_time": "2025-03-17T07:32:27.480Z",
    "user": 2,
    "content_type": 12,
    "object_id": "23",
    "object_repr": "iGluRs",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 141,
  "fields": {
    "action_time": "2025-03-17T07:33:19.481Z",
    "user": 2,
    "content_type": 10,
    "object_id": "61",
    "object_repr": "Methadone",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 142,
  "fields": {
    "action_time": "2025-03-17T07:39:15.542Z",
    "user": 2,
    "content_type": 10,
    "object_id": "62",
    "object_repr": "Tramadol",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 143,
  "fields": {
    "action_time": "2025-03-17T08:08:54.575Z",
    "user": 2,
    "content_type": 10,
    "object_id": "63",
    "object_repr": "Buprenorphine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 144,
  "fields": {
    "action_time": "2025-03-17T08:13:17.986Z",
    "user": 2,
    "content_type": 10,
    "object_id": "64",
    "object_repr": "Morphin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 145,
  "fields": {
    "action_time": "2025-03-17T08:17:41.878Z",
    "user": 2,
    "content_type": 10,
    "object_id": "65",
    "object_repr": "Heroin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 146,
  "fields": {
    "action_time": "2025-03-17T08:24:33.060Z",
    "user": 2,
    "content_type": 12,
    "object_id": "24",
    "object_repr": "Per",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 147,
  "fields": {
    "action_time": "2025-03-17T08:25:13.302Z",
    "user": 2,
    "content_type": 12,
    "object_id": "24",
    "object_repr": "Per",
    "action_flag": 3,
    "change_message": ""
  }
},
{
  "model": "admin.logentry",
  "pk": 148,
  "fields": {
    "action_time": "2025-03-17T08:25:38.253Z",
    "user": 2,
    "content_type": 12,
    "object_id": "25",
    "object_repr": "mPer2",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 149,
  "fields": {
    "action_time": "2025-03-17T08:26:31.134Z",
    "user": 2,
    "content_type": 12,
    "object_id": "26",
    "object_repr": "mPer1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 150,
  "fields": {
    "action_time": "2025-03-17T08:27:20.655Z",
    "user": 2,
    "content_type": 12,
    "object_id": "27",
    "object_repr": "CRY1-PER2 complex",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 151,
  "fields": {
    "action_time": "2025-03-17T08:27:46.892Z",
    "user": 2,
    "content_type": 12,
    "object_id": "28",
    "object_repr": "CRY1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 152,
  "fields": {
    "action_time": "2025-03-17T08:28:46.457Z",
    "user": 2,
    "content_type": 12,
    "object_id": "29",
    "object_repr": "CLOCK-BMAL1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 153,
  "fields": {
    "action_time": "2025-03-17T08:29:18.655Z",
    "user": 2,
    "content_type": 12,
    "object_id": "30",
    "object_repr": "Arntl (gene)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 154,
  "fields": {
    "action_time": "2025-03-17T08:33:53.195Z",
    "user": 2,
    "content_type": 10,
    "object_id": "66",
    "object_repr": "amphetamine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 155,
  "fields": {
    "action_time": "2025-03-17T08:34:04.676Z",
    "user": 2,
    "content_type": 10,
    "object_id": "66",
    "object_repr": "Amphetamine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 156,
  "fields": {
    "action_time": "2025-03-17T08:36:29.248Z",
    "user": 2,
    "content_type": 12,
    "object_id": "31",
    "object_repr": "Monoamine transporters",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 157,
  "fields": {
    "action_time": "2025-03-17T08:39:10.800Z",
    "user": 2,
    "content_type": 12,
    "object_id": "32",
    "object_repr": "SEROTONIN TRANSPORTER",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 158,
  "fields": {
    "action_time": "2025-03-17T08:39:58.651Z",
    "user": 2,
    "content_type": 12,
    "object_id": "33",
    "object_repr": "PPAR gamma",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 159,
  "fields": {
    "action_time": "2025-03-17T08:40:55.140Z",
    "user": 2,
    "content_type": 12,
    "object_id": "34",
    "object_repr": "D2R (dopamine receptor)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 160,
  "fields": {
    "action_time": "2025-03-17T08:41:14.331Z",
    "user": 2,
    "content_type": 9,
    "object_id": "22",
    "object_repr": "Dopamine receptor binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 161,
  "fields": {
    "action_time": "2025-03-17T08:43:29.872Z",
    "user": 2,
    "content_type": 10,
    "object_id": "67",
    "object_repr": "Cocaine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 162,
  "fields": {
    "action_time": "2025-03-17T08:44:26.586Z",
    "user": 2,
    "content_type": 10,
    "object_id": "67",
    "object_repr": "Cocaine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 163,
  "fields": {
    "action_time": "2025-03-17T08:46:40.729Z",
    "user": 2,
    "content_type": 12,
    "object_id": "35",
    "object_repr": "GABAA receptors",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 164,
  "fields": {
    "action_time": "2025-03-17T08:51:11.696Z",
    "user": 2,
    "content_type": 9,
    "object_id": "23",
    "object_repr": "GABA A receptor binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 165,
  "fields": {
    "action_time": "2025-03-17T08:51:21.704Z",
    "user": 2,
    "content_type": 10,
    "object_id": "68",
    "object_repr": "Propofol",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 166,
  "fields": {
    "action_time": "2025-03-17T08:52:36.168Z",
    "user": 2,
    "content_type": 9,
    "object_id": "24",
    "object_repr": "NMDA receptor antagonist",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 167,
  "fields": {
    "action_time": "2025-03-17T08:53:13.770Z",
    "user": 2,
    "content_type": 12,
    "object_id": "36",
    "object_repr": "NMDA receptor",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 168,
  "fields": {
    "action_time": "2025-03-17T08:57:59.872Z",
    "user": 2,
    "content_type": 10,
    "object_id": "69",
    "object_repr": "Ketamine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 169,
  "fields": {
    "action_time": "2025-03-17T09:01:13.771Z",
    "user": 2,
    "content_type": 9,
    "object_id": "25",
    "object_repr": "Affects melatonin synthesis",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 170,
  "fields": {
    "action_time": "2025-03-17T09:03:51.374Z",
    "user": 2,
    "content_type": 12,
    "object_id": "37",
    "object_repr": "Muscarinic acetilcholine receptror M1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 171,
  "fields": {
    "action_time": "2025-03-17T09:04:27.260Z",
    "user": 2,
    "content_type": 10,
    "object_id": "70",
    "object_repr": "Glycopyrrolate",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 172,
  "fields": {
    "action_time": "2025-03-17T09:11:00.598Z",
    "user": 2,
    "content_type": 10,
    "object_id": "71",
    "object_repr": "Remifentanil",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 173,
  "fields": {
    "action_time": "2025-03-17T09:17:35.459Z",
    "user": 2,
    "content_type": 10,
    "object_id": "72",
    "object_repr": "Sevoflurane",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 174,
  "fields": {
    "action_time": "2025-03-17T09:24:59.596Z",
    "user": 2,
    "content_type": 10,
    "object_id": "73",
    "object_repr": "Desflurane",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 175,
  "fields": {
    "action_time": "2025-03-17T09:29:19.852Z",
    "user": 2,
    "content_type": 9,
    "object_id": "26",
    "object_repr": "Core clock suppression",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 176,
  "fields": {
    "action_time": "2025-03-17T09:29:30.034Z",
    "user": 2,
    "content_type": 10,
    "object_id": "74",
    "object_repr": "Isoflurane",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 177,
  "fields": {
    "action_time": "2025-03-17T09:34:03.190Z",
    "user": 2,
    "content_type": 12,
    "object_id": "38",
    "object_repr": "ADCY1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 178,
  "fields": {
    "action_time": "2025-03-17T09:34:53.743Z",
    "user": 2,
    "content_type": 12,
    "object_id": "8",
    "object_repr": "T58921 Peroxisome proliferator-activated receptor gamma (PPAR-gamma)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Targetsname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 179,
  "fields": {
    "action_time": "2025-03-17T09:39:16.386Z",
    "user": 2,
    "content_type": 9,
    "object_id": "27",
    "object_repr": "Adenylate cyclase binding activity affects circadian clock",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 180,
  "fields": {
    "action_time": "2025-03-17T09:39:21.045Z",
    "user": 2,
    "content_type": 10,
    "object_id": "75",
    "object_repr": "Hyoscyamine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 181,
  "fields": {
    "action_time": "2025-03-17T11:24:10.427Z",
    "user": 2,
    "content_type": 12,
    "object_id": "39",
    "object_repr": "SIRT1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 182,
  "fields": {
    "action_time": "2025-03-17T11:25:03.920Z",
    "user": 2,
    "content_type": 10,
    "object_id": "76",
    "object_repr": "SRT2183",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 183,
  "fields": {
    "action_time": "2025-03-17T11:30:04.994Z",
    "user": 2,
    "content_type": 10,
    "object_id": "77",
    "object_repr": "SRT 1720 Hydrochloride",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 184,
  "fields": {
    "action_time": "2025-03-17T11:40:10.330Z",
    "user": 2,
    "content_type": 9,
    "object_id": "28",
    "object_repr": "Bmal1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 185,
  "fields": {
    "action_time": "2025-03-17T11:40:17.438Z",
    "user": 2,
    "content_type": 10,
    "object_id": "78",
    "object_repr": "Camptothecin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 186,
  "fields": {
    "action_time": "2025-03-17T11:40:52.608Z",
    "user": 2,
    "content_type": 10,
    "object_id": "77",
    "object_repr": "SRT 1720 Hydrochloride",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Article\", \"Pubchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 187,
  "fields": {
    "action_time": "2025-03-17T11:46:24.350Z",
    "user": 2,
    "content_type": 12,
    "object_id": "40",
    "object_repr": "RORα",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 188,
  "fields": {
    "action_time": "2025-03-17T11:46:41.183Z",
    "user": 2,
    "content_type": 10,
    "object_id": "79",
    "object_repr": "Harmine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 189,
  "fields": {
    "action_time": "2025-03-17T11:54:05.543Z",
    "user": 2,
    "content_type": 9,
    "object_id": "29",
    "object_repr": "modulation of nuclear receptor signaling pathways",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 190,
  "fields": {
    "action_time": "2025-03-17T11:54:37.155Z",
    "user": 2,
    "content_type": 10,
    "object_id": "80",
    "object_repr": "Prasterone (DHEA)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 191,
  "fields": {
    "action_time": "2025-03-17T11:58:42.376Z",
    "user": 2,
    "content_type": 9,
    "object_id": "30",
    "object_repr": "LXRα",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 192,
  "fields": {
    "action_time": "2025-03-17T11:58:49.707Z",
    "user": 2,
    "content_type": 9,
    "object_id": "31",
    "object_repr": "LXRβ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 193,
  "fields": {
    "action_time": "2025-03-17T11:59:33Z",
    "user": 2,
    "content_type": 12,
    "object_id": "41",
    "object_repr": "Liver X receptors",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 194,
  "fields": {
    "action_time": "2025-03-17T11:59:49.394Z",
    "user": 2,
    "content_type": 10,
    "object_id": "81",
    "object_repr": "T0901317",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 195,
  "fields": {
    "action_time": "2025-03-17T12:02:04.143Z",
    "user": 2,
    "content_type": 7,
    "object_id": "8",
    "object_repr": "Chronomodulator",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 196,
  "fields": {
    "action_time": "2025-03-17T12:02:23.129Z",
    "user": 2,
    "content_type": 9,
    "object_id": "32",
    "object_repr": "ROR",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 197,
  "fields": {
    "action_time": "2025-03-17T12:02:54.413Z",
    "user": 2,
    "content_type": 10,
    "object_id": "82",
    "object_repr": "SR 1078",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 198,
  "fields": {
    "action_time": "2025-03-17T20:25:09.346Z",
    "user": 2,
    "content_type": 10,
    "object_id": "83",
    "object_repr": "SR 3335",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 199,
  "fields": {
    "action_time": "2025-03-17T20:29:35.108Z",
    "user": 2,
    "content_type": 10,
    "object_id": "84",
    "object_repr": "SR1001",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 200,
  "fields": {
    "action_time": "2025-03-17T20:33:19.958Z",
    "user": 2,
    "content_type": 10,
    "object_id": "85",
    "object_repr": "SR2211",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 201,
  "fields": {
    "action_time": "2025-03-17T20:35:08.083Z",
    "user": 2,
    "content_type": 10,
    "object_id": "86",
    "object_repr": "SR1555",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 202,
  "fields": {
    "action_time": "2025-03-17T20:39:27.343Z",
    "user": 2,
    "content_type": 10,
    "object_id": "87",
    "object_repr": "ML 209",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 203,
  "fields": {
    "action_time": "2025-03-17T20:39:47.901Z",
    "user": 2,
    "content_type": 10,
    "object_id": "87",
    "object_repr": "ML209",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 204,
  "fields": {
    "action_time": "2025-03-17T20:43:05.671Z",
    "user": 2,
    "content_type": 10,
    "object_id": "88",
    "object_repr": "TMP778",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 205,
  "fields": {
    "action_time": "2025-03-17T20:47:42.804Z",
    "user": 2,
    "content_type": 10,
    "object_id": "89",
    "object_repr": "GSK805",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 206,
  "fields": {
    "action_time": "2025-03-17T21:22:47.915Z",
    "user": 2,
    "content_type": 9,
    "object_id": "33",
    "object_repr": "Selective stabilizer of CRY1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 207,
  "fields": {
    "action_time": "2025-03-17T21:23:25.607Z",
    "user": 2,
    "content_type": 12,
    "object_id": "42",
    "object_repr": "CRY1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 208,
  "fields": {
    "action_time": "2025-03-17T21:23:27.642Z",
    "user": 2,
    "content_type": 10,
    "object_id": "90",
    "object_repr": "KL101",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 209,
  "fields": {
    "action_time": "2025-03-17T21:26:28.003Z",
    "user": 2,
    "content_type": 10,
    "object_id": "91",
    "object_repr": "KL201",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 210,
  "fields": {
    "action_time": "2025-03-17T21:29:08.110Z",
    "user": 2,
    "content_type": 9,
    "object_id": "34",
    "object_repr": "Selectively stabilizes CRY2",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 211,
  "fields": {
    "action_time": "2025-03-17T21:29:25.328Z",
    "user": 2,
    "content_type": 10,
    "object_id": "92",
    "object_repr": "TH301",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 212,
  "fields": {
    "action_time": "2025-03-17T21:32:14.454Z",
    "user": 2,
    "content_type": 9,
    "object_id": "35",
    "object_repr": "Inhibits CK1δ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 213,
  "fields": {
    "action_time": "2025-03-17T21:32:49.031Z",
    "user": 2,
    "content_type": 12,
    "object_id": "43",
    "object_repr": "CK1δ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 214,
  "fields": {
    "action_time": "2025-03-17T21:32:50.615Z",
    "user": 2,
    "content_type": 10,
    "object_id": "93",
    "object_repr": "PF-670462",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 215,
  "fields": {
    "action_time": "2025-03-17T21:35:01.910Z",
    "user": 2,
    "content_type": 9,
    "object_id": "36",
    "object_repr": "Binds CRY1 FAD-binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 216,
  "fields": {
    "action_time": "2025-03-17T21:35:19.851Z",
    "user": 2,
    "content_type": 10,
    "object_id": "94",
    "object_repr": "M47",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 217,
  "fields": {
    "action_time": "2025-03-17T21:38:35.281Z",
    "user": 2,
    "content_type": 9,
    "object_id": "37",
    "object_repr": "Antagonist of Rev-Erb nuclear receptors",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 218,
  "fields": {
    "action_time": "2025-03-17T21:38:42.977Z",
    "user": 2,
    "content_type": 9,
    "object_id": "38",
    "object_repr": "de-repressing BMAL1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 219,
  "fields": {
    "action_time": "2025-03-17T21:38:48.625Z",
    "user": 2,
    "content_type": 10,
    "object_id": "95",
    "object_repr": "SR8278",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 220,
  "fields": {
    "action_time": "2025-03-18T07:51:56.843Z",
    "user": 2,
    "content_type": 9,
    "object_id": "39",
    "object_repr": "Muscarinic receptor binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 221,
  "fields": {
    "action_time": "2025-03-18T07:52:23.936Z",
    "user": 2,
    "content_type": 10,
    "object_id": "96",
    "object_repr": "Methohexital",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 222,
  "fields": {
    "action_time": "2025-03-18T07:59:37.273Z",
    "user": 2,
    "content_type": 9,
    "object_id": "40",
    "object_repr": "HSP90 binding (in Arabidopsis)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 223,
  "fields": {
    "action_time": "2025-03-18T08:00:36.811Z",
    "user": 2,
    "content_type": 10,
    "object_id": "97",
    "object_repr": "Geldanamycin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 224,
  "fields": {
    "action_time": "2025-03-18T08:05:38.846Z",
    "user": 2,
    "content_type": 7,
    "object_id": "9",
    "object_repr": "Potential modulator of circdain rhtyhms",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 225,
  "fields": {
    "action_time": "2025-03-18T08:06:24.163Z",
    "user": 2,
    "content_type": 10,
    "object_id": "98",
    "object_repr": "Herbimycin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 226,
  "fields": {
    "action_time": "2025-03-18T08:07:04.519Z",
    "user": 2,
    "content_type": 10,
    "object_id": "98",
    "object_repr": "Herbimycin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 227,
  "fields": {
    "action_time": "2025-03-18T08:13:27.211Z",
    "user": 2,
    "content_type": 12,
    "object_id": "44",
    "object_repr": "Microbiota",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 228,
  "fields": {
    "action_time": "2025-03-18T08:13:41.759Z",
    "user": 2,
    "content_type": 10,
    "object_id": "99",
    "object_repr": "Rifaximin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 229,
  "fields": {
    "action_time": "2025-03-18T08:20:58.004Z",
    "user": 2,
    "content_type": 12,
    "object_id": "45",
    "object_repr": "Fe deficiency",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 230,
  "fields": {
    "action_time": "2025-03-18T08:22:14.942Z",
    "user": 2,
    "content_type": 10,
    "object_id": "100",
    "object_repr": "Lincomycin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 231,
  "fields": {
    "action_time": "2025-03-18T08:25:16.796Z",
    "user": 2,
    "content_type": 9,
    "object_id": "41",
    "object_repr": "Unknown",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 232,
  "fields": {
    "action_time": "2025-03-18T08:25:22.773Z",
    "user": 2,
    "content_type": 10,
    "object_id": "101",
    "object_repr": "Clarithromycin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 233,
  "fields": {
    "action_time": "2025-03-18T08:29:13.029Z",
    "user": 2,
    "content_type": 10,
    "object_id": "102",
    "object_repr": "Sulfamethoxazole",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 234,
  "fields": {
    "action_time": "2025-03-18T08:30:55.818Z",
    "user": 2,
    "content_type": 12,
    "object_id": "46",
    "object_repr": "LUX (GENE)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 235,
  "fields": {
    "action_time": "2025-03-18T08:34:15.461Z",
    "user": 2,
    "content_type": 9,
    "object_id": "42",
    "object_repr": "Affects flowering rhythms (LUX)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 236,
  "fields": {
    "action_time": "2025-03-18T08:34:19.538Z",
    "user": 2,
    "content_type": 10,
    "object_id": "103",
    "object_repr": "Sulfanilimide",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 237,
  "fields": {
    "action_time": "2025-03-18T08:35:16.021Z",
    "user": 2,
    "content_type": 12,
    "object_id": "47",
    "object_repr": "REV-ERBα",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 238,
  "fields": {
    "action_time": "2025-03-18T08:38:27.350Z",
    "user": 2,
    "content_type": 10,
    "object_id": "104",
    "object_repr": "Sulfasalazine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 239,
  "fields": {
    "action_time": "2025-03-18T08:52:52.581Z",
    "user": 2,
    "content_type": 12,
    "object_id": "48",
    "object_repr": "Unknown",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 240,
  "fields": {
    "action_time": "2025-03-18T08:52:58.314Z",
    "user": 2,
    "content_type": 10,
    "object_id": "105",
    "object_repr": "Doxycycline",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 241,
  "fields": {
    "action_time": "2025-03-18T08:56:44.941Z",
    "user": 2,
    "content_type": 9,
    "object_id": "43",
    "object_repr": "Lenghthen the circadian period",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 242,
  "fields": {
    "action_time": "2025-03-18T08:58:06.810Z",
    "user": 2,
    "content_type": 12,
    "object_id": "49",
    "object_repr": "organellar transcription",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 243,
  "fields": {
    "action_time": "2025-03-18T08:58:14.186Z",
    "user": 2,
    "content_type": 10,
    "object_id": "106",
    "object_repr": "Rifampin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 244,
  "fields": {
    "action_time": "2025-03-18T09:34:43.286Z",
    "user": 2,
    "content_type": 9,
    "object_id": "44",
    "object_repr": "Chloramphenicol can inhibit both bacterial and mitochondrial protein synthesis",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 245,
  "fields": {
    "action_time": "2025-03-18T09:35:18.554Z",
    "user": 2,
    "content_type": 12,
    "object_id": "50",
    "object_repr": "Mitochondrial translation machine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 246,
  "fields": {
    "action_time": "2025-03-18T09:35:53.163Z",
    "user": 2,
    "content_type": 10,
    "object_id": "107",
    "object_repr": "Chloramphenicol",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 247,
  "fields": {
    "action_time": "2025-03-18T09:39:12.255Z",
    "user": 2,
    "content_type": 9,
    "object_id": "45",
    "object_repr": "Melatonin synthesis alteration",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 248,
  "fields": {
    "action_time": "2025-03-18T09:39:32.623Z",
    "user": 2,
    "content_type": 10,
    "object_id": "108",
    "object_repr": "Metronidazole",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 249,
  "fields": {
    "action_time": "2025-03-18T09:44:33.434Z",
    "user": 2,
    "content_type": 9,
    "object_id": "46",
    "object_repr": "Dopamine receptor binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 250,
  "fields": {
    "action_time": "2025-03-18T09:44:46.362Z",
    "user": 2,
    "content_type": 10,
    "object_id": "109",
    "object_repr": "aripiprazole",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 251,
  "fields": {
    "action_time": "2025-03-18T09:44:57.017Z",
    "user": 2,
    "content_type": 10,
    "object_id": "109",
    "object_repr": "Aripiprazole",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 252,
  "fields": {
    "action_time": "2025-03-18T09:51:31.229Z",
    "user": 2,
    "content_type": 10,
    "object_id": "110",
    "object_repr": "Quetiapine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 253,
  "fields": {
    "action_time": "2025-03-18T09:55:06.254Z",
    "user": 2,
    "content_type": 9,
    "object_id": "47",
    "object_repr": "PER gene exspression modulation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 254,
  "fields": {
    "action_time": "2025-03-18T09:55:20.158Z",
    "user": 2,
    "content_type": 9,
    "object_id": "48",
    "object_repr": "CRY gene expression modulation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 255,
  "fields": {
    "action_time": "2025-03-18T09:56:26.381Z",
    "user": 2,
    "content_type": 10,
    "object_id": "111",
    "object_repr": "Haloperidol",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 256,
  "fields": {
    "action_time": "2025-03-18T11:41:54.543Z",
    "user": 2,
    "content_type": 9,
    "object_id": "49",
    "object_repr": "5-HT7 binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 257,
  "fields": {
    "action_time": "2025-03-18T11:42:26.348Z",
    "user": 2,
    "content_type": 12,
    "object_id": "51",
    "object_repr": "5-HT7",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 258,
  "fields": {
    "action_time": "2025-03-18T11:43:00.362Z",
    "user": 2,
    "content_type": 10,
    "object_id": "112",
    "object_repr": "Asenapine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 259,
  "fields": {
    "action_time": "2025-03-18T11:50:36.144Z",
    "user": 2,
    "content_type": 9,
    "object_id": "50",
    "object_repr": "Dopamine receptor agonist",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 260,
  "fields": {
    "action_time": "2025-03-18T11:50:57.041Z",
    "user": 2,
    "content_type": 10,
    "object_id": "113",
    "object_repr": "Benperidol",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 261,
  "fields": {
    "action_time": "2025-03-18T11:56:39.665Z",
    "user": 2,
    "content_type": 10,
    "object_id": "114",
    "object_repr": "Cariprazine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 262,
  "fields": {
    "action_time": "2025-03-18T12:01:39.058Z",
    "user": 2,
    "content_type": 12,
    "object_id": "52",
    "object_repr": "NPAS2",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 263,
  "fields": {
    "action_time": "2025-03-18T12:02:13.281Z",
    "user": 2,
    "content_type": 10,
    "object_id": "115",
    "object_repr": "chlorpromazine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 264,
  "fields": {
    "action_time": "2025-03-18T12:18:35.171Z",
    "user": 2,
    "content_type": 12,
    "object_id": "53",
    "object_repr": "Unknown",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 265,
  "fields": {
    "action_time": "2025-03-18T12:18:37.467Z",
    "user": 2,
    "content_type": 10,
    "object_id": "116",
    "object_repr": "Zuclopentixol",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 266,
  "fields": {
    "action_time": "2025-03-18T12:25:59.227Z",
    "user": 2,
    "content_type": 10,
    "object_id": "117",
    "object_repr": "Clozapine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 267,
  "fields": {
    "action_time": "2025-03-18T12:32:15.404Z",
    "user": 2,
    "content_type": 10,
    "object_id": "118",
    "object_repr": "flupentixol",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 268,
  "fields": {
    "action_time": "2025-03-18T12:36:23.106Z",
    "user": 2,
    "content_type": 9,
    "object_id": "51",
    "object_repr": "BMAL1 expression modulation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 269,
  "fields": {
    "action_time": "2025-03-18T12:37:01.134Z",
    "user": 2,
    "content_type": 10,
    "object_id": "119",
    "object_repr": "Risperidon",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 270,
  "fields": {
    "action_time": "2025-03-18T12:41:12.414Z",
    "user": 2,
    "content_type": 10,
    "object_id": "120",
    "object_repr": "Sulpiride",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 271,
  "fields": {
    "action_time": "2025-03-18T12:46:35.908Z",
    "user": 2,
    "content_type": 9,
    "object_id": "52",
    "object_repr": "Binding to rat brainα- andβ-adrenergic, muscarinic cholinergic, dopamine and opiate receptors",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 272,
  "fields": {
    "action_time": "2025-03-18T12:46:44.163Z",
    "user": 2,
    "content_type": 10,
    "object_id": "121",
    "object_repr": "Fluphenazine decanoate",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 273,
  "fields": {
    "action_time": "2025-03-18T12:49:15.919Z",
    "user": 2,
    "content_type": 12,
    "object_id": "54",
    "object_repr": "5-HT 2A R",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 274,
  "fields": {
    "action_time": "2025-03-18T12:53:05.903Z",
    "user": 2,
    "content_type": 10,
    "object_id": "122",
    "object_repr": "Lurasidone",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 275,
  "fields": {
    "action_time": "2025-03-18T12:53:16.046Z",
    "user": 2,
    "content_type": 10,
    "object_id": "118",
    "object_repr": "Flupentixol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 276,
  "fields": {
    "action_time": "2025-03-18T12:53:24.921Z",
    "user": 2,
    "content_type": 10,
    "object_id": "115",
    "object_repr": "Chlorpromazine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 277,
  "fields": {
    "action_time": "2025-03-18T12:59:05.338Z",
    "user": 2,
    "content_type": 10,
    "object_id": "123",
    "object_repr": "Olanzapine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 278,
  "fields": {
    "action_time": "2025-03-18T13:02:29.531Z",
    "user": 2,
    "content_type": 10,
    "object_id": "124",
    "object_repr": "Pimozidine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 279,
  "fields": {
    "action_time": "2025-03-18T13:28:57.734Z",
    "user": 2,
    "content_type": 9,
    "object_id": "53",
    "object_repr": "Hypnotic effect",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 280,
  "fields": {
    "action_time": "2025-03-18T13:29:11.125Z",
    "user": 2,
    "content_type": 9,
    "object_id": "54",
    "object_repr": "Sleep promotion",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 281,
  "fields": {
    "action_time": "2025-03-18T13:30:13.301Z",
    "user": 2,
    "content_type": 10,
    "object_id": "125",
    "object_repr": "Promazine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 282,
  "fields": {
    "action_time": "2025-03-18T13:34:15.035Z",
    "user": 2,
    "content_type": 9,
    "object_id": "55",
    "object_repr": "Calmodulin inhibition",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 283,
  "fields": {
    "action_time": "2025-03-18T13:34:42.965Z",
    "user": 2,
    "content_type": 12,
    "object_id": "55",
    "object_repr": "Calmodulin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 284,
  "fields": {
    "action_time": "2025-03-18T13:36:46.393Z",
    "user": 2,
    "content_type": 9,
    "object_id": "56",
    "object_repr": "Calmodulin binding (Neurospora)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 285,
  "fields": {
    "action_time": "2025-03-18T13:37:39.926Z",
    "user": 2,
    "content_type": 12,
    "object_id": "56",
    "object_repr": "Calmodulin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 286,
  "fields": {
    "action_time": "2025-03-18T13:38:09.626Z",
    "user": 2,
    "content_type": 10,
    "object_id": "126",
    "object_repr": "Trifluoperazine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 287,
  "fields": {
    "action_time": "2025-03-18T13:45:03.275Z",
    "user": 2,
    "content_type": 7,
    "object_id": "10",
    "object_repr": "hypnotic",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 288,
  "fields": {
    "action_time": "2025-03-18T13:46:27.070Z",
    "user": 2,
    "content_type": 10,
    "object_id": "127",
    "object_repr": "Eszopiclone",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 289,
  "fields": {
    "action_time": "2025-03-18T13:50:55.300Z",
    "user": 2,
    "content_type": 9,
    "object_id": "57",
    "object_repr": "GABAergic system influence",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 290,
  "fields": {
    "action_time": "2025-03-18T13:51:07.511Z",
    "user": 2,
    "content_type": 10,
    "object_id": "128",
    "object_repr": "Zolpidem",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 291,
  "fields": {
    "action_time": "2025-03-18T13:51:46.490Z",
    "user": 2,
    "content_type": 10,
    "object_id": "128",
    "object_repr": "Zolpidem",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 292,
  "fields": {
    "action_time": "2025-03-18T13:56:13.411Z",
    "user": 2,
    "content_type": 9,
    "object_id": "58",
    "object_repr": "Dopamine receptor antagonist",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 293,
  "fields": {
    "action_time": "2025-03-18T13:56:21.042Z",
    "user": 2,
    "content_type": 10,
    "object_id": "129",
    "object_repr": "Droperidol",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 294,
  "fields": {
    "action_time": "2025-03-18T19:10:41.370Z",
    "user": 2,
    "content_type": 10,
    "object_id": "76",
    "object_repr": "SRT2183",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 295,
  "fields": {
    "action_time": "2025-03-18T19:11:03.335Z",
    "user": 2,
    "content_type": 10,
    "object_id": "77",
    "object_repr": "SRT 1720 Hydrochloride",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 296,
  "fields": {
    "action_time": "2025-03-18T19:12:26.969Z",
    "user": 2,
    "content_type": 10,
    "object_id": "79",
    "object_repr": "Harmine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 297,
  "fields": {
    "action_time": "2025-03-18T19:13:22.271Z",
    "user": 2,
    "content_type": 10,
    "object_id": "80",
    "object_repr": "Prasterone (DHEA)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 298,
  "fields": {
    "action_time": "2025-03-18T19:13:42.420Z",
    "user": 2,
    "content_type": 10,
    "object_id": "81",
    "object_repr": "T0901317",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 299,
  "fields": {
    "action_time": "2025-03-18T19:13:50.641Z",
    "user": 2,
    "content_type": 10,
    "object_id": "82",
    "object_repr": "SR 1078",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 300,
  "fields": {
    "action_time": "2025-03-18T19:13:59.379Z",
    "user": 2,
    "content_type": 10,
    "object_id": "83",
    "object_repr": "SR 3335",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 301,
  "fields": {
    "action_time": "2025-03-18T19:14:05.704Z",
    "user": 2,
    "content_type": 10,
    "object_id": "84",
    "object_repr": "SR1001",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 302,
  "fields": {
    "action_time": "2025-03-18T19:14:14.637Z",
    "user": 2,
    "content_type": 10,
    "object_id": "85",
    "object_repr": "SR2211",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 303,
  "fields": {
    "action_time": "2025-03-18T19:14:21.185Z",
    "user": 2,
    "content_type": 10,
    "object_id": "86",
    "object_repr": "SR1555",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 304,
  "fields": {
    "action_time": "2025-03-18T19:14:27.661Z",
    "user": 2,
    "content_type": 10,
    "object_id": "87",
    "object_repr": "ML209",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 305,
  "fields": {
    "action_time": "2025-03-18T19:14:35.777Z",
    "user": 2,
    "content_type": 10,
    "object_id": "88",
    "object_repr": "TMP778",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 306,
  "fields": {
    "action_time": "2025-03-18T19:14:42.493Z",
    "user": 2,
    "content_type": 10,
    "object_id": "89",
    "object_repr": "GSK805",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 307,
  "fields": {
    "action_time": "2025-03-18T19:14:48.159Z",
    "user": 2,
    "content_type": 10,
    "object_id": "90",
    "object_repr": "KL101",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 308,
  "fields": {
    "action_time": "2025-03-18T19:14:55.500Z",
    "user": 2,
    "content_type": 10,
    "object_id": "91",
    "object_repr": "KL201",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 309,
  "fields": {
    "action_time": "2025-03-18T19:15:02.060Z",
    "user": 2,
    "content_type": 10,
    "object_id": "92",
    "object_repr": "TH301",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 310,
  "fields": {
    "action_time": "2025-03-18T19:15:10.318Z",
    "user": 2,
    "content_type": 10,
    "object_id": "93",
    "object_repr": "PF-670462",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 311,
  "fields": {
    "action_time": "2025-03-18T19:15:16.897Z",
    "user": 2,
    "content_type": 10,
    "object_id": "94",
    "object_repr": "M47",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 312,
  "fields": {
    "action_time": "2025-03-18T19:15:25.824Z",
    "user": 2,
    "content_type": 10,
    "object_id": "95",
    "object_repr": "SR8278",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 313,
  "fields": {
    "action_time": "2025-03-18T19:15:36.915Z",
    "user": 2,
    "content_type": 10,
    "object_id": "96",
    "object_repr": "Methohexital",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 314,
  "fields": {
    "action_time": "2025-03-18T19:15:43.529Z",
    "user": 2,
    "content_type": 10,
    "object_id": "97",
    "object_repr": "Geldanamycin",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 315,
  "fields": {
    "action_time": "2025-03-18T19:16:12.344Z",
    "user": 2,
    "content_type": 10,
    "object_id": "73",
    "object_repr": "Desflurane",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 316,
  "fields": {
    "action_time": "2025-03-19T06:54:27.340Z",
    "user": 2,
    "content_type": 10,
    "object_id": "95",
    "object_repr": "SR8278",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Article\", \"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 317,
  "fields": {
    "action_time": "2025-03-19T06:55:03.451Z",
    "user": 2,
    "content_type": 10,
    "object_id": "35",
    "object_repr": "TIK-301",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 318,
  "fields": {
    "action_time": "2025-03-19T06:55:30.392Z",
    "user": 2,
    "content_type": 10,
    "object_id": "94",
    "object_repr": "M47",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 319,
  "fields": {
    "action_time": "2025-03-19T06:55:57.856Z",
    "user": 2,
    "content_type": 10,
    "object_id": "92",
    "object_repr": "TH301",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 320,
  "fields": {
    "action_time": "2025-03-19T07:01:25.932Z",
    "user": 2,
    "content_type": 9,
    "object_id": "59",
    "object_repr": "Serotoninergic signaling",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 321,
  "fields": {
    "action_time": "2025-03-19T07:03:47.472Z",
    "user": 2,
    "content_type": 12,
    "object_id": "57",
    "object_repr": "5-HT1A",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 322,
  "fields": {
    "action_time": "2025-03-19T07:05:32.977Z",
    "user": 2,
    "content_type": 10,
    "object_id": "130",
    "object_repr": "Buspirone",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 323,
  "fields": {
    "action_time": "2025-03-19T07:08:01.292Z",
    "user": 2,
    "content_type": 10,
    "object_id": "130",
    "object_repr": "Buspirone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Article\", \"Linkslists\", \"Classf\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 324,
  "fields": {
    "action_time": "2025-03-19T07:12:46.449Z",
    "user": 2,
    "content_type": 9,
    "object_id": "60",
    "object_repr": "Histamine 1 blocker",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 325,
  "fields": {
    "action_time": "2025-03-19T07:13:44.873Z",
    "user": 2,
    "content_type": 12,
    "object_id": "58",
    "object_repr": "Histamine 1 receptor",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 326,
  "fields": {
    "action_time": "2025-03-19T07:13:50.398Z",
    "user": 2,
    "content_type": 10,
    "object_id": "131",
    "object_repr": "Hydroxyzine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 327,
  "fields": {
    "action_time": "2025-03-19T07:16:25.863Z",
    "user": 2,
    "content_type": 9,
    "object_id": "61",
    "object_repr": "Orexin Receptor Antagonism",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 328,
  "fields": {
    "action_time": "2025-03-19T07:17:02.063Z",
    "user": 2,
    "content_type": 12,
    "object_id": "59",
    "object_repr": "Orexin Receptors OX1R and OX2R",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 329,
  "fields": {
    "action_time": "2025-03-19T07:17:03.637Z",
    "user": 2,
    "content_type": 10,
    "object_id": "132",
    "object_repr": "Lemborexant",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 330,
  "fields": {
    "action_time": "2025-03-19T07:20:07.090Z",
    "user": 2,
    "content_type": 10,
    "object_id": "133",
    "object_repr": "Dexmedetomidine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 331,
  "fields": {
    "action_time": "2025-03-19T07:20:39.745Z",
    "user": 2,
    "content_type": 10,
    "object_id": "134",
    "object_repr": "Daridorexant",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 332,
  "fields": {
    "action_time": "2025-03-19T07:21:11.648Z",
    "user": 2,
    "content_type": 10,
    "object_id": "132",
    "object_repr": "Lemborexant",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 333,
  "fields": {
    "action_time": "2025-03-19T07:25:56.772Z",
    "user": 2,
    "content_type": 10,
    "object_id": "135",
    "object_repr": "Zaleplon",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 334,
  "fields": {
    "action_time": "2025-03-19T07:26:04.752Z",
    "user": 2,
    "content_type": 10,
    "object_id": "136",
    "object_repr": "Filorexant",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 335,
  "fields": {
    "action_time": "2025-03-19T07:33:25.371Z",
    "user": 2,
    "content_type": 10,
    "object_id": "137",
    "object_repr": "Promethazine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 336,
  "fields": {
    "action_time": "2025-03-19T07:37:26.387Z",
    "user": 2,
    "content_type": 9,
    "object_id": "62",
    "object_repr": "Activation of Adenosine Receptors",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 337,
  "fields": {
    "action_time": "2025-03-19T07:38:36.157Z",
    "user": 2,
    "content_type": 12,
    "object_id": "60",
    "object_repr": "Adenosine A1, A2A, A2B, and A3 Receptors",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 338,
  "fields": {
    "action_time": "2025-03-19T07:39:32.986Z",
    "user": 2,
    "content_type": 10,
    "object_id": "138",
    "object_repr": "Adenosine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 339,
  "fields": {
    "action_time": "2025-03-19T07:41:02.901Z",
    "user": 2,
    "content_type": 10,
    "object_id": "139",
    "object_repr": "Zopiclone",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 340,
  "fields": {
    "action_time": "2025-03-19T07:41:14.600Z",
    "user": 2,
    "content_type": 10,
    "object_id": "139",
    "object_repr": "Zopiclone",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 341,
  "fields": {
    "action_time": "2025-03-19T07:41:21.452Z",
    "user": 2,
    "content_type": 10,
    "object_id": "139",
    "object_repr": "Zopiclone",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 342,
  "fields": {
    "action_time": "2025-03-19T07:43:47.228Z",
    "user": 2,
    "content_type": 9,
    "object_id": "63",
    "object_repr": "A2B receptor agonist.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 343,
  "fields": {
    "action_time": "2025-03-19T07:44:27.370Z",
    "user": 2,
    "content_type": 12,
    "object_id": "61",
    "object_repr": "ADORA2B",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 344,
  "fields": {
    "action_time": "2025-03-19T07:44:41.546Z",
    "user": 2,
    "content_type": 10,
    "object_id": "140",
    "object_repr": "BAY 60-6583",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 345,
  "fields": {
    "action_time": "2025-03-19T07:45:19.182Z",
    "user": 2,
    "content_type": 10,
    "object_id": "141",
    "object_repr": "Chloral hydrate",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 346,
  "fields": {
    "action_time": "2025-03-19T07:50:32.509Z",
    "user": 2,
    "content_type": 10,
    "object_id": "140",
    "object_repr": "BAY 60-6583",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 347,
  "fields": {
    "action_time": "2025-03-19T07:51:14.338Z",
    "user": 2,
    "content_type": 10,
    "object_id": "85",
    "object_repr": "SR2211",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 348,
  "fields": {
    "action_time": "2025-03-19T07:51:29.547Z",
    "user": 2,
    "content_type": 10,
    "object_id": "90",
    "object_repr": "KL101",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 349,
  "fields": {
    "action_time": "2025-03-19T07:51:47.585Z",
    "user": 2,
    "content_type": 10,
    "object_id": "87",
    "object_repr": "ML209",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 350,
  "fields": {
    "action_time": "2025-03-19T08:01:44.253Z",
    "user": 2,
    "content_type": 10,
    "object_id": "142",
    "object_repr": "Butisol (butabarbital)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 351,
  "fields": {
    "action_time": "2025-03-19T08:02:14.318Z",
    "user": 2,
    "content_type": 10,
    "object_id": "87",
    "object_repr": "ML209",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 352,
  "fields": {
    "action_time": "2025-03-19T08:09:51.004Z",
    "user": 2,
    "content_type": 10,
    "object_id": "143",
    "object_repr": "Doral (quazepam)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 353,
  "fields": {
    "action_time": "2025-03-19T08:13:04.134Z",
    "user": 2,
    "content_type": 10,
    "object_id": "144",
    "object_repr": "Estazolam",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 354,
  "fields": {
    "action_time": "2025-03-19T08:15:59.263Z",
    "user": 2,
    "content_type": 9,
    "object_id": "64",
    "object_repr": "Inhibits the fungal enzyme lanosterol 14-α-demethylase (CYP51)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 355,
  "fields": {
    "action_time": "2025-03-19T08:16:18.234Z",
    "user": 2,
    "content_type": 12,
    "object_id": "62",
    "object_repr": "Lanosterol 14-α-demethylase (fungal CYP51)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 356,
  "fields": {
    "action_time": "2025-03-19T08:16:20.849Z",
    "user": 2,
    "content_type": 10,
    "object_id": "145",
    "object_repr": "Fluconazole",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 357,
  "fields": {
    "action_time": "2025-03-19T08:16:29.032Z",
    "user": 2,
    "content_type": 10,
    "object_id": "146",
    "object_repr": "Flurazepam",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 358,
  "fields": {
    "action_time": "2025-03-19T08:19:13.245Z",
    "user": 2,
    "content_type": 10,
    "object_id": "147",
    "object_repr": "Halcion (triazolam)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 359,
  "fields": {
    "action_time": "2025-03-19T08:22:35.322Z",
    "user": 2,
    "content_type": 10,
    "object_id": "148",
    "object_repr": "Restoril (temazepam)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 360,
  "fields": {
    "action_time": "2025-03-19T08:26:09.747Z",
    "user": 2,
    "content_type": 10,
    "object_id": "149",
    "object_repr": "Seconal (secobarbital)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 361,
  "fields": {
    "action_time": "2025-03-19T08:28:55.638Z",
    "user": 2,
    "content_type": 10,
    "object_id": "150",
    "object_repr": "Silenor (doxepin)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 362,
  "fields": {
    "action_time": "2025-03-19T08:33:54.610Z",
    "user": 2,
    "content_type": 10,
    "object_id": "151",
    "object_repr": "Benadryl (diphenhydramine)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 363,
  "fields": {
    "action_time": "2025-03-19T08:37:55.602Z",
    "user": 2,
    "content_type": 10,
    "object_id": "152",
    "object_repr": "Unisom (doxylamine)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 364,
  "fields": {
    "action_time": "2025-03-19T08:40:48.312Z",
    "user": 2,
    "content_type": 10,
    "object_id": "153",
    "object_repr": "Lormetazepam",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 365,
  "fields": {
    "action_time": "2025-03-19T08:41:23.753Z",
    "user": 2,
    "content_type": 10,
    "object_id": "153",
    "object_repr": "Lormetazepam",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 366,
  "fields": {
    "action_time": "2025-03-19T08:41:24.053Z",
    "user": 2,
    "content_type": 10,
    "object_id": "153",
    "object_repr": "Lormetazepam",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 367,
  "fields": {
    "action_time": "2025-03-19T08:44:31.908Z",
    "user": 2,
    "content_type": 10,
    "object_id": "154",
    "object_repr": "Nitrazepam",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 368,
  "fields": {
    "action_time": "2025-03-19T08:48:30.939Z",
    "user": 2,
    "content_type": 10,
    "object_id": "155",
    "object_repr": "Loprazolam",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 369,
  "fields": {
    "action_time": "2025-03-19T08:51:20.766Z",
    "user": 2,
    "content_type": 9,
    "object_id": "65",
    "object_repr": "E3 ubiquitin-protein ligase XIAP",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 370,
  "fields": {
    "action_time": "2025-03-19T08:51:36.990Z",
    "user": 2,
    "content_type": 9,
    "object_id": "66",
    "object_repr": "cGMP-gated cation channel alpha-1 binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 371,
  "fields": {
    "action_time": "2025-03-19T08:51:52.536Z",
    "user": 2,
    "content_type": 9,
    "object_id": "67",
    "object_repr": "Calcium-activated potassium channel subunit alpha-1\"",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 372,
  "fields": {
    "action_time": "2025-03-19T08:58:18.763Z",
    "user": 2,
    "content_type": 10,
    "object_id": "156",
    "object_repr": "DEQUALINIUM CHLORIDE",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 373,
  "fields": {
    "action_time": "2025-03-19T09:01:28.134Z",
    "user": 2,
    "content_type": 10,
    "object_id": "157",
    "object_repr": "Berberine Chloride",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 374,
  "fields": {
    "action_time": "2025-03-19T09:03:55.483Z",
    "user": 2,
    "content_type": 10,
    "object_id": "156",
    "object_repr": "DEQUALINIUM CHLORIDE",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 375,
  "fields": {
    "action_time": "2025-03-19T09:04:29.772Z",
    "user": 2,
    "content_type": 9,
    "object_id": "68",
    "object_repr": "BMAL1 expression modulation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 376,
  "fields": {
    "action_time": "2025-03-19T09:05:02.155Z",
    "user": 2,
    "content_type": 10,
    "object_id": "158",
    "object_repr": "Protoporphyrin IX",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 377,
  "fields": {
    "action_time": "2025-03-19T09:08:30.821Z",
    "user": 2,
    "content_type": 10,
    "object_id": "159",
    "object_repr": "Nadifloxacin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 378,
  "fields": {
    "action_time": "2025-03-19T09:09:46.503Z",
    "user": 2,
    "content_type": 12,
    "object_id": "63",
    "object_repr": "BMAL1 expression (induction)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 379,
  "fields": {
    "action_time": "2025-03-19T09:12:58.371Z",
    "user": 2,
    "content_type": 10,
    "object_id": "160",
    "object_repr": "Metergoline",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 380,
  "fields": {
    "action_time": "2025-03-19T09:13:28.550Z",
    "user": 2,
    "content_type": 10,
    "object_id": "159",
    "object_repr": "Nadifloxacin",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 381,
  "fields": {
    "action_time": "2025-03-19T09:15:48.353Z",
    "user": 2,
    "content_type": 10,
    "object_id": "161",
    "object_repr": "Cyproterone",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 382,
  "fields": {
    "action_time": "2025-03-19T09:18:43.808Z",
    "user": 2,
    "content_type": 10,
    "object_id": "162",
    "object_repr": "Clorgyline hydrochloride",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 383,
  "fields": {
    "action_time": "2025-03-19T09:19:28.073Z",
    "user": 2,
    "content_type": 12,
    "object_id": "64",
    "object_repr": "Monoamine oxidase A",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 384,
  "fields": {
    "action_time": "2025-03-19T09:19:58.735Z",
    "user": 2,
    "content_type": 9,
    "object_id": "69",
    "object_repr": "Monoamine oxidase A binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 385,
  "fields": {
    "action_time": "2025-03-19T09:20:01.219Z",
    "user": 2,
    "content_type": 10,
    "object_id": "162",
    "object_repr": "Clorgyline hydrochloride",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Mechanisms\", \"Target\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 386,
  "fields": {
    "action_time": "2025-03-19T09:27:33.931Z",
    "user": 2,
    "content_type": 10,
    "object_id": "163",
    "object_repr": "Nitroxoline",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 387,
  "fields": {
    "action_time": "2025-03-19T09:30:00.789Z",
    "user": 2,
    "content_type": 10,
    "object_id": "164",
    "object_repr": "Artenimol",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 388,
  "fields": {
    "action_time": "2025-03-19T09:30:32.288Z",
    "user": 2,
    "content_type": 9,
    "object_id": "70",
    "object_repr": "\"Peptidyl-prolyl cis-trans isomerase A  Peroxiredoxin-1  60S ribosomal protein L10, L14, L18, L23a, L35, L4  40S ribosomal prote",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 389,
  "fields": {
    "action_time": "2025-03-19T09:30:36.246Z",
    "user": 2,
    "content_type": 10,
    "object_id": "164",
    "object_repr": "Artenimol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Mechanisms\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 390,
  "fields": {
    "action_time": "2025-03-19T09:33:07.283Z",
    "user": 2,
    "content_type": 10,
    "object_id": "165",
    "object_repr": "Hydroxyprogesterone",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 391,
  "fields": {
    "action_time": "2025-03-19T09:33:21.925Z",
    "user": 2,
    "content_type": 9,
    "object_id": "71",
    "object_repr": "Glyceraldehyde-3-phosphate dehydrogenase",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 392,
  "fields": {
    "action_time": "2025-03-19T09:33:56.147Z",
    "user": 2,
    "content_type": 12,
    "object_id": "65",
    "object_repr": "Glyceraldehyde-3-phosphate dehydrogenase",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 393,
  "fields": {
    "action_time": "2025-03-19T09:34:27.422Z",
    "user": 2,
    "content_type": 10,
    "object_id": "165",
    "object_repr": "Hydroxyprogesterone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Mechanisms\", \"Target\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 394,
  "fields": {
    "action_time": "2025-03-19T09:36:45.166Z",
    "user": 2,
    "content_type": 9,
    "object_id": "72",
    "object_repr": "mTOR signaling inhibition",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 395,
  "fields": {
    "action_time": "2025-03-19T09:38:09.808Z",
    "user": 2,
    "content_type": 10,
    "object_id": "166",
    "object_repr": "RAPAMYCIN",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 396,
  "fields": {
    "action_time": "2025-03-19T11:03:11.248Z",
    "user": 2,
    "content_type": 9,
    "object_id": "73",
    "object_repr": "Myosin-9 binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 397,
  "fields": {
    "action_time": "2025-03-19T11:04:26.340Z",
    "user": 2,
    "content_type": 10,
    "object_id": "167",
    "object_repr": "SERTACONAZOLE",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 398,
  "fields": {
    "action_time": "2025-03-19T11:09:10.395Z",
    "user": 2,
    "content_type": 10,
    "object_id": "168",
    "object_repr": "BLEOMYCIN SULFATE",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 399,
  "fields": {
    "action_time": "2025-03-19T11:14:28.051Z",
    "user": 2,
    "content_type": 12,
    "object_id": "66",
    "object_repr": "JAK2",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 400,
  "fields": {
    "action_time": "2025-03-19T11:14:54.126Z",
    "user": 2,
    "content_type": 9,
    "object_id": "74",
    "object_repr": "inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 401,
  "fields": {
    "action_time": "2025-03-19T11:16:28.654Z",
    "user": 2,
    "content_type": 12,
    "object_id": "67",
    "object_repr": "EGFR",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 402,
  "fields": {
    "action_time": "2025-03-19T11:17:00.477Z",
    "user": 2,
    "content_type": 10,
    "object_id": "169",
    "object_repr": "Erlotinib",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 403,
  "fields": {
    "action_time": "2025-03-19T11:21:01.100Z",
    "user": 2,
    "content_type": 9,
    "object_id": "75",
    "object_repr": "1,4-dihydropyridine calcium channel blocker",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 404,
  "fields": {
    "action_time": "2025-03-19T11:22:57.209Z",
    "user": 2,
    "content_type": 10,
    "object_id": "170",
    "object_repr": "Felodipine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 405,
  "fields": {
    "action_time": "2025-03-19T11:26:55.406Z",
    "user": 2,
    "content_type": 10,
    "object_id": "171",
    "object_repr": "BROMOCRIPTINE",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 406,
  "fields": {
    "action_time": "2025-03-19T11:27:11.115Z",
    "user": 2,
    "content_type": 10,
    "object_id": "171",
    "object_repr": "Bromocriptine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 407,
  "fields": {
    "action_time": "2025-03-19T11:30:15.663Z",
    "user": 2,
    "content_type": 10,
    "object_id": "172",
    "object_repr": "Acitretin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 408,
  "fields": {
    "action_time": "2025-03-19T11:33:43.142Z",
    "user": 2,
    "content_type": 9,
    "object_id": "76",
    "object_repr": "Vitamin D3 receptor,  Homeobox protein Hox-A10,  Vitamin D-binding protein",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 409,
  "fields": {
    "action_time": "2025-03-19T11:33:59.972Z",
    "user": 2,
    "content_type": 10,
    "object_id": "173",
    "object_repr": "CALCITRIOL",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 410,
  "fields": {
    "action_time": "2025-03-19T11:35:17.903Z",
    "user": 2,
    "content_type": 12,
    "object_id": "68",
    "object_repr": "Vitamin D3 receptor",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 411,
  "fields": {
    "action_time": "2025-03-19T11:36:04.350Z",
    "user": 2,
    "content_type": 12,
    "object_id": "69",
    "object_repr": "Vitamin D binding protein",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 412,
  "fields": {
    "action_time": "2025-03-19T11:37:02.810Z",
    "user": 2,
    "content_type": 10,
    "object_id": "173",
    "object_repr": "CALCITRIOL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Target\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 413,
  "fields": {
    "action_time": "2025-03-19T11:40:58.307Z",
    "user": 2,
    "content_type": 9,
    "object_id": "77",
    "object_repr": "Binding Androgen receptor,  17-hydroxylase,  Steroid 21-hydroxylase,  11-hydroxylase,  Cytochrome P450 19A1,  Potassium voltage-",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 414,
  "fields": {
    "action_time": "2025-03-19T11:41:24.819Z",
    "user": 2,
    "content_type": 10,
    "object_id": "174",
    "object_repr": "KETOCONAZOLE",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 415,
  "fields": {
    "action_time": "2025-03-19T11:44:15.221Z",
    "user": 2,
    "content_type": 10,
    "object_id": "175",
    "object_repr": "DAUNORUBICIN HCL",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 416,
  "fields": {
    "action_time": "2025-03-19T11:44:32.233Z",
    "user": 2,
    "content_type": 9,
    "object_id": "78",
    "object_repr": "\"DNA  DNA topoisomerase 2-alpha, beta\"",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 417,
  "fields": {
    "action_time": "2025-03-19T11:44:41.730Z",
    "user": 2,
    "content_type": 10,
    "object_id": "175",
    "object_repr": "DAUNORUBICIN HCL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Mechanisms\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 418,
  "fields": {
    "action_time": "2025-03-19T11:45:05.624Z",
    "user": 2,
    "content_type": 9,
    "object_id": "78",
    "object_repr": "DNA  DNA topoisomerase 2-alpha, beta binding",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Mechanismname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 419,
  "fields": {
    "action_time": "2025-03-19T11:46:17.518Z",
    "user": 2,
    "content_type": 9,
    "object_id": "79",
    "object_repr": "Retinoic acid receptor RXR-alpha, beta, gamma binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 420,
  "fields": {
    "action_time": "2025-03-19T11:48:13.102Z",
    "user": 2,
    "content_type": 10,
    "object_id": "176",
    "object_repr": "Bexarotene",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 421,
  "fields": {
    "action_time": "2025-03-19T12:12:14.815Z",
    "user": 2,
    "content_type": 10,
    "object_id": "177",
    "object_repr": "CLOFARABINE",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 422,
  "fields": {
    "action_time": "2025-03-19T12:14:56.087Z",
    "user": 2,
    "content_type": 10,
    "object_id": "178",
    "object_repr": "VINBLASTINE SULFATE",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 423,
  "fields": {
    "action_time": "2025-03-19T12:15:19.169Z",
    "user": 2,
    "content_type": 9,
    "object_id": "80",
    "object_repr": "Tubulin alpha-1A, beta, delta, gamma-1, epsilon chain  Transcription factor AP-1 binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 424,
  "fields": {
    "action_time": "2025-03-19T12:15:32.215Z",
    "user": 2,
    "content_type": 10,
    "object_id": "178",
    "object_repr": "VINBLASTINE SULFATE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Mechanisms\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 425,
  "fields": {
    "action_time": "2025-03-19T12:16:14.391Z",
    "user": 2,
    "content_type": 10,
    "object_id": "178",
    "object_repr": "VINBLASTINE SULFATE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Article\", \"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 426,
  "fields": {
    "action_time": "2025-03-19T12:16:22.668Z",
    "user": 2,
    "content_type": 10,
    "object_id": "177",
    "object_repr": "CLOFARABINE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 427,
  "fields": {
    "action_time": "2025-03-19T12:16:29.010Z",
    "user": 2,
    "content_type": 10,
    "object_id": "176",
    "object_repr": "Bexarotene",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 428,
  "fields": {
    "action_time": "2025-03-19T12:18:38.538Z",
    "user": 2,
    "content_type": 9,
    "object_id": "81",
    "object_repr": "DNA alkylation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 429,
  "fields": {
    "action_time": "2025-03-19T12:19:14.406Z",
    "user": 2,
    "content_type": 10,
    "object_id": "179",
    "object_repr": "CHLORAMBUCIL",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 430,
  "fields": {
    "action_time": "2025-03-19T12:20:57.089Z",
    "user": 2,
    "content_type": 9,
    "object_id": "82",
    "object_repr": "targeting DNA and DNA topoisomerase 2-alpha.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 431,
  "fields": {
    "action_time": "2025-03-19T12:22:08.843Z",
    "user": 2,
    "content_type": 10,
    "object_id": "180",
    "object_repr": "MITOXANTRONE HCL",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 432,
  "fields": {
    "action_time": "2025-03-19T12:22:32.415Z",
    "user": 2,
    "content_type": 10,
    "object_id": "180",
    "object_repr": "MITOXANTRONE HCL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 433,
  "fields": {
    "action_time": "2025-03-19T12:24:17.036Z",
    "user": 2,
    "content_type": 9,
    "object_id": "83",
    "object_repr": "Apoptosis regulator Bcl-2,  Tubulin beta-1 chain, Nuclear receptor subfamily 1 group I member 2  Microtubule-associated protein",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 434,
  "fields": {
    "action_time": "2025-03-19T12:24:35.707Z",
    "user": 2,
    "content_type": 10,
    "object_id": "181",
    "object_repr": "Paclitaxel (TAXOL)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 435,
  "fields": {
    "action_time": "2025-03-19T12:29:58.980Z",
    "user": 2,
    "content_type": 10,
    "object_id": "182",
    "object_repr": "NEFAZODONE HCL",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 436,
  "fields": {
    "action_time": "2025-03-19T12:30:35.819Z",
    "user": 2,
    "content_type": 9,
    "object_id": "84",
    "object_repr": "Nuclear receptor subfamily 1 group I member 2 binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 437,
  "fields": {
    "action_time": "2025-03-19T12:33:11.217Z",
    "user": 2,
    "content_type": 10,
    "object_id": "183",
    "object_repr": "Oxiconazole Nitrate",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 438,
  "fields": {
    "action_time": "2025-03-19T12:35:18.510Z",
    "user": 2,
    "content_type": 9,
    "object_id": "85",
    "object_repr": "\"Progesterone receptor  Estrogen receptor alpha  Mineralocorticoid receptor  Steroid 17-alpha-hydroxylase/17,20 lyase  Kappa-typ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 439,
  "fields": {
    "action_time": "2025-03-19T12:37:00.188Z",
    "user": 2,
    "content_type": 12,
    "object_id": "70",
    "object_repr": "Progesterone receptor",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 440,
  "fields": {
    "action_time": "2025-03-19T12:37:57.694Z",
    "user": 2,
    "content_type": 12,
    "object_id": "71",
    "object_repr": "Estrogen receptor alpha",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 441,
  "fields": {
    "action_time": "2025-03-19T12:38:50.627Z",
    "user": 2,
    "content_type": 10,
    "object_id": "184",
    "object_repr": "PROGESTERONE",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 442,
  "fields": {
    "action_time": "2025-03-19T12:41:37.971Z",
    "user": 2,
    "content_type": 10,
    "object_id": "185",
    "object_repr": "Nelfinavir mesylate",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 443,
  "fields": {
    "action_time": "2025-03-19T12:41:57.519Z",
    "user": 2,
    "content_type": 9,
    "object_id": "86",
    "object_repr": "HIV-1 protease binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 444,
  "fields": {
    "action_time": "2025-03-19T12:42:29.683Z",
    "user": 2,
    "content_type": 10,
    "object_id": "185",
    "object_repr": "Nelfinavir mesylate",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Mechanisms\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 445,
  "fields": {
    "action_time": "2025-03-19T12:42:59.252Z",
    "user": 2,
    "content_type": 9,
    "object_id": "85",
    "object_repr": "Progesterone receptor,  Estrogen receptor alpha, Mineralocorticoid receptor, Steroid 17-alpha-hydroxylase/17,20 lyase  Kappa-typ",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Mechanismname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 446,
  "fields": {
    "action_time": "2025-03-19T12:48:45.902Z",
    "user": 2,
    "content_type": 9,
    "object_id": "87",
    "object_repr": "DNA polymerase/reverse transcriptase (HBV-D) binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 447,
  "fields": {
    "action_time": "2025-03-19T12:48:48.218Z",
    "user": 2,
    "content_type": 10,
    "object_id": "186",
    "object_repr": "Adefovir Dipivoxil",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 448,
  "fields": {
    "action_time": "2025-03-19T12:49:42.103Z",
    "user": 2,
    "content_type": 9,
    "object_id": "88",
    "object_repr": "\"Inhibitor of nuclear factor kappa-B kinase subunit beta  Thioredoxin reductase 1, cytoplasmic  Transcription factor AP-1  G1/S-",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 449,
  "fields": {
    "action_time": "2025-03-19T12:53:09.536Z",
    "user": 2,
    "content_type": 10,
    "object_id": "187",
    "object_repr": "ARSENIC TRIOXIDE",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 450,
  "fields": {
    "action_time": "2025-03-19T12:55:28.587Z",
    "user": 2,
    "content_type": 10,
    "object_id": "188",
    "object_repr": "CIDOFOVIR",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 451,
  "fields": {
    "action_time": "2025-03-19T12:58:41.450Z",
    "user": 2,
    "content_type": 9,
    "object_id": "89",
    "object_repr": "calcimimetic and a P450 inhibitor",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 452,
  "fields": {
    "action_time": "2025-03-19T12:59:01.664Z",
    "user": 2,
    "content_type": 10,
    "object_id": "189",
    "object_repr": "CINACALCET HCL",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 453,
  "fields": {
    "action_time": "2025-03-19T13:01:51.424Z",
    "user": 2,
    "content_type": 10,
    "object_id": "190",
    "object_repr": "Cladribine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 454,
  "fields": {
    "action_time": "2025-03-19T13:02:33.478Z",
    "user": 2,
    "content_type": 10,
    "object_id": "190",
    "object_repr": "Cladribine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 455,
  "fields": {
    "action_time": "2025-03-19T13:03:35.862Z",
    "user": 2,
    "content_type": 9,
    "object_id": "90",
    "object_repr": "Intermediate conductance calcium-activated potassium channel, protein 4  Nuclear receptor subfamily 1 group I member 2, 3",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 456,
  "fields": {
    "action_time": "2025-03-19T13:05:55.452Z",
    "user": 2,
    "content_type": 10,
    "object_id": "191",
    "object_repr": "Clotrimazole",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 457,
  "fields": {
    "action_time": "2025-03-19T13:08:42.956Z",
    "user": 2,
    "content_type": 10,
    "object_id": "192",
    "object_repr": "Dasatinib",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 458,
  "fields": {
    "action_time": "2025-03-19T13:12:28.237Z",
    "user": 2,
    "content_type": 12,
    "object_id": "72",
    "object_repr": "Fe",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 459,
  "fields": {
    "action_time": "2025-03-19T13:13:55.546Z",
    "user": 2,
    "content_type": 10,
    "object_id": "193",
    "object_repr": "Deferasirox",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 460,
  "fields": {
    "action_time": "2025-03-19T13:15:17.692Z",
    "user": 2,
    "content_type": 9,
    "object_id": "91",
    "object_repr": "\"Tyrosine-protein kinase ABL1, Lck, Yes, Fyn, BTK, CSK, Fgr, FRK, Lyn  Proto-oncogene tyrosine-protein kinase Src  Ephrin type-A",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 461,
  "fields": {
    "action_time": "2025-03-19T13:15:23.298Z",
    "user": 2,
    "content_type": 10,
    "object_id": "192",
    "object_repr": "Dasatinib",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Mechanisms\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 462,
  "fields": {
    "action_time": "2025-03-19T13:21:21.819Z",
    "user": 2,
    "content_type": 10,
    "object_id": "87",
    "object_repr": "ML209",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 463,
  "fields": {
    "action_time": "2025-03-19T13:21:36.473Z",
    "user": 2,
    "content_type": 10,
    "object_id": "94",
    "object_repr": "M47",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 464,
  "fields": {
    "action_time": "2025-03-19T13:21:53.898Z",
    "user": 2,
    "content_type": 10,
    "object_id": "81",
    "object_repr": "T0901317",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 465,
  "fields": {
    "action_time": "2025-03-19T13:22:12.058Z",
    "user": 2,
    "content_type": 10,
    "object_id": "37",
    "object_repr": "DH97",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 466,
  "fields": {
    "action_time": "2025-03-19T21:43:41.833Z",
    "user": 2,
    "content_type": 9,
    "object_id": "92",
    "object_repr": "Competitive blockade of melanopsin’s retinal-binding site",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 467,
  "fields": {
    "action_time": "2025-03-19T21:44:12.356Z",
    "user": 2,
    "content_type": 12,
    "object_id": "73",
    "object_repr": "Melanopsin (Opn4)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 468,
  "fields": {
    "action_time": "2025-03-19T21:44:28.509Z",
    "user": 2,
    "content_type": 10,
    "object_id": "194",
    "object_repr": "AA92593",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 469,
  "fields": {
    "action_time": "2025-03-19T21:47:54.632Z",
    "user": 2,
    "content_type": 9,
    "object_id": "93",
    "object_repr": "Competitive binding at melanopsin’s retinal-binding site",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 470,
  "fields": {
    "action_time": "2025-03-19T21:48:01.548Z",
    "user": 2,
    "content_type": 10,
    "object_id": "195",
    "object_repr": "AA41612",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 471,
  "fields": {
    "action_time": "2025-03-19T21:52:18.093Z",
    "user": 2,
    "content_type": 9,
    "object_id": "94",
    "object_repr": "Inhibits p38 MAPK α/β isoforms",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 472,
  "fields": {
    "action_time": "2025-03-19T21:52:42.821Z",
    "user": 2,
    "content_type": 12,
    "object_id": "74",
    "object_repr": "p38 MAP kinase",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 473,
  "fields": {
    "action_time": "2025-03-19T21:52:46.628Z",
    "user": 2,
    "content_type": 10,
    "object_id": "196",
    "object_repr": "SB-202190",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 474,
  "fields": {
    "action_time": "2025-03-19T21:55:54.803Z",
    "user": 2,
    "content_type": 9,
    "object_id": "95",
    "object_repr": "Primarily a potent inhibitor of c-Jun N-terminal kinase (JNK)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 475,
  "fields": {
    "action_time": "2025-03-19T21:56:26.153Z",
    "user": 2,
    "content_type": 12,
    "object_id": "75",
    "object_repr": "c-Jun N-terminal kinase (JNK)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 476,
  "fields": {
    "action_time": "2025-03-19T22:01:23.673Z",
    "user": 2,
    "content_type": 9,
    "object_id": "96",
    "object_repr": "Highly selective, ATP-competitive inhibition of GSK-3 (both α and β isoforms)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 477,
  "fields": {
    "action_time": "2025-03-19T22:01:52.862Z",
    "user": 2,
    "content_type": 12,
    "object_id": "76",
    "object_repr": "GSK-3α/β",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 478,
  "fields": {
    "action_time": "2025-03-19T22:02:06.353Z",
    "user": 2,
    "content_type": 10,
    "object_id": "197",
    "object_repr": "Laduviglusib",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 479,
  "fields": {
    "action_time": "2025-03-20T07:00:46.461Z",
    "user": 2,
    "content_type": 9,
    "object_id": "97",
    "object_repr": "progesteron receptor binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 480,
  "fields": {
    "action_time": "2025-03-20T07:01:40.386Z",
    "user": 2,
    "content_type": 10,
    "object_id": "198",
    "object_repr": "DROSPIRENONE",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 481,
  "fields": {
    "action_time": "2025-03-20T07:02:07.732Z",
    "user": 2,
    "content_type": 9,
    "object_id": "98",
    "object_repr": "Mineral corticoid receptor binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 482,
  "fields": {
    "action_time": "2025-03-20T07:02:44.736Z",
    "user": 2,
    "content_type": 10,
    "object_id": "198",
    "object_repr": "DROSPIRENONE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Mechanisms\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 483,
  "fields": {
    "action_time": "2025-03-20T07:05:35.551Z",
    "user": 2,
    "content_type": 10,
    "object_id": "199",
    "object_repr": "EPIRUBICIN HCL",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 484,
  "fields": {
    "action_time": "2025-03-20T07:06:41.966Z",
    "user": 2,
    "content_type": 9,
    "object_id": "99",
    "object_repr": "Serine/threonine-protein kinase mTOR",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 485,
  "fields": {
    "action_time": "2025-03-20T07:08:35.842Z",
    "user": 2,
    "content_type": 10,
    "object_id": "200",
    "object_repr": "EVEROLIMUS",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 486,
  "fields": {
    "action_time": "2025-03-20T07:11:58.104Z",
    "user": 2,
    "content_type": 9,
    "object_id": "100",
    "object_repr": "inhibits topoisomerase I",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 487,
  "fields": {
    "action_time": "2025-03-20T07:12:26.934Z",
    "user": 2,
    "content_type": 12,
    "object_id": "77",
    "object_repr": "Topoisomerase I",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 488,
  "fields": {
    "action_time": "2025-03-20T07:13:02.362Z",
    "user": 2,
    "content_type": 10,
    "object_id": "201",
    "object_repr": "Irinotecan Hydrochloride",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 489,
  "fields": {
    "action_time": "2025-03-20T07:17:43.453Z",
    "user": 2,
    "content_type": 9,
    "object_id": "101",
    "object_repr": "Binding retinoic acid receptor alpha",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 490,
  "fields": {
    "action_time": "2025-03-20T07:18:47.175Z",
    "user": 2,
    "content_type": 12,
    "object_id": "78",
    "object_repr": "Retinoic acid receptor alpha",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 491,
  "fields": {
    "action_time": "2025-03-20T07:19:08.214Z",
    "user": 2,
    "content_type": 10,
    "object_id": "202",
    "object_repr": "ISOTRETINOIN (13-CIS-RETINOIC ACID)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 492,
  "fields": {
    "action_time": "2025-03-20T07:22:04.963Z",
    "user": 2,
    "content_type": 10,
    "object_id": "203",
    "object_repr": "MECLIZINE DIHYDROCHLORIDE",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 493,
  "fields": {
    "action_time": "2025-03-20T07:22:40.321Z",
    "user": 2,
    "content_type": 9,
    "object_id": "102",
    "object_repr": "Histamine H1 receptor,  Nuclear receptor subfamily 1 group I member 3",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 494,
  "fields": {
    "action_time": "2025-03-20T07:23:02.906Z",
    "user": 2,
    "content_type": 10,
    "object_id": "203",
    "object_repr": "MECLIZINE DIHYDROCHLORIDE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Mechanisms\", \"Target\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 495,
  "fields": {
    "action_time": "2025-03-20T07:25:49.745Z",
    "user": 2,
    "content_type": 9,
    "object_id": "103",
    "object_repr": "Beta-1, 2 adrenergic receptor binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 496,
  "fields": {
    "action_time": "2025-03-20T07:26:27.401Z",
    "user": 2,
    "content_type": 12,
    "object_id": "79",
    "object_repr": "Beta 1,2 adrenergic receptor",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 497,
  "fields": {
    "action_time": "2025-03-20T07:26:50.357Z",
    "user": 2,
    "content_type": 10,
    "object_id": "204",
    "object_repr": "NEBIVOLOL HCL",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 498,
  "fields": {
    "action_time": "2025-03-20T07:31:26.288Z",
    "user": 2,
    "content_type": 9,
    "object_id": "104",
    "object_repr": "\"Tyrosine-protein kinase ABL1  Mast/stem cell growth factor receptor binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 499,
  "fields": {
    "action_time": "2025-03-20T07:33:18.901Z",
    "user": 2,
    "content_type": 12,
    "object_id": "80",
    "object_repr": "Tyrosine proteine kinase ABL1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 500,
  "fields": {
    "action_time": "2025-03-20T07:33:42.873Z",
    "user": 2,
    "content_type": 10,
    "object_id": "205",
    "object_repr": "NILOTINIB",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 501,
  "fields": {
    "action_time": "2025-03-20T07:36:02.025Z",
    "user": 2,
    "content_type": 9,
    "object_id": "105",
    "object_repr": "Vascular endothelial growth factor receptor 1, 2, 3",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 502,
  "fields": {
    "action_time": "2025-03-20T07:36:11.156Z",
    "user": 2,
    "content_type": 9,
    "object_id": "106",
    "object_repr": "Platelet-derived growth factor receptor alpha, beta",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 503,
  "fields": {
    "action_time": "2025-03-20T07:36:20.497Z",
    "user": 2,
    "content_type": 9,
    "object_id": "107",
    "object_repr": "Mast/stem cell growth factor receptor Kit",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 504,
  "fields": {
    "action_time": "2025-03-20T07:36:31.424Z",
    "user": 2,
    "content_type": 9,
    "object_id": "108",
    "object_repr": "Fibroblast growth factor receptor 3",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 505,
  "fields": {
    "action_time": "2025-03-20T07:36:40.908Z",
    "user": 2,
    "content_type": 9,
    "object_id": "109",
    "object_repr": "Tyrosine-protein kinase ITK/TSK",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 506,
  "fields": {
    "action_time": "2025-03-20T07:36:49.131Z",
    "user": 2,
    "content_type": 9,
    "object_id": "110",
    "object_repr": "Fibroblast growth factor 1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 507,
  "fields": {
    "action_time": "2025-03-20T07:36:57.277Z",
    "user": 2,
    "content_type": 9,
    "object_id": "111",
    "object_repr": "SH2B adapter protein 3",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 508,
  "fields": {
    "action_time": "2025-03-20T07:37:21.888Z",
    "user": 2,
    "content_type": 10,
    "object_id": "206",
    "object_repr": "PAZOPANIB HCL",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 509,
  "fields": {
    "action_time": "2025-03-20T07:37:45.581Z",
    "user": 2,
    "content_type": 10,
    "object_id": "206",
    "object_repr": "PAZOPANIB HCL",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 510,
  "fields": {
    "action_time": "2025-03-20T07:39:47.686Z",
    "user": 2,
    "content_type": 9,
    "object_id": "112",
    "object_repr": "Calcineurin Inhibitor Immunosuppressant",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 511,
  "fields": {
    "action_time": "2025-03-20T07:40:39.044Z",
    "user": 2,
    "content_type": 10,
    "object_id": "207",
    "object_repr": "PIMECROLIMUS",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 512,
  "fields": {
    "action_time": "2025-03-20T07:44:31.217Z",
    "user": 2,
    "content_type": 9,
    "object_id": "113",
    "object_repr": "Tubulin alpha-4A, beta chain binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 513,
  "fields": {
    "action_time": "2025-03-20T07:45:55.184Z",
    "user": 2,
    "content_type": 10,
    "object_id": "208",
    "object_repr": "PODOFILOX",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 514,
  "fields": {
    "action_time": "2025-03-20T07:49:54.350Z",
    "user": 2,
    "content_type": 12,
    "object_id": "81",
    "object_repr": "H+ K+ ATPase",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 515,
  "fields": {
    "action_time": "2025-03-20T07:50:14.607Z",
    "user": 2,
    "content_type": 9,
    "object_id": "114",
    "object_repr": "Potassium-transporting ATPase alpha chain 1 binding activity",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 516,
  "fields": {
    "action_time": "2025-03-20T07:50:21.348Z",
    "user": 2,
    "content_type": 10,
    "object_id": "209",
    "object_repr": "Rabeprazole Sodium",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 517,
  "fields": {
    "action_time": "2025-03-20T07:53:11.212Z",
    "user": 2,
    "content_type": 10,
    "object_id": "210",
    "object_repr": "Tazarotene",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 518,
  "fields": {
    "action_time": "2025-03-20T07:57:25.065Z",
    "user": 2,
    "content_type": 10,
    "object_id": "211",
    "object_repr": "THIOTEPA",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 519,
  "fields": {
    "action_time": "2025-03-20T08:01:43.193Z",
    "user": 2,
    "content_type": 10,
    "object_id": "212",
    "object_repr": "TRETINOIN",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 520,
  "fields": {
    "action_time": "2025-03-20T08:05:59.009Z",
    "user": 2,
    "content_type": 9,
    "object_id": "115",
    "object_repr": "Angiotensin receptor binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 521,
  "fields": {
    "action_time": "2025-03-20T08:07:50.331Z",
    "user": 2,
    "content_type": 9,
    "object_id": "116",
    "object_repr": "PER3",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 522,
  "fields": {
    "action_time": "2025-03-20T08:08:21.906Z",
    "user": 2,
    "content_type": 12,
    "object_id": "82",
    "object_repr": "PER3",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 523,
  "fields": {
    "action_time": "2025-03-20T08:09:02.167Z",
    "user": 2,
    "content_type": 10,
    "object_id": "213",
    "object_repr": "Irbesartan",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 524,
  "fields": {
    "action_time": "2025-03-20T08:09:18.143Z",
    "user": 2,
    "content_type": 10,
    "object_id": "213",
    "object_repr": "Irbesartan",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 525,
  "fields": {
    "action_time": "2025-03-20T08:17:21.884Z",
    "user": 2,
    "content_type": 10,
    "object_id": "214",
    "object_repr": "KL001",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 526,
  "fields": {
    "action_time": "2025-03-20T08:20:26.870Z",
    "user": 2,
    "content_type": 9,
    "object_id": "117",
    "object_repr": "CRY1/2 inhibitor",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 527,
  "fields": {
    "action_time": "2025-03-20T08:21:11.998Z",
    "user": 2,
    "content_type": 9,
    "object_id": "118",
    "object_repr": "Activation of CLOCK/Bmal1 mediated transcription",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 528,
  "fields": {
    "action_time": "2025-03-20T08:21:46.936Z",
    "user": 2,
    "content_type": 12,
    "object_id": "83",
    "object_repr": "CRY2",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 529,
  "fields": {
    "action_time": "2025-03-20T08:21:51.887Z",
    "user": 2,
    "content_type": 10,
    "object_id": "215",
    "object_repr": "KS15",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 530,
  "fields": {
    "action_time": "2025-03-20T09:04:51.533Z",
    "user": 2,
    "content_type": 9,
    "object_id": "119",
    "object_repr": "CRY 2 Stabilizer",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 531,
  "fields": {
    "action_time": "2025-03-20T11:21:12.100Z",
    "user": 2,
    "content_type": 9,
    "object_id": "120",
    "object_repr": "Dual inhibitor of Cyclin-dependent kinases (CDK) and Glycogen Synthase Kinase-3 (GSK-3)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 532,
  "fields": {
    "action_time": "2025-03-20T11:21:30.732Z",
    "user": 2,
    "content_type": 10,
    "object_id": "216",
    "object_repr": "Azakenpaullone",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 533,
  "fields": {
    "action_time": "2025-03-20T11:31:44.692Z",
    "user": 2,
    "content_type": 9,
    "object_id": "121",
    "object_repr": "GSK‑3 Inhibition",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 534,
  "fields": {
    "action_time": "2025-03-20T11:54:57.940Z",
    "user": 2,
    "content_type": 9,
    "object_id": "122",
    "object_repr": "Interferes with CLOCK–BMAL1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 535,
  "fields": {
    "action_time": "2025-03-20T11:55:20.708Z",
    "user": 2,
    "content_type": 10,
    "object_id": "217",
    "object_repr": "CLK8",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 536,
  "fields": {
    "action_time": "2025-03-20T11:59:40.157Z",
    "user": 2,
    "content_type": 9,
    "object_id": "123",
    "object_repr": "Targets BMAL1–CLOCK DNA-binding activity",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 537,
  "fields": {
    "action_time": "2025-03-20T11:59:55.808Z",
    "user": 2,
    "content_type": 10,
    "object_id": "218",
    "object_repr": "5,8-Quinoxalinedione",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 538,
  "fields": {
    "action_time": "2025-03-20T12:03:23.682Z",
    "user": 2,
    "content_type": 9,
    "object_id": "124",
    "object_repr": "Serves as a cofactor in various hemoproteins (e.g., hemoglobin, cytochromes) and can modulate transcription factors (e.g., REV-E",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 539,
  "fields": {
    "action_time": "2025-03-20T12:03:44.129Z",
    "user": 2,
    "content_type": 10,
    "object_id": "219",
    "object_repr": "Protoheme",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 540,
  "fields": {
    "action_time": "2025-03-20T12:08:47.061Z",
    "user": 2,
    "content_type": 9,
    "object_id": "125",
    "object_repr": "Inhibits casein kinase 1 delta (CKIδ) activity",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 541,
  "fields": {
    "action_time": "2025-03-20T12:08:58.864Z",
    "user": 2,
    "content_type": 10,
    "object_id": "220",
    "object_repr": "LH-846",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 542,
  "fields": {
    "action_time": "2025-03-20T12:54:12.343Z",
    "user": 2,
    "content_type": 10,
    "object_id": "221",
    "object_repr": "naphthalene",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 543,
  "fields": {
    "action_time": "2025-03-20T12:55:22.452Z",
    "user": 2,
    "content_type": 9,
    "object_id": "126",
    "object_repr": "aryl hydrocarbon receptor (AhR) binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 544,
  "fields": {
    "action_time": "2025-03-20T12:58:31.895Z",
    "user": 2,
    "content_type": 10,
    "object_id": "222",
    "object_repr": "anthracene",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 545,
  "fields": {
    "action_time": "2025-03-20T13:01:47.549Z",
    "user": 2,
    "content_type": 10,
    "object_id": "223",
    "object_repr": "Benz[a]anthracene",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 546,
  "fields": {
    "action_time": "2025-03-20T13:05:36.735Z",
    "user": 2,
    "content_type": 10,
    "object_id": "224",
    "object_repr": "Dibenzopyrene",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 547,
  "fields": {
    "action_time": "2025-03-20T13:09:13.636Z",
    "user": 2,
    "content_type": 10,
    "object_id": "225",
    "object_repr": "Benzo[k]fluoranthene",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 548,
  "fields": {
    "action_time": "2025-03-20T13:10:13.128Z",
    "user": 2,
    "content_type": 10,
    "object_id": "225",
    "object_repr": "Benzo[k]fluoranthene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 549,
  "fields": {
    "action_time": "2025-03-20T13:10:19.394Z",
    "user": 2,
    "content_type": 10,
    "object_id": "221",
    "object_repr": "naphthalene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 550,
  "fields": {
    "action_time": "2025-03-20T13:10:53.340Z",
    "user": 2,
    "content_type": 10,
    "object_id": "222",
    "object_repr": "anthracene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 551,
  "fields": {
    "action_time": "2025-03-20T13:11:11.889Z",
    "user": 2,
    "content_type": 10,
    "object_id": "223",
    "object_repr": "Benz[a]anthracene",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 552,
  "fields": {
    "action_time": "2025-03-20T13:16:01.602Z",
    "user": 2,
    "content_type": 10,
    "object_id": "226",
    "object_repr": "Chrysene",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 553,
  "fields": {
    "action_time": "2025-03-20T13:20:27.694Z",
    "user": 2,
    "content_type": 10,
    "object_id": "227",
    "object_repr": "Benzo[b]fluoranthene",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 554,
  "fields": {
    "action_time": "2025-03-20T13:25:20.533Z",
    "user": 2,
    "content_type": 10,
    "object_id": "228",
    "object_repr": "Dibenzo[a,h]anthracene",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 555,
  "fields": {
    "action_time": "2025-03-20T13:27:20.645Z",
    "user": 2,
    "content_type": 10,
    "object_id": "229",
    "object_repr": "BENZO(ghi)PERYLENE",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 556,
  "fields": {
    "action_time": "2025-03-20T13:28:00.458Z",
    "user": 2,
    "content_type": 10,
    "object_id": "229",
    "object_repr": "BENZO(ghi)PERYLENE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Mechanisms\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 557,
  "fields": {
    "action_time": "2025-03-20T13:28:09.063Z",
    "user": 2,
    "content_type": 10,
    "object_id": "228",
    "object_repr": "Dibenzo[a,h]anthracene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Mechanisms\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 558,
  "fields": {
    "action_time": "2025-03-20T13:28:16.831Z",
    "user": 2,
    "content_type": 10,
    "object_id": "227",
    "object_repr": "Benzo[b]fluoranthene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Mechanisms\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 559,
  "fields": {
    "action_time": "2025-03-20T13:30:49.833Z",
    "user": 2,
    "content_type": 10,
    "object_id": "230",
    "object_repr": "Indeno[1,2,3-c,d]pyrene",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 560,
  "fields": {
    "action_time": "2025-03-20T13:33:07.534Z",
    "user": 2,
    "content_type": 10,
    "object_id": "217",
    "object_repr": "CLK8",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Article\", \"Classf\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 561,
  "fields": {
    "action_time": "2025-03-20T13:40:23.388Z",
    "user": 2,
    "content_type": 10,
    "object_id": "231",
    "object_repr": "KK-S6",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 562,
  "fields": {
    "action_time": "2025-03-20T13:45:42.814Z",
    "user": 2,
    "content_type": 10,
    "object_id": "232",
    "object_repr": "GSK4112",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 563,
  "fields": {
    "action_time": "2025-03-20T13:47:59.157Z",
    "user": 2,
    "content_type": 9,
    "object_id": "127",
    "object_repr": "Agonist REV-ERB alpha",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 564,
  "fields": {
    "action_time": "2025-03-20T13:49:11.262Z",
    "user": 2,
    "content_type": 12,
    "object_id": "84",
    "object_repr": "Per2 expression",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 565,
  "fields": {
    "action_time": "2025-03-20T13:51:49.177Z",
    "user": 2,
    "content_type": 10,
    "object_id": "233",
    "object_repr": "SR9009",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 566,
  "fields": {
    "action_time": "2025-03-20T13:55:02.717Z",
    "user": 2,
    "content_type": 10,
    "object_id": "234",
    "object_repr": "SR9011",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 567,
  "fields": {
    "action_time": "2025-03-20T13:59:26.841Z",
    "user": 2,
    "content_type": 9,
    "object_id": "128",
    "object_repr": "SIRT1-mediated peroxisome proliferator-activated receptor coactivator 1α (PGC-1α) deacetylation in sleep-restricted mice",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 568,
  "fields": {
    "action_time": "2025-03-20T14:01:14.298Z",
    "user": 2,
    "content_type": 10,
    "object_id": "235",
    "object_repr": "Pterostilbene",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 569,
  "fields": {
    "action_time": "2025-03-20T14:07:37.199Z",
    "user": 2,
    "content_type": 9,
    "object_id": "129",
    "object_repr": "Neuropeptide Y1 receptor binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 570,
  "fields": {
    "action_time": "2025-03-20T14:08:16.669Z",
    "user": 2,
    "content_type": 12,
    "object_id": "85",
    "object_repr": "Neuropeptide Y Y1 receptor",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 571,
  "fields": {
    "action_time": "2025-03-20T14:08:21.315Z",
    "user": 2,
    "content_type": 10,
    "object_id": "236",
    "object_repr": "BIBO 3304 trifluoroacetate",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 572,
  "fields": {
    "action_time": "2025-03-20T14:09:52.710Z",
    "user": 2,
    "content_type": 10,
    "object_id": "236",
    "object_repr": "BIBO 3304 trifluoroacetate",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 573,
  "fields": {
    "action_time": "2025-03-20T14:16:57.267Z",
    "user": 2,
    "content_type": 10,
    "object_id": "237",
    "object_repr": "BIBP3226",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 574,
  "fields": {
    "action_time": "2025-03-21T07:24:04.040Z",
    "user": 2,
    "content_type": 10,
    "object_id": "238",
    "object_repr": "Nobiletin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 575,
  "fields": {
    "action_time": "2025-03-21T07:28:33.143Z",
    "user": 2,
    "content_type": 12,
    "object_id": "86",
    "object_repr": "NR1F1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 576,
  "fields": {
    "action_time": "2025-03-21T07:28:55.806Z",
    "user": 2,
    "content_type": 10,
    "object_id": "239",
    "object_repr": "Neoruscogenin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 577,
  "fields": {
    "action_time": "2025-03-21T07:34:28.585Z",
    "user": 2,
    "content_type": 9,
    "object_id": "130",
    "object_repr": "RORγ binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 578,
  "fields": {
    "action_time": "2025-03-21T07:35:09.465Z",
    "user": 2,
    "content_type": 12,
    "object_id": "87",
    "object_repr": "ROR gamma",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 579,
  "fields": {
    "action_time": "2025-03-21T07:38:02.856Z",
    "user": 2,
    "content_type": 10,
    "object_id": "240",
    "object_repr": "Compound 1a",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 580,
  "fields": {
    "action_time": "2025-03-21T08:27:15.990Z",
    "user": 2,
    "content_type": 10,
    "object_id": "241",
    "object_repr": "Digoxin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 581,
  "fields": {
    "action_time": "2025-03-21T08:36:21.318Z",
    "user": 2,
    "content_type": 9,
    "object_id": "131",
    "object_repr": "PTEN",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 582,
  "fields": {
    "action_time": "2025-03-21T08:36:27.400Z",
    "user": 2,
    "content_type": 9,
    "object_id": "132",
    "object_repr": "ROCK",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 583,
  "fields": {
    "action_time": "2025-03-21T08:36:33.560Z",
    "user": 2,
    "content_type": 9,
    "object_id": "133",
    "object_repr": "p53",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 584,
  "fields": {
    "action_time": "2025-03-21T08:36:46.866Z",
    "user": 2,
    "content_type": 10,
    "object_id": "242",
    "object_repr": "Ursolic acid",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 585,
  "fields": {
    "action_time": "2025-03-21T09:02:10.047Z",
    "user": 2,
    "content_type": 9,
    "object_id": "134",
    "object_repr": "RORyt/RORc inhibitor",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 586,
  "fields": {
    "action_time": "2025-03-21T09:02:26.340Z",
    "user": 2,
    "content_type": 10,
    "object_id": "243",
    "object_repr": "Vtp-43742",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 587,
  "fields": {
    "action_time": "2025-03-21T09:05:18.357Z",
    "user": 2,
    "content_type": 10,
    "object_id": "244",
    "object_repr": "ARN-6039",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 588,
  "fields": {
    "action_time": "2025-03-21T09:08:09.705Z",
    "user": 2,
    "content_type": 10,
    "object_id": "245",
    "object_repr": "AZD -0284e",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 589,
  "fields": {
    "action_time": "2025-03-21T11:32:07.370Z",
    "user": 2,
    "content_type": 10,
    "object_id": "246",
    "object_repr": "Cintirorgon",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 590,
  "fields": {
    "action_time": "2025-03-21T11:36:01.203Z",
    "user": 2,
    "content_type": 10,
    "object_id": "247",
    "object_repr": "Gsk2981278",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 591,
  "fields": {
    "action_time": "2025-03-21T11:38:36.290Z",
    "user": 2,
    "content_type": 10,
    "object_id": "247",
    "object_repr": "Gsk2981278",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 592,
  "fields": {
    "action_time": "2025-03-21T11:41:31.767Z",
    "user": 2,
    "content_type": 9,
    "object_id": "135",
    "object_repr": "This inhibition of TRPV4-mediated signaling can affect downstream pathways involved in the regulation of the circadian clock.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 593,
  "fields": {
    "action_time": "2025-03-21T11:41:48.419Z",
    "user": 2,
    "content_type": 12,
    "object_id": "88",
    "object_repr": "TRPV4 Channel",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 594,
  "fields": {
    "action_time": "2025-03-21T11:41:51.413Z",
    "user": 2,
    "content_type": 10,
    "object_id": "248",
    "object_repr": "RN-1734",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 595,
  "fields": {
    "action_time": "2025-03-21T11:45:59.605Z",
    "user": 2,
    "content_type": 10,
    "object_id": "249",
    "object_repr": "HC067047",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 596,
  "fields": {
    "action_time": "2025-03-21T11:52:56.227Z",
    "user": 2,
    "content_type": 9,
    "object_id": "136",
    "object_repr": "Inhibits CKIδ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 597,
  "fields": {
    "action_time": "2025-03-21T11:53:02.080Z",
    "user": 2,
    "content_type": 9,
    "object_id": "137",
    "object_repr": "Stabilizes PER Proteins",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 598,
  "fields": {
    "action_time": "2025-03-21T11:54:04.965Z",
    "user": 2,
    "content_type": 12,
    "object_id": "89",
    "object_repr": "CKI delta",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 599,
  "fields": {
    "action_time": "2025-03-21T11:54:10.588Z",
    "user": 2,
    "content_type": 10,
    "object_id": "250",
    "object_repr": "Longdaysin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 600,
  "fields": {
    "action_time": "2025-03-21T11:57:45.359Z",
    "user": 2,
    "content_type": 9,
    "object_id": "138",
    "object_repr": "Selective GSK-3β Inhibition:",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 601,
  "fields": {
    "action_time": "2025-03-21T11:58:03.157Z",
    "user": 2,
    "content_type": 9,
    "object_id": "139",
    "object_repr": "Circadian Clock Impact",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 602,
  "fields": {
    "action_time": "2025-03-21T11:58:37.937Z",
    "user": 2,
    "content_type": 10,
    "object_id": "251",
    "object_repr": "BRD1652",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 603,
  "fields": {
    "action_time": "2025-03-21T12:03:01.578Z",
    "user": 2,
    "content_type": 9,
    "object_id": "140",
    "object_repr": "CK1 Inhibition",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 604,
  "fields": {
    "action_time": "2025-03-21T12:06:48.001Z",
    "user": 2,
    "content_type": 10,
    "object_id": "252",
    "object_repr": "DK325",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 605,
  "fields": {
    "action_time": "2025-03-21T12:09:36.335Z",
    "user": 2,
    "content_type": 10,
    "object_id": "253",
    "object_repr": "PF-4800567",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 606,
  "fields": {
    "action_time": "2025-03-21T12:15:30.488Z",
    "user": 2,
    "content_type": 9,
    "object_id": "141",
    "object_repr": "Binds to the ATP‑binding site of CK2",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 607,
  "fields": {
    "action_time": "2025-03-21T12:16:11.604Z",
    "user": 2,
    "content_type": 10,
    "object_id": "254",
    "object_repr": "DK359",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 608,
  "fields": {
    "action_time": "2025-03-21T12:16:57.454Z",
    "user": 2,
    "content_type": 10,
    "object_id": "255",
    "object_repr": "CX-4945",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 609,
  "fields": {
    "action_time": "2025-03-21T12:20:22.471Z",
    "user": 2,
    "content_type": 10,
    "object_id": "256",
    "object_repr": "LH846",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 610,
  "fields": {
    "action_time": "2025-03-21T12:20:37.254Z",
    "user": 2,
    "content_type": 10,
    "object_id": "255",
    "object_repr": "CX-4945",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 611,
  "fields": {
    "action_time": "2025-03-21T12:24:47.949Z",
    "user": 2,
    "content_type": 9,
    "object_id": "142",
    "object_repr": "Activation of activin receptor-like kinase (ALK)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 612,
  "fields": {
    "action_time": "2025-03-21T12:24:59.792Z",
    "user": 2,
    "content_type": 9,
    "object_id": "143",
    "object_repr": "by an immediate-early induction of Dec1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 613,
  "fields": {
    "action_time": "2025-03-21T12:26:13.521Z",
    "user": 2,
    "content_type": 12,
    "object_id": "90",
    "object_repr": "Dec1 gene expression",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 614,
  "fields": {
    "action_time": "2025-03-21T12:27:03.126Z",
    "user": 2,
    "content_type": 10,
    "object_id": "257",
    "object_repr": "4-(4-(benzo[d][1,3]dioxol-5-yl)-5-(pyridin-2-yl)-1H-imidazol-2-yl)benzamide",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 615,
  "fields": {
    "action_time": "2025-03-21T12:31:11.424Z",
    "user": 2,
    "content_type": 9,
    "object_id": "144",
    "object_repr": "inhibits glycogen synthase kinase-3β (GSK-3β)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 616,
  "fields": {
    "action_time": "2025-03-21T12:32:45.317Z",
    "user": 2,
    "content_type": 10,
    "object_id": "258",
    "object_repr": "Li",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 617,
  "fields": {
    "action_time": "2025-03-21T12:32:59.215Z",
    "user": 2,
    "content_type": 10,
    "object_id": "258",
    "object_repr": "Li (Lithium)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 618,
  "fields": {
    "action_time": "2025-03-21T12:39:09.336Z",
    "user": 2,
    "content_type": 9,
    "object_id": "145",
    "object_repr": "Non-specific kinase inhibitor",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 619,
  "fields": {
    "action_time": "2025-03-21T12:40:16.009Z",
    "user": 2,
    "content_type": 10,
    "object_id": "259",
    "object_repr": "PF670462",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 620,
  "fields": {
    "action_time": "2025-03-21T12:40:49.109Z",
    "user": 2,
    "content_type": 10,
    "object_id": "245",
    "object_repr": "AZD-0284e",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 621,
  "fields": {
    "action_time": "2025-03-21T12:47:01.620Z",
    "user": 2,
    "content_type": 10,
    "object_id": "260",
    "object_repr": "1-Azakenpaullone",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 622,
  "fields": {
    "action_time": "2025-03-21T12:51:27.117Z",
    "user": 2,
    "content_type": 10,
    "object_id": "261",
    "object_repr": "Indirubin (Couroupitine B)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 623,
  "fields": {
    "action_time": "2025-03-21T12:56:13.984Z",
    "user": 2,
    "content_type": 10,
    "object_id": "262",
    "object_repr": "CHIR99021 (Laduviglusib)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 624,
  "fields": {
    "action_time": "2025-03-22T07:45:36.802Z",
    "user": 2,
    "content_type": 9,
    "object_id": "146",
    "object_repr": "Unknown metabolites",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 625,
  "fields": {
    "action_time": "2025-03-22T07:46:12.677Z",
    "user": 2,
    "content_type": 12,
    "object_id": "91",
    "object_repr": "GUT MICROBIOTA",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 626,
  "fields": {
    "action_time": "2025-03-22T07:46:22.239Z",
    "user": 2,
    "content_type": 10,
    "object_id": "263",
    "object_repr": "Bifidobacterium breve CCFM1025",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 627,
  "fields": {
    "action_time": "2025-03-22T07:50:17.011Z",
    "user": 2,
    "content_type": 9,
    "object_id": "147",
    "object_repr": "TIMELESS",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 628,
  "fields": {
    "action_time": "2025-03-22T07:51:50.060Z",
    "user": 2,
    "content_type": 12,
    "object_id": "92",
    "object_repr": "TIMELESS",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 629,
  "fields": {
    "action_time": "2025-03-22T07:54:22.914Z",
    "user": 2,
    "content_type": 7,
    "object_id": "11",
    "object_repr": "Probiotic",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 630,
  "fields": {
    "action_time": "2025-03-22T07:54:26.566Z",
    "user": 2,
    "content_type": 10,
    "object_id": "264",
    "object_repr": "OMNi-BiOTiC® Stress Repair",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 631,
  "fields": {
    "action_time": "2025-03-22T07:54:45.249Z",
    "user": 2,
    "content_type": 10,
    "object_id": "263",
    "object_repr": "Bifidobacterium breve CCFM1025",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Classf\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 632,
  "fields": {
    "action_time": "2025-03-22T07:59:10.388Z",
    "user": 2,
    "content_type": 10,
    "object_id": "265",
    "object_repr": "Lactobacillus delbrueckii",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 633,
  "fields": {
    "action_time": "2025-03-22T08:02:27.763Z",
    "user": 2,
    "content_type": 7,
    "object_id": "12",
    "object_repr": "prebiotic",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 634,
  "fields": {
    "action_time": "2025-03-22T08:03:47.553Z",
    "user": 2,
    "content_type": 12,
    "object_id": "93",
    "object_repr": "CLOCK gene expression",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 635,
  "fields": {
    "action_time": "2025-03-22T08:04:18.724Z",
    "user": 2,
    "content_type": 10,
    "object_id": "266",
    "object_repr": "Urolithin A",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 636,
  "fields": {
    "action_time": "2025-03-22T08:10:31.716Z",
    "user": 2,
    "content_type": 9,
    "object_id": "148",
    "object_repr": "Affects heme",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 637,
  "fields": {
    "action_time": "2025-03-22T08:11:17.257Z",
    "user": 2,
    "content_type": 9,
    "object_id": "149",
    "object_repr": "Affects heme biosynthesis",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 638,
  "fields": {
    "action_time": "2025-03-22T08:11:26.890Z",
    "user": 2,
    "content_type": 12,
    "object_id": "94",
    "object_repr": "Heme",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 639,
  "fields": {
    "action_time": "2025-03-22T08:12:48.214Z",
    "user": 2,
    "content_type": 10,
    "object_id": "267",
    "object_repr": "Griseofulvin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 640,
  "fields": {
    "action_time": "2025-03-22T08:27:33.119Z",
    "user": 2,
    "content_type": 12,
    "object_id": "95",
    "object_repr": "CCA1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 641,
  "fields": {
    "action_time": "2025-03-22T08:29:38.483Z",
    "user": 2,
    "content_type": 9,
    "object_id": "150",
    "object_repr": "Orexin Receptor Antagonism",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 642,
  "fields": {
    "action_time": "2025-03-22T08:30:05.110Z",
    "user": 2,
    "content_type": 12,
    "object_id": "96",
    "object_repr": "orexin receptor subtypes (OX1 and OX2)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 643,
  "fields": {
    "action_time": "2025-03-22T08:30:07.414Z",
    "user": 2,
    "content_type": 10,
    "object_id": "268",
    "object_repr": "HTL‑6641",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 644,
  "fields": {
    "action_time": "2025-03-22T08:31:16.794Z",
    "user": 2,
    "content_type": 9,
    "object_id": "151",
    "object_repr": "PRR",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 645,
  "fields": {
    "action_time": "2025-03-22T08:31:23.593Z",
    "user": 2,
    "content_type": 10,
    "object_id": "269",
    "object_repr": "(TU-892)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 646,
  "fields": {
    "action_time": "2025-03-22T08:31:41.282Z",
    "user": 2,
    "content_type": 10,
    "object_id": "269",
    "object_repr": "TU-892 (5-(3,4-dichlorophenyl)-1-phenyl-1,7-dihydro-4H-pyrazolo[3,4-d] pyrimidine-4,6(5H)-dione)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 647,
  "fields": {
    "action_time": "2025-03-22T08:35:35.221Z",
    "user": 2,
    "content_type": 9,
    "object_id": "152",
    "object_repr": "p38 signaling",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 648,
  "fields": {
    "action_time": "2025-03-22T08:36:29.291Z",
    "user": 2,
    "content_type": 12,
    "object_id": "97",
    "object_repr": "p38 kinase",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 649,
  "fields": {
    "action_time": "2025-03-22T08:36:51.989Z",
    "user": 2,
    "content_type": 10,
    "object_id": "270",
    "object_repr": "SB203580 (152121-47-6; SB 203580; SB-203580; SB203580; Adezmapimod)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 650,
  "fields": {
    "action_time": "2025-03-22T09:32:13.594Z",
    "user": 2,
    "content_type": 9,
    "object_id": "153",
    "object_repr": "Orexin Receptor Blockade",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 651,
  "fields": {
    "action_time": "2025-03-22T09:32:21.545Z",
    "user": 2,
    "content_type": 10,
    "object_id": "271",
    "object_repr": "ACT‑462206",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 652,
  "fields": {
    "action_time": "2025-03-22T09:42:53.066Z",
    "user": 2,
    "content_type": 9,
    "object_id": "154",
    "object_repr": "OX₁ Receptor Blockade",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 653,
  "fields": {
    "action_time": "2025-03-22T09:42:57.074Z",
    "user": 2,
    "content_type": 10,
    "object_id": "272",
    "object_repr": "GSK1059865",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 654,
  "fields": {
    "action_time": "2025-03-22T09:50:37.350Z",
    "user": 2,
    "content_type": 9,
    "object_id": "155",
    "object_repr": "OX₁R Antagonism",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 655,
  "fields": {
    "action_time": "2025-03-22T09:50:46.808Z",
    "user": 2,
    "content_type": 10,
    "object_id": "273",
    "object_repr": "SB-334867",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 656,
  "fields": {
    "action_time": "2025-03-22T09:55:03.827Z",
    "user": 2,
    "content_type": 10,
    "object_id": "274",
    "object_repr": "SB-408124",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 657,
  "fields": {
    "action_time": "2025-03-22T09:59:42.310Z",
    "user": 2,
    "content_type": 9,
    "object_id": "156",
    "object_repr": "OX₂R Activation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 658,
  "fields": {
    "action_time": "2025-03-22T09:59:54.784Z",
    "user": 2,
    "content_type": 10,
    "object_id": "275",
    "object_repr": "TAK‑925",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 659,
  "fields": {
    "action_time": "2025-03-22T10:06:22.405Z",
    "user": 2,
    "content_type": 9,
    "object_id": "157",
    "object_repr": "Affects \"Circadian rhtyhm signaling\"",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 660,
  "fields": {
    "action_time": "2025-03-22T10:06:52.027Z",
    "user": 2,
    "content_type": 9,
    "object_id": "158",
    "object_repr": "Calcium signaling",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 661,
  "fields": {
    "action_time": "2025-03-22T10:07:12.181Z",
    "user": 2,
    "content_type": 9,
    "object_id": "159",
    "object_repr": "Glutamat receptor signaling",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 662,
  "fields": {
    "action_time": "2025-03-22T10:08:25.785Z",
    "user": 2,
    "content_type": 9,
    "object_id": "160",
    "object_repr": "Corticosteroid Hormone Receptor Agonist",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 663,
  "fields": {
    "action_time": "2025-03-22T10:09:16.872Z",
    "user": 2,
    "content_type": 12,
    "object_id": "98",
    "object_repr": "Corticosteroid hormone receptor",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 664,
  "fields": {
    "action_time": "2025-03-22T10:10:15.666Z",
    "user": 2,
    "content_type": 10,
    "object_id": "276",
    "object_repr": "triamcinolone",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 665,
  "fields": {
    "action_time": "2025-03-22T10:16:49.028Z",
    "user": 2,
    "content_type": 9,
    "object_id": "161",
    "object_repr": "Glucocorticoid Signaling",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 666,
  "fields": {
    "action_time": "2025-03-22T10:17:13.093Z",
    "user": 2,
    "content_type": 10,
    "object_id": "277",
    "object_repr": "Dexamethasone",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 667,
  "fields": {
    "action_time": "2025-03-22T10:41:57.856Z",
    "user": 2,
    "content_type": 10,
    "object_id": "278",
    "object_repr": "Prednisolone",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 668,
  "fields": {
    "action_time": "2025-03-22T10:43:27.191Z",
    "user": 2,
    "content_type": 10,
    "object_id": "276",
    "object_repr": "Triamcinolone (acetonide)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 669,
  "fields": {
    "action_time": "2025-03-22T10:47:57.265Z",
    "user": 2,
    "content_type": 9,
    "object_id": "162",
    "object_repr": "influences HPA axis",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 670,
  "fields": {
    "action_time": "2025-03-22T10:50:35.011Z",
    "user": 2,
    "content_type": 10,
    "object_id": "279",
    "object_repr": "Aldosterone",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 671,
  "fields": {
    "action_time": "2025-03-22T10:51:36.437Z",
    "user": 2,
    "content_type": 10,
    "object_id": "6",
    "object_repr": "Resveratrol",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 672,
  "fields": {
    "action_time": "2025-03-22T11:09:04.023Z",
    "user": 2,
    "content_type": 9,
    "object_id": "163",
    "object_repr": "Glucocorticoid receptors",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 673,
  "fields": {
    "action_time": "2025-03-22T11:10:06.964Z",
    "user": 2,
    "content_type": 10,
    "object_id": "280",
    "object_repr": "Hydrocortisone (Cortisole",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 674,
  "fields": {
    "action_time": "2025-03-22T11:10:18.427Z",
    "user": 2,
    "content_type": 10,
    "object_id": "280",
    "object_repr": "Hydrocortisone (Cortisole)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 675,
  "fields": {
    "action_time": "2025-03-24T10:59:14.217Z",
    "user": 2,
    "content_type": 10,
    "object_id": "281",
    "object_repr": "IIK7",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 676,
  "fields": {
    "action_time": "2025-03-24T11:47:06.898Z",
    "user": 2,
    "content_type": 10,
    "object_id": "282",
    "object_repr": "UCSF7447",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 677,
  "fields": {
    "action_time": "2025-03-25T07:39:08.176Z",
    "user": 2,
    "content_type": 10,
    "object_id": "8",
    "object_repr": "Melatonin",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 678,
  "fields": {
    "action_time": "2025-03-26T13:30:37.037Z",
    "user": 2,
    "content_type": 10,
    "object_id": "283",
    "object_repr": "MORICIZINE",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 679,
  "fields": {
    "action_time": "2025-03-26T13:35:56.630Z",
    "user": 2,
    "content_type": 12,
    "object_id": "99",
    "object_repr": "Per 1 expression (gene)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 680,
  "fields": {
    "action_time": "2025-03-26T13:36:31.363Z",
    "user": 2,
    "content_type": 12,
    "object_id": "100",
    "object_repr": "Per 1 (Rat gene)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 681,
  "fields": {
    "action_time": "2025-03-26T13:37:03.780Z",
    "user": 2,
    "content_type": 12,
    "object_id": "101",
    "object_repr": "Per 2 (gene Rat)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 682,
  "fields": {
    "action_time": "2025-03-26T13:37:14.144Z",
    "user": 2,
    "content_type": 10,
    "object_id": "284",
    "object_repr": "Forskolin (Colforsin)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 683,
  "fields": {
    "action_time": "2025-03-27T12:24:20.053Z",
    "user": 2,
    "content_type": 10,
    "object_id": "285",
    "object_repr": "Sudachitin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 684,
  "fields": {
    "action_time": "2025-03-27T12:24:56.896Z",
    "user": 2,
    "content_type": 10,
    "object_id": "285",
    "object_repr": "Sudachitin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 685,
  "fields": {
    "action_time": "2025-03-28T12:34:10.940Z",
    "user": 2,
    "content_type": 9,
    "object_id": "164",
    "object_repr": "Binding with factors affine to Period2 gene promoter",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 686,
  "fields": {
    "action_time": "2025-03-28T12:34:15.813Z",
    "user": 2,
    "content_type": 10,
    "object_id": "286",
    "object_repr": "cyclocybelide",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 687,
  "fields": {
    "action_time": "2025-03-28T12:34:24.002Z",
    "user": 2,
    "content_type": 10,
    "object_id": "286",
    "object_repr": "Cyclocybelide",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 688,
  "fields": {
    "action_time": "2025-03-28T12:39:31.542Z",
    "user": 2,
    "content_type": 10,
    "object_id": "286",
    "object_repr": "Cyclocybelide",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 689,
  "fields": {
    "action_time": "2025-03-28T12:49:37.261Z",
    "user": 2,
    "content_type": 10,
    "object_id": "287",
    "object_repr": "A190",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 690,
  "fields": {
    "action_time": "2025-03-28T12:54:42.548Z",
    "user": 2,
    "content_type": 12,
    "object_id": "102",
    "object_repr": "BMAL1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 691,
  "fields": {
    "action_time": "2025-03-28T12:54:50.112Z",
    "user": 2,
    "content_type": 10,
    "object_id": "288",
    "object_repr": "A340",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 692,
  "fields": {
    "action_time": "2025-03-28T12:54:57.707Z",
    "user": 2,
    "content_type": 10,
    "object_id": "287",
    "object_repr": "A190",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Target\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 693,
  "fields": {
    "action_time": "2025-03-28T12:55:52.454Z",
    "user": 2,
    "content_type": 10,
    "object_id": "287",
    "object_repr": "A190",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 694,
  "fields": {
    "action_time": "2025-03-28T12:56:05.541Z",
    "user": 2,
    "content_type": 10,
    "object_id": "288",
    "object_repr": "A340",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 695,
  "fields": {
    "action_time": "2025-03-28T13:01:08.669Z",
    "user": 2,
    "content_type": 10,
    "object_id": "289",
    "object_repr": "Core Circadian Modulator (CCM)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 696,
  "fields": {
    "action_time": "2025-03-28T13:01:17.234Z",
    "user": 2,
    "content_type": 10,
    "object_id": "289",
    "object_repr": "Core Circadian Modulator (CCM)",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 697,
  "fields": {
    "action_time": "2025-03-28T13:10:04.549Z",
    "user": 2,
    "content_type": 10,
    "object_id": "289",
    "object_repr": "Core Circadian Modulator (CCM)",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 698,
  "fields": {
    "action_time": "2025-03-28T14:34:49.865Z",
    "user": 1,
    "content_type": 10,
    "object_id": "7",
    "object_repr": "Rosiglitazone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 699,
  "fields": {
    "action_time": "2025-03-29T07:37:03.528Z",
    "user": 2,
    "content_type": 10,
    "object_id": "7",
    "object_repr": "Rosiglitazone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Article\", \"Linkslists\", \"Target\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 700,
  "fields": {
    "action_time": "2025-04-01T07:47:03.013Z",
    "user": 2,
    "content_type": 10,
    "object_id": "285",
    "object_repr": "Sudachitin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 701,
  "fields": {
    "action_time": "2025-04-01T07:48:02.571Z",
    "user": 2,
    "content_type": 10,
    "object_id": "284",
    "object_repr": "Forskolin (Colforsin)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 702,
  "fields": {
    "action_time": "2025-04-01T07:48:26.942Z",
    "user": 2,
    "content_type": 10,
    "object_id": "283",
    "object_repr": "MORICIZINE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 703,
  "fields": {
    "action_time": "2025-04-01T07:48:46.982Z",
    "user": 2,
    "content_type": 10,
    "object_id": "282",
    "object_repr": "UCSF7447",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 704,
  "fields": {
    "action_time": "2025-04-01T07:49:05.086Z",
    "user": 2,
    "content_type": 10,
    "object_id": "281",
    "object_repr": "IIK7",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 705,
  "fields": {
    "action_time": "2025-04-01T07:49:41.290Z",
    "user": 2,
    "content_type": 10,
    "object_id": "280",
    "object_repr": "Hydrocortisone (Cortisole)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 706,
  "fields": {
    "action_time": "2025-04-01T07:50:03.819Z",
    "user": 2,
    "content_type": 10,
    "object_id": "279",
    "object_repr": "Aldosterone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 707,
  "fields": {
    "action_time": "2025-04-01T07:50:26.090Z",
    "user": 2,
    "content_type": 10,
    "object_id": "278",
    "object_repr": "Prednisolone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 708,
  "fields": {
    "action_time": "2025-04-01T07:51:04.088Z",
    "user": 2,
    "content_type": 10,
    "object_id": "277",
    "object_repr": "Dexamethasone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 709,
  "fields": {
    "action_time": "2025-04-01T07:51:26.496Z",
    "user": 2,
    "content_type": 10,
    "object_id": "276",
    "object_repr": "Triamcinolone (acetonide)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 710,
  "fields": {
    "action_time": "2025-04-01T07:52:23.581Z",
    "user": 2,
    "content_type": 10,
    "object_id": "274",
    "object_repr": "SB-408124",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 711,
  "fields": {
    "action_time": "2025-04-01T07:52:40.121Z",
    "user": 2,
    "content_type": 10,
    "object_id": "273",
    "object_repr": "SB-334867",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 712,
  "fields": {
    "action_time": "2025-04-01T07:54:23.605Z",
    "user": 2,
    "content_type": 10,
    "object_id": "267",
    "object_repr": "Griseofulvin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 713,
  "fields": {
    "action_time": "2025-04-01T07:55:06.662Z",
    "user": 2,
    "content_type": 10,
    "object_id": "266",
    "object_repr": "Urolithin A",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 714,
  "fields": {
    "action_time": "2025-04-01T07:56:15.083Z",
    "user": 2,
    "content_type": 10,
    "object_id": "261",
    "object_repr": "Indirubin (Couroupitine B)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 715,
  "fields": {
    "action_time": "2025-04-01T07:56:38.181Z",
    "user": 2,
    "content_type": 10,
    "object_id": "260",
    "object_repr": "1-Azakenpaullone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 716,
  "fields": {
    "action_time": "2025-04-01T07:57:11.181Z",
    "user": 2,
    "content_type": 10,
    "object_id": "259",
    "object_repr": "PF670462",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 717,
  "fields": {
    "action_time": "2025-04-01T07:57:59.198Z",
    "user": 2,
    "content_type": 10,
    "object_id": "258",
    "object_repr": "Li (Lithium)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 718,
  "fields": {
    "action_time": "2025-04-01T07:58:11.628Z",
    "user": 2,
    "content_type": 10,
    "object_id": "260",
    "object_repr": "1-Azakenpaullone",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 719,
  "fields": {
    "action_time": "2025-04-01T07:58:37.801Z",
    "user": 2,
    "content_type": 10,
    "object_id": "256",
    "object_repr": "LH846",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 720,
  "fields": {
    "action_time": "2025-04-01T08:00:59.959Z",
    "user": 2,
    "content_type": 10,
    "object_id": "255",
    "object_repr": "CX-4945",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 721,
  "fields": {
    "action_time": "2025-04-01T08:01:24.240Z",
    "user": 2,
    "content_type": 10,
    "object_id": "253",
    "object_repr": "PF-4800567",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 722,
  "fields": {
    "action_time": "2025-04-01T08:02:14.497Z",
    "user": 2,
    "content_type": 10,
    "object_id": "251",
    "object_repr": "BRD1652",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 723,
  "fields": {
    "action_time": "2025-04-01T08:02:31.786Z",
    "user": 2,
    "content_type": 10,
    "object_id": "250",
    "object_repr": "Longdaysin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 724,
  "fields": {
    "action_time": "2025-04-01T08:03:08.200Z",
    "user": 2,
    "content_type": 10,
    "object_id": "249",
    "object_repr": "HC067047",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 725,
  "fields": {
    "action_time": "2025-04-01T08:03:36.092Z",
    "user": 2,
    "content_type": 10,
    "object_id": "248",
    "object_repr": "RN-1734",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 726,
  "fields": {
    "action_time": "2025-04-01T08:04:01.849Z",
    "user": 2,
    "content_type": 10,
    "object_id": "247",
    "object_repr": "Gsk2981278",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 727,
  "fields": {
    "action_time": "2025-04-01T08:04:25.736Z",
    "user": 2,
    "content_type": 10,
    "object_id": "246",
    "object_repr": "Cintirorgon",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 728,
  "fields": {
    "action_time": "2025-04-01T08:04:53.911Z",
    "user": 2,
    "content_type": 10,
    "object_id": "244",
    "object_repr": "ARN-6039",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 729,
  "fields": {
    "action_time": "2025-04-01T08:05:29.320Z",
    "user": 2,
    "content_type": 10,
    "object_id": "242",
    "object_repr": "Ursolic acid",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 730,
  "fields": {
    "action_time": "2025-04-01T08:07:45.952Z",
    "user": 2,
    "content_type": 10,
    "object_id": "241",
    "object_repr": "Digoxin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 731,
  "fields": {
    "action_time": "2025-04-01T08:08:05.506Z",
    "user": 2,
    "content_type": 10,
    "object_id": "239",
    "object_repr": "Neoruscogenin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 732,
  "fields": {
    "action_time": "2025-04-01T08:08:29.646Z",
    "user": 2,
    "content_type": 10,
    "object_id": "238",
    "object_repr": "Nobiletin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 733,
  "fields": {
    "action_time": "2025-04-01T08:09:44.140Z",
    "user": 2,
    "content_type": 10,
    "object_id": "237",
    "object_repr": "BIBP3226",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 734,
  "fields": {
    "action_time": "2025-04-01T08:10:04.206Z",
    "user": 2,
    "content_type": 10,
    "object_id": "236",
    "object_repr": "BIBO 3304 trifluoroacetate",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 735,
  "fields": {
    "action_time": "2025-04-01T08:10:33.151Z",
    "user": 2,
    "content_type": 10,
    "object_id": "235",
    "object_repr": "Pterostilbene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 736,
  "fields": {
    "action_time": "2025-04-01T08:11:03.558Z",
    "user": 2,
    "content_type": 10,
    "object_id": "234",
    "object_repr": "SR9011",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 737,
  "fields": {
    "action_time": "2025-04-01T08:11:25.292Z",
    "user": 2,
    "content_type": 10,
    "object_id": "233",
    "object_repr": "SR9009",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 738,
  "fields": {
    "action_time": "2025-04-01T08:11:45.846Z",
    "user": 2,
    "content_type": 10,
    "object_id": "232",
    "object_repr": "GSK4112",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 739,
  "fields": {
    "action_time": "2025-04-01T08:12:04.236Z",
    "user": 2,
    "content_type": 10,
    "object_id": "231",
    "object_repr": "KK-S6",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 740,
  "fields": {
    "action_time": "2025-04-01T08:12:42.291Z",
    "user": 2,
    "content_type": 10,
    "object_id": "230",
    "object_repr": "Indeno[1,2,3-c,d]pyrene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 741,
  "fields": {
    "action_time": "2025-04-01T08:13:14.907Z",
    "user": 2,
    "content_type": 10,
    "object_id": "229",
    "object_repr": "BENZO(ghi)PERYLENE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 742,
  "fields": {
    "action_time": "2025-04-01T08:13:42.028Z",
    "user": 2,
    "content_type": 10,
    "object_id": "228",
    "object_repr": "Dibenzo[a,h]anthracene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 743,
  "fields": {
    "action_time": "2025-04-01T08:14:21.267Z",
    "user": 2,
    "content_type": 10,
    "object_id": "227",
    "object_repr": "Benzo[b]fluoranthene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 744,
  "fields": {
    "action_time": "2025-04-01T08:15:27.507Z",
    "user": 2,
    "content_type": 10,
    "object_id": "226",
    "object_repr": "Chrysene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 745,
  "fields": {
    "action_time": "2025-04-01T08:16:12.539Z",
    "user": 2,
    "content_type": 10,
    "object_id": "225",
    "object_repr": "Benzo[k]fluoranthene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 746,
  "fields": {
    "action_time": "2025-04-01T08:20:50.556Z",
    "user": 2,
    "content_type": 10,
    "object_id": "224",
    "object_repr": "Dibenzopyrene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 747,
  "fields": {
    "action_time": "2025-04-01T08:21:18.150Z",
    "user": 2,
    "content_type": 10,
    "object_id": "223",
    "object_repr": "Benz[a]anthracene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 748,
  "fields": {
    "action_time": "2025-04-01T08:21:41.089Z",
    "user": 2,
    "content_type": 10,
    "object_id": "222",
    "object_repr": "anthracene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 749,
  "fields": {
    "action_time": "2025-04-01T08:22:02.729Z",
    "user": 2,
    "content_type": 10,
    "object_id": "221",
    "object_repr": "naphthalene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 750,
  "fields": {
    "action_time": "2025-04-01T08:22:33.784Z",
    "user": 2,
    "content_type": 10,
    "object_id": "220",
    "object_repr": "LH-846",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 751,
  "fields": {
    "action_time": "2025-04-01T08:22:59.030Z",
    "user": 2,
    "content_type": 10,
    "object_id": "219",
    "object_repr": "Protoheme",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 752,
  "fields": {
    "action_time": "2025-04-01T08:23:20.769Z",
    "user": 2,
    "content_type": 10,
    "object_id": "218",
    "object_repr": "5,8-Quinoxalinedione",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 753,
  "fields": {
    "action_time": "2025-04-01T08:23:50.256Z",
    "user": 2,
    "content_type": 10,
    "object_id": "217",
    "object_repr": "CLK8",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 754,
  "fields": {
    "action_time": "2025-04-01T08:25:51.754Z",
    "user": 2,
    "content_type": 10,
    "object_id": "216",
    "object_repr": "Azakenpaullone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 755,
  "fields": {
    "action_time": "2025-04-01T08:26:15.350Z",
    "user": 2,
    "content_type": 10,
    "object_id": "215",
    "object_repr": "KS15",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 756,
  "fields": {
    "action_time": "2025-04-01T08:26:39.823Z",
    "user": 2,
    "content_type": 10,
    "object_id": "214",
    "object_repr": "KL001",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 757,
  "fields": {
    "action_time": "2025-04-01T08:27:03.028Z",
    "user": 2,
    "content_type": 10,
    "object_id": "213",
    "object_repr": "Irbesartan",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 758,
  "fields": {
    "action_time": "2025-04-01T08:27:26.414Z",
    "user": 2,
    "content_type": 10,
    "object_id": "212",
    "object_repr": "TRETINOIN",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 759,
  "fields": {
    "action_time": "2025-04-01T08:27:48.881Z",
    "user": 2,
    "content_type": 10,
    "object_id": "211",
    "object_repr": "THIOTEPA",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 760,
  "fields": {
    "action_time": "2025-04-01T08:28:09.873Z",
    "user": 2,
    "content_type": 10,
    "object_id": "210",
    "object_repr": "Tazarotene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 761,
  "fields": {
    "action_time": "2025-04-01T08:28:31.578Z",
    "user": 2,
    "content_type": 10,
    "object_id": "209",
    "object_repr": "Rabeprazole Sodium",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 762,
  "fields": {
    "action_time": "2025-04-01T08:28:50.732Z",
    "user": 2,
    "content_type": 10,
    "object_id": "208",
    "object_repr": "PODOFILOX",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 763,
  "fields": {
    "action_time": "2025-04-01T08:29:21.442Z",
    "user": 2,
    "content_type": 10,
    "object_id": "207",
    "object_repr": "PIMECROLIMUS",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 764,
  "fields": {
    "action_time": "2025-04-01T08:29:40.949Z",
    "user": 2,
    "content_type": 10,
    "object_id": "206",
    "object_repr": "PAZOPANIB HCL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 765,
  "fields": {
    "action_time": "2025-04-01T08:30:05.238Z",
    "user": 2,
    "content_type": 10,
    "object_id": "205",
    "object_repr": "NILOTINIB",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 766,
  "fields": {
    "action_time": "2025-04-01T08:30:33.763Z",
    "user": 2,
    "content_type": 10,
    "object_id": "204",
    "object_repr": "NEBIVOLOL HCL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 767,
  "fields": {
    "action_time": "2025-04-01T08:30:57.794Z",
    "user": 2,
    "content_type": 10,
    "object_id": "203",
    "object_repr": "MECLIZINE DIHYDROCHLORIDE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 768,
  "fields": {
    "action_time": "2025-04-01T08:31:30.346Z",
    "user": 2,
    "content_type": 10,
    "object_id": "202",
    "object_repr": "ISOTRETINOIN (13-CIS-RETINOIC ACID)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 769,
  "fields": {
    "action_time": "2025-04-01T08:33:02.130Z",
    "user": 2,
    "content_type": 10,
    "object_id": "201",
    "object_repr": "Irinotecan Hydrochloride",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 770,
  "fields": {
    "action_time": "2025-04-01T08:33:28.184Z",
    "user": 2,
    "content_type": 10,
    "object_id": "200",
    "object_repr": "EVEROLIMUS",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 771,
  "fields": {
    "action_time": "2025-04-01T08:34:14.096Z",
    "user": 2,
    "content_type": 10,
    "object_id": "199",
    "object_repr": "EPIRUBICIN HCL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 772,
  "fields": {
    "action_time": "2025-04-01T08:34:34.563Z",
    "user": 2,
    "content_type": 10,
    "object_id": "198",
    "object_repr": "DROSPIRENONE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 773,
  "fields": {
    "action_time": "2025-04-01T08:34:52.489Z",
    "user": 2,
    "content_type": 10,
    "object_id": "197",
    "object_repr": "Laduviglusib",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 774,
  "fields": {
    "action_time": "2025-04-01T08:35:11.295Z",
    "user": 2,
    "content_type": 10,
    "object_id": "196",
    "object_repr": "SB-202190",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 775,
  "fields": {
    "action_time": "2025-04-01T08:36:51.455Z",
    "user": 2,
    "content_type": 10,
    "object_id": "195",
    "object_repr": "AA41612",
    "action_flag": 3,
    "change_message": ""
  }
},
{
  "model": "admin.logentry",
  "pk": 776,
  "fields": {
    "action_time": "2025-04-01T08:37:52.477Z",
    "user": 2,
    "content_type": 10,
    "object_id": "194",
    "object_repr": "AA92593",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 777,
  "fields": {
    "action_time": "2025-04-01T08:38:16.541Z",
    "user": 2,
    "content_type": 10,
    "object_id": "193",
    "object_repr": "Deferasirox",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 778,
  "fields": {
    "action_time": "2025-04-01T08:38:41.100Z",
    "user": 2,
    "content_type": 10,
    "object_id": "192",
    "object_repr": "Dasatinib",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 779,
  "fields": {
    "action_time": "2025-04-01T08:39:03.287Z",
    "user": 2,
    "content_type": 10,
    "object_id": "191",
    "object_repr": "Clotrimazole",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 780,
  "fields": {
    "action_time": "2025-04-01T08:40:08.780Z",
    "user": 2,
    "content_type": 10,
    "object_id": "190",
    "object_repr": "Cladribine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 781,
  "fields": {
    "action_time": "2025-04-01T08:41:02.308Z",
    "user": 2,
    "content_type": 10,
    "object_id": "189",
    "object_repr": "CINACALCET HCL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 782,
  "fields": {
    "action_time": "2025-04-02T07:09:11.738Z",
    "user": 2,
    "content_type": 10,
    "object_id": "188",
    "object_repr": "CIDOFOVIR",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 783,
  "fields": {
    "action_time": "2025-04-02T07:09:33.607Z",
    "user": 2,
    "content_type": 10,
    "object_id": "187",
    "object_repr": "ARSENIC TRIOXIDE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 784,
  "fields": {
    "action_time": "2025-04-02T07:09:55.412Z",
    "user": 2,
    "content_type": 10,
    "object_id": "186",
    "object_repr": "Adefovir Dipivoxil",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 785,
  "fields": {
    "action_time": "2025-04-02T07:10:15.341Z",
    "user": 2,
    "content_type": 10,
    "object_id": "185",
    "object_repr": "Nelfinavir mesylate",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 786,
  "fields": {
    "action_time": "2025-04-02T07:10:34.142Z",
    "user": 2,
    "content_type": 10,
    "object_id": "184",
    "object_repr": "PROGESTERONE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 787,
  "fields": {
    "action_time": "2025-04-02T07:10:53.894Z",
    "user": 2,
    "content_type": 10,
    "object_id": "183",
    "object_repr": "Oxiconazole Nitrate",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 788,
  "fields": {
    "action_time": "2025-04-02T07:11:40.527Z",
    "user": 2,
    "content_type": 10,
    "object_id": "182",
    "object_repr": "NEFAZODONE HCL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Pubchem\", \"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 789,
  "fields": {
    "action_time": "2025-04-02T07:12:12.853Z",
    "user": 2,
    "content_type": 10,
    "object_id": "181",
    "object_repr": "Paclitaxel (TAXOL)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Pubchem\", \"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 790,
  "fields": {
    "action_time": "2025-04-02T07:12:56.818Z",
    "user": 2,
    "content_type": 10,
    "object_id": "180",
    "object_repr": "MITOXANTRONE HCL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 791,
  "fields": {
    "action_time": "2025-04-02T07:13:14.823Z",
    "user": 2,
    "content_type": 10,
    "object_id": "179",
    "object_repr": "CHLORAMBUCIL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 792,
  "fields": {
    "action_time": "2025-04-02T07:13:37.299Z",
    "user": 2,
    "content_type": 10,
    "object_id": "176",
    "object_repr": "Bexarotene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 793,
  "fields": {
    "action_time": "2025-04-02T07:16:21.524Z",
    "user": 2,
    "content_type": 10,
    "object_id": "175",
    "object_repr": "DAUNORUBICIN HCL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 794,
  "fields": {
    "action_time": "2025-04-02T07:16:50.519Z",
    "user": 2,
    "content_type": 10,
    "object_id": "174",
    "object_repr": "KETOCONAZOLE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 795,
  "fields": {
    "action_time": "2025-04-02T07:17:19.289Z",
    "user": 2,
    "content_type": 10,
    "object_id": "173",
    "object_repr": "CALCITRIOL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 796,
  "fields": {
    "action_time": "2025-04-02T07:17:47.360Z",
    "user": 2,
    "content_type": 10,
    "object_id": "172",
    "object_repr": "Acitretin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 797,
  "fields": {
    "action_time": "2025-04-02T07:18:13.578Z",
    "user": 2,
    "content_type": 10,
    "object_id": "171",
    "object_repr": "Bromocriptine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 798,
  "fields": {
    "action_time": "2025-04-02T07:18:42.935Z",
    "user": 2,
    "content_type": 10,
    "object_id": "170",
    "object_repr": "Felodipine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 799,
  "fields": {
    "action_time": "2025-04-02T07:19:03.758Z",
    "user": 2,
    "content_type": 10,
    "object_id": "169",
    "object_repr": "Erlotinib",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 800,
  "fields": {
    "action_time": "2025-04-02T07:20:14.336Z",
    "user": 2,
    "content_type": 10,
    "object_id": "167",
    "object_repr": "SERTACONAZOLE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 801,
  "fields": {
    "action_time": "2025-04-02T07:21:03.946Z",
    "user": 2,
    "content_type": 10,
    "object_id": "166",
    "object_repr": "RAPAMYCIN",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 802,
  "fields": {
    "action_time": "2025-04-02T07:21:39.114Z",
    "user": 2,
    "content_type": 10,
    "object_id": "165",
    "object_repr": "Hydroxyprogesterone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 803,
  "fields": {
    "action_time": "2025-04-02T07:21:58.447Z",
    "user": 2,
    "content_type": 10,
    "object_id": "164",
    "object_repr": "Artenimol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 804,
  "fields": {
    "action_time": "2025-04-02T07:22:51.197Z",
    "user": 2,
    "content_type": 10,
    "object_id": "163",
    "object_repr": "Nitroxoline",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 805,
  "fields": {
    "action_time": "2025-04-02T07:24:17.931Z",
    "user": 2,
    "content_type": 10,
    "object_id": "162",
    "object_repr": "Clorgyline hydrochloride",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 806,
  "fields": {
    "action_time": "2025-04-02T08:01:24.631Z",
    "user": 2,
    "content_type": 10,
    "object_id": "161",
    "object_repr": "Cyproterone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 807,
  "fields": {
    "action_time": "2025-04-02T08:01:46.463Z",
    "user": 2,
    "content_type": 10,
    "object_id": "160",
    "object_repr": "Metergoline",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 808,
  "fields": {
    "action_time": "2025-04-02T08:02:12.245Z",
    "user": 2,
    "content_type": 10,
    "object_id": "159",
    "object_repr": "Nadifloxacin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 809,
  "fields": {
    "action_time": "2025-04-02T08:02:34.125Z",
    "user": 2,
    "content_type": 10,
    "object_id": "158",
    "object_repr": "Protoporphyrin IX",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 810,
  "fields": {
    "action_time": "2025-04-02T08:02:55.700Z",
    "user": 2,
    "content_type": 10,
    "object_id": "157",
    "object_repr": "Berberine Chloride",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 811,
  "fields": {
    "action_time": "2025-04-02T08:03:14.729Z",
    "user": 2,
    "content_type": 10,
    "object_id": "156",
    "object_repr": "DEQUALINIUM CHLORIDE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 812,
  "fields": {
    "action_time": "2025-04-02T08:03:56.575Z",
    "user": 2,
    "content_type": 10,
    "object_id": "155",
    "object_repr": "Loprazolam",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 813,
  "fields": {
    "action_time": "2025-04-02T08:04:13.875Z",
    "user": 2,
    "content_type": 10,
    "object_id": "154",
    "object_repr": "Nitrazepam",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 814,
  "fields": {
    "action_time": "2025-04-02T08:04:32.217Z",
    "user": 2,
    "content_type": 10,
    "object_id": "153",
    "object_repr": "Lormetazepam",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 815,
  "fields": {
    "action_time": "2025-04-02T08:06:10.630Z",
    "user": 2,
    "content_type": 10,
    "object_id": "150",
    "object_repr": "Silenor (doxepin)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 816,
  "fields": {
    "action_time": "2025-04-02T08:06:39.442Z",
    "user": 2,
    "content_type": 10,
    "object_id": "149",
    "object_repr": "Seconal (secobarbital)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 817,
  "fields": {
    "action_time": "2025-04-02T08:07:13.032Z",
    "user": 2,
    "content_type": 10,
    "object_id": "148",
    "object_repr": "Restoril (temazepam)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 818,
  "fields": {
    "action_time": "2025-04-02T08:07:37.513Z",
    "user": 2,
    "content_type": 10,
    "object_id": "147",
    "object_repr": "Halcion (triazolam)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 819,
  "fields": {
    "action_time": "2025-04-02T08:08:24.467Z",
    "user": 2,
    "content_type": 10,
    "object_id": "146",
    "object_repr": "Flurazepam",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 820,
  "fields": {
    "action_time": "2025-04-02T08:08:47.438Z",
    "user": 2,
    "content_type": 10,
    "object_id": "145",
    "object_repr": "Fluconazole",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 821,
  "fields": {
    "action_time": "2025-04-02T08:09:08.287Z",
    "user": 2,
    "content_type": 10,
    "object_id": "144",
    "object_repr": "Estazolam",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 822,
  "fields": {
    "action_time": "2025-04-02T08:09:35.186Z",
    "user": 2,
    "content_type": 10,
    "object_id": "143",
    "object_repr": "Doral (quazepam)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 823,
  "fields": {
    "action_time": "2025-04-02T08:09:57.472Z",
    "user": 2,
    "content_type": 10,
    "object_id": "142",
    "object_repr": "Butisol (butabarbital)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 824,
  "fields": {
    "action_time": "2025-04-02T08:10:19.607Z",
    "user": 2,
    "content_type": 10,
    "object_id": "141",
    "object_repr": "Chloral hydrate",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 825,
  "fields": {
    "action_time": "2025-04-02T08:10:52.098Z",
    "user": 2,
    "content_type": 10,
    "object_id": "140",
    "object_repr": "BAY 60-6583",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 826,
  "fields": {
    "action_time": "2025-04-02T08:11:16.967Z",
    "user": 2,
    "content_type": 10,
    "object_id": "139",
    "object_repr": "Zopiclone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 827,
  "fields": {
    "action_time": "2025-04-02T08:11:48.322Z",
    "user": 2,
    "content_type": 10,
    "object_id": "138",
    "object_repr": "Adenosine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 828,
  "fields": {
    "action_time": "2025-04-02T08:12:12.070Z",
    "user": 2,
    "content_type": 10,
    "object_id": "137",
    "object_repr": "Promethazine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 829,
  "fields": {
    "action_time": "2025-04-02T08:12:36.595Z",
    "user": 2,
    "content_type": 10,
    "object_id": "136",
    "object_repr": "Filorexant",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 830,
  "fields": {
    "action_time": "2025-04-02T08:12:56.250Z",
    "user": 2,
    "content_type": 10,
    "object_id": "135",
    "object_repr": "Zaleplon",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 831,
  "fields": {
    "action_time": "2025-04-02T08:13:13.396Z",
    "user": 2,
    "content_type": 10,
    "object_id": "134",
    "object_repr": "Daridorexant",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 832,
  "fields": {
    "action_time": "2025-04-02T08:13:31.665Z",
    "user": 2,
    "content_type": 10,
    "object_id": "133",
    "object_repr": "Dexmedetomidine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 833,
  "fields": {
    "action_time": "2025-04-02T08:14:00.348Z",
    "user": 2,
    "content_type": 10,
    "object_id": "132",
    "object_repr": "Lemborexant",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 834,
  "fields": {
    "action_time": "2025-04-02T08:14:22.924Z",
    "user": 2,
    "content_type": 10,
    "object_id": "131",
    "object_repr": "Hydroxyzine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 835,
  "fields": {
    "action_time": "2025-04-02T08:14:38.699Z",
    "user": 2,
    "content_type": 10,
    "object_id": "130",
    "object_repr": "Buspirone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 836,
  "fields": {
    "action_time": "2025-04-02T08:15:00.419Z",
    "user": 2,
    "content_type": 10,
    "object_id": "129",
    "object_repr": "Droperidol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 837,
  "fields": {
    "action_time": "2025-04-02T08:15:22.327Z",
    "user": 2,
    "content_type": 10,
    "object_id": "128",
    "object_repr": "Zolpidem",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 838,
  "fields": {
    "action_time": "2025-04-02T08:17:28.550Z",
    "user": 2,
    "content_type": 10,
    "object_id": "127",
    "object_repr": "Eszopiclone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 839,
  "fields": {
    "action_time": "2025-04-02T08:17:50.028Z",
    "user": 2,
    "content_type": 10,
    "object_id": "126",
    "object_repr": "Trifluoperazine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 840,
  "fields": {
    "action_time": "2025-04-02T08:18:14.918Z",
    "user": 2,
    "content_type": 10,
    "object_id": "125",
    "object_repr": "Promazine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 841,
  "fields": {
    "action_time": "2025-04-02T08:18:43.145Z",
    "user": 2,
    "content_type": 10,
    "object_id": "123",
    "object_repr": "Olanzapine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 842,
  "fields": {
    "action_time": "2025-04-02T08:19:03.725Z",
    "user": 2,
    "content_type": 10,
    "object_id": "122",
    "object_repr": "Lurasidone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 843,
  "fields": {
    "action_time": "2025-04-02T08:19:19.603Z",
    "user": 2,
    "content_type": 10,
    "object_id": "121",
    "object_repr": "Fluphenazine decanoate",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 844,
  "fields": {
    "action_time": "2025-04-02T08:19:38.918Z",
    "user": 2,
    "content_type": 10,
    "object_id": "120",
    "object_repr": "Sulpiride",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 845,
  "fields": {
    "action_time": "2025-04-02T08:19:58.782Z",
    "user": 2,
    "content_type": 10,
    "object_id": "117",
    "object_repr": "Clozapine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 846,
  "fields": {
    "action_time": "2025-04-02T08:20:19.165Z",
    "user": 2,
    "content_type": 10,
    "object_id": "116",
    "object_repr": "Zuclopentixol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 847,
  "fields": {
    "action_time": "2025-04-02T08:20:42.883Z",
    "user": 2,
    "content_type": 10,
    "object_id": "107",
    "object_repr": "Chloramphenicol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 848,
  "fields": {
    "action_time": "2025-04-02T08:21:04.707Z",
    "user": 2,
    "content_type": 10,
    "object_id": "114",
    "object_repr": "Cariprazine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 849,
  "fields": {
    "action_time": "2025-04-02T08:21:29.840Z",
    "user": 2,
    "content_type": 10,
    "object_id": "113",
    "object_repr": "Benperidol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 850,
  "fields": {
    "action_time": "2025-04-02T08:21:50.638Z",
    "user": 2,
    "content_type": 10,
    "object_id": "112",
    "object_repr": "Asenapine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 851,
  "fields": {
    "action_time": "2025-04-02T08:22:35.540Z",
    "user": 2,
    "content_type": 10,
    "object_id": "111",
    "object_repr": "Haloperidol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 852,
  "fields": {
    "action_time": "2025-04-02T08:22:57.145Z",
    "user": 2,
    "content_type": 10,
    "object_id": "110",
    "object_repr": "Quetiapine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 853,
  "fields": {
    "action_time": "2025-04-02T08:23:13.195Z",
    "user": 2,
    "content_type": 10,
    "object_id": "109",
    "object_repr": "Aripiprazole",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 854,
  "fields": {
    "action_time": "2025-04-02T08:23:30.015Z",
    "user": 2,
    "content_type": 10,
    "object_id": "108",
    "object_repr": "Metronidazole",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 855,
  "fields": {
    "action_time": "2025-04-02T08:24:15.611Z",
    "user": 2,
    "content_type": 10,
    "object_id": "106",
    "object_repr": "Rifampin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 856,
  "fields": {
    "action_time": "2025-04-02T08:24:37.247Z",
    "user": 2,
    "content_type": 10,
    "object_id": "105",
    "object_repr": "Doxycycline",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 857,
  "fields": {
    "action_time": "2025-04-02T08:24:56.821Z",
    "user": 2,
    "content_type": 10,
    "object_id": "104",
    "object_repr": "Sulfasalazine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 858,
  "fields": {
    "action_time": "2025-04-02T08:25:33.171Z",
    "user": 2,
    "content_type": 10,
    "object_id": "102",
    "object_repr": "Sulfamethoxazole",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 859,
  "fields": {
    "action_time": "2025-04-02T08:25:53.485Z",
    "user": 2,
    "content_type": 10,
    "object_id": "101",
    "object_repr": "Clarithromycin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 860,
  "fields": {
    "action_time": "2025-04-02T08:26:12.086Z",
    "user": 2,
    "content_type": 10,
    "object_id": "100",
    "object_repr": "Lincomycin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 861,
  "fields": {
    "action_time": "2025-04-02T08:26:36.436Z",
    "user": 2,
    "content_type": 10,
    "object_id": "99",
    "object_repr": "Rifaximin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 862,
  "fields": {
    "action_time": "2025-04-02T08:27:01.242Z",
    "user": 2,
    "content_type": 10,
    "object_id": "98",
    "object_repr": "Herbimycin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 863,
  "fields": {
    "action_time": "2025-04-02T08:27:24.080Z",
    "user": 2,
    "content_type": 10,
    "object_id": "97",
    "object_repr": "Geldanamycin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 864,
  "fields": {
    "action_time": "2025-04-02T08:27:42.169Z",
    "user": 2,
    "content_type": 10,
    "object_id": "96",
    "object_repr": "Methohexital",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 865,
  "fields": {
    "action_time": "2025-04-02T08:28:00.080Z",
    "user": 2,
    "content_type": 10,
    "object_id": "95",
    "object_repr": "SR8278",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 866,
  "fields": {
    "action_time": "2025-04-02T08:28:26.742Z",
    "user": 2,
    "content_type": 10,
    "object_id": "93",
    "object_repr": "PF-670462",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 867,
  "fields": {
    "action_time": "2025-04-02T08:28:49.979Z",
    "user": 2,
    "content_type": 10,
    "object_id": "91",
    "object_repr": "KL201",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 868,
  "fields": {
    "action_time": "2025-04-02T08:29:05.695Z",
    "user": 2,
    "content_type": 10,
    "object_id": "90",
    "object_repr": "KL101",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 869,
  "fields": {
    "action_time": "2025-04-02T08:29:20.342Z",
    "user": 2,
    "content_type": 10,
    "object_id": "89",
    "object_repr": "GSK805",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 870,
  "fields": {
    "action_time": "2025-04-02T09:00:23.969Z",
    "user": 2,
    "content_type": 10,
    "object_id": "258",
    "object_repr": "Li (Lithium Carbonate)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\", \"Smiles\", \"Molecula\", \"Updphoto\", \"Description\", \"Article\", \"Linkslists\", \"Pubchem\", \"Drugbank\", \"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 871,
  "fields": {
    "action_time": "2025-04-02T09:05:30.611Z",
    "user": 2,
    "content_type": 10,
    "object_id": "284",
    "object_repr": "Forskolin (Colforsin)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 872,
  "fields": {
    "action_time": "2025-04-02T09:09:35.686Z",
    "user": 2,
    "content_type": 10,
    "object_id": "280",
    "object_repr": "Hydrocortisone (Cortisole)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 873,
  "fields": {
    "action_time": "2025-04-02T09:10:15.839Z",
    "user": 2,
    "content_type": 10,
    "object_id": "277",
    "object_repr": "Dexamethasone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 874,
  "fields": {
    "action_time": "2025-04-02T09:11:14.242Z",
    "user": 2,
    "content_type": 10,
    "object_id": "276",
    "object_repr": "Triamcinolone (acetonide)",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 875,
  "fields": {
    "action_time": "2025-04-02T09:11:52.745Z",
    "user": 2,
    "content_type": 10,
    "object_id": "278",
    "object_repr": "Prednisolone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 876,
  "fields": {
    "action_time": "2025-04-02T09:12:27.957Z",
    "user": 2,
    "content_type": 10,
    "object_id": "279",
    "object_repr": "Aldosterone",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 877,
  "fields": {
    "action_time": "2025-04-02T09:13:51.082Z",
    "user": 2,
    "content_type": 10,
    "object_id": "200",
    "object_repr": "EVEROLIMUS",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Uniprot\", \"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 878,
  "fields": {
    "action_time": "2025-04-02T09:14:24.415Z",
    "user": 2,
    "content_type": 10,
    "object_id": "199",
    "object_repr": "EPIRUBICIN HCL",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 879,
  "fields": {
    "action_time": "2025-04-02T09:15:08.130Z",
    "user": 2,
    "content_type": 10,
    "object_id": "204",
    "object_repr": "NEBIVOLOL HCL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 880,
  "fields": {
    "action_time": "2025-04-02T09:15:33.159Z",
    "user": 2,
    "content_type": 10,
    "object_id": "205",
    "object_repr": "NILOTINIB",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 881,
  "fields": {
    "action_time": "2025-04-02T09:16:20.409Z",
    "user": 2,
    "content_type": 10,
    "object_id": "198",
    "object_repr": "DROSPIRENONE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 882,
  "fields": {
    "action_time": "2025-04-02T09:16:57.502Z",
    "user": 2,
    "content_type": 10,
    "object_id": "267",
    "object_repr": "Griseofulvin",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 883,
  "fields": {
    "action_time": "2025-04-02T09:17:31.684Z",
    "user": 2,
    "content_type": 10,
    "object_id": "241",
    "object_repr": "Digoxin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 884,
  "fields": {
    "action_time": "2025-04-02T09:18:08.098Z",
    "user": 2,
    "content_type": 10,
    "object_id": "213",
    "object_repr": "Irbesartan",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 885,
  "fields": {
    "action_time": "2025-04-02T09:18:43.057Z",
    "user": 2,
    "content_type": 10,
    "object_id": "193",
    "object_repr": "Deferasirox",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 886,
  "fields": {
    "action_time": "2025-04-02T09:19:12.629Z",
    "user": 2,
    "content_type": 10,
    "object_id": "192",
    "object_repr": "Dasatinib",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 887,
  "fields": {
    "action_time": "2025-04-02T09:19:37.802Z",
    "user": 2,
    "content_type": 10,
    "object_id": "191",
    "object_repr": "Clotrimazole",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 888,
  "fields": {
    "action_time": "2025-04-02T09:20:12.442Z",
    "user": 2,
    "content_type": 10,
    "object_id": "189",
    "object_repr": "CINACALCET HCL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 889,
  "fields": {
    "action_time": "2025-04-02T09:20:39.255Z",
    "user": 2,
    "content_type": 10,
    "object_id": "192",
    "object_repr": "Dasatinib",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 890,
  "fields": {
    "action_time": "2025-04-02T09:21:13.641Z",
    "user": 2,
    "content_type": 10,
    "object_id": "206",
    "object_repr": "PAZOPANIB HCL",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 891,
  "fields": {
    "action_time": "2025-04-02T09:21:33.028Z",
    "user": 2,
    "content_type": 10,
    "object_id": "211",
    "object_repr": "THIOTEPA",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 892,
  "fields": {
    "action_time": "2025-04-02T09:22:05.691Z",
    "user": 2,
    "content_type": 10,
    "object_id": "188",
    "object_repr": "CIDOFOVIR",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 893,
  "fields": {
    "action_time": "2025-04-02T09:22:31.017Z",
    "user": 2,
    "content_type": 10,
    "object_id": "186",
    "object_repr": "Adefovir Dipivoxil",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 894,
  "fields": {
    "action_time": "2025-04-02T09:22:37.629Z",
    "user": 2,
    "content_type": 10,
    "object_id": "187",
    "object_repr": "ARSENIC TRIOXIDE",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 895,
  "fields": {
    "action_time": "2025-04-02T09:23:06.227Z",
    "user": 2,
    "content_type": 10,
    "object_id": "185",
    "object_repr": "Nelfinavir mesylate",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 896,
  "fields": {
    "action_time": "2025-04-02T09:23:26.245Z",
    "user": 2,
    "content_type": 10,
    "object_id": "184",
    "object_repr": "PROGESTERONE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 897,
  "fields": {
    "action_time": "2025-04-02T09:24:03.875Z",
    "user": 2,
    "content_type": 10,
    "object_id": "182",
    "object_repr": "NEFAZODONE HCL",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 898,
  "fields": {
    "action_time": "2025-04-02T09:25:18.386Z",
    "user": 2,
    "content_type": 10,
    "object_id": "181",
    "object_repr": "Paclitaxel (TAXOL)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Drugbank\", \"Chebi\", \"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 899,
  "fields": {
    "action_time": "2025-04-02T09:26:38.603Z",
    "user": 2,
    "content_type": 10,
    "object_id": "180",
    "object_repr": "MITOXANTRONE HCL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chebi\", \"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 900,
  "fields": {
    "action_time": "2025-04-02T09:27:52.127Z",
    "user": 2,
    "content_type": 10,
    "object_id": "179",
    "object_repr": "CHLORAMBUCIL",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 901,
  "fields": {
    "action_time": "2025-04-02T09:28:43.082Z",
    "user": 2,
    "content_type": 10,
    "object_id": "178",
    "object_repr": "VINBLASTINE SULFATE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\", \"Chebi\", \"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 902,
  "fields": {
    "action_time": "2025-04-02T09:30:18.310Z",
    "user": 2,
    "content_type": 10,
    "object_id": "177",
    "object_repr": "CLOFARABINE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Drugbank\", \"Chebi\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 903,
  "fields": {
    "action_time": "2025-04-02T09:31:03.463Z",
    "user": 2,
    "content_type": 10,
    "object_id": "176",
    "object_repr": "Bexarotene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chebi\", \"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 904,
  "fields": {
    "action_time": "2025-04-02T09:32:25.917Z",
    "user": 2,
    "content_type": 10,
    "object_id": "175",
    "object_repr": "DAUNORUBICIN HCL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Article\", \"Chebi\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 905,
  "fields": {
    "action_time": "2025-04-02T09:33:07.808Z",
    "user": 2,
    "content_type": 10,
    "object_id": "174",
    "object_repr": "KETOCONAZOLE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chebi\", \"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 906,
  "fields": {
    "action_time": "2025-04-02T09:34:12.540Z",
    "user": 2,
    "content_type": 10,
    "object_id": "173",
    "object_repr": "CALCITRIOL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chebi\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 907,
  "fields": {
    "action_time": "2025-04-02T09:35:38.082Z",
    "user": 2,
    "content_type": 10,
    "object_id": "172",
    "object_repr": "Acitretin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chebi\", \"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 908,
  "fields": {
    "action_time": "2025-04-02T09:36:56.727Z",
    "user": 2,
    "content_type": 10,
    "object_id": "171",
    "object_repr": "Bromocriptine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chebi\", \"Kegg\", \"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 909,
  "fields": {
    "action_time": "2025-04-02T10:25:12.025Z",
    "user": 2,
    "content_type": 10,
    "object_id": "86",
    "object_repr": "SR1555",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 910,
  "fields": {
    "action_time": "2025-04-02T10:25:28.840Z",
    "user": 2,
    "content_type": 10,
    "object_id": "85",
    "object_repr": "SR2211",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 911,
  "fields": {
    "action_time": "2025-04-02T10:25:52.619Z",
    "user": 2,
    "content_type": 10,
    "object_id": "84",
    "object_repr": "SR1001",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 912,
  "fields": {
    "action_time": "2025-04-02T10:26:09.893Z",
    "user": 2,
    "content_type": 10,
    "object_id": "83",
    "object_repr": "SR 3335",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 913,
  "fields": {
    "action_time": "2025-04-02T10:26:52.526Z",
    "user": 2,
    "content_type": 10,
    "object_id": "82",
    "object_repr": "SR 1078",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 914,
  "fields": {
    "action_time": "2025-04-02T10:27:07.827Z",
    "user": 2,
    "content_type": 10,
    "object_id": "81",
    "object_repr": "T0901317",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 915,
  "fields": {
    "action_time": "2025-04-02T10:27:27.138Z",
    "user": 2,
    "content_type": 10,
    "object_id": "80",
    "object_repr": "Prasterone (DHEA)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 916,
  "fields": {
    "action_time": "2025-04-02T10:27:45.015Z",
    "user": 2,
    "content_type": 10,
    "object_id": "79",
    "object_repr": "Harmine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 917,
  "fields": {
    "action_time": "2025-04-02T10:28:14.281Z",
    "user": 2,
    "content_type": 10,
    "object_id": "78",
    "object_repr": "Camptothecin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 918,
  "fields": {
    "action_time": "2025-04-02T10:28:49.196Z",
    "user": 2,
    "content_type": 10,
    "object_id": "77",
    "object_repr": "SRT 1720 Hydrochloride",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 919,
  "fields": {
    "action_time": "2025-04-02T10:30:14.419Z",
    "user": 2,
    "content_type": 10,
    "object_id": "76",
    "object_repr": "SRT2183",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 920,
  "fields": {
    "action_time": "2025-04-02T10:30:55.201Z",
    "user": 2,
    "content_type": 10,
    "object_id": "75",
    "object_repr": "Hyoscyamine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 921,
  "fields": {
    "action_time": "2025-04-02T10:31:18.133Z",
    "user": 2,
    "content_type": 10,
    "object_id": "74",
    "object_repr": "Isoflurane",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 922,
  "fields": {
    "action_time": "2025-04-02T10:31:39.909Z",
    "user": 2,
    "content_type": 10,
    "object_id": "73",
    "object_repr": "Desflurane",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 923,
  "fields": {
    "action_time": "2025-04-02T10:31:59.576Z",
    "user": 2,
    "content_type": 10,
    "object_id": "72",
    "object_repr": "Sevoflurane",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 924,
  "fields": {
    "action_time": "2025-04-02T10:32:25.201Z",
    "user": 2,
    "content_type": 10,
    "object_id": "71",
    "object_repr": "Remifentanil",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 925,
  "fields": {
    "action_time": "2025-04-02T10:32:46.999Z",
    "user": 2,
    "content_type": 10,
    "object_id": "70",
    "object_repr": "Glycopyrrolate",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 926,
  "fields": {
    "action_time": "2025-04-02T10:33:10.024Z",
    "user": 2,
    "content_type": 10,
    "object_id": "69",
    "object_repr": "Ketamine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 927,
  "fields": {
    "action_time": "2025-04-02T10:33:58.431Z",
    "user": 2,
    "content_type": 10,
    "object_id": "68",
    "object_repr": "Propofol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 928,
  "fields": {
    "action_time": "2025-04-02T10:34:34.935Z",
    "user": 2,
    "content_type": 10,
    "object_id": "67",
    "object_repr": "Cocaine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 929,
  "fields": {
    "action_time": "2025-04-02T10:35:20.848Z",
    "user": 2,
    "content_type": 10,
    "object_id": "66",
    "object_repr": "Amphetamine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 930,
  "fields": {
    "action_time": "2025-04-02T10:35:39.949Z",
    "user": 2,
    "content_type": 10,
    "object_id": "65",
    "object_repr": "Heroin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 931,
  "fields": {
    "action_time": "2025-04-02T10:36:13.401Z",
    "user": 2,
    "content_type": 10,
    "object_id": "64",
    "object_repr": "Morphin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 932,
  "fields": {
    "action_time": "2025-04-02T10:36:30.105Z",
    "user": 2,
    "content_type": 10,
    "object_id": "63",
    "object_repr": "Buprenorphine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 933,
  "fields": {
    "action_time": "2025-04-02T10:36:59.135Z",
    "user": 2,
    "content_type": 10,
    "object_id": "62",
    "object_repr": "Tramadol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 934,
  "fields": {
    "action_time": "2025-04-02T10:37:31.731Z",
    "user": 2,
    "content_type": 10,
    "object_id": "61",
    "object_repr": "Methadone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 935,
  "fields": {
    "action_time": "2025-04-02T10:37:55.439Z",
    "user": 2,
    "content_type": 10,
    "object_id": "60",
    "object_repr": "Codeine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 936,
  "fields": {
    "action_time": "2025-04-02T10:38:16.249Z",
    "user": 2,
    "content_type": 10,
    "object_id": "59",
    "object_repr": "Fentanyl",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 937,
  "fields": {
    "action_time": "2025-04-02T10:38:32.972Z",
    "user": 2,
    "content_type": 10,
    "object_id": "58",
    "object_repr": "Hydromorphone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 938,
  "fields": {
    "action_time": "2025-04-02T10:38:48.202Z",
    "user": 2,
    "content_type": 10,
    "object_id": "57",
    "object_repr": "Hydrocodone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 939,
  "fields": {
    "action_time": "2025-04-02T10:39:08.841Z",
    "user": 2,
    "content_type": 10,
    "object_id": "56",
    "object_repr": "Oxymorphone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 940,
  "fields": {
    "action_time": "2025-04-02T10:39:35.556Z",
    "user": 2,
    "content_type": 10,
    "object_id": "55",
    "object_repr": "Oxycodone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 941,
  "fields": {
    "action_time": "2025-04-02T10:40:16.691Z",
    "user": 2,
    "content_type": 10,
    "object_id": "54",
    "object_repr": "Nabiximols",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 942,
  "fields": {
    "action_time": "2025-04-02T10:40:52.542Z",
    "user": 2,
    "content_type": 10,
    "object_id": "53",
    "object_repr": "Nabilone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 943,
  "fields": {
    "action_time": "2025-04-02T10:41:23.170Z",
    "user": 2,
    "content_type": 10,
    "object_id": "52",
    "object_repr": "Cannabinodiol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 944,
  "fields": {
    "action_time": "2025-04-02T10:41:51.313Z",
    "user": 2,
    "content_type": 10,
    "object_id": "50",
    "object_repr": "Dronabinol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 945,
  "fields": {
    "action_time": "2025-04-02T10:42:19.715Z",
    "user": 2,
    "content_type": 10,
    "object_id": "49",
    "object_repr": "Cannabichromenes",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 946,
  "fields": {
    "action_time": "2025-04-02T10:42:51.198Z",
    "user": 2,
    "content_type": 10,
    "object_id": "48",
    "object_repr": "Cannabigerol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 947,
  "fields": {
    "action_time": "2025-04-02T10:43:13.882Z",
    "user": 2,
    "content_type": 10,
    "object_id": "47",
    "object_repr": "Cannabidiol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 948,
  "fields": {
    "action_time": "2025-04-02T10:49:40.469Z",
    "user": 2,
    "content_type": 10,
    "object_id": "46",
    "object_repr": "SP600125",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 949,
  "fields": {
    "action_time": "2025-04-02T10:50:03.317Z",
    "user": 2,
    "content_type": 10,
    "object_id": "45",
    "object_repr": "S24014",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 950,
  "fields": {
    "action_time": "2025-04-02T10:51:16.245Z",
    "user": 2,
    "content_type": 10,
    "object_id": "43",
    "object_repr": "GR 128107",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 951,
  "fields": {
    "action_time": "2025-04-02T10:51:48.268Z",
    "user": 2,
    "content_type": 10,
    "object_id": "42",
    "object_repr": "Tasimelteon-d5",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 952,
  "fields": {
    "action_time": "2025-04-02T10:52:20.922Z",
    "user": 2,
    "content_type": 10,
    "object_id": "41",
    "object_repr": "Agomelatine (L(+)-Tartaric acid)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 953,
  "fields": {
    "action_time": "2025-04-02T10:52:51.497Z",
    "user": 2,
    "content_type": 10,
    "object_id": "40",
    "object_repr": "GR 196429",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 954,
  "fields": {
    "action_time": "2025-04-02T10:53:18.235Z",
    "user": 2,
    "content_type": 10,
    "object_id": "39",
    "object_repr": "6-Chloromelatonin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 955,
  "fields": {
    "action_time": "2025-04-02T10:53:41.088Z",
    "user": 2,
    "content_type": 10,
    "object_id": "38",
    "object_repr": "Ramelteon-d3",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 956,
  "fields": {
    "action_time": "2025-04-02T10:53:59.983Z",
    "user": 2,
    "content_type": 10,
    "object_id": "37",
    "object_repr": "DH97",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 957,
  "fields": {
    "action_time": "2025-04-02T10:54:20.638Z",
    "user": 2,
    "content_type": 10,
    "object_id": "36",
    "object_repr": "S-20928",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 958,
  "fields": {
    "action_time": "2025-04-02T10:54:50.684Z",
    "user": 2,
    "content_type": 10,
    "object_id": "35",
    "object_repr": "TIK-301",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 959,
  "fields": {
    "action_time": "2025-04-02T10:55:11.498Z",
    "user": 2,
    "content_type": 10,
    "object_id": "34",
    "object_repr": "Agomelatin-d3",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 960,
  "fields": {
    "action_time": "2025-04-02T10:55:40.507Z",
    "user": 2,
    "content_type": 10,
    "object_id": "32",
    "object_repr": "Ramelteon-d5",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 961,
  "fields": {
    "action_time": "2025-04-02T10:56:31.826Z",
    "user": 2,
    "content_type": 10,
    "object_id": "29",
    "object_repr": "Agomelatine-d4",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 962,
  "fields": {
    "action_time": "2025-04-02T10:57:30.619Z",
    "user": 2,
    "content_type": 10,
    "object_id": "26",
    "object_repr": "N-Acetyltryptamine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 963,
  "fields": {
    "action_time": "2025-04-02T10:57:57.814Z",
    "user": 2,
    "content_type": 10,
    "object_id": "24",
    "object_repr": "UCM 608 (N-[2-(5-methoxy-2-phenyl-1H-indol-3-yl)ethyl]acetamide)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 964,
  "fields": {
    "action_time": "2025-04-02T10:58:26.037Z",
    "user": 2,
    "content_type": 10,
    "object_id": "23",
    "object_repr": "Piromelatine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 965,
  "fields": {
    "action_time": "2025-04-02T10:58:44.127Z",
    "user": 2,
    "content_type": 10,
    "object_id": "22",
    "object_repr": "ACH-000143",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 966,
  "fields": {
    "action_time": "2025-04-02T10:59:03.212Z",
    "user": 2,
    "content_type": 10,
    "object_id": "21",
    "object_repr": "Agomelatine hydrochloride",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 967,
  "fields": {
    "action_time": "2025-04-02T10:59:22.378Z",
    "user": 2,
    "content_type": 10,
    "object_id": "20",
    "object_repr": "Tasimelteon",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 968,
  "fields": {
    "action_time": "2025-04-02T11:00:43.140Z",
    "user": 2,
    "content_type": 10,
    "object_id": "19",
    "object_repr": "8-M-PDOT",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 969,
  "fields": {
    "action_time": "2025-04-02T11:01:18.513Z",
    "user": 2,
    "content_type": 10,
    "object_id": "18",
    "object_repr": "2-Iodomelatonin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 970,
  "fields": {
    "action_time": "2025-04-02T11:01:48.195Z",
    "user": 2,
    "content_type": 10,
    "object_id": "17",
    "object_repr": "Melatonin-d4",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 971,
  "fields": {
    "action_time": "2025-04-02T11:02:19.070Z",
    "user": 2,
    "content_type": 10,
    "object_id": "16",
    "object_repr": "S26131",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 972,
  "fields": {
    "action_time": "2025-04-02T11:02:37.905Z",
    "user": 2,
    "content_type": 10,
    "object_id": "15",
    "object_repr": "5-MCA-NAT",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 973,
  "fields": {
    "action_time": "2025-04-02T11:03:04.643Z",
    "user": 2,
    "content_type": 10,
    "object_id": "13",
    "object_repr": "Agomelatine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 974,
  "fields": {
    "action_time": "2025-04-02T11:03:30.943Z",
    "user": 2,
    "content_type": 10,
    "object_id": "11",
    "object_repr": "Luzindole",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 975,
  "fields": {
    "action_time": "2025-04-02T11:03:53.225Z",
    "user": 2,
    "content_type": 10,
    "object_id": "10",
    "object_repr": "Ramelteon",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 976,
  "fields": {
    "action_time": "2025-04-02T11:04:21.543Z",
    "user": 2,
    "content_type": 10,
    "object_id": "9",
    "object_repr": "Indole",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 977,
  "fields": {
    "action_time": "2025-04-02T11:04:39.487Z",
    "user": 2,
    "content_type": 10,
    "object_id": "8",
    "object_repr": "Melatonin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\", \"Drugbank\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 978,
  "fields": {
    "action_time": "2025-04-02T11:04:57.894Z",
    "user": 2,
    "content_type": 10,
    "object_id": "7",
    "object_repr": "Rosiglitazone",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 979,
  "fields": {
    "action_time": "2025-04-02T11:05:02.945Z",
    "user": 2,
    "content_type": 10,
    "object_id": "6",
    "object_repr": "Resveratrol",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 980,
  "fields": {
    "action_time": "2025-04-02T11:22:42.338Z",
    "user": 2,
    "content_type": 10,
    "object_id": "170",
    "object_repr": "Felodipine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chebi\", \"Kegg\", \"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 981,
  "fields": {
    "action_time": "2025-04-03T08:05:20.908Z",
    "user": 2,
    "content_type": 10,
    "object_id": "164",
    "object_repr": "Artenimol (DHA, Dihydroartemisinin)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\", \"Chebi\", \"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 982,
  "fields": {
    "action_time": "2025-04-03T08:07:24.389Z",
    "user": 2,
    "content_type": 10,
    "object_id": "167",
    "object_repr": "SERTACONAZOLE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chebi\", \"Kegg\", \"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 983,
  "fields": {
    "action_time": "2025-04-03T08:13:46.904Z",
    "user": 2,
    "content_type": 10,
    "object_id": "168",
    "object_repr": "BLEOMYCIN SULFATE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Article\", \"Chemspider\", \"Drugbank\", \"Chebi\", \"Kegg\", \"Selleckchem\", \"Classf\", \"Mechanisms\", \"Target\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 984,
  "fields": {
    "action_time": "2025-04-03T08:16:37.297Z",
    "user": 2,
    "content_type": 10,
    "object_id": "166",
    "object_repr": "Rapamycin (Sirolimus)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\", \"Chebi\", \"Uniprot\", \"Kegg\", \"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 985,
  "fields": {
    "action_time": "2025-04-03T08:19:27.200Z",
    "user": 2,
    "content_type": 10,
    "object_id": "165",
    "object_repr": "Hydroxyprogesterone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chebi\", \"Uniprot\", \"Kegg\", \"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 986,
  "fields": {
    "action_time": "2025-04-03T08:21:49.242Z",
    "user": 2,
    "content_type": 10,
    "object_id": "161",
    "object_repr": "Cyproterone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chebi\", \"Kegg\", \"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 987,
  "fields": {
    "action_time": "2025-04-03T08:24:31.017Z",
    "user": 2,
    "content_type": 10,
    "object_id": "153",
    "object_repr": "Lormetazepam",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Article\", \"Chebi\", \"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 988,
  "fields": {
    "action_time": "2025-04-03T08:30:39.598Z",
    "user": 2,
    "content_type": 10,
    "object_id": "155",
    "object_repr": "Loprazolam",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Chebi\", \"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 989,
  "fields": {
    "action_time": "2025-04-03T08:33:10.444Z",
    "user": 2,
    "content_type": 10,
    "object_id": "154",
    "object_repr": "Nitrazepam",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Article\", \"Chebi\", \"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 990,
  "fields": {
    "action_time": "2025-04-03T08:34:53.425Z",
    "user": 2,
    "content_type": 10,
    "object_id": "156",
    "object_repr": "DEQUALINIUM CHLORIDE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chebi\", \"Kegg\", \"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 991,
  "fields": {
    "action_time": "2025-04-03T08:40:40.533Z",
    "user": 2,
    "content_type": 10,
    "object_id": "159",
    "object_repr": "Nadifloxacin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Linkname\", \"Description\", \"Article\", \"Pubchem\", \"Chebi\", \"Kegg\", \"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 992,
  "fields": {
    "action_time": "2025-04-03T08:47:34.871Z",
    "user": 2,
    "content_type": 12,
    "object_id": "103",
    "object_repr": "Rev-erb expression",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 993,
  "fields": {
    "action_time": "2025-04-03T08:48:32.076Z",
    "user": 2,
    "content_type": 9,
    "object_id": "165",
    "object_repr": "Rev-erb expression modulation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 994,
  "fields": {
    "action_time": "2025-04-03T08:48:41.124Z",
    "user": 2,
    "content_type": 10,
    "object_id": "157",
    "object_repr": "Berberine Chloride",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Linkslists\", \"Chebi\", \"Kegg\", \"Selleckchem\", \"Mechanisms\", \"Target\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 995,
  "fields": {
    "action_time": "2025-04-03T08:51:55.764Z",
    "user": 2,
    "content_type": 9,
    "object_id": "166",
    "object_repr": "NLRP3 inflammasome binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 996,
  "fields": {
    "action_time": "2025-04-03T08:52:36.547Z",
    "user": 2,
    "content_type": 12,
    "object_id": "104",
    "object_repr": "NLRP3 inflammasome",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 997,
  "fields": {
    "action_time": "2025-04-03T08:52:38.917Z",
    "user": 2,
    "content_type": 10,
    "object_id": "157",
    "object_repr": "Berberine Chloride",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Mechanisms\", \"Target\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 998,
  "fields": {
    "action_time": "2025-04-03T08:55:16.662Z",
    "user": 2,
    "content_type": 9,
    "object_id": "167",
    "object_repr": "Altering Circadian Metabolism via the SIRT1-AMPK-PP2A Axis",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 999,
  "fields": {
    "action_time": "2025-04-03T08:55:26.212Z",
    "user": 2,
    "content_type": 9,
    "object_id": "168",
    "object_repr": "Repression of PER/CRY feedback loops via deacetylation.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1000,
  "fields": {
    "action_time": "2025-04-03T08:55:33.103Z",
    "user": 2,
    "content_type": 9,
    "object_id": "169",
    "object_repr": "AMPK-PP2A axis suppresses mTOR, advancing circadian phase in muscle.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1001,
  "fields": {
    "action_time": "2025-04-03T08:56:19.446Z",
    "user": 2,
    "content_type": 12,
    "object_id": "105",
    "object_repr": "MTOR (Human)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1002,
  "fields": {
    "action_time": "2025-04-03T08:58:36.989Z",
    "user": 2,
    "content_type": 10,
    "object_id": "6",
    "object_repr": "Resveratrol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Article\", \"Linkslists\", \"Kegg\", \"Mechanisms\", \"Target\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1003,
  "fields": {
    "action_time": "2025-04-03T08:58:47.837Z",
    "user": 2,
    "content_type": 10,
    "object_id": "7",
    "object_repr": "Rosiglitazone",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1004,
  "fields": {
    "action_time": "2025-04-03T09:14:21.154Z",
    "user": 2,
    "content_type": 10,
    "object_id": "8",
    "object_repr": "Melatonin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Chebi\", \"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1005,
  "fields": {
    "action_time": "2025-04-03T09:16:58.271Z",
    "user": 2,
    "content_type": 12,
    "object_id": "106",
    "object_repr": "CLOCK-BMAL1 COMPLEX",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1006,
  "fields": {
    "action_time": "2025-04-03T09:17:00.745Z",
    "user": 2,
    "content_type": 10,
    "object_id": "6",
    "object_repr": "Resveratrol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Target\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1007,
  "fields": {
    "action_time": "2025-04-03T12:50:22.502Z",
    "user": 2,
    "content_type": 10,
    "object_id": "7",
    "object_repr": "Rosiglitazone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1008,
  "fields": {
    "action_time": "2025-04-03T12:58:43.985Z",
    "user": 2,
    "content_type": 10,
    "object_id": "220",
    "object_repr": "LH-846",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Article\", \"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1009,
  "fields": {
    "action_time": "2025-04-03T13:02:00.880Z",
    "user": 2,
    "content_type": 10,
    "object_id": "13",
    "object_repr": "Agomelatine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Chebi\", \"Uniprot\", \"Kegg\", \"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1010,
  "fields": {
    "action_time": "2025-04-03T13:08:34.904Z",
    "user": 2,
    "content_type": 10,
    "object_id": "20",
    "object_repr": "Tasimelteon",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chebi\", \"Uniprot\", \"Kegg\", \"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1011,
  "fields": {
    "action_time": "2025-04-03T14:00:00.939Z",
    "user": 2,
    "content_type": 10,
    "object_id": "23",
    "object_repr": "Piromelatine",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1012,
  "fields": {
    "action_time": "2025-04-03T14:00:47.654Z",
    "user": 2,
    "content_type": 10,
    "object_id": "61",
    "object_repr": "6-(dimethylamino)-4,4-diphenylheptan-3-one",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1013,
  "fields": {
    "action_time": "2025-04-03T14:01:29.468Z",
    "user": 2,
    "content_type": 10,
    "object_id": "65",
    "object_repr": "[(4R,4aR,7S,7aR,12bS)-9-acetyloxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl] acetate",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1014,
  "fields": {
    "action_time": "2025-04-03T14:01:58.698Z",
    "user": 2,
    "content_type": 10,
    "object_id": "66",
    "object_repr": "1-phenylpropan-2-amine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1015,
  "fields": {
    "action_time": "2025-04-03T14:02:33.630Z",
    "user": 2,
    "content_type": 10,
    "object_id": "67",
    "object_repr": "methyl (1R,2R,3S,5S)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1016,
  "fields": {
    "action_time": "2025-04-03T14:03:26.177Z",
    "user": 2,
    "content_type": 10,
    "object_id": "64",
    "object_repr": "(4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1017,
  "fields": {
    "action_time": "2025-04-03T14:05:57.705Z",
    "user": 2,
    "content_type": 10,
    "object_id": "241",
    "object_repr": "Digoxin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Chebi\", \"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1018,
  "fields": {
    "action_time": "2025-04-04T08:14:00.259Z",
    "user": 2,
    "content_type": 7,
    "object_id": "13",
    "object_repr": "Dopamine receptor binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1019,
  "fields": {
    "action_time": "2025-04-04T08:14:10.941Z",
    "user": 2,
    "content_type": 9,
    "object_id": "170",
    "object_repr": "Dopamine receptor binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1020,
  "fields": {
    "action_time": "2025-04-04T08:14:30.240Z",
    "user": 2,
    "content_type": 12,
    "object_id": "107",
    "object_repr": "5-HT 2A R",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1021,
  "fields": {
    "action_time": "2025-04-04T08:15:19.151Z",
    "user": 2,
    "content_type": 10,
    "object_id": "290",
    "object_repr": "Psilocin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1022,
  "fields": {
    "action_time": "2025-04-07T07:24:55.544Z",
    "user": 2,
    "content_type": 10,
    "object_id": "138",
    "object_repr": "Adenosine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1023,
  "fields": {
    "action_time": "2025-04-07T07:29:41.704Z",
    "user": 2,
    "content_type": 10,
    "object_id": "102",
    "object_repr": "Sulfamethoxazole",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Article\", \"Chebi\", \"Kegg\", \"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1024,
  "fields": {
    "action_time": "2025-04-07T07:40:01.251Z",
    "user": 2,
    "content_type": 10,
    "object_id": "98",
    "object_repr": "Herbimycin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Article\", \"Pubchem\", \"Chebi\", \"Kegg\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1025,
  "fields": {
    "action_time": "2025-04-07T07:43:13.987Z",
    "user": 2,
    "content_type": 10,
    "object_id": "97",
    "object_repr": "Geldanamycin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Article\", \"Linkslists\", \"Chebi\", \"Kegg\", \"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1026,
  "fields": {
    "action_time": "2025-04-07T07:46:16.675Z",
    "user": 2,
    "content_type": 10,
    "object_id": "99",
    "object_repr": "Rifaximin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Linkname\", \"Article\", \"Chebi\", \"Kegg\", \"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1027,
  "fields": {
    "action_time": "2025-04-07T07:48:08.052Z",
    "user": 2,
    "content_type": 10,
    "object_id": "100",
    "object_repr": "Lincomycin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chebi\", \"Kegg\", \"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1028,
  "fields": {
    "action_time": "2025-04-07T07:50:11.657Z",
    "user": 2,
    "content_type": 10,
    "object_id": "101",
    "object_repr": "Clarithromycin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Article\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1029,
  "fields": {
    "action_time": "2025-04-07T07:54:36.041Z",
    "user": 2,
    "content_type": 10,
    "object_id": "96",
    "object_repr": "Methohexital",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Linkslists\", \"Chebi\", \"Mechanisms\", \"Target\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1030,
  "fields": {
    "action_time": "2025-04-07T08:21:29.754Z",
    "user": 2,
    "content_type": 10,
    "object_id": "291",
    "object_repr": "Scopolamine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1031,
  "fields": {
    "action_time": "2025-04-07T08:28:37.781Z",
    "user": 2,
    "content_type": 10,
    "object_id": "290",
    "object_repr": "Psilocin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Linkslists\", \"Pubchem\", \"Chemspider\", \"Drugbank\", \"Chebi\", \"Kegg\", \"Classf\", \"Mechanisms\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1032,
  "fields": {
    "action_time": "2025-04-07T08:38:02.729Z",
    "user": 2,
    "content_type": 12,
    "object_id": "108",
    "object_repr": "CK1 epsilon",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1033,
  "fields": {
    "action_time": "2025-04-07T08:38:13.635Z",
    "user": 2,
    "content_type": 9,
    "object_id": "171",
    "object_repr": "Targets CK1 epsilon",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1034,
  "fields": {
    "action_time": "2025-04-07T08:43:26.250Z",
    "user": 2,
    "content_type": 10,
    "object_id": "292",
    "object_repr": "IC261",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1035,
  "fields": {
    "action_time": "2025-04-07T08:48:02.346Z",
    "user": 2,
    "content_type": 10,
    "object_id": "292",
    "object_repr": "IC261",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Chemspider\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1036,
  "fields": {
    "action_time": "2025-04-07T09:01:10.920Z",
    "user": 2,
    "content_type": 10,
    "object_id": "293",
    "object_repr": "SHP656",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1037,
  "fields": {
    "action_time": "2025-04-07T09:05:25.730Z",
    "user": 2,
    "content_type": 12,
    "object_id": "109",
    "object_repr": "Mouse CRY2 with shp656",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1038,
  "fields": {
    "action_time": "2025-04-07T09:05:34.476Z",
    "user": 2,
    "content_type": 10,
    "object_id": "293",
    "object_repr": "SHP656",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Target\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1039,
  "fields": {
    "action_time": "2025-04-07T09:12:12.232Z",
    "user": 2,
    "content_type": 10,
    "object_id": "294",
    "object_repr": "SHP1703 ( (R)-1-(3-(3,6-difluoro-9H-carbazol-9-yl)-2-hydroxypropyl)imid-azolidin-2-one )",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1040,
  "fields": {
    "action_time": "2025-04-11T12:14:29.981Z",
    "user": 2,
    "content_type": 10,
    "object_id": "20",
    "object_repr": "Tasimelteon",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1041,
  "fields": {
    "action_time": "2025-04-11T12:15:45.014Z",
    "user": 2,
    "content_type": 10,
    "object_id": "23",
    "object_repr": "Piromelatine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1042,
  "fields": {
    "action_time": "2025-04-11T12:20:30.561Z",
    "user": 2,
    "content_type": 10,
    "object_id": "40",
    "object_repr": "GR 196429",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1043,
  "fields": {
    "action_time": "2025-04-11T12:21:19.377Z",
    "user": 2,
    "content_type": 10,
    "object_id": "35",
    "object_repr": "TIK-301",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1044,
  "fields": {
    "action_time": "2025-04-11T12:23:16.280Z",
    "user": 2,
    "content_type": 10,
    "object_id": "81",
    "object_repr": "T0901317",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1045,
  "fields": {
    "action_time": "2025-04-11T12:24:10.551Z",
    "user": 2,
    "content_type": 10,
    "object_id": "84",
    "object_repr": "SR1001",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1046,
  "fields": {
    "action_time": "2025-04-11T12:25:08.364Z",
    "user": 2,
    "content_type": 10,
    "object_id": "85",
    "object_repr": "SR2211",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1047,
  "fields": {
    "action_time": "2025-04-11T12:28:42.516Z",
    "user": 2,
    "content_type": 10,
    "object_id": "86",
    "object_repr": "SR1555",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1048,
  "fields": {
    "action_time": "2025-04-11T12:30:11.480Z",
    "user": 2,
    "content_type": 10,
    "object_id": "82",
    "object_repr": "SR 1078",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1049,
  "fields": {
    "action_time": "2025-04-11T12:31:22.600Z",
    "user": 2,
    "content_type": 10,
    "object_id": "83",
    "object_repr": "SR 3335",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1050,
  "fields": {
    "action_time": "2025-04-11T12:31:33.930Z",
    "user": 2,
    "content_type": 10,
    "object_id": "81",
    "object_repr": "T0901317",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1051,
  "fields": {
    "action_time": "2025-04-11T12:33:08.358Z",
    "user": 2,
    "content_type": 10,
    "object_id": "76",
    "object_repr": "SRT2183",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1052,
  "fields": {
    "action_time": "2025-04-11T12:36:01.457Z",
    "user": 2,
    "content_type": 10,
    "object_id": "36",
    "object_repr": "S-20928",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Article\", \"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1053,
  "fields": {
    "action_time": "2025-04-11T12:36:35.237Z",
    "user": 2,
    "content_type": 10,
    "object_id": "87",
    "object_repr": "ML209",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1054,
  "fields": {
    "action_time": "2025-04-11T12:39:48.324Z",
    "user": 2,
    "content_type": 10,
    "object_id": "88",
    "object_repr": "TMP778",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Linkslists\", \"Chebi\", \"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1055,
  "fields": {
    "action_time": "2025-04-11T12:42:25.641Z",
    "user": 2,
    "content_type": 10,
    "object_id": "93",
    "object_repr": "PF-670462",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Linkslists\", \"Chebi\", \"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1056,
  "fields": {
    "action_time": "2025-04-11T12:45:05.104Z",
    "user": 2,
    "content_type": 10,
    "object_id": "94",
    "object_repr": "M47",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1057,
  "fields": {
    "action_time": "2025-04-11T12:47:08.151Z",
    "user": 2,
    "content_type": 10,
    "object_id": "95",
    "object_repr": "SR8278",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Article\", \"Linkslists\", \"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1058,
  "fields": {
    "action_time": "2025-04-11T12:48:31.219Z",
    "user": 2,
    "content_type": 10,
    "object_id": "140",
    "object_repr": "BAY 60-6583",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1059,
  "fields": {
    "action_time": "2025-04-11T12:48:31.777Z",
    "user": 2,
    "content_type": 10,
    "object_id": "140",
    "object_repr": "BAY 60-6583",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1060,
  "fields": {
    "action_time": "2025-04-11T12:51:24.785Z",
    "user": 2,
    "content_type": 10,
    "object_id": "194",
    "object_repr": "AA92593",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Article\", \"Linkslists\", \"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1061,
  "fields": {
    "action_time": "2025-04-11T12:55:32.932Z",
    "user": 2,
    "content_type": 10,
    "object_id": "196",
    "object_repr": "SB-202190",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Article\", \"Linkslists\", \"Pubchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1062,
  "fields": {
    "action_time": "2025-04-11T12:57:07.093Z",
    "user": 2,
    "content_type": 10,
    "object_id": "214",
    "object_repr": "KL001",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1063,
  "fields": {
    "action_time": "2025-04-11T12:59:55.591Z",
    "user": 2,
    "content_type": 10,
    "object_id": "215",
    "object_repr": "KS15",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1064,
  "fields": {
    "action_time": "2025-04-14T08:49:33.379Z",
    "user": 2,
    "content_type": 12,
    "object_id": "110",
    "object_repr": "DAT ( human Dopamine transporter)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1065,
  "fields": {
    "action_time": "2025-04-14T08:53:52.612Z",
    "user": 2,
    "content_type": 9,
    "object_id": "172",
    "object_repr": "DAT interaction (human dopamine transporter)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1066,
  "fields": {
    "action_time": "2025-04-14T08:54:03.658Z",
    "user": 2,
    "content_type": 10,
    "object_id": "295",
    "object_repr": "Modafinil",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1067,
  "fields": {
    "action_time": "2025-04-14T10:01:32.012Z",
    "user": 2,
    "content_type": 10,
    "object_id": "233",
    "object_repr": "SR9009",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1068,
  "fields": {
    "action_time": "2025-04-14T10:23:09.196Z",
    "user": 2,
    "content_type": 10,
    "object_id": "220",
    "object_repr": "LH-846",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Linkslists\", \"Selleckchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1069,
  "fields": {
    "action_time": "2025-04-15T08:03:37.024Z",
    "user": 2,
    "content_type": 10,
    "object_id": "296",
    "object_repr": "NCC007",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1070,
  "fields": {
    "action_time": "2025-04-15T08:15:07.259Z",
    "user": 2,
    "content_type": 9,
    "object_id": "173",
    "object_repr": "Chk1/2 inhibition",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1071,
  "fields": {
    "action_time": "2025-04-15T08:15:25.283Z",
    "user": 2,
    "content_type": 9,
    "object_id": "174",
    "object_repr": "PER2 phosphorylation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1072,
  "fields": {
    "action_time": "2025-04-15T08:36:55.215Z",
    "user": 2,
    "content_type": 10,
    "object_id": "297",
    "object_repr": "Prexasertib",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1073,
  "fields": {
    "action_time": "2025-04-15T08:45:14.777Z",
    "user": 2,
    "content_type": 9,
    "object_id": "175",
    "object_repr": "HSP90 Binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1074,
  "fields": {
    "action_time": "2025-04-15T08:45:38.180Z",
    "user": 2,
    "content_type": 9,
    "object_id": "176",
    "object_repr": "HSP90-mediated  BMAL1 modulation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1075,
  "fields": {
    "action_time": "2025-04-15T08:46:06.719Z",
    "user": 2,
    "content_type": 12,
    "object_id": "111",
    "object_repr": "HSP90",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1076,
  "fields": {
    "action_time": "2025-04-15T08:46:16.976Z",
    "user": 2,
    "content_type": 10,
    "object_id": "298",
    "object_repr": "17-DMAG",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1077,
  "fields": {
    "action_time": "2025-04-15T08:50:32.173Z",
    "user": 2,
    "content_type": 9,
    "object_id": "177",
    "object_repr": "CK2 inhibition",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1078,
  "fields": {
    "action_time": "2025-04-15T08:51:36.752Z",
    "user": 2,
    "content_type": 12,
    "object_id": "112",
    "object_repr": "CK2 beta",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1079,
  "fields": {
    "action_time": "2025-04-15T08:53:03.659Z",
    "user": 2,
    "content_type": 12,
    "object_id": "112",
    "object_repr": "CK2 alpha",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Targetsname\", \"Targetsfullname\", \"Targeturl\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1080,
  "fields": {
    "action_time": "2025-04-15T08:53:29.513Z",
    "user": 2,
    "content_type": 10,
    "object_id": "299",
    "object_repr": "GO289",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1081,
  "fields": {
    "action_time": "2025-04-15T10:16:58.757Z",
    "user": 2,
    "content_type": 9,
    "object_id": "178",
    "object_repr": "p53 stabilization and apoptosis induction",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1082,
  "fields": {
    "action_time": "2025-04-15T10:18:29.009Z",
    "user": 2,
    "content_type": 10,
    "object_id": "300",
    "object_repr": "SR1078",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1083,
  "fields": {
    "action_time": "2025-05-05T13:15:21.267Z",
    "user": 2,
    "content_type": 10,
    "object_id": "300",
    "object_repr": "SR1078",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1084,
  "fields": {
    "action_time": "2025-05-05T13:36:58.393Z",
    "user": 2,
    "content_type": 9,
    "object_id": "179",
    "object_repr": "Adenosine Monophosphate-Activated Protein Kinase (AMPK)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1085,
  "fields": {
    "action_time": "2025-05-05T13:37:41.994Z",
    "user": 2,
    "content_type": 9,
    "object_id": "180",
    "object_repr": "Nuclear Factor Kappa B (NF- κB)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1086,
  "fields": {
    "action_time": "2025-05-05T13:37:55.673Z",
    "user": 2,
    "content_type": 9,
    "object_id": "181",
    "object_repr": "Janus kinase (JAK)/signal transducer and activator of transcription (STAT)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1087,
  "fields": {
    "action_time": "2025-05-05T13:38:05.627Z",
    "user": 2,
    "content_type": 9,
    "object_id": "182",
    "object_repr": "Nod-like receptor family protein (NLRP)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1088,
  "fields": {
    "action_time": "2025-05-05T13:38:22.927Z",
    "user": 2,
    "content_type": 9,
    "object_id": "183",
    "object_repr": "Toll-like receptors (TLRs)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1089,
  "fields": {
    "action_time": "2025-05-05T13:38:33.293Z",
    "user": 2,
    "content_type": 9,
    "object_id": "184",
    "object_repr": "Mitogen-Activated Signaling Proteins (MAPK)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1090,
  "fields": {
    "action_time": "2025-05-05T13:38:48.138Z",
    "user": 2,
    "content_type": 9,
    "object_id": "185",
    "object_repr": "Mammalian Target of Rapamycin (mTOR) signaling pathway",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1091,
  "fields": {
    "action_time": "2025-05-05T13:40:25.045Z",
    "user": 2,
    "content_type": 12,
    "object_id": "113",
    "object_repr": "AMPK",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1092,
  "fields": {
    "action_time": "2025-05-05T13:41:55.763Z",
    "user": 2,
    "content_type": 12,
    "object_id": "114",
    "object_repr": "JAC (Janus kinase)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1093,
  "fields": {
    "action_time": "2025-05-05T13:42:25.799Z",
    "user": 2,
    "content_type": 10,
    "object_id": "301",
    "object_repr": "Vanillic Acid",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1094,
  "fields": {
    "action_time": "2025-05-05T13:51:02.921Z",
    "user": 2,
    "content_type": 9,
    "object_id": "186",
    "object_repr": "TRPV1 capsaicin site binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1095,
  "fields": {
    "action_time": "2025-05-05T13:51:12.340Z",
    "user": 2,
    "content_type": 12,
    "object_id": "115",
    "object_repr": "TRPV1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1096,
  "fields": {
    "action_time": "2025-05-05T13:51:41.498Z",
    "user": 2,
    "content_type": 10,
    "object_id": "302",
    "object_repr": "Capsaicin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1097,
  "fields": {
    "action_time": "2025-05-05T13:58:07.057Z",
    "user": 2,
    "content_type": 9,
    "object_id": "187",
    "object_repr": "adenosine receptor binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1098,
  "fields": {
    "action_time": "2025-05-05T14:00:14.624Z",
    "user": 2,
    "content_type": 10,
    "object_id": "303",
    "object_repr": "Caffeine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1099,
  "fields": {
    "action_time": "2025-05-05T14:15:31.495Z",
    "user": 2,
    "content_type": 9,
    "object_id": "188",
    "object_repr": "inhibition of serotonin N-acetyltransferase",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1100,
  "fields": {
    "action_time": "2025-05-05T14:16:21.994Z",
    "user": 2,
    "content_type": 12,
    "object_id": "116",
    "object_repr": "Serotonin N-acetyltransferase",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1101,
  "fields": {
    "action_time": "2025-05-05T14:17:59.898Z",
    "user": 2,
    "content_type": 10,
    "object_id": "304",
    "object_repr": "Myricetin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1102,
  "fields": {
    "action_time": "2025-05-06T08:04:35.555Z",
    "user": 2,
    "content_type": 10,
    "object_id": "305",
    "object_repr": "Physcione",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1103,
  "fields": {
    "action_time": "2025-05-06T08:26:14.348Z",
    "user": 2,
    "content_type": 10,
    "object_id": "306",
    "object_repr": "Piceatannol",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1104,
  "fields": {
    "action_time": "2025-05-06T08:33:06.214Z",
    "user": 2,
    "content_type": 10,
    "object_id": "307",
    "object_repr": "Puerarin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1105,
  "fields": {
    "action_time": "2025-05-06T08:34:07.923Z",
    "user": 2,
    "content_type": 10,
    "object_id": "307",
    "object_repr": "Puerarin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1106,
  "fields": {
    "action_time": "2025-05-06T08:43:16.762Z",
    "user": 2,
    "content_type": 9,
    "object_id": "189",
    "object_repr": "caspase, Bax, TNF-α, and NF-MB",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1107,
  "fields": {
    "action_time": "2025-05-06T08:43:26.173Z",
    "user": 2,
    "content_type": 9,
    "object_id": "190",
    "object_repr": "Antioxidant",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1108,
  "fields": {
    "action_time": "2025-05-06T08:44:47.354Z",
    "user": 2,
    "content_type": 10,
    "object_id": "308",
    "object_repr": "Hesperidin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1109,
  "fields": {
    "action_time": "2025-05-06T11:54:11.491Z",
    "user": 2,
    "content_type": 10,
    "object_id": "309",
    "object_repr": "Theanine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1110,
  "fields": {
    "action_time": "2025-05-06T12:08:52.903Z",
    "user": 2,
    "content_type": 9,
    "object_id": "191",
    "object_repr": "cAMP signaling cascade",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1111,
  "fields": {
    "action_time": "2025-05-06T12:10:07.096Z",
    "user": 2,
    "content_type": 9,
    "object_id": "192",
    "object_repr": "Modulation of PI3K/Akt",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1112,
  "fields": {
    "action_time": "2025-05-06T12:10:40.457Z",
    "user": 2,
    "content_type": 12,
    "object_id": "117",
    "object_repr": "PI3K/Akt",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1113,
  "fields": {
    "action_time": "2025-05-06T12:12:00.536Z",
    "user": 2,
    "content_type": 12,
    "object_id": "118",
    "object_repr": "NF-kB",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1114,
  "fields": {
    "action_time": "2025-05-06T12:12:03.817Z",
    "user": 2,
    "content_type": 10,
    "object_id": "310",
    "object_repr": "Theophylline",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1115,
  "fields": {
    "action_time": "2025-05-06T12:19:16.565Z",
    "user": 2,
    "content_type": 10,
    "object_id": "311",
    "object_repr": "Fisetin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1116,
  "fields": {
    "action_time": "2025-05-06T12:31:46.885Z",
    "user": 2,
    "content_type": 10,
    "object_id": "312",
    "object_repr": "Baicalein",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1117,
  "fields": {
    "action_time": "2025-05-06T12:40:49.435Z",
    "user": 2,
    "content_type": 10,
    "object_id": "313",
    "object_repr": "Chicoric acid",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1118,
  "fields": {
    "action_time": "2025-05-06T12:48:25.394Z",
    "user": 2,
    "content_type": 9,
    "object_id": "193",
    "object_repr": "Per2 expression induction",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1119,
  "fields": {
    "action_time": "2025-05-06T12:48:32.004Z",
    "user": 2,
    "content_type": 10,
    "object_id": "314",
    "object_repr": "Curcumin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1120,
  "fields": {
    "action_time": "2025-05-06T12:54:00.195Z",
    "user": 2,
    "content_type": 10,
    "object_id": "315",
    "object_repr": "Bavachalcone",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1121,
  "fields": {
    "action_time": "2025-05-06T12:54:45.936Z",
    "user": 2,
    "content_type": 10,
    "object_id": "315",
    "object_repr": "Bavachalcone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1122,
  "fields": {
    "action_time": "2025-05-06T13:04:29.697Z",
    "user": 2,
    "content_type": 10,
    "object_id": "316",
    "object_repr": "Genistein",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1123,
  "fields": {
    "action_time": "2025-05-12T11:29:31.711Z",
    "user": 2,
    "content_type": 10,
    "object_id": "6",
    "object_repr": "Resveratrol",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1124,
  "fields": {
    "action_time": "2025-05-15T07:48:06.797Z",
    "user": 2,
    "content_type": 10,
    "object_id": "8",
    "object_repr": "Melatonin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Target\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1125,
  "fields": {
    "action_time": "2025-05-15T07:49:40.475Z",
    "user": 2,
    "content_type": 9,
    "object_id": "194",
    "object_repr": "Melatonin receptor agonist",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1126,
  "fields": {
    "action_time": "2025-05-15T07:50:21.323Z",
    "user": 2,
    "content_type": 10,
    "object_id": "8",
    "object_repr": "Melatonin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Mechanisms\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1127,
  "fields": {
    "action_time": "2025-05-15T07:50:50.520Z",
    "user": 2,
    "content_type": 10,
    "object_id": "8",
    "object_repr": "Melatonin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Mechanisms\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1128,
  "fields": {
    "action_time": "2025-05-15T07:54:19.100Z",
    "user": 2,
    "content_type": 9,
    "object_id": "195",
    "object_repr": "Antioxidant",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1129,
  "fields": {
    "action_time": "2025-05-15T07:54:54.433Z",
    "user": 2,
    "content_type": 12,
    "object_id": "119",
    "object_repr": "Mel1C",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1130,
  "fields": {
    "action_time": "2025-05-15T07:55:31.899Z",
    "user": 2,
    "content_type": 12,
    "object_id": "120",
    "object_repr": "CAND2",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1131,
  "fields": {
    "action_time": "2025-05-15T07:56:37.163Z",
    "user": 2,
    "content_type": 12,
    "object_id": "121",
    "object_repr": "VDR",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1132,
  "fields": {
    "action_time": "2025-05-15T07:57:20.798Z",
    "user": 2,
    "content_type": 12,
    "object_id": "122",
    "object_repr": "QR2",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1133,
  "fields": {
    "action_time": "2025-05-15T07:57:58.032Z",
    "user": 2,
    "content_type": 12,
    "object_id": "123",
    "object_repr": "MMP9",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1134,
  "fields": {
    "action_time": "2025-05-15T07:58:33.035Z",
    "user": 2,
    "content_type": 12,
    "object_id": "124",
    "object_repr": "PEPSIN",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1135,
  "fields": {
    "action_time": "2025-05-15T07:59:00.103Z",
    "user": 2,
    "content_type": 12,
    "object_id": "125",
    "object_repr": "PP2A",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1136,
  "fields": {
    "action_time": "2025-05-15T08:00:06.480Z",
    "user": 2,
    "content_type": 12,
    "object_id": "126",
    "object_repr": "mPTP",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1137,
  "fields": {
    "action_time": "2025-05-15T08:00:48.177Z",
    "user": 2,
    "content_type": 12,
    "object_id": "127",
    "object_repr": "PEPT1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1138,
  "fields": {
    "action_time": "2025-05-15T08:01:14.076Z",
    "user": 2,
    "content_type": 12,
    "object_id": "128",
    "object_repr": "PEPT2",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1139,
  "fields": {
    "action_time": "2025-05-15T08:02:04.057Z",
    "user": 2,
    "content_type": 12,
    "object_id": "129",
    "object_repr": "GLUT1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1140,
  "fields": {
    "action_time": "2025-05-15T08:03:15.023Z",
    "user": 2,
    "content_type": 12,
    "object_id": "130",
    "object_repr": "HBS",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1141,
  "fields": {
    "action_time": "2025-05-15T08:03:44.600Z",
    "user": 2,
    "content_type": 12,
    "object_id": "131",
    "object_repr": "CaM",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1142,
  "fields": {
    "action_time": "2025-05-15T08:04:08.048Z",
    "user": 2,
    "content_type": 12,
    "object_id": "132",
    "object_repr": "TUBULIN",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1143,
  "fields": {
    "action_time": "2025-05-15T08:05:05.448Z",
    "user": 2,
    "content_type": 12,
    "object_id": "133",
    "object_repr": "Calreticulin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1144,
  "fields": {
    "action_time": "2025-05-15T08:06:27.828Z",
    "user": 2,
    "content_type": 10,
    "object_id": "8",
    "object_repr": "Melatonin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Mechanisms\", \"Target\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1145,
  "fields": {
    "action_time": "2025-05-15T08:07:16.184Z",
    "user": 2,
    "content_type": 12,
    "object_id": "133",
    "object_repr": "Calreticulin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Targetsfullname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1146,
  "fields": {
    "action_time": "2025-05-15T08:07:50.008Z",
    "user": 2,
    "content_type": 12,
    "object_id": "132",
    "object_repr": "TUBULIN",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Targetsfullname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1147,
  "fields": {
    "action_time": "2025-05-15T08:08:20.324Z",
    "user": 2,
    "content_type": 12,
    "object_id": "131",
    "object_repr": "CaM",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Targetsfullname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1148,
  "fields": {
    "action_time": "2025-05-15T08:09:23.148Z",
    "user": 2,
    "content_type": 12,
    "object_id": "130",
    "object_repr": "HBS",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Targetsfullname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1149,
  "fields": {
    "action_time": "2025-05-15T08:09:52.991Z",
    "user": 2,
    "content_type": 12,
    "object_id": "129",
    "object_repr": "GLUT1",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Targetsfullname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1150,
  "fields": {
    "action_time": "2025-05-15T08:10:14.366Z",
    "user": 2,
    "content_type": 12,
    "object_id": "128",
    "object_repr": "PEPT2",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Targetsfullname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1151,
  "fields": {
    "action_time": "2025-05-15T08:10:27.575Z",
    "user": 2,
    "content_type": 12,
    "object_id": "127",
    "object_repr": "PEPT1",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Targetsfullname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1152,
  "fields": {
    "action_time": "2025-05-15T08:12:48.373Z",
    "user": 2,
    "content_type": 12,
    "object_id": "126",
    "object_repr": "mPTP",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Targetsfullname\", \"Targeturl\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1153,
  "fields": {
    "action_time": "2025-05-15T08:13:21.122Z",
    "user": 2,
    "content_type": 12,
    "object_id": "120",
    "object_repr": "CAND2",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Targetsfullname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1154,
  "fields": {
    "action_time": "2025-05-15T08:13:56.870Z",
    "user": 2,
    "content_type": 12,
    "object_id": "121",
    "object_repr": "VDR",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Targetsfullname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1155,
  "fields": {
    "action_time": "2025-05-15T08:14:21.138Z",
    "user": 2,
    "content_type": 12,
    "object_id": "122",
    "object_repr": "QR2",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Targetsfullname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1156,
  "fields": {
    "action_time": "2025-05-15T08:14:43.122Z",
    "user": 2,
    "content_type": 12,
    "object_id": "125",
    "object_repr": "PP2A",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Targetsfullname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1157,
  "fields": {
    "action_time": "2025-05-24T07:25:05.439Z",
    "user": 2,
    "content_type": 14,
    "object_id": "4",
    "object_repr": "Sulaimani, N., Houghton, M.J., Bonham, M.P. and Williamson, G., 2024. Effects of (Poly) Phenols on Circadian Clock Gene–Mediated Metabolic Homeostasis in Cultured Mammalian Cells: A Scoping Review. Ad",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1158,
  "fields": {
    "action_time": "2025-05-24T07:26:11.312Z",
    "user": 2,
    "content_type": 14,
    "object_id": "5",
    "object_repr": "Zhou, L., Xiao, X., Zhang, Q., Zheng, J., Li, M., Yu, M., Wang, X., Deng, M., Zhai, X., Li, R. and Liu, J., 2019. Dietary genistein could modulate hypothalamic circadian entrainment, reduce body weigh",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1159,
  "fields": {
    "action_time": "2025-05-24T07:40:51.286Z",
    "user": 2,
    "content_type": 13,
    "object_id": "2",
    "object_repr": "Modulates circadian entrainment in hypothalamus",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1160,
  "fields": {
    "action_time": "2025-05-24T07:40:54.862Z",
    "user": 2,
    "content_type": 10,
    "object_id": "316",
    "object_repr": "Genistein",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1161,
  "fields": {
    "action_time": "2025-05-24T07:43:59.366Z",
    "user": 2,
    "content_type": 14,
    "object_id": "6",
    "object_repr": "Dang, Y., Ling, S., Ma, J., Ni, R. and Xu, J.W., 2015. Bavachalcone enhances RORα expression, controls Bmal1 circadian transcription, and depresses cellular senescence in human endothelial cells. Evid",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1162,
  "fields": {
    "action_time": "2025-05-24T07:44:53.458Z",
    "user": 2,
    "content_type": 13,
    "object_id": "3",
    "object_repr": "activated RORα1 luciferase reporter activity",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1163,
  "fields": {
    "action_time": "2025-05-24T07:44:59.422Z",
    "user": 2,
    "content_type": 10,
    "object_id": "315",
    "object_repr": "Bavachalcone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1164,
  "fields": {
    "action_time": "2025-05-24T07:46:27.442Z",
    "user": 2,
    "content_type": 14,
    "object_id": "7",
    "object_repr": "Sarma, A., Sharma, V.P., Sarkar, A.B., Sekar, M.C., Samuel, K. and Geusz, M.E., 2016. The circadian clock modulates anti-cancer properties of curcumin. BMC cancer, 16, pp.1-13.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1165,
  "fields": {
    "action_time": "2025-05-24T07:47:03.105Z",
    "user": 2,
    "content_type": 13,
    "object_id": "4",
    "object_repr": "Dose causes a rhythmic pattern of mPER2 with an average period of 24.48 h for PER2",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1166,
  "fields": {
    "action_time": "2025-05-24T07:48:01.514Z",
    "user": 2,
    "content_type": 10,
    "object_id": "314",
    "object_repr": "Curcumin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Chemspider\", \"Drugbank\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1167,
  "fields": {
    "action_time": "2025-05-24T07:49:37.580Z",
    "user": 2,
    "content_type": 14,
    "object_id": "8",
    "object_repr": "Guo, R., Zhao, B., Wang, Y., Wu, D., Wang, Y., Yu, Y., Yan, Y., Zhang, W., Liu, Z. and Liu, X., 2018. Cichoric acid prevents free-fatty-acid-induced lipid metabolism disorders via regulating Bmal1 in ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1168,
  "fields": {
    "action_time": "2025-05-24T07:49:59.459Z",
    "user": 2,
    "content_type": 13,
    "object_id": "5",
    "object_repr": "restores normal circadian rhythms",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1169,
  "fields": {
    "action_time": "2025-05-24T07:50:03.789Z",
    "user": 2,
    "content_type": 10,
    "object_id": "313",
    "object_repr": "Chicoric acid",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1170,
  "fields": {
    "action_time": "2025-05-24T07:52:54.123Z",
    "user": 2,
    "content_type": 9,
    "object_id": "196",
    "object_repr": "PGC-1α interaction",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1171,
  "fields": {
    "action_time": "2025-05-24T07:53:16.872Z",
    "user": 2,
    "content_type": 12,
    "object_id": "134",
    "object_repr": "PGC-1α",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1172,
  "fields": {
    "action_time": "2025-05-24T07:53:24.246Z",
    "user": 2,
    "content_type": 10,
    "object_id": "313",
    "object_repr": "Chicoric acid",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Mechanisms\", \"Target\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1173,
  "fields": {
    "action_time": "2025-05-24T07:55:11.026Z",
    "user": 2,
    "content_type": 14,
    "object_id": "9",
    "object_repr": "Paul, A., Das, P., Gogoi, M., Islam, M.A., Das, S. and Zaman, M.K., 2024. Baicalein: multiple pharmacological activities, pharmacokinetics, and clinical trials. Revista Brasileira de Farmacognosia, pp",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1174,
  "fields": {
    "action_time": "2025-05-24T07:56:57.601Z",
    "user": 2,
    "content_type": 13,
    "object_id": "6",
    "object_repr": "↑ RORα exprssion",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1175,
  "fields": {
    "action_time": "2025-05-24T07:57:00.316Z",
    "user": 2,
    "content_type": 10,
    "object_id": "312",
    "object_repr": "Baicalein",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1176,
  "fields": {
    "action_time": "2025-05-24T07:58:20.596Z",
    "user": 2,
    "content_type": 13,
    "object_id": "7",
    "object_repr": "increased protein expression of the core clocks BMAL1 and CLOCK",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1177,
  "fields": {
    "action_time": "2025-05-24T07:59:24.902Z",
    "user": 2,
    "content_type": 14,
    "object_id": "10",
    "object_repr": "Zhang, R., Liu, M., Lu, J., Lu, S., Wang, Y. and Guan, S., 2024. Fisetin Ameliorates Hepatocyte Lipid Droplet Accumulation via Targeting the Rhythmic Protein BMAL1 to Regulate Cell Death-Inducing DNA ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1178,
  "fields": {
    "action_time": "2025-05-24T07:59:32.367Z",
    "user": 2,
    "content_type": 10,
    "object_id": "311",
    "object_repr": "Fisetin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1179,
  "fields": {
    "action_time": "2025-05-24T08:00:41.355Z",
    "user": 2,
    "content_type": 14,
    "object_id": "11",
    "object_repr": "Ehret, C.F., Potter, V.R. and Dobra, K.W., 1975. Chronotypic action of theophylline and of pentobarbital as circadian zeitgebers in the rat. Science, 188(4194), pp.1212-1215.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1180,
  "fields": {
    "action_time": "2025-05-24T08:01:44.220Z",
    "user": 2,
    "content_type": 14,
    "object_id": "12",
    "object_repr": "Szarłowicz, J., Mazur, M., Waz, D., Goliszek, Z., Sobek, K.Ł., Tabin-Barczak, W., Sokołowska, A., Fikas, K., Chwaliszewski, K. and Samuła, S., 2025. Theophylline Revisited. Mechanisms, Challenges, and",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1181,
  "fields": {
    "action_time": "2025-05-24T08:03:08.457Z",
    "user": 2,
    "content_type": 14,
    "object_id": "13",
    "object_repr": "Olivares-Yañez, C., Alessandri, M.P., Salas, L. and Larrondo, L.F., 2023. Methylxanthines modulate circadian period length independently of the action of phosphodiesterase. Microbiology Spectrum, 11(4",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1182,
  "fields": {
    "action_time": "2025-05-24T08:03:17.038Z",
    "user": 2,
    "content_type": 13,
    "object_id": "8",
    "object_repr": "cause period lengthening in a concentration-dependent manner",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1183,
  "fields": {
    "action_time": "2025-05-24T08:03:25.235Z",
    "user": 2,
    "content_type": 10,
    "object_id": "310",
    "object_repr": "Theophylline",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1184,
  "fields": {
    "action_time": "2025-05-24T08:06:42.026Z",
    "user": 2,
    "content_type": 9,
    "object_id": "197",
    "object_repr": "canonical PDE-cAMP-PKA signaling axis",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1185,
  "fields": {
    "action_time": "2025-05-24T08:09:30.657Z",
    "user": 2,
    "content_type": 14,
    "object_id": "14",
    "object_repr": "Manrui, L., Xu, Y., Liu, J., Zhang, X., Yuan, R., Sun, Y., Sun, Y., Yang, Q., Liao, M., Lv, M. and Hu, X., 2025. Aminophylline targets miR-128-3p/Slc7a11 axis to attenuate neuronal ferroptosis after t",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1186,
  "fields": {
    "action_time": "2025-05-24T08:11:13.249Z",
    "user": 2,
    "content_type": 9,
    "object_id": "198",
    "object_repr": "cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1187,
  "fields": {
    "action_time": "2025-05-24T08:11:34.962Z",
    "user": 2,
    "content_type": 9,
    "object_id": "199",
    "object_repr": "cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Inhibitor",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1188,
  "fields": {
    "action_time": "2025-05-24T08:11:42.982Z",
    "user": 2,
    "content_type": 9,
    "object_id": "200",
    "object_repr": "Adenosine receptor A1Antagonist",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1189,
  "fields": {
    "action_time": "2025-05-24T08:11:50.221Z",
    "user": 2,
    "content_type": 9,
    "object_id": "201",
    "object_repr": "Adenosine receptor A3Antagonist",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1190,
  "fields": {
    "action_time": "2025-05-24T08:12:34.233Z",
    "user": 2,
    "content_type": 10,
    "object_id": "317",
    "object_repr": "aminophylline",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1191,
  "fields": {
    "action_time": "2025-05-24T08:12:48.110Z",
    "user": 2,
    "content_type": 10,
    "object_id": "317",
    "object_repr": "Aminophylline",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1192,
  "fields": {
    "action_time": "2025-05-24T08:13:58.456Z",
    "user": 2,
    "content_type": 13,
    "object_id": "9",
    "object_repr": "l-Theanine significantly enhanced the expression of BMAL1, a clock gene in melanoma cells.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1193,
  "fields": {
    "action_time": "2025-05-24T08:14:01.218Z",
    "user": 2,
    "content_type": 10,
    "object_id": "309",
    "object_repr": "Theanine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1194,
  "fields": {
    "action_time": "2025-05-24T08:14:27.152Z",
    "user": 2,
    "content_type": 13,
    "object_id": "10",
    "object_repr": "Increases amplitude of circadian rhtyhms",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1195,
  "fields": {
    "action_time": "2025-05-24T08:15:34.060Z",
    "user": 2,
    "content_type": 14,
    "object_id": "15",
    "object_repr": "Manjula, A., Subashini, R., Punitha, R. and Subramanian, P., 2017. Modulating effects of hesperidin on circadian pattern indices of rotenone induced redox homeostasis in clock mutant (cry b) of Drosop",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1196,
  "fields": {
    "action_time": "2025-05-24T08:16:40.817Z",
    "user": 2,
    "content_type": 14,
    "object_id": "16",
    "object_repr": "Tayal, R., Munjal, K., Gauttam, V.K., Popli, P., Khurana, L. and Choudhary, N., 2023. Potential role of hesperidin in lifestyle disorders: A scoping review. South African Journal of Botany, 161, pp.54",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1197,
  "fields": {
    "action_time": "2025-05-24T08:17:41.463Z",
    "user": 2,
    "content_type": 14,
    "object_id": "17",
    "object_repr": "Jayapalan, J.J., Subramanian, P., Kani, A., Hiji, J., Najjar, S.G., Abdul‐Rahman, P.S. and Hashim, O.H., 2020. Hesperidin modulates the rhythmic proteomic profiling in Drosophila melanogaster under ox",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1198,
  "fields": {
    "action_time": "2025-05-24T08:18:10.495Z",
    "user": 2,
    "content_type": 13,
    "object_id": "11",
    "object_repr": "reverses phase delay",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1199,
  "fields": {
    "action_time": "2025-05-24T08:18:13.308Z",
    "user": 2,
    "content_type": 10,
    "object_id": "308",
    "object_repr": "Hesperidin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1200,
  "fields": {
    "action_time": "2025-05-24T08:20:04.667Z",
    "user": 2,
    "content_type": 14,
    "object_id": "18",
    "object_repr": "Chen, M., Zhou, C., Xu, H., Zhang, T. and Wu, B., 2020. Chronopharmacological targeting of Rev-erbα by puerarin alleviates hyperhomocysteinemia in mice. Biomedicine & pharmacotherapy, 125, p.109936.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1201,
  "fields": {
    "action_time": "2025-05-24T08:20:54.016Z",
    "user": 2,
    "content_type": 14,
    "object_id": "19",
    "object_repr": "Liu, J., Xu, H., Zhang, L., Wang, S., Lu, D., Chen, M. and Wu, B., 2021. Chronoeffects of the herbal medicines Puerariae radix and Coptidis rhizoma in mice: A potential role of REV-ERBα. Frontiers in ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1202,
  "fields": {
    "action_time": "2025-05-24T08:22:13.356Z",
    "user": 2,
    "content_type": 13,
    "object_id": "12",
    "object_repr": "increased the expression levels of REV-ERBα target genes Bhmt, Cbs and Cth",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1203,
  "fields": {
    "action_time": "2025-05-24T08:22:38.013Z",
    "user": 2,
    "content_type": 10,
    "object_id": "307",
    "object_repr": "Puerarin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1204,
  "fields": {
    "action_time": "2025-05-24T08:24:03.783Z",
    "user": 2,
    "content_type": 14,
    "object_id": "20",
    "object_repr": "Yamamoto, T., Iwami, S., Aoyama, S., Maruki-Uchida, H., Mori, S., Hirooka, R., Takahashi, K., Morita, M. and Shibata, S., 2019. Effect of piceatannol on circadian Per2 expression in vitro and in vivo.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1205,
  "fields": {
    "action_time": "2025-05-24T08:24:30.392Z",
    "user": 2,
    "content_type": 13,
    "object_id": "13",
    "object_repr": "Piceatannol advanced PER2::LUC luminescence rhythm in peripheral organs in vivo.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1206,
  "fields": {
    "action_time": "2025-05-24T08:24:40.356Z",
    "user": 2,
    "content_type": 13,
    "object_id": "14",
    "object_repr": "recovered phase change of PER2::LUC disturbed by high-fat diet intake.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1207,
  "fields": {
    "action_time": "2025-05-24T08:24:47.532Z",
    "user": 2,
    "content_type": 13,
    "object_id": "15",
    "object_repr": "affects Per2 expression and may prevent circadian disturbance.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1208,
  "fields": {
    "action_time": "2025-05-24T08:24:50.696Z",
    "user": 2,
    "content_type": 10,
    "object_id": "306",
    "object_repr": "Piceatannol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1209,
  "fields": {
    "action_time": "2025-05-24T08:25:32.346Z",
    "user": 2,
    "content_type": 14,
    "object_id": "21",
    "object_repr": "Yao, Y., Zuo, A., Deng, Q., Liu, S., Zhan, T., Wang, M., Xu, H., Ma, J. and Zhao, Y., 2020. Physcion protects against ethanol-induced liver injury by reprogramming of circadian clock. Frontiers in Pha",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1210,
  "fields": {
    "action_time": "2025-05-24T08:26:23.917Z",
    "user": 2,
    "content_type": 14,
    "object_id": "22",
    "object_repr": "Huang, J.Q., Lu, M. and Ho, C.T., 2021. Health benefits of dietary chronobiotics: beyond resynchronizing internal clocks. Food & Function, 12(14), pp.6136-6156.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1211,
  "fields": {
    "action_time": "2025-05-24T08:26:56.711Z",
    "user": 2,
    "content_type": 13,
    "object_id": "16",
    "object_repr": "upregulate core circadian genes and reverse circadian misalignment caused by ethanol in liver cells.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1212,
  "fields": {
    "action_time": "2025-05-24T08:27:24.302Z",
    "user": 2,
    "content_type": 10,
    "object_id": "305",
    "object_repr": "Physcione",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1213,
  "fields": {
    "action_time": "2025-05-24T08:28:17.956Z",
    "user": 2,
    "content_type": 14,
    "object_id": "23",
    "object_repr": "Shin, J.C., Jung, H.Y., Harikishore, A., Kwon, O.D., Yoon, H.S., Kim, K.T. and Choi, B.H., 2013. The flavonoid myricetin reduces nocturnal melatonin levels in the blood through the inhibition of serot",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1214,
  "fields": {
    "action_time": "2025-05-24T08:28:41.088Z",
    "user": 2,
    "content_type": 13,
    "object_id": "17",
    "object_repr": "Night alertness",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1215,
  "fields": {
    "action_time": "2025-05-24T08:28:52.502Z",
    "user": 2,
    "content_type": 13,
    "object_id": "18",
    "object_repr": "Melatonin level reduction",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1216,
  "fields": {
    "action_time": "2025-05-24T08:28:54.936Z",
    "user": 2,
    "content_type": 10,
    "object_id": "304",
    "object_repr": "Myricetin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1217,
  "fields": {
    "action_time": "2025-05-24T08:31:32.203Z",
    "user": 2,
    "content_type": 14,
    "object_id": "24",
    "object_repr": "Burke, T.M., Markwald, R.R., McHill, A.W., Chinoy, E.D., Snider, J.A., Bessman, S.C., Jung, C.M., O’Neill, J.S. and Wright Jr, K.P., 2015. Effects of caffeine on the human circadian clock in vivo and ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1218,
  "fields": {
    "action_time": "2025-05-24T08:31:52.076Z",
    "user": 2,
    "content_type": 10,
    "object_id": "303",
    "object_repr": "Caffeine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1219,
  "fields": {
    "action_time": "2025-05-24T08:34:48.152Z",
    "user": 2,
    "content_type": 14,
    "object_id": "25",
    "object_repr": "Liu, L. and Tian, Y., 2023. Capsaicin changes the pattern of brain rhythms in sleeping rats. Molecules, 28(12), p.4736.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1220,
  "fields": {
    "action_time": "2025-05-24T08:35:43.020Z",
    "user": 2,
    "content_type": 13,
    "object_id": "19",
    "object_repr": "reduced weight gain induced by circadian rhythm disorder",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1221,
  "fields": {
    "action_time": "2025-05-24T08:36:04.648Z",
    "user": 2,
    "content_type": 10,
    "object_id": "302",
    "object_repr": "Capsaicin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1222,
  "fields": {
    "action_time": "2025-05-24T08:36:57.518Z",
    "user": 2,
    "content_type": 14,
    "object_id": "26",
    "object_repr": "Bhavani, P., Subramanian, P. and Shanmugapriya, S., 2016. Modulating effects of vanillic acid on circadian pattern of indices of redox homeostasis in N-Methly-N′-Nitro-N-Nitrosoguanidine induced endom",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1223,
  "fields": {
    "action_time": "2025-05-24T08:37:41.552Z",
    "user": 2,
    "content_type": 14,
    "object_id": "27",
    "object_repr": "Kiessig, R.S., Herz, J.M. and Sweeney, B.M., 1979. Shifting the phase of the circadian rhythm in bioluminescence in Gonyaulax with vanillic acid. Plant Physiology, 63(2), pp.324-327.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1224,
  "fields": {
    "action_time": "2025-05-24T08:38:09.564Z",
    "user": 2,
    "content_type": 14,
    "object_id": "28",
    "object_repr": "Lashgari, N.A., Roudsari, N.M., Momtaz, S., Abdolghaffari, A.H., Atkin, S.L. and Sahebkar, A., 2023. Regulatory mechanisms of vanillic acid in cardiovascular diseases: a review. Current Medicinal Chem",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1225,
  "fields": {
    "action_time": "2025-05-24T08:39:23.878Z",
    "user": 2,
    "content_type": 13,
    "object_id": "20",
    "object_repr": "Decreases phase",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1226,
  "fields": {
    "action_time": "2025-05-24T08:39:27.956Z",
    "user": 2,
    "content_type": 10,
    "object_id": "301",
    "object_repr": "Vanillic Acid",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1227,
  "fields": {
    "action_time": "2025-05-24T08:40:11.857Z",
    "user": 2,
    "content_type": 14,
    "object_id": "29",
    "object_repr": "Rahman S, Wittine K, Sedic M, Markova-Car EP (2020) Small molecules Targeting Biological clock; a novel prospective for anti-cancer drugs. Molecules. ;25(21); doi: ARTN 493710.3390/molecules25214937.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1228,
  "fields": {
    "action_time": "2025-05-24T08:41:03.377Z",
    "user": 2,
    "content_type": 13,
    "object_id": "21",
    "object_repr": "enhancing the expression of the core clock component BMAL1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1229,
  "fields": {
    "action_time": "2025-05-24T08:41:22.317Z",
    "user": 2,
    "content_type": 10,
    "object_id": "300",
    "object_repr": "SR1078",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1230,
  "fields": {
    "action_time": "2025-05-24T08:41:46.547Z",
    "user": 2,
    "content_type": 13,
    "object_id": "22",
    "object_repr": "disrupts the circadian clock specifically in cancer cells",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1231,
  "fields": {
    "action_time": "2025-05-24T08:42:22.586Z",
    "user": 2,
    "content_type": 14,
    "object_id": "30",
    "object_repr": "Oshima, T., Niwa, Y., Kuwata, K., Srivastava, A., Hyoda, T., Tsuchiya, Y., Kumagai, M., Tsuyuguchi, M., Tamaru, T., Sugiyama, A. and Ono, N., 2019. Cell-based screen identifies a new potent and highly",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1232,
  "fields": {
    "action_time": "2025-05-24T08:48:28.882Z",
    "user": 2,
    "content_type": 10,
    "object_id": "299",
    "object_repr": "GO289",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1233,
  "fields": {
    "action_time": "2025-05-24T08:49:21.876Z",
    "user": 2,
    "content_type": 14,
    "object_id": "31",
    "object_repr": "Lee, Y., Fong, S.Y., Shon, J., Zhang, S.L., Brooks, R., Lahens, N.F., Chen, D., Dang, C.V., Field, J.M. and Sehgal, A., 2021. Time-of-day specificity of anticancer drugs may be mediated by circadian r",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1234,
  "fields": {
    "action_time": "2025-05-24T08:49:54.279Z",
    "user": 2,
    "content_type": 14,
    "object_id": "32",
    "object_repr": "Schneider, R., Linka, R.M. and Reinke, H., 2014. HSP90 affects the stability of BMAL1 and circadian gene expression. Journal of Biological Rhythms, 29(2), pp.87-96.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1235,
  "fields": {
    "action_time": "2025-05-24T08:50:29.444Z",
    "user": 2,
    "content_type": 13,
    "object_id": "23",
    "object_repr": "via HSP90 affects the stability of BMAL1 and circadian gene expression.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1236,
  "fields": {
    "action_time": "2025-05-24T08:51:00.811Z",
    "user": 2,
    "content_type": 10,
    "object_id": "298",
    "object_repr": "17-DMAG",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1237,
  "fields": {
    "action_time": "2025-05-24T08:53:33.217Z",
    "user": 2,
    "content_type": 9,
    "object_id": "202",
    "object_repr": "CHK1 inhibitor crosstalk with caseine kinase 1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1238,
  "fields": {
    "action_time": "2025-05-24T08:58:59.421Z",
    "user": 2,
    "content_type": 14,
    "object_id": "33",
    "object_repr": "Collis SJ, Boulton SJ. Emerging links between the biological clock and the DNA damage response. Chromosoma (2007) 116:331–9. doi: 10.1007/s00412-007-0108-6",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1239,
  "fields": {
    "action_time": "2025-05-24T08:59:52.103Z",
    "user": 2,
    "content_type": 10,
    "object_id": "297",
    "object_repr": "Prexasertib",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\", \"Linkslists\", \"Mechanisms\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1240,
  "fields": {
    "action_time": "2025-05-24T09:00:25.492Z",
    "user": 2,
    "content_type": 13,
    "object_id": "24",
    "object_repr": "showed stronger period effects (0.32 μM for 5 h period lengthening) in a cell-based circadian assay",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1241,
  "fields": {
    "action_time": "2025-05-24T09:01:23.122Z",
    "user": 2,
    "content_type": 14,
    "object_id": "34",
    "object_repr": "Lee, J.W., Hirota, T., Ono, D., Honma, S., Honma, K.I., Park, K. and Kay, S.A., 2019. Chemical control of mammalian circadian behavior through dual inhibition of casein kinase Iα and δ. Journal of med",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1242,
  "fields": {
    "action_time": "2025-05-24T09:01:29.118Z",
    "user": 2,
    "content_type": 10,
    "object_id": "296",
    "object_repr": "NCC007",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1243,
  "fields": {
    "action_time": "2025-05-24T09:02:10.296Z",
    "user": 2,
    "content_type": 13,
    "object_id": "25",
    "object_repr": "dose dependently increases wakefulness at the expense of slow-wave and paradoxical sleep with no increase in locomotor activity per unit of time awake",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1244,
  "fields": {
    "action_time": "2025-05-24T09:02:37.126Z",
    "user": 2,
    "content_type": 14,
    "object_id": "35",
    "object_repr": "Kim, D., 2012. Practical use and risk of modafinil, a novel waking drug. Environmental health and toxicology, 27, p.e2012007.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1245,
  "fields": {
    "action_time": "2025-05-24T09:03:58.791Z",
    "user": 2,
    "content_type": 14,
    "object_id": "36",
    "object_repr": "Webb, I.C., Pollock, M.S. and Mistlberger, R.E., 2006. Modafinil [2-[(diphenylmethyl) sulfinyl] acetamide] and circadian rhythms in syrian hamsters: assessment of the chronobiotic potential of a novel",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1246,
  "fields": {
    "action_time": "2025-05-24T09:04:57.388Z",
    "user": 2,
    "content_type": 14,
    "object_id": "37",
    "object_repr": "Uyhelji, H.A., Munster, S.K., White, V.L. and Nicholson, S.J., 2023. Gene expression biomarkers of the response to sleep loss with and without modafinil (No. DOT/FAA/AM-23/25). United States. Departme",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1247,
  "fields": {
    "action_time": "2025-05-24T09:05:01.948Z",
    "user": 2,
    "content_type": 10,
    "object_id": "295",
    "object_repr": "Modafinil",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1248,
  "fields": {
    "action_time": "2025-05-24T09:05:57.123Z",
    "user": 2,
    "content_type": 14,
    "object_id": "38",
    "object_repr": "Miller, S., Kesherwani, M., Chan, P., Nagai, Y., Yagi, M., Cope, J., Tama, F., Kay, S.A. and Hirota, T., 2022. CRY2 isoform selectivity of a circadian clock modulator with antiglioblastoma efficacy. P",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1249,
  "fields": {
    "action_time": "2025-05-24T09:06:59.895Z",
    "user": 2,
    "content_type": 13,
    "object_id": "26",
    "object_repr": "disrupts glioblastoma clock",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1250,
  "fields": {
    "action_time": "2025-05-24T09:07:02.222Z",
    "user": 2,
    "content_type": 10,
    "object_id": "294",
    "object_repr": "SHP1703 ( (R)-1-(3-(3,6-difluoro-9H-carbazol-9-yl)-2-hydroxypropyl)imid-azolidin-2-one )",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1251,
  "fields": {
    "action_time": "2025-05-24T09:07:29.088Z",
    "user": 2,
    "content_type": 10,
    "object_id": "293",
    "object_repr": "SHP656",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1252,
  "fields": {
    "action_time": "2025-05-24T09:09:37.801Z",
    "user": 2,
    "content_type": 13,
    "object_id": "27",
    "object_repr": "can induce a phase delay in circadian rhythms",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1253,
  "fields": {
    "action_time": "2025-05-24T09:10:09.182Z",
    "user": 2,
    "content_type": 14,
    "object_id": "39",
    "object_repr": "Cheong, J.K., Hung, N.T., Wang, H., Tan, P., Voorhoeve, P.M., Lee, S.H. and Virshup, D.M., 2011. IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1δ/ɛ and Wnt/β-catenin indepe",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1254,
  "fields": {
    "action_time": "2025-05-24T09:10:13.043Z",
    "user": 2,
    "content_type": 10,
    "object_id": "292",
    "object_repr": "IC261",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1255,
  "fields": {
    "action_time": "2025-05-24T09:11:20.445Z",
    "user": 2,
    "content_type": 13,
    "object_id": "28",
    "object_repr": "can disrupt circadian rhythms. Studies show scopolamine can influence various aspects of sleep and wakefulness, including sleep onset, delta sleep, an",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1256,
  "fields": {
    "action_time": "2025-05-24T09:11:46.777Z",
    "user": 2,
    "content_type": 14,
    "object_id": "40",
    "object_repr": "Abdel-Rahman, M., Abdel-Kader, S., El-Masry, H. and El-Hennamy, R.E., 2020. Light exposure during late night attenuates the risk of scopolamine-induced Alzheimer disease in aged rats. Egyptian journal",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1257,
  "fields": {
    "action_time": "2025-05-24T09:12:13.416Z",
    "user": 2,
    "content_type": 10,
    "object_id": "291",
    "object_repr": "Scopolamine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1258,
  "fields": {
    "action_time": "2025-05-24T09:13:42.067Z",
    "user": 2,
    "content_type": 14,
    "object_id": "41",
    "object_repr": "Thomas, C.W., Blanco-Duque, C., Bréant, B.J., Goodwin, G.M., Sharp, T., Bannerman, D.M. and Vyazovskiy, V.V., 2022. Psilocin acutely alters sleep-wake architecture and cortical brain activity in labor",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1259,
  "fields": {
    "action_time": "2025-05-24T09:14:40.582Z",
    "user": 2,
    "content_type": 13,
    "object_id": "29",
    "object_repr": "led to delayed REM sleep onset and reduced NREM sleep maintenance for up to approximately 3 h after dosing",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1260,
  "fields": {
    "action_time": "2025-05-24T09:14:57.671Z",
    "user": 2,
    "content_type": 13,
    "object_id": "30",
    "object_repr": "is a rapidly-emerging treatment for depression",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1261,
  "fields": {
    "action_time": "2025-05-24T09:15:19.116Z",
    "user": 2,
    "content_type": 14,
    "object_id": "42",
    "object_repr": "Reid, M.J., Kettner, H., Blanken, T.F., Weiss, B. and Carhartt-Harris, R., 2024. Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1262,
  "fields": {
    "action_time": "2025-05-24T09:15:23.170Z",
    "user": 2,
    "content_type": 10,
    "object_id": "290",
    "object_repr": "Psilocin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1263,
  "fields": {
    "action_time": "2025-05-24T09:16:33.339Z",
    "user": 2,
    "content_type": 14,
    "object_id": "43",
    "object_repr": "Zeng, Y., Guo, Z., Wu, M., Chen, F. and Chen, L., 2024. Circadian rhythm regulates the function of immune cells and participates in the development of tumors. Cell death discovery, 10(1), p.199.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1264,
  "fields": {
    "action_time": "2025-05-24T09:17:12.591Z",
    "user": 2,
    "content_type": 13,
    "object_id": "31",
    "object_repr": "directly targets BMAL1, impacting its ability to regulate gene expression within the circadian clock and immune system",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1265,
  "fields": {
    "action_time": "2025-05-24T09:17:15.282Z",
    "user": 2,
    "content_type": 10,
    "object_id": "289",
    "object_repr": "Core Circadian Modulator (CCM)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1266,
  "fields": {
    "action_time": "2025-05-24T09:21:18.171Z",
    "user": 2,
    "content_type": 14,
    "object_id": "44",
    "object_repr": "Pu, H., Bailey, L.C., Bauer, L.G., Voronkov, M., Baxter, M., Huber, K.V., Khorasanizadeh, S., Ray, D. and Rastinejad, F., 2025. Pharmacological targeting of BMAL1 modulates circadian and immune pathwa",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1267,
  "fields": {
    "action_time": "2025-05-24T09:21:40.240Z",
    "user": 2,
    "content_type": 10,
    "object_id": "288",
    "object_repr": "A340",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1268,
  "fields": {
    "action_time": "2025-05-24T09:22:16.310Z",
    "user": 2,
    "content_type": 10,
    "object_id": "287",
    "object_repr": "A190",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1269,
  "fields": {
    "action_time": "2025-05-24T09:23:39.829Z",
    "user": 2,
    "content_type": 14,
    "object_id": "45",
    "object_repr": "Kobayashi, Y., Lu, Y., Li, N., Endo, N., Sotome, K., Ueno, K., Tahara, Y. and Ishihara, A., 2024. A new phthalide derivative from the mushroom Cyclocybe cf. erebia culture filtrate affects the phase o",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1270,
  "fields": {
    "action_time": "2025-05-24T09:24:34.473Z",
    "user": 2,
    "content_type": 13,
    "object_id": "32",
    "object_repr": "Advances circadian rhtyhms",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1271,
  "fields": {
    "action_time": "2025-05-24T09:24:37.170Z",
    "user": 2,
    "content_type": 10,
    "object_id": "286",
    "object_repr": "Cyclocybelide",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1272,
  "fields": {
    "action_time": "2025-05-24T09:25:18.772Z",
    "user": 2,
    "content_type": 14,
    "object_id": "46",
    "object_repr": "Mawatari, K., Koike, N., Nohara, K., Wirianto, M., Uebanso, T., Shimohata, T., Shikishima, Y., Miura, H., Nii, Y., Burish, M.J. and Yagita, K., 2023. The polymethoxyflavone sudachitin modulates the ci",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1273,
  "fields": {
    "action_time": "2025-05-24T09:26:05.597Z",
    "user": 2,
    "content_type": 10,
    "object_id": "285",
    "object_repr": "Sudachitin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1274,
  "fields": {
    "action_time": "2025-05-24T09:27:03.329Z",
    "user": 2,
    "content_type": 14,
    "object_id": "47",
    "object_repr": "Yagita, K. and Okamura, H., 2000. Forskolin induces circadian gene expression of rPer1, rPer2 and dbp in mammalian rat-1 fibroblasts. FEBS letters, 465(1), pp.79-82.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1275,
  "fields": {
    "action_time": "2025-05-24T09:27:06.826Z",
    "user": 2,
    "content_type": 10,
    "object_id": "284",
    "object_repr": "Forskolin (Colforsin)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1276,
  "fields": {
    "action_time": "2025-05-24T09:28:51.776Z",
    "user": 2,
    "content_type": 14,
    "object_id": "48",
    "object_repr": "Han, C., Wirianto, M., Kim, E., Burish, M.J., Yoo, S.H. and Chen, Z., 2021. Clock-modulating activities of the anti-arrhythmic drug moricizine. Clocks & sleep, 3(3), pp.351-365.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1277,
  "fields": {
    "action_time": "2025-05-24T09:29:33.822Z",
    "user": 2,
    "content_type": 13,
    "object_id": "33",
    "object_repr": "was found to promote sleep, alter circadian gene expression in the heart, and show a slight trend of increasing free-running periods. Together, these",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1278,
  "fields": {
    "action_time": "2025-05-24T09:29:36.331Z",
    "user": 2,
    "content_type": 10,
    "object_id": "283",
    "object_repr": "MORICIZINE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1279,
  "fields": {
    "action_time": "2025-05-24T09:31:02.492Z",
    "user": 2,
    "content_type": 14,
    "object_id": "49",
    "object_repr": "Stein, R.M., Kang, H.J., McCorvy, J.D., Glatfelter, G.C., Jones, A.J., Che, T., Slocum, S., Huang, X.P., Savych, O., Moroz, Y.S. and Stauch, B., 2020. Virtual discovery of melatonin receptor ligands t",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1280,
  "fields": {
    "action_time": "2025-05-24T09:32:13.525Z",
    "user": 2,
    "content_type": 13,
    "object_id": "34",
    "object_repr": "lengthened the periods of BMAL1 and PER2",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1281,
  "fields": {
    "action_time": "2025-05-24T09:32:20.259Z",
    "user": 2,
    "content_type": 10,
    "object_id": "282",
    "object_repr": "UCSF7447",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1282,
  "fields": {
    "action_time": "2025-05-24T09:33:13.700Z",
    "user": 2,
    "content_type": 14,
    "object_id": "50",
    "object_repr": "Fisher, S.P. and Sugden, D., 2009. Sleep-promoting action of IIK7, a selective MT2 melatonin receptor agonist in the rat. Neuroscience letters, 457(2), pp.93-96.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1283,
  "fields": {
    "action_time": "2025-05-24T09:33:38.348Z",
    "user": 2,
    "content_type": 13,
    "object_id": "35",
    "object_repr": "significantly reduced NREM sleep onset latency and transiently increased the time spent in NREM sleep, but did not alter REM sleep latency or the amou",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1284,
  "fields": {
    "action_time": "2025-05-24T09:33:51.971Z",
    "user": 2,
    "content_type": 13,
    "object_id": "36",
    "object_repr": "acute sleep-promoting activity",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1285,
  "fields": {
    "action_time": "2025-05-24T09:33:54.435Z",
    "user": 2,
    "content_type": 10,
    "object_id": "281",
    "object_repr": "IIK7",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1286,
  "fields": {
    "action_time": "2025-05-24T09:34:45.878Z",
    "user": 2,
    "content_type": 14,
    "object_id": "51",
    "object_repr": "Kanki, M. and Young, M.J., 2021. Corticosteroids and circadian rhythms in the cardiovascular system. Current Opinion in Pharmacology, 57, pp.21-27.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1287,
  "fields": {
    "action_time": "2025-05-24T09:35:22.697Z",
    "user": 2,
    "content_type": 10,
    "object_id": "280",
    "object_repr": "Hydrocortisone (Cortisole)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1288,
  "fields": {
    "action_time": "2025-05-24T09:35:51.635Z",
    "user": 2,
    "content_type": 13,
    "object_id": "37",
    "object_repr": "Aldosterone influences the expression of clock genes such as Per1, Per2, and Bmal1 in cardiomyoblasts",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1289,
  "fields": {
    "action_time": "2025-05-24T09:36:16.026Z",
    "user": 2,
    "content_type": 14,
    "object_id": "52",
    "object_repr": "Tanaka, K., Ashizawa, N., Kawano, H., Sato, O., Seto, S., Nishihara, E., Terazono, H., Isomoto, S., Shinohara, K. and Yano, K., 2007. Aldosterone induces circadian gene expression of clock genes in H9",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1290,
  "fields": {
    "action_time": "2025-05-24T09:36:18.901Z",
    "user": 2,
    "content_type": 10,
    "object_id": "279",
    "object_repr": "Aldosterone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1291,
  "fields": {
    "action_time": "2025-05-24T09:37:20.004Z",
    "user": 2,
    "content_type": 14,
    "object_id": "53",
    "object_repr": "Jiang, Y., Gen, N., Wang, P., Feng, N. and Lu, X., 2022. Prednisolone induces sleep disorders via inhibition of melatonin secretion by the circadian rhythm in zebrafish. Biomedicine & Pharmacotherapy,",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1292,
  "fields": {
    "action_time": "2025-05-24T09:37:28.574Z",
    "user": 2,
    "content_type": 13,
    "object_id": "38",
    "object_repr": "Disrupts sleep",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1293,
  "fields": {
    "action_time": "2025-05-24T09:37:32.035Z",
    "user": 2,
    "content_type": 10,
    "object_id": "278",
    "object_repr": "Prednisolone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1294,
  "fields": {
    "action_time": "2025-05-24T09:38:20.095Z",
    "user": 2,
    "content_type": 14,
    "object_id": "54",
    "object_repr": "Barnea, M., Madar, Z. and Froy, O., 2013. Dexamethasone induces high-amplitude rhythms in preadipocytes, but hinders circadian expression in differentiated adipocytes. Chronobiology International, 30(",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1295,
  "fields": {
    "action_time": "2025-05-24T09:39:09.240Z",
    "user": 2,
    "content_type": 14,
    "object_id": "55",
    "object_repr": "Balsalobre, A., Brown, S.A., Marcacci, L., Tronche, F., Kellendonk, C., Reichardt, H.M., Schutz, G. and Schibler, U., 2000. Resetting of circadian time in peripheral tissues by glucocorticoid signalin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1296,
  "fields": {
    "action_time": "2025-05-24T09:39:22.365Z",
    "user": 2,
    "content_type": 13,
    "object_id": "39",
    "object_repr": "Resetting of circadian time in peripheral tissues",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1297,
  "fields": {
    "action_time": "2025-05-24T09:39:26.852Z",
    "user": 2,
    "content_type": 10,
    "object_id": "277",
    "object_repr": "Dexamethasone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1298,
  "fields": {
    "action_time": "2025-05-24T09:40:12.333Z",
    "user": 2,
    "content_type": 14,
    "object_id": "56",
    "object_repr": "Smit-McBride, Z., Moisseiev, E., Modjtahedi, S.P., Telander, D.G., Hjelmeland, L.M. and Morse, L.S., 2016. Comparison of in vivo gene expression profiling of RPE/choroid following intravitreal injecti",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1299,
  "fields": {
    "action_time": "2025-05-24T09:40:53.046Z",
    "user": 2,
    "content_type": 13,
    "object_id": "40",
    "object_repr": "alters the circadian rhythm",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1300,
  "fields": {
    "action_time": "2025-05-24T09:40:56.036Z",
    "user": 2,
    "content_type": 10,
    "object_id": "276",
    "object_repr": "Triamcinolone (acetonide)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1301,
  "fields": {
    "action_time": "2025-05-24T09:41:42.922Z",
    "user": 2,
    "content_type": 14,
    "object_id": "57",
    "object_repr": "Yin, J., Kang, Y., McGrath, A.P., Chapman, K., Sjodt, M., Kimura, E., Okabe, A., Koike, T., Miyanohana, Y., Shimizu, Y. and Rallabandi, R., 2022. Molecular mechanism of the wake-promoting agent TAK-92",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1302,
  "fields": {
    "action_time": "2025-05-24T09:42:19.184Z",
    "user": 2,
    "content_type": 10,
    "object_id": "275",
    "object_repr": "TAK‑925 (Danavorexton)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\", \"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1303,
  "fields": {
    "action_time": "2025-05-24T09:43:07.205Z",
    "user": 2,
    "content_type": 13,
    "object_id": "41",
    "object_repr": "improve wakefulness in individuals with certain sleep disorders",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1304,
  "fields": {
    "action_time": "2025-05-24T09:43:09.209Z",
    "user": 2,
    "content_type": 10,
    "object_id": "275",
    "object_repr": "TAK‑925 (Danavorexton)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1305,
  "fields": {
    "action_time": "2025-05-24T09:44:06.154Z",
    "user": 2,
    "content_type": 14,
    "object_id": "58",
    "object_repr": "Morairty, S.R., Revel, F.G., Malherbe, P., Moreau, J.L., Valladao, D., Wettstein, J.G., Kilduff, T.S. and Borroni, E., 2012. Dual hypocretin receptor antagonism is more effective for sleep promotion t",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1306,
  "fields": {
    "action_time": "2025-05-24T09:44:41.837Z",
    "user": 2,
    "content_type": 13,
    "object_id": "42",
    "object_repr": "can attenuate the sleep-promoting effects of the OX2R antagonist",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1307,
  "fields": {
    "action_time": "2025-05-24T09:44:47.118Z",
    "user": 2,
    "content_type": 10,
    "object_id": "274",
    "object_repr": "SB-408124",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1308,
  "fields": {
    "action_time": "2025-05-24T09:45:04.356Z",
    "user": 2,
    "content_type": 10,
    "object_id": "273",
    "object_repr": "SB-334867",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1309,
  "fields": {
    "action_time": "2025-05-24T09:46:13.687Z",
    "user": 2,
    "content_type": 14,
    "object_id": "59",
    "object_repr": "Aluisio, L., Fraser, I., Berdyyeva, T., Tryputsen, V., Shireman, B.T., Shoblock, J., Lovenberg, T., Dugovic, C. and Bonaventure, P., 2014. Pharmacological or genetic orexin1 receptor inhibition attenu",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1310,
  "fields": {
    "action_time": "2025-05-24T09:46:49.611Z",
    "user": 2,
    "content_type": 13,
    "object_id": "43",
    "object_repr": "sleep-promoting effects",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1311,
  "fields": {
    "action_time": "2025-05-24T09:46:51.470Z",
    "user": 2,
    "content_type": 10,
    "object_id": "272",
    "object_repr": "GSK1059865",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1312,
  "fields": {
    "action_time": "2025-05-24T09:48:14.531Z",
    "user": 2,
    "content_type": 13,
    "object_id": "44",
    "object_repr": "reduces the levels of PRR7 protein in Arabidopsis",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1313,
  "fields": {
    "action_time": "2025-05-24T09:48:50.691Z",
    "user": 2,
    "content_type": 14,
    "object_id": "60",
    "object_repr": "Uehara, T.N., Takao, S., Matsuo, H., Saito, A.N., Ota, E., Ono, A., Itami, K., Kinoshita, T., Yamashino, T., Yamaguchi, J. and Nakamichi, N., 2023. A Small-Molecule Modulator Affecting the Clock-Assoc",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1314,
  "fields": {
    "action_time": "2025-05-24T09:56:47.978Z",
    "user": 2,
    "content_type": 10,
    "object_id": "269",
    "object_repr": "TU-892 (5-(3,4-dichlorophenyl)-1-phenyl-1,7-dihydro-4H-pyrazolo[3,4-d] pyrimidine-4,6(5H)-dione)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1315,
  "fields": {
    "action_time": "2025-05-24T09:59:08.605Z",
    "user": 2,
    "content_type": 14,
    "object_id": "61",
    "object_repr": "Christopher, J.A., Aves, S.J., Brown, J., Errey, J.C., Klair, S.S., Langmead, C.J., Mace, O.J., Mould, R., Patel, J.C., Tehan, B.G. and Zhukov, A., 2015. Discovery of HTL6641, a dual orexin receptor a",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1316,
  "fields": {
    "action_time": "2025-05-24T09:59:47.280Z",
    "user": 2,
    "content_type": 13,
    "object_id": "45",
    "object_repr": "primarily affect circadian rhythms by promoting sleep, particularly reducing wakefulness after sleep onset and improving sleep maintenance",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1317,
  "fields": {
    "action_time": "2025-05-24T09:59:51.388Z",
    "user": 2,
    "content_type": 10,
    "object_id": "268",
    "object_repr": "HTL‑6641",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1318,
  "fields": {
    "action_time": "2025-05-24T10:00:51.925Z",
    "user": 2,
    "content_type": 14,
    "object_id": "62",
    "object_repr": "Iwadate, R., Satoh, Y., Watanabe, Y., Kawai, H., Kudo, N., Kawashima, Y., Mashino, T. and Mitsumoto, A., 2012. Impairment of heme biosynthesis induces short circadian period in body temperature rhythm",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1319,
  "fields": {
    "action_time": "2025-05-24T10:01:17.897Z",
    "user": 2,
    "content_type": 13,
    "object_id": "46",
    "object_repr": "~0.3 h shortening of the period of circadian T(b) rhythms in mice kept under conditions of constant darkness (P < 0.01)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1320,
  "fields": {
    "action_time": "2025-05-24T10:01:35.888Z",
    "user": 2,
    "content_type": 10,
    "object_id": "267",
    "object_repr": "Griseofulvin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1321,
  "fields": {
    "action_time": "2025-05-24T10:02:35.374Z",
    "user": 2,
    "content_type": 14,
    "object_id": "63",
    "object_repr": "Du, Y., Chen, X., Kajiwara, S. and Orihara, K., 2024. Effect of Urolithin A on the Improvement of Circadian Rhythm Dysregulation in Intestinal Barrier Induced by Inflammation. Nutrients, 16(14), p.226",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1322,
  "fields": {
    "action_time": "2025-05-24T10:03:06.976Z",
    "user": 2,
    "content_type": 10,
    "object_id": "266",
    "object_repr": "Urolithin A",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\", \"Pubchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1323,
  "fields": {
    "action_time": "2025-05-24T10:04:12.940Z",
    "user": 2,
    "content_type": 14,
    "object_id": "64",
    "object_repr": "Luo, W., Yin, Z., Zhang, M., Huang, X. and Yin, J., 2024. Dietary Lactobacillus delbrueckii Affects Ileal Bacterial Composition and Circadian Rhythms in Pigs. Animals, 14(3), p.412.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1324,
  "fields": {
    "action_time": "2025-05-24T10:04:58.286Z",
    "user": 2,
    "content_type": 13,
    "object_id": "47",
    "object_repr": "improves circadian rhythms in pigs",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1325,
  "fields": {
    "action_time": "2025-05-24T10:05:00.226Z",
    "user": 2,
    "content_type": 10,
    "object_id": "265",
    "object_repr": "Lactobacillus delbrueckii",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1326,
  "fields": {
    "action_time": "2025-05-24T10:06:15.273Z",
    "user": 2,
    "content_type": 14,
    "object_id": "65",
    "object_repr": "Kreuzer, K., Birkl-Toeglhofer, A.M., Haybaeck, J., Reiter, A., Dalkner, N., Fellendorf, F.T., Maget, A., Platzer, M., Seidl, M., Mendel, L.M. and Lenger, M., 2024. PROVIT-CLOCK: A Potential Influence ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1327,
  "fields": {
    "action_time": "2025-05-24T10:07:29.837Z",
    "user": 2,
    "content_type": 10,
    "object_id": "264",
    "object_repr": "OMNi-BiOTiC® Stress Repair",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1328,
  "fields": {
    "action_time": "2025-05-24T10:09:38.456Z",
    "user": 2,
    "content_type": 14,
    "object_id": "66",
    "object_repr": "Wagner, P.M., Fornasier, S.J. and Guido, M.E., 2024. Pharmacological modulation of the cytosolic oscillator affects glioblastoma cell biology. Cellular and Molecular Neurobiology, 44(1), p.51.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1329,
  "fields": {
    "action_time": "2025-05-24T10:09:57.095Z",
    "user": 2,
    "content_type": 13,
    "object_id": "48",
    "object_repr": "Per2 disruption affected both GBM migration and cell cycle progression.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1330,
  "fields": {
    "action_time": "2025-05-24T10:10:14.071Z",
    "user": 2,
    "content_type": 10,
    "object_id": "262",
    "object_repr": "CHIR99021 (Laduviglusib)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1331,
  "fields": {
    "action_time": "2025-05-24T10:11:29.966Z",
    "user": 2,
    "content_type": 13,
    "object_id": "49",
    "object_repr": "period shortening of the mammalian circadian clock by specific inhibition of GSK-3β",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1332,
  "fields": {
    "action_time": "2025-05-24T10:11:46.948Z",
    "user": 2,
    "content_type": 14,
    "object_id": "67",
    "object_repr": "Hirota, T., Lewis, W.G., Liu, A.C., Lee, J.W., Schultz, P.G. and Kay, S.A., 2008. A chemical biology approach reveals period shortening of the mammalian circadian clock by specific inhibition of GSK-3",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1333,
  "fields": {
    "action_time": "2025-05-24T10:11:50.291Z",
    "user": 2,
    "content_type": 10,
    "object_id": "261",
    "object_repr": "Indirubin (Couroupitine B)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1334,
  "fields": {
    "action_time": "2025-05-24T11:18:12.624Z",
    "user": 2,
    "content_type": 14,
    "object_id": "68",
    "object_repr": "Miller, S. and Hirota, T., 2020. Pharmacological interventions to circadian clocks and their molecular bases. Journal of molecular biology, 432(12), pp.3498-3514.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1335,
  "fields": {
    "action_time": "2025-05-24T11:18:18.702Z",
    "user": 2,
    "content_type": 10,
    "object_id": "260",
    "object_repr": "1-Azakenpaullone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1336,
  "fields": {
    "action_time": "2025-05-24T11:19:24.672Z",
    "user": 2,
    "content_type": 10,
    "object_id": "259",
    "object_repr": "PF670462",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1337,
  "fields": {
    "action_time": "2025-05-24T11:20:04.060Z",
    "user": 2,
    "content_type": 14,
    "object_id": "69",
    "object_repr": "Rohr, K.E. and McCarthy, M.J., 2022. The impact of lithium on circadian rhythms and implications for bipolar disorder pharmacotherapy. Neuroscience letters, 786, p.136772.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1338,
  "fields": {
    "action_time": "2025-05-24T11:20:11.589Z",
    "user": 2,
    "content_type": 10,
    "object_id": "258",
    "object_repr": "Li (Lithium Carbonate)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1339,
  "fields": {
    "action_time": "2025-05-24T11:21:06.586Z",
    "user": 2,
    "content_type": 14,
    "object_id": "70",
    "object_repr": "Kon, N., Hirota, T., Kawamoto, T., Kato, Y., Tsubota, T. and Fukada, Y., 2008. Activation of TGF-β/activin signalling resets the circadian clock through rapid induction of Dec1 transcripts. Nature cel",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1340,
  "fields": {
    "action_time": "2025-05-24T11:21:17.095Z",
    "user": 2,
    "content_type": 10,
    "object_id": "257",
    "object_repr": "4-(4-(benzo[d][1,3]dioxol-5-yl)-5-(pyridin-2-yl)-1H-imidazol-2-yl)benzamide",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1341,
  "fields": {
    "action_time": "2025-05-24T11:22:48.784Z",
    "user": 2,
    "content_type": 14,
    "object_id": "71",
    "object_repr": "Lee, J.W., Hirota, T., Peters, E.C., Garcia, M., Gonzalez, R., Cho, C.Y., Wu, X., Schultz, P.G. and Kay, S.A., 2011. A small molecule modulates circadian rhythms through phosphorylation of the period ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1342,
  "fields": {
    "action_time": "2025-05-24T11:22:52.200Z",
    "user": 2,
    "content_type": 10,
    "object_id": "256",
    "object_repr": "LH846",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1343,
  "fields": {
    "action_time": "2025-05-24T11:23:33.263Z",
    "user": 2,
    "content_type": 14,
    "object_id": "72",
    "object_repr": "Siddiqui-Jain, A., Drygin, D., Streiner, N., Chua, P., Pierre, F., O'Brien, S.E., Bliesath, J., Omori, M., Huser, N., Ho, C. and Proffitt, C., 2010. CX-4945, an orally bioavailable selective inhibitor",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1344,
  "fields": {
    "action_time": "2025-05-24T11:23:36.247Z",
    "user": 2,
    "content_type": 10,
    "object_id": "255",
    "object_repr": "CX-4945",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1345,
  "fields": {
    "action_time": "2025-05-24T11:24:46.635Z",
    "user": 2,
    "content_type": 14,
    "object_id": "73",
    "object_repr": "Kolarski, D., Sugiyama, A., Breton, G., Rakers, C., Ono, D., Schulte, A., Tama, F., Itami, K., Szymanski, W., Hirota, T. and Feringa, B.L., 2019. Controlling the circadian clock with high temporal res",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1346,
  "fields": {
    "action_time": "2025-05-24T11:24:50.848Z",
    "user": 2,
    "content_type": 10,
    "object_id": "254",
    "object_repr": "DK359",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1347,
  "fields": {
    "action_time": "2025-05-24T11:26:08.960Z",
    "user": 2,
    "content_type": 14,
    "object_id": "74",
    "object_repr": "Wagner, F.F., Bishop, J.A., Gale, J.P., Shi, X., Walk, M., Ketterman, J., Patnaik, D., Barker, D., Walpita, D., Campbell, A.J. and Nguyen, S., 2016. Inhibitors of glycogen synthase kinase 3 with exqui",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1348,
  "fields": {
    "action_time": "2025-05-24T11:26:24.216Z",
    "user": 2,
    "content_type": 10,
    "object_id": "251",
    "object_repr": "BRD1652",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1349,
  "fields": {
    "action_time": "2025-05-24T11:27:12.742Z",
    "user": 2,
    "content_type": 14,
    "object_id": "75",
    "object_repr": "Hirota, T., Lee, J.W., Lewis, W.G., Zhang, E.E., Breton, G., Liu, X., Garcia, M., Peters, E.C., Etchegaray, J.P., Traver, D. and Schultz, P.G., 2010. High-throughput chemical screen identifies a novel",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1350,
  "fields": {
    "action_time": "2025-05-24T11:27:22.019Z",
    "user": 2,
    "content_type": 10,
    "object_id": "250",
    "object_repr": "Longdaysin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1351,
  "fields": {
    "action_time": "2025-05-24T11:29:54.317Z",
    "user": 2,
    "content_type": 14,
    "object_id": "76",
    "object_repr": "Li, W., Xu, Y., Liu, Z., Shi, M., Zhang, Y., Deng, Y., Zhong, X., Chen, L., He, J., Zeng, J. and Luo, M., 2021. TRPV4 inhibitor HC067047 produces antidepressant-like effect in LPS-induced depression m",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1352,
  "fields": {
    "action_time": "2025-05-24T11:29:58.430Z",
    "user": 2,
    "content_type": 10,
    "object_id": "249",
    "object_repr": "HC067047",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1353,
  "fields": {
    "action_time": "2025-05-24T11:31:04.011Z",
    "user": 2,
    "content_type": 14,
    "object_id": "77",
    "object_repr": "Alkozi, H.A., de Lara, M.J.P. and Pintor, J., 2017. Melatonin synthesis in the human ciliary body triggered by TRPV4 activation: Involvement of AANAT phosphorylation. Experimental eye research, 162, p",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1354,
  "fields": {
    "action_time": "2025-05-24T11:31:06.673Z",
    "user": 2,
    "content_type": 10,
    "object_id": "248",
    "object_repr": "RN-1734",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1355,
  "fields": {
    "action_time": "2025-05-24T11:31:29.626Z",
    "user": 2,
    "content_type": 13,
    "object_id": "50",
    "object_repr": "Affects melatonin synthsis",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1356,
  "fields": {
    "action_time": "2025-05-24T11:31:31.879Z",
    "user": 2,
    "content_type": 10,
    "object_id": "248",
    "object_repr": "RN-1734",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1357,
  "fields": {
    "action_time": "2025-05-24T11:32:07.889Z",
    "user": 2,
    "content_type": 14,
    "object_id": "78",
    "object_repr": "Amaudrut, J., Argiriadi, M.A., Barth, M., Breinlinger, E.C., Bressac, D., Broqua, P., Calderwood, D.J., Chatar, M., Cusack, K.P., Gauld, S.B. and Jacquet, S., 2019. Discovery of novel quinoline sulpho",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1358,
  "fields": {
    "action_time": "2025-05-24T11:32:12.585Z",
    "user": 2,
    "content_type": 10,
    "object_id": "247",
    "object_repr": "Gsk2981278",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1359,
  "fields": {
    "action_time": "2025-05-24T11:33:28.784Z",
    "user": 2,
    "content_type": 14,
    "object_id": "79",
    "object_repr": "Mahalingam, D., Wang, J.S., Hamilton, E.P., Sarantopoulos, J., Nemunaitis, J., Weems, G., Carter, L., Hu, X., Schreeder, M. and Wilkins, H.J., 2019. Phase 1 open-label, multicenter study of first-in-c",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1360,
  "fields": {
    "action_time": "2025-05-24T11:33:31.644Z",
    "user": 2,
    "content_type": 10,
    "object_id": "246",
    "object_repr": "Cintirorgon",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1361,
  "fields": {
    "action_time": "2025-05-24T11:34:20.034Z",
    "user": 2,
    "content_type": 14,
    "object_id": "80",
    "object_repr": "Ribeiro, R.F., Cavadas, C. and Silva, M.M.C., 2021. Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases. Drug Discovery Today, 26(7), pp.1620-164",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1362,
  "fields": {
    "action_time": "2025-05-24T11:34:23.502Z",
    "user": 2,
    "content_type": 10,
    "object_id": "245",
    "object_repr": "AZD-0284e",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1363,
  "fields": {
    "action_time": "2025-05-24T11:34:44.166Z",
    "user": 2,
    "content_type": 10,
    "object_id": "244",
    "object_repr": "ARN-6039",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1364,
  "fields": {
    "action_time": "2025-05-24T11:36:08.821Z",
    "user": 2,
    "content_type": 14,
    "object_id": "81",
    "object_repr": "Liu, S., Liu, D., Shen, R., Li, D., Hu, Q., Yan, Y., Sun, J., Zhang, F., Wan, H., Dong, P. and Feng, J., 2021. Discovery of a novel RORγ antagonist with skin-restricted exposure for topical treatment ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1365,
  "fields": {
    "action_time": "2025-05-24T11:36:13.000Z",
    "user": 2,
    "content_type": 10,
    "object_id": "243",
    "object_repr": "Vtp-43742",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1366,
  "fields": {
    "action_time": "2025-05-24T11:36:52.933Z",
    "user": 2,
    "content_type": 14,
    "object_id": "82",
    "object_repr": "Kojetin, D.J. and Burris, T.P., 2014. REV-ERB and ROR nuclear receptors as drug targets. Nature reviews Drug discovery, 13(3), pp.197-216.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1367,
  "fields": {
    "action_time": "2025-05-24T11:38:24.799Z",
    "user": 2,
    "content_type": 14,
    "object_id": "83",
    "object_repr": "Kwon, E.Y., Shin, S.K. and Choi, M.S., 2018. Ursolic acid attenuates hepatic steatosis, fibrosis, and insulin resistance by modulating the circadian rhythm pathway in diet-induced obese mice. Nutrient",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1368,
  "fields": {
    "action_time": "2025-05-24T11:38:30.801Z",
    "user": 2,
    "content_type": 10,
    "object_id": "242",
    "object_repr": "Ursolic acid",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1369,
  "fields": {
    "action_time": "2025-05-24T11:39:53.541Z",
    "user": 2,
    "content_type": 14,
    "object_id": "84",
    "object_repr": "Zahran, E.M., Mohamad, S.A., Elsayed, M.M., Hisham, M., Maher, S.A., Abdelmohsen, U.R., Elrehany, M., Desoukey, S.Y. and Kamel, M.S., 2024. Ursolic acid inhibits NF-κB signaling and attenuates MMP-9/T",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1370,
  "fields": {
    "action_time": "2025-05-24T11:39:56.875Z",
    "user": 2,
    "content_type": 10,
    "object_id": "242",
    "object_repr": "Ursolic acid",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1371,
  "fields": {
    "action_time": "2025-05-24T11:40:40.597Z",
    "user": 2,
    "content_type": 14,
    "object_id": "85",
    "object_repr": "Huh, J.R., Leung, M.W., Huang, P., Ryan, D.A., Krout, M.R., Malapaka, R.R., Chow, J., Manel, N., Ciofani, M., Kim, S.V. and Cuesta, A., 2011. Digoxin and its derivatives suppress TH17 cell differentia",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1372,
  "fields": {
    "action_time": "2025-05-24T11:40:58.496Z",
    "user": 2,
    "content_type": 10,
    "object_id": "241",
    "object_repr": "Digoxin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1373,
  "fields": {
    "action_time": "2025-05-24T11:41:58.469Z",
    "user": 2,
    "content_type": 14,
    "object_id": "86",
    "object_repr": "Zhang, W., Zhang, J., Fang, L., Zhou, L., Wang, S., Xiang, Z., Li, Y., Wisely, B., Zhang, G., An, G. and Wang, Y., 2012. Increasing human Th17 differentiation through activation of orphan nuclear rece",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1374,
  "fields": {
    "action_time": "2025-05-24T11:42:49.219Z",
    "user": 2,
    "content_type": 14,
    "object_id": "87",
    "object_repr": "Trebucq, L.L., Cardama, G.A., Lorenzano Menna, P., Golombek, D.A., Chiesa, J.J. and Marpegan, L., 2021. Timing of novel drug 1A-116 to circadian rhythms improves therapeutic effects against glioblasto",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1375,
  "fields": {
    "action_time": "2025-05-24T11:42:52.728Z",
    "user": 2,
    "content_type": 10,
    "object_id": "240",
    "object_repr": "Compound 1a",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1376,
  "fields": {
    "action_time": "2025-05-24T11:43:41.117Z",
    "user": 2,
    "content_type": 14,
    "object_id": "88",
    "object_repr": "Helleboid, S., Haug, C., Lamottke, K., Zhou, Y., Wei, J., Daix, S., Cambula, L., Rigou, G., Hum, D.W. and Walczak, R., 2014. The identification of naturally occurring neoruscogenin as a bioavailable, ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1377,
  "fields": {
    "action_time": "2025-05-24T11:43:44.868Z",
    "user": 2,
    "content_type": 10,
    "object_id": "239",
    "object_repr": "Neoruscogenin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1378,
  "fields": {
    "action_time": "2025-05-24T11:45:16.087Z",
    "user": 2,
    "content_type": 13,
    "object_id": "51",
    "object_repr": "prolonged period, increased amplitude, and phase modulation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1379,
  "fields": {
    "action_time": "2025-05-24T11:45:36.427Z",
    "user": 2,
    "content_type": 14,
    "object_id": "89",
    "object_repr": "Ryan, C., Tahara, Y., Haraguchi, A., Lu, Y. and Shibata, S., 2024. Nobiletin stimulates adrenal hormones and modulates the circadian clock in mice. Nutrients, 16(10), p.1491.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1380,
  "fields": {
    "action_time": "2025-05-24T11:45:58.927Z",
    "user": 2,
    "content_type": 14,
    "object_id": "90",
    "object_repr": "Neba Ambe, G.N., Breda, C., Bhambra, A.S. and Arroo, R.R., 2022. Effect of the citrus flavone nobiletin on circadian rhythms and metabolic syndrome. Molecules, 27(22), p.7727.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1381,
  "fields": {
    "action_time": "2025-05-24T11:46:23.822Z",
    "user": 2,
    "content_type": 14,
    "object_id": "91",
    "object_repr": "Lellupitiyage Don, S.S., Robertson, K.L., Lin, H.H., Labriola, C., Harrington, M.E., Taylor, S.R. and Farkas, M.E., 2020. Nobiletin affects circadian rhythms and oncogenic characteristics in a cell-de",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1382,
  "fields": {
    "action_time": "2025-05-24T11:46:43.723Z",
    "user": 2,
    "content_type": 14,
    "object_id": "92",
    "object_repr": "Martchenko, A., Biancolin, A.D., Martchenko, S.E. and Brubaker, P.L., 2022. Nobiletin ameliorates high fat-induced disruptions in rhythmic glucagon-like peptide-1 secretion. Scientific Reports, 12(1),",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1383,
  "fields": {
    "action_time": "2025-05-24T11:47:08.378Z",
    "user": 2,
    "content_type": 14,
    "object_id": "93",
    "object_repr": "Lellupitiyage Don, S.S., Robertson, K.L., Lin, H.H., Labriola, C., Harrington, M.E., Taylor, S.R. and Farkas, M.E., 2020. Nobiletin affects circadian rhythms and oncogenic characteristics in a cell-de",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1384,
  "fields": {
    "action_time": "2025-05-24T11:48:17.605Z",
    "user": 2,
    "content_type": 10,
    "object_id": "238",
    "object_repr": "Nobiletin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1385,
  "fields": {
    "action_time": "2025-05-24T11:49:00.286Z",
    "user": 2,
    "content_type": 14,
    "object_id": "94",
    "object_repr": "Sautel, M., Rudolf, K., Wittneben, H., Herzog, H., Martinez, R., Munoz, M., Eberlein, W., Engel, W., Walker, P. and Beck-Sickinger, A.G., 1996. Neuropeptide Y and the nonpeptide antagonist BIBP 3226 s",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1386,
  "fields": {
    "action_time": "2025-05-24T11:49:05.642Z",
    "user": 2,
    "content_type": 10,
    "object_id": "237",
    "object_repr": "BIBP3226",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1387,
  "fields": {
    "action_time": "2025-05-24T11:49:45.307Z",
    "user": 2,
    "content_type": 14,
    "object_id": "95",
    "object_repr": "Cohen, S., Vainer, E., Matar, M.A., Kozlovsky, N., Kaplan, Z., Zohar, J., Mathé, A.A. and Cohen, H., 2015. Diurnal fluctuations in HPA and neuropeptide Y-ergic systems underlie differences in vulnerab",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1388,
  "fields": {
    "action_time": "2025-05-24T11:49:47.982Z",
    "user": 2,
    "content_type": 10,
    "object_id": "236",
    "object_repr": "BIBO 3304 trifluoroacetate",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1389,
  "fields": {
    "action_time": "2025-05-24T11:51:18.445Z",
    "user": 2,
    "content_type": 14,
    "object_id": "96",
    "object_repr": "Liu, Y., Lang, H., Zhou, M., Huang, L., Hui, S., Wang, X., Chen, K. and Mi, M., 2020. The preventive effects of pterostilbene on the exercise intolerance and circadian misalignment of mice subjected t",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1390,
  "fields": {
    "action_time": "2025-05-24T11:52:00.568Z",
    "user": 2,
    "content_type": 14,
    "object_id": "97",
    "object_repr": "Zhang, J., Chang, M., Wang, X., Zhou, X., Bai, Q., Lang, H., Zhang, Q., Yi, L., Mi, M. and Chen, K., 2024. Pterostilbene targets the molecular oscillator RORγ to restore circadian rhythm oscillation a",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1391,
  "fields": {
    "action_time": "2025-05-24T11:52:06.507Z",
    "user": 2,
    "content_type": 10,
    "object_id": "235",
    "object_repr": "Pterostilbene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1392,
  "fields": {
    "action_time": "2025-05-24T11:52:50.711Z",
    "user": 2,
    "content_type": 14,
    "object_id": "98",
    "object_repr": "Solt, L.A., et al, 2012. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature, 485(7396), pp.62-68.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1393,
  "fields": {
    "action_time": "2025-05-24T11:52:57.144Z",
    "user": 2,
    "content_type": 10,
    "object_id": "234",
    "object_repr": "SR9011",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1394,
  "fields": {
    "action_time": "2025-05-24T11:53:50.586Z",
    "user": 2,
    "content_type": 14,
    "object_id": "99",
    "object_repr": "Yang, M.Y., Lin, H.Y.H., Chen, Y.Y.M., Hu, M.L., Chen, I.Y. and Yang, C.H., 2025. Chronic low-dose REV-ERBs agonist SR9009 mitigates constant light-induced weight gain and insulin resistance via adipo",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1395,
  "fields": {
    "action_time": "2025-05-24T11:53:55.343Z",
    "user": 2,
    "content_type": 10,
    "object_id": "233",
    "object_repr": "SR9009",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1396,
  "fields": {
    "action_time": "2025-05-24T11:54:33.650Z",
    "user": 2,
    "content_type": 14,
    "object_id": "100",
    "object_repr": "Grant, D., Yin, L., Collins, J.L., Parks, D.J., Orband-Miller, L.A., Wisely, G.B., Joshi, S., Lazar, M.A., Willson, T.M. and Zuercher, W.J., 2010. GSK4112, a small molecule chemical probe for the cell",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1397,
  "fields": {
    "action_time": "2025-05-24T11:54:36.762Z",
    "user": 2,
    "content_type": 10,
    "object_id": "232",
    "object_repr": "GSK4112",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1398,
  "fields": {
    "action_time": "2025-05-24T11:55:19.394Z",
    "user": 2,
    "content_type": 14,
    "object_id": "101",
    "object_repr": "Huang, S., Jiao, X., Lu, D., Pei, X., Qi, D. and Li, Z., 2020. Recent advances in modulators of circadian rhythms: an update and perspective. Journal of Enzyme Inhibition and Medicinal Chemistry, 35(1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1399,
  "fields": {
    "action_time": "2025-05-24T11:55:24.091Z",
    "user": 2,
    "content_type": 10,
    "object_id": "231",
    "object_repr": "KK-S6",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1400,
  "fields": {
    "action_time": "2025-05-24T11:55:54.055Z",
    "user": 2,
    "content_type": 14,
    "object_id": "102",
    "object_repr": "Koh, Y.C. and Pan, M.H., 2024. Food-Borne Polycyclic Aromatic Hydrocarbons and Circadian Disruption. ACS omega, 9(29), pp.31298-31312.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1401,
  "fields": {
    "action_time": "2025-05-24T11:55:58.923Z",
    "user": 2,
    "content_type": 10,
    "object_id": "230",
    "object_repr": "Indeno[1,2,3-c,d]pyrene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1402,
  "fields": {
    "action_time": "2025-05-24T11:56:20.380Z",
    "user": 2,
    "content_type": 10,
    "object_id": "229",
    "object_repr": "BENZO(ghi)PERYLENE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1403,
  "fields": {
    "action_time": "2025-05-24T11:56:43.092Z",
    "user": 2,
    "content_type": 10,
    "object_id": "228",
    "object_repr": "Dibenzo[a,h]anthracene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1404,
  "fields": {
    "action_time": "2025-05-24T11:57:08.055Z",
    "user": 2,
    "content_type": 10,
    "object_id": "226",
    "object_repr": "Chrysene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1405,
  "fields": {
    "action_time": "2025-05-24T11:57:23.510Z",
    "user": 2,
    "content_type": 10,
    "object_id": "225",
    "object_repr": "Benzo[k]fluoranthene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1406,
  "fields": {
    "action_time": "2025-05-24T11:57:48.239Z",
    "user": 2,
    "content_type": 10,
    "object_id": "224",
    "object_repr": "Dibenzopyrene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1407,
  "fields": {
    "action_time": "2025-05-24T11:58:02.091Z",
    "user": 2,
    "content_type": 10,
    "object_id": "222",
    "object_repr": "anthracene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1408,
  "fields": {
    "action_time": "2025-05-24T11:58:19.425Z",
    "user": 2,
    "content_type": 10,
    "object_id": "221",
    "object_repr": "naphthalene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1409,
  "fields": {
    "action_time": "2025-05-24T11:59:17.707Z",
    "user": 2,
    "content_type": 14,
    "object_id": "103",
    "object_repr": "Lee, J.W., Hirota, T., Peters, E.C., Garcia, M., Gonzalez, R., Cho, C.Y., Wu, X., Schultz, P.G. and Kay, S.A., 2011. A small molecule modulates circadian rhythms through phosphorylation of the period ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1410,
  "fields": {
    "action_time": "2025-05-24T11:59:49.094Z",
    "user": 2,
    "content_type": 14,
    "object_id": "104",
    "object_repr": "Ray, S., Lach, R., Heesom, K.J., Valekunja, U.K., Encheva, V., Snijders, A.P. and Reddy, A.B., 2019. Phenotypic proteomic profiling identifies a landscape of targets for circadian clock–modulating com",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1411,
  "fields": {
    "action_time": "2025-05-24T11:59:52.481Z",
    "user": 2,
    "content_type": 10,
    "object_id": "220",
    "object_repr": "LH-846",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1412,
  "fields": {
    "action_time": "2025-05-24T12:00:32.725Z",
    "user": 2,
    "content_type": 14,
    "object_id": "105",
    "object_repr": "Freeman, S.L., Kwon, H., Portolano, N., Parkin, G., Venkatraman Girija, U., Basran, J., Fielding, A.J., Fairall, L., Svistunenko, D.A., Moody, P.C. and Schwabe, J.W., 2019. Heme binding to human CLOCK",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1413,
  "fields": {
    "action_time": "2025-05-24T12:00:35.720Z",
    "user": 2,
    "content_type": 10,
    "object_id": "219",
    "object_repr": "Protoheme",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1414,
  "fields": {
    "action_time": "2025-05-24T12:01:40.871Z",
    "user": 2,
    "content_type": 14,
    "object_id": "106",
    "object_repr": "Hosoya, Y., Nojo, W., Kii, I., Suzuki, T., Imanishi, M. and Ohkanda, J., 2020. Identification of synthetic inhibitors for the DNA binding of intrinsically disordered circadian clock transcription fact",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1415,
  "fields": {
    "action_time": "2025-05-24T12:01:43.368Z",
    "user": 2,
    "content_type": 10,
    "object_id": "218",
    "object_repr": "5,8-Quinoxalinedione",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1416,
  "fields": {
    "action_time": "2025-05-24T12:02:24.365Z",
    "user": 2,
    "content_type": 14,
    "object_id": "107",
    "object_repr": "Doruk, Y.U., Yarparvar, D., Akyel, Y.K., Gul, S., Taskin, A.C., Yilmaz, F., Baris, I., Ozturk, N., Türkay, M., Ozturk, N. and Okyar, A., 2020. A CLOCK-binding small molecule disrupts the interaction b",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1417,
  "fields": {
    "action_time": "2025-05-24T12:02:27.427Z",
    "user": 2,
    "content_type": 10,
    "object_id": "217",
    "object_repr": "CLK8",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1418,
  "fields": {
    "action_time": "2025-05-24T12:03:26.612Z",
    "user": 2,
    "content_type": 14,
    "object_id": "108",
    "object_repr": "He, B. and Chen, Z., 2016. Molecular targets for small-molecule modulators of circadian clocks. Current drug metabolism, 17(5), pp.503-512.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1419,
  "fields": {
    "action_time": "2025-05-24T12:03:31.384Z",
    "user": 2,
    "content_type": 10,
    "object_id": "216",
    "object_repr": "Azakenpaullone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1420,
  "fields": {
    "action_time": "2025-05-24T12:04:05.285Z",
    "user": 2,
    "content_type": 14,
    "object_id": "109",
    "object_repr": "Chun, S.K., Jang, J., Chung, S., Yun, H., Kim, N.J., Jung, J.W., Son, G.H., Suh, Y.G. and Kim, K., 2014. Identification and validation of cryptochrome inhibitors that modulate the molecular circadian ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1421,
  "fields": {
    "action_time": "2025-05-24T12:04:31.905Z",
    "user": 2,
    "content_type": 14,
    "object_id": "110",
    "object_repr": "전승국, 2014. Development of circadian clock modulator and its application (Doctoral dissertation, 서울대학교 대학원).",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1422,
  "fields": {
    "action_time": "2025-05-24T12:05:01.727Z",
    "user": 2,
    "content_type": 14,
    "object_id": "111",
    "object_repr": "Jang, J., Chung, S., Choi, Y., Lim, H.Y., Son, Y., Chun, S.K., Son, G.H., Kim, K., Suh, Y.G. and Jung, J.W., 2018. The cryptochrome inhibitor KS15 enhances E-box-mediated transcription by disrupting t",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1423,
  "fields": {
    "action_time": "2025-05-24T12:05:31.468Z",
    "user": 2,
    "content_type": 14,
    "object_id": "112",
    "object_repr": "Solovev, I.A., Shaposhnikov, M.V. and Moskalev, A.A., 2021. Chronobiotics KL001 and KS15 extend lifespan and modify circadian rhythms of Drosophila melanogaster. Clocks & Sleep, 3(3), pp.429-441.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1424,
  "fields": {
    "action_time": "2025-05-24T12:05:34.736Z",
    "user": 2,
    "content_type": 10,
    "object_id": "215",
    "object_repr": "KS15",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1425,
  "fields": {
    "action_time": "2025-05-24T12:07:14.845Z",
    "user": 2,
    "content_type": 14,
    "object_id": "113",
    "object_repr": "Hirota, T., Lee, J.W., St. John, P.C., Sawa, M., Iwaisako, K., Noguchi, T., Pongsawakul, P.Y., Sonntag, T., Welsh, D.K., Brenner, D.A. and Doyle III, F.J., 2012. Identification of small molecule activ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1426,
  "fields": {
    "action_time": "2025-05-24T12:07:59.830Z",
    "user": 2,
    "content_type": 14,
    "object_id": "114",
    "object_repr": "Iida, M., Nakane, Y., Yoshimura, T. and Hirota, T., 2022. Effects of cryptochrome-modulating compounds on circadian behavioural rhythms in zebrafish. Journal of Biochemistry, 171(5), pp.501-507.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1427,
  "fields": {
    "action_time": "2025-05-24T12:08:02.701Z",
    "user": 2,
    "content_type": 10,
    "object_id": "214",
    "object_repr": "KL001",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1428,
  "fields": {
    "action_time": "2025-05-24T19:41:20.708Z",
    "user": 2,
    "content_type": 14,
    "object_id": "115",
    "object_repr": "Zhao, et al., 2024. Irbesartan ameliorates diabetic kidney injury in db/db mice by restoring circadian rhythm and cell cycle. Journal of translational internal medicine, 12(2), pp.157-169.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1429,
  "fields": {
    "action_time": "2025-05-24T19:41:20.981Z",
    "user": 2,
    "content_type": 14,
    "object_id": "116",
    "object_repr": "Zhao, et al., 2024. Irbesartan ameliorates diabetic kidney injury in db/db mice by restoring circadian rhythm and cell cycle. Journal of translational internal medicine, 12(2), pp.157-169.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1430,
  "fields": {
    "action_time": "2025-05-24T19:41:31.592Z",
    "user": 2,
    "content_type": 10,
    "object_id": "213",
    "object_repr": "Irbesartan",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1431,
  "fields": {
    "action_time": "2025-05-24T19:43:20.140Z",
    "user": 2,
    "content_type": 14,
    "object_id": "117",
    "object_repr": "Tamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulat",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1432,
  "fields": {
    "action_time": "2025-05-24T19:43:38.254Z",
    "user": 2,
    "content_type": 10,
    "object_id": "212",
    "object_repr": "TRETINOIN",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1433,
  "fields": {
    "action_time": "2025-05-24T19:43:50.204Z",
    "user": 2,
    "content_type": 10,
    "object_id": "211",
    "object_repr": "THIOTEPA",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1434,
  "fields": {
    "action_time": "2025-05-24T19:44:07.182Z",
    "user": 2,
    "content_type": 10,
    "object_id": "210",
    "object_repr": "Tazarotene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1435,
  "fields": {
    "action_time": "2025-05-24T19:44:28.501Z",
    "user": 2,
    "content_type": 10,
    "object_id": "210",
    "object_repr": "Tazarotene",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1436,
  "fields": {
    "action_time": "2025-05-24T19:44:43.658Z",
    "user": 2,
    "content_type": 10,
    "object_id": "209",
    "object_repr": "Rabeprazole Sodium",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1437,
  "fields": {
    "action_time": "2025-05-24T19:45:41.077Z",
    "user": 2,
    "content_type": 10,
    "object_id": "208",
    "object_repr": "PODOFILOX",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1438,
  "fields": {
    "action_time": "2025-05-24T19:45:56.335Z",
    "user": 2,
    "content_type": 10,
    "object_id": "207",
    "object_repr": "PIMECROLIMUS",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1439,
  "fields": {
    "action_time": "2025-05-24T19:46:13.159Z",
    "user": 2,
    "content_type": 10,
    "object_id": "206",
    "object_repr": "PAZOPANIB HCL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1440,
  "fields": {
    "action_time": "2025-05-24T19:46:31.527Z",
    "user": 2,
    "content_type": 10,
    "object_id": "205",
    "object_repr": "NILOTINIB",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1441,
  "fields": {
    "action_time": "2025-05-24T19:46:41.930Z",
    "user": 2,
    "content_type": 10,
    "object_id": "204",
    "object_repr": "NEBIVOLOL HCL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1442,
  "fields": {
    "action_time": "2025-05-24T19:47:00.819Z",
    "user": 2,
    "content_type": 10,
    "object_id": "203",
    "object_repr": "MECLIZINE DIHYDROCHLORIDE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1443,
  "fields": {
    "action_time": "2025-05-24T19:47:13.164Z",
    "user": 2,
    "content_type": 10,
    "object_id": "202",
    "object_repr": "ISOTRETINOIN (13-CIS-RETINOIC ACID)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1444,
  "fields": {
    "action_time": "2025-05-24T19:47:40.271Z",
    "user": 2,
    "content_type": 10,
    "object_id": "201",
    "object_repr": "Irinotecan Hydrochloride",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1445,
  "fields": {
    "action_time": "2025-05-24T19:48:02.188Z",
    "user": 2,
    "content_type": 10,
    "object_id": "200",
    "object_repr": "EVEROLIMUS",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1446,
  "fields": {
    "action_time": "2025-05-24T19:48:28.068Z",
    "user": 2,
    "content_type": 10,
    "object_id": "199",
    "object_repr": "EPIRUBICIN HCL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1447,
  "fields": {
    "action_time": "2025-05-24T19:48:58.418Z",
    "user": 2,
    "content_type": 10,
    "object_id": "198",
    "object_repr": "DROSPIRENONE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1448,
  "fields": {
    "action_time": "2025-05-24T19:50:15.006Z",
    "user": 2,
    "content_type": 14,
    "object_id": "118",
    "object_repr": "Hirota, T., Lewis, W.G., Liu, A.C., Lee, J.W., Schultz, P.G. and Kay, S.A., 2008. A chemical biology approach reveals period shortening of the mammalian circadian clock by specific inhibition of GSK-3",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1449,
  "fields": {
    "action_time": "2025-05-24T19:50:46.171Z",
    "user": 2,
    "content_type": 10,
    "object_id": "197",
    "object_repr": "Laduviglusib (CHIR-99021)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\", \"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1450,
  "fields": {
    "action_time": "2025-05-24T19:51:38.688Z",
    "user": 2,
    "content_type": 14,
    "object_id": "119",
    "object_repr": "Shanware, N.P., Williams, L.M., Bowler, M.J. and Tibbetts, R.S., 2009. Non-specific in vivo inhibition of CK1 by the pyridinyl imidazole p38 inhibitors SB 203580 and SB 202190. BMB reports, 42(3), p.1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1451,
  "fields": {
    "action_time": "2025-05-24T19:52:22.241Z",
    "user": 2,
    "content_type": 14,
    "object_id": "120",
    "object_repr": "Sankrithi, N. and Eskin, A., 1999. Effects of Cyclin‐Dependent Kinase Inhibitors on Transcription and Ocular Circadian Rhythm of Aplysia. Journal of neurochemistry, 72(2), pp.605-613.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1452,
  "fields": {
    "action_time": "2025-05-24T19:52:25.656Z",
    "user": 2,
    "content_type": 10,
    "object_id": "196",
    "object_repr": "SB-202190",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1453,
  "fields": {
    "action_time": "2025-05-24T19:53:32.599Z",
    "user": 2,
    "content_type": 9,
    "object_id": "203",
    "object_repr": "Photoreception inhibition",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1454,
  "fields": {
    "action_time": "2025-05-24T19:54:50.927Z",
    "user": 2,
    "content_type": 14,
    "object_id": "121",
    "object_repr": "Jones, K.A., Hatori, M., Mure, L.S., Bramley, J.R., Artymyshyn, R., Hong, S.P., Marzabadi, M., Zhong, H., Sprouse, J., Zhu, Q. and Hartwick, A.T., 2013. Small-molecule antagonists of melanopsin-mediat",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1455,
  "fields": {
    "action_time": "2025-05-24T19:54:55.293Z",
    "user": 2,
    "content_type": 10,
    "object_id": "195",
    "object_repr": "AA41612",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\", \"Mechanisms\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1456,
  "fields": {
    "action_time": "2025-05-24T19:56:25.902Z",
    "user": 2,
    "content_type": 14,
    "object_id": "122",
    "object_repr": "Obayashi, K., Zou, R., Kawaguchi, T., Mori, T. and Tsukamoto, H., 2025. Molecular basis underlying the specificity of an antagonist AA92593 for mammalian melanopsins. Journal of Biological Chemistry, ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1457,
  "fields": {
    "action_time": "2025-05-24T19:57:48.786Z",
    "user": 2,
    "content_type": 14,
    "object_id": "123",
    "object_repr": "Bertolesi, G.E., Debnath, N., Malik, H.R., Man, L.L. and McFarlane, S., 2022. Type II opsins in the eye, the pineal complex and the skin of Xenopus laevis: Using changes in skin pigmentation as a read",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1458,
  "fields": {
    "action_time": "2025-05-24T19:57:52.339Z",
    "user": 2,
    "content_type": 10,
    "object_id": "194",
    "object_repr": "AA92593",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1459,
  "fields": {
    "action_time": "2025-05-24T19:58:21.076Z",
    "user": 2,
    "content_type": 10,
    "object_id": "193",
    "object_repr": "Deferasirox",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1460,
  "fields": {
    "action_time": "2025-05-24T19:58:35.326Z",
    "user": 2,
    "content_type": 10,
    "object_id": "192",
    "object_repr": "Dasatinib",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1461,
  "fields": {
    "action_time": "2025-05-24T19:59:00.832Z",
    "user": 2,
    "content_type": 10,
    "object_id": "191",
    "object_repr": "Clotrimazole",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1462,
  "fields": {
    "action_time": "2025-05-24T19:59:21.828Z",
    "user": 2,
    "content_type": 10,
    "object_id": "190",
    "object_repr": "Cladribine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1463,
  "fields": {
    "action_time": "2025-05-24T19:59:42.039Z",
    "user": 2,
    "content_type": 10,
    "object_id": "189",
    "object_repr": "CINACALCET HCL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1464,
  "fields": {
    "action_time": "2025-05-24T19:59:57.305Z",
    "user": 2,
    "content_type": 10,
    "object_id": "188",
    "object_repr": "CIDOFOVIR",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1465,
  "fields": {
    "action_time": "2025-05-24T20:00:24.266Z",
    "user": 2,
    "content_type": 10,
    "object_id": "187",
    "object_repr": "ARSENIC TRIOXIDE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1466,
  "fields": {
    "action_time": "2025-05-24T20:00:40.268Z",
    "user": 2,
    "content_type": 10,
    "object_id": "186",
    "object_repr": "Adefovir Dipivoxil",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1467,
  "fields": {
    "action_time": "2025-05-24T20:00:57.325Z",
    "user": 2,
    "content_type": 10,
    "object_id": "185",
    "object_repr": "Nelfinavir mesylate",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1468,
  "fields": {
    "action_time": "2025-05-24T20:01:37.027Z",
    "user": 2,
    "content_type": 10,
    "object_id": "184",
    "object_repr": "PROGESTERONE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1469,
  "fields": {
    "action_time": "2025-05-24T20:02:07.040Z",
    "user": 2,
    "content_type": 10,
    "object_id": "183",
    "object_repr": "Oxiconazole Nitrate",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1470,
  "fields": {
    "action_time": "2025-05-24T20:02:35.805Z",
    "user": 2,
    "content_type": 10,
    "object_id": "182",
    "object_repr": "NEFAZODONE HCL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1471,
  "fields": {
    "action_time": "2025-05-24T20:05:09.860Z",
    "user": 2,
    "content_type": 14,
    "object_id": "124",
    "object_repr": "Sullivan, K.A., Grant, C.V., Jordan, K.R., Obrietan, K. and Pyter, L.M., 2022. Paclitaxel chemotherapy disrupts behavioral and molecular circadian clocks in mice. Brain, behavior, and immunity, 99, pp",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1472,
  "fields": {
    "action_time": "2025-05-24T20:05:33.055Z",
    "user": 2,
    "content_type": 10,
    "object_id": "181",
    "object_repr": "Paclitaxel (TAXOL)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1473,
  "fields": {
    "action_time": "2025-05-24T20:06:04.895Z",
    "user": 2,
    "content_type": 10,
    "object_id": "180",
    "object_repr": "MITOXANTRONE HCL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1474,
  "fields": {
    "action_time": "2025-05-24T20:06:30.388Z",
    "user": 2,
    "content_type": 10,
    "object_id": "179",
    "object_repr": "CHLORAMBUCIL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1475,
  "fields": {
    "action_time": "2025-05-24T20:07:16.083Z",
    "user": 2,
    "content_type": 10,
    "object_id": "178",
    "object_repr": "VINBLASTINE SULFATE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1476,
  "fields": {
    "action_time": "2025-05-24T20:07:36.562Z",
    "user": 2,
    "content_type": 10,
    "object_id": "177",
    "object_repr": "CLOFARABINE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1477,
  "fields": {
    "action_time": "2025-05-24T20:08:07.045Z",
    "user": 2,
    "content_type": 10,
    "object_id": "176",
    "object_repr": "Bexarotene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1478,
  "fields": {
    "action_time": "2025-05-24T20:08:34.902Z",
    "user": 2,
    "content_type": 10,
    "object_id": "174",
    "object_repr": "KETOCONAZOLE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1479,
  "fields": {
    "action_time": "2025-05-24T20:09:07.053Z",
    "user": 2,
    "content_type": 10,
    "object_id": "173",
    "object_repr": "CALCITRIOL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1480,
  "fields": {
    "action_time": "2025-05-24T20:09:45.751Z",
    "user": 2,
    "content_type": 10,
    "object_id": "172",
    "object_repr": "Acitretin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1481,
  "fields": {
    "action_time": "2025-05-24T20:10:13.717Z",
    "user": 2,
    "content_type": 10,
    "object_id": "171",
    "object_repr": "Bromocriptine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1482,
  "fields": {
    "action_time": "2025-05-24T20:10:37.361Z",
    "user": 2,
    "content_type": 10,
    "object_id": "170",
    "object_repr": "Felodipine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1483,
  "fields": {
    "action_time": "2025-05-24T20:10:57.821Z",
    "user": 2,
    "content_type": 10,
    "object_id": "169",
    "object_repr": "Erlotinib",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1484,
  "fields": {
    "action_time": "2025-05-24T20:12:15.482Z",
    "user": 2,
    "content_type": 14,
    "object_id": "125",
    "object_repr": "Chen, S.J., Yu, F., Feng, X., Li, Q., Jiang, Y.H., Zhao, L.Q., Cheng, P.P., Wang, M., Song, L.J., Liang, L.M. and He, X.L., 2024. DEC1 is involved in circadian rhythm disruption-exacerbated pulmonary ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1485,
  "fields": {
    "action_time": "2025-05-24T20:12:20.288Z",
    "user": 2,
    "content_type": 10,
    "object_id": "168",
    "object_repr": "BLEOMYCIN SULFATE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1486,
  "fields": {
    "action_time": "2025-05-24T20:13:18.576Z",
    "user": 2,
    "content_type": 10,
    "object_id": "167",
    "object_repr": "SERTACONAZOLE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1487,
  "fields": {
    "action_time": "2025-05-24T20:13:45.768Z",
    "user": 2,
    "content_type": 10,
    "object_id": "166",
    "object_repr": "Rapamycin (Sirolimus)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1488,
  "fields": {
    "action_time": "2025-05-24T20:14:03.342Z",
    "user": 2,
    "content_type": 10,
    "object_id": "165",
    "object_repr": "Hydroxyprogesterone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1489,
  "fields": {
    "action_time": "2025-05-24T20:14:21.800Z",
    "user": 2,
    "content_type": 10,
    "object_id": "164",
    "object_repr": "Artenimol (DHA, Dihydroartemisinin)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1490,
  "fields": {
    "action_time": "2025-05-24T20:14:44.942Z",
    "user": 2,
    "content_type": 10,
    "object_id": "163",
    "object_repr": "Nitroxoline",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1491,
  "fields": {
    "action_time": "2025-05-24T20:15:29.201Z",
    "user": 2,
    "content_type": 10,
    "object_id": "162",
    "object_repr": "Clorgyline hydrochloride",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1492,
  "fields": {
    "action_time": "2025-05-24T20:16:19.085Z",
    "user": 2,
    "content_type": 10,
    "object_id": "161",
    "object_repr": "Cyproterone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1493,
  "fields": {
    "action_time": "2025-05-24T20:16:29.483Z",
    "user": 2,
    "content_type": 10,
    "object_id": "160",
    "object_repr": "Metergoline",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1494,
  "fields": {
    "action_time": "2025-05-24T20:17:31.711Z",
    "user": 2,
    "content_type": 14,
    "object_id": "126",
    "object_repr": "Jacob, H., Curtis, A.M. and Kearney, C.J., 2020. Therapeutics on the clock: circadian medicine in the treatment of chronic inflammatory diseases. Biochemical pharmacology, 182, p.114254.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1495,
  "fields": {
    "action_time": "2025-05-24T20:17:38.354Z",
    "user": 2,
    "content_type": 10,
    "object_id": "159",
    "object_repr": "Nadifloxacin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1496,
  "fields": {
    "action_time": "2025-05-24T20:18:15.657Z",
    "user": 2,
    "content_type": 10,
    "object_id": "158",
    "object_repr": "Protoporphyrin IX",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1497,
  "fields": {
    "action_time": "2025-05-24T20:19:08.415Z",
    "user": 2,
    "content_type": 14,
    "object_id": "127",
    "object_repr": "Zhou, Z., Lin, Y., Gao, L., Yang, Z., Wang, S. and Wu, B., 2020. Circadian pharmacological effects of berberine on chronic colitis in mice: role of the clock component Rev-erbα. Biochemical pharmacolo",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1498,
  "fields": {
    "action_time": "2025-05-24T20:19:37.188Z",
    "user": 2,
    "content_type": 14,
    "object_id": "128",
    "object_repr": "Ye, C., Zhang, Y., Lin, S., Chen, Y., Wang, Z., Feng, H., Fang, G. and Quan, S., 2023. Berberine ameliorates metabolic-associated fatty liver disease mediated metabolism disorder and redox homeostasis",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1499,
  "fields": {
    "action_time": "2025-05-24T20:19:40.161Z",
    "user": 2,
    "content_type": 10,
    "object_id": "157",
    "object_repr": "Berberine Chloride",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1500,
  "fields": {
    "action_time": "2025-05-24T20:20:28.923Z",
    "user": 2,
    "content_type": 10,
    "object_id": "156",
    "object_repr": "DEQUALINIUM CHLORIDE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1501,
  "fields": {
    "action_time": "2025-05-24T20:22:13.607Z",
    "user": 2,
    "content_type": 14,
    "object_id": "129",
    "object_repr": "De Crescenzo, F., D'Alò, G.L., Ostinelli, E.G., Ciabattini, M., Di Franco, V., Watanabe, N., Kurtulmus, A., Tomlinson, A., Mitrova, Z., Foti, F. and Del Giovane, C., 2022. Comparative effects of pharm",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1502,
  "fields": {
    "action_time": "2025-05-24T20:22:19.061Z",
    "user": 2,
    "content_type": 10,
    "object_id": "155",
    "object_repr": "Loprazolam",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1503,
  "fields": {
    "action_time": "2025-05-24T20:23:22.020Z",
    "user": 2,
    "content_type": 14,
    "object_id": "130",
    "object_repr": "Turek, F.W. and Van Reeth, O., 1989. Use of benzodiazepines to manipulate the circadian clock regulating behavioral and endocrine rhythms. Hormone Research in Paediatrics, 31(1-2), pp.59-65.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1504,
  "fields": {
    "action_time": "2025-05-24T20:23:25.620Z",
    "user": 2,
    "content_type": 10,
    "object_id": "154",
    "object_repr": "Nitrazepam",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1505,
  "fields": {
    "action_time": "2025-05-24T20:24:12.052Z",
    "user": 2,
    "content_type": 14,
    "object_id": "131",
    "object_repr": "https://pubmed.ncbi.nlm.nih.gov/35052310/",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1506,
  "fields": {
    "action_time": "2025-05-24T20:24:15.063Z",
    "user": 2,
    "content_type": 10,
    "object_id": "153",
    "object_repr": "Lormetazepam",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1507,
  "fields": {
    "action_time": "2025-05-24T20:25:07.814Z",
    "user": 2,
    "content_type": 14,
    "object_id": "132",
    "object_repr": "Ward, L.G., Bourjeily, G., Guthrie, K., Salmoirago-Blotcher, E., Sharp, M., Desmarattes, A. and Bublitz, M., 2024. Sleep Quality in High-Risk Pregnancies: Mixed Methods Results from a Randomized Contr",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1508,
  "fields": {
    "action_time": "2025-05-24T20:25:11.482Z",
    "user": 2,
    "content_type": 10,
    "object_id": "152",
    "object_repr": "Unisom (doxylamine)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1509,
  "fields": {
    "action_time": "2025-05-24T20:26:10.422Z",
    "user": 2,
    "content_type": 14,
    "object_id": "133",
    "object_repr": "Wang, Y.Q., Takata, Y., Li, R., Zhang, Z., Zhang, M.Q., Urade, Y., Qu, W.M. and Huang, Z.L., 2015. Doxepin and diphenhydramine increased non-rapid eye movement sleep through blockade of histamine H1 r",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1510,
  "fields": {
    "action_time": "2025-05-24T20:26:40.880Z",
    "user": 2,
    "content_type": 14,
    "object_id": "134",
    "object_repr": "Morioka, E., Kanda, Y., Koizumi, H., Miyamoto, T. and Ikeda, M., 2018. Histamine regulates molecular clock oscillations in human retinal pigment epithelial cells via H1 receptors. Frontiers in endocri",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1511,
  "fields": {
    "action_time": "2025-05-24T20:26:43.574Z",
    "user": 2,
    "content_type": 10,
    "object_id": "151",
    "object_repr": "Benadryl (diphenhydramine)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1512,
  "fields": {
    "action_time": "2025-05-24T20:27:46.156Z",
    "user": 2,
    "content_type": 14,
    "object_id": "135",
    "object_repr": "Yeung, W.F., Chung, K.F., Yung, K.P. and Ng, T.H.Y., 2015. Doxepin for insomnia: a systematic review of randomized placebo-controlled trials. Sleep medicine reviews, 19, pp.75-83.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1513,
  "fields": {
    "action_time": "2025-05-24T20:27:51.162Z",
    "user": 2,
    "content_type": 10,
    "object_id": "150",
    "object_repr": "Silenor (doxepin)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1514,
  "fields": {
    "action_time": "2025-05-24T20:28:54.604Z",
    "user": 2,
    "content_type": 14,
    "object_id": "136",
    "object_repr": "Brunet, R., Caza, N. and Cyr, A., 1996. Food intake and circadian rhythms of activity of red-winged blackbirds (Agelaius phoeniceus). A time-course study on the effects of alpha-chloralose and secobar",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1515,
  "fields": {
    "action_time": "2025-05-24T20:28:57.450Z",
    "user": 2,
    "content_type": 10,
    "object_id": "149",
    "object_repr": "Seconal (secobarbital)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1516,
  "fields": {
    "action_time": "2025-05-24T20:29:54.723Z",
    "user": 2,
    "content_type": 14,
    "object_id": "137",
    "object_repr": "Heel, C., Brogden, R.N., Speight, T.M. and Avery, G.S., 1981. Temazepam: a review of its pharmacological properties and therapeutic efficacy as an hypnotic. Drugs, 21, pp.321-340.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1517,
  "fields": {
    "action_time": "2025-05-24T20:29:58.320Z",
    "user": 2,
    "content_type": 10,
    "object_id": "148",
    "object_repr": "Restoril (temazepam)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1518,
  "fields": {
    "action_time": "2025-05-24T20:31:20.991Z",
    "user": 2,
    "content_type": 14,
    "object_id": "138",
    "object_repr": "Seidel, W.F., Cohen, S.A., Bliwise, N.G., Roth, T. and Dement, W.C., 1986. Dose‐related effects of triazolam and flurazepam on a circadian rhythm insomnia. Clinical Pharmacology & Therapeutics, 40(3),",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1519,
  "fields": {
    "action_time": "2025-05-24T20:31:50.996Z",
    "user": 2,
    "content_type": 14,
    "object_id": "139",
    "object_repr": "Turek, F.W. and Losee-Olson, S.H., 1987. Dose response curve for the phase-shifting effect of triazolam on the mammalian circadian clock. Life sciences, 40(11), pp.1033-1038.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1520,
  "fields": {
    "action_time": "2025-05-24T20:31:54.184Z",
    "user": 2,
    "content_type": 10,
    "object_id": "147",
    "object_repr": "Halcion (triazolam)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1521,
  "fields": {
    "action_time": "2025-05-24T20:32:45.466Z",
    "user": 2,
    "content_type": 14,
    "object_id": "140",
    "object_repr": "Crowley, T.J. and Hydinger-Macdonald, M., 1979. Bedtime flurazepam and the human circadian rhythm of spontaneous motility. Psychopharmacology, 62, pp.157-161.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1522,
  "fields": {
    "action_time": "2025-05-24T20:32:48.184Z",
    "user": 2,
    "content_type": 10,
    "object_id": "146",
    "object_repr": "Flurazepam",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1523,
  "fields": {
    "action_time": "2025-05-24T20:36:28.238Z",
    "user": 2,
    "content_type": 14,
    "object_id": "141",
    "object_repr": "Nikolenko, M.V., TKh, T. and Paromova, Y.I., 2015. EFFECT OF FLUCONAZOLE ON TEMPORAL ORGANIZATION OF BIOLOGICAL PROPERTIES OF CANDIDA ALBICANS. Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii, (",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1524,
  "fields": {
    "action_time": "2025-05-24T20:36:31.784Z",
    "user": 2,
    "content_type": 10,
    "object_id": "145",
    "object_repr": "Fluconazole",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1525,
  "fields": {
    "action_time": "2025-05-24T20:37:16.279Z",
    "user": 2,
    "content_type": 14,
    "object_id": "142",
    "object_repr": "Vogel, G.W. and Morris, D., 1992. The effects of estazolam on sleep, performance, and memory: a long‐term sleep laboratory study of elderly insomniacs. The Journal of Clinical Pharmacology, 32(7), pp.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1526,
  "fields": {
    "action_time": "2025-05-24T20:37:20.160Z",
    "user": 2,
    "content_type": 10,
    "object_id": "144",
    "object_repr": "Estazolam",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1527,
  "fields": {
    "action_time": "2025-05-24T20:37:20.834Z",
    "user": 2,
    "content_type": 10,
    "object_id": "144",
    "object_repr": "Estazolam",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1528,
  "fields": {
    "action_time": "2025-05-24T20:38:14.773Z",
    "user": 2,
    "content_type": 14,
    "object_id": "143",
    "object_repr": "Hilbert, J.M., Chung, M., Maier, G., Gural, R., Symchowicz, S. and Zampaglione, N., 1984. Effect of sleep on quazepam kinetics. Clinical Pharmacology & Therapeutics, 36(1), pp.99-104.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1529,
  "fields": {
    "action_time": "2025-05-24T20:38:20.699Z",
    "user": 2,
    "content_type": 10,
    "object_id": "143",
    "object_repr": "Doral (quazepam)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1530,
  "fields": {
    "action_time": "2025-05-24T20:39:03.322Z",
    "user": 2,
    "content_type": 14,
    "object_id": "144",
    "object_repr": "Prinz, P.N., Vitiello, M.V., Raskind, M.A. and Thorpy, M.J., 1990. Sleep disorders and aging. New England Journal of Medicine, 323(8), pp.520-526.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1531,
  "fields": {
    "action_time": "2025-05-24T20:39:08.670Z",
    "user": 2,
    "content_type": 10,
    "object_id": "142",
    "object_repr": "Butisol (butabarbital)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1532,
  "fields": {
    "action_time": "2025-05-24T20:39:42.361Z",
    "user": 2,
    "content_type": 14,
    "object_id": "145",
    "object_repr": "Ashrafi, M.R., Mohammadi, M., Tafarroji, J., Shabanian, R., Salamati, P. and Zamani, G.R., 2010. Melatonin versus chloral hydrate for recording sleep EEG. european journal of paediatric neurology, 14(",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1533,
  "fields": {
    "action_time": "2025-05-24T20:39:44.950Z",
    "user": 2,
    "content_type": 10,
    "object_id": "141",
    "object_repr": "Chloral hydrate",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1534,
  "fields": {
    "action_time": "2025-05-24T20:40:25.645Z",
    "user": 2,
    "content_type": 14,
    "object_id": "146",
    "object_repr": "Hinz, S., Lacher, S.K., Seibt, B.F. and Müller, C.E., 2014. BAY60-6583 acts as a partial agonist at adenosine A2B receptors. The Journal of pharmacology and experimental therapeutics, 349(3), pp.427-4",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1535,
  "fields": {
    "action_time": "2025-05-24T20:40:29.746Z",
    "user": 2,
    "content_type": 10,
    "object_id": "140",
    "object_repr": "BAY 60-6583",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1536,
  "fields": {
    "action_time": "2025-05-24T20:41:20.119Z",
    "user": 2,
    "content_type": 14,
    "object_id": "147",
    "object_repr": "Masse, M., Henry, H., Cuvelier, E., Pinçon, C., Pavy, M., Beeuwsaert, A., Barthélémy, C., Cuny, D., Gautier, S., Kambia, N. and Lefebvre, J.M., 2022, January. Sleep medication in older adults: identif",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1537,
  "fields": {
    "action_time": "2025-05-24T20:41:22.990Z",
    "user": 2,
    "content_type": 10,
    "object_id": "139",
    "object_repr": "Zopiclone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1538,
  "fields": {
    "action_time": "2025-05-24T20:43:18.257Z",
    "user": 2,
    "content_type": 14,
    "object_id": "148",
    "object_repr": "Jagannath, A., Varga, N., Dallmann, R., Rando, G., Gosselin, P., Ebrahimjee, F., Taylor, L., Mosneagu, D., Stefaniak, J., Walsh, S. and Palumaa, T., 2021. Adenosine integrates light and sleep signalli",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1539,
  "fields": {
    "action_time": "2025-05-24T20:43:23.339Z",
    "user": 2,
    "content_type": 10,
    "object_id": "138",
    "object_repr": "Adenosine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1540,
  "fields": {
    "action_time": "2025-05-24T20:44:28.006Z",
    "user": 2,
    "content_type": 7,
    "object_id": "14",
    "object_repr": "Sedative drug",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1541,
  "fields": {
    "action_time": "2025-05-24T20:44:54.046Z",
    "user": 2,
    "content_type": 14,
    "object_id": "149",
    "object_repr": "Cantisani, C., Ricci, S., Grieco, T., Paolino, G., Faina, V., Silvestri, E. and Calvieri, S., 2013. Topical promethazine side effects: our experience and review of the literature. BioMed research inte",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1542,
  "fields": {
    "action_time": "2025-05-24T20:45:26.806Z",
    "user": 2,
    "content_type": 10,
    "object_id": "137",
    "object_repr": "Promethazine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Classf\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1543,
  "fields": {
    "action_time": "2025-05-24T20:47:46.276Z",
    "user": 2,
    "content_type": 14,
    "object_id": "150",
    "object_repr": "Hoyer, D., Dürst, T., Fendt, M., Jacobson, L.H., Betschart, C., Hintermann, S., Behnke, D., Cotesta, S., Laue, G., Ofner, S. and Legangneux, E., 2013. Distinct effects of IPSU and suvorexant on mouse ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1544,
  "fields": {
    "action_time": "2025-05-24T20:47:48.763Z",
    "user": 2,
    "content_type": 10,
    "object_id": "136",
    "object_repr": "Filorexant",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1545,
  "fields": {
    "action_time": "2025-05-24T20:48:42.591Z",
    "user": 2,
    "content_type": 14,
    "object_id": "151",
    "object_repr": "Morera, A.L., Abreu-Gonzalez, P. and Henry, M., 2009. Zaleplon increases nocturnal melatonin secretion in humans. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 33(6), pp.1013-1016.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1546,
  "fields": {
    "action_time": "2025-05-24T20:48:58.033Z",
    "user": 2,
    "content_type": 13,
    "object_id": "52",
    "object_repr": "increases melatonin synthesis",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1547,
  "fields": {
    "action_time": "2025-05-24T20:49:03.450Z",
    "user": 2,
    "content_type": 10,
    "object_id": "135",
    "object_repr": "Zaleplon",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1548,
  "fields": {
    "action_time": "2025-05-24T20:50:08.007Z",
    "user": 2,
    "content_type": 14,
    "object_id": "152",
    "object_repr": "Amodeo, L.R., Wills, D.N., Benedict, J. and Ehlers, C.L., 2025. Effects of daridorexant on rest/wake activity patterns and drinking in adult rats exposed to chronic ethanol vapor in adolescence. Alcoh",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1549,
  "fields": {
    "action_time": "2025-05-24T20:50:10.485Z",
    "user": 2,
    "content_type": 10,
    "object_id": "134",
    "object_repr": "Daridorexant",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1550,
  "fields": {
    "action_time": "2025-05-24T20:50:57.786Z",
    "user": 2,
    "content_type": 14,
    "object_id": "153",
    "object_repr": "Huang, X., Lin, D., Sun, Y., Wu, A. and Wei, C., 2021. Effect of dexmedetomidine on postoperative sleep quality: a systematic review. Drug design, development and therapy, pp.2161-2170.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1551,
  "fields": {
    "action_time": "2025-05-24T20:51:01.128Z",
    "user": 2,
    "content_type": 10,
    "object_id": "133",
    "object_repr": "Dexmedetomidine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1552,
  "fields": {
    "action_time": "2025-05-24T20:51:52.974Z",
    "user": 2,
    "content_type": 14,
    "object_id": "154",
    "object_repr": "https://pubmed.ncbi.nlm.nih.gov/33336219/",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1553,
  "fields": {
    "action_time": "2025-05-24T20:51:57.696Z",
    "user": 2,
    "content_type": 10,
    "object_id": "132",
    "object_repr": "Lemborexant",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1554,
  "fields": {
    "action_time": "2025-05-24T20:52:42.894Z",
    "user": 2,
    "content_type": 14,
    "object_id": "155",
    "object_repr": "Spahr, L., Coeytaux, A., Giostra, E., Hadengue, A. and Annoni, J.M., 2007. Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized c",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1555,
  "fields": {
    "action_time": "2025-05-24T20:52:45.964Z",
    "user": 2,
    "content_type": 10,
    "object_id": "131",
    "object_repr": "Hydroxyzine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1556,
  "fields": {
    "action_time": "2025-05-24T20:53:36.903Z",
    "user": 2,
    "content_type": 14,
    "object_id": "156",
    "object_repr": "Smith, V.M., Iannatonne, S., Achal, S., Jeffers, R.T. and Antle, M.C., 2014. The serotonergic anxiolytic buspirone attenuates circadian responses to light. European Journal of Neuroscience, 40(10), pp",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1557,
  "fields": {
    "action_time": "2025-05-24T20:53:44.393Z",
    "user": 2,
    "content_type": 10,
    "object_id": "130",
    "object_repr": "Buspirone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1558,
  "fields": {
    "action_time": "2025-05-24T20:56:05.883Z",
    "user": 2,
    "content_type": 14,
    "object_id": "157",
    "object_repr": "Cugini, P., Delogu, G., Casula, M.A., Gatta, L., Cascioli, C. and Di Palma, L., 1991. Anaesthesia‐induced dissociation between the circadian rhythms of blood pressure and heart rate. Biological Rhythm",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1559,
  "fields": {
    "action_time": "2025-05-24T20:56:10.884Z",
    "user": 2,
    "content_type": 10,
    "object_id": "129",
    "object_repr": "Droperidol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1560,
  "fields": {
    "action_time": "2025-05-24T20:56:48.083Z",
    "user": 2,
    "content_type": 14,
    "object_id": "158",
    "object_repr": "Keuroghlian, A.S., Barry, A.S. and Weiss, R.D., 2012. Circadian dysregulation, zolpidem dependence, and withdrawal seizure in a resident physician performing shift work. The American Journal on Addict",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1561,
  "fields": {
    "action_time": "2025-05-24T20:57:15.267Z",
    "user": 2,
    "content_type": 14,
    "object_id": "159",
    "object_repr": "Keating, G.M., 2005. Zolpidem: a review of its use in the management of insomnia. CNS Drugs, 19(1), pp.65-89.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1562,
  "fields": {
    "action_time": "2025-05-24T20:57:51.473Z",
    "user": 2,
    "content_type": 14,
    "object_id": "160",
    "object_repr": "Copinschi, G., Akseki, E., Moreno-Reyes, R., Leproult, R., L'Hermite-Balériaux, M., Caufriez, A., Vertongen, F. and Cauter, E.V., 1995. Effects of Bedtime Administration of Zolpidem on Orcadian and Sl",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1563,
  "fields": {
    "action_time": "2025-05-24T20:57:54.593Z",
    "user": 2,
    "content_type": 10,
    "object_id": "128",
    "object_repr": "Zolpidem",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1564,
  "fields": {
    "action_time": "2025-05-24T20:58:31.736Z",
    "user": 2,
    "content_type": 13,
    "object_id": "53",
    "object_repr": "helps with sleep, it doesn't necessarily reset or re-establish the body's internal clock",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1565,
  "fields": {
    "action_time": "2025-05-24T20:58:56.875Z",
    "user": 2,
    "content_type": 14,
    "object_id": "161",
    "object_repr": "Krystal, A.D., Walsh, J.K., Laska, E., Caron, J., Amato, D.A., Wessel, T.C. and Roth, T., 2003. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-bl",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1566,
  "fields": {
    "action_time": "2025-05-24T20:58:59.231Z",
    "user": 2,
    "content_type": 10,
    "object_id": "127",
    "object_repr": "Eszopiclone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1567,
  "fields": {
    "action_time": "2025-05-24T20:59:39.885Z",
    "user": 2,
    "content_type": 14,
    "object_id": "162",
    "object_repr": "Suzuki, S., Katagiri, S. and Nakashima, H., 1996. Mutants with altered sensitivity to a calmodulin antagonist affect the circadian clock in Neurospora crassa. Genetics, 143(3), pp.1175-1180.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1568,
  "fields": {
    "action_time": "2025-05-24T20:59:48.588Z",
    "user": 2,
    "content_type": 10,
    "object_id": "126",
    "object_repr": "Trifluoperazine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1569,
  "fields": {
    "action_time": "2025-05-24T21:02:06.836Z",
    "user": 2,
    "content_type": 14,
    "object_id": "163",
    "object_repr": "Nagayama, H., Takagi, A., Sakurai, Y., Nishiwaki, K. and Takahashi, R., 1978. Chronopharmacological study of neuroleptics: II. Circadian susceptibility rhythm to chlorpromazine. Psychopharmacology, 58",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1570,
  "fields": {
    "action_time": "2025-05-24T21:02:13.308Z",
    "user": 2,
    "content_type": 10,
    "object_id": "125",
    "object_repr": "Promazine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Classf\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1571,
  "fields": {
    "action_time": "2025-05-24T21:03:23.021Z",
    "user": 2,
    "content_type": 14,
    "object_id": "164",
    "object_repr": "Davies, J.A., 1979. The Influence of Dopaminergic Mechanism on 24-Hour Temperature and Activity Rhythms in Rodents. In Neuro-Psychopharmacology (pp. 611-620). Pergamon.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1572,
  "fields": {
    "action_time": "2025-05-24T21:03:25.557Z",
    "user": 2,
    "content_type": 10,
    "object_id": "124",
    "object_repr": "Pimozidine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1573,
  "fields": {
    "action_time": "2025-05-24T21:04:09.966Z",
    "user": 2,
    "content_type": 14,
    "object_id": "165",
    "object_repr": "Romo‐Nava, F., Buijs, F.N., Valdés‐Tovar, M., Benítez‐King, G., Basualdo, M., Perusquía, M., Heinze, G., Escobar, C. and Buijs, R.M., 2017. Olanzapine‐induced early cardiovascular effects are mediated",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1574,
  "fields": {
    "action_time": "2025-05-24T21:04:40.198Z",
    "user": 2,
    "content_type": 14,
    "object_id": "166",
    "object_repr": "Vidarsdottir, S., Roelfsema, F., Frolich, M. and Pijl, H., 2009. Olanzapine shifts the temporal relationship between the daily acrophase of serum prolactin and cortisol concentrations rhythm in health",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1575,
  "fields": {
    "action_time": "2025-05-24T21:04:42.724Z",
    "user": 2,
    "content_type": 10,
    "object_id": "123",
    "object_repr": "Olanzapine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1576,
  "fields": {
    "action_time": "2025-05-24T21:05:28.501Z",
    "user": 2,
    "content_type": 14,
    "object_id": "167",
    "object_repr": "Calabrese, F., Savino, E., Papp, M., Molteni, R. and Riva, M.A., 2016. Chronic mild stress-induced alterations of clock gene expression in rat prefrontal cortex: modulatory effects of prolonged lurasi",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1577,
  "fields": {
    "action_time": "2025-05-24T21:05:45.380Z",
    "user": 2,
    "content_type": 14,
    "object_id": "168",
    "object_repr": "Krystal, A.D. and Zammit, G., 2016. The sleep effects of lurasidone: a placebo‐controlled cross‐over study using a 4‐h phase‐advance model of transient insomnia. Human Psychopharmacology: Clinical and",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1578,
  "fields": {
    "action_time": "2025-05-24T21:05:50.130Z",
    "user": 2,
    "content_type": 10,
    "object_id": "122",
    "object_repr": "Lurasidone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1579,
  "fields": {
    "action_time": "2025-05-24T21:06:22.559Z",
    "user": 2,
    "content_type": 14,
    "object_id": "169",
    "object_repr": "Naber, D., Wirz-Justice, A. and Kafka, M.S., 1982. Chronic fluphenazine treatment modifies circadian rhythms of neurotransmitter receptor binding in rat brain. Journal of Neural Transmission, 55, pp.2",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1580,
  "fields": {
    "action_time": "2025-05-24T21:06:25.835Z",
    "user": 2,
    "content_type": 10,
    "object_id": "121",
    "object_repr": "Fluphenazine decanoate",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1581,
  "fields": {
    "action_time": "2025-05-24T21:07:56.824Z",
    "user": 2,
    "content_type": 14,
    "object_id": "170",
    "object_repr": "Wei, H., Zapata, R.C., Lopez-Valencia, M., Aslanoglou, D., Farino, Z.J., Benner, V., Osborn, O., Freyberg, Z. and McCarthy, M.J., 2020. Dopamine D2 receptor signaling modulates pancreatic beta cell ci",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1582,
  "fields": {
    "action_time": "2025-05-24T21:08:15.332Z",
    "user": 2,
    "content_type": 13,
    "object_id": "54",
    "object_repr": "Modulates insulin release rhtyhms",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1583,
  "fields": {
    "action_time": "2025-05-24T21:08:24.124Z",
    "user": 2,
    "content_type": 10,
    "object_id": "120",
    "object_repr": "Sulpiride",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1584,
  "fields": {
    "action_time": "2025-05-24T21:08:59.228Z",
    "user": 2,
    "content_type": 14,
    "object_id": "171",
    "object_repr": "Zapata, R.C., Silver, A., Yoon, D., Chaudry, B., Libster, A., McCarthy, M.J. and Osborn, O., 2022. Adverse effects of antipsychotic drugs on metabolism depend on drug dosing and feeding times. medRxiv",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1585,
  "fields": {
    "action_time": "2025-05-24T21:09:24.932Z",
    "user": 2,
    "content_type": 14,
    "object_id": "172",
    "object_repr": "Cherukalady, R., Kumar, D., Basu, P. and Singaravel, M., 2017. Risperidone resets the circadian clock in mice. Biological Rhythm Research, 48(4), pp.583-591.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1586,
  "fields": {
    "action_time": "2025-05-24T21:09:32.366Z",
    "user": 2,
    "content_type": 10,
    "object_id": "119",
    "object_repr": "Risperidon",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1587,
  "fields": {
    "action_time": "2025-05-24T21:10:11.986Z",
    "user": 2,
    "content_type": 14,
    "object_id": "173",
    "object_repr": "Dagan, Y. and Borodkin, K., 2005. Behavioral and psychiatric consequences of sleep-wake schedule disorders. Dialogues in clinical neuroscience, 7(4), pp.357-365.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1588,
  "fields": {
    "action_time": "2025-05-24T21:10:58.075Z",
    "user": 2,
    "content_type": 14,
    "object_id": "174",
    "object_repr": "Bad News for Antipsychotics and Circadian Rhythms",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1589,
  "fields": {
    "action_time": "2025-05-24T21:11:02.376Z",
    "user": 2,
    "content_type": 10,
    "object_id": "118",
    "object_repr": "Flupentixol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1590,
  "fields": {
    "action_time": "2025-05-24T21:11:13.281Z",
    "user": 2,
    "content_type": 10,
    "object_id": "118",
    "object_repr": "Flupentixol",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1591,
  "fields": {
    "action_time": "2025-05-25T12:11:13.970Z",
    "user": 1,
    "content_type": 14,
    "object_id": "175",
    "object_repr": "Resveratrol restores the circadian rhythmic disorder of lipid metabolism induced by high-fat diet in mice",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1592,
  "fields": {
    "action_time": "2025-05-25T12:11:18.285Z",
    "user": 1,
    "content_type": 10,
    "object_id": "6",
    "object_repr": "Resveratrol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1593,
  "fields": {
    "action_time": "2025-05-25T12:14:22.917Z",
    "user": 1,
    "content_type": 14,
    "object_id": "175",
    "object_repr": "Resveratrol restores the circadian rhythmic disorder of lipid metabolism induced by high-fat diet in mice",
    "action_flag": 3,
    "change_message": ""
  }
},
{
  "model": "admin.logentry",
  "pk": 1594,
  "fields": {
    "action_time": "2025-05-25T12:14:46.857Z",
    "user": 1,
    "content_type": 14,
    "object_id": "176",
    "object_repr": "Sun, L., Wang, Y., Song, Y., Cheng, X.R., Xia, S., Rahman, M.R., Shi, Y. and Le, G., 2015. Resveratrol restores the circadian rhythmic disorder of lipid metabolism induced by high-fat diet in mice. Bi",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1595,
  "fields": {
    "action_time": "2025-05-25T12:14:54.698Z",
    "user": 1,
    "content_type": 10,
    "object_id": "6",
    "object_repr": "Resveratrol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1596,
  "fields": {
    "action_time": "2025-05-25T12:16:52.681Z",
    "user": 1,
    "content_type": 14,
    "object_id": "177",
    "object_repr": "Spaleniak, W. and Cuendet, M., 2023. Resveratrol as a circadian clock modulator: mechanisms of action and therapeutic applications. Molecular Biology Reports, 50, pp.6159–6170.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1597,
  "fields": {
    "action_time": "2025-05-25T12:17:44.856Z",
    "user": 1,
    "content_type": 14,
    "object_id": "178",
    "object_repr": "Avital-Cohen, N., Chapnik, N. and Froy, O., 2024. Resveratrol induces myotube development by altering circadian metabolism via the SIRT1-AMPK-PP2A axis. Cells, 13, p.1069.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1598,
  "fields": {
    "action_time": "2025-05-25T12:17:48.419Z",
    "user": 1,
    "content_type": 10,
    "object_id": "6",
    "object_repr": "Resveratrol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1599,
  "fields": {
    "action_time": "2025-05-25T12:18:56.319Z",
    "user": 1,
    "content_type": 14,
    "object_id": "179",
    "object_repr": "Tian, Y., Luan, X. and Yang, K., 2024. Chronotherapy involving rosiglitazone regulates the phenotypic switch of vascular smooth muscle cells by shifting the phase of TNF-α rhythm through triglyceride ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1600,
  "fields": {
    "action_time": "2025-05-25T12:20:28.055Z",
    "user": 1,
    "content_type": 14,
    "object_id": "180",
    "object_repr": "Tian, Y., Luan, X. and Yang, K., 2024. Chronotherapy involving rosiglitazone regulates the phenotypic switch of vascular smooth muscle cells by shifting the phase of TNF-α rhythm through triglyceride ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1601,
  "fields": {
    "action_time": "2025-05-25T12:20:30.869Z",
    "user": 1,
    "content_type": 10,
    "object_id": "7",
    "object_repr": "Rosiglitazone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1602,
  "fields": {
    "action_time": "2025-05-25T12:21:48.412Z",
    "user": 1,
    "content_type": 14,
    "object_id": "181",
    "object_repr": "Arendt, J. and Skene, D.J., 2005. Melatonin as a chronobiotic. Sleep Medicine Reviews, 9(1), pp.25–39.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1603,
  "fields": {
    "action_time": "2025-05-25T12:22:25.654Z",
    "user": 1,
    "content_type": 14,
    "object_id": "182",
    "object_repr": "Pévet, P., Bothorel, B., Slotten, H. and Saboureau, M., 2002. The chronobiotic properties of melatonin. Cell and Tissue Research, 309, pp.183–191.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1604,
  "fields": {
    "action_time": "2025-05-25T12:23:08.022Z",
    "user": 1,
    "content_type": 14,
    "object_id": "183",
    "object_repr": "Cardinali, D.P., 2024. Melatonin as a chronobiotic/cytoprotective agent in bone. Doses involved. Journal of Pineal Research, 76(1), p.e12931.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1605,
  "fields": {
    "action_time": "2025-05-25T12:23:11.166Z",
    "user": 1,
    "content_type": 10,
    "object_id": "8",
    "object_repr": "Melatonin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1606,
  "fields": {
    "action_time": "2025-05-25T12:39:42.271Z",
    "user": 1,
    "content_type": 14,
    "object_id": "184",
    "object_repr": "Richardson, G.S., Zee, P.C., Wang-Weigand, S., Rodriguez, L. and Peng, X., 2008. Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. Journal of Clinical Sleep Medi",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1607,
  "fields": {
    "action_time": "2025-05-25T12:40:14.992Z",
    "user": 1,
    "content_type": 14,
    "object_id": "185",
    "object_repr": "Takeshima, M., Shimizu, T., Ishikawa, H. and Kanbayashi, T., 2020. Ramelteon for delayed sleep-wake phase disorder: a case report. Clinical Psychopharmacology and Neuroscience, 18(1), pp.167–169.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1608,
  "fields": {
    "action_time": "2025-05-25T12:41:04.050Z",
    "user": 1,
    "content_type": 14,
    "object_id": "186",
    "object_repr": "Zammit, G.K., 2007. Ramelteon: a novel hypnotic indicated for the treatment of insomnia. Psychiatry (Edgmont), 4(9), pp.36–42.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1609,
  "fields": {
    "action_time": "2025-05-25T12:41:07.262Z",
    "user": 1,
    "content_type": 10,
    "object_id": "10",
    "object_repr": "Ramelteon",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1610,
  "fields": {
    "action_time": "2025-05-25T12:46:30.121Z",
    "user": 1,
    "content_type": 14,
    "object_id": "187",
    "object_repr": "Liu, W., Chen, Z., Li, R., Zheng, M., Pang, X., Wen, A., Yang, B. and Wang, S., 2023. High and low dose of luzindole or 4-phenyl-2-propionamidotetralin (4-P-PDOT) reverse bovine granulosa cell respons",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1611,
  "fields": {
    "action_time": "2025-05-25T12:46:33.337Z",
    "user": 1,
    "content_type": 10,
    "object_id": "12",
    "object_repr": "4-P-PDOT (N-(4-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1612,
  "fields": {
    "action_time": "2025-05-25T12:47:52.303Z",
    "user": 1,
    "content_type": 14,
    "object_id": "188",
    "object_repr": "Pandi-Perumal, S.R., Moscovitch, A., Srinivasan, V., Spence, D.W., Cardinali, D.P. and Brown, G.M., 2009. Bidirectional communication between sleep and circadian rhythms and its implications for depre",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1613,
  "fields": {
    "action_time": "2025-05-25T12:49:18.334Z",
    "user": 1,
    "content_type": 14,
    "object_id": "189",
    "object_repr": "Tchekalarova, J., Stoynova, T., Ilieva, K., Mitreva, R. and Atanasova, M., 2018. Agomelatine treatment corrects symptoms of depression and anxiety by restoring the disrupted melatonin circadian rhythm",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1614,
  "fields": {
    "action_time": "2025-05-25T12:49:20.790Z",
    "user": 1,
    "content_type": 10,
    "object_id": "13",
    "object_repr": "Agomelatine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1615,
  "fields": {
    "action_time": "2025-05-25T12:51:41.552Z",
    "user": 1,
    "content_type": 14,
    "object_id": "190",
    "object_repr": "Spadoni, G., Bedini, A., Diamantini, G., Tarzia, G., Rivara, S., Lorenzi, S., Lodola, A., Mor, M., Lucini, V., Pannacci, M., Caronno, A. and Fraschini, F., 2007. Synthesis, enantiomeric resolution, an",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1616,
  "fields": {
    "action_time": "2025-05-25T12:52:11.274Z",
    "user": 1,
    "content_type": 14,
    "object_id": "191",
    "object_repr": "Lucini, V., Pannacci, M., Scaglione, F., Fraschini, F., Rivara, S., Mor, M., Bordi, F., Plazzi, P.V., Spadoni, G., Bedini, A., Piersanti, G., Diamantini, G. and Tarzia, G., 2004. Tricyclic alkylamides",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1617,
  "fields": {
    "action_time": "2025-05-25T12:52:16.470Z",
    "user": 1,
    "content_type": 10,
    "object_id": "14",
    "object_repr": "N-[(6-Methoxy-9-tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaenyl)methyl]acetamide (UCM 549)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1618,
  "fields": {
    "action_time": "2025-05-25T12:54:42.650Z",
    "user": 1,
    "content_type": 14,
    "object_id": "192",
    "object_repr": "Pintor, J., Peláez, T., Hoyle, C.H. and Peral, A., 2003. Ocular hypotensive effects of melatonin receptor agonists in the rabbit: further evidence for an MT3 receptor. British Journal of Pharmacology,",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1619,
  "fields": {
    "action_time": "2025-05-25T12:55:38.401Z",
    "user": 1,
    "content_type": 14,
    "object_id": "193",
    "object_repr": "Crooke, A., Huete-Toral, F., Martínez-Águila, A., Martín-Gil, A. and Pintor, J., 2012. Involvement of carbonic anhydrases in the ocular hypotensive effect of melatonin analogue 5-MCA-NAT. Journal of P",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1620,
  "fields": {
    "action_time": "2025-05-25T12:55:42.315Z",
    "user": 1,
    "content_type": 10,
    "object_id": "15",
    "object_repr": "5-MCA-NAT",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1621,
  "fields": {
    "action_time": "2025-05-25T12:59:54.997Z",
    "user": 1,
    "content_type": 14,
    "object_id": "194",
    "object_repr": "Descamps-François, C., Yous, S., Chavatte, P., Audinot, V., Bonnaud, A., Boutin, J.A., Delagrange, P., Bennejean, C., Renard, P. and Lesieur, D., 2003. Design and synthesis of naphthalenic dimers as s",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1622,
  "fields": {
    "action_time": "2025-05-25T13:01:01.165Z",
    "user": 1,
    "content_type": 14,
    "object_id": "195",
    "object_repr": "Audinot, V., Mailliet, F., Lahaye-Brasseur, C., Bonnaud, A., Le Gall, A., Amossé, C., Dromaint, S., Rodriguez, M., Nagel, N., Galizzi, J.P., Malpaux, B., Guillaumet, G., Lesieur, D., Lefoulon, F., Ren",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1623,
  "fields": {
    "action_time": "2025-05-25T13:01:27.794Z",
    "user": 1,
    "content_type": 10,
    "object_id": "16",
    "object_repr": "S26131",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1624,
  "fields": {
    "action_time": "2025-05-25T13:02:16.512Z",
    "user": 1,
    "content_type": 14,
    "object_id": "196",
    "object_repr": "González, S., Moreno-Delgado, D., Moreno, E., Pérez-Capote, K., Franco, R., Mallol, J., Cortés, A., Casadó, V., Lluís, C., Ortiz, J., Ferré, S., Canela, E. and McCormick, P.J., 2012. Circadian-related",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1625,
  "fields": {
    "action_time": "2025-05-25T13:03:09.690Z",
    "user": 1,
    "content_type": 10,
    "object_id": "17",
    "object_repr": "Melatonin-d4",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1626,
  "fields": {
    "action_time": "2025-05-25T13:04:18.793Z",
    "user": 1,
    "content_type": 14,
    "object_id": "197",
    "object_repr": "Masana, M.I., Benloucif, S. and Dubocovich, M.L., 2000. Circadian rhythm of MT1 melatonin receptor expression in the suprachiasmatic nucleus of the C3H/HeN mouse. Journal of Pineal Research, 28(3), pp",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1627,
  "fields": {
    "action_time": "2025-05-25T13:05:22.601Z",
    "user": 1,
    "content_type": 14,
    "object_id": "198",
    "object_repr": "Larson-Prior, L.J., Siuciak, J.A. and Dubocovich, M.L., 1996. Localization of 2-[¹²⁵I]iodomelatonin binding sites in visual areas of the turtle brain. European Journal of Pharmacology, 297(1–2), pp.18",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1628,
  "fields": {
    "action_time": "2025-05-25T13:05:28.121Z",
    "user": 1,
    "content_type": 10,
    "object_id": "18",
    "object_repr": "2-Iodomelatonin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1629,
  "fields": {
    "action_time": "2025-05-25T13:06:05.337Z",
    "user": 1,
    "content_type": 14,
    "object_id": "199",
    "object_repr": "Mendoza-Vargas, L., Solís-Chagoyán, H., Benítez-King, G. and Fuentes-Pardo, B., 2009. MT2-like melatonin receptor modulates amplitude receptor potential in visual cells of crayfish during a 24-hour cy",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1630,
  "fields": {
    "action_time": "2025-05-25T13:07:04.196Z",
    "user": 1,
    "content_type": 14,
    "object_id": "200",
    "object_repr": "Ambriz-Tututi, M. and Granados-Soto, V., 2007. Oral and spinal melatonin reduces tactile allodynia in rats via activation of MT2 and opioid receptors. Pain, 132(3), pp.273–280.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1631,
  "fields": {
    "action_time": "2025-05-25T13:07:07.437Z",
    "user": 1,
    "content_type": 10,
    "object_id": "19",
    "object_repr": "8-M-PDOT",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1632,
  "fields": {
    "action_time": "2025-05-25T13:10:16.714Z",
    "user": 1,
    "content_type": 14,
    "object_id": "201",
    "object_repr": "Nishimon, S., Nishimon, M. and Nishino, S., 2019. Tasimelteon for treating non-24-h sleep–wake rhythm disorder. Expert Opinion on Pharmacotherapy, 20(9), pp.1065–1073.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1633,
  "fields": {
    "action_time": "2025-05-25T13:10:36.283Z",
    "user": 1,
    "content_type": 14,
    "object_id": "202",
    "object_repr": "Torres, R., Kramer, W.G. and Baroldi, P., 2015. Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects with hepatic or renal impairment. Journal of Clinical Pharmacology, 55(5",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1634,
  "fields": {
    "action_time": "2025-05-25T13:10:41.437Z",
    "user": 1,
    "content_type": 10,
    "object_id": "20",
    "object_repr": "Tasimelteon",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1635,
  "fields": {
    "action_time": "2025-05-25T13:11:38.157Z",
    "user": 1,
    "content_type": 14,
    "object_id": "203",
    "object_repr": "Tchekalarova, J., Stoynova, T., Ilieva, K., Mitreva, R. and Atanasova, M., 2018. Agomelatine treatment corrects symptoms of depression and anxiety by restoring the disrupted melatonin circadian rhythm",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1636,
  "fields": {
    "action_time": "2025-05-25T13:12:02.673Z",
    "user": 1,
    "content_type": 14,
    "object_id": "204",
    "object_repr": "Mairesse, J., Silletti, V., Laloux, C., Zuena, A.R., Giovine, A., Consolazione, M., van Camp, G., Malagodi, M., Gaetani, S., Cianci, S., Catalani, A., Mennuni, G., Mazzetta, A., van Reeth, O., Gabriel",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1637,
  "fields": {
    "action_time": "2025-05-25T13:12:11.300Z",
    "user": 1,
    "content_type": 10,
    "object_id": "21",
    "object_repr": "Agomelatine hydrochloride",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1638,
  "fields": {
    "action_time": "2025-05-25T13:13:04.586Z",
    "user": 1,
    "content_type": 14,
    "object_id": "205",
    "object_repr": "Ferreira, M.A. Jr, Azevedo, H., Mascarello, A., Segretti, N.D., Russo, E., Russo, V. and Guimarães, C.R.W., 2021. Discovery of ACH-000143: a novel potent and peripherally preferred melatonin receptor ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1639,
  "fields": {
    "action_time": "2025-05-25T13:14:51.463Z",
    "user": 1,
    "content_type": 10,
    "object_id": "22",
    "object_repr": "ACH-000143",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1640,
  "fields": {
    "action_time": "2025-05-25T13:15:44.060Z",
    "user": 1,
    "content_type": 14,
    "object_id": "206",
    "object_repr": "Tchekalarova, J., Kortenska, L., Marinov, P. and Ivanova, N., 2022. Sex-dependent effects of piromelatine treatment on sleep–wake cycle and sleep structure of prenatally stressed rats. International J",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1641,
  "fields": {
    "action_time": "2025-05-25T13:16:30.680Z",
    "user": 1,
    "content_type": 14,
    "object_id": "207",
    "object_repr": "She, M., Hu, X., Su, Z., Zhang, C., Yang, S., Ding, L., Laudon, M. and Yin, W., 2014. Piromelatine, a novel melatonin receptor agonist, stabilizes metabolic profiles and ameliorates insulin resistance",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1642,
  "fields": {
    "action_time": "2025-05-25T13:16:34.041Z",
    "user": 1,
    "content_type": 10,
    "object_id": "23",
    "object_repr": "Piromelatine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1643,
  "fields": {
    "action_time": "2025-05-25T13:19:25.774Z",
    "user": 1,
    "content_type": 14,
    "object_id": "208",
    "object_repr": "Radogna, F., Paternoster, L., De Nicola, M., Cerella, C., Ammendola, S., Bedini, A., Tarzia, G., Aquilano, K., Ciriolo, M. and Ghibelli, L., 2009. Rapid and transient stimulation of intracellular reac",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1644,
  "fields": {
    "action_time": "2025-05-25T13:20:04.094Z",
    "user": 1,
    "content_type": 14,
    "object_id": "209",
    "object_repr": "Mor, M., Spadoni, G., Di Giacomo, B., Diamantini, G., Bedini, A., Tarzia, G., Plazzi, P.V., Rivara, S., Nonno, R., Lucini, V., Pannacci, M., Fraschini, F. and Stankov, B.M., 2001. Synthesis, pharmacol",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1645,
  "fields": {
    "action_time": "2025-05-25T13:20:06.728Z",
    "user": 1,
    "content_type": 10,
    "object_id": "24",
    "object_repr": "UCM 608 (N-[2-(5-methoxy-2-phenyl-1H-indol-3-yl)ethyl]acetamide)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1646,
  "fields": {
    "action_time": "2025-05-25T13:36:51.064Z",
    "user": 1,
    "content_type": 14,
    "object_id": "210",
    "object_repr": "Richardson, G.S., Zee, P.C., Wang-Weigand, S., Rodriguez, L. and Peng, X., 2008. Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. Journal of Clinical Sleep Medi",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1647,
  "fields": {
    "action_time": "2025-05-25T13:37:23.557Z",
    "user": 1,
    "content_type": 14,
    "object_id": "211",
    "object_repr": "Richardson, G.S., Zee, P.C., Wang-Weigand, S., Rodriguez, L. and Peng, X., 2008. Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. Journal of Clinical Sleep Medi",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1648,
  "fields": {
    "action_time": "2025-05-25T13:37:27.949Z",
    "user": 1,
    "content_type": 10,
    "object_id": "25",
    "object_repr": "Ramelteon metabolite M-II-d3",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1649,
  "fields": {
    "action_time": "2025-05-25T13:38:08.730Z",
    "user": 1,
    "content_type": 14,
    "object_id": "212",
    "object_repr": "Backlund, P.S., Urbanski, H.F., Doll, M.A., Hein, D.W., Bozinoski, M., Mason, C.E., Coon, S.L. and Klein, D.C., 2017. Daily rhythm in plasma N-acetyltryptamine. Journal of Biological Rhythms, 32(3), p",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1650,
  "fields": {
    "action_time": "2025-05-25T13:38:49.835Z",
    "user": 1,
    "content_type": 14,
    "object_id": "213",
    "object_repr": "Backlund, P.S., Urbanski, H.F., Doll, M.A., Hein, D.W., Bozinoski, M., Mason, C.E., Coon, S.L. and Klein, D.C., 2017. Daily rhythm in plasma N-acetyltryptamine. Journal of Biological Rhythms, 32(3), p",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1651,
  "fields": {
    "action_time": "2025-05-25T13:40:29.222Z",
    "user": 1,
    "content_type": 14,
    "object_id": "214",
    "object_repr": "Pohanka, M., 2022. New uses of melatonin as a drug: a review. Current Medicinal Chemistry, 29(20), pp.3622–3637.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1652,
  "fields": {
    "action_time": "2025-05-25T13:40:32.958Z",
    "user": 1,
    "content_type": 10,
    "object_id": "26",
    "object_repr": "N-Acetyltryptamine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1653,
  "fields": {
    "action_time": "2025-05-25T13:42:13.126Z",
    "user": 1,
    "content_type": 14,
    "object_id": "215",
    "object_repr": "Karim, A., Tolbert, D. and Cao, C., 2006. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1654,
  "fields": {
    "action_time": "2025-05-25T13:42:44.698Z",
    "user": 1,
    "content_type": 10,
    "object_id": "25",
    "object_repr": "Ramelteon metabolite M-II-d3",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1655,
  "fields": {
    "action_time": "2025-05-25T13:43:51.492Z",
    "user": 1,
    "content_type": 14,
    "object_id": "216",
    "object_repr": "Rajaratnam, S.M., Middleton, B., Stone, B.M., Arendt, J. and Dijk, D.J., 2004. Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in exte",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1656,
  "fields": {
    "action_time": "2025-05-25T13:44:23.207Z",
    "user": 1,
    "content_type": 10,
    "object_id": "28",
    "object_repr": "Melatonin-d3",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1657,
  "fields": {
    "action_time": "2025-05-25T13:47:54.890Z",
    "user": 1,
    "content_type": 14,
    "object_id": "217",
    "object_repr": "Dubocovich, M.L., 2007. Melatonin receptors: role on sleep and circadian rhythm regulation. Sleep Medicine, 8(Suppl 3), pp.34–42.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1658,
  "fields": {
    "action_time": "2025-05-25T13:48:01.368Z",
    "user": 1,
    "content_type": 10,
    "object_id": "30",
    "object_repr": "Melatonin receptor agonist 1",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1659,
  "fields": {
    "action_time": "2025-05-25T13:55:12.323Z",
    "user": 1,
    "content_type": 14,
    "object_id": "218",
    "object_repr": "Bogaards, J.J., Hissink, E.M., Briggs, M., Weaver, R., Jochemsen, R., Jackson, P., Bertrand, M. and van Bladeren, P.J., 2000. Prediction of interindividual variation in drug plasma levels in vivo from",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1660,
  "fields": {
    "action_time": "2025-05-25T13:55:15.753Z",
    "user": 1,
    "content_type": 10,
    "object_id": "33",
    "object_repr": "7-Desmethyl-3-hydroxyagomelatine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1661,
  "fields": {
    "action_time": "2025-05-25T13:56:53.701Z",
    "user": 1,
    "content_type": 14,
    "object_id": "219",
    "object_repr": "Hardeland, R., 2016. Melatonin and synthetic melatoninergic agonists in psychiatric and age-associated disorders: successful and unsuccessful approaches. Current Pharmaceutical Design, 22(8), pp.1086–",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1662,
  "fields": {
    "action_time": "2025-05-25T13:57:49.782Z",
    "user": 1,
    "content_type": 14,
    "object_id": "220",
    "object_repr": "Szabadi, E., 2015. Neuronal networks regulating sleep and arousal: effect of drugs. In: Guglietta, A. (ed.) Drug Treatment of Sleep Disorders. Milestones in Drug Therapy. Springer, Cham, pp.25–70.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1663,
  "fields": {
    "action_time": "2025-05-25T13:57:51.854Z",
    "user": 1,
    "content_type": 10,
    "object_id": "35",
    "object_repr": "TIK-301",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1664,
  "fields": {
    "action_time": "2025-05-25T14:22:04.983Z",
    "user": 1,
    "content_type": 14,
    "object_id": "221",
    "object_repr": "Masson-Pévet, M., Recio, J., Guerrero, H.Y., Mocaer, E., Delagrange, P., Guardiola-Lemaitre, B. and Pévet, P., 1998. Effects of two melatonin analogues, S-20098 and S-20928, on melatonin receptors in ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1665,
  "fields": {
    "action_time": "2025-05-25T14:22:45.694Z",
    "user": 1,
    "content_type": 14,
    "object_id": "222",
    "object_repr": "Willis, G.L. and Robertson, A.D., 2005. Recovery from experimental Parkinson's disease in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride treated marmoset with the melatonin analogue ML",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1666,
  "fields": {
    "action_time": "2025-05-25T14:22:50.344Z",
    "user": 1,
    "content_type": 10,
    "object_id": "36",
    "object_repr": "S-20928",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1667,
  "fields": {
    "action_time": "2025-05-25T14:24:40.381Z",
    "user": 1,
    "content_type": 14,
    "object_id": "223",
    "object_repr": "Behrens, U.D., Douglas, R.H., Sugden, D., Davies, D.J. and Wagner, H.J., 2000. Effect of melatonin agonists and antagonists on horizontal cell spinule formation and dopamine release in a fish retina. ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1668,
  "fields": {
    "action_time": "2025-05-25T14:25:55.378Z",
    "user": 1,
    "content_type": 10,
    "object_id": "37",
    "object_repr": "DH97",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1669,
  "fields": {
    "action_time": "2025-05-25T14:28:34.777Z",
    "user": 1,
    "content_type": 14,
    "object_id": "224",
    "object_repr": "Beresford, I.J., Harvey, F.J., Hall, D.A. and Giles, H., 1998. Pharmacological characterisation of melatonin MT1 receptor-mediated stimulation of [³⁵S]-GTPγS binding. Biochemical Pharmacology, 56(9), ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1670,
  "fields": {
    "action_time": "2025-05-25T14:29:37.021Z",
    "user": 1,
    "content_type": 14,
    "object_id": "225",
    "object_repr": "Fratter, A., 2013. Nanoemulsion technology for sublingual delivery of melatonin: characterization and preliminary data on a new administration system. In: New Developments in Melatonin Research. Nova ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1671,
  "fields": {
    "action_time": "2025-05-25T14:29:40.702Z",
    "user": 1,
    "content_type": 10,
    "object_id": "40",
    "object_repr": "GR 196429",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1672,
  "fields": {
    "action_time": "2025-05-25T14:30:44.798Z",
    "user": 1,
    "content_type": 14,
    "object_id": "226",
    "object_repr": "Audinot, V., Mailliet, F., Lahaye-Brasseur, C., Bonnaud, A., Le Gall, A., Amossé, C., Dromaint, S., Rodriguez, M., Nagel, N., Galizzi, J.P., Malpaux, B., Guillaumet, G., Lesieur, D., Lefoulon, F., Ren",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1673,
  "fields": {
    "action_time": "2025-05-25T14:31:23.790Z",
    "user": 1,
    "content_type": 14,
    "object_id": "227",
    "object_repr": "Millan, M.J., Gobert, A., Lejeune, F., Dekeyne, A., Newman-Tancredi, A., Pasteau, V., Rivet, J.M. and Cussac, D., 2003. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytr",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1674,
  "fields": {
    "action_time": "2025-05-25T14:32:02.156Z",
    "user": 1,
    "content_type": 14,
    "object_id": "228",
    "object_repr": "Aguiar, C.C., Almeida, A.B., Araújo, P.V., Vasconcelos, G.S., Chaves, E.M., do Vale, O.C., Macêdo, D.S., Leal, L.K., de Barros Viana, G.S. and Vasconcelos, S.M., 2013. Effects of agomelatine on oxidat",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1675,
  "fields": {
    "action_time": "2025-05-25T14:32:03.613Z",
    "user": 1,
    "content_type": 10,
    "object_id": "41",
    "object_repr": "Agomelatine (L(+)-Tartaric acid)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1676,
  "fields": {
    "action_time": "2025-05-25T14:33:56.239Z",
    "user": 1,
    "content_type": 14,
    "object_id": "229",
    "object_repr": "Teh, M.T. and Sugden, D., 1999. The putative melatonin receptor antagonist GR128107 is a partial agonist on Xenopus laevis melanophores. British Journal of Pharmacology, 126(5), pp.1237–1245.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1677,
  "fields": {
    "action_time": "2025-05-25T14:34:26.771Z",
    "user": 1,
    "content_type": 14,
    "object_id": "230",
    "object_repr": "Teh, M.T. and Sugden, D., 1999. The putative melatonin receptor antagonist GR128107 is a partial agonist on Xenopus laevis melanophores. British Journal of Pharmacology, 126(5), pp.1237–1245.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1678,
  "fields": {
    "action_time": "2025-05-25T14:34:29.610Z",
    "user": 1,
    "content_type": 10,
    "object_id": "43",
    "object_repr": "GR 128107",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1679,
  "fields": {
    "action_time": "2025-05-25T14:35:17.986Z",
    "user": 1,
    "content_type": 14,
    "object_id": "231",
    "object_repr": "Ferreira, M.A. Jr, Azevedo, H., Mascarello, A., Segretti, N.D., Russo, E., Russo, V. and Guimarães, C.R.W., 2021. Discovery of ACH-000143: a novel potent and peripherally preferred melatonin receptor ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1680,
  "fields": {
    "action_time": "2025-05-25T14:36:22.443Z",
    "user": 1,
    "content_type": 10,
    "object_id": "44",
    "object_repr": "ACH 000143",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1681,
  "fields": {
    "action_time": "2025-05-25T14:36:59.665Z",
    "user": 1,
    "content_type": 14,
    "object_id": "232",
    "object_repr": "Jockers, R., Delagrange, P., Dubocovich, M.L., Markus, R.P., Renault, N., Tosini, G., Cecon, E. and Zlotos, D.P., 2016. Update on melatonin receptors: IUPHAR Review 20. British Journal of Pharmacology",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1682,
  "fields": {
    "action_time": "2025-05-25T14:37:34.200Z",
    "user": 1,
    "content_type": 14,
    "object_id": "233",
    "object_repr": "Boutin, J.A., Witt-Enderby, P.A., Sotriffer, C. and Zlotos, D.P., 2020. Melatonin receptor ligands: a pharmaco-chemical perspective. Journal of Pineal Research, 69(2), p.e12672.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1683,
  "fields": {
    "action_time": "2025-05-25T14:37:37.991Z",
    "user": 1,
    "content_type": 10,
    "object_id": "45",
    "object_repr": "S24014",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1684,
  "fields": {
    "action_time": "2025-05-25T15:54:58.629Z",
    "user": 1,
    "content_type": 14,
    "object_id": "234",
    "object_repr": "Park, W.R., Choi, B., Kim, Y.J., Kim, Y.H., Park, M.J., Kim, D.I., Choi, H.S. and Kim, D.K., 2022. Melatonin regulates iron homeostasis by inducing hepcidin expression in hepatocytes. International Jo",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1685,
  "fields": {
    "action_time": "2025-05-25T15:55:27.256Z",
    "user": 1,
    "content_type": 14,
    "object_id": "235",
    "object_repr": "Wu, H.M., Shen, Q.Y., Fang, L., Zhang, S.H., Shen, P.T., Liu, Y.J. and Liu, R.Y., 2016. JNK-TLR9 signal pathway mediates allergic airway inflammation through suppressing melatonin biosynthesis. Journa",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1686,
  "fields": {
    "action_time": "2025-05-25T15:55:30.216Z",
    "user": 1,
    "content_type": 10,
    "object_id": "46",
    "object_repr": "SP600125",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1687,
  "fields": {
    "action_time": "2025-05-25T15:57:24.380Z",
    "user": 1,
    "content_type": 14,
    "object_id": "236",
    "object_repr": "Lafaye, G., Desterke, C., Marulaz, L. and Benyamina, A., 2019. Cannabidiol affects circadian clock core complex and its regulation in microglia cells. Addiction Biology, 24(5), pp.921–934.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1688,
  "fields": {
    "action_time": "2025-05-25T15:58:08.405Z",
    "user": 1,
    "content_type": 14,
    "object_id": "237",
    "object_repr": "Koch, M., Dehghani, F., Habazettl, I., Schomerus, C. and Korf, H.W., 2006. Cannabinoids attenuate norepinephrine-induced melatonin biosynthesis in the rat pineal gland by reducing arylalkylamine N-ace",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1689,
  "fields": {
    "action_time": "2025-05-25T15:58:11.504Z",
    "user": 1,
    "content_type": 10,
    "object_id": "47",
    "object_repr": "Cannabidiol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1690,
  "fields": {
    "action_time": "2025-05-25T16:03:01.202Z",
    "user": 1,
    "content_type": 14,
    "object_id": "238",
    "object_repr": "Kaul, M., Zee, P.C. and Sahni, A.S., 2021. Effects of cannabinoids on sleep and their therapeutic potential for sleep disorders. Neurotherapeutics, 18(1), pp.217–227.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1691,
  "fields": {
    "action_time": "2025-05-25T16:03:04.935Z",
    "user": 1,
    "content_type": 10,
    "object_id": "50",
    "object_repr": "Dronabinol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1692,
  "fields": {
    "action_time": "2025-05-25T16:03:48.453Z",
    "user": 1,
    "content_type": 14,
    "object_id": "239",
    "object_repr": "Peball, M., Heim, B., Carbone, F., Schorr, O., Werkmann, M., Ellmerer, P., Marini, K., Krismer, F., Knaus, H.G., Poewe, W., Djamshidian, A. and Seppi, K., 2024. Long-term safety and efficacy of open-l",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1693,
  "fields": {
    "action_time": "2025-05-25T16:03:50.996Z",
    "user": 1,
    "content_type": 10,
    "object_id": "53",
    "object_repr": "Nabilone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1694,
  "fields": {
    "action_time": "2025-05-25T19:22:03.097Z",
    "user": 1,
    "content_type": 14,
    "object_id": "240",
    "object_repr": "Gulledge, M., Carlezon, W.A. Jr, McHugh, R.K., Kinard, E.A., Prerau, M.J. and Chartoff, E.H., 2025. Spontaneous oxycodone withdrawal disrupts sleep, diurnal, and electrophysiological dynamics in rats.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1695,
  "fields": {
    "action_time": "2025-05-25T19:22:46.913Z",
    "user": 1,
    "content_type": 14,
    "object_id": "241",
    "object_repr": "Pierce, B.E., Holter, K., Morton, A., Lekander, A., Bedingham, E., Curry, R. and Gould, R.W., 2022. Effects of oxycodone self-administration on sleep duration and quality in male and female rats. The ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1696,
  "fields": {
    "action_time": "2025-05-25T19:22:49.568Z",
    "user": 1,
    "content_type": 10,
    "object_id": "55",
    "object_repr": "Oxycodone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1697,
  "fields": {
    "action_time": "2025-05-25T19:28:09.276Z",
    "user": 1,
    "content_type": 14,
    "object_id": "242",
    "object_repr": "Du, K., Shi, Q., Zhou, X., Zhang, L., Su, H., Zhang, C., Wei, Z., Liu, T., Wang, L., Wang, X., Cong, B. and Yun, K., 2024. Melatonin attenuates fentanyl-induced behavioral sensitization and circadian ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1698,
  "fields": {
    "action_time": "2025-05-25T19:28:46.590Z",
    "user": 1,
    "content_type": 14,
    "object_id": "243",
    "object_repr": "Gillman, A.G., Leffel, J.K. 2nd, Kosobud, A.E. and Timberlake, W., 2009. Fentanyl, but not haloperidol, entrains persisting circadian activity episodes when administered at 24- and 31-h intervals. Beh",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1699,
  "fields": {
    "action_time": "2025-05-25T19:28:49.665Z",
    "user": 1,
    "content_type": 10,
    "object_id": "59",
    "object_repr": "Fentanyl",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1700,
  "fields": {
    "action_time": "2025-05-25T19:29:38.110Z",
    "user": 1,
    "content_type": 14,
    "object_id": "244",
    "object_repr": "Young, A.M., Thompson, T., Jensen, M.A. and Muchow, L.R., 1979. Effects of response-contingent clock stimuli on behavior maintained by intravenous codeine in the rhesus monkey. Pharmacology Biochemist",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1701,
  "fields": {
    "action_time": "2025-05-25T19:30:19.174Z",
    "user": 1,
    "content_type": 14,
    "object_id": "245",
    "object_repr": "Warfield, A.E., Prather, J.F. and Todd, W.D., 2021. Systems and circuits linking chronic pain and circadian rhythms. Frontiers in Neuroscience, 15, p.705173.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1702,
  "fields": {
    "action_time": "2025-05-25T19:31:05.675Z",
    "user": 1,
    "content_type": 14,
    "object_id": "246",
    "object_repr": "Sharma, P. and Nelson, R.J., 2024. Disrupted circadian rhythms and substance use disorders: a narrative review. Clocks & Sleep, 6(3), pp.446–467.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1703,
  "fields": {
    "action_time": "2025-05-25T19:31:10.703Z",
    "user": 1,
    "content_type": 10,
    "object_id": "60",
    "object_repr": "Codeine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1704,
  "fields": {
    "action_time": "2025-05-25T19:31:52.653Z",
    "user": 1,
    "content_type": 14,
    "object_id": "247",
    "object_repr": "Pačesová, D., Novotný, J. and Bendová, Z., 2016. The effect of chronic morphine or methadone exposure and withdrawal on clock gene expression in the rat suprachiasmatic nucleus and AA-NAT activity in ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1705,
  "fields": {
    "action_time": "2025-05-25T19:32:45.729Z",
    "user": 1,
    "content_type": 14,
    "object_id": "248",
    "object_repr": "Pačesová, D., Spišská, V., Novotný, J. and Bendová, Z., 2023. Methadone administered to rat dams during pregnancy and lactation affects the circadian rhythms of their pups. Journal of Neuroscience Res",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1706,
  "fields": {
    "action_time": "2025-05-25T19:32:49.873Z",
    "user": 1,
    "content_type": 10,
    "object_id": "61",
    "object_repr": "6-(dimethylamino)-4,4-diphenylheptan-3-one",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1707,
  "fields": {
    "action_time": "2025-05-25T19:34:10.542Z",
    "user": 1,
    "content_type": 14,
    "object_id": "249",
    "object_repr": "Hakami, A.Y., Alghamdi, B.S. and Alshehri, F.S., 2024. Exploring the potential use of melatonin as a modulator of tramadol-induced rewarding effects in rats. Frontiers in Pharmacology, 15, p.1373746.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1708,
  "fields": {
    "action_time": "2025-05-25T19:34:59.321Z",
    "user": 1,
    "content_type": 14,
    "object_id": "250",
    "object_repr": "Liu, X.P. and Song, J.G., 2001. [Chronopharmacology of tramadol in mice]. Yao Xue Xue Bao (Acta Pharmaceutica Sinica), 36(8), pp.561–564.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1709,
  "fields": {
    "action_time": "2025-05-25T19:35:02.156Z",
    "user": 1,
    "content_type": 10,
    "object_id": "62",
    "object_repr": "Tramadol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1710,
  "fields": {
    "action_time": "2025-05-25T19:35:45.566Z",
    "user": 1,
    "content_type": 14,
    "object_id": "251",
    "object_repr": "Pjrek, E., Frey, R., Naderi-Heiden, A., Strnad, A., Kowarik, A., Kasper, S. and Winkler, D., 2012. Actigraphic measurements in opioid detoxification with methadone or buprenorphine. Journal of Clinica",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1711,
  "fields": {
    "action_time": "2025-05-25T19:36:27.383Z",
    "user": 1,
    "content_type": 14,
    "object_id": "252",
    "object_repr": "Gauthier, E.A., Guzick, S.E., Brummett, C.M., Baghdoyan, H.A. and Lydic, R., 2011. Buprenorphine disrupts sleep and decreases adenosine concentrations in sleep-regulating brain regions of Sprague Dawl",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1712,
  "fields": {
    "action_time": "2025-05-25T19:36:31.252Z",
    "user": 1,
    "content_type": 10,
    "object_id": "63",
    "object_repr": "Buprenorphine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1713,
  "fields": {
    "action_time": "2025-05-25T19:37:35.790Z",
    "user": 1,
    "content_type": 14,
    "object_id": "253",
    "object_repr": "Challet, E., Gourmelen, S., Pevet, P., Oberling, P. and Pain, L., 2007. Reciprocal relationships between general (propofol) anesthesia and circadian time in rats. Neuropsychopharmacology, 32(3), pp.72",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1714,
  "fields": {
    "action_time": "2025-05-25T19:38:10.021Z",
    "user": 1,
    "content_type": 14,
    "object_id": "254",
    "object_repr": "Bienert, A., Kusza, K., Wawrzyniak, K., Grześkowiak, E., Kokot, Z.J., Matysiak, J., Grabowski, T., Wolc, A., Wiczling, P. and Regulski, M., 2010. Assessing circadian rhythms in propofol PK and PD duri",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1715,
  "fields": {
    "action_time": "2025-05-25T19:39:01.231Z",
    "user": 1,
    "content_type": 14,
    "object_id": "255",
    "object_repr": "Touitou, Y., Mauvieux, B., Reinberg, A. and Dispersyn, G., 2016. Disruption of the circadian period of body temperature by the anesthetic propofol. Chronobiology International, 33(9), pp.1247–1254.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1716,
  "fields": {
    "action_time": "2025-05-25T19:39:04.169Z",
    "user": 1,
    "content_type": 10,
    "object_id": "68",
    "object_repr": "Propofol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1717,
  "fields": {
    "action_time": "2025-05-25T19:40:45.738Z",
    "user": 1,
    "content_type": 14,
    "object_id": "256",
    "object_repr": "Bellet, M.M., Vawter, M.P., Bunney, B.G., Bunney, W.E. and Sassone-Corsi, P., 2011. Ketamine influences CLOCK:BMAL1 function leading to altered circadian gene expression. PLoS One, 6(8), p.e23982.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1718,
  "fields": {
    "action_time": "2025-05-25T19:41:18.367Z",
    "user": 1,
    "content_type": 14,
    "object_id": "257",
    "object_repr": "Zhuo, C., Tian, H., Li, G., Chen, M., Jiang, D., Lin, X., Xu, Y. and Wang, W., 2019. Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment-resistant depression: a",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1719,
  "fields": {
    "action_time": "2025-05-25T19:41:50.224Z",
    "user": 1,
    "content_type": 14,
    "object_id": "258",
    "object_repr": "Mihara, T., Kikuchi, T., Kamiya, Y., Koga, M., Uchimoto, K., Kurahashi, K. and Goto, T., 2012. Day or night administration of ketamine and pentobarbital differentially affect circadian rhythms of pine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1720,
  "fields": {
    "action_time": "2025-05-25T19:41:53.332Z",
    "user": 1,
    "content_type": 10,
    "object_id": "69",
    "object_repr": "Ketamine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1721,
  "fields": {
    "action_time": "2025-05-25T19:42:43.073Z",
    "user": 1,
    "content_type": 14,
    "object_id": "259",
    "object_repr": "Kärkelä, J., Vakkuri, O., Kaukinen, S., Huang, W.Q. and Pasanen, M., 2002. The influence of anaesthesia and surgery on the circadian rhythm of melatonin. Acta Anaesthesiologica Scandinavica, 46(1), pp",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1722,
  "fields": {
    "action_time": "2025-05-25T19:43:28.474Z",
    "user": 1,
    "content_type": 14,
    "object_id": "260",
    "object_repr": "Christensen, K.C., Stadil, F., Malmström, J. and Rehfeld, J.F., 1978. The effect of beta-adrenergic and cholinergic blockade on the circadian rhythm of gastrins in serum. Scandinavian Journal of Gastr",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1723,
  "fields": {
    "action_time": "2025-05-25T19:43:32.756Z",
    "user": 1,
    "content_type": 10,
    "object_id": "70",
    "object_repr": "Glycopyrrolate",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1724,
  "fields": {
    "action_time": "2025-05-25T19:44:22.617Z",
    "user": 1,
    "content_type": 14,
    "object_id": "261",
    "object_repr": "Bonafide, C.P., Aucutt-Walter, N., Divittore, N., King, T., Bixler, E.O. and Cronin, A.J., 2008. Remifentanil inhibits rapid eye movement sleep but not the nocturnal melatonin surge in humans. Anesthe",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1725,
  "fields": {
    "action_time": "2025-05-25T19:45:06.968Z",
    "user": 1,
    "content_type": 14,
    "object_id": "262",
    "object_repr": "Wenk, M., Pöpping, D.M., Chapman, G., Grenda, H. and Ledowski, T., 2013. Long-term quality of sleep after remifentanil-based anaesthesia: a randomized controlled trial. British Journal of Anaesthesia,",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1726,
  "fields": {
    "action_time": "2025-05-25T19:45:14.094Z",
    "user": 1,
    "content_type": 10,
    "object_id": "71",
    "object_repr": "Remifentanil",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1727,
  "fields": {
    "action_time": "2025-05-25T19:46:00.885Z",
    "user": 1,
    "content_type": 14,
    "object_id": "263",
    "object_repr": "Kobayashi, K., Takemori, K. and Sakamoto, A., 2007. Circadian gene expression is suppressed during sevoflurane anesthesia and the suppression persists after awakening. Brain Research, 1185, pp.1–7.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1728,
  "fields": {
    "action_time": "2025-05-25T19:46:54.792Z",
    "user": 1,
    "content_type": 14,
    "object_id": "264",
    "object_repr": "Sugimura, S., Imai, R., Katoh, T., Makino, H., Hokamura, K., Kurita, T., Suzuki, Y., Aoki, Y., Kimura, T., Umemura, K. and Nakajima, Y., 2024. Effects of volatile anesthetics on circadian rhythm in mi",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1729,
  "fields": {
    "action_time": "2025-05-25T19:46:57.785Z",
    "user": 1,
    "content_type": 10,
    "object_id": "72",
    "object_repr": "Sevoflurane",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1730,
  "fields": {
    "action_time": "2025-05-25T19:47:53.538Z",
    "user": 1,
    "content_type": 14,
    "object_id": "265",
    "object_repr": "Sugimura, S., Imai, R., Katoh, T., Makino, H., Hokamura, K., Kurita, T., Suzuki, Y., Aoki, Y., Kimura, T., Umemura, K. and Nakajima, Y., 2024. Effects of volatile anesthetics on circadian rhythm in mi",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1731,
  "fields": {
    "action_time": "2025-05-25T19:48:30.873Z",
    "user": 1,
    "content_type": 14,
    "object_id": "266",
    "object_repr": "Anzai, M., Iijima, N., Higo, S., Takumi, K., Matsuo, I., Mori, K., Ohe, Y., Kadota, K., Akimoto, T., Sakamoto, A. and Ozawa, H., 2013. Direct and specific effect of sevoflurane anesthesia on rat Per2 ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1732,
  "fields": {
    "action_time": "2025-05-25T19:48:38.798Z",
    "user": 1,
    "content_type": 10,
    "object_id": "73",
    "object_repr": "Desflurane",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1733,
  "fields": {
    "action_time": "2025-05-25T19:48:45.229Z",
    "user": 2,
    "content_type": 14,
    "object_id": "267",
    "object_repr": "Wirz-Justice, A., Werth, E., Savaskan, E., Knoblauch, V., Gasio, P.F. and Müller-Spahn, F., 2000. Haloperidol disrupts, clozapine reinstates the circadian rest–activity cycle in a patient with early-o",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1734,
  "fields": {
    "action_time": "2025-05-25T19:48:58.864Z",
    "user": 2,
    "content_type": 10,
    "object_id": "117",
    "object_repr": "Clozapine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1735,
  "fields": {
    "action_time": "2025-05-25T19:51:24.875Z",
    "user": 2,
    "content_type": 14,
    "object_id": "268",
    "object_repr": "Herberger, S., Ruether, E. and Hajak, G., 2021. Somnologics: Medicines for the Treatment of Sleep Disorders. In NeuroPsychopharmacotherapy (pp. 1-39). Cham: Springer International Publishing.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1736,
  "fields": {
    "action_time": "2025-05-25T19:51:27.699Z",
    "user": 2,
    "content_type": 10,
    "object_id": "116",
    "object_repr": "Zuclopentixol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1737,
  "fields": {
    "action_time": "2025-05-25T19:52:02.266Z",
    "user": 2,
    "content_type": 14,
    "object_id": "269",
    "object_repr": "Nagayama, H., Takagi, A., Sakurai, Y., Nishiwaki, K. and Takahashi, R., 1978. Chronopharmacological study of neuroleptics: II. Circadian susceptibility rhythm to chlorpromazine. Psychopharmacology, 58",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1738,
  "fields": {
    "action_time": "2025-05-25T19:52:06.696Z",
    "user": 2,
    "content_type": 10,
    "object_id": "115",
    "object_repr": "Chlorpromazine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1739,
  "fields": {
    "action_time": "2025-05-25T19:52:42.836Z",
    "user": 2,
    "content_type": 14,
    "object_id": "270",
    "object_repr": "Nyitrai, G., et al. 2021. Cariprazine modulates sleep architecture in rats. Journal of Psychopharmacology, 35(3), pp.303-310.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1740,
  "fields": {
    "action_time": "2025-05-25T19:54:21.477Z",
    "user": 2,
    "content_type": 10,
    "object_id": "114",
    "object_repr": "Cariprazine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1741,
  "fields": {
    "action_time": "2025-05-25T19:55:57.994Z",
    "user": 2,
    "content_type": 14,
    "object_id": "271",
    "object_repr": "Altenhofen, S. and Bonan, C.D., 2022. Zebrafish as a Tool in the Study of Sleep and Memory-related Disorders. Current neuropharmacology, 20(3), pp.540-549.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1742,
  "fields": {
    "action_time": "2025-05-25T19:56:00.728Z",
    "user": 2,
    "content_type": 10,
    "object_id": "113",
    "object_repr": "Benperidol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1743,
  "fields": {
    "action_time": "2025-05-25T19:56:33.703Z",
    "user": 2,
    "content_type": 14,
    "object_id": "272",
    "object_repr": "Delcourte, S., Abrial, E., Etiévant, A., Rovera, R., Arnt, J., Didriksen, M. and Haddjeri, N., 2017. Asenapine modulates mood‐related behaviors and 5‐HT 1A/7 receptors‐mediated neurotransmission. CNS ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1744,
  "fields": {
    "action_time": "2025-05-25T19:57:08.788Z",
    "user": 2,
    "content_type": 14,
    "object_id": "273",
    "object_repr": "Colita, C.I., Hermann, D.M., Filfan, M., Colita, D., Doepnner, T.R., Tica, O., Glavan, D. and Popa-Wagner, A., 2024. Optimizing Chronotherapy in Psychiatric Care: The Impact of Circadian Rhythms on Me",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1745,
  "fields": {
    "action_time": "2025-05-25T19:57:39.074Z",
    "user": 2,
    "content_type": 14,
    "object_id": "274",
    "object_repr": "McCall, W.V., Riley, M.A., Hodges, C., McCloud, L., Phillips, M. and Rosenquist, P.B., 2014. Asenapine-induced restless legs syndrome: differentiation from akathisia. Journal of Clinical Sleep Medicin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1746,
  "fields": {
    "action_time": "2025-05-25T19:58:33.701Z",
    "user": 2,
    "content_type": 13,
    "object_id": "55",
    "object_repr": "Induces resless legs syndrome",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1747,
  "fields": {
    "action_time": "2025-05-25T19:58:41.649Z",
    "user": 2,
    "content_type": 10,
    "object_id": "112",
    "object_repr": "Asenapine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\", \"Classf\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1748,
  "fields": {
    "action_time": "2025-05-25T19:59:23.087Z",
    "user": 2,
    "content_type": 14,
    "object_id": "275",
    "object_repr": "Mokros, Ł., Karbownik, M.S., Nowakowska-Domagała, K., Szemraj, J., Wieteska, Ł., Woźniak, K., Witusik, A., Antczak, A. and Pietras, T., 2016. Haloperidol, but not olanzapine, may affect expression of ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1749,
  "fields": {
    "action_time": "2025-05-25T19:59:48.834Z",
    "user": 2,
    "content_type": 13,
    "object_id": "56",
    "object_repr": "affect expression of PER1 and CRY1 genes in human glioblastoma cell line",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1750,
  "fields": {
    "action_time": "2025-05-25T19:59:51.003Z",
    "user": 2,
    "content_type": 10,
    "object_id": "111",
    "object_repr": "Haloperidol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1751,
  "fields": {
    "action_time": "2025-05-25T20:01:03.950Z",
    "user": 2,
    "content_type": 14,
    "object_id": "276",
    "object_repr": "Caruso, V., Geoffroy, P.A., Alfì, G., Miniati, M., Riemann, D., Gemignani, A. and Palagini, L., 2024. Effects of Mood Stabilizers on Sleep and Circadian Rhythms: A Systematic Review. Current Sleep Med",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1752,
  "fields": {
    "action_time": "2025-05-25T20:02:30.361Z",
    "user": 2,
    "content_type": 14,
    "object_id": "277",
    "object_repr": "Endicott, J., Paulsson, B., Gustafsson, U., Schiöler, H. and Hassan, M., 2008. Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: improvements in quality of l",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1753,
  "fields": {
    "action_time": "2025-05-25T20:02:44.132Z",
    "user": 2,
    "content_type": 13,
    "object_id": "57",
    "object_repr": "improves sleep in insomnia",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1754,
  "fields": {
    "action_time": "2025-05-25T20:02:48.611Z",
    "user": 2,
    "content_type": 10,
    "object_id": "110",
    "object_repr": "Quetiapine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1755,
  "fields": {
    "action_time": "2025-05-25T20:03:35.427Z",
    "user": 2,
    "content_type": 14,
    "object_id": "278",
    "object_repr": "Li, R., Masuda, K., Ono, D., Kanbayashi, T., Hirano, A. and Sakurai, T., 2023. Aripiprazole disrupts cellular synchrony in the suprachiasmatic nucleus and enhances entrainment to environmental light–d",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1756,
  "fields": {
    "action_time": "2025-05-25T20:04:04.208Z",
    "user": 2,
    "content_type": 13,
    "object_id": "58",
    "object_repr": "Disrupts cellular synchrony in suprachiasmatic nucleus",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1757,
  "fields": {
    "action_time": "2025-05-25T20:04:06.745Z",
    "user": 2,
    "content_type": 10,
    "object_id": "109",
    "object_repr": "Aripiprazole",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1758,
  "fields": {
    "action_time": "2025-05-25T20:06:05.583Z",
    "user": 2,
    "content_type": 14,
    "object_id": "279",
    "object_repr": "Manickam, R., Oh, H.Y.P., Tan, C.K., Paramalingam, E. and Wahli, W., 2018. Metronidazole causes skeletal muscle atrophy and modulates muscle chronometabolism. International journal of molecular scienc",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1759,
  "fields": {
    "action_time": "2025-05-25T20:06:08.905Z",
    "user": 2,
    "content_type": 10,
    "object_id": "108",
    "object_repr": "Metronidazole",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1760,
  "fields": {
    "action_time": "2025-05-25T20:07:32.370Z",
    "user": 2,
    "content_type": 14,
    "object_id": "280",
    "object_repr": "Feldman, J.F. and Dunlap, J.C., 1983. Neurospora crassa: a unique system for studying circadian rhythms. In Photochemical and Photobiological Reviews: Volume 7 (pp. 319-368). Boston, MA: Springer US.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1761,
  "fields": {
    "action_time": "2025-05-25T20:07:40.599Z",
    "user": 2,
    "content_type": 13,
    "object_id": "59",
    "object_repr": "shortened the period length of the circadian rhythm by 2 hours",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1762,
  "fields": {
    "action_time": "2025-05-25T20:07:58.876Z",
    "user": 2,
    "content_type": 10,
    "object_id": "107",
    "object_repr": "Chloramphenicol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1763,
  "fields": {
    "action_time": "2025-05-25T20:08:15.618Z",
    "user": 2,
    "content_type": 13,
    "object_id": "60",
    "object_repr": "Rifampicin lengthened the circadian period under darkness in plants.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1764,
  "fields": {
    "action_time": "2025-05-25T20:09:40.114Z",
    "user": 2,
    "content_type": 14,
    "object_id": "281",
    "object_repr": "Philippou, K., Davis, A.M., Davis, S.J. and Sánchez-Villarreal, A., 2020. Chemical perturbation of chloroplast-related processes affects circadian rhythms of gene expression in Arabidopsis: salicylic ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1765,
  "fields": {
    "action_time": "2025-05-25T20:09:42.528Z",
    "user": 2,
    "content_type": 10,
    "object_id": "106",
    "object_repr": "Rifampin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1766,
  "fields": {
    "action_time": "2025-05-25T20:13:56.473Z",
    "user": 2,
    "content_type": 13,
    "object_id": "61",
    "object_repr": "Salicylic acid (SA) increased oscillatory robustness and shortened the period in plants",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1767,
  "fields": {
    "action_time": "2025-05-25T20:14:36.472Z",
    "user": 2,
    "content_type": 9,
    "object_id": "204",
    "object_repr": "Plastoquinone interaction",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1768,
  "fields": {
    "action_time": "2025-05-25T20:15:07.598Z",
    "user": 2,
    "content_type": 13,
    "object_id": "62",
    "object_repr": "Application Can Entrain the Clock",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1769,
  "fields": {
    "action_time": "2025-05-25T20:15:47.939Z",
    "user": 2,
    "content_type": 12,
    "object_id": "135",
    "object_repr": "Unknown | Multiple plant targets",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1770,
  "fields": {
    "action_time": "2025-05-25T20:15:59.100Z",
    "user": 2,
    "content_type": 10,
    "object_id": "318",
    "object_repr": "Salicilic acid",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1771,
  "fields": {
    "action_time": "2025-05-25T20:17:02.921Z",
    "user": 2,
    "content_type": 13,
    "object_id": "63",
    "object_repr": "may cause daytime sleepiness",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1772,
  "fields": {
    "action_time": "2025-05-25T20:17:10.690Z",
    "user": 2,
    "content_type": 13,
    "object_id": "64",
    "object_repr": "rescues recognition memory and circadian motor rhythmicity but does not prevent terminal disease in fatal familial insomnia mice",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1773,
  "fields": {
    "action_time": "2025-05-25T20:17:31.060Z",
    "user": 2,
    "content_type": 14,
    "object_id": "282",
    "object_repr": "Lavigna, G., Masone, A., Bouybayoune, I., Bertani, I., Lucchetti, J., Gobbi, M., Porcu, L., Zordan, S., Rigamonti, M., Imeri, L. and Restelli, E., 2021. Doxycycline rescues recognition memory and circ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1774,
  "fields": {
    "action_time": "2025-05-25T20:17:54.299Z",
    "user": 2,
    "content_type": 10,
    "object_id": "105",
    "object_repr": "Doxycycline",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1775,
  "fields": {
    "action_time": "2025-05-25T20:20:24.676Z",
    "user": 2,
    "content_type": 13,
    "object_id": "65",
    "object_repr": "circadian clock mediated antitumor effect",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1776,
  "fields": {
    "action_time": "2025-05-25T20:20:53.261Z",
    "user": 2,
    "content_type": 14,
    "object_id": "283",
    "object_repr": "Okazaki, F., Matsunaga, N., Hamamura, K., Suzuki, K., Nakao, T., Okazaki, H., Kutsukake, M., Fukumori, S., Tsuji, Y. and To, H., 2017. Administering xCT inhibitors based on circadian clock improves an",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1777,
  "fields": {
    "action_time": "2025-05-25T20:20:57.384Z",
    "user": 2,
    "content_type": 10,
    "object_id": "104",
    "object_repr": "Sulfasalazine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1778,
  "fields": {
    "action_time": "2025-05-25T20:22:42.639Z",
    "user": 2,
    "content_type": 14,
    "object_id": "284",
    "object_repr": "Hirohata, A., Yamatsuta, Y., Ogawa, K., Kubota, A., Suzuki, T., Shimizu, H., Kanesaka, Y., Takahashi, N. and Endo, M., 2022. Sulfanilamide regulates flowering time through expression of the circadian ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1779,
  "fields": {
    "action_time": "2025-05-25T20:22:54.458Z",
    "user": 2,
    "content_type": 13,
    "object_id": "66",
    "object_repr": "Regulates Flowering Time through Expression of the Circadian Clock Gene LUX",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1780,
  "fields": {
    "action_time": "2025-05-25T20:23:10.539Z",
    "user": 2,
    "content_type": 10,
    "object_id": "103",
    "object_repr": "Sulfanilamide",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\", \"Linkname\", \"Description\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1781,
  "fields": {
    "action_time": "2025-05-25T20:24:12.892Z",
    "user": 2,
    "content_type": 14,
    "object_id": "285",
    "object_repr": "Yu, Z., Shen, J., Li, Z., Yao, J., Li, W., Xue, L., Vandenberg, L.N. and Yin, D., 2020. Obesogenic effect of sulfamethoxazole on Drosophila melanogaster with simultaneous disturbances on eclosion rhyt",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1782,
  "fields": {
    "action_time": "2025-05-25T20:24:17.595Z",
    "user": 2,
    "content_type": 10,
    "object_id": "102",
    "object_repr": "Sulfamethoxazole",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1783,
  "fields": {
    "action_time": "2025-05-25T20:26:31.968Z",
    "user": 2,
    "content_type": 14,
    "object_id": "286",
    "object_repr": "Trotti, L.M., Saini, P., Freeman, A.A., Bliwise, D.L., García, P.S., Jenkins, A. and Rye, D.B., 2014. Improvement in daytime sleepiness with clarithromycin in patients with GABA-related hypersomnia: c",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1784,
  "fields": {
    "action_time": "2025-05-25T20:26:37.402Z",
    "user": 2,
    "content_type": 10,
    "object_id": "101",
    "object_repr": "Clarithromycin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\", \"Linkslists\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1785,
  "fields": {
    "action_time": "2025-05-25T20:27:13.212Z",
    "user": 2,
    "content_type": 13,
    "object_id": "67",
    "object_repr": "Improvement in daytime sleepiness in patients with GABA-related hypersomnia",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1786,
  "fields": {
    "action_time": "2025-05-25T20:27:15.405Z",
    "user": 2,
    "content_type": 10,
    "object_id": "101",
    "object_repr": "Clarithromycin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1787,
  "fields": {
    "action_time": "2025-05-25T20:28:32.703Z",
    "user": 2,
    "content_type": 13,
    "object_id": "68",
    "object_repr": "alone caused a long circadian period. However, the degree of lengthening was less than with Fe deficiency alone",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1788,
  "fields": {
    "action_time": "2025-05-25T20:29:26.660Z",
    "user": 2,
    "content_type": 14,
    "object_id": "287",
    "object_repr": "Chen, Y.Y., Wang, Y., Shin, L.J., Wu, J.F., Shanmugam, V., Tsednee, M., Lo, J.C., Chen, C.C., Wu, S.H. and Yeh, K.C., 2013. Iron is involved in the maintenance of circadian period length in Arabidopsi",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1789,
  "fields": {
    "action_time": "2025-05-25T20:29:40.611Z",
    "user": 2,
    "content_type": 10,
    "object_id": "100",
    "object_repr": "Lincomycin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1790,
  "fields": {
    "action_time": "2025-05-25T20:31:10.560Z",
    "user": 2,
    "content_type": 14,
    "object_id": "288",
    "object_repr": "Meng, D., Yang, M., Hu, L., Liu, T., Zhang, H., Sun, X., Wang, X., Chen, Y.U., Jin, Y.U. and Liu, R., 2022. Rifaximin protects against circadian rhythm disruption–induced cognitive impairment through ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1791,
  "fields": {
    "action_time": "2025-05-25T20:31:15.538Z",
    "user": 2,
    "content_type": 13,
    "object_id": "69",
    "object_repr": "protective effects against cognitive impairment caused by circadian rhythm disruption (CRD).",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1792,
  "fields": {
    "action_time": "2025-05-25T20:31:20.635Z",
    "user": 2,
    "content_type": 10,
    "object_id": "99",
    "object_repr": "Rifaximin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1793,
  "fields": {
    "action_time": "2025-05-25T20:32:15.532Z",
    "user": 2,
    "content_type": 14,
    "object_id": "289",
    "object_repr": "Davis, M.A. and Carbott, D.E., 1999. Herbimycin A and geldanamycin inhibit okadaic acid-induced apoptosis and p38 activation in NRK-52E renal epithelial cells. Toxicology and applied pharmacology, 161",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1794,
  "fields": {
    "action_time": "2025-05-25T20:32:33.006Z",
    "user": 2,
    "content_type": 10,
    "object_id": "98",
    "object_repr": "Herbimycin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1795,
  "fields": {
    "action_time": "2025-05-25T20:34:06.136Z",
    "user": 2,
    "content_type": 10,
    "object_id": "100",
    "object_repr": "Lincomycin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1796,
  "fields": {
    "action_time": "2025-05-25T20:35:54.273Z",
    "user": 2,
    "content_type": 14,
    "object_id": "290",
    "object_repr": "Zhang, Z., Xue, N., Bian, C., Yan, R., Jin, L., Chen, X. and Yu, X., 2016. C15-methoxyphenylated 18-deoxy-herbimycin A analogues, their in vitro anticancer activity and heat shock protein 90 binding a",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1797,
  "fields": {
    "action_time": "2025-05-25T20:35:59.369Z",
    "user": 2,
    "content_type": 10,
    "object_id": "98",
    "object_repr": "Herbimycin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1798,
  "fields": {
    "action_time": "2025-05-25T20:36:41.962Z",
    "user": 2,
    "content_type": 13,
    "object_id": "70",
    "object_repr": "heat shock protein 90 binding affinity affectin circadian clock (indirect effects",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1799,
  "fields": {
    "action_time": "2025-05-25T20:36:44.794Z",
    "user": 2,
    "content_type": 10,
    "object_id": "97",
    "object_repr": "Geldanamycin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1800,
  "fields": {
    "action_time": "2025-05-25T20:38:03.934Z",
    "user": 2,
    "content_type": 14,
    "object_id": "291",
    "object_repr": "Song, Y., Liu, Y., Yuan, Y., Jia, X., Zhang, W., Wang, G., Jia, Y., Wang, X., Liu, L., Li, W. and Li, X., 2021. Effects of general versus subarachnoid anaesthesia on circadian melatonin rhythm and pos",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1801,
  "fields": {
    "action_time": "2025-05-25T20:38:06.988Z",
    "user": 2,
    "content_type": 10,
    "object_id": "96",
    "object_repr": "Methohexital",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1802,
  "fields": {
    "action_time": "2025-05-25T20:38:55.781Z",
    "user": 2,
    "content_type": 14,
    "object_id": "292",
    "object_repr": "Kojetin, D., Wang, Y., Kamenecka, T.M. and Burris, T.P., 2011. Identification of SR8278, a synthetic antagonist of the nuclear heme receptor REV-ERB. ACS chemical biology, 6(2), pp.131-134.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1803,
  "fields": {
    "action_time": "2025-05-25T20:39:29.525Z",
    "user": 2,
    "content_type": 14,
    "object_id": "293",
    "object_repr": "Anabtawi, N., Cvammen, W. and Kemp, M.G., 2021. Pharmacological inhibition of cryptochrome and REV-ERB promotes DNA repair and cell cycle arrest in cisplatin-treated human cells. Scientific Reports, 1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1804,
  "fields": {
    "action_time": "2025-05-25T20:39:32.069Z",
    "user": 2,
    "content_type": 10,
    "object_id": "95",
    "object_repr": "SR8278",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1805,
  "fields": {
    "action_time": "2025-05-25T20:40:08.151Z",
    "user": 2,
    "content_type": 14,
    "object_id": "294",
    "object_repr": "Gul, S., Akyel, Y.K., Gul, Z.M., Isin, S., Ozcan, O., Korkmaz, T., Selvi, S., Danis, I., Ipek, O.S., Aygenli, F. and Taskin, A.C., 2022. Discovery of a small molecule that selectively destabilizes Cry",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1806,
  "fields": {
    "action_time": "2025-05-25T20:40:10.616Z",
    "user": 2,
    "content_type": 10,
    "object_id": "94",
    "object_repr": "M47",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1807,
  "fields": {
    "action_time": "2025-05-25T20:40:53.947Z",
    "user": 2,
    "content_type": 14,
    "object_id": "295",
    "object_repr": "Meng, Q.J., Maywood, E.S., Bechtold, D.A., Lu, W.Q., Li, J., Gibbs, J.E., Dupré, S.M., Chesham, J.E., Rajamohan, F., Knafels, J. and Sneed, B., 2010. Entrainment of disrupted circadian behavior throug",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1808,
  "fields": {
    "action_time": "2025-05-25T20:40:56.548Z",
    "user": 2,
    "content_type": 10,
    "object_id": "93",
    "object_repr": "PF-670462",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1809,
  "fields": {
    "action_time": "2025-05-25T20:41:31.003Z",
    "user": 2,
    "content_type": 14,
    "object_id": "296",
    "object_repr": "Miller, S., Son, Y.L., Aikawa, Y., Makino, E., Nagai, Y., Srivastava, A., Oshima, T., Sugiyama, A., Hara, A., Abe, K. and Hirata, K., 2020. Isoform-selective regulation of mammalian cryptochromes. Nat",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1810,
  "fields": {
    "action_time": "2025-05-25T20:41:33.192Z",
    "user": 2,
    "content_type": 10,
    "object_id": "92",
    "object_repr": "TH301",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1811,
  "fields": {
    "action_time": "2025-05-25T20:42:37.463Z",
    "user": 2,
    "content_type": 14,
    "object_id": "297",
    "object_repr": "Crane, B.R., 2020. Winding down: Selectively drugging a promiscuous pocket in cryptochrome slows circadian rhythms. Cell chemical biology, 27(9), pp.1109-1111.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1812,
  "fields": {
    "action_time": "2025-05-25T20:42:53.404Z",
    "user": 2,
    "content_type": 13,
    "object_id": "71",
    "object_repr": "lengthen circadian rhtyhms",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1813,
  "fields": {
    "action_time": "2025-05-25T20:42:55.872Z",
    "user": 2,
    "content_type": 10,
    "object_id": "91",
    "object_repr": "KL201",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1814,
  "fields": {
    "action_time": "2025-05-25T20:42:56.255Z",
    "user": 2,
    "content_type": 10,
    "object_id": "91",
    "object_repr": "KL201",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1815,
  "fields": {
    "action_time": "2025-05-25T20:43:43.830Z",
    "user": 2,
    "content_type": 14,
    "object_id": "298",
    "object_repr": "Miller, S., Son, Y.L., Aikawa, Y., Makino, E., Nagai, Y., Srivastava, A., Oshima, T., Sugiyama, A., Hara, A., Abe, K. and Hirata, K., 2020. Isoform-selective regulation of mammalian cryptochromes. Nat",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1816,
  "fields": {
    "action_time": "2025-05-25T20:43:49.557Z",
    "user": 2,
    "content_type": 10,
    "object_id": "90",
    "object_repr": "KL101",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1817,
  "fields": {
    "action_time": "2025-05-25T20:44:48.526Z",
    "user": 2,
    "content_type": 13,
    "object_id": "72",
    "object_repr": "Disrupts cellular circadian system",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1818,
  "fields": {
    "action_time": "2025-05-25T20:45:13.910Z",
    "user": 2,
    "content_type": 14,
    "object_id": "299",
    "object_repr": "Borrmann, H., Ulkar, G., Kliszczak, A.E., Ismed, D., Schilling, M., Magri, A., Harris, J.M., Balfe, P., Vasudevan, S., Borrow, P. and Zhuang, X., 2023. Molecular components of the circadian clock regu",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1819,
  "fields": {
    "action_time": "2025-05-25T20:45:17.262Z",
    "user": 2,
    "content_type": 10,
    "object_id": "89",
    "object_repr": "GSK805",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Classf\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1820,
  "fields": {
    "action_time": "2025-05-25T20:46:15.397Z",
    "user": 2,
    "content_type": 14,
    "object_id": "300",
    "object_repr": "Lyu, C., Bing, S.J., Wandu, W.S., Xu, B., Shi, G., Hinshaw, S.J., Lobera, M., Caspi, R.R., Lu, L., Yang, J. and Gery, I., 2018. TMP778, a selective inhibitor of RORγt, suppresses experimental autoimmu",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1821,
  "fields": {
    "action_time": "2025-05-25T20:47:00.888Z",
    "user": 2,
    "content_type": 14,
    "object_id": "301",
    "object_repr": "Venken, K., Jacques, P., Mortier, C., Labadia, M.E., Decruy, T., Coudenys, J., Hoyt, K., Wayne, A.L., Hughes, R., Turner, M. and Van Gassen, S., 2019. RORγt inhibition selectively targets IL-17 produc",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1822,
  "fields": {
    "action_time": "2025-05-25T20:47:03.718Z",
    "user": 2,
    "content_type": 10,
    "object_id": "88",
    "object_repr": "TMP778",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1823,
  "fields": {
    "action_time": "2025-05-25T20:47:36.696Z",
    "user": 2,
    "content_type": 10,
    "object_id": "71",
    "object_repr": "methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1824,
  "fields": {
    "action_time": "2025-05-25T20:47:51.599Z",
    "user": 2,
    "content_type": 10,
    "object_id": "69",
    "object_repr": "2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1825,
  "fields": {
    "action_time": "2025-05-25T20:48:09.825Z",
    "user": 2,
    "content_type": 10,
    "object_id": "60",
    "object_repr": "(4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1826,
  "fields": {
    "action_time": "2025-05-25T20:48:27.288Z",
    "user": 2,
    "content_type": 10,
    "object_id": "59",
    "object_repr": "N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1827,
  "fields": {
    "action_time": "2025-05-25T20:49:39.138Z",
    "user": 2,
    "content_type": 14,
    "object_id": "302",
    "object_repr": "Lafaye G, Desterke C, Marulaz L, Benyamina A. Cannabidiol affects circadian clock core complex and its regulation in microglia cells. Addiction Biology. 2018.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1828,
  "fields": {
    "action_time": "2025-05-25T20:49:41.845Z",
    "user": 2,
    "content_type": 10,
    "object_id": "52",
    "object_repr": "Cannabinodiol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1829,
  "fields": {
    "action_time": "2025-05-25T20:50:42.345Z",
    "user": 2,
    "content_type": 14,
    "object_id": "303",
    "object_repr": "Avital-Cohen, N., Chapnik, N. and Froy, O., 2024. Resveratrol Induces Myotube Development by Altering Circadian Metabolism via the SIRT1-AMPK-PP2A Axis. Cells, 13(12), p.1069.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1830,
  "fields": {
    "action_time": "2025-05-25T20:50:51.017Z",
    "user": 2,
    "content_type": 10,
    "object_id": "6",
    "object_repr": "Resveratrol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1831,
  "fields": {
    "action_time": "2025-05-25T20:51:28.554Z",
    "user": 2,
    "content_type": 10,
    "object_id": "8",
    "object_repr": "Melatonin",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1832,
  "fields": {
    "action_time": "2025-05-25T20:51:38.686Z",
    "user": 2,
    "content_type": 10,
    "object_id": "8",
    "object_repr": "Melatonin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1833,
  "fields": {
    "action_time": "2025-05-25T20:52:36.217Z",
    "user": 2,
    "content_type": 10,
    "object_id": "51",
    "object_repr": "6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1834,
  "fields": {
    "action_time": "2025-05-25T20:52:54.350Z",
    "user": 2,
    "content_type": 10,
    "object_id": "47",
    "object_repr": "Cannabidiol",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1835,
  "fields": {
    "action_time": "2025-05-25T20:53:56.727Z",
    "user": 2,
    "content_type": 14,
    "object_id": "303",
    "object_repr": "Avital-Cohen, N., Chapnik, N. and Froy, O., 2024. Resveratrol Induces Myotube Development by Altering Circadian Metabolism via the SIRT1-AMPK-PP2A Axis. Cells, 13(12), p.1069.",
    "action_flag": 3,
    "change_message": ""
  }
},
{
  "model": "admin.logentry",
  "pk": 1836,
  "fields": {
    "action_time": "2025-05-25T20:56:09.286Z",
    "user": 2,
    "content_type": 13,
    "object_id": "73",
    "object_repr": "Resveratrol can influence the expression of key clock genes like CLOCK, BMAL1, PER, and CRY, which are involved in establishing and maintaining the 24",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1837,
  "fields": {
    "action_time": "2025-05-25T20:56:11.678Z",
    "user": 2,
    "content_type": 10,
    "object_id": "6",
    "object_repr": "Resveratrol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1838,
  "fields": {
    "action_time": "2025-05-25T20:57:09.417Z",
    "user": 2,
    "content_type": 13,
    "object_id": "74",
    "object_repr": "shifted the phases",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1839,
  "fields": {
    "action_time": "2025-05-25T20:57:33.615Z",
    "user": 2,
    "content_type": 10,
    "object_id": "7",
    "object_repr": "Rosiglitazone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1840,
  "fields": {
    "action_time": "2025-05-26T06:13:56.051Z",
    "user": 1,
    "content_type": 14,
    "object_id": "304",
    "object_repr": "Dubocovich, M.L., 1988. Luzindole (N-0774): a novel melatonin receptor antagonist. Journal of Pharmacology and Experimental Therapeutics, 246(3), pp.902–910.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1841,
  "fields": {
    "action_time": "2025-05-26T06:14:36.136Z",
    "user": 1,
    "content_type": 14,
    "object_id": "305",
    "object_repr": "Estarás, M., Ameur, F.Z., Roncero, V., Fernández-Bermejo, M., Blanco, G., López, D., Mateos, J.M., Salido, G.M. and González, A., 2019. The melatonin receptor antagonist luzindole induces Ca²⁺ mobiliz",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1842,
  "fields": {
    "action_time": "2025-05-26T06:14:39.598Z",
    "user": 1,
    "content_type": 10,
    "object_id": "11",
    "object_repr": "Luzindole",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1843,
  "fields": {
    "action_time": "2025-05-26T06:16:24.428Z",
    "user": 1,
    "content_type": 14,
    "object_id": "306",
    "object_repr": "De Berardis, D., Marini, S., Fornaro, M., Srinivasan, V., Iasevoli, F., Tomasetti, C., Valchera, A., Perna, G., Quera-Salva, M.A., Martinotti, G. and Di Giannantonio, M., 2013. The melatonergic system",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1844,
  "fields": {
    "action_time": "2025-05-26T06:16:28.228Z",
    "user": 1,
    "content_type": 10,
    "object_id": "29",
    "object_repr": "Agomelatine-d4",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1845,
  "fields": {
    "action_time": "2025-05-26T06:18:03.619Z",
    "user": 1,
    "content_type": 14,
    "object_id": "307",
    "object_repr": "Fourtillan, J.B., Brisson, A.M., Gobin, P., Ingrand, I., Decourt, J.P. and Girault, J., 2000. Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. Biopharmaceutics &",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1846,
  "fields": {
    "action_time": "2025-05-26T06:18:12.427Z",
    "user": 1,
    "content_type": 10,
    "object_id": "31",
    "object_repr": "Melatonin-d7",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1847,
  "fields": {
    "action_time": "2025-05-26T06:19:33.504Z",
    "user": 1,
    "content_type": 14,
    "object_id": "308",
    "object_repr": "McGechan, A. and Wellington, K., 2005. Ramelteon. CNS Drugs, 19(12), pp.1057–1065; discussion 1066–1067.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1848,
  "fields": {
    "action_time": "2025-05-26T06:19:37.813Z",
    "user": 1,
    "content_type": 10,
    "object_id": "32",
    "object_repr": "Ramelteon-d5",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1849,
  "fields": {
    "action_time": "2025-05-26T06:20:21.740Z",
    "user": 1,
    "content_type": 14,
    "object_id": "309",
    "object_repr": "Russak, E.M. and Bednarczyk, E.M., 2019. Impact of deuterium substitution on the pharmacokinetics of pharmaceuticals. Annals of Pharmacotherapy, 53(2), pp.211–216.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1850,
  "fields": {
    "action_time": "2025-05-26T06:21:25.760Z",
    "user": 1,
    "content_type": 14,
    "object_id": "310",
    "object_repr": "Audinot, V., Mailliet, F., Lahaye-Brasseur, C., Bonnaud, A., Le Gall, A., Amossé, C., Dromaint, S., Rodriguez, M., Nagel, N., Galizzi, J.P., Malpaux, B., Guillaumet, G., Lesieur, D., Lefoulon, F., Ren",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1851,
  "fields": {
    "action_time": "2025-05-26T06:21:29.398Z",
    "user": 1,
    "content_type": 10,
    "object_id": "34",
    "object_repr": "Agomelatin-d3",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1852,
  "fields": {
    "action_time": "2025-05-26T06:22:19.105Z",
    "user": 1,
    "content_type": 14,
    "object_id": "311",
    "object_repr": "ChatGPT сказал: Nishiyama, K., Nishikawa, H., Kato, K., Miyamoto, M., Tsukamoto, T. and Hirai, K., 2014. Pharmacological characterization of M-II, the major human metabolite of ramelteon. Pharmacology",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1853,
  "fields": {
    "action_time": "2025-05-26T06:22:25.607Z",
    "user": 1,
    "content_type": 10,
    "object_id": "27",
    "object_repr": "Ramelteon metabolite M-II (DES(1-oxopropyl)-2-hydroxy-1-oxopropyl-ramelteon)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1854,
  "fields": {
    "action_time": "2025-05-26T06:26:23.353Z",
    "user": 1,
    "content_type": 14,
    "object_id": "312",
    "object_repr": "Miyamoto, M., 2009. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neuroscience & Therapeutics, 15(1), pp.32–51.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1855,
  "fields": {
    "action_time": "2025-05-26T06:26:26.158Z",
    "user": 1,
    "content_type": 10,
    "object_id": "38",
    "object_repr": "Ramelteon-d3",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1856,
  "fields": {
    "action_time": "2025-05-26T06:28:36.247Z",
    "user": 1,
    "content_type": 14,
    "object_id": "313",
    "object_repr": "Kumari, Y., Choo, B.K.M., Shaikh, M.F. and Othman, I., 2019. Melatonin receptor agonist Piper betle L. ameliorates dexamethasone-induced early life stress in adult zebrafish. Experimental and Therapeu",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1857,
  "fields": {
    "action_time": "2025-05-26T06:28:41.800Z",
    "user": 1,
    "content_type": 10,
    "object_id": "39",
    "object_repr": "6-Chloromelatonin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1858,
  "fields": {
    "action_time": "2025-05-26T06:30:34.744Z",
    "user": 1,
    "content_type": 14,
    "object_id": "314",
    "object_repr": "Russak, E.M. and Bednarczyk, E.M., 2019. Impact of deuterium substitution on the pharmacokinetics of pharmaceuticals. Annals of Pharmacotherapy, 53(2), pp.211–216",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1859,
  "fields": {
    "action_time": "2025-05-26T06:31:04.097Z",
    "user": 1,
    "content_type": 14,
    "object_id": "315",
    "object_repr": "Lavedan, C., Forsberg, M. and Gentile, A.J., 2015. Tasimelteon: a selective and unique receptor binding profile. Neuropharmacology, 91, pp.142–147",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1860,
  "fields": {
    "action_time": "2025-05-26T06:31:08.098Z",
    "user": 1,
    "content_type": 10,
    "object_id": "42",
    "object_repr": "Tasimelteon-d5",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1861,
  "fields": {
    "action_time": "2025-05-26T06:32:12.764Z",
    "user": 2,
    "content_type": 14,
    "object_id": "316",
    "object_repr": "Huang, W., Wang, H., Johnson, R.L., Huang, R., Englund, E.E., Huh, J. and Littman, D.R., 2013. Identification of potent and selective RORγ antagonists. Probe Reports from the NIH Molecular Libraries P",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1862,
  "fields": {
    "action_time": "2025-05-26T06:32:24.539Z",
    "user": 2,
    "content_type": 10,
    "object_id": "87",
    "object_repr": "ML209",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1863,
  "fields": {
    "action_time": "2025-05-26T06:33:41.792Z",
    "user": 2,
    "content_type": 13,
    "object_id": "75",
    "object_repr": "inhibited the transcriptional activity of RORγt",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1864,
  "fields": {
    "action_time": "2025-05-26T06:33:45.411Z",
    "user": 2,
    "content_type": 10,
    "object_id": "87",
    "object_repr": "ML209",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1865,
  "fields": {
    "action_time": "2025-05-26T06:34:30.526Z",
    "user": 2,
    "content_type": 14,
    "object_id": "317",
    "object_repr": "Xiang, K., Xu, Z., Hu, Y.Q., He, Y.S., Wu, G.C., Li, T.Y., Wang, X.R., Ding, L.H., Zhang, Q., Tao, S.S. and Ye, D.Q., 2021. Circadian clock genes as promising therapeutic targets for autoimmune diseas",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1866,
  "fields": {
    "action_time": "2025-05-26T06:34:57.964Z",
    "user": 2,
    "content_type": 14,
    "object_id": "318",
    "object_repr": "Chang, M.R., He, Y., Khan, T.M., Kuruvilla, D.S., Garcia-Ordonez, R., Corzo, C.A., Unger, T.J., White, D.W., Khan, S., Lin, L. and Cameron, M.D., 2015. Antiobesity effect of a small molecule repressor",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1867,
  "fields": {
    "action_time": "2025-05-26T06:35:01.886Z",
    "user": 1,
    "content_type": 14,
    "object_id": "319",
    "object_repr": "Pertwee, R.G. (Ed.), 2014. Handbook of Cannabis. Oxford University Press, USA.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1868,
  "fields": {
    "action_time": "2025-05-26T06:35:04.307Z",
    "user": 1,
    "content_type": 10,
    "object_id": "48",
    "object_repr": "Cannabigerol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1869,
  "fields": {
    "action_time": "2025-05-26T06:36:14.363Z",
    "user": 2,
    "content_type": 14,
    "object_id": "320",
    "object_repr": "Solt, L.A., Kumar, N., He, Y., Kamenecka, T.M., Griffin, P.R. and Burris, T.P., 2012. Identification of a selective RORγ ligand that suppresses TH17 cells and stimulates T regulatory cells. ACS chemic",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1870,
  "fields": {
    "action_time": "2025-05-26T06:36:31.400Z",
    "user": 2,
    "content_type": 13,
    "object_id": "76",
    "object_repr": "Suppresses TH17 cells and Stimulates T Regulatory Cells",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1871,
  "fields": {
    "action_time": "2025-05-26T06:37:44.224Z",
    "user": 1,
    "content_type": 14,
    "object_id": "321",
    "object_repr": "Outen, J.D., Burhanullah, M.H., Vandrey, R., Amjad, H., Harper, D.G., Patrick, R.E., May, R.L., Agronin, M.E., Forester, B.P. and Rosenberg, P.B., 2021. Cannabinoids for agitation in Alzheimer's disea",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1872,
  "fields": {
    "action_time": "2025-05-26T06:37:47.008Z",
    "user": 1,
    "content_type": 10,
    "object_id": "54",
    "object_repr": "Nabiximols",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1873,
  "fields": {
    "action_time": "2025-05-26T06:38:01.480Z",
    "user": 2,
    "content_type": 13,
    "object_id": "77",
    "object_repr": "In obese diabetic mice, SR1555 reduces food intake, fat mass, and body weight, while improving insulin sensitivity, suggesting a role in regulating e",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1874,
  "fields": {
    "action_time": "2025-05-26T06:38:04.783Z",
    "user": 2,
    "content_type": 10,
    "object_id": "86",
    "object_repr": "SR1555",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Classf\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1875,
  "fields": {
    "action_time": "2025-05-26T06:38:51.160Z",
    "user": 2,
    "content_type": 14,
    "object_id": "322",
    "object_repr": "Kumar, N., Lyda, B., Chang, M.R., Lauer, J.L., Solt, L.A., Burris, T.P., Kamenecka, T.M. and Griffin, P.R., 2012. Identification of SR2211: a potent synthetic RORγ-selective modulator. ACS chemical bi",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1876,
  "fields": {
    "action_time": "2025-05-26T06:39:45.164Z",
    "user": 2,
    "content_type": 13,
    "object_id": "78",
    "object_repr": "SR2211 acts as an inverse agonist of RORγ, meaning it blocks the activity of the receptor. This can have implications for circadian rhythms, as RORγ's",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1877,
  "fields": {
    "action_time": "2025-05-26T06:40:19.342Z",
    "user": 2,
    "content_type": 10,
    "object_id": "85",
    "object_repr": "SR2211",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1878,
  "fields": {
    "action_time": "2025-05-26T06:41:16.520Z",
    "user": 2,
    "content_type": 14,
    "object_id": "323",
    "object_repr": "Ribeiro, R.F., Cavadas, C. and Silva, M.M.C., 2021. Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases. Drug Discovery Today, 26(7), pp.1620-164",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1879,
  "fields": {
    "action_time": "2025-05-26T06:41:45.090Z",
    "user": 1,
    "content_type": 14,
    "object_id": "324",
    "object_repr": "Shin, S.H., Lee, H.S., Kim, Y.S., Choi, Y.J., Kim, S.H., Kwon, H.C., Oh, S.Y., Kang, J.H., Sohn, C.H., Lee, S.M., Baek, J.H., Min, Y.J., Kim, C. and Chung, J.S., 2014. Clinical usefulness of hydromorp",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1880,
  "fields": {
    "action_time": "2025-05-26T06:41:47.860Z",
    "user": 1,
    "content_type": 10,
    "object_id": "58",
    "object_repr": "Hydromorphone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1881,
  "fields": {
    "action_time": "2025-05-26T06:41:55.880Z",
    "user": 2,
    "content_type": 13,
    "object_id": "79",
    "object_repr": "resets the molecular circadian clock in eosinophils",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1882,
  "fields": {
    "action_time": "2025-05-26T06:42:13.960Z",
    "user": 2,
    "content_type": 14,
    "object_id": "325",
    "object_repr": "Teppan, J., Bärnthaler, T., Farzi, A., Durrington, H., Gioan-Tavernier, G., Platt, H., Wolf, P., Heinemann, A. and Böhm, E., 2025. The molecular circadian clock of eosinophils: A potential therapeutic",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1883,
  "fields": {
    "action_time": "2025-05-26T06:42:34.780Z",
    "user": 2,
    "content_type": 10,
    "object_id": "84",
    "object_repr": "SR1001",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1884,
  "fields": {
    "action_time": "2025-05-26T06:43:22.433Z",
    "user": 2,
    "content_type": 14,
    "object_id": "326",
    "object_repr": "Kumar, N., Kojetin, D.J., Solt, L.A., Kumar, K.G., Nuhant, P., Duckett, D.R., Cameron, M.D., Butler, A.A., Roush, W.R., Griffin, P.R. and Burris, T.P., 2011. Identification of SR3335 (ML-176): a synth",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1885,
  "fields": {
    "action_time": "2025-05-26T06:44:12.311Z",
    "user": 2,
    "content_type": 10,
    "object_id": "83",
    "object_repr": "SR3335 (ML-176)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\", \"Linkname\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1886,
  "fields": {
    "action_time": "2025-05-26T06:44:22.890Z",
    "user": 1,
    "content_type": 14,
    "object_id": "327",
    "object_repr": "Boss, C., Roch-Brisbare, C., Steiner, M.A., Treiber, A., Dietrich, H., Jenck, F., von Raumer, M., Sifferlen, T., Brotschi, C., Heidmann, B., Williams, J.T., Aissaoui, H., Siegrist, R. and Gatfield, J.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1887,
  "fields": {
    "action_time": "2025-05-26T06:44:24.878Z",
    "user": 1,
    "content_type": 10,
    "object_id": "271",
    "object_repr": "ACT‑462206",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1888,
  "fields": {
    "action_time": "2025-05-26T06:45:29.004Z",
    "user": 2,
    "content_type": 13,
    "object_id": "80",
    "object_repr": "leading to a decrease in the expression of core clock genes, which are essential for maintaining circadian rhythms. This can affect various aspects of",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1889,
  "fields": {
    "action_time": "2025-05-26T06:45:30.940Z",
    "user": 2,
    "content_type": 10,
    "object_id": "83",
    "object_repr": "SR3335 (ML-176)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1890,
  "fields": {
    "action_time": "2025-05-26T06:45:57.933Z",
    "user": 1,
    "content_type": 14,
    "object_id": "328",
    "object_repr": "Smyth, C., FitzGerald, R. and Waddington, J.L., 1995. Morphine phase-shifts circadian rhythms in mice: role of behavioural activation. Neuroreport, 7(1), pp.209–212.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1891,
  "fields": {
    "action_time": "2025-05-26T06:46:02.769Z",
    "user": 1,
    "content_type": 10,
    "object_id": "64",
    "object_repr": "(4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1892,
  "fields": {
    "action_time": "2025-05-26T06:46:08.286Z",
    "user": 2,
    "content_type": 14,
    "object_id": "329",
    "object_repr": "Wang, Y., Kumar, N., Nuhant, P., Cameron, M.D., Istrate, M.A., Roush, W.R., Griffin, P.R. and Burris, T.P., 2010. Identification of SR1078, a synthetic agonist for the orphan nuclear receptors RORα an",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1893,
  "fields": {
    "action_time": "2025-05-26T06:46:34.064Z",
    "user": 2,
    "content_type": 10,
    "object_id": "82",
    "object_repr": "SR  1078",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1894,
  "fields": {
    "action_time": "2025-05-26T06:47:01.603Z",
    "user": 1,
    "content_type": 14,
    "object_id": "330",
    "object_repr": "Coffey, A.A., Guan, Z., Grigson, P.S. and Fang, J., 2016. Reversal of the sleep-wake cycle by heroin self-administration in rats. Brain Research Bulletin, 123, pp.33–46.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1895,
  "fields": {
    "action_time": "2025-05-26T06:47:03.738Z",
    "user": 1,
    "content_type": 10,
    "object_id": "65",
    "object_repr": "[(4R,4aR,7S,7aR,12bS)-9-acetyloxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl] acetate",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1896,
  "fields": {
    "action_time": "2025-05-26T06:47:47.002Z",
    "user": 2,
    "content_type": 13,
    "object_id": "81",
    "object_repr": "It affects circadian rhythms by activating RORα/γ, which in turn regulates the transcription of target genes, including the core clock component BMAL1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1897,
  "fields": {
    "action_time": "2025-05-26T06:47:48.860Z",
    "user": 2,
    "content_type": 10,
    "object_id": "82",
    "object_repr": "SR  1078",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1898,
  "fields": {
    "action_time": "2025-05-26T06:48:05.133Z",
    "user": 1,
    "content_type": 14,
    "object_id": "331",
    "object_repr": "Wongchitrat, P., Mukda, S., Phansuwan-Pujito, P. and Govitrapong, P., 2013. Effect of amphetamine on the clock gene expression in rat striatum. Neuroscience Letters, 542, pp.126–130.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1899,
  "fields": {
    "action_time": "2025-05-26T06:48:41.154Z",
    "user": 1,
    "content_type": 14,
    "object_id": "332",
    "object_repr": "Khazaie, H., Ahmadi, H.R., Kiani, A. and Ghadami, M.R., 2019. Circadian melatonin profile in opium and amphetamine dependent patients: A preliminary study. Neurobiology of Sleep and Circadian Rhythms,",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1900,
  "fields": {
    "action_time": "2025-05-26T06:48:43.489Z",
    "user": 1,
    "content_type": 10,
    "object_id": "66",
    "object_repr": "1-phenylpropan-2-amine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1901,
  "fields": {
    "action_time": "2025-05-26T06:50:05.408Z",
    "user": 1,
    "content_type": 14,
    "object_id": "333",
    "object_repr": "Prosser, R.A., Stowie, A., Amicarelli, M., Nackenoff, A.G., Blakely, R.D. and Glass, J.D., 2014. Cocaine modulates mammalian circadian clock timing by decreasing serotonin transport in the SCN. Neuros",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1902,
  "fields": {
    "action_time": "2025-05-26T06:50:30.514Z",
    "user": 2,
    "content_type": 14,
    "object_id": "334",
    "object_repr": "Gbaguidi, G.F. and Agellon, L.B., 2004. The inhibition of the human cholesterol 7α‐hydroxylase gene (CYP7A1) promoter by fibrates in cultured cells is mediated via the liver x receptor α and peroxisom",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1903,
  "fields": {
    "action_time": "2025-05-26T06:50:37.402Z",
    "user": 2,
    "content_type": 14,
    "object_id": "335",
    "object_repr": "Feillet, C., Guérin, S., Lonchampt, M., Dacquet, C., Gustafsson, J.Å., Delaunay, F. and Teboul, M., 2016. Sexual Dimorphism in Circadian Physiology Is Altered in LXR α Deficient Mice. PLoS One, 11(3),",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1904,
  "fields": {
    "action_time": "2025-05-26T06:50:37.590Z",
    "user": 1,
    "content_type": 14,
    "object_id": "336",
    "object_repr": "Wang, D.Q., Wang, X.L., Wang, C.Y., Wang, Y., Li, S.X. and Liu, K.Z., 2019. Effects of chronic cocaine exposure on the circadian rhythmic expression of the clock genes in reward-related brain areas in",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1905,
  "fields": {
    "action_time": "2025-05-26T06:50:39.565Z",
    "user": 1,
    "content_type": 10,
    "object_id": "67",
    "object_repr": "methyl (1R,2R,3S,5S)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1906,
  "fields": {
    "action_time": "2025-05-26T06:50:40.459Z",
    "user": 2,
    "content_type": 10,
    "object_id": "81",
    "object_repr": "T0901317",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1907,
  "fields": {
    "action_time": "2025-05-26T06:51:37.059Z",
    "user": 2,
    "content_type": 13,
    "object_id": "82",
    "object_repr": "shortens the circadian period in a dose-dependent manner in cultured human cells",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1908,
  "fields": {
    "action_time": "2025-05-26T06:51:49.711Z",
    "user": 1,
    "content_type": 14,
    "object_id": "337",
    "object_repr": "Kobayashi, K., Takemori, K. and Sakamoto, A., 2007. Circadian gene expression is suppressed during sevoflurane anesthesia and the suppression persists after awakening. Brain Research, 1185, pp.1–7.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1909,
  "fields": {
    "action_time": "2025-05-26T06:52:07.225Z",
    "user": 2,
    "content_type": 13,
    "object_id": "83",
    "object_repr": "However, at very high doses, DHEA can also lengthen the circadian period and decrease its amplitude. DHEA's impact on the circadian rhythm can be attr",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1910,
  "fields": {
    "action_time": "2025-05-26T06:52:24.344Z",
    "user": 1,
    "content_type": 14,
    "object_id": "338",
    "object_repr": "Wren-Dail, M.A., Dauchy, R.T., Blask, D.E., Hill, S.M., Ooms, T.G., Dupepe, L.M. and Bohm, R.P. Jr., 2017. Effect of Isoflurane Anesthesia on Circadian Metabolism and Physiology in Rats. Comparative M",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1911,
  "fields": {
    "action_time": "2025-05-26T06:52:27.100Z",
    "user": 1,
    "content_type": 10,
    "object_id": "74",
    "object_repr": "Isoflurane",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1912,
  "fields": {
    "action_time": "2025-05-26T06:52:55.230Z",
    "user": 2,
    "content_type": 13,
    "object_id": "83",
    "object_repr": "However, at very high doses, DHEA can also lengthen the circadian period and decrease its amplitude. DHEA's impact on the circadian rhythm can be attr",
    "action_flag": 3,
    "change_message": ""
  }
},
{
  "model": "admin.logentry",
  "pk": 1913,
  "fields": {
    "action_time": "2025-05-26T06:53:09.247Z",
    "user": 1,
    "content_type": 14,
    "object_id": "339",
    "object_repr": "Pérez-Llorca, M. and Müller, M., 2024. Unlocking nature’s rhythms: insights into secondary metabolite modulation by the circadian clock. International Journal of Molecular Sciences, 25(13), p.7308.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1914,
  "fields": {
    "action_time": "2025-05-26T06:53:36.209Z",
    "user": 1,
    "content_type": 14,
    "object_id": "340",
    "object_repr": "Nilsen, N.G., Gilson, S.J., Pedersen, H.R., Hagen, L.A., Wildsoet, C.F. and Baraas, R.C., 2024. The effect of topical 1% atropine on ocular dimensions and diurnal rhythms of the human eye. Vision Rese",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1915,
  "fields": {
    "action_time": "2025-05-26T06:53:38.706Z",
    "user": 1,
    "content_type": 10,
    "object_id": "75",
    "object_repr": "Hyoscyamine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1916,
  "fields": {
    "action_time": "2025-05-26T06:54:19.866Z",
    "user": 2,
    "content_type": 13,
    "object_id": "84",
    "object_repr": "Recent reports, however, have shown that high doses of DHEA (e.g., 100 μM) lengthen circadian period and decrease amplitude",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1917,
  "fields": {
    "action_time": "2025-05-26T06:54:24.143Z",
    "user": 1,
    "content_type": 14,
    "object_id": "341",
    "object_repr": "Sultan, A., Ali, R., Sultan, T., Ali, S., Khan, N.J. and Parganiha, A., 2021. Circadian clock modulating small molecules repurposing as inhibitors of SARS-CoV-2 Mpro for pharmacological interventions ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1918,
  "fields": {
    "action_time": "2025-05-26T06:54:26.133Z",
    "user": 1,
    "content_type": 10,
    "object_id": "76",
    "object_repr": "SRT2183",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1919,
  "fields": {
    "action_time": "2025-05-26T06:54:50.748Z",
    "user": 2,
    "content_type": 14,
    "object_id": "342",
    "object_repr": "Rey, G., Valekunja, U.K., Feeney, K.A., Wulund, L., Milev, N.B., Stangherlin, A., Ansel-Bollepalli, L., Velagapudi, V., O’Neill, J.S. and Reddy, A.B., 2016. The pentose phosphate pathway regulates the",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1920,
  "fields": {
    "action_time": "2025-05-26T06:55:17.318Z",
    "user": 2,
    "content_type": 14,
    "object_id": "343",
    "object_repr": "Putker, M., Crosby, P., Feeney, K.A., Hoyle, N.P., Costa, A.S., Gaude, E., Frezza, C. and O'Neill, J.S., 2018. Mammalian circadian period, but not phase and amplitude, is robust against redox and meta",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1921,
  "fields": {
    "action_time": "2025-05-26T06:55:17.665Z",
    "user": 1,
    "content_type": 14,
    "object_id": "344",
    "object_repr": "Bellet, M.M., Nakahata, Y., Boudjelal, M., Watts, E., Mossakowska, D.E., Edwards, K.A., Cervantes, M., Astarita, G., Loh, C., Ellis, J.L., Vlasuk, G.P. and Sassone-Corsi, P., 2013. Pharmacological mod",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1922,
  "fields": {
    "action_time": "2025-05-26T06:55:20.337Z",
    "user": 2,
    "content_type": 10,
    "object_id": "80",
    "object_repr": "Prasterone (DHEA)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1923,
  "fields": {
    "action_time": "2025-05-26T06:55:20.395Z",
    "user": 1,
    "content_type": 10,
    "object_id": "77",
    "object_repr": "SRT 1720 Hydrochloride",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1924,
  "fields": {
    "action_time": "2025-05-26T06:56:17.692Z",
    "user": 2,
    "content_type": 13,
    "object_id": "85",
    "object_repr": "lengthen the circadian period, meaning the time it takes for the clock to complete one cycle",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1925,
  "fields": {
    "action_time": "2025-05-26T06:56:26.132Z",
    "user": 2,
    "content_type": 13,
    "object_id": "86",
    "object_repr": "Specifically, it can increase the stability of PER2 protein, a key player in the molecular clock, and enhance the function of RORα, another protein in",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1926,
  "fields": {
    "action_time": "2025-05-26T06:56:57.642Z",
    "user": 2,
    "content_type": 14,
    "object_id": "345",
    "object_repr": "Onishi, Y., Oishi, K., Kawano, Y. and Yamazaki, Y., 2012. The harmala alkaloid harmine is a modulator of circadian Bmal1 transcription. Bioscience Reports, 32(1), pp.45-52.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1927,
  "fields": {
    "action_time": "2025-05-26T06:57:29.229Z",
    "user": 1,
    "content_type": 14,
    "object_id": "346",
    "object_repr": "Onishi, Y., Oishi, K., Kawano, Y., & Yamazaki, Y. (2012). The harmala alkaloid harmine is a modulator of circadian Bmal1 transcription. Bioscience Reports, 32(1), 45–52.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1928,
  "fields": {
    "action_time": "2025-05-26T06:57:32.103Z",
    "user": 1,
    "content_type": 10,
    "object_id": "79",
    "object_repr": "Harmine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1929,
  "fields": {
    "action_time": "2025-05-26T06:57:51.300Z",
    "user": 2,
    "content_type": 14,
    "object_id": "347",
    "object_repr": "Kondoh, D., Yamamoto, S., Tomita, T., Miyazaki, K., Itoh, N., Yasumoto, Y., Oike, H., Doi, R. and Oishi, K., 2014. Harmine lengthens circadian period of the mammalian molecular clock in the suprachias",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1930,
  "fields": {
    "action_time": "2025-05-26T06:57:54.960Z",
    "user": 2,
    "content_type": 10,
    "object_id": "79",
    "object_repr": "Harmine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1931,
  "fields": {
    "action_time": "2025-05-26T06:58:21.332Z",
    "user": 1,
    "content_type": 14,
    "object_id": "348",
    "object_repr": "Tamai, T. K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M., Nishiwaki-Ohkawa, T., Sato, A., & Yoshimura, T. (2018). Identification ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1932,
  "fields": {
    "action_time": "2025-05-26T06:58:23.364Z",
    "user": 1,
    "content_type": 10,
    "object_id": "80",
    "object_repr": "Prasterone (DHEA)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1933,
  "fields": {
    "action_time": "2025-05-26T06:59:13.185Z",
    "user": 2,
    "content_type": 14,
    "object_id": "349",
    "object_repr": "Raju, U., Koumenis, C., Nunez-Regueiro, M. and Eskin, A., 1991. Alteration of the phase and period of a circadian oscillator by a reversible transcription inhibitor. Science, 253(5020), pp.673-675.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1934,
  "fields": {
    "action_time": "2025-05-26T06:59:14.725Z",
    "user": 1,
    "content_type": 14,
    "object_id": "350",
    "object_repr": "Ribeiro, R. F. N., Cavadas, C., & Silva, M. M. C. (2021). Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases. Drug Discovery Today, 26(7), 1620–",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1935,
  "fields": {
    "action_time": "2025-05-26T06:59:16.682Z",
    "user": 1,
    "content_type": 10,
    "object_id": "81",
    "object_repr": "T0901317",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1936,
  "fields": {
    "action_time": "2025-05-26T06:59:59.823Z",
    "user": 1,
    "content_type": 14,
    "object_id": "351",
    "object_repr": "Wang, Y., Kumar, N., Nuhant, P., Cameron, M. D., Istrate, M. A., Roush, W. R., Griffin, P. R., & Burris, T. P. (2010). Identification of SR1078, a synthetic agonist for the orphan nuclear receptors RO",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1937,
  "fields": {
    "action_time": "2025-05-26T07:00:01.661Z",
    "user": 1,
    "content_type": 10,
    "object_id": "82",
    "object_repr": "SR  1078",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1938,
  "fields": {
    "action_time": "2025-05-26T07:00:31.357Z",
    "user": 2,
    "content_type": 13,
    "object_id": "87",
    "object_repr": "lengthening of the circadian period, as Bmal1 is involved in determining the length of the clock's oscillation.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1939,
  "fields": {
    "action_time": "2025-05-26T07:00:36.425Z",
    "user": 2,
    "content_type": 10,
    "object_id": "78",
    "object_repr": "Camptothecin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1940,
  "fields": {
    "action_time": "2025-05-26T07:01:20.006Z",
    "user": 2,
    "content_type": 13,
    "object_id": "88",
    "object_repr": "Studies using SRT1720 have demonstrated that it can alter the expression of genes involved in the circadian clock. Specifically, SRT1720 has been show",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1941,
  "fields": {
    "action_time": "2025-05-26T07:01:52.481Z",
    "user": 2,
    "content_type": 14,
    "object_id": "352",
    "object_repr": "Yao, H., Sundar, I.K., Huang, Y., Gerloff, J., Sellix, M.T., Sime, P.J. and Rahman, I., 2015. Disruption of sirtuin 1–mediated control of circadian molecular clock and inflammation in chronic obstruct",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1942,
  "fields": {
    "action_time": "2025-05-26T07:01:56.827Z",
    "user": 2,
    "content_type": 10,
    "object_id": "77",
    "object_repr": "SRT 1720 Hydrochloride",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1943,
  "fields": {
    "action_time": "2025-05-26T07:02:12.362Z",
    "user": 2,
    "content_type": 10,
    "object_id": "76",
    "object_repr": "SRT2183",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1944,
  "fields": {
    "action_time": "2025-05-26T07:02:14.471Z",
    "user": 1,
    "content_type": 14,
    "object_id": "353",
    "object_repr": "Schmitt, E. E., Barhoumi, R., Metz, R. P., & Porter, W. W. (2017). Circadian Regulation of Benzo[a]Pyrene Metabolism and DNA Adduct Formation in Breast Cells and the Mouse Mammary Gland. Molecular Pha",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1945,
  "fields": {
    "action_time": "2025-05-26T07:02:16.761Z",
    "user": 1,
    "content_type": 10,
    "object_id": "227",
    "object_repr": "Benzo[b]fluoranthene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1946,
  "fields": {
    "action_time": "2025-05-26T07:02:57.760Z",
    "user": 2,
    "content_type": 13,
    "object_id": "89",
    "object_repr": "RT2183, a SIRT1 activator, affects circadian rhythms by reducing the expression of circadian genes. This is achieved by decreasing the acetylation of",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1947,
  "fields": {
    "action_time": "2025-05-26T07:03:46.951Z",
    "user": 2,
    "content_type": 14,
    "object_id": "354",
    "object_repr": "Bellet, M.M., Nakahata, Y., Boudjelal, M., Watts, E., Mossakowska, D.E., Edwards, K.A., Cervantes, M., Astarita, G., Loh, C., Ellis, J.L. and Vlasuk, G.P., 2013. Pharmacological modulation of circadia",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1948,
  "fields": {
    "action_time": "2025-05-26T07:05:48.738Z",
    "user": 2,
    "content_type": 10,
    "object_id": "76",
    "object_repr": "SRT2183",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1949,
  "fields": {
    "action_time": "2025-05-26T07:06:46.078Z",
    "user": 2,
    "content_type": 13,
    "object_id": "90",
    "object_repr": "non-psychoactive cannabinoid, can influence circadian rhythms through its interaction with the endocannabinoid system (ECS) and potentially by modulat",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1950,
  "fields": {
    "action_time": "2025-05-26T07:07:08.960Z",
    "user": 2,
    "content_type": 14,
    "object_id": "355",
    "object_repr": "Hodges, E.L. and Ashpole, N.M., 2019. Aging circadian rhythms and cannabinoids. Neurobiology of aging, 79, pp.110-118.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1951,
  "fields": {
    "action_time": "2025-05-26T07:07:11.455Z",
    "user": 2,
    "content_type": 10,
    "object_id": "49",
    "object_repr": "Cannabichromenes",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1952,
  "fields": {
    "action_time": "2025-05-26T07:08:27.198Z",
    "user": 2,
    "content_type": 13,
    "object_id": "91",
    "object_repr": "Oxycodone, like other opioids, can disrupt circadian rhythms, the body's natural 24-hour cycle. This disruption can affect various aspects of the circ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1953,
  "fields": {
    "action_time": "2025-05-26T07:09:06.675Z",
    "user": 2,
    "content_type": 10,
    "object_id": "55",
    "object_repr": "Oxycodone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Classf\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1954,
  "fields": {
    "action_time": "2025-05-26T07:09:56.018Z",
    "user": 2,
    "content_type": 10,
    "object_id": "55",
    "object_repr": "Oxycodone",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1955,
  "fields": {
    "action_time": "2025-05-26T07:16:42.805Z",
    "user": 2,
    "content_type": 13,
    "object_id": "92",
    "object_repr": "shortens the circadian period in a dose-dependent manner. However, high doses can also lengthen the circadian period and decrease its amplitude.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1956,
  "fields": {
    "action_time": "2025-05-26T07:17:43.367Z",
    "user": 2,
    "content_type": 13,
    "object_id": "91",
    "object_repr": "Oxycodone, like other opioids, can disrupt circadian rhythms, the body's natural 24-hour cycle.",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effectname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1957,
  "fields": {
    "action_time": "2025-05-26T07:18:10.399Z",
    "user": 2,
    "content_type": 13,
    "object_id": "88",
    "object_repr": "Studies using SRT1720 have demonstrated that it can alter the expression of genes involved in the circadian clock.",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effectname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1958,
  "fields": {
    "action_time": "2025-05-26T07:19:53.909Z",
    "user": 2,
    "content_type": 13,
    "object_id": "77",
    "object_repr": "It reduces food intake, fat mass, and improves insulin sensitivity in obese diabetic mice, indicating potential as an anti-diabetic and anti-obesity",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effectname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1959,
  "fields": {
    "action_time": "2025-05-26T07:20:17.276Z",
    "user": 2,
    "content_type": 13,
    "object_id": "28",
    "object_repr": "can disrupt circadian rhythms, can influence various aspects of sleep and wakefulness, including sleep onset, delta sleep, an",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effectname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1960,
  "fields": {
    "action_time": "2025-05-26T07:20:34.726Z",
    "user": 2,
    "content_type": 13,
    "object_id": "69",
    "object_repr": "protective effects against cognitive impairment caused by circadian rhythm disruption",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effectname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1961,
  "fields": {
    "action_time": "2025-05-26T07:21:15.198Z",
    "user": 2,
    "content_type": 13,
    "object_id": "89",
    "object_repr": "RT2183, a SIRT1 activator, affects circadian rhythms by reducing the expression of circadian genes, achieved by decreasing the hidstone acetylation",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effectname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1962,
  "fields": {
    "action_time": "2025-05-26T07:34:39.756Z",
    "user": 2,
    "content_type": 9,
    "object_id": "205",
    "object_repr": "Central clock rescue via microbial community alteration",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1963,
  "fields": {
    "action_time": "2025-05-26T07:34:45.777Z",
    "user": 2,
    "content_type": 10,
    "object_id": "105",
    "object_repr": "Doxycycline",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Mechanisms\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1964,
  "fields": {
    "action_time": "2025-05-26T10:56:18.989Z",
    "user": 1,
    "content_type": 13,
    "object_id": "93",
    "object_repr": "Period shortening in plants",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1965,
  "fields": {
    "action_time": "2025-05-26T10:56:22.165Z",
    "user": 1,
    "content_type": 10,
    "object_id": "318",
    "object_repr": "Salicilic acid",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1966,
  "fields": {
    "action_time": "2025-05-26T10:56:49.206Z",
    "user": 1,
    "content_type": 10,
    "object_id": "318",
    "object_repr": "Salicilic acid",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1967,
  "fields": {
    "action_time": "2025-05-26T10:57:02.008Z",
    "user": 1,
    "content_type": 10,
    "object_id": "318",
    "object_repr": "Salicilic acid",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1968,
  "fields": {
    "action_time": "2025-05-26T10:57:40.224Z",
    "user": 1,
    "content_type": 13,
    "object_id": "94",
    "object_repr": "Period lengthening in fungi",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1969,
  "fields": {
    "action_time": "2025-05-26T10:57:42.400Z",
    "user": 1,
    "content_type": 10,
    "object_id": "317",
    "object_repr": "Aminophylline",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1970,
  "fields": {
    "action_time": "2025-05-26T10:57:55.606Z",
    "user": 1,
    "content_type": 10,
    "object_id": "317",
    "object_repr": "Aminophylline",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1971,
  "fields": {
    "action_time": "2025-05-26T10:58:25.776Z",
    "user": 1,
    "content_type": 13,
    "object_id": "95",
    "object_repr": "Phase shift and PER1 suppression in mammals",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1972,
  "fields": {
    "action_time": "2025-05-26T10:58:32.999Z",
    "user": 1,
    "content_type": 10,
    "object_id": "316",
    "object_repr": "Genistein",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1973,
  "fields": {
    "action_time": "2025-05-26T10:58:53.291Z",
    "user": 1,
    "content_type": 13,
    "object_id": "96",
    "object_repr": "Amplitude enhancement in human cells",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1974,
  "fields": {
    "action_time": "2025-05-26T10:59:01.501Z",
    "user": 1,
    "content_type": 10,
    "object_id": "315",
    "object_repr": "Bavachalcone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1975,
  "fields": {
    "action_time": "2025-05-26T10:59:39.433Z",
    "user": 1,
    "content_type": 13,
    "object_id": "97",
    "object_repr": "Phase-dependent cell death modulation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1976,
  "fields": {
    "action_time": "2025-05-26T10:59:46.816Z",
    "user": 1,
    "content_type": 10,
    "object_id": "314",
    "object_repr": "Curcumin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1977,
  "fields": {
    "action_time": "2025-05-26T11:00:42.272Z",
    "user": 1,
    "content_type": 13,
    "object_id": "98",
    "object_repr": "BMAL1 amplitude enhancement via RORα-dependent pathway.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1978,
  "fields": {
    "action_time": "2025-05-26T11:00:47.696Z",
    "user": 1,
    "content_type": 10,
    "object_id": "312",
    "object_repr": "Baicalein",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1979,
  "fields": {
    "action_time": "2025-05-26T11:02:22.336Z",
    "user": 1,
    "content_type": 13,
    "object_id": "99",
    "object_repr": "Period lengthening in Aplysia.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1980,
  "fields": {
    "action_time": "2025-05-26T11:02:23.465Z",
    "user": 1,
    "content_type": 10,
    "object_id": "196",
    "object_repr": "SB-202190",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1981,
  "fields": {
    "action_time": "2025-05-26T11:03:01.980Z",
    "user": 1,
    "content_type": 13,
    "object_id": "100",
    "object_repr": "blocks melatonin-induced phase shifts",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1982,
  "fields": {
    "action_time": "2025-05-26T11:03:02.959Z",
    "user": 1,
    "content_type": 10,
    "object_id": "12",
    "object_repr": "4-P-PDOT (N-(4-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1983,
  "fields": {
    "action_time": "2025-05-26T11:03:37.699Z",
    "user": 1,
    "content_type": 13,
    "object_id": "101",
    "object_repr": "Inhibition of light-induced phase shifts via melanopsin antagonism",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1984,
  "fields": {
    "action_time": "2025-05-26T11:03:38.709Z",
    "user": 1,
    "content_type": 10,
    "object_id": "194",
    "object_repr": "AA92593",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1985,
  "fields": {
    "action_time": "2025-05-26T11:04:15.040Z",
    "user": 1,
    "content_type": 13,
    "object_id": "102",
    "object_repr": "Melatonin receptor agonism",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1986,
  "fields": {
    "action_time": "2025-05-26T11:04:16.287Z",
    "user": 1,
    "content_type": 10,
    "object_id": "15",
    "object_repr": "5-MCA-NAT",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1987,
  "fields": {
    "action_time": "2025-05-26T11:04:44.536Z",
    "user": 1,
    "content_type": 13,
    "object_id": "103",
    "object_repr": "Circadian phase entrainment via MT1/MT2 receptor agonism",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1988,
  "fields": {
    "action_time": "2025-05-26T11:04:45.612Z",
    "user": 1,
    "content_type": 10,
    "object_id": "20",
    "object_repr": "Tasimelteon",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1989,
  "fields": {
    "action_time": "2025-05-26T11:05:12.453Z",
    "user": 1,
    "content_type": 13,
    "object_id": "104",
    "object_repr": "Period lengthening in human U2OS cells",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1990,
  "fields": {
    "action_time": "2025-05-26T11:05:13.378Z",
    "user": 1,
    "content_type": 10,
    "object_id": "193",
    "object_repr": "Deferasirox",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1991,
  "fields": {
    "action_time": "2025-05-26T11:05:40.898Z",
    "user": 1,
    "content_type": 10,
    "object_id": "192",
    "object_repr": "Dasatinib",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1992,
  "fields": {
    "action_time": "2025-05-26T11:06:09.561Z",
    "user": 1,
    "content_type": 13,
    "object_id": "105",
    "object_repr": "Circadian rhythm synchronization via melatonin receptor agonism",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1993,
  "fields": {
    "action_time": "2025-05-26T11:06:11.075Z",
    "user": 1,
    "content_type": 10,
    "object_id": "23",
    "object_repr": "Piromelatine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1994,
  "fields": {
    "action_time": "2025-05-26T11:06:50.116Z",
    "user": 1,
    "content_type": 13,
    "object_id": "106",
    "object_repr": "Circadian modulation via Bmal1 activation (U2OS cells)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1995,
  "fields": {
    "action_time": "2025-05-26T11:06:51.208Z",
    "user": 1,
    "content_type": 10,
    "object_id": "178",
    "object_repr": "VINBLASTINE SULFATE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1996,
  "fields": {
    "action_time": "2025-05-26T11:07:21.567Z",
    "user": 1,
    "content_type": 13,
    "object_id": "107",
    "object_repr": "Circadian phase modulation via MT1/MT2 agonism",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1997,
  "fields": {
    "action_time": "2025-05-26T11:07:22.699Z",
    "user": 1,
    "content_type": 10,
    "object_id": "41",
    "object_repr": "Agomelatine (L(+)-Tartaric acid)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1998,
  "fields": {
    "action_time": "2025-05-26T11:07:52.240Z",
    "user": 1,
    "content_type": 13,
    "object_id": "108",
    "object_repr": "Circadian modulation detected in Bmal1-reporter assay",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 1999,
  "fields": {
    "action_time": "2025-05-26T11:07:53.358Z",
    "user": 1,
    "content_type": 10,
    "object_id": "176",
    "object_repr": "Bexarotene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2000,
  "fields": {
    "action_time": "2025-05-26T11:08:20.651Z",
    "user": 1,
    "content_type": 10,
    "object_id": "44",
    "object_repr": "ACH 000143",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2001,
  "fields": {
    "action_time": "2025-05-26T11:08:51.379Z",
    "user": 1,
    "content_type": 13,
    "object_id": "109",
    "object_repr": "Circadian modulator activity",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2002,
  "fields": {
    "action_time": "2025-05-26T11:08:52.356Z",
    "user": 1,
    "content_type": 10,
    "object_id": "174",
    "object_repr": "KETOCONAZOLE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2003,
  "fields": {
    "action_time": "2025-05-26T11:09:20.543Z",
    "user": 1,
    "content_type": 13,
    "object_id": "110",
    "object_repr": "Period lengthening",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2004,
  "fields": {
    "action_time": "2025-05-26T11:09:21.659Z",
    "user": 1,
    "content_type": 10,
    "object_id": "46",
    "object_repr": "SP600125",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2005,
  "fields": {
    "action_time": "2025-05-26T11:09:52.652Z",
    "user": 1,
    "content_type": 13,
    "object_id": "111",
    "object_repr": "Circadian rhythm induction",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2006,
  "fields": {
    "action_time": "2025-05-26T11:09:53.706Z",
    "user": 1,
    "content_type": 10,
    "object_id": "284",
    "object_repr": "Forskolin (Colforsin)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2007,
  "fields": {
    "action_time": "2025-05-26T11:10:28.223Z",
    "user": 1,
    "content_type": 13,
    "object_id": "112",
    "object_repr": "Circadian gene modulation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2008,
  "fields": {
    "action_time": "2025-05-26T11:10:29.576Z",
    "user": 1,
    "content_type": 10,
    "object_id": "173",
    "object_repr": "CALCITRIOL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2009,
  "fields": {
    "action_time": "2025-05-26T11:10:58.577Z",
    "user": 1,
    "content_type": 13,
    "object_id": "113",
    "object_repr": "Sleep improvement; potential indirect circadian stabilization via CB1 activation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2010,
  "fields": {
    "action_time": "2025-05-26T11:11:00.054Z",
    "user": 1,
    "content_type": 10,
    "object_id": "53",
    "object_repr": "Nabilone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2011,
  "fields": {
    "action_time": "2025-05-26T11:12:09.185Z",
    "user": 1,
    "content_type": 13,
    "object_id": "114",
    "object_repr": "potential period alteration via EGFR/JAK2 inhibition",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2012,
  "fields": {
    "action_time": "2025-05-26T11:12:10.035Z",
    "user": 1,
    "content_type": 10,
    "object_id": "169",
    "object_repr": "Erlotinib",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2013,
  "fields": {
    "action_time": "2025-05-26T11:12:38.698Z",
    "user": 1,
    "content_type": 13,
    "object_id": "115",
    "object_repr": "Circadian rhythm disruption",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2014,
  "fields": {
    "action_time": "2025-05-26T11:12:39.738Z",
    "user": 1,
    "content_type": 10,
    "object_id": "168",
    "object_repr": "BLEOMYCIN SULFATE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2015,
  "fields": {
    "action_time": "2025-05-26T11:13:26.331Z",
    "user": 1,
    "content_type": 13,
    "object_id": "116",
    "object_repr": "Circadian entrainment of activity episodes",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2016,
  "fields": {
    "action_time": "2025-05-26T11:13:27.206Z",
    "user": 1,
    "content_type": 10,
    "object_id": "59",
    "object_repr": "N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2017,
  "fields": {
    "action_time": "2025-05-26T11:14:51.327Z",
    "user": 1,
    "content_type": 13,
    "object_id": "117",
    "object_repr": "Period lengthening in human cells",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2018,
  "fields": {
    "action_time": "2025-05-26T11:14:52.733Z",
    "user": 1,
    "content_type": 10,
    "object_id": "166",
    "object_repr": "Rapamycin (Sirolimus)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2019,
  "fields": {
    "action_time": "2025-05-26T11:16:15.339Z",
    "user": 1,
    "content_type": 13,
    "object_id": "118",
    "object_repr": "Phase advance",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2020,
  "fields": {
    "action_time": "2025-05-26T11:16:16.236Z",
    "user": 1,
    "content_type": 10,
    "object_id": "68",
    "object_repr": "Propofol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2021,
  "fields": {
    "action_time": "2025-05-26T11:17:12.610Z",
    "user": 1,
    "content_type": 13,
    "object_id": "119",
    "object_repr": "Circadian gene modulation in human U2OS cells",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2022,
  "fields": {
    "action_time": "2025-05-26T11:17:13.921Z",
    "user": 1,
    "content_type": 10,
    "object_id": "161",
    "object_repr": "Cyproterone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2023,
  "fields": {
    "action_time": "2025-05-26T11:58:38.605Z",
    "user": 1,
    "content_type": 13,
    "object_id": "120",
    "object_repr": "Modulation of circadian gene expression and CLOCK:BMAL1 transcriptional activity in neuronal cells and rats",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2024,
  "fields": {
    "action_time": "2025-05-26T11:58:39.748Z",
    "user": 1,
    "content_type": 10,
    "object_id": "69",
    "object_repr": "2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2025,
  "fields": {
    "action_time": "2025-05-26T11:59:17.068Z",
    "user": 1,
    "content_type": 13,
    "object_id": "121",
    "object_repr": "Modulation of circadian gene expression in human U2OS cells",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2026,
  "fields": {
    "action_time": "2025-05-26T11:59:18.024Z",
    "user": 1,
    "content_type": 10,
    "object_id": "156",
    "object_repr": "DEQUALINIUM CHLORIDE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2027,
  "fields": {
    "action_time": "2025-05-26T12:00:23.885Z",
    "user": 1,
    "content_type": 13,
    "object_id": "122",
    "object_repr": "REM sleep suppression in humans",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2028,
  "fields": {
    "action_time": "2025-05-26T12:00:27.121Z",
    "user": 1,
    "content_type": 10,
    "object_id": "71",
    "object_repr": "methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2029,
  "fields": {
    "action_time": "2025-05-26T12:01:20.204Z",
    "user": 1,
    "content_type": 13,
    "object_id": "123",
    "object_repr": "NREM sleep promotion in humans",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2030,
  "fields": {
    "action_time": "2025-05-26T12:01:23.241Z",
    "user": 1,
    "content_type": 10,
    "object_id": "151",
    "object_repr": "Benadryl (diphenhydramine)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2031,
  "fields": {
    "action_time": "2025-05-26T12:01:57.994Z",
    "user": 1,
    "content_type": 13,
    "object_id": "124",
    "object_repr": "Period shortening in mammalian cells",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2032,
  "fields": {
    "action_time": "2025-05-26T12:01:59.875Z",
    "user": 1,
    "content_type": 10,
    "object_id": "260",
    "object_repr": "1-Azakenpaullone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2033,
  "fields": {
    "action_time": "2025-05-26T12:03:39.524Z",
    "user": 1,
    "content_type": 13,
    "object_id": "125",
    "object_repr": "Sleep induction and jet lag symptom relief in humans",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2034,
  "fields": {
    "action_time": "2025-05-26T12:03:41.019Z",
    "user": 1,
    "content_type": 10,
    "object_id": "148",
    "object_repr": "Restoril (temazepam)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2035,
  "fields": {
    "action_time": "2025-05-26T12:06:40.154Z",
    "user": 1,
    "content_type": 13,
    "object_id": "126",
    "object_repr": "Phase shift via Dec1 induction in mammalian cells",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2036,
  "fields": {
    "action_time": "2025-05-26T12:06:41.583Z",
    "user": 1,
    "content_type": 10,
    "object_id": "257",
    "object_repr": "4-(4-(benzo[d][1,3]dioxol-5-yl)-5-(pyridin-2-yl)-1H-imidazol-2-yl)benzamide",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2037,
  "fields": {
    "action_time": "2025-05-26T12:08:07.798Z",
    "user": 1,
    "content_type": 13,
    "object_id": "127",
    "object_repr": "Circadian disruption in skeletal muscle and pineal gland (in animals)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2038,
  "fields": {
    "action_time": "2025-05-26T12:08:09.471Z",
    "user": 1,
    "content_type": 10,
    "object_id": "108",
    "object_repr": "Metronidazole",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2039,
  "fields": {
    "action_time": "2025-05-26T12:08:39.391Z",
    "user": 1,
    "content_type": 13,
    "object_id": "128",
    "object_repr": "Period shortening in mammalian cells",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2040,
  "fields": {
    "action_time": "2025-05-26T12:08:40.902Z",
    "user": 1,
    "content_type": 10,
    "object_id": "251",
    "object_repr": "BRD1652",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2041,
  "fields": {
    "action_time": "2025-05-26T12:09:26.454Z",
    "user": 1,
    "content_type": 13,
    "object_id": "129",
    "object_repr": "sleep modulation in humans",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2042,
  "fields": {
    "action_time": "2025-05-26T12:09:27.754Z",
    "user": 1,
    "content_type": 10,
    "object_id": "144",
    "object_repr": "Estazolam",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2043,
  "fields": {
    "action_time": "2025-05-26T12:10:35.316Z",
    "user": 1,
    "content_type": 13,
    "object_id": "130",
    "object_repr": "potential circadian entrainment via TRPV4 in eye (mammals)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2044,
  "fields": {
    "action_time": "2025-05-26T12:10:36.246Z",
    "user": 1,
    "content_type": 10,
    "object_id": "249",
    "object_repr": "HC067047",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2045,
  "fields": {
    "action_time": "2025-05-26T12:11:03.374Z",
    "user": 1,
    "content_type": 13,
    "object_id": "131",
    "object_repr": "Indirect circadian disruption via altered sleep–wake timing (in humans)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2046,
  "fields": {
    "action_time": "2025-05-26T12:11:04.998Z",
    "user": 1,
    "content_type": 10,
    "object_id": "142",
    "object_repr": "Butisol (butabarbital)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2047,
  "fields": {
    "action_time": "2025-05-26T12:11:34.390Z",
    "user": 1,
    "content_type": 13,
    "object_id": "132",
    "object_repr": "Circadian modulation via RORγ activation in human immune cells",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2048,
  "fields": {
    "action_time": "2025-05-26T12:11:35.644Z",
    "user": 1,
    "content_type": 10,
    "object_id": "246",
    "object_repr": "Cintirorgon",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2049,
  "fields": {
    "action_time": "2025-05-26T12:12:02.090Z",
    "user": 1,
    "content_type": 13,
    "object_id": "133",
    "object_repr": "Phase shift modulation and period regulation via adenosine receptor signaling (in mice and mammals)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2050,
  "fields": {
    "action_time": "2025-05-26T12:12:03.158Z",
    "user": 1,
    "content_type": 10,
    "object_id": "138",
    "object_repr": "Adenosine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2051,
  "fields": {
    "action_time": "2025-05-26T12:12:41.041Z",
    "user": 1,
    "content_type": 13,
    "object_id": "134",
    "object_repr": "Modulation of clock gene expression and metabolic rhythm regulation in liver (in mammals)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2052,
  "fields": {
    "action_time": "2025-05-26T12:12:41.897Z",
    "user": 1,
    "content_type": 10,
    "object_id": "242",
    "object_repr": "Ursolic acid",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2053,
  "fields": {
    "action_time": "2025-05-26T12:13:12.455Z",
    "user": 1,
    "content_type": 13,
    "object_id": "135",
    "object_repr": "Circadian phase shift and dysrhythmia in eclosion rhythm in Drosophila melanogaster",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2054,
  "fields": {
    "action_time": "2025-05-26T12:13:13.747Z",
    "user": 1,
    "content_type": 10,
    "object_id": "102",
    "object_repr": "Sulfamethoxazole",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2055,
  "fields": {
    "action_time": "2025-05-26T12:13:55.554Z",
    "user": 1,
    "content_type": 13,
    "object_id": "136",
    "object_repr": "Phase shift via Y1 receptor antagonism in rodents",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2056,
  "fields": {
    "action_time": "2025-05-26T12:13:56.494Z",
    "user": 1,
    "content_type": 10,
    "object_id": "236",
    "object_repr": "BIBO 3304 trifluoroacetate",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2057,
  "fields": {
    "action_time": "2025-05-26T12:14:32.028Z",
    "user": 1,
    "content_type": 13,
    "object_id": "137",
    "object_repr": "Altered expression of clock genes in mice",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2058,
  "fields": {
    "action_time": "2025-05-26T12:14:32.987Z",
    "user": 1,
    "content_type": 10,
    "object_id": "133",
    "object_repr": "Dexmedetomidine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2059,
  "fields": {
    "action_time": "2025-05-26T12:15:07.252Z",
    "user": 1,
    "content_type": 13,
    "object_id": "138",
    "object_repr": "Phase stabilization and circadian gene modulation in mice",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2060,
  "fields": {
    "action_time": "2025-05-26T12:15:08.146Z",
    "user": 1,
    "content_type": 10,
    "object_id": "233",
    "object_repr": "SR9009",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2061,
  "fields": {
    "action_time": "2025-05-26T12:16:51.845Z",
    "user": 1,
    "content_type": 13,
    "object_id": "139",
    "object_repr": "Phase advance and reduced amplitude in mice and hamsters",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2062,
  "fields": {
    "action_time": "2025-05-26T12:16:52.683Z",
    "user": 1,
    "content_type": 10,
    "object_id": "130",
    "object_repr": "Buspirone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2063,
  "fields": {
    "action_time": "2025-05-26T12:17:48.990Z",
    "user": 1,
    "content_type": 13,
    "object_id": "140",
    "object_repr": "Circadian rhythm disruption in mammals",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2064,
  "fields": {
    "action_time": "2025-05-26T12:17:50.259Z",
    "user": 1,
    "content_type": 10,
    "object_id": "230",
    "object_repr": "Indeno[1,2,3-c,d]pyrene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2065,
  "fields": {
    "action_time": "2025-05-26T12:18:16.695Z",
    "user": 1,
    "content_type": 13,
    "object_id": "141",
    "object_repr": "Phase shift in fungi (Neurospora)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2066,
  "fields": {
    "action_time": "2025-05-26T12:18:17.527Z",
    "user": 1,
    "content_type": 10,
    "object_id": "126",
    "object_repr": "Trifluoperazine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2067,
  "fields": {
    "action_time": "2025-05-26T12:19:15.100Z",
    "user": 1,
    "content_type": 13,
    "object_id": "142",
    "object_repr": "Amplitude enhancement and phase shift in human cells",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2068,
  "fields": {
    "action_time": "2025-05-26T12:19:16.103Z",
    "user": 1,
    "content_type": 10,
    "object_id": "95",
    "object_repr": "SR8278",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2069,
  "fields": {
    "action_time": "2025-05-26T12:19:48.143Z",
    "user": 1,
    "content_type": 13,
    "object_id": "143",
    "object_repr": "Circadian rhythm disruption in mammals",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2070,
  "fields": {
    "action_time": "2025-05-26T12:19:49.209Z",
    "user": 1,
    "content_type": 10,
    "object_id": "229",
    "object_repr": "BENZO(ghi)PERYLENE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2071,
  "fields": {
    "action_time": "2025-05-26T12:20:28.332Z",
    "user": 1,
    "content_type": 13,
    "object_id": "144",
    "object_repr": "Circadian rhythm disruption in humans",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2072,
  "fields": {
    "action_time": "2025-05-26T12:20:29.504Z",
    "user": 1,
    "content_type": 10,
    "object_id": "125",
    "object_repr": "Promazine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2073,
  "fields": {
    "action_time": "2025-05-26T12:21:04.519Z",
    "user": 1,
    "content_type": 13,
    "object_id": "145",
    "object_repr": "Period lengthening in human cells (U2OS)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2074,
  "fields": {
    "action_time": "2025-05-26T12:21:05.569Z",
    "user": 1,
    "content_type": 10,
    "object_id": "94",
    "object_repr": "M47",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2075,
  "fields": {
    "action_time": "2025-05-26T12:21:50.232Z",
    "user": 1,
    "content_type": 13,
    "object_id": "146",
    "object_repr": "Circadian disruption via core clock interference (in mammals)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2076,
  "fields": {
    "action_time": "2025-05-26T12:21:51.357Z",
    "user": 1,
    "content_type": 10,
    "object_id": "228",
    "object_repr": "Dibenzo[a,h]anthracene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2077,
  "fields": {
    "action_time": "2025-05-26T12:22:24.432Z",
    "user": 1,
    "content_type": 13,
    "object_id": "147",
    "object_repr": "Phase-dependent modulation of activity amplitude and onset (in rodents)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2078,
  "fields": {
    "action_time": "2025-05-26T12:22:25.448Z",
    "user": 1,
    "content_type": 10,
    "object_id": "124",
    "object_repr": "Pimozidine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2079,
  "fields": {
    "action_time": "2025-05-26T12:32:22.125Z",
    "user": 1,
    "content_type": 13,
    "object_id": "148",
    "object_repr": "Period lengthening and phase delay in rodents and SCN slices",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2080,
  "fields": {
    "action_time": "2025-05-26T12:32:23.078Z",
    "user": 1,
    "content_type": 10,
    "object_id": "93",
    "object_repr": "PF-670462",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2081,
  "fields": {
    "action_time": "2025-05-26T12:32:55.977Z",
    "user": 1,
    "content_type": 13,
    "object_id": "149",
    "object_repr": "Circadian disruption via core clock targeting in mammals",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2082,
  "fields": {
    "action_time": "2025-05-26T12:32:57.091Z",
    "user": 1,
    "content_type": 10,
    "object_id": "226",
    "object_repr": "Chrysene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2083,
  "fields": {
    "action_time": "2025-05-26T12:33:25.619Z",
    "user": 1,
    "content_type": 13,
    "object_id": "150",
    "object_repr": "Clock gene normalization and potential phase shift in rats",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2084,
  "fields": {
    "action_time": "2025-05-26T12:33:26.660Z",
    "user": 1,
    "content_type": 10,
    "object_id": "122",
    "object_repr": "Lurasidone",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2085,
  "fields": {
    "action_time": "2025-05-26T12:33:56.494Z",
    "user": 1,
    "content_type": 13,
    "object_id": "151",
    "object_repr": "Modulation of circadian gene expression via RORγt inhibition in mice/human immune cells",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2086,
  "fields": {
    "action_time": "2025-05-26T12:33:57.567Z",
    "user": 1,
    "content_type": 10,
    "object_id": "88",
    "object_repr": "TMP778",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2087,
  "fields": {
    "action_time": "2025-05-26T12:34:22.784Z",
    "user": 1,
    "content_type": 13,
    "object_id": "152",
    "object_repr": "Circadian disruption via core clock gene targeting in animals (PAH exposure model)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2088,
  "fields": {
    "action_time": "2025-05-26T12:34:23.732Z",
    "user": 1,
    "content_type": 10,
    "object_id": "225",
    "object_repr": "Benzo[k]fluoranthene",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2089,
  "fields": {
    "action_time": "2025-05-26T12:36:22.338Z",
    "user": 1,
    "content_type": 13,
    "object_id": "153",
    "object_repr": "Circadian disruption in humans (rest-activity rhythm disturbance with flupentixol)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2090,
  "fields": {
    "action_time": "2025-05-26T12:36:23.460Z",
    "user": 1,
    "content_type": 10,
    "object_id": "118",
    "object_repr": "Flupentixol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2091,
  "fields": {
    "action_time": "2025-05-26T12:38:19.270Z",
    "user": 1,
    "content_type": 13,
    "object_id": "154",
    "object_repr": "ChatGPT сказал: Circadian modulation potential via CB2 in mammals (indirect, immune-related pathways)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2092,
  "fields": {
    "action_time": "2025-05-26T12:38:40.870Z",
    "user": 1,
    "content_type": 13,
    "object_id": "155",
    "object_repr": "Circadian modulation potential via CB2 in mammals (indirect, immune-related pathways)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2093,
  "fields": {
    "action_time": "2025-05-26T12:38:44.672Z",
    "user": 1,
    "content_type": 10,
    "object_id": "51",
    "object_repr": "6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2094,
  "fields": {
    "action_time": "2025-05-26T12:39:16.514Z",
    "user": 1,
    "content_type": 13,
    "object_id": "154",
    "object_repr": "ChatGPT сказал: Circadian modulation potential via CB2 in mammals (indirect, immune-related pathways)",
    "action_flag": 3,
    "change_message": ""
  }
},
{
  "model": "admin.logentry",
  "pk": 2095,
  "fields": {
    "action_time": "2025-05-26T12:39:55.934Z",
    "user": 1,
    "content_type": 13,
    "object_id": "156",
    "object_repr": "Period lengthening in human cells (U2OS)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2096,
  "fields": {
    "action_time": "2025-05-26T12:39:57.041Z",
    "user": 1,
    "content_type": 10,
    "object_id": "220",
    "object_repr": "LH-846",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2097,
  "fields": {
    "action_time": "2025-05-26T12:40:43.259Z",
    "user": 1,
    "content_type": 13,
    "object_id": "157",
    "object_repr": "Phase shifting in humans (via MT1/MT2 receptor activation)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2098,
  "fields": {
    "action_time": "2025-05-26T12:40:44.642Z",
    "user": 1,
    "content_type": 10,
    "object_id": "34",
    "object_repr": "Agomelatin-d3",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2099,
  "fields": {
    "action_time": "2025-05-26T12:41:18.350Z",
    "user": 1,
    "content_type": 13,
    "object_id": "158",
    "object_repr": "Transcriptional inhibition of BMAL1–CLOCK complex in human cells",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2100,
  "fields": {
    "action_time": "2025-05-26T12:41:19.227Z",
    "user": 1,
    "content_type": 10,
    "object_id": "218",
    "object_repr": "5,8-Quinoxalinedione",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2101,
  "fields": {
    "action_time": "2025-05-26T12:44:29.271Z",
    "user": 1,
    "content_type": 13,
    "object_id": "159",
    "object_repr": "CRY1/2 inhibition",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2102,
  "fields": {
    "action_time": "2025-05-26T12:44:30.389Z",
    "user": 1,
    "content_type": 10,
    "object_id": "215",
    "object_repr": "KS15",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2103,
  "fields": {
    "action_time": "2025-05-26T12:44:57.087Z",
    "user": 1,
    "content_type": 13,
    "object_id": "160",
    "object_repr": "inhibition of photic phase shifts in mice (SCN-dependent)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2104,
  "fields": {
    "action_time": "2025-05-26T12:44:59.685Z",
    "user": 1,
    "content_type": 10,
    "object_id": "67",
    "object_repr": "methyl (1R,2R,3S,5S)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2105,
  "fields": {
    "action_time": "2025-05-26T12:45:39.853Z",
    "user": 1,
    "content_type": 13,
    "object_id": "161",
    "object_repr": "Circadian modulation in human U2OS cells",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2106,
  "fields": {
    "action_time": "2025-05-26T12:45:40.969Z",
    "user": 1,
    "content_type": 10,
    "object_id": "212",
    "object_repr": "TRETINOIN",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2107,
  "fields": {
    "action_time": "2025-05-26T12:46:19.580Z",
    "user": 1,
    "content_type": 13,
    "object_id": "162",
    "object_repr": "Circadian modulation in human U2OS cells",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2108,
  "fields": {
    "action_time": "2025-05-26T12:46:20.586Z",
    "user": 1,
    "content_type": 10,
    "object_id": "206",
    "object_repr": "PAZOPANIB HCL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2109,
  "fields": {
    "action_time": "2025-05-26T12:46:50.112Z",
    "user": 1,
    "content_type": 13,
    "object_id": "163",
    "object_repr": "Circadian modulation via nuclear receptor pathways (LXRα/β) in mammalian cells",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2110,
  "fields": {
    "action_time": "2025-05-26T12:46:51.035Z",
    "user": 1,
    "content_type": 10,
    "object_id": "81",
    "object_repr": "T0901317",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2111,
  "fields": {
    "action_time": "2025-05-26T12:47:29.730Z",
    "user": 1,
    "content_type": 13,
    "object_id": "164",
    "object_repr": "Circadian gene expression modulation in human cells (U2OS)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2112,
  "fields": {
    "action_time": "2025-05-26T12:47:30.621Z",
    "user": 1,
    "content_type": 10,
    "object_id": "205",
    "object_repr": "NILOTINIB",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2113,
  "fields": {
    "action_time": "2025-05-26T12:48:11.604Z",
    "user": 1,
    "content_type": 13,
    "object_id": "165",
    "object_repr": "Phase shift disruption in animals",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2114,
  "fields": {
    "action_time": "2025-05-26T12:48:12.542Z",
    "user": 1,
    "content_type": 10,
    "object_id": "11",
    "object_repr": "Luzindole",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2115,
  "fields": {
    "action_time": "2025-05-26T12:49:00.930Z",
    "user": 1,
    "content_type": 13,
    "object_id": "166",
    "object_repr": "Circadian modulation in human cells",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2116,
  "fields": {
    "action_time": "2025-05-26T12:49:05.471Z",
    "user": 1,
    "content_type": 10,
    "object_id": "200",
    "object_repr": "EVEROLIMUS",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2117,
  "fields": {
    "action_time": "2025-05-26T13:01:48.690Z",
    "user": 1,
    "content_type": 13,
    "object_id": "167",
    "object_repr": "Phase shifting in mammals",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2118,
  "fields": {
    "action_time": "2025-05-26T13:02:37.567Z",
    "user": 1,
    "content_type": 13,
    "object_id": "168",
    "object_repr": "Phase advance in humans",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2119,
  "fields": {
    "action_time": "2025-05-26T13:02:38.517Z",
    "user": 1,
    "content_type": 10,
    "object_id": "10",
    "object_repr": "Ramelteon",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2120,
  "fields": {
    "action_time": "2025-05-26T13:03:27.701Z",
    "user": 1,
    "content_type": 13,
    "object_id": "169",
    "object_repr": "Circadian disruption via melatonin receptor antagonism",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2121,
  "fields": {
    "action_time": "2025-05-26T13:03:28.889Z",
    "user": 1,
    "content_type": 10,
    "object_id": "43",
    "object_repr": "GR 128107",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2122,
  "fields": {
    "action_time": "2025-05-26T13:03:58.949Z",
    "user": 1,
    "content_type": 13,
    "object_id": "170",
    "object_repr": "Phase shift in humans via MT1/MT2 receptor agonism",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2123,
  "fields": {
    "action_time": "2025-05-26T13:03:59.856Z",
    "user": 1,
    "content_type": 10,
    "object_id": "13",
    "object_repr": "Agomelatine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2124,
  "fields": {
    "action_time": "2025-05-26T13:06:46.077Z",
    "user": 1,
    "content_type": 13,
    "object_id": "171",
    "object_repr": "Phase shift disruption in mammals",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2125,
  "fields": {
    "action_time": "2025-05-26T13:06:46.817Z",
    "user": 1,
    "content_type": 10,
    "object_id": "14",
    "object_repr": "N-[(6-Methoxy-9-tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaenyl)methyl]acetamide (UCM 549)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2126,
  "fields": {
    "action_time": "2025-05-26T13:08:52.762Z",
    "user": 1,
    "content_type": 13,
    "object_id": "172",
    "object_repr": "Phase shift disruption in mammals via MT1/MT2 receptor antagonism",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2127,
  "fields": {
    "action_time": "2025-05-26T13:08:53.799Z",
    "user": 1,
    "content_type": 10,
    "object_id": "16",
    "object_repr": "S26131",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2128,
  "fields": {
    "action_time": "2025-05-26T13:09:19.045Z",
    "user": 1,
    "content_type": 13,
    "object_id": "173",
    "object_repr": "Phase shift induction in mammals via MT1/MT2 receptor agonism",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2129,
  "fields": {
    "action_time": "2025-05-26T13:09:19.941Z",
    "user": 1,
    "content_type": 10,
    "object_id": "17",
    "object_repr": "Melatonin-d4",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2130,
  "fields": {
    "action_time": "2025-05-26T13:09:50.314Z",
    "user": 1,
    "content_type": 13,
    "object_id": "174",
    "object_repr": "Phase shift induction in mammals via MT1/MT2 receptor agonism",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2131,
  "fields": {
    "action_time": "2025-05-26T13:09:51.313Z",
    "user": 1,
    "content_type": 10,
    "object_id": "18",
    "object_repr": "2-Iodomelatonin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2132,
  "fields": {
    "action_time": "2025-05-26T13:11:22.337Z",
    "user": 1,
    "content_type": 13,
    "object_id": "175",
    "object_repr": "Phase shift modulation in mammals via selective MT2 receptor agonism",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2133,
  "fields": {
    "action_time": "2025-05-26T13:11:31.070Z",
    "user": 1,
    "content_type": 10,
    "object_id": "19",
    "object_repr": "8-M-PDOT",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2134,
  "fields": {
    "action_time": "2025-05-26T13:11:58.625Z",
    "user": 1,
    "content_type": 13,
    "object_id": "176",
    "object_repr": "Circadian rhythm entrainment in diet-induced obese rats via MT1/MT2 agonism",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2135,
  "fields": {
    "action_time": "2025-05-26T13:12:46.087Z",
    "user": 1,
    "content_type": 10,
    "object_id": "22",
    "object_repr": "ACH-000143",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2136,
  "fields": {
    "action_time": "2025-05-26T13:13:11.425Z",
    "user": 1,
    "content_type": 13,
    "object_id": "177",
    "object_repr": "MT1/MT2 receptor agonist; potential circadian phase modulation in mammals",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2137,
  "fields": {
    "action_time": "2025-05-26T13:13:12.377Z",
    "user": 1,
    "content_type": 10,
    "object_id": "24",
    "object_repr": "UCM 608 (N-[2-(5-methoxy-2-phenyl-1H-indol-3-yl)ethyl]acetamide)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2138,
  "fields": {
    "action_time": "2025-05-26T13:27:48.728Z",
    "user": 1,
    "content_type": 13,
    "object_id": "178",
    "object_repr": "Partial MT2 receptor agonist; modulates circadian signaling in retina (mammals)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2139,
  "fields": {
    "action_time": "2025-05-26T13:27:49.692Z",
    "user": 1,
    "content_type": 10,
    "object_id": "26",
    "object_repr": "N-Acetyltryptamine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2140,
  "fields": {
    "action_time": "2025-05-26T13:29:17.388Z",
    "user": 1,
    "content_type": 13,
    "object_id": "179",
    "object_repr": "improves sleep (cats)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2141,
  "fields": {
    "action_time": "2025-05-26T13:29:18.389Z",
    "user": 1,
    "content_type": 10,
    "object_id": "25",
    "object_repr": "Ramelteon metabolite M-II-d3",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2142,
  "fields": {
    "action_time": "2025-05-26T13:31:34.524Z",
    "user": 1,
    "content_type": 13,
    "object_id": "180",
    "object_repr": "Weak MT1/MT2 agonist",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2143,
  "fields": {
    "action_time": "2025-05-26T13:31:36.033Z",
    "user": 1,
    "content_type": 10,
    "object_id": "33",
    "object_repr": "7-Desmethyl-3-hydroxyagomelatine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2144,
  "fields": {
    "action_time": "2025-05-26T13:32:07.957Z",
    "user": 1,
    "content_type": 13,
    "object_id": "181",
    "object_repr": "derivative of chronobiotic agomelatine (MT1/MT2)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2145,
  "fields": {
    "action_time": "2025-05-26T13:32:08.916Z",
    "user": 1,
    "content_type": 10,
    "object_id": "29",
    "object_repr": "Agomelatine-d4",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2146,
  "fields": {
    "action_time": "2025-05-26T13:32:36.352Z",
    "user": 1,
    "content_type": 13,
    "object_id": "182",
    "object_repr": "MT1/MT2 receptor agonist",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2147,
  "fields": {
    "action_time": "2025-05-26T13:32:37.270Z",
    "user": 1,
    "content_type": 10,
    "object_id": "31",
    "object_repr": "Melatonin-d7",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2148,
  "fields": {
    "action_time": "2025-05-26T13:33:52.650Z",
    "user": 1,
    "content_type": 13,
    "object_id": "183",
    "object_repr": "MT1/MT2 receptor agonist",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2149,
  "fields": {
    "action_time": "2025-05-26T13:33:53.980Z",
    "user": 1,
    "content_type": 10,
    "object_id": "32",
    "object_repr": "Ramelteon-d5",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2150,
  "fields": {
    "action_time": "2025-05-26T13:34:51.670Z",
    "user": 1,
    "content_type": 13,
    "object_id": "184",
    "object_repr": "MT1/MT2 partial agonist",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2151,
  "fields": {
    "action_time": "2025-05-26T13:34:53.274Z",
    "user": 1,
    "content_type": 10,
    "object_id": "27",
    "object_repr": "Ramelteon metabolite M-II (DES(1-oxopropyl)-2-hydroxy-1-oxopropyl-ramelteon)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2152,
  "fields": {
    "action_time": "2025-05-26T13:35:17.988Z",
    "user": 1,
    "content_type": 13,
    "object_id": "185",
    "object_repr": "MT2 antagonist; disrupts melatonin signaling (in human receptor models)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2153,
  "fields": {
    "action_time": "2025-05-26T13:35:19.232Z",
    "user": 1,
    "content_type": 10,
    "object_id": "37",
    "object_repr": "DH97",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2154,
  "fields": {
    "action_time": "2025-05-26T13:35:50.316Z",
    "user": 1,
    "content_type": 13,
    "object_id": "186",
    "object_repr": "Sleep-promoting and circadian phase-altering effects in mice",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2155,
  "fields": {
    "action_time": "2025-05-26T13:35:51.202Z",
    "user": 1,
    "content_type": 10,
    "object_id": "40",
    "object_repr": "GR 196429",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2156,
  "fields": {
    "action_time": "2025-05-26T21:28:07.702Z",
    "user": 2,
    "content_type": 10,
    "object_id": "8",
    "object_repr": "Melatonin",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2157,
  "fields": {
    "action_time": "2025-05-26T21:34:18.607Z",
    "user": 2,
    "content_type": 14,
    "object_id": "356",
    "object_repr": "Axelrod, J., 1983. Regulation of circadian rhythms of indoleamines in the pineal gland. In The pineal gland and its endocrine role (pp. 1-13). Boston, MA: Springer US.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2158,
  "fields": {
    "action_time": "2025-05-26T21:35:09.989Z",
    "user": 2,
    "content_type": 13,
    "object_id": "187",
    "object_repr": "Phase-shift",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2159,
  "fields": {
    "action_time": "2025-05-26T21:35:11.646Z",
    "user": 2,
    "content_type": 10,
    "object_id": "9",
    "object_repr": "Indole",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2160,
  "fields": {
    "action_time": "2025-05-29T07:59:08.535Z",
    "user": 2,
    "content_type": 14,
    "object_id": "357",
    "object_repr": "Barnes, S.J., Alanazi, M., Yamazaki, S. and Stefanovska, A., 2025. Methamphetamine alters the circadian oscillator and its couplings on multiple scales in Per1/2/3 knockout mice. PNAS nexus, 4(4), p.p",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2161,
  "fields": {
    "action_time": "2025-05-29T08:01:14.499Z",
    "user": 2,
    "content_type": 14,
    "object_id": "358",
    "object_repr": "Mohawk, J.A., Baer, M.L. and Menaker, M., 2009. The methamphetamine-sensitive circadian oscillator does not employ canonical clock genes. Proceedings of the National Academy of Sciences, 106(9), pp.35",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2162,
  "fields": {
    "action_time": "2025-05-29T08:09:37.667Z",
    "user": 2,
    "content_type": 12,
    "object_id": "136",
    "object_repr": "SLC6A2",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2163,
  "fields": {
    "action_time": "2025-05-29T08:10:39.645Z",
    "user": 2,
    "content_type": 9,
    "object_id": "206",
    "object_repr": "Monoamine transporter inhibitor",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2164,
  "fields": {
    "action_time": "2025-05-29T08:11:45.486Z",
    "user": 2,
    "content_type": 13,
    "object_id": "188",
    "object_repr": "Ultradian oscillations induction in Per1/2/3knockout mice",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2165,
  "fields": {
    "action_time": "2025-05-29T08:12:02.947Z",
    "user": 2,
    "content_type": 13,
    "object_id": "189",
    "object_repr": "exposure induces atime-varying circadian rhythm",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2166,
  "fields": {
    "action_time": "2025-05-29T08:13:36.911Z",
    "user": 2,
    "content_type": 9,
    "object_id": "207",
    "object_repr": "Non-canonical circadian genes",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2167,
  "fields": {
    "action_time": "2025-05-29T08:14:03.709Z",
    "user": 2,
    "content_type": 9,
    "object_id": "208",
    "object_repr": "methamphetamine-sensitive circadian oscillator (MASCO)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2168,
  "fields": {
    "action_time": "2025-05-29T08:16:09.990Z",
    "user": 2,
    "content_type": 13,
    "object_id": "190",
    "object_repr": "induced a  very long free-running period (~27 h) in heterozygous Gsk3β mutant mice in DD",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2169,
  "fields": {
    "action_time": "2025-05-29T08:17:39.548Z",
    "user": 2,
    "content_type": 9,
    "object_id": "209",
    "object_repr": "increase dopamine signalling",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2170,
  "fields": {
    "action_time": "2025-05-29T08:19:36.616Z",
    "user": 2,
    "content_type": 14,
    "object_id": "359",
    "object_repr": "Genetics and functional significance of the understudied methamphetamine sensitive circadian oscillator (MASCO)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2171,
  "fields": {
    "action_time": "2025-05-29T08:20:17.319Z",
    "user": 2,
    "content_type": 10,
    "object_id": "319",
    "object_repr": "(2S)-N-methyl-1-phenylpropan-2-amine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2172,
  "fields": {
    "action_time": "2025-05-29T08:22:20.630Z",
    "user": 2,
    "content_type": 13,
    "object_id": "191",
    "object_repr": "5-h phase advance in the sleep-wake cycle",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2173,
  "fields": {
    "action_time": "2025-05-29T08:22:38.655Z",
    "user": 2,
    "content_type": 10,
    "object_id": "10",
    "object_repr": "Ramelteon",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2174,
  "fields": {
    "action_time": "2025-05-29T08:24:18.147Z",
    "user": 2,
    "content_type": 14,
    "object_id": "360",
    "object_repr": "Souza, L.C., Martynhak, B.J., Bassani, T.B., Turnes, J.D.M., Machado, M.M., Moura, E., Andreatini, R. and Vital, M.A., 2018. Agomelatine's effect on circadian locomotor rhythm alteration and depressiv",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2175,
  "fields": {
    "action_time": "2025-05-29T08:25:13.049Z",
    "user": 2,
    "content_type": 13,
    "object_id": "192",
    "object_repr": "Agomelatine has been shown to induce robust circadian phase shifts",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2176,
  "fields": {
    "action_time": "2025-05-29T08:25:30.899Z",
    "user": 2,
    "content_type": 13,
    "object_id": "193",
    "object_repr": "can improve sleep continuity and quality, shorten sleep latency (time it takes to fall asleep",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2177,
  "fields": {
    "action_time": "2025-05-29T08:25:45.238Z",
    "user": 2,
    "content_type": 13,
    "object_id": "194",
    "object_repr": "advance the timing of sleep onset and other circadian rhythms like core body temperature and heart rate.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2178,
  "fields": {
    "action_time": "2025-05-29T08:25:53.592Z",
    "user": 2,
    "content_type": 10,
    "object_id": "13",
    "object_repr": "Agomelatine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Fdastatus\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2179,
  "fields": {
    "action_time": "2025-05-29T08:26:22.749Z",
    "user": 2,
    "content_type": 10,
    "object_id": "19",
    "object_repr": "8-M-PDOT",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2180,
  "fields": {
    "action_time": "2025-05-29T13:23:08.159Z",
    "user": 2,
    "content_type": 10,
    "object_id": "69",
    "object_repr": "2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2181,
  "fields": {
    "action_time": "2025-05-29T13:23:32.021Z",
    "user": 2,
    "content_type": 10,
    "object_id": "319",
    "object_repr": "(2S)-N-methyl-1-phenylpropan-2-amine",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2182,
  "fields": {
    "action_time": "2025-05-29T14:33:11.204Z",
    "user": 2,
    "content_type": 14,
    "object_id": "361",
    "object_repr": "Surme, S., Ergun, C., Gul, S., Akyel, Y.K., Gul, Z.M., Ozcan, O., Ipek, O.S., Akarlar, B.A., Ozlu, N., Taskin, A.C. and Turkay, M., 2023. TW68, cryptochromes stabilizer, regulates fasting blood glucos",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2183,
  "fields": {
    "action_time": "2025-06-04T08:55:30.116Z",
    "user": 2,
    "content_type": 14,
    "object_id": "362",
    "object_repr": "Surme, S., Ergun, C., Gul, S., Akyel, Y.K., Gul, Z.M., Ozcan, O., Ipek, O.S., Akarlar, B.A., Ozlu, N., Taskin, A.C. and Turkay, M., 2023. TW68, cryptochromes stabilizer, regulates fasting blood glucos",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2184,
  "fields": {
    "action_time": "2025-06-04T08:56:53.266Z",
    "user": 2,
    "content_type": 13,
    "object_id": "195",
    "object_repr": "Lengthen perion of circadian rhythm",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2185,
  "fields": {
    "action_time": "2025-06-04T08:57:25.387Z",
    "user": 2,
    "content_type": 9,
    "object_id": "210",
    "object_repr": "CRY1 stabilizer",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2186,
  "fields": {
    "action_time": "2025-06-04T09:00:01.871Z",
    "user": 2,
    "content_type": 10,
    "object_id": "320",
    "object_repr": "TW68",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2187,
  "fields": {
    "action_time": "2025-06-04T09:02:23.956Z",
    "user": 2,
    "content_type": 10,
    "object_id": "320",
    "object_repr": "TW68",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Fdastatus\", \"Mechanisms\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2188,
  "fields": {
    "action_time": "2025-06-04T10:41:08.570Z",
    "user": 1,
    "content_type": 14,
    "object_id": "363",
    "object_repr": "Nakamura TJ, Sellix MT, Menaker M, Block GD. Estrogen directly modulates circadian rhythms of PER2 expression in the uterus. Am J Physiol Endocrinol Metab. 2008 Nov;295(5):E1025-31. doi: 10.1152/ajpen",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2189,
  "fields": {
    "action_time": "2025-06-04T10:43:43.356Z",
    "user": 1,
    "content_type": 9,
    "object_id": "211",
    "object_repr": "BMAL1 expression modulation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2190,
  "fields": {
    "action_time": "2025-06-04T10:44:20.251Z",
    "user": 1,
    "content_type": 12,
    "object_id": "137",
    "object_repr": "PER2 gene expression",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2191,
  "fields": {
    "action_time": "2025-06-04T10:44:37.874Z",
    "user": 1,
    "content_type": 13,
    "object_id": "196",
    "object_repr": "Period shortening of the circadian rhythm in the uterus",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2192,
  "fields": {
    "action_time": "2025-06-04T10:44:38.900Z",
    "user": 1,
    "content_type": 10,
    "object_id": "321",
    "object_repr": "Raloxifene",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2193,
  "fields": {
    "action_time": "2025-06-04T10:53:11.893Z",
    "user": 1,
    "content_type": 14,
    "object_id": "364",
    "object_repr": "Burish MJ, Han C, Mawatari K, Wirianto M, Kim E, Ono K, Parakramaweera R, Chen Z, Yoo SH. The first-line cluster headache medication verapamil alters the circadian period and elicits sex-specific slee",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2194,
  "fields": {
    "action_time": "2025-06-04T10:55:06.649Z",
    "user": 1,
    "content_type": 13,
    "object_id": "197",
    "object_repr": "Shortening of circadian period",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2195,
  "fields": {
    "action_time": "2025-06-04T10:55:07.884Z",
    "user": 1,
    "content_type": 10,
    "object_id": "322",
    "object_repr": "verapamil",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2196,
  "fields": {
    "action_time": "2025-06-04T11:23:07.514Z",
    "user": 1,
    "content_type": 14,
    "object_id": "365",
    "object_repr": "Silva S, Bicker J, Falcão A, Fortuna A. Antidepressants and Circadian Rhythm: Exploring Their Bidirectional Interaction for the Treatment of Depression. Pharmaceutics. 2021 Nov 21;13(11):1975. doi: 10",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2197,
  "fields": {
    "action_time": "2025-06-04T11:25:42.007Z",
    "user": 1,
    "content_type": 13,
    "object_id": "198",
    "object_repr": "sleep architecture modulation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2198,
  "fields": {
    "action_time": "2025-06-04T11:25:43.107Z",
    "user": 1,
    "content_type": 10,
    "object_id": "323",
    "object_repr": "amitriptyline",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2199,
  "fields": {
    "action_time": "2025-06-04T11:37:52.333Z",
    "user": 1,
    "content_type": 14,
    "object_id": "366",
    "object_repr": "Carboni L, Rullo L, Caputi FF, Stamatakos S, Candeletti S, Romualdi P. Chronic Trazodone and Citalopram Treatments Increase Trophic Factor and Circadian Rhythm Gene Expression in Rat Brain Regions Rel",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2200,
  "fields": {
    "action_time": "2025-06-04T11:39:38.379Z",
    "user": 1,
    "content_type": 9,
    "object_id": "212",
    "object_repr": "Modulates sleep architecture via H1-histamine receptor antagonism",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2201,
  "fields": {
    "action_time": "2025-06-04T11:40:09.196Z",
    "user": 1,
    "content_type": 13,
    "object_id": "199",
    "object_repr": "Increases expression of circadian rhythm genes (Bmal1, Per1, Per2) in a brain-region-specific",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2202,
  "fields": {
    "action_time": "2025-06-04T11:45:07.619Z",
    "user": 1,
    "content_type": 10,
    "object_id": "324",
    "object_repr": "Trazodon",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2203,
  "fields": {
    "action_time": "2025-06-05T09:14:03.387Z",
    "user": 2,
    "content_type": 13,
    "object_id": "200",
    "object_repr": "Progesterone regulates the expression of clock genes like PER1, which is crucial for circadian timing.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2204,
  "fields": {
    "action_time": "2025-06-05T09:14:05.185Z",
    "user": 2,
    "content_type": 10,
    "object_id": "184",
    "object_repr": "PROGESTERONE",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2205,
  "fields": {
    "action_time": "2025-06-05T09:16:29.468Z",
    "user": 2,
    "content_type": 13,
    "object_id": "201",
    "object_repr": "delaying melatonin secretion, particularly when consumed in the evening, and potentially disrupting sleep patterns. It can shift the CCGs rhtyhms",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2206,
  "fields": {
    "action_time": "2025-06-05T09:16:31.255Z",
    "user": 2,
    "content_type": 10,
    "object_id": "303",
    "object_repr": "Caffeine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2207,
  "fields": {
    "action_time": "2025-06-05T09:17:53.949Z",
    "user": 2,
    "content_type": 13,
    "object_id": "202",
    "object_repr": "Nefazodone decreased both sleep latency and stage 1 sleep and increased sleep efficiency.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2208,
  "fields": {
    "action_time": "2025-06-05T09:17:56.374Z",
    "user": 2,
    "content_type": 10,
    "object_id": "182",
    "object_repr": "NEFAZODONE HCL",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2209,
  "fields": {
    "action_time": "2025-06-05T09:20:06.023Z",
    "user": 2,
    "content_type": 13,
    "object_id": "203",
    "object_repr": "efficacy in readjusting phase shifts in all physiological systems. Reduces sleep latancy.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2210,
  "fields": {
    "action_time": "2025-06-05T09:20:09.975Z",
    "user": 2,
    "content_type": 10,
    "object_id": "35",
    "object_repr": "TIK-301",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2211,
  "fields": {
    "action_time": "2025-06-05T09:21:55.629Z",
    "user": 2,
    "content_type": 13,
    "object_id": "204",
    "object_repr": "AA41612 alters the body's response to light, potentially influencing the timing and duration of circadian rhythms, such as sleep-wake cycles,",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2212,
  "fields": {
    "action_time": "2025-06-05T09:21:58.051Z",
    "user": 2,
    "content_type": 10,
    "object_id": "195",
    "object_repr": "AA41612",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2213,
  "fields": {
    "action_time": "2025-06-05T09:24:30.509Z",
    "user": 2,
    "content_type": 13,
    "object_id": "205",
    "object_repr": "effects on the circadian rhythm, also known as the body's natural sleep-wake cycle, are primarily related to its drowsiness and sedation properties",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2214,
  "fields": {
    "action_time": "2025-06-05T09:24:37.264Z",
    "user": 2,
    "content_type": 10,
    "object_id": "152",
    "object_repr": "Unisom (doxylamine)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2215,
  "fields": {
    "action_time": "2025-06-05T09:26:55.504Z",
    "user": 2,
    "content_type": 13,
    "object_id": "206",
    "object_repr": "Discrupts temporal organization in Candida albicans",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2216,
  "fields": {
    "action_time": "2025-06-05T09:26:58.156Z",
    "user": 2,
    "content_type": 10,
    "object_id": "145",
    "object_repr": "Fluconazole",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2217,
  "fields": {
    "action_time": "2025-06-05T09:28:13.815Z",
    "user": 2,
    "content_type": 13,
    "object_id": "207",
    "object_repr": "decreased the amplitude of circadian rhythm significantly while having no effect on the period",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2218,
  "fields": {
    "action_time": "2025-06-05T09:28:15.938Z",
    "user": 2,
    "content_type": 10,
    "object_id": "215",
    "object_repr": "KS15",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2219,
  "fields": {
    "action_time": "2025-06-05T09:29:42.679Z",
    "user": 2,
    "content_type": 13,
    "object_id": "208",
    "object_repr": "Resynchronization of the circadian clock, potentially improving sleep quality and alleviating symptoms associated with sleep disturbances.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2220,
  "fields": {
    "action_time": "2025-06-05T09:29:48.955Z",
    "user": 2,
    "content_type": 10,
    "object_id": "21",
    "object_repr": "Agomelatine hydrochloride",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2221,
  "fields": {
    "action_time": "2025-06-05T09:30:29.759Z",
    "user": 2,
    "content_type": 10,
    "object_id": "16",
    "object_repr": "S26131",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2222,
  "fields": {
    "action_time": "2025-06-05T09:32:16.231Z",
    "user": 2,
    "content_type": 14,
    "object_id": "367",
    "object_repr": "Williams III, W.P., McLin III, D.E., Dressman, M.A. and Neubauer, D.N., 2016. Comparative review of approved melatonin agonists for the treatment of circadian rhythm sleep‐wake disorders. Pharmacother",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2223,
  "fields": {
    "action_time": "2025-06-05T09:39:33.295Z",
    "user": 2,
    "content_type": 13,
    "object_id": "209",
    "object_repr": "UNKNOWN",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2224,
  "fields": {
    "action_time": "2025-06-05T09:39:37.231Z",
    "user": 2,
    "content_type": 10,
    "object_id": "45",
    "object_repr": "S24014",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\", \"Articles\", \"Effect\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2225,
  "fields": {
    "action_time": "2025-06-05T09:51:37.024Z",
    "user": 2,
    "content_type": 13,
    "object_id": "210",
    "object_repr": "possesses very different efficacies at the two melatonin receptors, beha full melatonin receptor agonist mt1, as an antagonist MT2 effect not studied",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2226,
  "fields": {
    "action_time": "2025-06-05T09:52:09.116Z",
    "user": 2,
    "content_type": 14,
    "object_id": "368",
    "object_repr": "Nonno, R., Lucini, V., Spadoni, G., Pannacci, M., Croce, A., Esposti, D., Balsamini, C., Tarzia, G., Fraschini, F. and Stankov, B.M., 2000. A new melatonin receptor ligand with mt1‐agonist and MT2‐ant",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2227,
  "fields": {
    "action_time": "2025-06-05T09:55:31.725Z",
    "user": 2,
    "content_type": 10,
    "object_id": "325",
    "object_repr": "5‐HEAT",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2228,
  "fields": {
    "action_time": "2025-06-05T09:56:53.192Z",
    "user": 2,
    "content_type": 14,
    "object_id": "369",
    "object_repr": "Zlotos, D.P., Attia, M.I., Julius, J., Sethi, S. and Witt-Enderby, P.A., 2009. 2-[(2, 3-Dihydro-1 H-indol-1-yl) methyl] melatonin Analogues: A Novel Class of MT2-Selective Melatonin Receptor Antagonis",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2229,
  "fields": {
    "action_time": "2025-06-05T10:00:56.359Z",
    "user": 2,
    "content_type": 13,
    "object_id": "211",
    "object_repr": "suggests it could potentially interact with the circadian system, which involves processes like sleep-wake cycles and hormone production",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2230,
  "fields": {
    "action_time": "2025-06-05T10:02:01.029Z",
    "user": 2,
    "content_type": 10,
    "object_id": "326",
    "object_repr": "2‐(indolin‐1yl)‐melatonin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2231,
  "fields": {
    "action_time": "2025-06-05T10:07:54.505Z",
    "user": 2,
    "content_type": 14,
    "object_id": "370",
    "object_repr": "Morellato, L., Lefas-Le Gall, M., Langlois, M., Caignard, D.H., Renard, P., Delagrange, P. and Mathé-Allainmat, M., 2013. Synthesis of new N-(arylcyclopropyl) acetamides and N-(arylvinyl) acetamides a",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2232,
  "fields": {
    "action_time": "2025-06-05T10:34:59.255Z",
    "user": 2,
    "content_type": 13,
    "object_id": "212",
    "object_repr": "MT1 agonist with poorly described",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2233,
  "fields": {
    "action_time": "2025-06-05T10:35:31.095Z",
    "user": 2,
    "content_type": 10,
    "object_id": "327",
    "object_repr": "2-methoxy-α,β-didehydro-agomelatine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2234,
  "fields": {
    "action_time": "2025-06-05T10:42:10.264Z",
    "user": 2,
    "content_type": 14,
    "object_id": "371",
    "object_repr": "Dubocovich, M.L., Masana, M.I., Iacob, S. and Sauri, D.M., 1997. Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmac",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2235,
  "fields": {
    "action_time": "2025-06-05T10:44:23.845Z",
    "user": 2,
    "content_type": 10,
    "object_id": "328",
    "object_repr": "5‐Methoxyluzindole",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2236,
  "fields": {
    "action_time": "2025-06-05T10:50:43.491Z",
    "user": 2,
    "content_type": 9,
    "object_id": "213",
    "object_repr": "MT2 receptor agonist",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2237,
  "fields": {
    "action_time": "2025-06-05T10:51:28.527Z",
    "user": 2,
    "content_type": 13,
    "object_id": "213",
    "object_repr": "Partial agonist MT2 and associated effects",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2238,
  "fields": {
    "action_time": "2025-06-05T10:55:23.967Z",
    "user": 2,
    "content_type": 14,
    "object_id": "372",
    "object_repr": "Ettaoussi, M., Sabaouni, A., Rami, M., Boutin, J.A., Delagrange, P., Renard, P., Spedding, M., Caignard, D.H., Berthelot, P. and Yous, S., 2012. Design, synthesis and pharmacological evaluation of new",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2239,
  "fields": {
    "action_time": "2025-06-05T10:56:15.986Z",
    "user": 2,
    "content_type": 10,
    "object_id": "329",
    "object_repr": "AAE‐M‐PBP amine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2240,
  "fields": {
    "action_time": "2025-06-05T10:56:54.701Z",
    "user": 2,
    "content_type": 10,
    "object_id": "329",
    "object_repr": "AAE‐M‐PBP amine (Isoamyl-agomelatine)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\", \"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2241,
  "fields": {
    "action_time": "2025-06-05T11:03:22.069Z",
    "user": 2,
    "content_type": 13,
    "object_id": "214",
    "object_repr": "Full mt2 rexeptor agonist",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2242,
  "fields": {
    "action_time": "2025-06-05T11:04:21.447Z",
    "user": 2,
    "content_type": 14,
    "object_id": "373",
    "object_repr": "Hu, Y., Zhu, J., Chan, K.H. and Wong, Y.H., 2013. Development of substituted N-[3-(3-methoxylphenyl) propyl] amides as MT2-selective melatonin agonists: Improving metabolic stability. Bioorganic & med",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2243,
  "fields": {
    "action_time": "2025-06-05T11:04:40.041Z",
    "user": 2,
    "content_type": 10,
    "object_id": "330",
    "object_repr": "benzyloxy-methoxyphenyl-propylamide (Bomppa)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2244,
  "fields": {
    "action_time": "2025-06-05T11:13:13.770Z",
    "user": 2,
    "content_type": 9,
    "object_id": "214",
    "object_repr": "HCN1 activator",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2245,
  "fields": {
    "action_time": "2025-06-05T11:13:38.146Z",
    "user": 2,
    "content_type": 9,
    "object_id": "215",
    "object_repr": "CNGA3 activation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2246,
  "fields": {
    "action_time": "2025-06-05T11:13:47.300Z",
    "user": 2,
    "content_type": 9,
    "object_id": "216",
    "object_repr": "HCN2 activation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2247,
  "fields": {
    "action_time": "2025-06-05T11:14:00.511Z",
    "user": 2,
    "content_type": 9,
    "object_id": "217",
    "object_repr": "CNGA2 activation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2248,
  "fields": {
    "action_time": "2025-06-05T11:14:58.744Z",
    "user": 2,
    "content_type": 9,
    "object_id": "218",
    "object_repr": "OATP4C1 transportation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2249,
  "fields": {
    "action_time": "2025-06-05T11:16:12.643Z",
    "user": 2,
    "content_type": 12,
    "object_id": "138",
    "object_repr": "HCN1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2250,
  "fields": {
    "action_time": "2025-06-05T11:16:57.390Z",
    "user": 2,
    "content_type": 12,
    "object_id": "139",
    "object_repr": "CNGA3",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2251,
  "fields": {
    "action_time": "2025-06-05T11:17:42.443Z",
    "user": 2,
    "content_type": 12,
    "object_id": "140",
    "object_repr": "HCN2",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2252,
  "fields": {
    "action_time": "2025-06-05T11:18:01.482Z",
    "user": 2,
    "content_type": 12,
    "object_id": "141",
    "object_repr": "CNGA2",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2253,
  "fields": {
    "action_time": "2025-06-05T11:18:49.158Z",
    "user": 2,
    "content_type": 13,
    "object_id": "215",
    "object_repr": "influencing the expression and stability of key circadian clock genes",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2254,
  "fields": {
    "action_time": "2025-06-05T11:19:29.437Z",
    "user": 2,
    "content_type": 14,
    "object_id": "374",
    "object_repr": "Levine, J.D., Casey, C.I., Kalderon, D.D. and Jackson, F.R., 1994. Altered circadian pacemaker functions and cyclic AMP rhythms in the Drosophila learning mutant dunce. Neuron, 13(4), pp.967-974.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2255,
  "fields": {
    "action_time": "2025-06-05T11:19:50.595Z",
    "user": 2,
    "content_type": 14,
    "object_id": "375",
    "object_repr": "Ono, D., Wang, H., Hung, C.J., Wang, H.T., Kon, N., Yamanaka, A., Li, Y. and Sugiyama, T., 2023. Network-driven intracellular cAMP coordinates circadian rhythm in the suprachiasmatic nucleus. Science ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2256,
  "fields": {
    "action_time": "2025-06-05T11:20:09.694Z",
    "user": 2,
    "content_type": 14,
    "object_id": "376",
    "object_repr": "O'Neill, J.S. and Reddy, A.B., 2012. The essential role of cAMP/Ca2+ signalling in mammalian circadian timekeeping.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2257,
  "fields": {
    "action_time": "2025-06-05T11:22:48.932Z",
    "user": 2,
    "content_type": 10,
    "object_id": "331",
    "object_repr": "Adenosine cyclic phosphate (cAMP)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2258,
  "fields": {
    "action_time": "2025-06-05T11:27:29.113Z",
    "user": 2,
    "content_type": 9,
    "object_id": "219",
    "object_repr": "selective MT1A receptor agonist",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2259,
  "fields": {
    "action_time": "2025-06-05T11:29:23.462Z",
    "user": 2,
    "content_type": 10,
    "object_id": "332",
    "object_repr": "Cbobnea",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2260,
  "fields": {
    "action_time": "2025-06-05T11:29:38.729Z",
    "user": 2,
    "content_type": 10,
    "object_id": "332",
    "object_repr": "CBOBNEA",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2261,
  "fields": {
    "action_time": "2025-06-05T11:33:37.722Z",
    "user": 2,
    "content_type": 14,
    "object_id": "377",
    "object_repr": "Koike, T., Hoashi, Y., Takai, T., Nakayama, M., Yukuhiro, N., Ishikawa, T., Hirai, K. and Uchikawa, O., 2011. 1, 6-Dihydro-2 H-indeno [5, 4-b] furan Derivatives: Design, Synthesis, and Pharmacological",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2262,
  "fields": {
    "action_time": "2025-06-05T11:34:26.774Z",
    "user": 2,
    "content_type": 10,
    "object_id": "333",
    "object_repr": "cyclohexylmethyl-indenofurane-ethylacetamide (CIFEA)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2263,
  "fields": {
    "action_time": "2025-06-05T11:48:59.391Z",
    "user": 2,
    "content_type": 13,
    "object_id": "216",
    "object_repr": "increases the amplitude of circadian rhythm activity in mice with corticosterone-induced depression/anxiety",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2264,
  "fields": {
    "action_time": "2025-06-05T11:49:45.094Z",
    "user": 2,
    "content_type": 14,
    "object_id": "378",
    "object_repr": "Ettaoussi, M., Sabaouni, A., Rami, M., Boutin, J.A., Delagrange, P., Renard, P., Spedding, M., Caignard, D.H., Berthelot, P. and Yous, S., 2012. Design, synthesis and pharmacological evaluation of new",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2265,
  "fields": {
    "action_time": "2025-06-05T11:53:54.636Z",
    "user": 2,
    "content_type": 10,
    "object_id": "334",
    "object_repr": "Difluoroagomelatine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2266,
  "fields": {
    "action_time": "2025-06-05T11:55:46.115Z",
    "user": 2,
    "content_type": 14,
    "object_id": "379",
    "object_repr": "Legros, C., Brasseur, C., Delagrange, P., Ducrot, P., Nosjean, O. and Boutin, J.A., 2016. Alternative radioligands for investigating the molecular pharmacology of melatonin receptors. The Journal of P",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2267,
  "fields": {
    "action_time": "2025-06-05T11:56:04.815Z",
    "user": 2,
    "content_type": 14,
    "object_id": "380",
    "object_repr": "Legros, C., Matthey, U., Grelak, T., Pedragona-Moreau, S., Hassler, W., Yous, S., Thomas, E., Suzenet, F., Folleas, B., Lefoulon, F. and Berthelot, P., 2013. New radioligands for describing the molecu",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2268,
  "fields": {
    "action_time": "2025-06-05T11:57:26.953Z",
    "user": 2,
    "content_type": 10,
    "object_id": "335",
    "object_repr": "(125I)Div880",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2269,
  "fields": {
    "action_time": "2025-06-05T12:01:29.957Z",
    "user": 2,
    "content_type": 14,
    "object_id": "381",
    "object_repr": "Koike, T., Takai, T., Hoashi, Y., Nakayama, M., Kosugi, Y., Nakashima, M., Yoshikubo, S.I., Hirai, K. and Uchikawa, O., 2011. Synthesis of a novel series of tricyclic dihydrofuran derivatives: discove",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2270,
  "fields": {
    "action_time": "2025-06-05T12:01:54.347Z",
    "user": 2,
    "content_type": 13,
    "object_id": "217",
    "object_repr": "sleep-promoting action in freely moving cats",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2271,
  "fields": {
    "action_time": "2025-06-05T12:03:49.315Z",
    "user": 2,
    "content_type": 10,
    "object_id": "336",
    "object_repr": "EFPPEA",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2272,
  "fields": {
    "action_time": "2025-06-05T12:06:45.641Z",
    "user": 2,
    "content_type": 9,
    "object_id": "220",
    "object_repr": "FPR2 full agonist",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2273,
  "fields": {
    "action_time": "2025-06-05T12:06:57.994Z",
    "user": 2,
    "content_type": 9,
    "object_id": "221",
    "object_repr": "FPR1 full agonist",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2274,
  "fields": {
    "action_time": "2025-06-05T12:07:16.873Z",
    "user": 2,
    "content_type": 12,
    "object_id": "142",
    "object_repr": "FPR2",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2275,
  "fields": {
    "action_time": "2025-06-05T12:07:35.741Z",
    "user": 2,
    "content_type": 12,
    "object_id": "143",
    "object_repr": "FPR1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2276,
  "fields": {
    "action_time": "2025-06-05T12:13:32.492Z",
    "user": 2,
    "content_type": 13,
    "object_id": "218",
    "object_repr": "neutrophil activation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2277,
  "fields": {
    "action_time": "2025-06-05T12:13:48.447Z",
    "user": 2,
    "content_type": 13,
    "object_id": "219",
    "object_repr": "chemotaxis stimulation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2278,
  "fields": {
    "action_time": "2025-06-05T12:14:02.759Z",
    "user": 2,
    "content_type": 13,
    "object_id": "220",
    "object_repr": "activates G protein-coupled receptors, specifically FPR1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2279,
  "fields": {
    "action_time": "2025-06-05T12:14:10.008Z",
    "user": 2,
    "content_type": 13,
    "object_id": "221",
    "object_repr": "actin polymerization",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2280,
  "fields": {
    "action_time": "2025-06-05T12:14:22.419Z",
    "user": 2,
    "content_type": 13,
    "object_id": "222",
    "object_repr": "oxidative burst",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2281,
  "fields": {
    "action_time": "2025-06-05T12:20:29.527Z",
    "user": 2,
    "content_type": 13,
    "object_id": "223",
    "object_repr": "Affects circadia nchemotaxis and phagocytosis",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2282,
  "fields": {
    "action_time": "2025-06-05T12:22:49.719Z",
    "user": 2,
    "content_type": 13,
    "object_id": "224",
    "object_repr": "fMLP-mediated activation of human eosinophils is influenced by the circadian clock",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2283,
  "fields": {
    "action_time": "2025-06-05T12:23:52.622Z",
    "user": 2,
    "content_type": 14,
    "object_id": "382",
    "object_repr": "Baumann, A., Feilhauer, K., Bischoff, S.C., Froy, O. and Lorentz, A., 2015. IgE-dependent activation of human mast cells and fMLP-mediated activation of human eosinophils is controlled by the circadia",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2284,
  "fields": {
    "action_time": "2025-06-05T12:23:55.832Z",
    "user": 2,
    "content_type": 10,
    "object_id": "337",
    "object_repr": "fMet-Leu-Phe",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2285,
  "fields": {
    "action_time": "2025-06-05T12:29:43.175Z",
    "user": 2,
    "content_type": 13,
    "object_id": "225",
    "object_repr": "Normalization of circadian rhythms in elderly, blind and people with social jet lag.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2286,
  "fields": {
    "action_time": "2025-06-05T12:34:37.707Z",
    "user": 2,
    "content_type": 9,
    "object_id": "222",
    "object_repr": "MT1 antagonist",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2287,
  "fields": {
    "action_time": "2025-06-05T12:35:10.844Z",
    "user": 2,
    "content_type": 14,
    "object_id": "383",
    "object_repr": "Faust, R., Garratt, P.J., Jones, R., Yeh, L.K., Tsotinis, A., Panoussopoulou, M., Calogeropoulou, T., Teh, M.T. and Sugden, D., 2000. Mapping the melatonin receptor. 6. Melatonin agonists and antagoni",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2288,
  "fields": {
    "action_time": "2025-06-05T12:35:38.523Z",
    "user": 2,
    "content_type": 14,
    "object_id": "384",
    "object_repr": "Sugden, D., Yeh, L.K. and Teh, M.T., 1999. Design of subtype selective melatonin receptor agonists and antagonists. Reproduction Nutrition Development, 39(3), pp.335-344.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2289,
  "fields": {
    "action_time": "2025-06-05T12:36:02.463Z",
    "user": 2,
    "content_type": 10,
    "object_id": "338",
    "object_repr": "K185 (K-185)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2290,
  "fields": {
    "action_time": "2025-06-09T10:31:51.063Z",
    "user": 2,
    "content_type": 14,
    "object_id": "385",
    "object_repr": "Jockers R, Delagrange P, Dubocovich ML, Markus RP, Renault N, Tosini G, Cecon E, Zlotos DP. Update on melatonin receptors: IUPHAR Review 20. Br J Pharmacol. 2016 Sep;173(18):2702-25.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2291,
  "fields": {
    "action_time": "2025-06-09T10:32:23.946Z",
    "user": 2,
    "content_type": 14,
    "object_id": "386",
    "object_repr": "Jockers R, Delagrange P, Dubocovich ML, Markus RP, Renault N, Tosini G, Cecon E, Zlotos DP. Update on melatonin receptors: IUPHAR Review 20. Br J Pharmacol. 2016 Sep;173(18):2702-25.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2292,
  "fields": {
    "action_time": "2025-06-09T10:32:45.461Z",
    "user": 2,
    "content_type": 14,
    "object_id": "387",
    "object_repr": "Jockers R, Delagrange P, Dubocovich ML, Markus RP, Renault N, Tosini G, Cecon E, Zlotos DP. Update on melatonin receptors: IUPHAR Review 20. Br J Pharmacol. 2016 Sep;173(18):2702-25.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2293,
  "fields": {
    "action_time": "2025-06-09T10:35:22.997Z",
    "user": 2,
    "content_type": 13,
    "object_id": "226",
    "object_repr": "Circadian rhythm modulation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2294,
  "fields": {
    "action_time": "2025-06-09T10:51:47.498Z",
    "user": 2,
    "content_type": 9,
    "object_id": "223",
    "object_repr": "Melatonin receptor binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2295,
  "fields": {
    "action_time": "2025-06-09T10:52:09.943Z",
    "user": 2,
    "content_type": 13,
    "object_id": "227",
    "object_repr": "Circadian rhythm modulation",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2296,
  "fields": {
    "action_time": "2025-06-09T10:52:18.963Z",
    "user": 2,
    "content_type": 10,
    "object_id": "339",
    "object_repr": "N‐acetyl‐serotonin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2297,
  "fields": {
    "action_time": "2025-06-20T12:28:43.280Z",
    "user": 2,
    "content_type": 14,
    "object_id": "386",
    "object_repr": "Jockers R, Delagrange P, Dubocovich ML, Markus RP, Renault N, Tosini G, Cecon E, Zlotos DP. Update on melatonin receptors: IUPHAR Review 20. Br J Pharmacol. 2016 Sep;173(18):2702-25.",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2298,
  "fields": {
    "action_time": "2025-06-20T12:30:27.821Z",
    "user": 2,
    "content_type": 14,
    "object_id": "386",
    "object_repr": "Jockers R, Delagrange P, Dubocovich ML, Markus RP, Renault N, Tosini G, Cecon E, Zlotos DP. Update on melatonin receptors: IUPHAR Review 20. Br J Pharmacol. 2016 Sep;173(18):2702-25.",
    "action_flag": 3,
    "change_message": ""
  }
},
{
  "model": "admin.logentry",
  "pk": 2299,
  "fields": {
    "action_time": "2025-06-20T12:30:27.821Z",
    "user": 2,
    "content_type": 14,
    "object_id": "385",
    "object_repr": "Jockers R, Delagrange P, Dubocovich ML, Markus RP, Renault N, Tosini G, Cecon E, Zlotos DP. Update on melatonin receptors: IUPHAR Review 20. Br J Pharmacol. 2016 Sep;173(18):2702-25.",
    "action_flag": 3,
    "change_message": ""
  }
},
{
  "model": "admin.logentry",
  "pk": 2300,
  "fields": {
    "action_time": "2025-06-20T12:30:44.544Z",
    "user": 2,
    "content_type": 10,
    "object_id": "339",
    "object_repr": "N‐acetyl‐serotonin",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2301,
  "fields": {
    "action_time": "2025-06-20T12:48:41.898Z",
    "user": 2,
    "content_type": 14,
    "object_id": "388",
    "object_repr": "Koczor, C.A., Ludlow, I., Hight, R.S., Jiao, Z., Fields, E., Ludaway, T., Russ, R., Torres, R.A. and Lewis, W., 2015. Ecstasy (MDMA) alters cardiac gene expression and DNA methylation: implications fo",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2302,
  "fields": {
    "action_time": "2025-06-20T12:52:24.094Z",
    "user": 2,
    "content_type": 9,
    "object_id": "224",
    "object_repr": "Synaptic vesicular amine transporter interaction",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2303,
  "fields": {
    "action_time": "2025-06-20T12:52:30.100Z",
    "user": 2,
    "content_type": 9,
    "object_id": "225",
    "object_repr": "Sodium-dependent noradrenaline transporter",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2304,
  "fields": {
    "action_time": "2025-06-20T12:52:44.635Z",
    "user": 2,
    "content_type": 9,
    "object_id": "226",
    "object_repr": "Sodium-dependent serotonin transporter",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2305,
  "fields": {
    "action_time": "2025-06-20T12:53:07.657Z",
    "user": 2,
    "content_type": 9,
    "object_id": "227",
    "object_repr": "5-hydroxytryptamine receptor 2C binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2306,
  "fields": {
    "action_time": "2025-06-20T12:53:19.109Z",
    "user": 2,
    "content_type": 9,
    "object_id": "228",
    "object_repr": "5-hydroxytryptamine receptor 2A binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2307,
  "fields": {
    "action_time": "2025-06-20T12:53:30.941Z",
    "user": 2,
    "content_type": 9,
    "object_id": "229",
    "object_repr": "5-hydroxytryptamine receptor 2B binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2308,
  "fields": {
    "action_time": "2025-06-20T12:53:43.286Z",
    "user": 2,
    "content_type": 9,
    "object_id": "230",
    "object_repr": "Sodium-dependent dopamine transporter binding",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2309,
  "fields": {
    "action_time": "2025-06-20T12:54:46.345Z",
    "user": 2,
    "content_type": 12,
    "object_id": "144",
    "object_repr": "SLC18A2",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2310,
  "fields": {
    "action_time": "2025-06-20T12:55:10.633Z",
    "user": 2,
    "content_type": 12,
    "object_id": "145",
    "object_repr": "SLC6A2",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2311,
  "fields": {
    "action_time": "2025-06-20T12:55:28.342Z",
    "user": 2,
    "content_type": 12,
    "object_id": "146",
    "object_repr": "SLC6A4",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2312,
  "fields": {
    "action_time": "2025-06-20T12:55:50.534Z",
    "user": 2,
    "content_type": 12,
    "object_id": "147",
    "object_repr": "HTR2C",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2313,
  "fields": {
    "action_time": "2025-06-20T12:56:09.082Z",
    "user": 2,
    "content_type": 12,
    "object_id": "148",
    "object_repr": "HTR2A",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2314,
  "fields": {
    "action_time": "2025-06-20T12:56:34.318Z",
    "user": 2,
    "content_type": 12,
    "object_id": "149",
    "object_repr": "HTR2B",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2315,
  "fields": {
    "action_time": "2025-06-20T12:56:52.170Z",
    "user": 2,
    "content_type": 12,
    "object_id": "150",
    "object_repr": "SLC6A3",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2316,
  "fields": {
    "action_time": "2025-06-20T12:57:43.597Z",
    "user": 2,
    "content_type": 14,
    "object_id": "389",
    "object_repr": "Colbron, S., Jones, M. and Biello, S.M., 2002. MDMA alters the response of the circadian clock to a photic and non-photic stimulus. Brain research, 956(1), pp.45-52.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2317,
  "fields": {
    "action_time": "2025-06-20T12:57:53.131Z",
    "user": 2,
    "content_type": 13,
    "object_id": "228",
    "object_repr": "alters the response of the circadian clock to a photic and non-photic stimulus",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2318,
  "fields": {
    "action_time": "2025-06-20T12:58:22.974Z",
    "user": 2,
    "content_type": 10,
    "object_id": "340",
    "object_repr": "3,4-Methylenedioxymethamphetamine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2319,
  "fields": {
    "action_time": "2025-06-20T13:06:34.950Z",
    "user": 2,
    "content_type": 14,
    "object_id": "390",
    "object_repr": "Mitchell, E.J., Brett, R.R., Armstrong, J.D., Sillito, R.R. and Pratt, J.A., 2020. Temporal dissociation of phencyclidine: Induced locomotor and social alterations in rats using an automated homecage ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2320,
  "fields": {
    "action_time": "2025-06-20T13:10:34.113Z",
    "user": 2,
    "content_type": 14,
    "object_id": "391",
    "object_repr": "McCann, U.D. and Ricaurte, G.A., 2007. Effects of (±) 3, 4‐Methylenedioxymethamphetamine (MDMA) on Sleep and Circadian Rhythms. The Scientific World Journal, 7(1), pp.231-238.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2321,
  "fields": {
    "action_time": "2025-06-20T13:10:45.121Z",
    "user": 2,
    "content_type": 10,
    "object_id": "340",
    "object_repr": "3,4-Methylenedioxymethamphetamine",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Articles\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2322,
  "fields": {
    "action_time": "2025-06-20T13:18:01.450Z",
    "user": 2,
    "content_type": 9,
    "object_id": "231",
    "object_repr": "Glutamate receptor ionotropic, NMDA 3A antagonist",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2323,
  "fields": {
    "action_time": "2025-06-20T13:18:07.778Z",
    "user": 2,
    "content_type": 9,
    "object_id": "232",
    "object_repr": "Glutamate receptor ionotropic, NMDA 2A",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2324,
  "fields": {
    "action_time": "2025-06-20T13:18:17.381Z",
    "user": 2,
    "content_type": 9,
    "object_id": "233",
    "object_repr": "Glutamate receptor ionotropic, NMDA 2B",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2325,
  "fields": {
    "action_time": "2025-06-20T13:18:24.466Z",
    "user": 2,
    "content_type": 9,
    "object_id": "234",
    "object_repr": "Glutamate receptor ionotropic, NMDA 1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2326,
  "fields": {
    "action_time": "2025-06-20T13:18:30.635Z",
    "user": 2,
    "content_type": 9,
    "object_id": "235",
    "object_repr": "USigma non-opioid intracellular receptor 1",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2327,
  "fields": {
    "action_time": "2025-06-20T13:19:49.637Z",
    "user": 2,
    "content_type": 13,
    "object_id": "229",
    "object_repr": "Disrupts circadian rhtyhms, depressant",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2328,
  "fields": {
    "action_time": "2025-06-20T13:19:56.220Z",
    "user": 2,
    "content_type": 10,
    "object_id": "341",
    "object_repr": "Phencyclidine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2329,
  "fields": {
    "action_time": "2025-06-20T13:20:39.439Z",
    "user": 2,
    "content_type": 10,
    "object_id": "341",
    "object_repr": "Phencyclidine (PCP)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Gname\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2330,
  "fields": {
    "action_time": "2025-06-20T13:22:07.667Z",
    "user": 2,
    "content_type": 10,
    "object_id": "341",
    "object_repr": "Phencyclidine (PCP)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2331,
  "fields": {
    "action_time": "2025-08-10T21:16:58.040Z",
    "user": 2,
    "content_type": 14,
    "object_id": "392",
    "object_repr": "Lee, S., Sim, Y., Lee, M., Choi, Y., Lim, J.Y., Lee, J.H. and Kim, E., 2025. Riboflavin as a circadian modulator mitigates D-galactose-induced muscle senescence via oxidative stress and mitochondrial ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2332,
  "fields": {
    "action_time": "2025-08-10T21:20:00.933Z",
    "user": 2,
    "content_type": 9,
    "object_id": "236",
    "object_repr": "Restores oscillations of circadian genes",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2333,
  "fields": {
    "action_time": "2025-08-10T21:21:29.025Z",
    "user": 2,
    "content_type": 13,
    "object_id": "230",
    "object_repr": "restored the circadian oscillations of differentiation-related genes and core clock genes that were reduced by D-galactose",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2334,
  "fields": {
    "action_time": "2025-08-10T21:21:33.935Z",
    "user": 2,
    "content_type": 10,
    "object_id": "342",
    "object_repr": "Riboflavin",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2335,
  "fields": {
    "action_time": "2025-08-27T20:48:54.718Z",
    "user": 2,
    "content_type": 14,
    "object_id": "393",
    "object_repr": "Lee, J., Kim, J.Y., Lee, J.H. and Lee, K.H., 2025. Protocatechuic acid modulates the circadian rhythm of keratinocytes and maintains skin barrier integrity. Molecular Biology Reports, 52(1), p.765.",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2336,
  "fields": {
    "action_time": "2025-08-27T20:53:59.424Z",
    "user": 2,
    "content_type": 13,
    "object_id": "231",
    "object_repr": "reduced reactive oxygen species (ROS) levels and upregulated antioxidant enzymes",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2337,
  "fields": {
    "action_time": "2025-08-27T20:54:21.414Z",
    "user": 2,
    "content_type": 13,
    "object_id": "232",
    "object_repr": "promoted skin barrier integrity by increasing structural protein and ceramide-related gene expression",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2338,
  "fields": {
    "action_time": "2025-08-27T20:54:44.896Z",
    "user": 2,
    "content_type": 13,
    "object_id": "233",
    "object_repr": "enhanced cellular longevity markers, such as cyclin-dependent kinase inhibitor 1B (CDKN1B) and telomerase reverse transcriptase (TERT)",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2339,
  "fields": {
    "action_time": "2025-08-27T20:56:25.071Z",
    "user": 2,
    "content_type": 10,
    "object_id": "343",
    "object_repr": "Protocatechuic Acid",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2340,
  "fields": {
    "action_time": "2025-08-27T21:07:37.723Z",
    "user": 2,
    "content_type": 13,
    "object_id": "234",
    "object_repr": "causes instability in the pulse period and a slight reduction of amplitude in cyclic PER2::LUC expression",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2341,
  "fields": {
    "action_time": "2025-08-27T21:08:13.140Z",
    "user": 2,
    "content_type": 13,
    "object_id": "235",
    "object_repr": "Blockade of gap junctions uncouples PER2::LUC-expressing cells, in terms of phase transition, which weakens synchrony among individual cellular rhythm",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2342,
  "fields": {
    "action_time": "2025-08-27T21:09:05.436Z",
    "user": 2,
    "content_type": 9,
    "object_id": "237",
    "object_repr": "Per2 expression alteration",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2343,
  "fields": {
    "action_time": "2025-08-27T21:09:45.300Z",
    "user": 2,
    "content_type": 14,
    "object_id": "394",
    "object_repr": "Koo, J., Choe, H.K., Kim, H.D., Chun, S.K., Son, G.H. and Kim, K., 2015. Effect of mefloquine, a gap junction blocker, on circadian period2 gene oscillation in the mouse suprachiasmatic nucleus ex viv",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2344,
  "fields": {
    "action_time": "2025-08-27T21:09:49.915Z",
    "user": 2,
    "content_type": 10,
    "object_id": "344",
    "object_repr": "Mefloquine",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2345,
  "fields": {
    "action_time": "2025-08-27T21:10:42.049Z",
    "user": 2,
    "content_type": 10,
    "object_id": "335",
    "object_repr": "(125I)Div880",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Description\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2346,
  "fields": {
    "action_time": "2025-09-04T06:42:15.780Z",
    "user": 2,
    "content_type": 13,
    "object_id": "236",
    "object_repr": "lengthens the period of the U2-OS circadian rhythm",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2347,
  "fields": {
    "action_time": "2025-09-04T06:42:34.335Z",
    "user": 2,
    "content_type": 13,
    "object_id": "237",
    "object_repr": "decreases the transcription of clock-controlled genes in a concentration-dependent manner",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2348,
  "fields": {
    "action_time": "2025-09-04T06:44:20.900Z",
    "user": 2,
    "content_type": 9,
    "object_id": "238",
    "object_repr": "binds CRY1 ubiquitination site",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2349,
  "fields": {
    "action_time": "2025-09-04T06:46:15.508Z",
    "user": 2,
    "content_type": 14,
    "object_id": "395",
    "object_repr": "Gül, Z.M., Aydoğan, S., Sürme, S., Efendi, S.N.H., Özcan, O., Uyanık, E., Baris, I., Gül, S. and Kavakli, I.H., 2025. M54 selectively stabilizes the circadian clock component of CRY1 and enhances the ",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2350,
  "fields": {
    "action_time": "2025-09-04T06:46:48.626Z",
    "user": 2,
    "content_type": 10,
    "object_id": "345",
    "object_repr": "M54",
    "action_flag": 1,
    "change_message": "[{\"added\": {}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2351,
  "fields": {
    "action_time": "2025-09-27T08:38:47.432Z",
    "user": 2,
    "content_type": 10,
    "object_id": "336",
    "object_repr": "EFPPEA",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Pubchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2352,
  "fields": {
    "action_time": "2025-09-27T08:41:06.091Z",
    "user": 2,
    "content_type": 10,
    "object_id": "332",
    "object_repr": "CBOBNEA",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Pubchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2353,
  "fields": {
    "action_time": "2025-09-27T08:46:39.564Z",
    "user": 2,
    "content_type": 10,
    "object_id": "320",
    "object_repr": "TW68",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Pubchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2354,
  "fields": {
    "action_time": "2025-09-27T08:48:28.114Z",
    "user": 2,
    "content_type": 10,
    "object_id": "318",
    "object_repr": "Salicilic acid",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Pubchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2355,
  "fields": {
    "action_time": "2025-09-27T08:49:23.763Z",
    "user": 2,
    "content_type": 10,
    "object_id": "318",
    "object_repr": "Salicilic acid",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Pubchem\"]}}]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2356,
  "fields": {
    "action_time": "2025-09-27T08:50:51.676Z",
    "user": 2,
    "content_type": 10,
    "object_id": "314",
    "object_repr": "Curcumin",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2357,
  "fields": {
    "action_time": "2025-09-27T08:57:04.944Z",
    "user": 2,
    "content_type": 10,
    "object_id": "296",
    "object_repr": "NCC007",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2358,
  "fields": {
    "action_time": "2025-09-27T09:12:12.424Z",
    "user": 2,
    "content_type": 10,
    "object_id": "287",
    "object_repr": "A190",
    "action_flag": 2,
    "change_message": "[]"
  }
},
{
  "model": "admin.logentry",
  "pk": 2359,
  "fields": {
    "action_time": "2025-09-29T09:53:46.948Z",
    "user": 2,
    "content_type": 10,
    "object_id": "269",
    "object_repr": "TU-892 (5-(3,4-dichlorophenyl)-1-phenyl-1,7-dihydro-4H-pyrazolo[3,4-d] pyrimidine-4,6(5H)-dione)",
    "action_flag": 2,
    "change_message": "[{\"changed\": {\"fields\": [\"Pubchem\"]}}]"
  }
},
{
  "model": "auth.permission",
  "pk": 1,
  "fields": {
    "name": "Can add log entry",
    "content_type": 1,
    "codename": "add_logentry"
  }
},
{
  "model": "auth.permission",
  "pk": 2,
  "fields": {
    "name": "Can change log entry",
    "content_type": 1,
    "codename": "change_logentry"
  }
},
{
  "model": "auth.permission",
  "pk": 3,
  "fields": {
    "name": "Can delete log entry",
    "content_type": 1,
    "codename": "delete_logentry"
  }
},
{
  "model": "auth.permission",
  "pk": 4,
  "fields": {
    "name": "Can view log entry",
    "content_type": 1,
    "codename": "view_logentry"
  }
},
{
  "model": "auth.permission",
  "pk": 5,
  "fields": {
    "name": "Can add permission",
    "content_type": 2,
    "codename": "add_permission"
  }
},
{
  "model": "auth.permission",
  "pk": 6,
  "fields": {
    "name": "Can change permission",
    "content_type": 2,
    "codename": "change_permission"
  }
},
{
  "model": "auth.permission",
  "pk": 7,
  "fields": {
    "name": "Can delete permission",
    "content_type": 2,
    "codename": "delete_permission"
  }
},
{
  "model": "auth.permission",
  "pk": 8,
  "fields": {
    "name": "Can view permission",
    "content_type": 2,
    "codename": "view_permission"
  }
},
{
  "model": "auth.permission",
  "pk": 9,
  "fields": {
    "name": "Can add group",
    "content_type": 3,
    "codename": "add_group"
  }
},
{
  "model": "auth.permission",
  "pk": 10,
  "fields": {
    "name": "Can change group",
    "content_type": 3,
    "codename": "change_group"
  }
},
{
  "model": "auth.permission",
  "pk": 11,
  "fields": {
    "name": "Can delete group",
    "content_type": 3,
    "codename": "delete_group"
  }
},
{
  "model": "auth.permission",
  "pk": 12,
  "fields": {
    "name": "Can view group",
    "content_type": 3,
    "codename": "view_group"
  }
},
{
  "model": "auth.permission",
  "pk": 13,
  "fields": {
    "name": "Can add user",
    "content_type": 4,
    "codename": "add_user"
  }
},
{
  "model": "auth.permission",
  "pk": 14,
  "fields": {
    "name": "Can change user",
    "content_type": 4,
    "codename": "change_user"
  }
},
{
  "model": "auth.permission",
  "pk": 15,
  "fields": {
    "name": "Can delete user",
    "content_type": 4,
    "codename": "delete_user"
  }
},
{
  "model": "auth.permission",
  "pk": 16,
  "fields": {
    "name": "Can view user",
    "content_type": 4,
    "codename": "view_user"
  }
},
{
  "model": "auth.permission",
  "pk": 17,
  "fields": {
    "name": "Can add content type",
    "content_type": 5,
    "codename": "add_contenttype"
  }
},
{
  "model": "auth.permission",
  "pk": 18,
  "fields": {
    "name": "Can change content type",
    "content_type": 5,
    "codename": "change_contenttype"
  }
},
{
  "model": "auth.permission",
  "pk": 19,
  "fields": {
    "name": "Can delete content type",
    "content_type": 5,
    "codename": "delete_contenttype"
  }
},
{
  "model": "auth.permission",
  "pk": 20,
  "fields": {
    "name": "Can view content type",
    "content_type": 5,
    "codename": "view_contenttype"
  }
},
{
  "model": "auth.permission",
  "pk": 21,
  "fields": {
    "name": "Can add session",
    "content_type": 6,
    "codename": "add_session"
  }
},
{
  "model": "auth.permission",
  "pk": 22,
  "fields": {
    "name": "Can change session",
    "content_type": 6,
    "codename": "change_session"
  }
},
{
  "model": "auth.permission",
  "pk": 23,
  "fields": {
    "name": "Can delete session",
    "content_type": 6,
    "codename": "delete_session"
  }
},
{
  "model": "auth.permission",
  "pk": 24,
  "fields": {
    "name": "Can view session",
    "content_type": 6,
    "codename": "view_session"
  }
},
{
  "model": "auth.permission",
  "pk": 25,
  "fields": {
    "name": "Can add bioclass",
    "content_type": 7,
    "codename": "add_bioclass"
  }
},
{
  "model": "auth.permission",
  "pk": 26,
  "fields": {
    "name": "Can change bioclass",
    "content_type": 7,
    "codename": "change_bioclass"
  }
},
{
  "model": "auth.permission",
  "pk": 27,
  "fields": {
    "name": "Can delete bioclass",
    "content_type": 7,
    "codename": "delete_bioclass"
  }
},
{
  "model": "auth.permission",
  "pk": 28,
  "fields": {
    "name": "Can view bioclass",
    "content_type": 7,
    "codename": "view_bioclass"
  }
},
{
  "model": "auth.permission",
  "pk": 29,
  "fields": {
    "name": "Can add clinicaltrials",
    "content_type": 8,
    "codename": "add_clinicaltrials"
  }
},
{
  "model": "auth.permission",
  "pk": 30,
  "fields": {
    "name": "Can change clinicaltrials",
    "content_type": 8,
    "codename": "change_clinicaltrials"
  }
},
{
  "model": "auth.permission",
  "pk": 31,
  "fields": {
    "name": "Can delete clinicaltrials",
    "content_type": 8,
    "codename": "delete_clinicaltrials"
  }
},
{
  "model": "auth.permission",
  "pk": 32,
  "fields": {
    "name": "Can view clinicaltrials",
    "content_type": 8,
    "codename": "view_clinicaltrials"
  }
},
{
  "model": "auth.permission",
  "pk": 33,
  "fields": {
    "name": "Can add mechanism",
    "content_type": 9,
    "codename": "add_mechanism"
  }
},
{
  "model": "auth.permission",
  "pk": 34,
  "fields": {
    "name": "Can change mechanism",
    "content_type": 9,
    "codename": "change_mechanism"
  }
},
{
  "model": "auth.permission",
  "pk": 35,
  "fields": {
    "name": "Can delete mechanism",
    "content_type": 9,
    "codename": "delete_mechanism"
  }
},
{
  "model": "auth.permission",
  "pk": 36,
  "fields": {
    "name": "Can view mechanism",
    "content_type": 9,
    "codename": "view_mechanism"
  }
},
{
  "model": "auth.permission",
  "pk": 37,
  "fields": {
    "name": "Can add chronobiotic",
    "content_type": 10,
    "codename": "add_chronobiotic"
  }
},
{
  "model": "auth.permission",
  "pk": 38,
  "fields": {
    "name": "Can change chronobiotic",
    "content_type": 10,
    "codename": "change_chronobiotic"
  }
},
{
  "model": "auth.permission",
  "pk": 39,
  "fields": {
    "name": "Can delete chronobiotic",
    "content_type": 10,
    "codename": "delete_chronobiotic"
  }
},
{
  "model": "auth.permission",
  "pk": 40,
  "fields": {
    "name": "Can view chronobiotic",
    "content_type": 10,
    "codename": "view_chronobiotic"
  }
},
{
  "model": "auth.permission",
  "pk": 41,
  "fields": {
    "name": "Can add synonyms",
    "content_type": 11,
    "codename": "add_synonyms"
  }
},
{
  "model": "auth.permission",
  "pk": 42,
  "fields": {
    "name": "Can change synonyms",
    "content_type": 11,
    "codename": "change_synonyms"
  }
},
{
  "model": "auth.permission",
  "pk": 43,
  "fields": {
    "name": "Can delete synonyms",
    "content_type": 11,
    "codename": "delete_synonyms"
  }
},
{
  "model": "auth.permission",
  "pk": 44,
  "fields": {
    "name": "Can view synonyms",
    "content_type": 11,
    "codename": "view_synonyms"
  }
},
{
  "model": "auth.permission",
  "pk": 45,
  "fields": {
    "name": "Can add targets",
    "content_type": 12,
    "codename": "add_targets"
  }
},
{
  "model": "auth.permission",
  "pk": 46,
  "fields": {
    "name": "Can change targets",
    "content_type": 12,
    "codename": "change_targets"
  }
},
{
  "model": "auth.permission",
  "pk": 47,
  "fields": {
    "name": "Can delete targets",
    "content_type": 12,
    "codename": "delete_targets"
  }
},
{
  "model": "auth.permission",
  "pk": 48,
  "fields": {
    "name": "Can view targets",
    "content_type": 12,
    "codename": "view_targets"
  }
},
{
  "model": "auth.permission",
  "pk": 49,
  "fields": {
    "name": "Can add effect",
    "content_type": 13,
    "codename": "add_effect"
  }
},
{
  "model": "auth.permission",
  "pk": 50,
  "fields": {
    "name": "Can change effect",
    "content_type": 13,
    "codename": "change_effect"
  }
},
{
  "model": "auth.permission",
  "pk": 51,
  "fields": {
    "name": "Can delete effect",
    "content_type": 13,
    "codename": "delete_effect"
  }
},
{
  "model": "auth.permission",
  "pk": 52,
  "fields": {
    "name": "Can view effect",
    "content_type": 13,
    "codename": "view_effect"
  }
},
{
  "model": "auth.permission",
  "pk": 53,
  "fields": {
    "name": "Can add articles",
    "content_type": 14,
    "codename": "add_articles"
  }
},
{
  "model": "auth.permission",
  "pk": 54,
  "fields": {
    "name": "Can change articles",
    "content_type": 14,
    "codename": "change_articles"
  }
},
{
  "model": "auth.permission",
  "pk": 55,
  "fields": {
    "name": "Can delete articles",
    "content_type": 14,
    "codename": "delete_articles"
  }
},
{
  "model": "auth.permission",
  "pk": 56,
  "fields": {
    "name": "Can view articles",
    "content_type": 14,
    "codename": "view_articles"
  }
},
{
  "model": "auth.user",
  "pk": 1,
  "fields": {
    "password": "pbkdf2_sha256$870000$BqPKYUpOY04oHK5N2l3GzO$D3zjMUho83oke/gkeHKgQAzIp3OJibmhLD4pkVVUiNw=",
    "last_login": "2025-11-02T12:47:27.402Z",
    "is_superuser": true,
    "username": "solar",
    "first_name": "",
    "last_name": "",
    "email": "",
    "is_staff": true,
    "is_active": true,
    "date_joined": "2024-11-19T07:53:03.440Z",
    "groups": [],
    "user_permissions": []
  }
},
{
  "model": "auth.user",
  "pk": 2,
  "fields": {
    "password": "pbkdf2_sha256$870000$JIVR6SQMCUwIW7NA4bG7Oe$ccMAxyzgHok3MRItS+9p5VuoakI9ZYBlyNkwssoiMX4=",
    "last_login": "2025-10-20T06:04:09.137Z",
    "is_superuser": true,
    "username": "beta",
    "first_name": "",
    "last_name": "",
    "email": "",
    "is_staff": true,
    "is_active": true,
    "date_joined": "2025-02-04T14:03:53.855Z",
    "groups": [],
    "user_permissions": []
  }
},
{
  "model": "contenttypes.contenttype",
  "pk": 1,
  "fields": {
    "app_label": "admin",
    "model": "logentry"
  }
},
{
  "model": "contenttypes.contenttype",
  "pk": 2,
  "fields": {
    "app_label": "auth",
    "model": "permission"
  }
},
{
  "model": "contenttypes.contenttype",
  "pk": 3,
  "fields": {
    "app_label": "auth",
    "model": "group"
  }
},
{
  "model": "contenttypes.contenttype",
  "pk": 4,
  "fields": {
    "app_label": "auth",
    "model": "user"
  }
},
{
  "model": "contenttypes.contenttype",
  "pk": 5,
  "fields": {
    "app_label": "contenttypes",
    "model": "contenttype"
  }
},
{
  "model": "contenttypes.contenttype",
  "pk": 6,
  "fields": {
    "app_label": "sessions",
    "model": "session"
  }
},
{
  "model": "contenttypes.contenttype",
  "pk": 7,
  "fields": {
    "app_label": "main",
    "model": "bioclass"
  }
},
{
  "model": "contenttypes.contenttype",
  "pk": 8,
  "fields": {
    "app_label": "main",
    "model": "clinicaltrials"
  }
},
{
  "model": "contenttypes.contenttype",
  "pk": 9,
  "fields": {
    "app_label": "main",
    "model": "mechanism"
  }
},
{
  "model": "contenttypes.contenttype",
  "pk": 10,
  "fields": {
    "app_label": "main",
    "model": "chronobiotic"
  }
},
{
  "model": "contenttypes.contenttype",
  "pk": 11,
  "fields": {
    "app_label": "main",
    "model": "synonyms"
  }
},
{
  "model": "contenttypes.contenttype",
  "pk": 12,
  "fields": {
    "app_label": "main",
    "model": "targets"
  }
},
{
  "model": "contenttypes.contenttype",
  "pk": 13,
  "fields": {
    "app_label": "main",
    "model": "effect"
  }
},
{
  "model": "contenttypes.contenttype",
  "pk": 14,
  "fields": {
    "app_label": "main",
    "model": "articles"
  }
},
{
  "model": "sessions.session",
  "pk": "09u12ic166389b83fm9yaigv8q9gl451",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD6dm:nFMTGKe4VENwuL8o0Oe5Kg-yzl2XW0zQTBIm_gr4ImM",
    "expire_date": "2025-11-09T19:42:58.173Z"
  }
},
{
  "model": "sessions.session",
  "pk": "0u43wkfqfkdk4ytjfyfpypondrlv52nu",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uylr4:1ekviRbgTFHAcRZ3zlkT7LEwEkeE_u_rXRcwA0xTih4",
    "expire_date": "2025-10-01T06:41:26.610Z"
  }
},
{
  "model": "sessions.session",
  "pk": "0wsw5qzf3fl26qu79issb2k10oxgt5jy",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD66d:o8hyqxOBC4XDQSX7ZkmsNyDluI9p1uQgLu-h3zkNEHk",
    "expire_date": "2025-11-09T19:08:43.023Z"
  }
},
{
  "model": "sessions.session",
  "pk": "0yp91jh1jzdo70xps1pnytgbheaqljhd",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uFTEY:pHCLp5d1Azt31pUqAbBD2LiVT4TRucrvqNw9suz2YyI",
    "expire_date": "2025-05-29T07:42:26.494Z"
  }
},
{
  "model": "sessions.session",
  "pk": "1ebj8bg8zwe4ky9h2o82iu44ovxij3no",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1tvvYT:CkmETQ-XTYuQbr8xRYy1nLx9CTqrNgmVttQJUc4v8U4",
    "expire_date": "2025-04-05T09:54:13.552Z"
  }
},
{
  "model": "sessions.session",
  "pk": "1f1fn6nf94yw7r1t1w4fuk3qbqg6tep2",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uRSV1:IGdgw1zeioZWBCuYZEqOzIw5q5g2Do8ZfKFb8JXcvA4",
    "expire_date": "2025-07-01T09:20:59.889Z"
  }
},
{
  "model": "sessions.session",
  "pk": "1kn1tpww1ms1x3uzqu6xbbrh5cm57tks",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uKdAq:9HWHoZrz3ITLY_wlMOzL_RRuB1m1Py9nXd8RAMgyAs8",
    "expire_date": "2025-06-12T13:19:56.661Z"
  }
},
{
  "model": "sessions.session",
  "pk": "1zms4sli2toqi5ck3x5h4kd4i36af9ok",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vE67P:6rI1kOR47f-uL8FZkjWL7GNZSC0kShMoGTHkbWVjxmw",
    "expire_date": "2025-11-12T13:21:39.810Z"
  }
},
{
  "model": "sessions.session",
  "pk": "28hct699s2grzs0kkf8mwiq1if2mbshp",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uMjk4:WmYaUSf9E3MaaDrZtBFlm2H5DZO6smBwJOir_HVuR_o",
    "expire_date": "2025-06-18T08:45:00.631Z"
  }
},
{
  "model": "sessions.session",
  "pk": "2bps1zu4v4rjpm1x2bkfvtxc7vo8qd8d",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD4yR:LwpUzMAObPi-TxZZgrxZfOnOHt8mu25hAz6N0Q56rCM",
    "expire_date": "2025-11-09T17:56:11.844Z"
  }
},
{
  "model": "sessions.session",
  "pk": "3a6243hg0no9mtayp79xjo2vahme9tqz",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1v3AQx:uWQiXjNkNGJE1NOXus9QkVWWA4698xQHmlhBeXlHvpw",
    "expire_date": "2025-10-13T09:44:39.247Z"
  }
},
{
  "model": "sessions.session",
  "pk": "3jt57wai4flo42scxghoobab4echomdm",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD6d4:ntOyBqzLiAYCeYufdFJ6KD2SY90-OEwT4IiTgOtfogM",
    "expire_date": "2025-11-09T19:42:14.783Z"
  }
},
{
  "model": "sessions.session",
  "pk": "48efowxqrek7xwyteskvmrkjx2sces5s",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1tu41N:l9RAoE43y4my_hG5DUCc77lT3dxlFrxEHxo2l-9pLmY",
    "expire_date": "2025-03-31T06:32:21.881Z"
  }
},
{
  "model": "sessions.session",
  "pk": "4lt5p0ccxyh0irwz9ozy7jbwoht48n3t",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1tvWdf:4721X3iYc6mRbmQ7B6GUZbpt1viihyaEjLipPGDxFNo",
    "expire_date": "2025-04-04T07:17:55.186Z"
  }
},
{
  "model": "sessions.session",
  "pk": "4sgzmkv4a7235tzw0pwbafts9bpc1mbb",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD5up:1ni7gMQi3yv8Qa2olZ1nNj6gKaxPpKP9FavNqvGIOrA",
    "expire_date": "2025-11-09T18:56:31.214Z"
  }
},
{
  "model": "sessions.session",
  "pk": "4ucfwk6t601ho1o1sbjm5j5i9a7xn0x4",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD2WH:zCVQxGu4KYVPtLi3jjWExRCKk9dEQCa01i_ujjoM3HU",
    "expire_date": "2025-11-09T15:18:57.944Z"
  }
},
{
  "model": "sessions.session",
  "pk": "4xr4h5ndmoq7dj28psqlnfurw3k6gj5c",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD5Ma:yqBaFxPYqp8IwVLgwJGXoFxkVmdGS3x4UUql414ZAEg",
    "expire_date": "2025-11-09T18:21:08.917Z"
  }
},
{
  "model": "sessions.session",
  "pk": "59vrm7lzkj9ipkuh41xv9vlwlg93b3y5",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD1K6:7Yq1PriSme_ujTZqC528s2Qy8kz9w25pw4xs7-M8oso",
    "expire_date": "2025-11-09T14:02:18.332Z"
  }
},
{
  "model": "sessions.session",
  "pk": "5ejem3sstms5veglviwwuj2qoydv0flm",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vCeGh:0ps3cqnEYgciq8YFwG-WD5fN8KiGTU6fQBSAj9IN-LI",
    "expire_date": "2025-11-08T13:25:15.783Z"
  }
},
{
  "model": "sessions.session",
  "pk": "5k4f62mpfsr91yan6igsqownxsfv35yr",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1tu7ru:yYSSmcNDlR1qyzFbo7H0gleO46WTRmfoH7fKz-0tEUo",
    "expire_date": "2025-03-31T10:38:50.351Z"
  }
},
{
  "model": "sessions.session",
  "pk": "62cvn0sgt8sbp59d1oyuk2zkyq82xddf",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vCesB:W5CWBIHK0q1wg9rvF_Ss7KEM-hdKUI51HDzfor-0faQ",
    "expire_date": "2025-11-08T14:03:59.775Z"
  }
},
{
  "model": "sessions.session",
  "pk": "6cvvrpa0w90nah31e5n6rkyakkao9r3u",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1tv9p0:gLAru6gq_jVJtLUnj51ktvSvVeO1CJy1-KhWAjMSDEw",
    "expire_date": "2025-04-03T06:56:06.210Z"
  }
},
{
  "model": "sessions.session",
  "pk": "79793wabzhsp9khfhuhbc0vdsfss6r0m",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD0bZ:M8v3OdZENDaiy5aAY0ykvspYKFX6WU00SCv5vDN0e4Q",
    "expire_date": "2025-11-09T13:16:17.086Z"
  }
},
{
  "model": "sessions.session",
  "pk": "7a8ruxelqr0ivc5x0xelib01daaaavqn",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vCeUf:xK164WebR1uf1mUSNql2_ISrKk4R2kghnYASDkCi3UU",
    "expire_date": "2025-11-08T13:39:41.108Z"
  }
},
{
  "model": "sessions.session",
  "pk": "7ytizhn6p0rpeerpfiwsq5788cngokt2",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uERIP:IgwQlAT2713XmQpUYmQei0nKZ92SZAbek5uJwPnrt3k",
    "expire_date": "2025-05-26T11:26:09.532Z"
  }
},
{
  "model": "sessions.session",
  "pk": "85n13nspvif41kj8ow10ljgeln420imj",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD6Uw:UZ21dYqYRrwjFB7zoIbcibT6g1E7mvVlrd4jVB5VXrA",
    "expire_date": "2025-11-09T19:33:50.689Z"
  }
},
{
  "model": "sessions.session",
  "pk": "8j0gvn2w16nh87gupugpk0awp9yz64vz",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD1HW:bzslY1jBxZ11d6rZl4rjPVqshiAT4A8RnpkK0PA6Hbc",
    "expire_date": "2025-11-09T13:59:38.075Z"
  }
},
{
  "model": "sessions.session",
  "pk": "8nw6nheokllgn3793gmyk7es39mma7a8",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uSaqm:vAQIbz0HFMRtTaLQSMOKfOCP84PkIwCCSssn_aT2fNU",
    "expire_date": "2025-07-04T12:28:08.576Z"
  }
},
{
  "model": "sessions.session",
  "pk": "9tbzqk6aim9lv64sl8yexsqqo64wpaoe",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1twypB:bXYEDQDenTYCJopg54RvS8QbZ-I8WTFqsQ9pwHvOT7A",
    "expire_date": "2025-04-08T07:35:49.045Z"
  }
},
{
  "model": "sessions.session",
  "pk": "9vrgr74c9r8wt356wdszdw919irk848m",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vCeSV:dMG6uoRrfahHOFXkLD2UlXkz1YiQ0sTSMXNdpmyUFns",
    "expire_date": "2025-11-08T13:37:27.135Z"
  }
},
{
  "model": "sessions.session",
  "pk": "9ye0p8ca8eqjv0xcuseda2v7vgsvcva5",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1u4FMy:o8SGNCxvTfhhfxyEHLla0AVfVz6X5h26JS5iigbBPs4",
    "expire_date": "2025-04-28T08:40:44.758Z"
  }
},
{
  "model": "sessions.session",
  "pk": "a5dou9bh080xwhvonayv82rhyqfwc5n0",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uFB7m:Lt8wYG39zwbLxlCm_uV96bNqWf-36bDLIQpygwz5Dyg",
    "expire_date": "2025-05-28T12:22:14.001Z"
  }
},
{
  "model": "sessions.session",
  "pk": "aclmahsh74fheb46aa65um0ki12au5mk",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1v2QMG:vRFcdTEoOfwRPWcCIogJikKXH8tlMW1qy_8AlDHuF1w",
    "expire_date": "2025-10-11T08:32:44.937Z"
  }
},
{
  "model": "sessions.session",
  "pk": "ah3ul5ni5axr074nv73lxxj3johh0ty4",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1trljL:n6W5Ad0XulU0JsGdK-RKHv0u0B6L1yf_9aWumqm3J5I",
    "expire_date": "2025-03-24T22:36:15.869Z"
  }
},
{
  "model": "sessions.session",
  "pk": "ax2igl802a97i14ef2p4b3hyx4sfbuei",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD6Eb:7nQwo7rl-VxxKMQtnHh2MAWqv5nwX0KOu0k2-GryGxM",
    "expire_date": "2025-11-09T19:16:57.903Z"
  }
},
{
  "model": "sessions.session",
  "pk": "bkfn72kzmac0vq2885r5mloxbmft5wxn",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1v269y:ZF9egHME1BGpdRIy5iu4iYkPmfBsxm6OE81QK-xWzhY",
    "expire_date": "2025-10-10T10:58:42.669Z"
  }
},
{
  "model": "sessions.session",
  "pk": "bw9vdt03jacahw9n7h4wn0sxp0o4xz5w",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vCf6s:wTtg411xyD4Mm-AZ6w73l2yhbaoYZF4mrQDgs3SA0ro",
    "expire_date": "2025-11-08T14:19:10.350Z"
  }
},
{
  "model": "sessions.session",
  "pk": "ceeh7o7de03y29zi58szzyl4a8pui86w",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD1Tl:az0ySuENU5ygnulsBpvAqLrwMmpFFeU8kLAX9QVqVhg",
    "expire_date": "2025-11-09T14:12:17.206Z"
  }
},
{
  "model": "sessions.session",
  "pk": "crzql5olj9u5h9vnzjoumng4fxx1mjqc",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1tsd6r:UitX8e6BqkDtPEpxR5oSHx0zORNDyaLiZ7aawmaqUoQ",
    "expire_date": "2025-03-27T07:36:05.446Z"
  }
},
{
  "model": "sessions.session",
  "pk": "cu6s33u1zyveg8nsosr13gu4hi39c6gu",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD67J:bbkD2rQlCay0AuyZ9n7_mMQmNmdxaenenR4M7ARUhto",
    "expire_date": "2025-11-09T19:09:25.105Z"
  }
},
{
  "model": "sessions.session",
  "pk": "dgfu5hb68ms0ljkecd6lp1og9yaegp9q",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1tu4zl:W1vfjZsaRJvWo5AxBsGrEg-ywnyebL88Cqik5_wxKtg",
    "expire_date": "2025-03-31T07:34:45.893Z"
  }
},
{
  "model": "sessions.session",
  "pk": "dhyouc7cikkvjitp9zq9ykk9vejdgsh7",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uCxoI:eogPWUPnvT-ploPyKRdwBQksUKAd5EE8CfY6tRX6-xY",
    "expire_date": "2025-05-22T09:44:58.621Z"
  }
},
{
  "model": "sessions.session",
  "pk": "dv1k0802sajpjnm6loehm0l450htkj9j",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1tDJFs:WUaGaCPRJDLege96QT8f2YAdkL5J6Hi02ZWZRCzt7pk",
    "expire_date": "2024-12-03T08:06:36.992Z"
  }
},
{
  "model": "sessions.session",
  "pk": "dwsiua78nsy5zrhi4srae2xnl6s6ye8e",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD5O0:ePjglV9S1Ttc25HhYzoO6e768ClZzEPNepn6Ja68CdQ",
    "expire_date": "2025-11-09T18:22:36.545Z"
  }
},
{
  "model": "sessions.session",
  "pk": "e0r96fv2i7knrd8yutoltmli75qzmf6v",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uN6f0:0vphQYCVwwHN-wAbcIgJNRBT3UgzQct-yVcV3YBi4hk",
    "expire_date": "2025-06-19T09:13:18.558Z"
  }
},
{
  "model": "sessions.session",
  "pk": "e734jxoe8m1l2l9gcswidwg05dwz9c3h",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uJHIq:ZOHE9iPeDbFoO5Qf0aFTvwaGnjltCP3cuymb0sJtOTI",
    "expire_date": "2025-06-08T19:46:36.079Z"
  }
},
{
  "model": "sessions.session",
  "pk": "eky1jlipa99yrnuz091tf9ibjw3uog96",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vCeUv:T_qsHli_rFWs_31m0jbsvL9CV9wMYKjiowBoAAQCcmY",
    "expire_date": "2025-11-08T13:39:57.333Z"
  }
},
{
  "model": "sessions.session",
  "pk": "enqd3wicnl22qmfv1jscsxgte4rygrbn",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1u1nez:zZocFZ_W7DS0mwNLF9NFnldBZE_R2kdhOZbwmHXFjT8",
    "expire_date": "2025-04-21T14:41:13.978Z"
  }
},
{
  "model": "sessions.session",
  "pk": "f3x4xlyp575hk7mcm5vv1bryy9xf7sut",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD1IT:eiV2h1M9CyWpNgHYiGZkOuA6HrtoS5p9zJV3VrXGi_I",
    "expire_date": "2025-11-09T14:00:37.364Z"
  }
},
{
  "model": "sessions.session",
  "pk": "fb7sxoqorxugxzab0ofl6hjk1cupqmuy",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1tyAi5:IsONhgfvw9GQ0ylzw157zyYY8cyEOD-cgju5Q_1TXXA",
    "expire_date": "2025-04-11T14:29:25.160Z"
  }
},
{
  "model": "sessions.session",
  "pk": "fomhwzriic3ggdrgksbbq5v14sbzmg0h",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vCoDb:S8eVXnjx4cJiwbFgIlgjU2UjdArDw4NBUmHOgT-8jjs",
    "expire_date": "2025-11-09T00:02:43.927Z"
  }
},
{
  "model": "sessions.session",
  "pk": "fzoheqnpz4aafsazdm1vjtc5tf7k4717",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD1Dc:Y3sVT4OIW0R-cyMJbvmkGSfCTB3rVFvNf5684aujyBI",
    "expire_date": "2025-11-09T13:55:36.260Z"
  }
},
{
  "model": "sessions.session",
  "pk": "gdbm3e2466z1dwx46jb4a4ib61r7qssb",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1urMu6:gA5kpUmk6IIgD1ftRwPoGiOjdXHMJmhWA_-jXHABOt8",
    "expire_date": "2025-09-10T20:37:58.412Z"
  }
},
{
  "model": "sessions.session",
  "pk": "gkpmw0368cn9i0yv8c304jzh26cl7l6m",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uR57I:ot2WrQ6cc0IHt5OG92OiEHy-xNDHC2wXnOvwl33N7gg",
    "expire_date": "2025-06-30T08:22:56.221Z"
  }
},
{
  "model": "sessions.session",
  "pk": "gxmbypb6mb7nfyo1wxgz09rh376cxecf",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1tt3Z5:cay8XpiK7dbM9oGWzq-lTQv55Td5umCE7ntIETiD6Y8",
    "expire_date": "2025-03-28T11:50:59.526Z"
  }
},
{
  "model": "sessions.session",
  "pk": "h4sax2yhsbvaa5ljnyjbm3a2mjmcj8oj",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vFDCN:IgWBnGjsEtHlMJqkGe4EEA2m05JsARwreSj3GyV5uNs",
    "expire_date": "2025-11-15T15:07:23.076Z"
  }
},
{
  "model": "sessions.session",
  "pk": "h6c93audla8zqnemij8fh8qmgj7ntn84",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1tvtRu:rr8LuktwCjModPZQP8Px8Ah28mz26k5-e99eJmAqMaI",
    "expire_date": "2025-04-05T07:39:18.807Z"
  }
},
{
  "model": "sessions.session",
  "pk": "h6zhp0c9gfcljmo4bcxpo8xoz93eh9w2",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD5R8:eT7cHwJRoWmrOdvjbYYkHJreyUcdudLyo6Q0c5CWG0A",
    "expire_date": "2025-11-09T18:25:50.909Z"
  }
},
{
  "model": "sessions.session",
  "pk": "hlsqtttgqfhf2yo0olh2426jphkv2hmi",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uWDLF:3zhzfAfsV7iFCpegcduErLEbG8iO4dDM4ptRlj1pRjk",
    "expire_date": "2025-07-14T12:10:33.179Z"
  }
},
{
  "model": "sessions.session",
  "pk": "huw6j9aa9na5a9p2arxfspgb8ati1j6j",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1ulDG0:ulNy3fKWitLQAmxAhTlxLm5zQXJITvLgM47hEiX8SQE",
    "expire_date": "2025-08-24T21:07:08.882Z"
  }
},
{
  "model": "sessions.session",
  "pk": "i45q9omi7qhkgvv4x1fradgommp9sd9t",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1ty8gY:y7qL1ATiPk5I0gofAg_68_lLv1D7gu35WZN9uMaqmys",
    "expire_date": "2025-04-11T12:19:42.536Z"
  }
},
{
  "model": "sessions.session",
  "pk": "iossjpo2cy9jffgomuskzip4fke3f7gh",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD0NA:wLbRxSfGhngs0S9VT1mD_SBE032HQ3oyrCUCFBCo5eA",
    "expire_date": "2025-11-09T13:01:24.714Z"
  }
},
{
  "model": "sessions.session",
  "pk": "ito8c7awa4hu7ii2a8k1f0x13zf3i19o",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1vAj05:yPUDGghPFwLek7UgHzTsx14wdbD03RozOUhwVbxv7JI",
    "expire_date": "2025-11-03T06:04:09.140Z"
  }
},
{
  "model": "sessions.session",
  "pk": "ix0il9ikdyyx7ef4v3g2ll8170ve0oqm",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1txmE4:xDJJSDxL5CbYQxwkbGCQZF-k156V39055nwuLuoClf0",
    "expire_date": "2025-04-10T12:20:48.947Z"
  }
},
{
  "model": "sessions.session",
  "pk": "iyiakdysxo6nwwltx1br0d9ssfw3235x",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD0Vr:FA6U5ExnEmV9syd2x6iWM_3gOg5-eJDG0cPQhaFxC_w",
    "expire_date": "2025-11-09T13:10:23.555Z"
  }
},
{
  "model": "sessions.session",
  "pk": "j34ej6gdv3z243md1evgv3qbwlrp5kgc",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uIuj8:u34LRehs99DU_Qk0ARIN1_wBXdncUJffzcW3WDn5xmo",
    "expire_date": "2025-06-07T19:40:14.041Z"
  }
},
{
  "model": "sessions.session",
  "pk": "j5lxz9cpzq7pmv03vrhrdpa9tf4f9nbs",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vCe6K:sodKNqFB-_bIYewVkckIGsqXXdNjR5u6jwRm0m5m5W0",
    "expire_date": "2025-11-08T13:14:32.203Z"
  }
},
{
  "model": "sessions.session",
  "pk": "jnujaxb6rlmn452h75s7czytbf6pkwsq",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1tuRZO:b9kyF8mOvywnS6iC9aCx06iD8H9PP0FA6ouPi0p2Gik",
    "expire_date": "2025-04-01T07:41:02.770Z"
  }
},
{
  "model": "sessions.session",
  "pk": "kewz1hprzmzlndw0hhb609dp1tva3a0m",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1uJA0I:IS_9skRPo0Jax_WwsU5lt9WdBUnTDwuA7D9XJNop624",
    "expire_date": "2025-06-08T11:58:58.394Z"
  }
},
{
  "model": "sessions.session",
  "pk": "kpw84fzuwe5u5jonzgtdpx4c6mh709ud",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1tunJH:lQL7iEy8lMI6VFeBbj-Q_DI9QuStiJGHOTtPeeYWF4A",
    "expire_date": "2025-04-02T06:53:51.103Z"
  }
},
{
  "model": "sessions.session",
  "pk": "l1kzelftfsivlvar196ljza9qredksbc",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1uIRBK:8N4VtltGCyXsAAzpOwbU_XTFFw-YJM0zwR5CHpL_yYY",
    "expire_date": "2025-06-06T12:07:22.164Z"
  }
},
{
  "model": "sessions.session",
  "pk": "l5xqrijv5jvppldga194j2gvnbinznhz",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vCzzN:BO7j-UuT8NC9c8N6j3qNIYKobPFYuJTHTrGAsrc5McA",
    "expire_date": "2025-11-09T12:36:49.485Z"
  }
},
{
  "model": "sessions.session",
  "pk": "la21a4epanueckh2y053j5nogtc58cch",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uIS7j:2uRD6zm52v84BQ9yoSil18IeLR861pwZt_I_4D1cqO0",
    "expire_date": "2025-06-06T13:07:43.252Z"
  }
},
{
  "model": "sessions.session",
  "pk": "lbqg3rqikpu8nd5gevij6u9l5u2qqmmc",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1tzWCf:TIjZw6O9CUamWu00Mri4o2UNQ52ZhByHBmKcZbeQETs",
    "expire_date": "2025-04-15T07:38:33.601Z"
  }
},
{
  "model": "sessions.session",
  "pk": "lc0uf6vnr0vv4uteuf6kxo58tbozxxkw",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD1Hz:qtf-yBlOSzur7i8nX_HjpE8GUbgzMzZEWIfXVcD04fE",
    "expire_date": "2025-11-09T14:00:07.096Z"
  }
},
{
  "model": "sessions.session",
  "pk": "ldda3rlfn0krnmatfjdhb69imt43l78j",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1uFAYe:6BJ82YmDwZtDRbS3IsJmc3OPskFiGGm-8CyvIHzcPDs",
    "expire_date": "2025-05-28T11:45:56.626Z"
  }
},
{
  "model": "sessions.session",
  "pk": "le52iiwxw772pjan9d6acz628miej3jy",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD0ul:wt2qcNTQC025nT5wFKPCYNZqvoHLqhPh8LIPJ4VLzgw",
    "expire_date": "2025-11-09T13:36:07.757Z"
  }
},
{
  "model": "sessions.session",
  "pk": "lfoyn0xogdndopseaanhf9vpptv3glrg",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uJAVU:uQoH-uAZjxjco4kHXCFQNMgAWSeXXJHjwnVDSuQ9Wpw",
    "expire_date": "2025-06-08T12:31:12.316Z"
  }
},
{
  "model": "sessions.session",
  "pk": "lkp2xdjd1l453x6igkmnwqynunc58czm",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1ttKxV:_tCoDhoEXxBFR2cjnXDPJGjCOAoIpfPiWcJl_m7tseA",
    "expire_date": "2025-03-29T06:25:21.897Z"
  }
},
{
  "model": "sessions.session",
  "pk": "lqy8a1d5qqq8o52ujazzr3pzoligey40",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vFX8m:xvFSHT3Zj9tACSAFLGe7EebHxAvwXlzr0437bliiql4",
    "expire_date": "2025-11-16T12:25:00.160Z"
  }
},
{
  "model": "sessions.session",
  "pk": "m23nx5u9jbeocrs3wgevkow980bqt4k4",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1vAZm4:AC2qGdJ5hKYU_UFvKAfr8FHwPDOlo9QM1Vu6PNiJU3M",
    "expire_date": "2025-11-02T20:13:04.057Z"
  }
},
{
  "model": "sessions.session",
  "pk": "m9mk2r9gxpjahe2qygd5nql7iaadg2vu",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1txQlU:MOEaBQBw95iKm5-YW58ooRskNaK1dK6Y7g02JNYZ3IQ",
    "expire_date": "2025-04-09T13:25:52.231Z"
  }
},
{
  "model": "sessions.session",
  "pk": "n0kbbjlw5tpm8uytbwpebq6xmw3ciw64",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD0LZ:XZ8AtbPKS6NV4FLQSe5GlAZUHh246RQmSBDrhFZ0qJk",
    "expire_date": "2025-11-09T12:59:45.580Z"
  }
},
{
  "model": "sessions.session",
  "pk": "niqjk9syow1ez5ntnib9eemld27euy5b",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD0MM:HYsSlFmppd0kfWeauYCRY9mTFMLc4zd5m1s0Py4Hj6g",
    "expire_date": "2025-11-09T13:00:34.783Z"
  }
},
{
  "model": "sessions.session",
  "pk": "nkiqn7mr96an1q3wblzeyoberauydiy0",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1ttfjY:Bj8aIRYRDJiceYKXAEx9sNtdV-muEPPEq39u9yeaVJI",
    "expire_date": "2025-03-30T04:36:20.736Z"
  }
},
{
  "model": "sessions.session",
  "pk": "npauyxnw3vqbsc2qwjaapoepwxr8i5y9",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1twcw1:WZkwxcdAnmThSDkOPs584Bfvg3_Y8giGUiMsAOTY6PA",
    "expire_date": "2025-04-07T08:13:25.623Z"
  }
},
{
  "model": "sessions.session",
  "pk": "o7k9dvdn3lcthu9emfapb07ackf1l6eg",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1tyAlr:zRvaLu_dY9Ln8Zu2bxIhyjAgPfPCMUP7IqgNOz8Fdac",
    "expire_date": "2025-04-11T14:33:19.735Z"
  }
},
{
  "model": "sessions.session",
  "pk": "o90jemms7b4z80xw4d8974dsib7lw3ox",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD6Ha:jzOUUKX6gdGrb2wVyvEYEQg81bNju2JfsJobg3nQFlA",
    "expire_date": "2025-11-09T19:20:02.372Z"
  }
},
{
  "model": "sessions.session",
  "pk": "oml8xilp7jr9pl5ncz8wnnd5fls353ss",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uyVnr:FMQxpm-4LTxCIlXTF4OelnV3TzSyXduYwnKTWScI3Pw",
    "expire_date": "2025-09-30T13:33:03.758Z"
  }
},
{
  "model": "sessions.session",
  "pk": "ouihosyd0kneld7cwmv4xa27uq8lxosi",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD0gP:vOfapYQwjGS4d7Ecsb5R4-djMrkxLbIvX-oppKhtUjQ",
    "expire_date": "2025-11-09T13:21:17.079Z"
  }
},
{
  "model": "sessions.session",
  "pk": "oyxz499vjxlyox6nsy5prnoyeoqn0o39",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uJRJ7:uaTJtGlmqP3Iw31oh32ATvc6hmF3b7p6V4W-RiMj_Ok",
    "expire_date": "2025-06-09T06:27:33.361Z"
  }
},
{
  "model": "sessions.session",
  "pk": "p3ric2nj5qh8bx7jxwy1r6h6u9nyzapd",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD00p:CX3x8V8FAPXygwLYp33bYFHX15WkUvdS6B5_aI5G5v8",
    "expire_date": "2025-11-09T12:38:19.757Z"
  }
},
{
  "model": "sessions.session",
  "pk": "p7rt5tr92ho1l1l37ztd5pg5ujfoz24u",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1tyQhS:jhcSqxf23xE8knKdRHtKDrXKUCSOn839CYp6H-79yB0",
    "expire_date": "2025-04-12T07:33:50.549Z"
  }
},
{
  "model": "sessions.session",
  "pk": "pa5m9x2ksldoedkdl7eg1r6iioq52dr5",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vCe4z:fqDM-XHvs_wPTTFQyegyBX33WLxGTSW4UUEpMXKtG-U",
    "expire_date": "2025-11-08T13:13:09.873Z"
  }
},
{
  "model": "sessions.session",
  "pk": "q91aae1z4dg617ys8pr5ws3gz8a3al7e",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uIjDk:KBQokVqjLbiR54yCVWExdOKZ5Pp6D-s1cDYF8T7afZE",
    "expire_date": "2025-06-07T07:23:04.523Z"
  }
},
{
  "model": "sessions.session",
  "pk": "q9pnx8s1jfaj6jh77i73tqyywtkwy7ei",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vCeaz:9JOLh9XVJFrM_GeyzREuWLQl8uzshq_PT4DvR8qOI9g",
    "expire_date": "2025-11-08T13:46:13.084Z"
  }
},
{
  "model": "sessions.session",
  "pk": "qfcgnxlrb5e4nb2ir6np2n7ut44k0e9y",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uJWDe:TYJbQJlok5RWHE4CVs-5Dw5L23Nl0GJ5lJtTkhEDuMI",
    "expire_date": "2025-06-09T11:42:14.499Z"
  }
},
{
  "model": "sessions.session",
  "pk": "qh1i0oexxcduunfplfsgyuv7k4ca4wxl",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uu3aK:ZGz19zf-siKoQQPjFqTodGe0-8auizW7roHMXyPk5N0",
    "expire_date": "2025-09-18T06:36:40.590Z"
  }
},
{
  "model": "sessions.session",
  "pk": "qohq8f8vsrupof2wti0bhhveqrezd04g",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD6To:hJkh5102fLBETq6zc-zqqhreRp7-kBGPngF07lo-g1A",
    "expire_date": "2025-11-09T19:32:40.808Z"
  }
},
{
  "model": "sessions.session",
  "pk": "rlksrum1vwptmemv66bhjbudl0x91a8g",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uBuR5:mN9ayVZ3M4MbJ-QHL7P4co-qykXckBMcAN6N9XA8Zb4",
    "expire_date": "2025-05-19T11:56:39.510Z"
  }
},
{
  "model": "sessions.session",
  "pk": "rmhzghrpmd1qfvmyafh2n3ep09u8rrfb",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1v1TS8:TOA5R-wSPXqdNYENWci1JnHnaazXhFKiumETypbv1no",
    "expire_date": "2025-10-08T17:38:52.849Z"
  }
},
{
  "model": "sessions.session",
  "pk": "rzpinipqg2j6v3t6lucsrt4vqqi231nx",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1u3DFm:V4-Mza3MO_PqkVs-DNmQMH5j4NIRzJ5Nu9eljDTEZ_0",
    "expire_date": "2025-04-25T12:13:02.824Z"
  }
},
{
  "model": "sessions.session",
  "pk": "ssw6dv9mbk3m4fcrjyvx7e4i82yxz4zu",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1uIRHZ:NXhvNtYWAwWWuafE0k4pmxDjaZdVAiPHjqCZnRHzWOY",
    "expire_date": "2025-06-06T12:13:49.140Z"
  }
},
{
  "model": "sessions.session",
  "pk": "sz19ur2yh2eke0kxjknvn5c51j7fe10f",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1tfJXm:wVlkr6bB73tpFnpiuLX8h0QqPHHUQap_1C3csh3h4yQ",
    "expire_date": "2025-02-18T14:04:50.096Z"
  }
},
{
  "model": "sessions.session",
  "pk": "t323i3kuyjqqytfd1sc99l9eznnok445",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uCGi9:7F7kM6g1YiQNok5LqKUCkMaKtv1L6VzaU8O6Nt05Tok",
    "expire_date": "2025-05-20T11:43:45.272Z"
  }
},
{
  "model": "sessions.session",
  "pk": "tks9fj30nyipjnufototyvkxeltdyh1h",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vCoHx:7asi7MTJQpNPMaQy3APdsfrCptItljtcTjympC1kE5Q",
    "expire_date": "2025-11-09T00:07:13.389Z"
  }
},
{
  "model": "sessions.session",
  "pk": "u18q3l5w1rcu4cxw32oy81icpq1b6a6z",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uJfMY:mA5dLFcRYTYRTENrUsjwhdGUFFjKM0Ip62svkYMp-E8",
    "expire_date": "2025-06-09T21:28:02.894Z"
  }
},
{
  "model": "sessions.session",
  "pk": "ufjmvcqe6m0m1k3m99datgkvla4qnnoc",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD0cY:zC85cPuEn_f0ulByEp8ae8rdsBRJECLsRH38HGK0glk",
    "expire_date": "2025-11-09T13:17:18.645Z"
  }
},
{
  "model": "sessions.session",
  "pk": "uhruim4nkx3xersfxb11dadkfdsnnd0k",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vFXUV:05DHb2YQu7vNr6ydQKb2mJ6d1ZHBkYWiln19HKawc78",
    "expire_date": "2025-11-16T12:47:27.404Z"
  }
},
{
  "model": "sessions.session",
  "pk": "uqsv0q3nf1c2r8n291sh53gxjjli57pf",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1u4b1h:ulwrpPO5xK43rCxnG6DyUD9cqFNNQsKT1SCf-XnU3po",
    "expire_date": "2025-04-29T07:48:13.589Z"
  }
},
{
  "model": "sessions.session",
  "pk": "vjtdaa7vq8jcipt0pue0dqffit0gk3xa",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vAJaj:qtMfz-qQhYiTG73Gk2pt0Cc-lCaPQ06LU0Y6Jz33irM",
    "expire_date": "2025-11-02T02:56:17.328Z"
  }
},
{
  "model": "sessions.session",
  "pk": "vka0ct4m3cnrajp44l1wlb0u8dcwyebm",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD0eP:pWpTK47jhBaZSjtgTFoHh5Mjc7ZXhNh5d8qe42mnb9k",
    "expire_date": "2025-11-09T13:19:13.211Z"
  }
},
{
  "model": "sessions.session",
  "pk": "vt4nwamih1bfixelxi2ftbyirqm5wazv",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1u1go5:9dW9THOCeNa1hj8W6qsOu9HHfcx_uf8gAVnGFqNUQ5c",
    "expire_date": "2025-04-21T07:22:09.798Z"
  }
},
{
  "model": "sessions.session",
  "pk": "vzc5h4afvknek3wcvschwbtv3vqjmea2",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD5U9:HkNbn-j_D-h_07xk9BCoPo4JZPfVhMClDuF8SgXdIHE",
    "expire_date": "2025-11-09T18:28:57.870Z"
  }
},
{
  "model": "sessions.session",
  "pk": "vzgl40m0dn9s52rn2jcy0xzqsq3svhhi",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uKY4d:2AkkbApd6CCxSl2Z9jl-PU5lsfPj33nG323XMs9xcxo",
    "expire_date": "2025-06-12T07:53:11.680Z"
  }
},
{
  "model": "sessions.session",
  "pk": "w11bttjbdfy2ksubpvxr62pc5bq3sfb3",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD6bc:nsSmB9EDzEs4SYxH-7vwInF8hRzWoE2lenMa4g94ZZI",
    "expire_date": "2025-11-09T19:40:44.218Z"
  }
},
{
  "model": "sessions.session",
  "pk": "w29nl0r6r4crghzrh5u8fpo9bjyj66fa",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1u5mCt:V92qE2povB3Q86S1xz4lFKAB-L-HD6VXv0xx0HHQtE0",
    "expire_date": "2025-05-02T13:56:39.927Z"
  }
},
{
  "model": "sessions.session",
  "pk": "wh035x17ig0xbhahkz4quue6zrv071hl",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uCDAu:MLNFMxwcXHW9IOIFsTAxi2kmzNewDPoWZQNdlHoODo0",
    "expire_date": "2025-05-20T07:57:12.855Z"
  }
},
{
  "model": "sessions.session",
  "pk": "wmaqbo522u2mdjcisal9w4r6a4nb0hx8",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vCoI8:h0J2-wWZUCVXj3LmIynLfzbcVv_lWs3RMczKw2eyhyk",
    "expire_date": "2025-11-09T00:07:24.410Z"
  }
},
{
  "model": "sessions.session",
  "pk": "x21ppps1eit8dob6c2ug96w43vlx8qs8",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD5TF:EF_E0JVXr5Pm7rYDlU7r5GkHKlneRvfAOOXcyUAo0zU",
    "expire_date": "2025-11-09T18:28:01.802Z"
  }
},
{
  "model": "sessions.session",
  "pk": "x7hwfvk39p44uncrtsmyvcto6w1ma0ci",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1tt3wt:4kbZf2pJ2o8kBLqB7zNvcY0TT6N5DIp0RkDm-3PHsuI",
    "expire_date": "2025-03-28T12:15:35.197Z"
  }
},
{
  "model": "sessions.session",
  "pk": "x7j6bbhozuf0y1wqfs8hbboyugagdd0y",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1v3BGw:pS_8RAJoSaV4vtVpPGB6rz19tg9ZAtLO7MDJPHEkbj0",
    "expire_date": "2025-10-13T10:38:22.039Z"
  }
},
{
  "model": "sessions.session",
  "pk": "xxl1uncsvv6lccrpjrwpbtlvr5l6efxr",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1tztsn:ixxRdn_OepxWDowcTncNunTo3TauJzUX6ksOmKUP7kY",
    "expire_date": "2025-04-16T08:55:37.640Z"
  }
},
{
  "model": "sessions.session",
  "pk": "y49695pd2zyup7jz9dgor6gbkucadu9b",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD5Qb:_DdGxRqxD8c_RoYwBe9UAJd3bzKyq6aP-0FlQLDpC5Y",
    "expire_date": "2025-11-09T18:25:17.186Z"
  }
},
{
  "model": "sessions.session",
  "pk": "yb11yecz5s5ethwna0w4mabpj1aaiv35",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uRnNm:mOL6lDnbUpo_hJcx2w8-g41K1FJtTHZIjBGVqaQ3smI",
    "expire_date": "2025-07-02T07:38:54.163Z"
  }
},
{
  "model": "sessions.session",
  "pk": "ykahjpud4rqe19ldk1gvxfzwrh1oe7qn",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1u0FXE:t3j5IPQ5XYeNirJkU8t96MRZc_VRnnOQsRDcuZoRdIg",
    "expire_date": "2025-04-17T08:02:48.770Z"
  }
},
{
  "model": "sessions.session",
  "pk": "yns4epan2hdfuv3q9q4xudv4lkww5uvc",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD5tM:Q_X1o2eSfiz-aN-v1EeyHAa_pW4cYE3CHKC0ejmeg60",
    "expire_date": "2025-11-09T18:55:00.649Z"
  }
},
{
  "model": "sessions.session",
  "pk": "z36zwzer11hiyp6x6sk7bzsfs6pcwv86",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSFToDxcuvcbCDMDUjU0Ke3K-O_apAvd3nPOfYmYtrXGreclTizOQonT74aJHrntgO-p3WZJc1uXCeWuyIN2eZ05Py-H-3dQU6_f2rMH560CrYLFHIA0IJTRIWMJxmRrSRWHOhjWZvRAOJSMxhIPzikW7w_Mizes:1uOZfy:Jw4lyIt78zZawm47RbiuauRBy3b_wqvTOPIDD_xQibc",
    "expire_date": "2025-06-23T10:24:22.979Z"
  }
},
{
  "model": "sessions.session",
  "pk": "z45f0b1c8a0p1384c7fq4l8584b1408g",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD6AX:X08KPuIa9x0uls39RHA0qngZzBbvwf9KFQUmU4rDW-o",
    "expire_date": "2025-11-09T19:12:45.263Z"
  }
},
{
  "model": "sessions.session",
  "pk": "zocf1bx6yqcn6o2qkduj9h486wmclt0z",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vCdU0:wu770ZqEJBO4yRIRn9jCLrzxyp6xLR5yl0OTryXFPkQ",
    "expire_date": "2025-11-08T12:34:56.706Z"
  }
},
{
  "model": "sessions.session",
  "pk": "zp2gt2geog99fjt4frwznq5yucryyceg",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD0W9:eyzxz4kuFr8AcopoO68ExQmo8UX62b-LGC1lo9OaKRg",
    "expire_date": "2025-11-09T13:10:41.062Z"
  }
},
{
  "model": "sessions.session",
  "pk": "zt61mqig31lepaot1anwzgs3kx0a5mer",
  "fields": {
    "session_data": ".eJxVjMsOwiAQRf-FtSGAPF267zeQgRmkaiAp7cr479qkC93ec859sQjbWuM2aIkzsguT7PS7JcgPajvAO7Rb57m3dZkT3xV-0MGnjvS8Hu7fQYVRv_XZAQGpgmgESTTeKKcDEQUNjjB5KwWBcEJqG3RQRSibc8BkijdSGvb-APcpN9o:1vD0Uo:E0E7bbYpQix3g0twc46wwyMwSAJQZEYBJmkIhO0aGQs",
    "expire_date": "2025-11-09T13:09:18.088Z"
  }
},
{
  "model": "main.synonyms",
  "pk": 3,
  "fields": {
    "synonymsmname": "blob",
    "originalbiotic": 288
  }
},
{
  "model": "main.articles",
  "pk": 2,
  "fields": {
    "articlename": "nature",
    "articleurl": "https://www.nature.com/articles/s41589-025-01863-x"
  }
},
{
  "model": "main.articles",
  "pk": 3,
  "fields": {
    "articlename": "Iwadate, R., Satoh, Y., Watanabe, Y., Kawai, H., Kudo, N., Kawashima, Y., Mashino, T. and Mitsumoto, A., 2012. Impairment of heme biosynthesis induces short circadian period in body temperature rhythms in mice. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 303(1), pp.R8-R18.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/22552790/"
  }
},
{
  "model": "main.articles",
  "pk": 4,
  "fields": {
    "articlename": "Sulaimani, N., Houghton, M.J., Bonham, M.P. and Williamson, G., 2024. Effects of (Poly) Phenols on Circadian Clock Gene–Mediated Metabolic Homeostasis in Cultured Mammalian Cells: A Scoping Review. Advances in Nutrition, 15(6), p.100232.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/38648895/"
  }
},
{
  "model": "main.articles",
  "pk": 5,
  "fields": {
    "articlename": "Zhou, L., Xiao, X., Zhang, Q., Zheng, J., Li, M., Yu, M., Wang, X., Deng, M., Zhai, X., Li, R. and Liu, J., 2019. Dietary genistein could modulate hypothalamic circadian entrainment, reduce body weight, and improve glucose and lipid metabolism in female mice. International Journal of Endocrinology, 2019(1), p.2163838.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/31139215/"
  }
},
{
  "model": "main.articles",
  "pk": 6,
  "fields": {
    "articlename": "Dang, Y., Ling, S., Ma, J., Ni, R. and Xu, J.W., 2015. Bavachalcone enhances RORα expression, controls Bmal1 circadian transcription, and depresses cellular senescence in human endothelial cells. Evidence‐based Complementary and Alternative Medicine, 2015(1), p.920431.",
    "articleurl": "https://onlinelibrary.wiley.com/doi/full/10.1155/2015/920431"
  }
},
{
  "model": "main.articles",
  "pk": 7,
  "fields": {
    "articlename": "Sarma, A., Sharma, V.P., Sarkar, A.B., Sekar, M.C., Samuel, K. and Geusz, M.E., 2016. The circadian clock modulates anti-cancer properties of curcumin. BMC cancer, 16, pp.1-13.",
    "articleurl": "https://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2789-9"
  }
},
{
  "model": "main.articles",
  "pk": 8,
  "fields": {
    "articlename": "Guo, R., Zhao, B., Wang, Y., Wu, D., Wang, Y., Yu, Y., Yan, Y., Zhang, W., Liu, Z. and Liu, X., 2018. Cichoric acid prevents free-fatty-acid-induced lipid metabolism disorders via regulating Bmal1 in HepG2 cells. Journal of agricultural and food chemistry, 66(37), pp.9667-9678.",
    "articleurl": "https://ufl-flvc.primo.exlibrisgroup.com/discovery/fulldisplay?docid=cdi_proquest_miscellaneous_2075545516&context=PC&vid=01FALSC_UFL:UFL&lang=en&search_scope=MyInst_and_CI&adaptor=Primo%20Central&query=null,,iPad&facet=citedby,exact,cdi_FETCH-LOGICA"
  }
},
{
  "model": "main.articles",
  "pk": 9,
  "fields": {
    "articlename": "Paul, A., Das, P., Gogoi, M., Islam, M.A., Das, S. and Zaman, M.K., 2024. Baicalein: multiple pharmacological activities, pharmacokinetics, and clinical trials. Revista Brasileira de Farmacognosia, pp.1-15.",
    "articleurl": "https://link.springer.com/article/10.1007/s43450-024-00575-y"
  }
},
{
  "model": "main.articles",
  "pk": 10,
  "fields": {
    "articlename": "Zhang, R., Liu, M., Lu, J., Lu, S., Wang, Y. and Guan, S., 2024. Fisetin Ameliorates Hepatocyte Lipid Droplet Accumulation via Targeting the Rhythmic Protein BMAL1 to Regulate Cell Death-Inducing DNA Fragmentation Factor-α-like Effector C-Mediated Lipid Droplet Fusion. Journal of Agricultural and Food Chemistry, 72(48), pp.26884-26897.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/39563624/"
  }
},
{
  "model": "main.articles",
  "pk": 11,
  "fields": {
    "articlename": "Ehret, C.F., Potter, V.R. and Dobra, K.W., 1975. Chronotypic action of theophylline and of pentobarbital as circadian zeitgebers in the rat. Science, 188(4194), pp.1212-1215.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/1145192/"
  }
},
{
  "model": "main.articles",
  "pk": 12,
  "fields": {
    "articlename": "Szarłowicz, J., Mazur, M., Waz, D., Goliszek, Z., Sobek, K.Ł., Tabin-Barczak, W., Sokołowska, A., Fikas, K., Chwaliszewski, K. and Samuła, S., 2025. Theophylline Revisited. Mechanisms, Challenges, and New Horizons. Quality in Sport, 37, pp.57009-57009.",
    "articleurl": "https://apcz.umk.pl/QS/article/view/57009"
  }
},
{
  "model": "main.articles",
  "pk": 13,
  "fields": {
    "articlename": "Olivares-Yañez, C., Alessandri, M.P., Salas, L. and Larrondo, L.F., 2023. Methylxanthines modulate circadian period length independently of the action of phosphodiesterase. Microbiology Spectrum, 11(4), pp.e03727-22.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/37272789/"
  }
},
{
  "model": "main.articles",
  "pk": 14,
  "fields": {
    "articlename": "Manrui, L., Xu, Y., Liu, J., Zhang, X., Yuan, R., Sun, Y., Sun, Y., Yang, Q., Liao, M., Lv, M. and Hu, X., 2025. Aminophylline targets miR-128-3p/Slc7a11 axis to attenuate neuronal ferroptosis after traumatic brain injury. Cellular and Molecular Life Sciences, 82(1), pp.1-23.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/39985589/#:~:text=Aminophylline%20targets%20miR%2D128%2D3p,ferroptosis%20after%20traumatic%20brain%20injury"
  }
},
{
  "model": "main.articles",
  "pk": 15,
  "fields": {
    "articlename": "Manjula, A., Subashini, R., Punitha, R. and Subramanian, P., 2017. Modulating effects of hesperidin on circadian pattern indices of rotenone induced redox homeostasis in clock mutant (cry b) of Drosophila melanogaster. Biological Rhythm Research, 48(6), pp.897-906.",
    "articleurl": "https://www.tandfonline.com/doi/abs/10.1080/09291016.2017.1319641"
  }
},
{
  "model": "main.articles",
  "pk": 16,
  "fields": {
    "articlename": "Tayal, R., Munjal, K., Gauttam, V.K., Popli, P., Khurana, L. and Choudhary, N., 2023. Potential role of hesperidin in lifestyle disorders: A scoping review. South African Journal of Botany, 161, pp.542-554.",
    "articleurl": "https://www.sciencedirect.com/science/article/abs/pii/S0254629923004982"
  }
},
{
  "model": "main.articles",
  "pk": 17,
  "fields": {
    "articlename": "Jayapalan, J.J., Subramanian, P., Kani, A., Hiji, J., Najjar, S.G., Abdul‐Rahman, P.S. and Hashim, O.H., 2020. Hesperidin modulates the rhythmic proteomic profiling in Drosophila melanogaster under oxidative stress. Archives of Insect Biochemistry and Physiology, 105(3), p.e21738.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/32924199/"
  }
},
{
  "model": "main.articles",
  "pk": 18,
  "fields": {
    "articlename": "Chen, M., Zhou, C., Xu, H., Zhang, T. and Wu, B., 2020. Chronopharmacological targeting of Rev-erbα by puerarin alleviates hyperhomocysteinemia in mice. Biomedicine & pharmacotherapy, 125, p.109936.",
    "articleurl": "https://www.sciencedirect.com/science/article/pii/S0753332220301268"
  }
},
{
  "model": "main.articles",
  "pk": 19,
  "fields": {
    "articlename": "Liu, J., Xu, H., Zhang, L., Wang, S., Lu, D., Chen, M. and Wu, B., 2021. Chronoeffects of the herbal medicines Puerariae radix and Coptidis rhizoma in mice: A potential role of REV-ERBα. Frontiers in Pharmacology, 12, p.707844.",
    "articleurl": "https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.707844/full"
  }
},
{
  "model": "main.articles",
  "pk": 20,
  "fields": {
    "articlename": "Yamamoto, T., Iwami, S., Aoyama, S., Maruki-Uchida, H., Mori, S., Hirooka, R., Takahashi, K., Morita, M. and Shibata, S., 2019. Effect of piceatannol on circadian Per2 expression in vitro and in vivo. Journal of functional foods, 56, pp.49-56.",
    "articleurl": "https://www.sciencedirect.com/science/article/abs/pii/S1756464619301045?via%3Dihub"
  }
},
{
  "model": "main.articles",
  "pk": 21,
  "fields": {
    "articlename": "Yao, Y., Zuo, A., Deng, Q., Liu, S., Zhan, T., Wang, M., Xu, H., Ma, J. and Zhao, Y., 2020. Physcion protects against ethanol-induced liver injury by reprogramming of circadian clock. Frontiers in Pharmacology, 11, p.573074.",
    "articleurl": "https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.573074/full"
  }
},
{
  "model": "main.articles",
  "pk": 22,
  "fields": {
    "articlename": "Huang, J.Q., Lu, M. and Ho, C.T., 2021. Health benefits of dietary chronobiotics: beyond resynchronizing internal clocks. Food & Function, 12(14), pp.6136-6156.",
    "articleurl": "https://www.researchwithrutgers.com/en/publications/health-benefits-of-dietary-chronobiotics-beyond-resynchronizing-i"
  }
},
{
  "model": "main.articles",
  "pk": 23,
  "fields": {
    "articlename": "Shin, J.C., Jung, H.Y., Harikishore, A., Kwon, O.D., Yoon, H.S., Kim, K.T. and Choi, B.H., 2013. The flavonoid myricetin reduces nocturnal melatonin levels in the blood through the inhibition of serotonin N-acetyltransferase. Biochemical and biophysical research communications, 440(2), pp.312-316.",
    "articleurl": "https://www.sciencedirect.com/science/article/abs/pii/S0006291X1301557X"
  }
},
{
  "model": "main.articles",
  "pk": 24,
  "fields": {
    "articlename": "Burke, T.M., Markwald, R.R., McHill, A.W., Chinoy, E.D., Snider, J.A., Bessman, S.C., Jung, C.M., O’Neill, J.S. and Wright Jr, K.P., 2015. Effects of caffeine on the human circadian clock in vivo and in vitro. Science translational medicine, 7(305), pp.305ra146-305ra146.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/26378246/"
  }
},
{
  "model": "main.articles",
  "pk": 25,
  "fields": {
    "articlename": "Liu, L. and Tian, Y., 2023. Capsaicin changes the pattern of brain rhythms in sleeping rats. Molecules, 28(12), p.4736.",
    "articleurl": "https://www.mdpi.com/1420-3049/28/12/4736"
  }
},
{
  "model": "main.articles",
  "pk": 26,
  "fields": {
    "articlename": "Bhavani, P., Subramanian, P. and Shanmugapriya, S., 2016. Modulating effects of vanillic acid on circadian pattern of indices of redox homeostasis in N-Methly-N′-Nitro-N-Nitrosoguanidine induced endometrial carcinoma in rats. Biological Rhythm Research, 47(4), pp.609-619.",
    "articleurl": "https://www.tandfonline.com/doi/abs/10.1080/09291016.2016.1173362"
  }
},
{
  "model": "main.articles",
  "pk": 27,
  "fields": {
    "articlename": "Kiessig, R.S., Herz, J.M. and Sweeney, B.M., 1979. Shifting the phase of the circadian rhythm in bioluminescence in Gonyaulax with vanillic acid. Plant Physiology, 63(2), pp.324-327.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/16660722/"
  }
},
{
  "model": "main.articles",
  "pk": 28,
  "fields": {
    "articlename": "Lashgari, N.A., Roudsari, N.M., Momtaz, S., Abdolghaffari, A.H., Atkin, S.L. and Sahebkar, A., 2023. Regulatory mechanisms of vanillic acid in cardiovascular diseases: a review. Current Medicinal Chemistry, 30(22), pp.2562-2576.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/36045525/"
  }
},
{
  "model": "main.articles",
  "pk": 29,
  "fields": {
    "articlename": "Rahman S, Wittine K, Sedic M, Markova-Car EP (2020) Small molecules Targeting Biological clock; a novel prospective for anti-cancer drugs. Molecules. ;25(21); doi: ARTN 493710.3390/molecules25214937.",
    "articleurl": "https://www.mdpi.com/1420-3049/25/21/4937"
  }
},
{
  "model": "main.articles",
  "pk": 30,
  "fields": {
    "articlename": "Oshima, T., Niwa, Y., Kuwata, K., Srivastava, A., Hyoda, T., Tsuchiya, Y., Kumagai, M., Tsuyuguchi, M., Tamaru, T., Sugiyama, A. and Ono, N., 2019. Cell-based screen identifies a new potent and highly selective CK2 inhibitor for modulation of circadian rhythms and cancer cell growth. Science advances, 5(1), p.eaau9060.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/30746467/"
  }
},
{
  "model": "main.articles",
  "pk": 31,
  "fields": {
    "articlename": "Lee, Y., Fong, S.Y., Shon, J., Zhang, S.L., Brooks, R., Lahens, N.F., Chen, D., Dang, C.V., Field, J.M. and Sehgal, A., 2021. Time-of-day specificity of anticancer drugs may be mediated by circadian regulation of the cell cycle. Science advances, 7(7), p.eabd2645.",
    "articleurl": "https://www.science.org/doi/10.1126/sciadv.abd2645"
  }
},
{
  "model": "main.articles",
  "pk": 32,
  "fields": {
    "articlename": "Schneider, R., Linka, R.M. and Reinke, H., 2014. HSP90 affects the stability of BMAL1 and circadian gene expression. Journal of Biological Rhythms, 29(2), pp.87-96.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/24682203/"
  }
},
{
  "model": "main.articles",
  "pk": 33,
  "fields": {
    "articlename": "Collis SJ, Boulton SJ. Emerging links between the biological clock and the DNA damage response. Chromosoma (2007) 116:331–9. doi: 10.1007/s00412-007-0108-6",
    "articleurl": "https://link.springer.com/article/10.1007/s00412-007-0108-6"
  }
},
{
  "model": "main.articles",
  "pk": 34,
  "fields": {
    "articlename": "Lee, J.W., Hirota, T., Ono, D., Honma, S., Honma, K.I., Park, K. and Kay, S.A., 2019. Chemical control of mammalian circadian behavior through dual inhibition of casein kinase Iα and δ. Journal of medicinal chemistry, 62(4), pp.1989-1998.",
    "articleurl": "https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01541"
  }
},
{
  "model": "main.articles",
  "pk": 35,
  "fields": {
    "articlename": "Kim, D., 2012. Practical use and risk of modafinil, a novel waking drug. Environmental health and toxicology, 27, p.e2012007.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/22375280/"
  }
},
{
  "model": "main.articles",
  "pk": 36,
  "fields": {
    "articlename": "Webb, I.C., Pollock, M.S. and Mistlberger, R.E., 2006. Modafinil [2-[(diphenylmethyl) sulfinyl] acetamide] and circadian rhythms in syrian hamsters: assessment of the chronobiotic potential of a novel alerting compound. The Journal of pharmacology and experimental therapeutics, 317(2), pp.882-889.",
    "articleurl": "https://www.sciencedirect.com/science/article/abs/pii/S0022356524326825"
  }
},
{
  "model": "main.articles",
  "pk": 37,
  "fields": {
    "articlename": "Uyhelji, H.A., Munster, S.K., White, V.L. and Nicholson, S.J., 2023. Gene expression biomarkers of the response to sleep loss with and without modafinil (No. DOT/FAA/AM-23/25). United States. Department of Transportation. Federal Aviation Administration. Office of Aviation. Civil Aerospace Medical Institute.",
    "articleurl": "https://rosap.ntl.bts.gov/view/dot/72388"
  }
},
{
  "model": "main.articles",
  "pk": 38,
  "fields": {
    "articlename": "Miller, S., Kesherwani, M., Chan, P., Nagai, Y., Yagi, M., Cope, J., Tama, F., Kay, S.A. and Hirota, T., 2022. CRY2 isoform selectivity of a circadian clock modulator with antiglioblastoma efficacy. Proceedings of the National Academy of Sciences, 119(40), p.e2203936119.",
    "articleurl": "https://www.pnas.org/doi/10.1073/pnas.2203936119"
  }
},
{
  "model": "main.articles",
  "pk": 39,
  "fields": {
    "articlename": "Cheong, J.K., Hung, N.T., Wang, H., Tan, P., Voorhoeve, P.M., Lee, S.H. and Virshup, D.M., 2011. IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1δ/ɛ and Wnt/β-catenin independent inhibition of mitotic spindle formation. Oncogene, 30(22), pp.2558-2569.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3109269/"
  }
},
{
  "model": "main.articles",
  "pk": 40,
  "fields": {
    "articlename": "Abdel-Rahman, M., Abdel-Kader, S., El-Masry, H. and El-Hennamy, R.E., 2020. Light exposure during late night attenuates the risk of scopolamine-induced Alzheimer disease in aged rats. Egyptian journal of basic and applied sciences, 7(1), pp.126-140.",
    "articleurl": "https://www.tandfonline.com/doi/full/10.1080/2314808X.2020.1763033"
  }
},
{
  "model": "main.articles",
  "pk": 41,
  "fields": {
    "articlename": "Thomas, C.W., Blanco-Duque, C., Bréant, B.J., Goodwin, G.M., Sharp, T., Bannerman, D.M. and Vyazovskiy, V.V., 2022. Psilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice. Translational psychiatry, 12(1), p.77.",
    "articleurl": "https://www.nature.com/articles/s41398-022-01846-9"
  }
},
{
  "model": "main.articles",
  "pk": 42,
  "fields": {
    "articlename": "Reid, M.J., Kettner, H., Blanken, T.F., Weiss, B. and Carhartt-Harris, R., 2024. Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action. Current psychiatry reports, pp.1-11.",
    "articleurl": "https://link.springer.com/article/10.1007/s11920-024-01539-8"
  }
},
{
  "model": "main.articles",
  "pk": 43,
  "fields": {
    "articlename": "Zeng, Y., Guo, Z., Wu, M., Chen, F. and Chen, L., 2024. Circadian rhythm regulates the function of immune cells and participates in the development of tumors. Cell death discovery, 10(1), p.199.",
    "articleurl": "https://www.nature.com/articles/s41420-024-01960-1"
  }
},
{
  "model": "main.articles",
  "pk": 44,
  "fields": {
    "articlename": "Pu, H., Bailey, L.C., Bauer, L.G., Voronkov, M., Baxter, M., Huber, K.V., Khorasanizadeh, S., Ray, D. and Rastinejad, F., 2025. Pharmacological targeting of BMAL1 modulates circadian and immune pathways. Nature Chemical Biology, pp.1-10.",
    "articleurl": "https://www.nature.com/articles/s41589-025-01863-x"
  }
},
{
  "model": "main.articles",
  "pk": 45,
  "fields": {
    "articlename": "Kobayashi, Y., Lu, Y., Li, N., Endo, N., Sotome, K., Ueno, K., Tahara, Y. and Ishihara, A., 2024. A new phthalide derivative from the mushroom Cyclocybe cf. erebia culture filtrate affects the phase of circadian rhythms in mouse fibroblasts. Bioscience, Biotechnology, and Biochemistry, p.zbae187.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/39657072/"
  }
},
{
  "model": "main.articles",
  "pk": 46,
  "fields": {
    "articlename": "Mawatari, K., Koike, N., Nohara, K., Wirianto, M., Uebanso, T., Shimohata, T., Shikishima, Y., Miura, H., Nii, Y., Burish, M.J. and Yagita, K., 2023. The polymethoxyflavone sudachitin modulates the circadian clock and improves liver physiology. Molecular Nutrition & Food Research, 67(9), p.2200270.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/36829302/"
  }
},
{
  "model": "main.articles",
  "pk": 47,
  "fields": {
    "articlename": "Yagita, K. and Okamura, H., 2000. Forskolin induces circadian gene expression of rPer1, rPer2 and dbp in mammalian rat-1 fibroblasts. FEBS letters, 465(1), pp.79-82.",
    "articleurl": "https://febs.onlinelibrary.wiley.com/doi/10.1016/S0014-5793%2899%2901724-X"
  }
},
{
  "model": "main.articles",
  "pk": 48,
  "fields": {
    "articlename": "Han, C., Wirianto, M., Kim, E., Burish, M.J., Yoo, S.H. and Chen, Z., 2021. Clock-modulating activities of the anti-arrhythmic drug moricizine. Clocks & sleep, 3(3), pp.351-365.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8293187/"
  }
},
{
  "model": "main.articles",
  "pk": 49,
  "fields": {
    "articlename": "Stein, R.M., Kang, H.J., McCorvy, J.D., Glatfelter, G.C., Jones, A.J., Che, T., Slocum, S., Huang, X.P., Savych, O., Moroz, Y.S. and Stauch, B., 2020. Virtual discovery of melatonin receptor ligands to modulate circadian rhythms. Nature, 579(7800), pp.609-614.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/32040955/"
  }
},
{
  "model": "main.articles",
  "pk": 50,
  "fields": {
    "articlename": "Fisher, S.P. and Sugden, D., 2009. Sleep-promoting action of IIK7, a selective MT2 melatonin receptor agonist in the rat. Neuroscience letters, 457(2), pp.93-96.",
    "articleurl": "https://eurekamag.com/research/055/813/055813577.php?srsltid=AfmBOoqmHMLlbqhOCdyfLNz7W6FpJXWX1RDyvR_N-_zc8yu80oprYeL6"
  }
},
{
  "model": "main.articles",
  "pk": 51,
  "fields": {
    "articlename": "Kanki, M. and Young, M.J., 2021. Corticosteroids and circadian rhythms in the cardiovascular system. Current Opinion in Pharmacology, 57, pp.21-27.",
    "articleurl": "https://www.sciencedirect.com/science/article/abs/pii/S1471489220301053"
  }
},
{
  "model": "main.articles",
  "pk": 52,
  "fields": {
    "articlename": "Tanaka, K., Ashizawa, N., Kawano, H., Sato, O., Seto, S., Nishihara, E., Terazono, H., Isomoto, S., Shinohara, K. and Yano, K., 2007. Aldosterone induces circadian gene expression of clock genes in H9c2 cardiomyoblasts. Heart and vessels, 22, pp.254-260.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/17653520/"
  }
},
{
  "model": "main.articles",
  "pk": 53,
  "fields": {
    "articlename": "Jiang, Y., Gen, N., Wang, P., Feng, N. and Lu, X., 2022. Prednisolone induces sleep disorders via inhibition of melatonin secretion by the circadian rhythm in zebrafish. Biomedicine & Pharmacotherapy, 147, p.112590.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/35007999/"
  }
},
{
  "model": "main.articles",
  "pk": 54,
  "fields": {
    "articlename": "Barnea, M., Madar, Z. and Froy, O., 2013. Dexamethasone induces high-amplitude rhythms in preadipocytes, but hinders circadian expression in differentiated adipocytes. Chronobiology International, 30(6), pp.837-842.",
    "articleurl": "https://cris.huji.ac.il/en/publications/dexamethasone-induces-high-amplitude-rhythms-in-preadipocytes-but"
  }
},
{
  "model": "main.articles",
  "pk": 55,
  "fields": {
    "articlename": "Balsalobre, A., Brown, S.A., Marcacci, L., Tronche, F., Kellendonk, C., Reichardt, H.M., Schutz, G. and Schibler, U., 2000. Resetting of circadian time in peripheral tissues by glucocorticoid signaling. Science, 289(5488), pp.2344-2347.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/11009419/"
  }
},
{
  "model": "main.articles",
  "pk": 56,
  "fields": {
    "articlename": "Smit-McBride, Z., Moisseiev, E., Modjtahedi, S.P., Telander, D.G., Hjelmeland, L.M. and Morse, L.S., 2016. Comparison of in vivo gene expression profiling of RPE/choroid following intravitreal injection of dexamethasone and triamcinolone acetonide. Journal of Ophthalmology, 2016(1), p.9856736.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/27429799/"
  }
},
{
  "model": "main.articles",
  "pk": 57,
  "fields": {
    "articlename": "Yin, J., Kang, Y., McGrath, A.P., Chapman, K., Sjodt, M., Kimura, E., Okabe, A., Koike, T., Miyanohana, Y., Shimizu, Y. and Rallabandi, R., 2022. Molecular mechanism of the wake-promoting agent TAK-925. Nature communications, 13(1), p.2902.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9133036/"
  }
},
{
  "model": "main.articles",
  "pk": 58,
  "fields": {
    "articlename": "Morairty, S.R., Revel, F.G., Malherbe, P., Moreau, J.L., Valladao, D., Wettstein, J.G., Kilduff, T.S. and Borroni, E., 2012. Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PloS one, 7(7), p.e39131.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3388080/"
  }
},
{
  "model": "main.articles",
  "pk": 59,
  "fields": {
    "articlename": "Aluisio, L., Fraser, I., Berdyyeva, T., Tryputsen, V., Shireman, B.T., Shoblock, J., Lovenberg, T., Dugovic, C. and Bonaventure, P., 2014. Pharmacological or genetic orexin1 receptor inhibition attenuates MK-801 induced glutamate release in mouse cortex. Frontiers in neuroscience, 8, p.107.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4033200/"
  }
},
{
  "model": "main.articles",
  "pk": 60,
  "fields": {
    "articlename": "Uehara, T.N., Takao, S., Matsuo, H., Saito, A.N., Ota, E., Ono, A., Itami, K., Kinoshita, T., Yamashino, T., Yamaguchi, J. and Nakamichi, N., 2023. A Small-Molecule Modulator Affecting the Clock-Associated PSEUDO-RESPONSE REGULATOR 7 Amount. Plant And Cell Physiology, 64(11), pp.1397-1406.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/37705303/"
  }
},
{
  "model": "main.articles",
  "pk": 61,
  "fields": {
    "articlename": "Christopher, J.A., Aves, S.J., Brown, J., Errey, J.C., Klair, S.S., Langmead, C.J., Mace, O.J., Mould, R., Patel, J.C., Tehan, B.G. and Zhukov, A., 2015. Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties. MedChemComm, 6(5), pp.947-955.",
    "articleurl": "https://pubs.rsc.org/en/content/articlelanding/2015/md/c5md00027k"
  }
},
{
  "model": "main.articles",
  "pk": 62,
  "fields": {
    "articlename": "Iwadate, R., Satoh, Y., Watanabe, Y., Kawai, H., Kudo, N., Kawashima, Y., Mashino, T. and Mitsumoto, A., 2012. Impairment of heme biosynthesis induces short circadian period in body temperature rhythms in mice. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 303(1), pp.R8-R18.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/22552790/"
  }
},
{
  "model": "main.articles",
  "pk": 63,
  "fields": {
    "articlename": "Du, Y., Chen, X., Kajiwara, S. and Orihara, K., 2024. Effect of Urolithin A on the Improvement of Circadian Rhythm Dysregulation in Intestinal Barrier Induced by Inflammation. Nutrients, 16(14), p.2263.",
    "articleurl": "https://www.mdpi.com/2072-6643/16/14/2263"
  }
},
{
  "model": "main.articles",
  "pk": 64,
  "fields": {
    "articlename": "Luo, W., Yin, Z., Zhang, M., Huang, X. and Yin, J., 2024. Dietary Lactobacillus delbrueckii Affects Ileal Bacterial Composition and Circadian Rhythms in Pigs. Animals, 14(3), p.412.",
    "articleurl": "https://www.mdpi.com/2076-2615/14/3/412"
  }
},
{
  "model": "main.articles",
  "pk": 65,
  "fields": {
    "articlename": "Kreuzer, K., Birkl-Toeglhofer, A.M., Haybaeck, J., Reiter, A., Dalkner, N., Fellendorf, F.T., Maget, A., Platzer, M., Seidl, M., Mendel, L.M. and Lenger, M., 2024. PROVIT-CLOCK: A Potential Influence of Probiotics and Vitamin B7 Add-On Treatment and Metabolites on Clock Gene Expression in Major Depression. Neuropsychobiology, 83(3-4), pp.135-151.",
    "articleurl": "https://karger.com/nps/article/83/3-4/135/907513/PROVIT-CLOCK-A-Potential-Influence-of-Probiotics"
  }
},
{
  "model": "main.articles",
  "pk": 66,
  "fields": {
    "articlename": "Wagner, P.M., Fornasier, S.J. and Guido, M.E., 2024. Pharmacological modulation of the cytosolic oscillator affects glioblastoma cell biology. Cellular and Molecular Neurobiology, 44(1), p.51.",
    "articleurl": "https://link.springer.com/article/10.1007/s10571-024-01485-2"
  }
},
{
  "model": "main.articles",
  "pk": 67,
  "fields": {
    "articlename": "Hirota, T., Lewis, W.G., Liu, A.C., Lee, J.W., Schultz, P.G. and Kay, S.A., 2008. A chemical biology approach reveals period shortening of the mammalian circadian clock by specific inhibition of GSK-3β. Proceedings of the National Academy of Sciences, 105(52), pp.20746-20751.",
    "articleurl": "https://www.pnas.org/doi/abs/10.1073/pnas.0811410106"
  }
},
{
  "model": "main.articles",
  "pk": 68,
  "fields": {
    "articlename": "Miller, S. and Hirota, T., 2020. Pharmacological interventions to circadian clocks and their molecular bases. Journal of molecular biology, 432(12), pp.3498-3514.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/31931005/"
  }
},
{
  "model": "main.articles",
  "pk": 69,
  "fields": {
    "articlename": "Rohr, K.E. and McCarthy, M.J., 2022. The impact of lithium on circadian rhythms and implications for bipolar disorder pharmacotherapy. Neuroscience letters, 786, p.136772.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/35798199/"
  }
},
{
  "model": "main.articles",
  "pk": 70,
  "fields": {
    "articlename": "Kon, N., Hirota, T., Kawamoto, T., Kato, Y., Tsubota, T. and Fukada, Y., 2008. Activation of TGF-β/activin signalling resets the circadian clock through rapid induction of Dec1 transcripts. Nature cell biology, 10(12), pp.1463-1469.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/19029909/"
  }
},
{
  "model": "main.articles",
  "pk": 71,
  "fields": {
    "articlename": "Lee, J.W., Hirota, T., Peters, E.C., Garcia, M., Gonzalez, R., Cho, C.Y., Wu, X., Schultz, P.G. and Kay, S.A., 2011. A small molecule modulates circadian rhythms through phosphorylation of the period protein. Angewandte Chemie (International ed. in English), 50(45), p.10608.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/21954091/"
  }
},
{
  "model": "main.articles",
  "pk": 72,
  "fields": {
    "articlename": "Siddiqui-Jain, A., Drygin, D., Streiner, N., Chua, P., Pierre, F., O'Brien, S.E., Bliesath, J., Omori, M., Huser, N., Ho, C. and Proffitt, C., 2010. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer research, 70(24), pp.10288-10298.",
    "articleurl": "https://aacrjournals.org/cancerres/article/70/24/10288/561243/CX-4945-an-Orally-Bioavailable-Selective-Inhibitor"
  }
},
{
  "model": "main.articles",
  "pk": 73,
  "fields": {
    "articlename": "Kolarski, D., Sugiyama, A., Breton, G., Rakers, C., Ono, D., Schulte, A., Tama, F., Itami, K., Szymanski, W., Hirota, T. and Feringa, B.L., 2019. Controlling the circadian clock with high temporal resolution through photodosing. Journal of the American Chemical Society, 141(40), pp.15784-15791.",
    "articleurl": "https://pubs.acs.org/doi/10.1021/jacs.9b05445?src=getftr"
  }
},
{
  "model": "main.articles",
  "pk": 74,
  "fields": {
    "articlename": "Wagner, F.F., Bishop, J.A., Gale, J.P., Shi, X., Walk, M., Ketterman, J., Patnaik, D., Barker, D., Walpita, D., Campbell, A.J. and Nguyen, S., 2016. Inhibitors of glycogen synthase kinase 3 with exquisite kinome-wide selectivity and their functional effects. ACS Chemical Biology, 11(7), pp.1952-1963.",
    "articleurl": "https://pubs.acs.org/doi/abs/10.1021/acschembio.6b00306"
  }
},
{
  "model": "main.articles",
  "pk": 75,
  "fields": {
    "articlename": "Hirota, T., Lee, J.W., Lewis, W.G., Zhang, E.E., Breton, G., Liu, X., Garcia, M., Peters, E.C., Etchegaray, J.P., Traver, D. and Schultz, P.G., 2010. High-throughput chemical screen identifies a novel potent modulator of cellular circadian rhythms and reveals CKIα as a clock regulatory kinase. PLoS biology, 8(12), p.e1000559.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/21179498/"
  }
},
{
  "model": "main.articles",
  "pk": 76,
  "fields": {
    "articlename": "Li, W., Xu, Y., Liu, Z., Shi, M., Zhang, Y., Deng, Y., Zhong, X., Chen, L., He, J., Zeng, J. and Luo, M., 2021. TRPV4 inhibitor HC067047 produces antidepressant-like effect in LPS-induced depression mouse model. Neuropharmacology, 201, p.108834.",
    "articleurl": "https://www.sciencedirect.com/science/article/abs/pii/S0028390821003890"
  }
},
{
  "model": "main.articles",
  "pk": 77,
  "fields": {
    "articlename": "Alkozi, H.A., de Lara, M.J.P. and Pintor, J., 2017. Melatonin synthesis in the human ciliary body triggered by TRPV4 activation: Involvement of AANAT phosphorylation. Experimental eye research, 162, pp.1-8.",
    "articleurl": "https://www.sciencedirect.com/science/article/abs/pii/S0014483517300684"
  }
},
{
  "model": "main.articles",
  "pk": 78,
  "fields": {
    "articlename": "Amaudrut, J., Argiriadi, M.A., Barth, M., Breinlinger, E.C., Bressac, D., Broqua, P., Calderwood, D.J., Chatar, M., Cusack, K.P., Gauld, S.B. and Jacquet, S., 2019. Discovery of novel quinoline sulphonamide derivatives as potent, selective and orally active RORγ inverse agonists. Bioorganic & Medicinal Chemistry Letters, 29(14), pp.1799-1806.",
    "articleurl": "https://www.sciencedirect.com/science/article/abs/pii/S0960894X19303014"
  }
},
{
  "model": "main.articles",
  "pk": 79,
  "fields": {
    "articlename": "Mahalingam, D., Wang, J.S., Hamilton, E.P., Sarantopoulos, J., Nemunaitis, J., Weems, G., Carter, L., Hu, X., Schreeder, M. and Wilkins, H.J., 2019. Phase 1 open-label, multicenter study of first-in-class RORγ agonist LYC-55716 (cintirorgon): safety, tolerability, and preliminary evidence of antitumor activity. Clinical Cancer Research, 25(12), pp.3508-3516.",
    "articleurl": "https://aacrjournals.org/clincancerres/article/25/12/3508/81598/Phase-1-Open-Label-Multicenter-Study-of-First-in"
  }
},
{
  "model": "main.articles",
  "pk": 80,
  "fields": {
    "articlename": "Ribeiro, R.F., Cavadas, C. and Silva, M.M.C., 2021. Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases. Drug Discovery Today, 26(7), pp.1620-1641.",
    "articleurl": "https://www.sciencedirect.com/science/article/abs/pii/S1359644621001525#b0265"
  }
},
{
  "model": "main.articles",
  "pk": 81,
  "fields": {
    "articlename": "Liu, S., Liu, D., Shen, R., Li, D., Hu, Q., Yan, Y., Sun, J., Zhang, F., Wan, H., Dong, P. and Feng, J., 2021. Discovery of a novel RORγ antagonist with skin-restricted exposure for topical treatment of mild to moderate psoriasis. Scientific Reports, 11(1), p.9132.",
    "articleurl": "https://www.nature.com/articles/s41598-021-88492-1"
  }
},
{
  "model": "main.articles",
  "pk": 82,
  "fields": {
    "articlename": "Kojetin, D.J. and Burris, T.P., 2014. REV-ERB and ROR nuclear receptors as drug targets. Nature reviews Drug discovery, 13(3), pp.197-216.",
    "articleurl": "https://www.nature.com/articles/nrd4100"
  }
},
{
  "model": "main.articles",
  "pk": 83,
  "fields": {
    "articlename": "Kwon, E.Y., Shin, S.K. and Choi, M.S., 2018. Ursolic acid attenuates hepatic steatosis, fibrosis, and insulin resistance by modulating the circadian rhythm pathway in diet-induced obese mice. Nutrients, 10(11), p.1719.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6266464/"
  }
},
{
  "model": "main.articles",
  "pk": 84,
  "fields": {
    "articlename": "Zahran, E.M., Mohamad, S.A., Elsayed, M.M., Hisham, M., Maher, S.A., Abdelmohsen, U.R., Elrehany, M., Desoukey, S.Y. and Kamel, M.S., 2024. Ursolic acid inhibits NF-κB signaling and attenuates MMP-9/TIMP-1 in progressive osteoarthritis: a network pharmacology-based analysis. RSC advances, 14(26), pp.18296-18310.",
    "articleurl": "https://pubs.rsc.org/en/journals/journalissues/ra#!issueid=ra015022&type=current&issnonline=2046-2069"
  }
},
{
  "model": "main.articles",
  "pk": 85,
  "fields": {
    "articlename": "Huh, J.R., Leung, M.W., Huang, P., Ryan, D.A., Krout, M.R., Malapaka, R.R., Chow, J., Manel, N., Ciofani, M., Kim, S.V. and Cuesta, A., 2011. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity. Nature, 472(7344), pp.486-490.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/21441909/"
  }
},
{
  "model": "main.articles",
  "pk": 86,
  "fields": {
    "articlename": "Zhang, W., Zhang, J., Fang, L., Zhou, L., Wang, S., Xiang, Z., Li, Y., Wisely, B., Zhang, G., An, G. and Wang, Y., 2012. Increasing human Th17 differentiation through activation of orphan nuclear receptor retinoid acid-related orphan receptor γ (RORγ) by a class of aryl amide compounds. Molecular pharmacology, 82(4), pp.583-590.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/22700697/"
  }
},
{
  "model": "main.articles",
  "pk": 87,
  "fields": {
    "articlename": "Trebucq, L.L., Cardama, G.A., Lorenzano Menna, P., Golombek, D.A., Chiesa, J.J. and Marpegan, L., 2021. Timing of novel drug 1A-116 to circadian rhythms improves therapeutic effects against glioblastoma. Pharmaceutics, 13(7), p.1091.",
    "articleurl": "https://www.mdpi.com/1999-4923/13/7/1091"
  }
},
{
  "model": "main.articles",
  "pk": 88,
  "fields": {
    "articlename": "Helleboid, S., Haug, C., Lamottke, K., Zhou, Y., Wei, J., Daix, S., Cambula, L., Rigou, G., Hum, D.W. and Walczak, R., 2014. The identification of naturally occurring neoruscogenin as a bioavailable, potent, and high-affinity agonist of the nuclear receptor RORα (NR1F1). Journal of biomolecular screening, 19(3), pp.399-406.",
    "articleurl": "https://www.tandfonline.com/doi/full/10.1080/09291016.2018.1498197"
  }
},
{
  "model": "main.articles",
  "pk": 89,
  "fields": {
    "articlename": "Ryan, C., Tahara, Y., Haraguchi, A., Lu, Y. and Shibata, S., 2024. Nobiletin stimulates adrenal hormones and modulates the circadian clock in mice. Nutrients, 16(10), p.1491.",
    "articleurl": "https://www.mdpi.com/2072-6643/16/10/1491#:~:text=In%20vitro%20screening%20assays%20have,modulation%20%5B7%2C8%5D."
  }
},
{
  "model": "main.articles",
  "pk": 90,
  "fields": {
    "articlename": "Neba Ambe, G.N., Breda, C., Bhambra, A.S. and Arroo, R.R., 2022. Effect of the citrus flavone nobiletin on circadian rhythms and metabolic syndrome. Molecules, 27(22), p.7727.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9695244/"
  }
},
{
  "model": "main.articles",
  "pk": 91,
  "fields": {
    "articlename": "Lellupitiyage Don, S.S., Robertson, K.L., Lin, H.H., Labriola, C., Harrington, M.E., Taylor, S.R. and Farkas, M.E., 2020. Nobiletin affects circadian rhythms and oncogenic characteristics in a cell-dependent manner. PLoS One, 15(7), p.e0236315.",
    "articleurl": "https://scholarworks.umass.edu/server/api/core/bitstreams/5bcf403d-add2-4a6b-aacb-47284751548a/content"
  }
},
{
  "model": "main.articles",
  "pk": 92,
  "fields": {
    "articlename": "Martchenko, A., Biancolin, A.D., Martchenko, S.E. and Brubaker, P.L., 2022. Nobiletin ameliorates high fat-induced disruptions in rhythmic glucagon-like peptide-1 secretion. Scientific Reports, 12(1), p.7271.",
    "articleurl": "https://www.nature.com/articles/s41598-022-11223-7"
  }
},
{
  "model": "main.articles",
  "pk": 93,
  "fields": {
    "articlename": "Lellupitiyage Don, S.S., Robertson, K.L., Lin, H.H., Labriola, C., Harrington, M.E., Taylor, S.R. and Farkas, M.E., 2020. Nobiletin affects circadian rhythms and oncogenic characteristics in a cell-dependent manner. PLoS One, 15(7), p.e0236315.",
    "articleurl": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0236315"
  }
},
{
  "model": "main.articles",
  "pk": 94,
  "fields": {
    "articlename": "Sautel, M., Rudolf, K., Wittneben, H., Herzog, H., Martinez, R., Munoz, M., Eberlein, W., Engel, W., Walker, P. and Beck-Sickinger, A.G., 1996. Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor. Molecular pharmacology, 50(2), pp.285-292.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/8700135/"
  }
},
{
  "model": "main.articles",
  "pk": 95,
  "fields": {
    "articlename": "Cohen, S., Vainer, E., Matar, M.A., Kozlovsky, N., Kaplan, Z., Zohar, J., Mathé, A.A. and Cohen, H., 2015. Diurnal fluctuations in HPA and neuropeptide Y-ergic systems underlie differences in vulnerability to traumatic stress responses at different zeitgeber times. Neuropsychopharmacology, 40(3), pp.774-790.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/25241802/"
  }
},
{
  "model": "main.articles",
  "pk": 96,
  "fields": {
    "articlename": "Liu, Y., Lang, H., Zhou, M., Huang, L., Hui, S., Wang, X., Chen, K. and Mi, M., 2020. The preventive effects of pterostilbene on the exercise intolerance and circadian misalignment of mice subjected to sleep restriction. Molecular Nutrition & Food Research, 64(11), p.1900991.",
    "articleurl": "https://onlinelibrary.wiley.com/doi/abs/10.1002/mnfr.201900991"
  }
},
{
  "model": "main.articles",
  "pk": 97,
  "fields": {
    "articlename": "Zhang, J., Chang, M., Wang, X., Zhou, X., Bai, Q., Lang, H., Zhang, Q., Yi, L., Mi, M. and Chen, K., 2024. Pterostilbene targets the molecular oscillator RORγ to restore circadian rhythm oscillation and protect against sleep restriction induced metabolic disorders. Phytomedicine, 125, p.155327.",
    "articleurl": "https://www.sciencedirect.com/science/article/abs/pii/S0944711323006852"
  }
},
{
  "model": "main.articles",
  "pk": 98,
  "fields": {
    "articlename": "Solt, L.A., et al, 2012. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature, 485(7396), pp.62-68.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/22460951/"
  }
},
{
  "model": "main.articles",
  "pk": 99,
  "fields": {
    "articlename": "Yang, M.Y., Lin, H.Y.H., Chen, Y.Y.M., Hu, M.L., Chen, I.Y. and Yang, C.H., 2025. Chronic low-dose REV-ERBs agonist SR9009 mitigates constant light-induced weight gain and insulin resistance via adipogenesis modulation. Biomedical Journal, p.100830.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/39800061/"
  }
},
{
  "model": "main.articles",
  "pk": 100,
  "fields": {
    "articlename": "Grant, D., Yin, L., Collins, J.L., Parks, D.J., Orband-Miller, L.A., Wisely, G.B., Joshi, S., Lazar, M.A., Willson, T.M. and Zuercher, W.J., 2010. GSK4112, a small molecule chemical probe for the cell biology of the nuclear heme receptor Rev-erbα. ACS chemical biology, 5(10), pp.925-932.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/20677822/"
  }
},
{
  "model": "main.articles",
  "pk": 101,
  "fields": {
    "articlename": "Huang, S., Jiao, X., Lu, D., Pei, X., Qi, D. and Li, Z., 2020. Recent advances in modulators of circadian rhythms: an update and perspective. Journal of Enzyme Inhibition and Medicinal Chemistry, 35(1), pp.1267-1286.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7717701/"
  }
},
{
  "model": "main.articles",
  "pk": 102,
  "fields": {
    "articlename": "Koh, Y.C. and Pan, M.H., 2024. Food-Borne Polycyclic Aromatic Hydrocarbons and Circadian Disruption. ACS omega, 9(29), pp.31298-31312.",
    "articleurl": "https://pubs.acs.org/doi/10.1021/acsomega.4c04120"
  }
},
{
  "model": "main.articles",
  "pk": 103,
  "fields": {
    "articlename": "Lee, J.W., Hirota, T., Peters, E.C., Garcia, M., Gonzalez, R., Cho, C.Y., Wu, X., Schultz, P.G. and Kay, S.A., 2011. A small molecule modulates circadian rhythms through phosphorylation of the period protein. Angewandte Chemie (International ed. in English), 50(45), p.10608.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/21954091/"
  }
},
{
  "model": "main.articles",
  "pk": 104,
  "fields": {
    "articlename": "Ray, S., Lach, R., Heesom, K.J., Valekunja, U.K., Encheva, V., Snijders, A.P. and Reddy, A.B., 2019. Phenotypic proteomic profiling identifies a landscape of targets for circadian clock–modulating compounds. Life Science Alliance, 2(6).",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/31792063/"
  }
},
{
  "model": "main.articles",
  "pk": 105,
  "fields": {
    "articlename": "Freeman, S.L., Kwon, H., Portolano, N., Parkin, G., Venkatraman Girija, U., Basran, J., Fielding, A.J., Fairall, L., Svistunenko, D.A., Moody, P.C. and Schwabe, J.W., 2019. Heme binding to human CLOCK affects interactions with the E-box. Proceedings of the National Academy of Sciences, 116(40), pp.19911-19916.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6778266/"
  }
},
{
  "model": "main.articles",
  "pk": 106,
  "fields": {
    "articlename": "Hosoya, Y., Nojo, W., Kii, I., Suzuki, T., Imanishi, M. and Ohkanda, J., 2020. Identification of synthetic inhibitors for the DNA binding of intrinsically disordered circadian clock transcription factors. Chemical Communications, 56(76), pp.11203-11206.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/32969426/"
  }
},
{
  "model": "main.articles",
  "pk": 107,
  "fields": {
    "articlename": "Doruk, Y.U., Yarparvar, D., Akyel, Y.K., Gul, S., Taskin, A.C., Yilmaz, F., Baris, I., Ozturk, N., Türkay, M., Ozturk, N. and Okyar, A., 2020. A CLOCK-binding small molecule disrupts the interaction between CLOCK and BMAL1 and enhances circadian rhythm amplitude. Journal of Biological Chemistry, 295(11), pp.3518-3531.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/32019867/"
  }
},
{
  "model": "main.articles",
  "pk": 108,
  "fields": {
    "articlename": "He, B. and Chen, Z., 2016. Molecular targets for small-molecule modulators of circadian clocks. Current drug metabolism, 17(5), pp.503-512.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4825319/"
  }
},
{
  "model": "main.articles",
  "pk": 109,
  "fields": {
    "articlename": "Chun, S.K., Jang, J., Chung, S., Yun, H., Kim, N.J., Jung, J.W., Son, G.H., Suh, Y.G. and Kim, K., 2014. Identification and validation of cryptochrome inhibitors that modulate the molecular circadian clock. ACS chemical biology, 9(3), pp.703-710.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/24387302/"
  }
},
{
  "model": "main.articles",
  "pk": 110,
  "fields": {
    "articlename": "전승국, 2014. Development of circadian clock modulator and its application (Doctoral dissertation, 서울대학교 대학원).",
    "articleurl": "https://s-space.snu.ac.kr/handle/10371/121386"
  }
},
{
  "model": "main.articles",
  "pk": 111,
  "fields": {
    "articlename": "Jang, J., Chung, S., Choi, Y., Lim, H.Y., Son, Y., Chun, S.K., Son, G.H., Kim, K., Suh, Y.G. and Jung, J.W., 2018. The cryptochrome inhibitor KS15 enhances E-box-mediated transcription by disrupting the feedback action of a circadian transcription-repressor complex. Life sciences, 200, pp.49-55.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/29534992/"
  }
},
{
  "model": "main.articles",
  "pk": 112,
  "fields": {
    "articlename": "Solovev, I.A., Shaposhnikov, M.V. and Moskalev, A.A., 2021. Chronobiotics KL001 and KS15 extend lifespan and modify circadian rhythms of Drosophila melanogaster. Clocks & Sleep, 3(3), pp.429-441.",
    "articleurl": "https://www.mdpi.com/2624-5175/3/3/30"
  }
},
{
  "model": "main.articles",
  "pk": 113,
  "fields": {
    "articlename": "Hirota, T., Lee, J.W., St. John, P.C., Sawa, M., Iwaisako, K., Noguchi, T., Pongsawakul, P.Y., Sonntag, T., Welsh, D.K., Brenner, D.A. and Doyle III, F.J., 2012. Identification of small molecule activators of cryptochrome. Science, 337(6098), pp.1094-1097",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/22798407/"
  }
},
{
  "model": "main.articles",
  "pk": 114,
  "fields": {
    "articlename": "Iida, M., Nakane, Y., Yoshimura, T. and Hirota, T., 2022. Effects of cryptochrome-modulating compounds on circadian behavioural rhythms in zebrafish. Journal of Biochemistry, 171(5), pp.501-507.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/34528676/"
  }
},
{
  "model": "main.articles",
  "pk": 115,
  "fields": {
    "articlename": "Zhao, et al., 2024. Irbesartan ameliorates diabetic kidney injury in db/db mice by restoring circadian rhythm and cell cycle. Journal of translational internal medicine, 12(2), pp.157-169.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11117442/"
  }
},
{
  "model": "main.articles",
  "pk": 116,
  "fields": {
    "articlename": "Zhao, et al., 2024. Irbesartan ameliorates diabetic kidney injury in db/db mice by restoring circadian rhythm and cell cycle. Journal of translational internal medicine, 12(2), pp.157-169.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11117442/"
  }
},
{
  "model": "main.articles",
  "pk": 117,
  "fields": {
    "articlename": "Tamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10(5), p.e8724.",
    "articleurl": "https://www.embopress.org/action/oidcStart?redirectUri=%2Fdoi%2Fabs%2F10.15252%2Femmm.201708724"
  }
},
{
  "model": "main.articles",
  "pk": 118,
  "fields": {
    "articlename": "Hirota, T., Lewis, W.G., Liu, A.C., Lee, J.W., Schultz, P.G. and Kay, S.A., 2008. A chemical biology approach reveals period shortening of the mammalian circadian clock by specific inhibition of GSK-3β. Proceedings of the National Academy of Sciences, 105(52), pp.20746-20751.",
    "articleurl": "https://www.pnas.org/doi/abs/10.1073/pnas.0811410106"
  }
},
{
  "model": "main.articles",
  "pk": 119,
  "fields": {
    "articlename": "Shanware, N.P., Williams, L.M., Bowler, M.J. and Tibbetts, R.S., 2009. Non-specific in vivo inhibition of CK1 by the pyridinyl imidazole p38 inhibitors SB 203580 and SB 202190. BMB reports, 42(3), p.142.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4412876/"
  }
},
{
  "model": "main.articles",
  "pk": 120,
  "fields": {
    "articlename": "Sankrithi, N. and Eskin, A., 1999. Effects of Cyclin‐Dependent Kinase Inhibitors on Transcription and Ocular Circadian Rhythm of Aplysia. Journal of neurochemistry, 72(2), pp.605-613.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4412876/"
  }
},
{
  "model": "main.articles",
  "pk": 121,
  "fields": {
    "articlename": "Jones, K.A., Hatori, M., Mure, L.S., Bramley, J.R., Artymyshyn, R., Hong, S.P., Marzabadi, M., Zhong, H., Sprouse, J., Zhu, Q. and Hartwick, A.T., 2013. Small-molecule antagonists of melanopsin-mediated phototransduction. Nature chemical biology, 9(10), pp.630-635.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3839535/"
  }
},
{
  "model": "main.articles",
  "pk": 122,
  "fields": {
    "articlename": "Obayashi, K., Zou, R., Kawaguchi, T., Mori, T. and Tsukamoto, H., 2025. Molecular basis underlying the specificity of an antagonist AA92593 for mammalian melanopsins. Journal of Biological Chemistry, 301(5), p.108461.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/40154611/"
  }
},
{
  "model": "main.articles",
  "pk": 123,
  "fields": {
    "articlename": "Bertolesi, G.E., Debnath, N., Malik, H.R., Man, L.L. and McFarlane, S., 2022. Type II opsins in the eye, the pineal complex and the skin of Xenopus laevis: Using changes in skin pigmentation as a readout of visual and circadian activity. Frontiers in Neuroanatomy, 15, p.784478.",
    "articleurl": "https://www.frontiersin.org/journals/neuroanatomy/articles/10.3389/fnana.2021.784478/full"
  }
},
{
  "model": "main.articles",
  "pk": 124,
  "fields": {
    "articlename": "Sullivan, K.A., Grant, C.V., Jordan, K.R., Obrietan, K. and Pyter, L.M., 2022. Paclitaxel chemotherapy disrupts behavioral and molecular circadian clocks in mice. Brain, behavior, and immunity, 99, pp.106-118.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8671246/"
  }
},
{
  "model": "main.articles",
  "pk": 125,
  "fields": {
    "articlename": "Chen, S.J., Yu, F., Feng, X., Li, Q., Jiang, Y.H., Zhao, L.Q., Cheng, P.P., Wang, M., Song, L.J., Liang, L.M. and He, X.L., 2024. DEC1 is involved in circadian rhythm disruption-exacerbated pulmonary fibrosis. Cell Communication and Signaling, 22(1), p.245.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/38671456/"
  }
},
{
  "model": "main.articles",
  "pk": 126,
  "fields": {
    "articlename": "Jacob, H., Curtis, A.M. and Kearney, C.J., 2020. Therapeutics on the clock: circadian medicine in the treatment of chronic inflammatory diseases. Biochemical pharmacology, 182, p.114254.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/33010213/"
  }
},
{
  "model": "main.articles",
  "pk": 127,
  "fields": {
    "articlename": "Zhou, Z., Lin, Y., Gao, L., Yang, Z., Wang, S. and Wu, B., 2020. Circadian pharmacological effects of berberine on chronic colitis in mice: role of the clock component Rev-erbα. Biochemical pharmacology, 172, p.113773.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/31866303/"
  }
},
{
  "model": "main.articles",
  "pk": 128,
  "fields": {
    "articlename": "Ye, C., Zhang, Y., Lin, S., Chen, Y., Wang, Z., Feng, H., Fang, G. and Quan, S., 2023. Berberine ameliorates metabolic-associated fatty liver disease mediated metabolism disorder and redox homeostasis by upregulating clock genes: Clock and Bmal1 expressions. Molecules, 28(4), p.1874.",
    "articleurl": "https://www.mdpi.com/1420-3049/28/4/1874"
  }
},
{
  "model": "main.articles",
  "pk": 129,
  "fields": {
    "articlename": "De Crescenzo, F., D'Alò, G.L., Ostinelli, E.G., Ciabattini, M., Di Franco, V., Watanabe, N., Kurtulmus, A., Tomlinson, A., Mitrova, Z., Foti, F. and Del Giovane, C., 2022. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. The Lancet, 400(10347), pp.170-184.",
    "articleurl": "https://www.thelancet.com/article/S0140-6736(22)00878-9/fulltext"
  }
},
{
  "model": "main.articles",
  "pk": 130,
  "fields": {
    "articlename": "Turek, F.W. and Van Reeth, O., 1989. Use of benzodiazepines to manipulate the circadian clock regulating behavioral and endocrine rhythms. Hormone Research in Paediatrics, 31(1-2), pp.59-65.",
    "articleurl": "https://karger.com/hrp/article-abstract/31/1-2/59/365242/Use-of-Benzodiazepines-to-Manipulate-the-Circadian"
  }
},
{
  "model": "main.articles",
  "pk": 131,
  "fields": {
    "articlename": "https://pubmed.ncbi.nlm.nih.gov/35052310/",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/35052310/"
  }
},
{
  "model": "main.articles",
  "pk": 132,
  "fields": {
    "articlename": "Ward, L.G., Bourjeily, G., Guthrie, K., Salmoirago-Blotcher, E., Sharp, M., Desmarattes, A. and Bublitz, M., 2024. Sleep Quality in High-Risk Pregnancies: Mixed Methods Results from a Randomized Controlled Trial of a Mindfulness Training Intervention. Journal of Integrative and Complementary Medicine, 30(10), pp.953-960.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/38629887/"
  }
},
{
  "model": "main.articles",
  "pk": 133,
  "fields": {
    "articlename": "Wang, Y.Q., Takata, Y., Li, R., Zhang, Z., Zhang, M.Q., Urade, Y., Qu, W.M. and Huang, Z.L., 2015. Doxepin and diphenhydramine increased non-rapid eye movement sleep through blockade of histamine H1 receptors. Pharmacology Biochemistry and Behavior, 129, pp.56-64.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/25498564/"
  }
},
{
  "model": "main.articles",
  "pk": 134,
  "fields": {
    "articlename": "Morioka, E., Kanda, Y., Koizumi, H., Miyamoto, T. and Ikeda, M., 2018. Histamine regulates molecular clock oscillations in human retinal pigment epithelial cells via H1 receptors. Frontiers in endocrinology, 9, p.108.",
    "articleurl": "https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2018.00108/full"
  }
},
{
  "model": "main.articles",
  "pk": 135,
  "fields": {
    "articlename": "Yeung, W.F., Chung, K.F., Yung, K.P. and Ng, T.H.Y., 2015. Doxepin for insomnia: a systematic review of randomized placebo-controlled trials. Sleep medicine reviews, 19, pp.75-83.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/25047681/"
  }
},
{
  "model": "main.articles",
  "pk": 136,
  "fields": {
    "articlename": "Brunet, R., Caza, N. and Cyr, A., 1996. Food intake and circadian rhythms of activity of red-winged blackbirds (Agelaius phoeniceus). A time-course study on the effects of alpha-chloralose and secobarbital. Biological Rhythm Research, 27(2), pp.227-240.",
    "articleurl": "https://www.collectionscanada.gc.ca/obj/s4/f2/dsk3/ftp04/nq26376.pdf"
  }
},
{
  "model": "main.articles",
  "pk": 137,
  "fields": {
    "articlename": "Heel, C., Brogden, R.N., Speight, T.M. and Avery, G.S., 1981. Temazepam: a review of its pharmacological properties and therapeutic efficacy as an hypnotic. Drugs, 21, pp.321-340.",
    "articleurl": "https://europepmc.org/article/med/6112127"
  }
},
{
  "model": "main.articles",
  "pk": 138,
  "fields": {
    "articlename": "Seidel, W.F., Cohen, S.A., Bliwise, N.G., Roth, T. and Dement, W.C., 1986. Dose‐related effects of triazolam and flurazepam on a circadian rhythm insomnia. Clinical Pharmacology & Therapeutics, 40(3), pp.314-320.",
    "articleurl": "https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1038/clpt.1986.182"
  }
},
{
  "model": "main.articles",
  "pk": 139,
  "fields": {
    "articlename": "Turek, F.W. and Losee-Olson, S.H., 1987. Dose response curve for the phase-shifting effect of triazolam on the mammalian circadian clock. Life sciences, 40(11), pp.1033-1038.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/3821371/"
  }
},
{
  "model": "main.articles",
  "pk": 140,
  "fields": {
    "articlename": "Crowley, T.J. and Hydinger-Macdonald, M., 1979. Bedtime flurazepam and the human circadian rhythm of spontaneous motility. Psychopharmacology, 62, pp.157-161.",
    "articleurl": "https://link.springer.com/article/10.1007/BF00427130"
  }
},
{
  "model": "main.articles",
  "pk": 141,
  "fields": {
    "articlename": "Nikolenko, M.V., TKh, T. and Paromova, Y.I., 2015. EFFECT OF FLUCONAZOLE ON TEMPORAL ORGANIZATION OF BIOLOGICAL PROPERTIES OF CANDIDA ALBICANS. Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii, (4), pp.30-35.",
    "articleurl": "https://europepmc.org/article/med/26470415"
  }
},
{
  "model": "main.articles",
  "pk": 142,
  "fields": {
    "articlename": "Vogel, G.W. and Morris, D., 1992. The effects of estazolam on sleep, performance, and memory: a long‐term sleep laboratory study of elderly insomniacs. The Journal of Clinical Pharmacology, 32(7), pp.647-651.",
    "articleurl": "https://accp1.onlinelibrary.wiley.com/doi/abs/10.1002/j.1552-4604.1992.tb05776.x?casa_token=6B3qnViTGeIAAAAA:x5buso9R3HWdiI5_myhafaZrTUg8tNiaqTkTlunvjJPahl1_R44MXw8Q8uF0w265H_wDiLRUvlyIj8PR"
  }
},
{
  "model": "main.articles",
  "pk": 143,
  "fields": {
    "articlename": "Hilbert, J.M., Chung, M., Maier, G., Gural, R., Symchowicz, S. and Zampaglione, N., 1984. Effect of sleep on quazepam kinetics. Clinical Pharmacology & Therapeutics, 36(1), pp.99-104.",
    "articleurl": "https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1038/clpt.1984.146?casa_token=KKF3ysdqITMAAAAA:pD7a0Nf9UolDjgTQwlFu1zcM83EYd90kkALauwqRZUcKgDtzd6hc5Dn6kcqzeJaL-fWtmLCuHhQpfS6Z"
  }
},
{
  "model": "main.articles",
  "pk": 144,
  "fields": {
    "articlename": "Prinz, P.N., Vitiello, M.V., Raskind, M.A. and Thorpy, M.J., 1990. Sleep disorders and aging. New England Journal of Medicine, 323(8), pp.520-526.",
    "articleurl": "https://www.nejm.org/doi/abs/10.1056/NEJM199008233230805"
  }
},
{
  "model": "main.articles",
  "pk": 145,
  "fields": {
    "articlename": "Ashrafi, M.R., Mohammadi, M., Tafarroji, J., Shabanian, R., Salamati, P. and Zamani, G.R., 2010. Melatonin versus chloral hydrate for recording sleep EEG. european journal of paediatric neurology, 14(3), pp.235-238.",
    "articleurl": "https://www.sciencedirect.com/science/article/pii/S1090379809001111"
  }
},
{
  "model": "main.articles",
  "pk": 146,
  "fields": {
    "articlename": "Hinz, S., Lacher, S.K., Seibt, B.F. and Müller, C.E., 2014. BAY60-6583 acts as a partial agonist at adenosine A2B receptors. The Journal of pharmacology and experimental therapeutics, 349(3), pp.427-436.",
    "articleurl": "https://www.sciencedirect.com/science/article/pii/S0022356524186867"
  }
},
{
  "model": "main.articles",
  "pk": 147,
  "fields": {
    "articlename": "Masse, M., Henry, H., Cuvelier, E., Pinçon, C., Pavy, M., Beeuwsaert, A., Barthélémy, C., Cuny, D., Gautier, S., Kambia, N. and Lefebvre, J.M., 2022, January. Sleep medication in older adults: identifying the need for support by a community pharmacist. In Healthcare (Vol. 10, No. 1, p. 147). MDPI.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/35052310/"
  }
},
{
  "model": "main.articles",
  "pk": 148,
  "fields": {
    "articlename": "Jagannath, A., Varga, N., Dallmann, R., Rando, G., Gosselin, P., Ebrahimjee, F., Taylor, L., Mosneagu, D., Stefaniak, J., Walsh, S. and Palumaa, T., 2021. Adenosine integrates light and sleep signalling for the regulation of circadian timing in mice. Nature communications, 12(1), p.2113.",
    "articleurl": "https://www.nature.com/articles/s41467-021-22179-z#:~:text=Adenosine%20encodes%20sleep%20history%20and%20this%20signal,regulate%20the%20clock%20genes%20Per1%20and%20Per2."
  }
},
{
  "model": "main.articles",
  "pk": 149,
  "fields": {
    "articlename": "Cantisani, C., Ricci, S., Grieco, T., Paolino, G., Faina, V., Silvestri, E. and Calvieri, S., 2013. Topical promethazine side effects: our experience and review of the literature. BioMed research international, 2013(1), p.151509.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3852816/"
  }
},
{
  "model": "main.articles",
  "pk": 150,
  "fields": {
    "articlename": "Hoyer, D., Dürst, T., Fendt, M., Jacobson, L.H., Betschart, C., Hintermann, S., Behnke, D., Cotesta, S., Laue, G., Ofner, S. and Legangneux, E., 2013. Distinct effects of IPSU and suvorexant on mouse sleep architecture. Frontiers in neuroscience, 7, p.235.",
    "articleurl": "https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2013.00235/full"
  }
},
{
  "model": "main.articles",
  "pk": 151,
  "fields": {
    "articlename": "Morera, A.L., Abreu-Gonzalez, P. and Henry, M., 2009. Zaleplon increases nocturnal melatonin secretion in humans. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 33(6), pp.1013-1016.",
    "articleurl": "https://www.sciencedirect.com/science/article/abs/pii/S0278584609001638"
  }
},
{
  "model": "main.articles",
  "pk": 152,
  "fields": {
    "articlename": "Amodeo, L.R., Wills, D.N., Benedict, J. and Ehlers, C.L., 2025. Effects of daridorexant on rest/wake activity patterns and drinking in adult rats exposed to chronic ethanol vapor in adolescence. Alcohol, 124, pp.35-46.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/39870333/#:~:text=Both%20daridorexant%20doses%20led%20to,duration%20and%20inactive%20fragmentation%20ratio."
  }
},
{
  "model": "main.articles",
  "pk": 153,
  "fields": {
    "articlename": "Huang, X., Lin, D., Sun, Y., Wu, A. and Wei, C., 2021. Effect of dexmedetomidine on postoperative sleep quality: a systematic review. Drug design, development and therapy, pp.2161-2170.",
    "articleurl": "https://www.dovepress.com/effect-of-dexmedetomidine-on-postoperative-sleep-quality-a-systematic--peer-reviewed-fulltext-article-DDDT"
  }
},
{
  "model": "main.articles",
  "pk": 154,
  "fields": {
    "articlename": "https://pubmed.ncbi.nlm.nih.gov/33336219/",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/33336219/"
  }
},
{
  "model": "main.articles",
  "pk": 155,
  "fields": {
    "articlename": "Spahr, L., Coeytaux, A., Giostra, E., Hadengue, A. and Annoni, J.M., 2007. Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized controlled pilot trial. Official journal of the American College of Gastroenterology| ACG, 102(4), pp.744-753.",
    "articleurl": "https://journals.lww.com/ajg/abstract/2007/04000/histamine_h1_blocker_hydroxyzine_improves_sleep_in.9.aspx"
  }
},
{
  "model": "main.articles",
  "pk": 156,
  "fields": {
    "articlename": "Smith, V.M., Iannatonne, S., Achal, S., Jeffers, R.T. and Antle, M.C., 2014. The serotonergic anxiolytic buspirone attenuates circadian responses to light. European Journal of Neuroscience, 40(10), pp.3512-3525.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/25195769/"
  }
},
{
  "model": "main.articles",
  "pk": 157,
  "fields": {
    "articlename": "Cugini, P., Delogu, G., Casula, M.A., Gatta, L., Cascioli, C. and Di Palma, L., 1991. Anaesthesia‐induced dissociation between the circadian rhythms of blood pressure and heart rate. Biological Rhythm Research, 22(4), pp.333-340.",
    "articleurl": "https://www.tandfonline.com/doi/abs/10.1080/09291019109360118"
  }
},
{
  "model": "main.articles",
  "pk": 158,
  "fields": {
    "articlename": "Keuroghlian, A.S., Barry, A.S. and Weiss, R.D., 2012. Circadian dysregulation, zolpidem dependence, and withdrawal seizure in a resident physician performing shift work. The American Journal on Addictions/American Academy of Psychiatrists in Alcoholism and Addictions, 21(6), p.576.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3744365/"
  }
},
{
  "model": "main.articles",
  "pk": 159,
  "fields": {
    "articlename": "Keating, G.M., 2005. Zolpidem: a review of its use in the management of insomnia. CNS Drugs, 19(1), pp.65-89.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/15651908/"
  }
},
{
  "model": "main.articles",
  "pk": 160,
  "fields": {
    "articlename": "Copinschi, G., Akseki, E., Moreno-Reyes, R., Leproult, R., L'Hermite-Balériaux, M., Caufriez, A., Vertongen, F. and Cauter, E.V., 1995. Effects of Bedtime Administration of Zolpidem on Orcadian and Sleep-Related Hormonal Profiles in Normal Women. Sleep, 18(6), pp.417-424.",
    "articleurl": "https://academic.oup.com/sleep/article-abstract/18/6/417/2749661?redirectedFrom=fulltext"
  }
},
{
  "model": "main.articles",
  "pk": 161,
  "fields": {
    "articlename": "Krystal, A.D., Walsh, J.K., Laska, E., Caron, J., Amato, D.A., Wessel, T.C. and Roth, T., 2003. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep, 26(7), pp.793-799.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/14655910/"
  }
},
{
  "model": "main.articles",
  "pk": 162,
  "fields": {
    "articlename": "Suzuki, S., Katagiri, S. and Nakashima, H., 1996. Mutants with altered sensitivity to a calmodulin antagonist affect the circadian clock in Neurospora crassa. Genetics, 143(3), pp.1175-1180.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC1207388/"
  }
},
{
  "model": "main.articles",
  "pk": 163,
  "fields": {
    "articlename": "Nagayama, H., Takagi, A., Sakurai, Y., Nishiwaki, K. and Takahashi, R., 1978. Chronopharmacological study of neuroleptics: II. Circadian susceptibility rhythm to chlorpromazine. Psychopharmacology, 58, pp.49-53.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/97719/"
  }
},
{
  "model": "main.articles",
  "pk": 164,
  "fields": {
    "articlename": "Davies, J.A., 1979. The Influence of Dopaminergic Mechanism on 24-Hour Temperature and Activity Rhythms in Rodents. In Neuro-Psychopharmacology (pp. 611-620). Pergamon.",
    "articleurl": "https://www.sciencedirect.com/science/article/pii/B9780080230894500715"
  }
},
{
  "model": "main.articles",
  "pk": 165,
  "fields": {
    "articlename": "Romo‐Nava, F., Buijs, F.N., Valdés‐Tovar, M., Benítez‐King, G., Basualdo, M., Perusquía, M., Heinze, G., Escobar, C. and Buijs, R.M., 2017. Olanzapine‐induced early cardiovascular effects are mediated by the biological clock and prevented by melatonin. Journal of Pineal Research, 62(4), p.e12402.",
    "articleurl": "https://onlinelibrary.wiley.com/doi/full/10.1111/jpi.12402?casa_token=qj5Il6Iqz4EAAAAA%3AsXE22eVIh0so2TCQSfCsP7qwVi-dvhpkcn0wLlOOOCrmKTPsikGPubFm2SaNegDemAjM-1IRSG9iQxhs"
  }
},
{
  "model": "main.articles",
  "pk": 166,
  "fields": {
    "articlename": "Vidarsdottir, S., Roelfsema, F., Frolich, M. and Pijl, H., 2009. Olanzapine shifts the temporal relationship between the daily acrophase of serum prolactin and cortisol concentrations rhythm in healthy men. Psychoneuroendocrinology, 34(5), pp.705-712.",
    "articleurl": "https://www.sciencedirect.com/science/article/abs/pii/S030645300800320X"
  }
},
{
  "model": "main.articles",
  "pk": 167,
  "fields": {
    "articlename": "Calabrese, F., Savino, E., Papp, M., Molteni, R. and Riva, M.A., 2016. Chronic mild stress-induced alterations of clock gene expression in rat prefrontal cortex: modulatory effects of prolonged lurasidone treatment. Pharmacological research, 104, pp.140-150.",
    "articleurl": "https://www.sciencedirect.com/science/article/pii/S1043661815300864"
  }
},
{
  "model": "main.articles",
  "pk": 168,
  "fields": {
    "articlename": "Krystal, A.D. and Zammit, G., 2016. The sleep effects of lurasidone: a placebo‐controlled cross‐over study using a 4‐h phase‐advance model of transient insomnia. Human Psychopharmacology: Clinical and Experimental, 31(3), pp.206-216.",
    "articleurl": "https://onlinelibrary.wiley.com/doi/abs/10.1002/hup.2533?casa_token=D1QiuVEEzzwAAAAA:XBpsffY_W5zuUdpts41nWNqx-s9XH7WfHFTTOurXrjroBOyQFFvYJ-OedVaBcayEnxvDGl7MKbGhMwvi"
  }
},
{
  "model": "main.articles",
  "pk": 169,
  "fields": {
    "articlename": "Naber, D., Wirz-Justice, A. and Kafka, M.S., 1982. Chronic fluphenazine treatment modifies circadian rhythms of neurotransmitter receptor binding in rat brain. Journal of Neural Transmission, 55, pp.277-288.",
    "articleurl": "https://link.springer.com/article/10.1007/BF01243449"
  }
},
{
  "model": "main.articles",
  "pk": 170,
  "fields": {
    "articlename": "Wei, H., Zapata, R.C., Lopez-Valencia, M., Aslanoglou, D., Farino, Z.J., Benner, V., Osborn, O., Freyberg, Z. and McCarthy, M.J., 2020. Dopamine D2 receptor signaling modulates pancreatic beta cell circadian rhythms. Psychoneuroendocrinology, 113, p.104551.",
    "articleurl": "https://www.sciencedirect.com/science/article/abs/pii/S0306453019312922"
  }
},
{
  "model": "main.articles",
  "pk": 171,
  "fields": {
    "articlename": "Zapata, R.C., Silver, A., Yoon, D., Chaudry, B., Libster, A., McCarthy, M.J. and Osborn, O., 2022. Adverse effects of antipsychotic drugs on metabolism depend on drug dosing and feeding times. medRxiv, pp.2022-02.",
    "articleurl": "https://www.medrxiv.org/content/10.1101/2022.02.23.22271365.abstract"
  }
},
{
  "model": "main.articles",
  "pk": 172,
  "fields": {
    "articlename": "Cherukalady, R., Kumar, D., Basu, P. and Singaravel, M., 2017. Risperidone resets the circadian clock in mice. Biological Rhythm Research, 48(4), pp.583-591.",
    "articleurl": "https://www.tandfonline.com/doi/abs/10.1080/09291016.2017.1287820"
  }
},
{
  "model": "main.articles",
  "pk": 173,
  "fields": {
    "articlename": "Dagan, Y. and Borodkin, K., 2005. Behavioral and psychiatric consequences of sleep-wake schedule disorders. Dialogues in clinical neuroscience, 7(4), pp.357-365.",
    "articleurl": "https://www.tandfonline.com/doi/full/10.31887/DCNS.2005.7.4/ydagan"
  }
},
{
  "model": "main.articles",
  "pk": 174,
  "fields": {
    "articlename": "Bad News for Antipsychotics and Circadian Rhythms",
    "articleurl": "https://www.thecarlatreport.com/blogs/2-the-carlat-psychiatry-podcast/post/3338-bad-news-for-antipsychotics-and-circadian-rhythms-60-sec-psych-"
  }
},
{
  "model": "main.articles",
  "pk": 176,
  "fields": {
    "articlename": "Sun, L., Wang, Y., Song, Y., Cheng, X.R., Xia, S., Rahman, M.R., Shi, Y. and Le, G., 2015. Resveratrol restores the circadian rhythmic disorder of lipid metabolism induced by high-fat diet in mice. Biochemical and Biophysical Research Communications, 458(1), pp.86–91.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/25640840/"
  }
},
{
  "model": "main.articles",
  "pk": 177,
  "fields": {
    "articlename": "Spaleniak, W. and Cuendet, M., 2023. Resveratrol as a circadian clock modulator: mechanisms of action and therapeutic applications. Molecular Biology Reports, 50, pp.6159–6170.",
    "articleurl": "https://link.springer.com/article/10.1007/s11033-023-08513-2"
  }
},
{
  "model": "main.articles",
  "pk": 178,
  "fields": {
    "articlename": "Avital-Cohen, N., Chapnik, N. and Froy, O., 2024. Resveratrol induces myotube development by altering circadian metabolism via the SIRT1-AMPK-PP2A axis. Cells, 13, p.1069.",
    "articleurl": "https://www.mdpi.com/2073-4409/13/12/1069"
  }
},
{
  "model": "main.articles",
  "pk": 179,
  "fields": {
    "articlename": "Tian, Y., Luan, X. and Yang, K., 2024. Chronotherapy involving rosiglitazone regulates the phenotypic switch of vascular smooth muscle cells by shifting the phase of TNF-α rhythm through triglyceride accumulation in macrophages. Heliyon, 10(10), p.e30708.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/38803898/"
  }
},
{
  "model": "main.articles",
  "pk": 180,
  "fields": {
    "articlename": "Tian, Y., Luan, X. and Yang, K., 2024. Chronotherapy involving rosiglitazone regulates the phenotypic switch of vascular smooth muscle cells by shifting the phase of TNF-α rhythm through triglyceride accumulation in macrophages. Heliyon, 10(10), p.e30708.",
    "articleurl": "https://www.sciencedirect.com/science/article/pii/S2405844024067392"
  }
},
{
  "model": "main.articles",
  "pk": 181,
  "fields": {
    "articlename": "Arendt, J. and Skene, D.J., 2005. Melatonin as a chronobiotic. Sleep Medicine Reviews, 9(1), pp.25–39.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/15649736/"
  }
},
{
  "model": "main.articles",
  "pk": 182,
  "fields": {
    "articlename": "Pévet, P., Bothorel, B., Slotten, H. and Saboureau, M., 2002. The chronobiotic properties of melatonin. Cell and Tissue Research, 309, pp.183–191.",
    "articleurl": "https://link.springer.com/article/10.1007/s00441-002-0584-1"
  }
},
{
  "model": "main.articles",
  "pk": 183,
  "fields": {
    "articlename": "Cardinali, D.P., 2024. Melatonin as a chronobiotic/cytoprotective agent in bone. Doses involved. Journal of Pineal Research, 76(1), p.e12931.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/38083808/"
  }
},
{
  "model": "main.articles",
  "pk": 184,
  "fields": {
    "articlename": "Richardson, G.S., Zee, P.C., Wang-Weigand, S., Rodriguez, L. and Peng, X., 2008. Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. Journal of Clinical Sleep Medicine, 4(5), pp.456–461.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2576313/#:~:text=Conclusion,treatment%20of%20specific%20clinical%20conditions."
  }
},
{
  "model": "main.articles",
  "pk": 185,
  "fields": {
    "articlename": "Takeshima, M., Shimizu, T., Ishikawa, H. and Kanbayashi, T., 2020. Ramelteon for delayed sleep-wake phase disorder: a case report. Clinical Psychopharmacology and Neuroscience, 18(1), pp.167–169.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7006983/#:~:text=In%20a%20previous%20study%20investigating,to%20have%20remained%20in%20remission."
  }
},
{
  "model": "main.articles",
  "pk": 186,
  "fields": {
    "articlename": "Zammit, G.K., 2007. Ramelteon: a novel hypnotic indicated for the treatment of insomnia. Psychiatry (Edgmont), 4(9), pp.36–42.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2880941/#:~:text=Unlike%20other%20sedative%2Dhypnotics%2C%20which,for%20addiction%20to%20traditional%20hypnotics."
  }
},
{
  "model": "main.articles",
  "pk": 187,
  "fields": {
    "articlename": "Liu, W., Chen, Z., Li, R., Zheng, M., Pang, X., Wen, A., Yang, B. and Wang, S., 2023. High and low dose of luzindole or 4-phenyl-2-propionamidotetralin (4-P-PDOT) reverse bovine granulosa cell response to melatonin. PeerJ, 11, p.e14612.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/36684672/"
  }
},
{
  "model": "main.articles",
  "pk": 188,
  "fields": {
    "articlename": "Pandi-Perumal, S.R., Moscovitch, A., Srinivasan, V., Spence, D.W., Cardinali, D.P. and Brown, G.M., 2009. Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine. Progress in Neurobiology, 88(4), pp.264–271.",
    "articleurl": "https://www.sciencedirect.com/science/article/abs/pii/S0301008209000628#:~:text=Because%20agomelatine%20is%20a%20specific,SCN%20is%20a%20prolonged%20one."
  }
},
{
  "model": "main.articles",
  "pk": 189,
  "fields": {
    "articlename": "Tchekalarova, J., Stoynova, T., Ilieva, K., Mitreva, R. and Atanasova, M., 2018. Agomelatine treatment corrects symptoms of depression and anxiety by restoring the disrupted melatonin circadian rhythms of rats exposed to chronic constant light. Pharmacology Biochemistry and Behavior, 171, pp.1–9.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/29807067/"
  }
},
{
  "model": "main.articles",
  "pk": 190,
  "fields": {
    "articlename": "Spadoni, G., Bedini, A., Diamantini, G., Tarzia, G., Rivara, S., Lorenzi, S., Lodola, A., Mor, M., Lucini, V., Pannacci, M., Caronno, A. and Fraschini, F., 2007. Synthesis, enantiomeric resolution, and structure–activity relationship study of a series of 10,11-dihydro-5H-dibenzo[a,d]cycloheptene MT2 receptor antagonists. ChemMedChem, 2(12), pp.1741–1749.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/17907131/"
  }
},
{
  "model": "main.articles",
  "pk": 191,
  "fields": {
    "articlename": "Lucini, V., Pannacci, M., Scaglione, F., Fraschini, F., Rivara, S., Mor, M., Bordi, F., Plazzi, P.V., Spadoni, G., Bedini, A., Piersanti, G., Diamantini, G. and Tarzia, G., 2004. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity. Journal of Medicinal Chemistry, 47(17), pp.4202–4212.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/15293992/"
  }
},
{
  "model": "main.articles",
  "pk": 192,
  "fields": {
    "articlename": "Pintor, J., Peláez, T., Hoyle, C.H. and Peral, A., 2003. Ocular hypotensive effects of melatonin receptor agonists in the rabbit: further evidence for an MT3 receptor. British Journal of Pharmacology, 138(5), pp.831–836.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/12642384/"
  }
},
{
  "model": "main.articles",
  "pk": 193,
  "fields": {
    "articlename": "Crooke, A., Huete-Toral, F., Martínez-Águila, A., Martín-Gil, A. and Pintor, J., 2012. Involvement of carbonic anhydrases in the ocular hypotensive effect of melatonin analogue 5-MCA-NAT. Journal of Pineal Research, 52(3), pp.265–270.",
    "articleurl": "https://onlinelibrary.wiley.com/doi/full/10.1111/j.1600-079X.2011.00938.x?casa_token=7Ryr8cVAOGsAAAAA%3AjR8DYkfYN1Efvc5BeD_j0VhbDFkuvUgjuB6XXDzKIn9jwdivrMzocs77wTaft_ml96vEKnXoGseZt957"
  }
},
{
  "model": "main.articles",
  "pk": 194,
  "fields": {
    "articlename": "Descamps-François, C., Yous, S., Chavatte, P., Audinot, V., Bonnaud, A., Boutin, J.A., Delagrange, P., Bennejean, C., Renard, P. and Lesieur, D., 2003. Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands. Journal of Medicinal Chemistry, 46(7), pp.1127–1129.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/12646022/"
  }
},
{
  "model": "main.articles",
  "pk": 195,
  "fields": {
    "articlename": "Audinot, V., Mailliet, F., Lahaye-Brasseur, C., Bonnaud, A., Le Gall, A., Amossé, C., Dromaint, S., Rodriguez, M., Nagel, N., Galizzi, J.P., Malpaux, B., Guillaumet, G., Lesieur, D., Lefoulon, F., Renard, P., Delagrange, P. and Boutin, J.A., 2003. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn–Schmiedeberg’s Archives of Pharmacology, 367(6), pp.553–561.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/12764576/"
  }
},
{
  "model": "main.articles",
  "pk": 196,
  "fields": {
    "articlename": "González, S., Moreno-Delgado, D., Moreno, E., Pérez-Capote, K., Franco, R., Mallol, J., Cortés, A., Casadó, V., Lluís, C., Ortiz, J., Ferré, S., Canela, E. and McCormick, P.J., 2012. Circadian-related heteromerization of adrenergic and dopamine D₄ receptors modulates melatonin synthesis and release in the pineal gland. PLoS Biology, 10(6), p.e1001347.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/22723743/"
  }
},
{
  "model": "main.articles",
  "pk": 197,
  "fields": {
    "articlename": "Masana, M.I., Benloucif, S. and Dubocovich, M.L., 2000. Circadian rhythm of MT1 melatonin receptor expression in the suprachiasmatic nucleus of the C3H/HeN mouse. Journal of Pineal Research, 28(3), pp.185–192.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/10739306/#:~:text=2%2D%5B125I%5D%2DIodomelatonin,cycle%20and%20constant%20dark%20conditions."
  }
},
{
  "model": "main.articles",
  "pk": 198,
  "fields": {
    "articlename": "Larson-Prior, L.J., Siuciak, J.A. and Dubocovich, M.L., 1996. Localization of 2-[¹²⁵I]iodomelatonin binding sites in visual areas of the turtle brain. European Journal of Pharmacology, 297(1–2), pp.181–185.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/8851181/#:~:text=Abstract,within%20the%20central%20nervous%20system."
  }
},
{
  "model": "main.articles",
  "pk": 199,
  "fields": {
    "articlename": "Mendoza-Vargas, L., Solís-Chagoyán, H., Benítez-King, G. and Fuentes-Pardo, B., 2009. MT2-like melatonin receptor modulates amplitude receptor potential in visual cells of crayfish during a 24-hour cycle. Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology, 154(4), pp.486–492.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/19666131/"
  }
},
{
  "model": "main.articles",
  "pk": 200,
  "fields": {
    "articlename": "Ambriz-Tututi, M. and Granados-Soto, V., 2007. Oral and spinal melatonin reduces tactile allodynia in rats via activation of MT2 and opioid receptors. Pain, 132(3), pp.273–280.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/17346886/"
  }
},
{
  "model": "main.articles",
  "pk": 201,
  "fields": {
    "articlename": "Nishimon, S., Nishimon, M. and Nishino, S., 2019. Tasimelteon for treating non-24-h sleep–wake rhythm disorder. Expert Opinion on Pharmacotherapy, 20(9), pp.1065–1073.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/30990759/#:~:text=Tasimelteon%20entrains%20circadian%20rhythms%20and,continued%20it%20maintained%20circadian%20entrainment."
  }
},
{
  "model": "main.articles",
  "pk": 202,
  "fields": {
    "articlename": "Torres, R., Kramer, W.G. and Baroldi, P., 2015. Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects with hepatic or renal impairment. Journal of Clinical Pharmacology, 55(5), pp.525–533.",
    "articleurl": "https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/jcph.440"
  }
},
{
  "model": "main.articles",
  "pk": 203,
  "fields": {
    "articlename": "Tchekalarova, J., Stoynova, T., Ilieva, K., Mitreva, R. and Atanasova, M., 2018. Agomelatine treatment corrects symptoms of depression and anxiety by restoring the disrupted melatonin circadian rhythms of rats exposed to chronic constant light. Pharmacology Biochemistry and Behavior, 171, pp.1–9.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/29807067/"
  }
},
{
  "model": "main.articles",
  "pk": 204,
  "fields": {
    "articlename": "Mairesse, J., Silletti, V., Laloux, C., Zuena, A.R., Giovine, A., Consolazione, M., van Camp, G., Malagodi, M., Gaetani, S., Cianci, S., Catalani, A., Mennuni, G., Mazzetta, A., van Reeth, O., Gabriel, C., Mocaër, E., Nicoletti, F., Morley-Fletcher, S. and Maccari, S., 2013. Chronic agomelatine treatment corrects the abnormalities in the circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restraint stress in adult rats. International Journal of Neuropsychopharmacology, 16",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/22310059/#:~:text=PRS%20was%20delivered%20to%20the,circadian%20rhythms%20under%20pathological%20conditions."
  }
},
{
  "model": "main.articles",
  "pk": 205,
  "fields": {
    "articlename": "Ferreira, M.A. Jr, Azevedo, H., Mascarello, A., Segretti, N.D., Russo, E., Russo, V. and Guimarães, C.R.W., 2021. Discovery of ACH-000143: a novel potent and peripherally preferred melatonin receptor agonist that reduces liver triglycerides and steatosis in diet-induced obese rats. Journal of Medicinal Chemistry, 64(4), pp.1904–1929.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/33626870/"
  }
},
{
  "model": "main.articles",
  "pk": 206,
  "fields": {
    "articlename": "Tchekalarova, J., Kortenska, L., Marinov, P. and Ivanova, N., 2022. Sex-dependent effects of piromelatine treatment on sleep–wake cycle and sleep structure of prenatally stressed rats. International Journal of Molecular Sciences, 23(18), p.10349.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/36142262/"
  }
},
{
  "model": "main.articles",
  "pk": 207,
  "fields": {
    "articlename": "She, M., Hu, X., Su, Z., Zhang, C., Yang, S., Ding, L., Laudon, M. and Yin, W., 2014. Piromelatine, a novel melatonin receptor agonist, stabilizes metabolic profiles and ameliorates insulin resistance in chronic sleep restricted rats. European Journal of Pharmacology, 727, pp.60–65.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/24486392/"
  }
},
{
  "model": "main.articles",
  "pk": 208,
  "fields": {
    "articlename": "Radogna, F., Paternoster, L., De Nicola, M., Cerella, C., Ammendola, S., Bedini, A., Tarzia, G., Aquilano, K., Ciriolo, M. and Ghibelli, L., 2009. Rapid and transient stimulation of intracellular reactive oxygen species by melatonin in normal and tumor leukocytes. Toxicology and Applied Pharmacology, 239(1), pp.37–45.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/19463840/"
  }
},
{
  "model": "main.articles",
  "pk": 209,
  "fields": {
    "articlename": "Mor, M., Spadoni, G., Di Giacomo, B., Diamantini, G., Bedini, A., Tarzia, G., Plazzi, P.V., Rivara, S., Nonno, R., Lucini, V., Pannacci, M., Fraschini, F. and Stankov, B.M., 2001. Synthesis, pharmacological characterization and QSAR studies on 2-substituted indole melatonin receptor ligands. Bioorganic & Medicinal Chemistry, 9(4), pp.1045–1057.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/11354661/"
  }
},
{
  "model": "main.articles",
  "pk": 210,
  "fields": {
    "articlename": "Richardson, G.S., Zee, P.C., Wang-Weigand, S., Rodriguez, L. and Peng, X., 2008. Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. Journal of Clinical Sleep Medicine, 4(5), pp.456–461.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2576313/#:~:text=Ramelteon%20(1%2C%202%2C%20or,in%20the%20sleep%2Dwake%20cycle."
  }
},
{
  "model": "main.articles",
  "pk": 211,
  "fields": {
    "articlename": "Richardson, G.S., Zee, P.C., Wang-Weigand, S., Rodriguez, L. and Peng, X., 2008. Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. Journal of Clinical Sleep Medicine, 4(5), pp.456–461.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/18853704/"
  }
},
{
  "model": "main.articles",
  "pk": 212,
  "fields": {
    "articlename": "Backlund, P.S., Urbanski, H.F., Doll, M.A., Hein, D.W., Bozinoski, M., Mason, C.E., Coon, S.L. and Klein, D.C., 2017. Daily rhythm in plasma N-acetyltryptamine. Journal of Biological Rhythms, 32(3), pp.195–211.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/28466676/#:~:text=Analysis%20of%2024%2Dh%20blood,among%20the%204%20animals%20studied."
  }
},
{
  "model": "main.articles",
  "pk": 213,
  "fields": {
    "articlename": "Backlund, P.S., Urbanski, H.F., Doll, M.A., Hein, D.W., Bozinoski, M., Mason, C.E., Coon, S.L. and Klein, D.C., 2017. Daily rhythm in plasma N-acetyltryptamine. Journal of Biological Rhythms, 32(3), pp.195–211.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/28466676/"
  }
},
{
  "model": "main.articles",
  "pk": 214,
  "fields": {
    "articlename": "Pohanka, M., 2022. New uses of melatonin as a drug: a review. Current Medicinal Chemistry, 29(20), pp.3622–3637.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/28466676/"
  }
},
{
  "model": "main.articles",
  "pk": 215,
  "fields": {
    "articlename": "Karim, A., Tolbert, D. and Cao, C., 2006. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. Journal of Clinical Pharmacology, 46(2), pp.140–148.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/16432265/"
  }
},
{
  "model": "main.articles",
  "pk": 216,
  "fields": {
    "articlename": "Rajaratnam, S.M., Middleton, B., Stone, B.M., Arendt, J. and Dijk, D.J., 2004. Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in extended sleep opportunities in humans. Journal of Physiology, 561(1), pp.339–351.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC1665336/#:~:text=Each%20laboratory%20trial%20commenced%20at,2003)."
  }
},
{
  "model": "main.articles",
  "pk": 217,
  "fields": {
    "articlename": "Dubocovich, M.L., 2007. Melatonin receptors: role on sleep and circadian rhythm regulation. Sleep Medicine, 8(Suppl 3), pp.34–42.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/18032103/"
  }
},
{
  "model": "main.articles",
  "pk": 218,
  "fields": {
    "articlename": "Bogaards, J.J., Hissink, E.M., Briggs, M., Weaver, R., Jochemsen, R., Jackson, P., Bertrand, M. and van Bladeren, P.J., 2000. Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling. European Journal of Pharmaceutical Sciences, 12(2), pp.117–124.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/11102739/"
  }
},
{
  "model": "main.articles",
  "pk": 219,
  "fields": {
    "articlename": "Hardeland, R., 2016. Melatonin and synthetic melatoninergic agonists in psychiatric and age-associated disorders: successful and unsuccessful approaches. Current Pharmaceutical Design, 22(8), pp.1086–1101.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/25248806/"
  }
},
{
  "model": "main.articles",
  "pk": 220,
  "fields": {
    "articlename": "Szabadi, E., 2015. Neuronal networks regulating sleep and arousal: effect of drugs. In: Guglietta, A. (ed.) Drug Treatment of Sleep Disorders. Milestones in Drug Therapy. Springer, Cham, pp.25–70.",
    "articleurl": "https://link.springer.com/chapter/10.1007/978-3-319-11514-6_2#:~:text=The%20drugs%20to%20treat%20insomnia,classified%20as%20general%20(nonselective)%20CNS"
  }
},
{
  "model": "main.articles",
  "pk": 221,
  "fields": {
    "articlename": "Masson-Pévet, M., Recio, J., Guerrero, H.Y., Mocaer, E., Delagrange, P., Guardiola-Lemaitre, B. and Pévet, P., 1998. Effects of two melatonin analogues, S-20098 and S-20928, on melatonin receptors in the pars tuberalis of the rat. Journal of Pineal Research, 25(3), pp.172–176.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/9745986/"
  }
},
{
  "model": "main.articles",
  "pk": 222,
  "fields": {
    "articlename": "Willis, G.L. and Robertson, A.D., 2005. Recovery from experimental Parkinson's disease in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride treated marmoset with the melatonin analogue ML-23. Pharmacology Biochemistry and Behavior, 80(1), pp.9–26.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/15652376/"
  }
},
{
  "model": "main.articles",
  "pk": 223,
  "fields": {
    "articlename": "Behrens, U.D., Douglas, R.H., Sugden, D., Davies, D.J. and Wagner, H.J., 2000. Effect of melatonin agonists and antagonists on horizontal cell spinule formation and dopamine release in a fish retina. Cell and Tissue Research, 299(3), pp.299–306.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/10772244/"
  }
},
{
  "model": "main.articles",
  "pk": 224,
  "fields": {
    "articlename": "Beresford, I.J., Harvey, F.J., Hall, D.A. and Giles, H., 1998. Pharmacological characterisation of melatonin MT1 receptor-mediated stimulation of [³⁵S]-GTPγS binding. Biochemical Pharmacology, 56(9), pp.1167–1174.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/9802327/"
  }
},
{
  "model": "main.articles",
  "pk": 225,
  "fields": {
    "articlename": "Fratter, A., 2013. Nanoemulsion technology for sublingual delivery of melatonin: characterization and preliminary data on a new administration system. In: New Developments in Melatonin Research. Nova Science Publishers, New York. ISBN: 978-1-62618-880-8.",
    "articleurl": "https://www.researchgate.net/publication/304172087_New_Development_in_Melatonine_Research"
  }
},
{
  "model": "main.articles",
  "pk": 226,
  "fields": {
    "articlename": "Audinot, V., Mailliet, F., Lahaye-Brasseur, C., Bonnaud, A., Le Gall, A., Amossé, C., Dromaint, S., Rodriguez, M., Nagel, N., Galizzi, J.P., Malpaux, B., Guillaumet, G., Lesieur, D., Lefoulon, F., Renard, P., Delagrange, P. and Boutin, J.A., 2003. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn–Schmiedeberg’s Archives of Pharmacology, 367(6), pp.553–561.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/12764576/"
  }
},
{
  "model": "main.articles",
  "pk": 227,
  "fields": {
    "articlename": "Millan, M.J., Gobert, A., Lejeune, F., Dekeyne, A., Newman-Tancredi, A., Pasteau, V., Rivet, J.M. and Cussac, D., 2003. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. Journal of Pharmacology and Experimental Therapeutics, 306(3), pp.954–964.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/12750432/"
  }
},
{
  "model": "main.articles",
  "pk": 228,
  "fields": {
    "articlename": "Aguiar, C.C., Almeida, A.B., Araújo, P.V., Vasconcelos, G.S., Chaves, E.M., do Vale, O.C., Macêdo, D.S., Leal, L.K., de Barros Viana, G.S. and Vasconcelos, S.M., 2013. Effects of agomelatine on oxidative stress in the brain of mice after chemically induced seizures. Cellular and Molecular Neurobiology, 33(6), pp.825–835.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/23801192/"
  }
},
{
  "model": "main.articles",
  "pk": 229,
  "fields": {
    "articlename": "Teh, M.T. and Sugden, D., 1999. The putative melatonin receptor antagonist GR128107 is a partial agonist on Xenopus laevis melanophores. British Journal of Pharmacology, 126(5), pp.1237–1245.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/10205014/"
  }
},
{
  "model": "main.articles",
  "pk": 230,
  "fields": {
    "articlename": "Teh, M.T. and Sugden, D., 1999. The putative melatonin receptor antagonist GR128107 is a partial agonist on Xenopus laevis melanophores. British Journal of Pharmacology, 126(5), pp.1237–1245.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC1565880/"
  }
},
{
  "model": "main.articles",
  "pk": 231,
  "fields": {
    "articlename": "Ferreira, M.A. Jr, Azevedo, H., Mascarello, A., Segretti, N.D., Russo, E., Russo, V. and Guimarães, C.R.W., 2021. Discovery of ACH-000143: a novel potent and peripherally preferred melatonin receptor agonist that reduces liver triglycerides and steatosis in diet-induced obese rats. Journal of Medicinal Chemistry, 64(4), pp.1904–1929.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/33626870/"
  }
},
{
  "model": "main.articles",
  "pk": 232,
  "fields": {
    "articlename": "Jockers, R., Delagrange, P., Dubocovich, M.L., Markus, R.P., Renault, N., Tosini, G., Cecon, E. and Zlotos, D.P., 2016. Update on melatonin receptors: IUPHAR Review 20. British Journal of Pharmacology, 173(18), pp.2702–2725.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4995287/"
  }
},
{
  "model": "main.articles",
  "pk": 233,
  "fields": {
    "articlename": "Boutin, J.A., Witt-Enderby, P.A., Sotriffer, C. and Zlotos, D.P., 2020. Melatonin receptor ligands: a pharmaco-chemical perspective. Journal of Pineal Research, 69(2), p.e12672.",
    "articleurl": "https://onlinelibrary.wiley.com/doi/10.1111/jpi.12672"
  }
},
{
  "model": "main.articles",
  "pk": 234,
  "fields": {
    "articlename": "Park, W.R., Choi, B., Kim, Y.J., Kim, Y.H., Park, M.J., Kim, D.I., Choi, H.S. and Kim, D.K., 2022. Melatonin regulates iron homeostasis by inducing hepcidin expression in hepatocytes. International Journal of Molecular Sciences, 23(7), p.3593.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/35408955/"
  }
},
{
  "model": "main.articles",
  "pk": 235,
  "fields": {
    "articlename": "Wu, H.M., Shen, Q.Y., Fang, L., Zhang, S.H., Shen, P.T., Liu, Y.J. and Liu, R.Y., 2016. JNK-TLR9 signal pathway mediates allergic airway inflammation through suppressing melatonin biosynthesis. Journal of Pineal Research, 60(4), pp.415–423.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/26914888/"
  }
},
{
  "model": "main.articles",
  "pk": 236,
  "fields": {
    "articlename": "Lafaye, G., Desterke, C., Marulaz, L. and Benyamina, A., 2019. Cannabidiol affects circadian clock core complex and its regulation in microglia cells. Addiction Biology, 24(5), pp.921–934.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/30307084/"
  }
},
{
  "model": "main.articles",
  "pk": 237,
  "fields": {
    "articlename": "Koch, M., Dehghani, F., Habazettl, I., Schomerus, C. and Korf, H.W., 2006. Cannabinoids attenuate norepinephrine-induced melatonin biosynthesis in the rat pineal gland by reducing arylalkylamine N-acetyltransferase activity without involvement of cannabinoid receptors. Journal of Neurochemistry, 98(1), pp.267–278.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/30307084/"
  }
},
{
  "model": "main.articles",
  "pk": 238,
  "fields": {
    "articlename": "Kaul, M., Zee, P.C. and Sahni, A.S., 2021. Effects of cannabinoids on sleep and their therapeutic potential for sleep disorders. Neurotherapeutics, 18(1), pp.217–227.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8116407/"
  }
},
{
  "model": "main.articles",
  "pk": 239,
  "fields": {
    "articlename": "Peball, M., Heim, B., Carbone, F., Schorr, O., Werkmann, M., Ellmerer, P., Marini, K., Krismer, F., Knaus, H.G., Poewe, W., Djamshidian, A. and Seppi, K., 2024. Long-term safety and efficacy of open-label nabilone on sleep and pain in Parkinson’s disease. NPJ Parkinson’s Disease, 10(1), p.61.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/38491070/"
  }
},
{
  "model": "main.articles",
  "pk": 240,
  "fields": {
    "articlename": "Gulledge, M., Carlezon, W.A. Jr, McHugh, R.K., Kinard, E.A., Prerau, M.J. and Chartoff, E.H., 2025. Spontaneous oxycodone withdrawal disrupts sleep, diurnal, and electrophysiological dynamics in rats. PLoS One, 20(1), p.e0312794.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/39823427/#:~:text=We%20continuously%20recorded%20EEG%20and,mechanisms%20of%20opioid%2Dsleep%20interactions."
  }
},
{
  "model": "main.articles",
  "pk": 241,
  "fields": {
    "articlename": "Pierce, B.E., Holter, K., Morton, A., Lekander, A., Bedingham, E., Curry, R. and Gould, R.W., 2022. Effects of oxycodone self-administration on sleep duration and quality in male and female rats. The FASEB Journal, 36(S1), p.R3946.",
    "articleurl": "https://faseb.onlinelibrary.wiley.com/doi/10.1096/fasebj.2022.36.S1.R3946"
  }
},
{
  "model": "main.articles",
  "pk": 242,
  "fields": {
    "articlename": "Du, K., Shi, Q., Zhou, X., Zhang, L., Su, H., Zhang, C., Wei, Z., Liu, T., Wang, L., Wang, X., Cong, B. and Yun, K., 2024. Melatonin attenuates fentanyl-induced behavioral sensitization and circadian rhythm disorders in mice. Physiology & Behavior, 279, p.114523",
    "articleurl": "https://www.sciencedirect.com/science/article/abs/pii/S0031938424000684"
  }
},
{
  "model": "main.articles",
  "pk": 243,
  "fields": {
    "articlename": "Gillman, A.G., Leffel, J.K. 2nd, Kosobud, A.E. and Timberlake, W., 2009. Fentanyl, but not haloperidol, entrains persisting circadian activity episodes when administered at 24- and 31-h intervals. Behavioural Brain Research, 205(1), pp.102–114.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/19595707/"
  }
},
{
  "model": "main.articles",
  "pk": 244,
  "fields": {
    "articlename": "Young, A.M., Thompson, T., Jensen, M.A. and Muchow, L.R., 1979. Effects of response-contingent clock stimuli on behavior maintained by intravenous codeine in the rhesus monkey. Pharmacology Biochemistry and Behavior, 11(1), pp.43–49.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/115015/"
  }
},
{
  "model": "main.articles",
  "pk": 245,
  "fields": {
    "articlename": "Warfield, A.E., Prather, J.F. and Todd, W.D., 2021. Systems and circuits linking chronic pain and circadian rhythms. Frontiers in Neuroscience, 15, p.705173.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/34276301/"
  }
},
{
  "model": "main.articles",
  "pk": 246,
  "fields": {
    "articlename": "Sharma, P. and Nelson, R.J., 2024. Disrupted circadian rhythms and substance use disorders: a narrative review. Clocks & Sleep, 6(3), pp.446–467.",
    "articleurl": "https://www.mdpi.com/2624-5175/6/3/30"
  }
},
{
  "model": "main.articles",
  "pk": 247,
  "fields": {
    "articlename": "Pačesová, D., Novotný, J. and Bendová, Z., 2016. The effect of chronic morphine or methadone exposure and withdrawal on clock gene expression in the rat suprachiasmatic nucleus and AA-NAT activity in the pineal gland. Physiological Research, 65(3), pp.517–525.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/27070740/"
  }
},
{
  "model": "main.articles",
  "pk": 248,
  "fields": {
    "articlename": "Pačesová, D., Spišská, V., Novotný, J. and Bendová, Z., 2023. Methadone administered to rat dams during pregnancy and lactation affects the circadian rhythms of their pups. Journal of Neuroscience Research, 101(11), pp.1737–1756.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/37551165/#:~:text=Methadone%20administered%20to%20rat%20dams,circadian%20rhythms%20of%20their%20pups"
  }
},
{
  "model": "main.articles",
  "pk": 249,
  "fields": {
    "articlename": "Hakami, A.Y., Alghamdi, B.S. and Alshehri, F.S., 2024. Exploring the potential use of melatonin as a modulator of tramadol-induced rewarding effects in rats. Frontiers in Pharmacology, 15, p.1373746.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/38738177/"
  }
},
{
  "model": "main.articles",
  "pk": 250,
  "fields": {
    "articlename": "Liu, X.P. and Song, J.G., 2001. [Chronopharmacology of tramadol in mice]. Yao Xue Xue Bao (Acta Pharmaceutica Sinica), 36(8), pp.561–564.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/12579929/"
  }
},
{
  "model": "main.articles",
  "pk": 251,
  "fields": {
    "articlename": "Pjrek, E., Frey, R., Naderi-Heiden, A., Strnad, A., Kowarik, A., Kasper, S. and Winkler, D., 2012. Actigraphic measurements in opioid detoxification with methadone or buprenorphine. Journal of Clinical Psychopharmacology, 32(1), pp.75–82",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/22198453/"
  }
},
{
  "model": "main.articles",
  "pk": 252,
  "fields": {
    "articlename": "Gauthier, E.A., Guzick, S.E., Brummett, C.M., Baghdoyan, H.A. and Lydic, R., 2011. Buprenorphine disrupts sleep and decreases adenosine concentrations in sleep-regulating brain regions of Sprague Dawley rat. Anesthesiology, 115(4), pp.743–753.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3197808/"
  }
},
{
  "model": "main.articles",
  "pk": 253,
  "fields": {
    "articlename": "Challet, E., Gourmelen, S., Pevet, P., Oberling, P. and Pain, L., 2007. Reciprocal relationships between general (propofol) anesthesia and circadian time in rats. Neuropsychopharmacology, 32(3), pp.728–735.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/16641940/"
  }
},
{
  "model": "main.articles",
  "pk": 254,
  "fields": {
    "articlename": "Bienert, A., Kusza, K., Wawrzyniak, K., Grześkowiak, E., Kokot, Z.J., Matysiak, J., Grabowski, T., Wolc, A., Wiczling, P. and Regulski, M., 2010. Assessing circadian rhythms in propofol PK and PD during prolonged infusion in ICU patients. Journal of Pharmacokinetics and Pharmacodynamics, 37, pp.289–304.",
    "articleurl": "https://link.springer.com/article/10.1007/s10928-010-9161-5"
  }
},
{
  "model": "main.articles",
  "pk": 255,
  "fields": {
    "articlename": "Touitou, Y., Mauvieux, B., Reinberg, A. and Dispersyn, G., 2016. Disruption of the circadian period of body temperature by the anesthetic propofol. Chronobiology International, 33(9), pp.1247–1254.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/27463411/"
  }
},
{
  "model": "main.articles",
  "pk": 256,
  "fields": {
    "articlename": "Bellet, M.M., Vawter, M.P., Bunney, B.G., Bunney, W.E. and Sassone-Corsi, P., 2011. Ketamine influences CLOCK:BMAL1 function leading to altered circadian gene expression. PLoS One, 6(8), p.e23982.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/21887357/"
  }
},
{
  "model": "main.articles",
  "pk": 257,
  "fields": {
    "articlename": "Zhuo, C., Tian, H., Li, G., Chen, M., Jiang, D., Lin, X., Xu, Y. and Wang, W., 2019. Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment-resistant depression: a protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans. Brain and Behavior, 9(11), p.e01423",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/31617335/"
  }
},
{
  "model": "main.articles",
  "pk": 258,
  "fields": {
    "articlename": "Mihara, T., Kikuchi, T., Kamiya, Y., Koga, M., Uchimoto, K., Kurahashi, K. and Goto, T., 2012. Day or night administration of ketamine and pentobarbital differentially affect circadian rhythms of pineal melatonin secretion and locomotor activity in rats. Anesthesia & Analgesia, 115(4), pp.805–813.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/22886841/"
  }
},
{
  "model": "main.articles",
  "pk": 259,
  "fields": {
    "articlename": "Kärkelä, J., Vakkuri, O., Kaukinen, S., Huang, W.Q. and Pasanen, M., 2002. The influence of anaesthesia and surgery on the circadian rhythm of melatonin. Acta Anaesthesiologica Scandinavica, 46(1), pp.30–36.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/11903069/"
  }
},
{
  "model": "main.articles",
  "pk": 260,
  "fields": {
    "articlename": "Christensen, K.C., Stadil, F., Malmström, J. and Rehfeld, J.F., 1978. The effect of beta-adrenergic and cholinergic blockade on the circadian rhythm of gastrins in serum. Scandinavian Journal of Gastroenterology, 13(3), pp.263–272.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/39327/"
  }
},
{
  "model": "main.articles",
  "pk": 261,
  "fields": {
    "articlename": "Bonafide, C.P., Aucutt-Walter, N., Divittore, N., King, T., Bixler, E.O. and Cronin, A.J., 2008. Remifentanil inhibits rapid eye movement sleep but not the nocturnal melatonin surge in humans. Anesthesiology, 108(4), pp.627–633.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/18362594/"
  }
},
{
  "model": "main.articles",
  "pk": 262,
  "fields": {
    "articlename": "Wenk, M., Pöpping, D.M., Chapman, G., Grenda, H. and Ledowski, T., 2013. Long-term quality of sleep after remifentanil-based anaesthesia: a randomized controlled trial. British Journal of Anaesthesia, 110(2), pp.250–257",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/23166147/"
  }
},
{
  "model": "main.articles",
  "pk": 263,
  "fields": {
    "articlename": "Kobayashi, K., Takemori, K. and Sakamoto, A., 2007. Circadian gene expression is suppressed during sevoflurane anesthesia and the suppression persists after awakening. Brain Research, 1185, pp.1–7.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/17942082/"
  }
},
{
  "model": "main.articles",
  "pk": 264,
  "fields": {
    "articlename": "Sugimura, S., Imai, R., Katoh, T., Makino, H., Hokamura, K., Kurita, T., Suzuki, Y., Aoki, Y., Kimura, T., Umemura, K. and Nakajima, Y., 2024. Effects of volatile anesthetics on circadian rhythm in mice: a comparative study of sevoflurane, desflurane, and isoflurane. Journal of Anesthesia, 38(1), pp.10–18.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/37741919/"
  }
},
{
  "model": "main.articles",
  "pk": 265,
  "fields": {
    "articlename": "Sugimura, S., Imai, R., Katoh, T., Makino, H., Hokamura, K., Kurita, T., Suzuki, Y., Aoki, Y., Kimura, T., Umemura, K. and Nakajima, Y., 2024. Effects of volatile anesthetics on circadian rhythm in mice: a comparative study of sevoflurane, desflurane, and isoflurane. Journal of Anesthesia, 38(1), pp.10–18.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/37741919/"
  }
},
{
  "model": "main.articles",
  "pk": 266,
  "fields": {
    "articlename": "Anzai, M., Iijima, N., Higo, S., Takumi, K., Matsuo, I., Mori, K., Ohe, Y., Kadota, K., Akimoto, T., Sakamoto, A. and Ozawa, H., 2013. Direct and specific effect of sevoflurane anesthesia on rat Per2 expression in the suprachiasmatic nucleus. PLoS One, 8(3), p.e59454.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/23555676/"
  }
},
{
  "model": "main.articles",
  "pk": 267,
  "fields": {
    "articlename": "Wirz-Justice, A., Werth, E., Savaskan, E., Knoblauch, V., Gasio, P.F. and Müller-Spahn, F., 2000. Haloperidol disrupts, clozapine reinstates the circadian rest–activity cycle in a patient with early-onset Alzheimer disease. Alzheimer Disease & Associated Disorders, 14(4), pp.212-215.",
    "articleurl": "https://journals.lww.com/alzheimerjournal/abstract/2000/10000/haloperidol_disrupts,_clozapine_reinstates_the.5.aspx"
  }
},
{
  "model": "main.articles",
  "pk": 268,
  "fields": {
    "articlename": "Herberger, S., Ruether, E. and Hajak, G., 2021. Somnologics: Medicines for the Treatment of Sleep Disorders. In NeuroPsychopharmacotherapy (pp. 1-39). Cham: Springer International Publishing.",
    "articleurl": "https://link.springer.com/referenceworkentry/10.1007/978-3-319-56015-1_421-1"
  }
},
{
  "model": "main.articles",
  "pk": 269,
  "fields": {
    "articlename": "Nagayama, H., Takagi, A., Sakurai, Y., Nishiwaki, K. and Takahashi, R., 1978. Chronopharmacological study of neuroleptics: II. Circadian susceptibility rhythm to chlorpromazine. Psychopharmacology, 58, pp.49-53.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/97719/"
  }
},
{
  "model": "main.articles",
  "pk": 270,
  "fields": {
    "articlename": "Nyitrai, G., et al. 2021. Cariprazine modulates sleep architecture in rats. Journal of Psychopharmacology, 35(3), pp.303-310.",
    "articleurl": "https://journals.sagepub.com/doi/10.1177/0269881120981378"
  }
},
{
  "model": "main.articles",
  "pk": 271,
  "fields": {
    "articlename": "Altenhofen, S. and Bonan, C.D., 2022. Zebrafish as a Tool in the Study of Sleep and Memory-related Disorders. Current neuropharmacology, 20(3), pp.540-549.",
    "articleurl": "https://benthamscience.com/public/article/116642"
  }
},
{
  "model": "main.articles",
  "pk": 272,
  "fields": {
    "articlename": "Delcourte, S., Abrial, E., Etiévant, A., Rovera, R., Arnt, J., Didriksen, M. and Haddjeri, N., 2017. Asenapine modulates mood‐related behaviors and 5‐HT 1A/7 receptors‐mediated neurotransmission. CNS Neuroscience & Therapeutics, 23(6), pp.518-525.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6492759/"
  }
},
{
  "model": "main.articles",
  "pk": 273,
  "fields": {
    "articlename": "Colita, C.I., Hermann, D.M., Filfan, M., Colita, D., Doepnner, T.R., Tica, O., Glavan, D. and Popa-Wagner, A., 2024. Optimizing Chronotherapy in Psychiatric Care: The Impact of Circadian Rhythms on Medication Timing and Efficacy. Clocks & Sleep, 6(4), pp.635-655.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11586979/"
  }
},
{
  "model": "main.articles",
  "pk": 274,
  "fields": {
    "articlename": "McCall, W.V., Riley, M.A., Hodges, C., McCloud, L., Phillips, M. and Rosenquist, P.B., 2014. Asenapine-induced restless legs syndrome: differentiation from akathisia. Journal of Clinical Sleep Medicine, 10(12), pp.1341-1342.",
    "articleurl": "https://jcsm.aasm.org/doi/10.5664/jcsm.4296"
  }
},
{
  "model": "main.articles",
  "pk": 275,
  "fields": {
    "articlename": "Mokros, Ł., Karbownik, M.S., Nowakowska-Domagała, K., Szemraj, J., Wieteska, Ł., Woźniak, K., Witusik, A., Antczak, A. and Pietras, T., 2016. Haloperidol, but not olanzapine, may affect expression of PER1 and CRY1 genes in human glioblastoma cell line. Biological Rhythm Research, 47(6), pp.865-871.",
    "articleurl": "https://www.tandfonline.com/doi/full/10.1080/09291016.2016.1202379"
  }
},
{
  "model": "main.articles",
  "pk": 276,
  "fields": {
    "articlename": "Caruso, V., Geoffroy, P.A., Alfì, G., Miniati, M., Riemann, D., Gemignani, A. and Palagini, L., 2024. Effects of Mood Stabilizers on Sleep and Circadian Rhythms: A Systematic Review. Current Sleep Medicine Reports, 10(3), pp.329-357.",
    "articleurl": "https://link.springer.com/article/10.1007/s40675-024-00298-5"
  }
},
{
  "model": "main.articles",
  "pk": 277,
  "fields": {
    "articlename": "Endicott, J., Paulsson, B., Gustafsson, U., Schiöler, H. and Hassan, M., 2008. Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: improvements in quality of life and quality of sleep. Journal of affective disorders, 111(2-3), pp.306-319.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/18774180/"
  }
},
{
  "model": "main.articles",
  "pk": 278,
  "fields": {
    "articlename": "Li, R., Masuda, K., Ono, D., Kanbayashi, T., Hirano, A. and Sakurai, T., 2023. Aripiprazole disrupts cellular synchrony in the suprachiasmatic nucleus and enhances entrainment to environmental light–dark cycles in mice. Frontiers in Neuroscience, 17, p.1201137.",
    "articleurl": "https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2023.1201137/full"
  }
},
{
  "model": "main.articles",
  "pk": 279,
  "fields": {
    "articlename": "Manickam, R., Oh, H.Y.P., Tan, C.K., Paramalingam, E. and Wahli, W., 2018. Metronidazole causes skeletal muscle atrophy and modulates muscle chronometabolism. International journal of molecular sciences, 19(8), p.2418.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6121908/#sec1-ijms-19-02418"
  }
},
{
  "model": "main.articles",
  "pk": 280,
  "fields": {
    "articlename": "Feldman, J.F. and Dunlap, J.C., 1983. Neurospora crassa: a unique system for studying circadian rhythms. In Photochemical and Photobiological Reviews: Volume 7 (pp. 319-368). Boston, MA: Springer US.",
    "articleurl": "https://link.springer.com/chapter/10.1007/978-1-4684-4505-3_7"
  }
},
{
  "model": "main.articles",
  "pk": 281,
  "fields": {
    "articlename": "Philippou, K., Davis, A.M., Davis, S.J. and Sánchez-Villarreal, A., 2020. Chemical perturbation of chloroplast-related processes affects circadian rhythms of gene expression in Arabidopsis: salicylic acid application can entrain the clock. Frontiers in physiology, 11, p.429.",
    "articleurl": "https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2020.00429/full"
  }
},
{
  "model": "main.articles",
  "pk": 282,
  "fields": {
    "articlename": "Lavigna, G., Masone, A., Bouybayoune, I., Bertani, I., Lucchetti, J., Gobbi, M., Porcu, L., Zordan, S., Rigamonti, M., Imeri, L. and Restelli, E., 2021. Doxycycline rescues recognition memory and circadian motor rhythmicity but does not prevent terminal disease in fatal familial insomnia mice. Neurobiology of Disease, 158, p.105455.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/34358614/"
  }
},
{
  "model": "main.articles",
  "pk": 283,
  "fields": {
    "articlename": "Okazaki, F., Matsunaga, N., Hamamura, K., Suzuki, K., Nakao, T., Okazaki, H., Kutsukake, M., Fukumori, S., Tsuji, Y. and To, H., 2017. Administering xCT inhibitors based on circadian clock improves antitumor effects. Cancer research, 77(23), pp.6603-6613.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/29038345/"
  }
},
{
  "model": "main.articles",
  "pk": 284,
  "fields": {
    "articlename": "Hirohata, A., Yamatsuta, Y., Ogawa, K., Kubota, A., Suzuki, T., Shimizu, H., Kanesaka, Y., Takahashi, N. and Endo, M., 2022. Sulfanilamide regulates flowering time through expression of the circadian clock gene LUX. Plant and Cell Physiology, 63(5), pp.649-657.",
    "articleurl": "https://academic.oup.com/pcp/article/63/5/649/6541824"
  }
},
{
  "model": "main.articles",
  "pk": 285,
  "fields": {
    "articlename": "Yu, Z., Shen, J., Li, Z., Yao, J., Li, W., Xue, L., Vandenberg, L.N. and Yin, D., 2020. Obesogenic effect of sulfamethoxazole on Drosophila melanogaster with simultaneous disturbances on eclosion rhythm, glucolipid metabolism, and microbiota. Environmental Science & Technology, 54(9), pp.5667-5675.",
    "articleurl": "https://pubs.acs.org/doi/abs/10.1021/acs.est.9b07889"
  }
},
{
  "model": "main.articles",
  "pk": 286,
  "fields": {
    "articlename": "Trotti, L.M., Saini, P., Freeman, A.A., Bliwise, D.L., García, P.S., Jenkins, A. and Rye, D.B., 2014. Improvement in daytime sleepiness with clarithromycin in patients with GABA-related hypersomnia: clinical experience. Journal of psychopharmacology, 28(7), pp.697-702.",
    "articleurl": "https://journals.sagepub.com/doi/10.1177/0269881113515062"
  }
},
{
  "model": "main.articles",
  "pk": 287,
  "fields": {
    "articlename": "Chen, Y.Y., Wang, Y., Shin, L.J., Wu, J.F., Shanmugam, V., Tsednee, M., Lo, J.C., Chen, C.C., Wu, S.H. and Yeh, K.C., 2013. Iron is involved in the maintenance of circadian period length in Arabidopsis. Plant physiology, 161(3), pp.1409-1420.",
    "articleurl": "https://academic.oup.com/plphys/article/161/3/1409/6110716?login=false"
  }
},
{
  "model": "main.articles",
  "pk": 288,
  "fields": {
    "articlename": "Meng, D., Yang, M., Hu, L., Liu, T., Zhang, H., Sun, X., Wang, X., Chen, Y.U., Jin, Y.U. and Liu, R., 2022. Rifaximin protects against circadian rhythm disruption–induced cognitive impairment through preventing gut barrier damage and neuroinflammation. Journal of neurochemistry, 163(5), pp.406-418.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/36189686/"
  }
},
{
  "model": "main.articles",
  "pk": 289,
  "fields": {
    "articlename": "Davis, M.A. and Carbott, D.E., 1999. Herbimycin A and geldanamycin inhibit okadaic acid-induced apoptosis and p38 activation in NRK-52E renal epithelial cells. Toxicology and applied pharmacology, 161(1), pp.59-74.",
    "articleurl": "https://www.sciencedirect.com/science/article/abs/pii/S0041008X99987653"
  }
},
{
  "model": "main.articles",
  "pk": 290,
  "fields": {
    "articlename": "Zhang, Z., Xue, N., Bian, C., Yan, R., Jin, L., Chen, X. and Yu, X., 2016. C15-methoxyphenylated 18-deoxy-herbimycin A analogues, their in vitro anticancer activity and heat shock protein 90 binding affinity. Bioorganic & Medicinal Chemistry Letters, 26(17), pp.4287-4291.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/27476419/"
  }
},
{
  "model": "main.articles",
  "pk": 291,
  "fields": {
    "articlename": "Song, Y., Liu, Y., Yuan, Y., Jia, X., Zhang, W., Wang, G., Jia, Y., Wang, X., Liu, L., Li, W. and Li, X., 2021. Effects of general versus subarachnoid anaesthesia on circadian melatonin rhythm and postoperative delirium in elderly patients undergoing hip fracture surgery: a prospective cohort clinical trial. EBioMedicine, 70.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8318871"
  }
},
{
  "model": "main.articles",
  "pk": 292,
  "fields": {
    "articlename": "Kojetin, D., Wang, Y., Kamenecka, T.M. and Burris, T.P., 2011. Identification of SR8278, a synthetic antagonist of the nuclear heme receptor REV-ERB. ACS chemical biology, 6(2), pp.131-134.",
    "articleurl": "https://pubs.acs.org/doi/abs/10.1021/cb1002575"
  }
},
{
  "model": "main.articles",
  "pk": 293,
  "fields": {
    "articlename": "Anabtawi, N., Cvammen, W. and Kemp, M.G., 2021. Pharmacological inhibition of cryptochrome and REV-ERB promotes DNA repair and cell cycle arrest in cisplatin-treated human cells. Scientific Reports, 11(1), p.17997.",
    "articleurl": "https://www.nature.com/articles/s41598-021-97603-x"
  }
},
{
  "model": "main.articles",
  "pk": 294,
  "fields": {
    "articlename": "Gul, S., Akyel, Y.K., Gul, Z.M., Isin, S., Ozcan, O., Korkmaz, T., Selvi, S., Danis, I., Ipek, O.S., Aygenli, F. and Taskin, A.C., 2022. Discovery of a small molecule that selectively destabilizes Cryptochrome 1 and enhances life span in p53 knockout mice. Nature Communications, 13(1), p.6742.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/36347873/"
  }
},
{
  "model": "main.articles",
  "pk": 295,
  "fields": {
    "articlename": "Meng, Q.J., Maywood, E.S., Bechtold, D.A., Lu, W.Q., Li, J., Gibbs, J.E., Dupré, S.M., Chesham, J.E., Rajamohan, F., Knafels, J. and Sneed, B., 2010. Entrainment of disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymes. Proceedings of the National Academy of Sciences, 107(34), pp.15240-15245.",
    "articleurl": "https://www.pnas.org/doi/10.1073/pnas.1005101107"
  }
},
{
  "model": "main.articles",
  "pk": 296,
  "fields": {
    "articlename": "Miller, S., Son, Y.L., Aikawa, Y., Makino, E., Nagai, Y., Srivastava, A., Oshima, T., Sugiyama, A., Hara, A., Abe, K. and Hirata, K., 2020. Isoform-selective regulation of mammalian cryptochromes. Nature chemical biology, 16(6), pp.676-685.",
    "articleurl": "https://www.nature.com/articles/s41589-020-0505-1"
  }
},
{
  "model": "main.articles",
  "pk": 297,
  "fields": {
    "articlename": "Crane, B.R., 2020. Winding down: Selectively drugging a promiscuous pocket in cryptochrome slows circadian rhythms. Cell chemical biology, 27(9), pp.1109-1111.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8042606/"
  }
},
{
  "model": "main.articles",
  "pk": 298,
  "fields": {
    "articlename": "Miller, S., Son, Y.L., Aikawa, Y., Makino, E., Nagai, Y., Srivastava, A., Oshima, T., Sugiyama, A., Hara, A., Abe, K. and Hirata, K., 2020. Isoform-selective regulation of mammalian cryptochromes. Nature chemical biology, 16(6), pp.676-685.",
    "articleurl": "https://www.nature.com/articles/s41589-020-0505-1"
  }
},
{
  "model": "main.articles",
  "pk": 299,
  "fields": {
    "articlename": "Borrmann, H., Ulkar, G., Kliszczak, A.E., Ismed, D., Schilling, M., Magri, A., Harris, J.M., Balfe, P., Vasudevan, S., Borrow, P. and Zhuang, X., 2023. Molecular components of the circadian clock regulate HIV-1 replication. Iscience, 26(7).",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10391662/"
  }
},
{
  "model": "main.articles",
  "pk": 300,
  "fields": {
    "articlename": "Lyu, C., Bing, S.J., Wandu, W.S., Xu, B., Shi, G., Hinshaw, S.J., Lobera, M., Caspi, R.R., Lu, L., Yang, J. and Gery, I., 2018. TMP778, a selective inhibitor of RORγt, suppresses experimental autoimmune uveitis development, but affects both Th17 and Th1 cell populations. European journal of immunology, 48(11), pp.1810-1816.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6392427/"
  }
},
{
  "model": "main.articles",
  "pk": 301,
  "fields": {
    "articlename": "Venken, K., Jacques, P., Mortier, C., Labadia, M.E., Decruy, T., Coudenys, J., Hoyt, K., Wayne, A.L., Hughes, R., Turner, M. and Van Gassen, S., 2019. RORγt inhibition selectively targets IL-17 producing iNKT and γδ-T cells enriched in Spondyloarthritis patients. Nature communications, 10(1), p.9.",
    "articleurl": "https://www.nature.com/articles/s41467-018-07911-6"
  }
},
{
  "model": "main.articles",
  "pk": 302,
  "fields": {
    "articlename": "Lafaye G, Desterke C, Marulaz L, Benyamina A. Cannabidiol affects circadian clock core complex and its regulation in microglia cells. Addiction Biology. 2018.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/30307084/"
  }
},
{
  "model": "main.articles",
  "pk": 304,
  "fields": {
    "articlename": "Dubocovich, M.L., 1988. Luzindole (N-0774): a novel melatonin receptor antagonist. Journal of Pharmacology and Experimental Therapeutics, 246(3), pp.902–910.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/2843633/"
  }
},
{
  "model": "main.articles",
  "pk": 305,
  "fields": {
    "articlename": "Estarás, M., Ameur, F.Z., Roncero, V., Fernández-Bermejo, M., Blanco, G., López, D., Mateos, J.M., Salido, G.M. and González, A., 2019. The melatonin receptor antagonist luzindole induces Ca²⁺ mobilization, reactive oxygen species generation and impairs trypsin secretion in mouse pancreatic acinar cells. Biochimica et Biophysica Acta (BBA) - General Subjects, 1863(11), p.129407.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/31381958/"
  }
},
{
  "model": "main.articles",
  "pk": 306,
  "fields": {
    "articlename": "De Berardis, D., Marini, S., Fornaro, M., Srinivasan, V., Iasevoli, F., Tomasetti, C., Valchera, A., Perna, G., Quera-Salva, M.A., Martinotti, G. and Di Giannantonio, M., 2013. The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice. International Journal of Molecular Sciences, 14(6), pp.12458–12483.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3709794/"
  }
},
{
  "model": "main.articles",
  "pk": 307,
  "fields": {
    "articlename": "Fourtillan, J.B., Brisson, A.M., Gobin, P., Ingrand, I., Decourt, J.P. and Girault, J., 2000. Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. Biopharmaceutics & Drug Disposition, 21(1), pp.15–22.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/11038434/"
  }
},
{
  "model": "main.articles",
  "pk": 308,
  "fields": {
    "articlename": "McGechan, A. and Wellington, K., 2005. Ramelteon. CNS Drugs, 19(12), pp.1057–1065; discussion 1066–1067.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/16332146/"
  }
},
{
  "model": "main.articles",
  "pk": 309,
  "fields": {
    "articlename": "Russak, E.M. and Bednarczyk, E.M., 2019. Impact of deuterium substitution on the pharmacokinetics of pharmaceuticals. Annals of Pharmacotherapy, 53(2), pp.211–216.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/30136594/"
  }
},
{
  "model": "main.articles",
  "pk": 310,
  "fields": {
    "articlename": "Audinot, V., Mailliet, F., Lahaye-Brasseur, C., Bonnaud, A., Le Gall, A., Amossé, C., Dromaint, S., Rodriguez, M., Nagel, N., Galizzi, J.P., Malpaux, B., Guillaumet, G., Lesieur, D., Lefoulon, F., Renard, P., Delagrange, P. and Boutin, J.A., 2003. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 367(6), pp.553–561.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/12764576/"
  }
},
{
  "model": "main.articles",
  "pk": 311,
  "fields": {
    "articlename": "ChatGPT сказал: Nishiyama, K., Nishikawa, H., Kato, K., Miyamoto, M., Tsukamoto, T. and Hirai, K., 2014. Pharmacological characterization of M-II, the major human metabolite of ramelteon. Pharmacology, 93(3–4), pp.197–201.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/24923230/"
  }
},
{
  "model": "main.articles",
  "pk": 312,
  "fields": {
    "articlename": "Miyamoto, M., 2009. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neuroscience & Therapeutics, 15(1), pp.32–51.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2871175/"
  }
},
{
  "model": "main.articles",
  "pk": 313,
  "fields": {
    "articlename": "Kumari, Y., Choo, B.K.M., Shaikh, M.F. and Othman, I., 2019. Melatonin receptor agonist Piper betle L. ameliorates dexamethasone-induced early life stress in adult zebrafish. Experimental and Therapeutic Medicine, 18(2), pp.1095–1102.",
    "articleurl": "https://www.researchgate.net/publication/333855278_Melatonin_receptor_agonist_Piper_betle_L_ameliorates_dexamethasone-induced_early_life_stress_in_adult_zebrafish/figures?lo=1&utm_source=google&utm_medium=organic"
  }
},
{
  "model": "main.articles",
  "pk": 314,
  "fields": {
    "articlename": "Russak, E.M. and Bednarczyk, E.M., 2019. Impact of deuterium substitution on the pharmacokinetics of pharmaceuticals. Annals of Pharmacotherapy, 53(2), pp.211–216",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/30136594/"
  }
},
{
  "model": "main.articles",
  "pk": 315,
  "fields": {
    "articlename": "Lavedan, C., Forsberg, M. and Gentile, A.J., 2015. Tasimelteon: a selective and unique receptor binding profile. Neuropharmacology, 91, pp.142–147",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/25534555/"
  }
},
{
  "model": "main.articles",
  "pk": 316,
  "fields": {
    "articlename": "Huang, W., Wang, H., Johnson, R.L., Huang, R., Englund, E.E., Huh, J. and Littman, D.R., 2013. Identification of potent and selective RORγ antagonists. Probe Reports from the NIH Molecular Libraries Program [Internet].",
    "articleurl": "https://www.ncbi.nlm.nih.gov/books/NBK133441/"
  }
},
{
  "model": "main.articles",
  "pk": 317,
  "fields": {
    "articlename": "Xiang, K., Xu, Z., Hu, Y.Q., He, Y.S., Wu, G.C., Li, T.Y., Wang, X.R., Ding, L.H., Zhang, Q., Tao, S.S. and Ye, D.Q., 2021. Circadian clock genes as promising therapeutic targets for autoimmune diseases. Autoimmunity Reviews, 20(8), p.102866.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/34118460/"
  }
},
{
  "model": "main.articles",
  "pk": 318,
  "fields": {
    "articlename": "Chang, M.R., He, Y., Khan, T.M., Kuruvilla, D.S., Garcia-Ordonez, R., Corzo, C.A., Unger, T.J., White, D.W., Khan, S., Lin, L. and Cameron, M.D., 2015. Antiobesity effect of a small molecule repressor of RORγ. Molecular Pharmacology, 88(1), pp.48-56.",
    "articleurl": "https://europepmc.org/article/pmc/pmc4468634"
  }
},
{
  "model": "main.articles",
  "pk": 319,
  "fields": {
    "articlename": "Pertwee, R.G. (Ed.), 2014. Handbook of Cannabis. Oxford University Press, USA.",
    "articleurl": "https://books.google.ru/books?hl=ru&lr=&id=hPVwBAAAQBAJ&oi=fnd&pg=PP1&ots=yw8lCIUJZf&sig=8gbmjbBl9ssFNx-Hj0lrdbSVF3E&redir_esc=y#v=onepage&q&f=false"
  }
},
{
  "model": "main.articles",
  "pk": 320,
  "fields": {
    "articlename": "Solt, L.A., Kumar, N., He, Y., Kamenecka, T.M., Griffin, P.R. and Burris, T.P., 2012. Identification of a selective RORγ ligand that suppresses TH17 cells and stimulates T regulatory cells. ACS chemical biology, 7(9), pp.1515-1519.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3448878/#:~:text=We%20report%20here%20the%20identification,of%20therapeutics%20targeting%20autoimmune%20diseases."
  }
},
{
  "model": "main.articles",
  "pk": 321,
  "fields": {
    "articlename": "Outen, J.D., Burhanullah, M.H., Vandrey, R., Amjad, H., Harper, D.G., Patrick, R.E., May, R.L., Agronin, M.E., Forester, B.P. and Rosenberg, P.B., 2021. Cannabinoids for agitation in Alzheimer's disease. American Journal of Geriatric Psychiatry, 29(12), pp.1253–1263",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8313629/"
  }
},
{
  "model": "main.articles",
  "pk": 322,
  "fields": {
    "articlename": "Kumar, N., Lyda, B., Chang, M.R., Lauer, J.L., Solt, L.A., Burris, T.P., Kamenecka, T.M. and Griffin, P.R., 2012. Identification of SR2211: a potent synthetic RORγ-selective modulator. ACS chemical biology, 7(4), pp.672-677.",
    "articleurl": "https://europepmc.org/article/pmc/3331898"
  }
},
{
  "model": "main.articles",
  "pk": 323,
  "fields": {
    "articlename": "Ribeiro, R.F., Cavadas, C. and Silva, M.M.C., 2021. Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases. Drug Discovery Today, 26(7), pp.1620-1641.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/33781946/"
  }
},
{
  "model": "main.articles",
  "pk": 324,
  "fields": {
    "articlename": "Shin, S.H., Lee, H.S., Kim, Y.S., Choi, Y.J., Kim, S.H., Kwon, H.C., Oh, S.Y., Kang, J.H., Sohn, C.H., Lee, S.M., Baek, J.H., Min, Y.J., Kim, C. and Chung, J.S., 2014. Clinical usefulness of hydromorphone-OROS in improving sleep disturbances in Korean cancer patients: a multicenter, prospective, open-label study. Cancer Research and Treatment, 46(4), pp.331–338.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4206066/"
  }
},
{
  "model": "main.articles",
  "pk": 325,
  "fields": {
    "articlename": "Teppan, J., Bärnthaler, T., Farzi, A., Durrington, H., Gioan-Tavernier, G., Platt, H., Wolf, P., Heinemann, A. and Böhm, E., 2025. The molecular circadian clock of eosinophils: A potential therapeutic target for asthma. American Journal of Physiology-Cell Physiology, 328(5), pp.C1394-C1408.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/40131242/"
  }
},
{
  "model": "main.articles",
  "pk": 326,
  "fields": {
    "articlename": "Kumar, N., Kojetin, D.J., Solt, L.A., Kumar, K.G., Nuhant, P., Duckett, D.R., Cameron, M.D., Butler, A.A., Roush, W.R., Griffin, P.R. and Burris, T.P., 2011. Identification of SR3335 (ML-176): a synthetic RORα selective inverse agonist. ACS chemical biology, 6(3), pp.218-222.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/21090593/"
  }
},
{
  "model": "main.articles",
  "pk": 327,
  "fields": {
    "articlename": "Boss, C., Roch-Brisbare, C., Steiner, M.A., Treiber, A., Dietrich, H., Jenck, F., von Raumer, M., Sifferlen, T., Brotschi, C., Heidmann, B., Williams, J.T., Aissaoui, H., Siegrist, R. and Gatfield, J., 2014. Structure-activity relationship, biological, and pharmacological characterization of the proline sulfonamide ACT-462206: a potent, brain-penetrant dual orexin 1/orexin 2 receptor antagonist. ChemMedChem, 9(11), pp.2486–2496.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/25147058/"
  }
},
{
  "model": "main.articles",
  "pk": 328,
  "fields": {
    "articlename": "Smyth, C., FitzGerald, R. and Waddington, J.L., 1995. Morphine phase-shifts circadian rhythms in mice: role of behavioural activation. Neuroreport, 7(1), pp.209–212.",
    "articleurl": "https://journals.lww.com/neuroreport/abstract/1995/12290/morphine_phase_shifts_circadian_rhythms_in_mice_.50.aspx"
  }
},
{
  "model": "main.articles",
  "pk": 329,
  "fields": {
    "articlename": "Wang, Y., Kumar, N., Nuhant, P., Cameron, M.D., Istrate, M.A., Roush, W.R., Griffin, P.R. and Burris, T.P., 2010. Identification of SR1078, a synthetic agonist for the orphan nuclear receptors RORα and RORγ. ACS chemical biology, 5(11), pp.1029-1034.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/20735016/"
  }
},
{
  "model": "main.articles",
  "pk": 330,
  "fields": {
    "articlename": "Coffey, A.A., Guan, Z., Grigson, P.S. and Fang, J., 2016. Reversal of the sleep-wake cycle by heroin self-administration in rats. Brain Research Bulletin, 123, pp.33–46.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/26431774/"
  }
},
{
  "model": "main.articles",
  "pk": 331,
  "fields": {
    "articlename": "Wongchitrat, P., Mukda, S., Phansuwan-Pujito, P. and Govitrapong, P., 2013. Effect of amphetamine on the clock gene expression in rat striatum. Neuroscience Letters, 542, pp.126–130.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/23518151/"
  }
},
{
  "model": "main.articles",
  "pk": 332,
  "fields": {
    "articlename": "Khazaie, H., Ahmadi, H.R., Kiani, A. and Ghadami, M.R., 2019. Circadian melatonin profile in opium and amphetamine dependent patients: A preliminary study. Neurobiology of Sleep and Circadian Rhythms, 7, p.100046.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/31463419/"
  }
},
{
  "model": "main.articles",
  "pk": 333,
  "fields": {
    "articlename": "Prosser, R.A., Stowie, A., Amicarelli, M., Nackenoff, A.G., Blakely, R.D. and Glass, J.D., 2014. Cocaine modulates mammalian circadian clock timing by decreasing serotonin transport in the SCN. Neuroscience, 275, pp.184–193",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/24950119/"
  }
},
{
  "model": "main.articles",
  "pk": 334,
  "fields": {
    "articlename": "Gbaguidi, G.F. and Agellon, L.B., 2004. The inhibition of the human cholesterol 7α‐hydroxylase gene (CYP7A1) promoter by fibrates in cultured cells is mediated via the liver x receptor α and peroxisome proliferator‐activated receptor α heterodimer. Nucleic acids research, 32(3), pp.1113-1121.",
    "articleurl": "https://academic.oup.com/nar/article-abstract/32/3/1113/2904513"
  }
},
{
  "model": "main.articles",
  "pk": 335,
  "fields": {
    "articlename": "Feillet, C., Guérin, S., Lonchampt, M., Dacquet, C., Gustafsson, J.Å., Delaunay, F. and Teboul, M., 2016. Sexual Dimorphism in Circadian Physiology Is Altered in LXR α Deficient Mice. PLoS One, 11(3), p.e0150665.",
    "articleurl": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0150665#pone.0150665.ref061"
  }
},
{
  "model": "main.articles",
  "pk": 336,
  "fields": {
    "articlename": "Wang, D.Q., Wang, X.L., Wang, C.Y., Wang, Y., Li, S.X. and Liu, K.Z., 2019. Effects of chronic cocaine exposure on the circadian rhythmic expression of the clock genes in reward-related brain areas in rats. Behavioural Brain Research, 363, pp.61–69.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/30682435/"
  }
},
{
  "model": "main.articles",
  "pk": 337,
  "fields": {
    "articlename": "Kobayashi, K., Takemori, K. and Sakamoto, A., 2007. Circadian gene expression is suppressed during sevoflurane anesthesia and the suppression persists after awakening. Brain Research, 1185, pp.1–7.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/17942082/"
  }
},
{
  "model": "main.articles",
  "pk": 338,
  "fields": {
    "articlename": "Wren-Dail, M.A., Dauchy, R.T., Blask, D.E., Hill, S.M., Ooms, T.G., Dupepe, L.M. and Bohm, R.P. Jr., 2017. Effect of Isoflurane Anesthesia on Circadian Metabolism and Physiology in Rats. Comparative Medicine, 67(2), pp.138–146.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/28381314/"
  }
},
{
  "model": "main.articles",
  "pk": 339,
  "fields": {
    "articlename": "Pérez-Llorca, M. and Müller, M., 2024. Unlocking nature’s rhythms: insights into secondary metabolite modulation by the circadian clock. International Journal of Molecular Sciences, 25(13), p.7308.",
    "articleurl": "https://www.mdpi.com/1422-0067/25/13/7308"
  }
},
{
  "model": "main.articles",
  "pk": 340,
  "fields": {
    "articlename": "Nilsen, N.G., Gilson, S.J., Pedersen, H.R., Hagen, L.A., Wildsoet, C.F. and Baraas, R.C., 2024. The effect of topical 1% atropine on ocular dimensions and diurnal rhythms of the human eye. Vision Research, 214, p.108341.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/38065032/"
  }
},
{
  "model": "main.articles",
  "pk": 341,
  "fields": {
    "articlename": "Sultan, A., Ali, R., Sultan, T., Ali, S., Khan, N.J. and Parganiha, A., 2021. Circadian clock modulating small molecules repurposing as inhibitors of SARS-CoV-2 Mpro for pharmacological interventions in COVID-19 pandemic. Chronobiology International, 38(7), pp.971–985.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/33820462/"
  }
},
{
  "model": "main.articles",
  "pk": 342,
  "fields": {
    "articlename": "Rey, G., Valekunja, U.K., Feeney, K.A., Wulund, L., Milev, N.B., Stangherlin, A., Ansel-Bollepalli, L., Velagapudi, V., O’Neill, J.S. and Reddy, A.B., 2016. The pentose phosphate pathway regulates the circadian clock. Cell metabolism, 24(3), pp.462-473.",
    "articleurl": "https://www.cell.com/cell-metabolism/fulltext/S1550-4131(16)30375-8"
  }
},
{
  "model": "main.articles",
  "pk": 343,
  "fields": {
    "articlename": "Putker, M., Crosby, P., Feeney, K.A., Hoyle, N.P., Costa, A.S., Gaude, E., Frezza, C. and O'Neill, J.S., 2018. Mammalian circadian period, but not phase and amplitude, is robust against redox and metabolic perturbations. Antioxidants & Redox Signaling, 28(7), pp.507-520.",
    "articleurl": "https://www.liebertpub.com/doi/abs/10.1089/ars.2016.6911"
  }
},
{
  "model": "main.articles",
  "pk": 344,
  "fields": {
    "articlename": "Bellet, M.M., Nakahata, Y., Boudjelal, M., Watts, E., Mossakowska, D.E., Edwards, K.A., Cervantes, M., Astarita, G., Loh, C., Ellis, J.L., Vlasuk, G.P. and Sassone-Corsi, P., 2013. Pharmacological modulation of circadian rhythms by synthetic activators of the deacetylase SIRT1. Proceedings of the National Academy of Sciences of the United States of America, 110(9), pp.3333–3338.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3587185/"
  }
},
{
  "model": "main.articles",
  "pk": 345,
  "fields": {
    "articlename": "Onishi, Y., Oishi, K., Kawano, Y. and Yamazaki, Y., 2012. The harmala alkaloid harmine is a modulator of circadian Bmal1 transcription. Bioscience Reports, 32(1), pp.45-52.",
    "articleurl": "https://portlandpress.com/bioscirep/article-abstract/32/1/45/55977/The-harmala-alkaloid-harmine-is-a-modulator-of?redirectedFrom=fulltext"
  }
},
{
  "model": "main.articles",
  "pk": 346,
  "fields": {
    "articlename": "Onishi, Y., Oishi, K., Kawano, Y., & Yamazaki, Y. (2012). The harmala alkaloid harmine is a modulator of circadian Bmal1 transcription. Bioscience Reports, 32(1), 45–52.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/21401525/"
  }
},
{
  "model": "main.articles",
  "pk": 347,
  "fields": {
    "articlename": "Kondoh, D., Yamamoto, S., Tomita, T., Miyazaki, K., Itoh, N., Yasumoto, Y., Oike, H., Doi, R. and Oishi, K., 2014. Harmine lengthens circadian period of the mammalian molecular clock in the suprachiasmatic nucleus. Biological and Pharmaceutical Bulletin, 37(8), pp.1422-1427.",
    "articleurl": "https://www.jstage.jst.go.jp/article/bpb/37/8/37_b14-00229/_article/-char/en"
  }
},
{
  "model": "main.articles",
  "pk": 348,
  "fields": {
    "articlename": "Tamai, T. K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M., Nishiwaki-Ohkawa, T., Sato, A., & Yoshimura, T. (2018). Identification of circadian clock modulators from existing drugs. EMBO Molecular Medicine, 10(5), e8724.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/29666146/"
  }
},
{
  "model": "main.articles",
  "pk": 349,
  "fields": {
    "articlename": "Raju, U., Koumenis, C., Nunez-Regueiro, M. and Eskin, A., 1991. Alteration of the phase and period of a circadian oscillator by a reversible transcription inhibitor. Science, 253(5020), pp.673-675.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/1871602/"
  }
},
{
  "model": "main.articles",
  "pk": 350,
  "fields": {
    "articlename": "Ribeiro, R. F. N., Cavadas, C., & Silva, M. M. C. (2021). Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases. Drug Discovery Today, 26(7), 1620–1641.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/33781946/"
  }
},
{
  "model": "main.articles",
  "pk": 351,
  "fields": {
    "articlename": "Wang, Y., Kumar, N., Nuhant, P., Cameron, M. D., Istrate, M. A., Roush, W. R., Griffin, P. R., & Burris, T. P. (2010). Identification of SR1078, a synthetic agonist for the orphan nuclear receptors RORα and RORγ. ACS Chemical Biology, 5(11), 1029–1034",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/20735016/"
  }
},
{
  "model": "main.articles",
  "pk": 352,
  "fields": {
    "articlename": "Yao, H., Sundar, I.K., Huang, Y., Gerloff, J., Sellix, M.T., Sime, P.J. and Rahman, I., 2015. Disruption of sirtuin 1–mediated control of circadian molecular clock and inflammation in chronic obstructive pulmonary disease. American journal of respiratory cell and molecular biology, 53(6), pp.782-792.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4742939/#:~:text=SRT1720%20Attenuated%20LPS%2DInduced%20Reduction,partly%20due%20to%20SIRT1%20reduction."
  }
},
{
  "model": "main.articles",
  "pk": 353,
  "fields": {
    "articlename": "Schmitt, E. E., Barhoumi, R., Metz, R. P., & Porter, W. W. (2017). Circadian Regulation of Benzo[a]Pyrene Metabolism and DNA Adduct Formation in Breast Cells and the Mouse Mammary Gland. Molecular Pharmacology, 91(3), 178–188.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5325081/"
  }
},
{
  "model": "main.articles",
  "pk": 354,
  "fields": {
    "articlename": "Bellet, M.M., Nakahata, Y., Boudjelal, M., Watts, E., Mossakowska, D.E., Edwards, K.A., Cervantes, M., Astarita, G., Loh, C., Ellis, J.L. and Vlasuk, G.P., 2013. Pharmacological modulation of circadian rhythms by synthetic activators of the deacetylase SIRT1. Proceedings of the National Academy of Sciences, 110(9), pp.3333-3338.",
    "articleurl": "https://www.pnas.org/doi/10.1073/pnas.1214266110"
  }
},
{
  "model": "main.articles",
  "pk": 355,
  "fields": {
    "articlename": "Hodges, E.L. and Ashpole, N.M., 2019. Aging circadian rhythms and cannabinoids. Neurobiology of aging, 79, pp.110-118.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6591053/"
  }
},
{
  "model": "main.articles",
  "pk": 356,
  "fields": {
    "articlename": "Axelrod, J., 1983. Regulation of circadian rhythms of indoleamines in the pineal gland. In The pineal gland and its endocrine role (pp. 1-13). Boston, MA: Springer US.",
    "articleurl": "https://link.springer.com/chapter/10.1007/978-1-4757-1451-7_1"
  }
},
{
  "model": "main.articles",
  "pk": 357,
  "fields": {
    "articlename": "Barnes, S.J., Alanazi, M., Yamazaki, S. and Stefanovska, A., 2025. Methamphetamine alters the circadian oscillator and its couplings on multiple scales in Per1/2/3 knockout mice. PNAS nexus, 4(4), p.pgaf070.",
    "articleurl": "https://academic.oup.com/pnasnexus/article/4/4/pgaf070/8068901?login=false"
  }
},
{
  "model": "main.articles",
  "pk": 358,
  "fields": {
    "articlename": "Mohawk, J.A., Baer, M.L. and Menaker, M., 2009. The methamphetamine-sensitive circadian oscillator does not employ canonical clock genes. Proceedings of the National Academy of Sciences, 106(9), pp.3519-3524.",
    "articleurl": "https://www.pnas.org/doi/10.1073/pnas.0813366106"
  }
},
{
  "model": "main.articles",
  "pk": 359,
  "fields": {
    "articlename": "Genetics and functional significance of the understudied methamphetamine sensitive circadian oscillator (MASCO)",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/36226037/"
  }
},
{
  "model": "main.articles",
  "pk": 360,
  "fields": {
    "articlename": "Souza, L.C., Martynhak, B.J., Bassani, T.B., Turnes, J.D.M., Machado, M.M., Moura, E., Andreatini, R. and Vital, M.A., 2018. Agomelatine's effect on circadian locomotor rhythm alteration and depressive-like behavior in 6-OHDA lesioned rats. Physiology & Behavior, 188, pp.298-310.",
    "articleurl": "https://www.sciencedirect.com/science/article/abs/pii/S0031938418301264"
  }
},
{
  "model": "main.articles",
  "pk": 361,
  "fields": {
    "articlename": "Surme, S., Ergun, C., Gul, S., Akyel, Y.K., Gul, Z.M., Ozcan, O., Ipek, O.S., Akarlar, B.A., Ozlu, N., Taskin, A.C. and Turkay, M., 2023. TW68, cryptochromes stabilizer, regulates fasting blood glucose levels in diabetic ob/ob and high fat-diet-induced obese mice. Biochemical Pharmacology, 218, p.115896.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/37898388/"
  }
},
{
  "model": "main.articles",
  "pk": 362,
  "fields": {
    "articlename": "Surme, S., Ergun, C., Gul, S., Akyel, Y.K., Gul, Z.M., Ozcan, O., Ipek, O.S., Akarlar, B.A., Ozlu, N., Taskin, A.C. and Turkay, M., 2023. TW68, cryptochromes stabilizer, regulates fasting blood glucose levels in diabetic ob/ob and high fat-diet-induced obese mice. Biochemical Pharmacology, 218, p.115896.",
    "articleurl": "https://www.sciencedirect.com/science/article/abs/pii/S0006295223004896"
  }
},
{
  "model": "main.articles",
  "pk": 363,
  "fields": {
    "articlename": "Nakamura TJ, Sellix MT, Menaker M, Block GD. Estrogen directly modulates circadian rhythms of PER2 expression in the uterus. Am J Physiol Endocrinol Metab. 2008 Nov;295(5):E1025-31. doi: 10.1152/ajpendo.90392.2008. Epub 2008 Aug 26. PMID: 18728223; PMCID: PMC2584820.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2584820/"
  }
},
{
  "model": "main.articles",
  "pk": 364,
  "fields": {
    "articlename": "Burish MJ, Han C, Mawatari K, Wirianto M, Kim E, Ono K, Parakramaweera R, Chen Z, Yoo SH. The first-line cluster headache medication verapamil alters the circadian period and elicits sex-specific sleep changes in mice. Chronobiol Int. 2021 Jun;38(6):839-850. doi: 10.1080/07420528.2021.1892127. Epub 2021 Apr 8. PMID: 33829951.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/33829951/"
  }
},
{
  "model": "main.articles",
  "pk": 365,
  "fields": {
    "articlename": "Silva S, Bicker J, Falcão A, Fortuna A. Antidepressants and Circadian Rhythm: Exploring Their Bidirectional Interaction for the Treatment of Depression. Pharmaceutics. 2021 Nov 21;13(11):1975. doi: 10.3390/pharmaceutics13111975.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8624696/"
  }
},
{
  "model": "main.articles",
  "pk": 366,
  "fields": {
    "articlename": "Carboni L, Rullo L, Caputi FF, Stamatakos S, Candeletti S, Romualdi P. Chronic Trazodone and Citalopram Treatments Increase Trophic Factor and Circadian Rhythm Gene Expression in Rat Brain Regions Relevant for Antidepressant Efficacy. Int J Mol Sci. 2022 Nov 14;23(22):14041. doi: 10.3390/ijms232214041.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9698904/"
  }
},
{
  "model": "main.articles",
  "pk": 367,
  "fields": {
    "articlename": "Williams III, W.P., McLin III, D.E., Dressman, M.A. and Neubauer, D.N., 2016. Comparative review of approved melatonin agonists for the treatment of circadian rhythm sleep‐wake disorders. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 36(9), pp.1028-1041.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5108473/"
  }
},
{
  "model": "main.articles",
  "pk": 368,
  "fields": {
    "articlename": "Nonno, R., Lucini, V., Spadoni, G., Pannacci, M., Croce, A., Esposti, D., Balsamini, C., Tarzia, G., Fraschini, F. and Stankov, B.M., 2000. A new melatonin receptor ligand with mt1‐agonist and MT2‐antagonist properties. Journal of pineal research, 29(4), pp.234-240.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/11068946/"
  }
},
{
  "model": "main.articles",
  "pk": 369,
  "fields": {
    "articlename": "Zlotos, D.P., Attia, M.I., Julius, J., Sethi, S. and Witt-Enderby, P.A., 2009. 2-[(2, 3-Dihydro-1 H-indol-1-yl) methyl] melatonin Analogues: A Novel Class of MT2-Selective Melatonin Receptor Antagonists. Journal of medicinal chemistry, 52(3), pp.826-833.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/19193160/"
  }
},
{
  "model": "main.articles",
  "pk": 370,
  "fields": {
    "articlename": "Morellato, L., Lefas-Le Gall, M., Langlois, M., Caignard, D.H., Renard, P., Delagrange, P. and Mathé-Allainmat, M., 2013. Synthesis of new N-(arylcyclopropyl) acetamides and N-(arylvinyl) acetamides as conformationally-restricted ligands for melatonin receptors. Bioorganic & medicinal chemistry letters, 23(2), pp.430-434.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/23265885/"
  }
},
{
  "model": "main.articles",
  "pk": 371,
  "fields": {
    "articlename": "Dubocovich, M.L., Masana, M.I., Iacob, S. and Sauri, D.M., 1997. Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn-Schmiedeberg's archives of pharmacology, 355, pp.365-375.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/9089668/"
  }
},
{
  "model": "main.articles",
  "pk": 372,
  "fields": {
    "articlename": "Ettaoussi, M., Sabaouni, A., Rami, M., Boutin, J.A., Delagrange, P., Renard, P., Spedding, M., Caignard, D.H., Berthelot, P. and Yous, S., 2012. Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I). European journal of medicinal chemistry, 49, pp.310-323.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/22301214/"
  }
},
{
  "model": "main.articles",
  "pk": 373,
  "fields": {
    "articlename": "Hu, Y., Zhu, J., Chan, K.H. and Wong, Y.H., 2013. Development of substituted N-[3-(3-methoxylphenyl) propyl] amides as MT2-selective melatonin agonists: Improving metabolic stability. Bioorganic & medicinal chemistry, 21(2), pp.547-552.",
    "articleurl": "https://www.sciencedirect.com/science/article/abs/pii/S0968089612008917"
  }
},
{
  "model": "main.articles",
  "pk": 374,
  "fields": {
    "articlename": "Levine, J.D., Casey, C.I., Kalderon, D.D. and Jackson, F.R., 1994. Altered circadian pacemaker functions and cyclic AMP rhythms in the Drosophila learning mutant dunce. Neuron, 13(4), pp.967-974.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/7946340/"
  }
},
{
  "model": "main.articles",
  "pk": 375,
  "fields": {
    "articlename": "Ono, D., Wang, H., Hung, C.J., Wang, H.T., Kon, N., Yamanaka, A., Li, Y. and Sugiyama, T., 2023. Network-driven intracellular cAMP coordinates circadian rhythm in the suprachiasmatic nucleus. Science Advances, 9(1), p.eabq7032.",
    "articleurl": "https://www.science.org/doi/10.1126/sciadv.abq7032"
  }
},
{
  "model": "main.articles",
  "pk": 376,
  "fields": {
    "articlename": "O'Neill, J.S. and Reddy, A.B., 2012. The essential role of cAMP/Ca2+ signalling in mammalian circadian timekeeping.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3399769/"
  }
},
{
  "model": "main.articles",
  "pk": 377,
  "fields": {
    "articlename": "Koike, T., Hoashi, Y., Takai, T., Nakayama, M., Yukuhiro, N., Ishikawa, T., Hirai, K. and Uchikawa, O., 2011. 1, 6-Dihydro-2 H-indeno [5, 4-b] furan Derivatives: Design, Synthesis, and Pharmacological Characterization of a Novel Class of Highly Potent MT2-Selective Agonists. Journal of medicinal chemistry, 54(9), pp.3436-3444.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/21473625/"
  }
},
{
  "model": "main.articles",
  "pk": 378,
  "fields": {
    "articlename": "Ettaoussi, M., Sabaouni, A., Rami, M., Boutin, J.A., Delagrange, P., Renard, P., Spedding, M., Caignard, D.H., Berthelot, P. and Yous, S., 2012. Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I). European journal of medicinal chemistry, 49, pp.310-323.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/22301214/"
  }
},
{
  "model": "main.articles",
  "pk": 379,
  "fields": {
    "articlename": "Legros, C., Brasseur, C., Delagrange, P., Ducrot, P., Nosjean, O. and Boutin, J.A., 2016. Alternative radioligands for investigating the molecular pharmacology of melatonin receptors. The Journal of Pharmacology and Experimental Therapeutics, 356(3), pp.681-692.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/26759496/"
  }
},
{
  "model": "main.articles",
  "pk": 380,
  "fields": {
    "articlename": "Legros, C., Matthey, U., Grelak, T., Pedragona-Moreau, S., Hassler, W., Yous, S., Thomas, E., Suzenet, F., Folleas, B., Lefoulon, F. and Berthelot, P., 2013. New radioligands for describing the molecular pharmacology of MT1 and MT2 melatonin receptors. International journal of molecular sciences, 14(5), pp.8948-8962.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/23698757/"
  }
},
{
  "model": "main.articles",
  "pk": 381,
  "fields": {
    "articlename": "Koike, T., Takai, T., Hoashi, Y., Nakayama, M., Kosugi, Y., Nakashima, M., Yoshikubo, S.I., Hirai, K. and Uchikawa, O., 2011. Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8, 9-dihydrofuro [3, 2-c] pyrazolo [1, 5-a] pyridines as melatonin receptor (MT1/MT2) ligands. Journal of medicinal chemistry, 54(12), pp.4207-4218.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/21568291/"
  }
},
{
  "model": "main.articles",
  "pk": 382,
  "fields": {
    "articlename": "Baumann, A., Feilhauer, K., Bischoff, S.C., Froy, O. and Lorentz, A., 2015. IgE-dependent activation of human mast cells and fMLP-mediated activation of human eosinophils is controlled by the circadian clock. Molecular immunology, 64(1), pp.76-81.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/25466613/"
  }
},
{
  "model": "main.articles",
  "pk": 383,
  "fields": {
    "articlename": "Faust, R., Garratt, P.J., Jones, R., Yeh, L.K., Tsotinis, A., Panoussopoulou, M., Calogeropoulou, T., Teh, M.T. and Sugden, D., 2000. Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6 H-isoindolo [2, 1-a] indoles, 5, 6-dihydroindolo [2, 1-a] isoquinolines, and 6, 7-dihydro-5 H-benzo [c] azepino [2, 1-a] indoles. Journal of medicinal chemistry, 43(6), pp.1050-1061.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/10737738/"
  }
},
{
  "model": "main.articles",
  "pk": 384,
  "fields": {
    "articlename": "Sugden, D., Yeh, L.K. and Teh, M.T., 1999. Design of subtype selective melatonin receptor agonists and antagonists. Reproduction Nutrition Development, 39(3), pp.335-344.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/10420436/"
  }
},
{
  "model": "main.articles",
  "pk": 387,
  "fields": {
    "articlename": "Jockers R, Delagrange P, Dubocovich ML, Markus RP, Renault N, Tosini G, Cecon E, Zlotos DP. Update on melatonin receptors: IUPHAR Review 20. Br J Pharmacol. 2016 Sep;173(18):2702-25.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4995287/"
  }
},
{
  "model": "main.articles",
  "pk": 388,
  "fields": {
    "articlename": "Koczor, C.A., Ludlow, I., Hight, R.S., Jiao, Z., Fields, E., Ludaway, T., Russ, R., Torres, R.A. and Lewis, W., 2015. Ecstasy (MDMA) alters cardiac gene expression and DNA methylation: implications for circadian rhythm dysfunction in the heart. Toxicological Sciences, 148(1), pp.183-191.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/26251327/"
  }
},
{
  "model": "main.articles",
  "pk": 389,
  "fields": {
    "articlename": "Colbron, S., Jones, M. and Biello, S.M., 2002. MDMA alters the response of the circadian clock to a photic and non-photic stimulus. Brain research, 956(1), pp.45-52.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/12426045/"
  }
},
{
  "model": "main.articles",
  "pk": 390,
  "fields": {
    "articlename": "Mitchell, E.J., Brett, R.R., Armstrong, J.D., Sillito, R.R. and Pratt, J.A., 2020. Temporal dissociation of phencyclidine: Induced locomotor and social alterations in rats using an automated homecage monitoring system–implications for the 3Rs and preclinical drug discovery. Journal of Psychopharmacology, 34(7), pp.709-715.",
    "articleurl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7675779/"
  }
},
{
  "model": "main.articles",
  "pk": 391,
  "fields": {
    "articlename": "McCann, U.D. and Ricaurte, G.A., 2007. Effects of (±) 3, 4‐Methylenedioxymethamphetamine (MDMA) on Sleep and Circadian Rhythms. The Scientific World Journal, 7(1), pp.231-238.",
    "articleurl": "https://onlinelibrary.wiley.com/doi/abs/10.1100/tsw.2007.214"
  }
},
{
  "model": "main.articles",
  "pk": 392,
  "fields": {
    "articlename": "Lee, S., Sim, Y., Lee, M., Choi, Y., Lim, J.Y., Lee, J.H. and Kim, E., 2025. Riboflavin as a circadian modulator mitigates D-galactose-induced muscle senescence via oxidative stress and mitochondrial regulation in C2C12 cells. Journal of Functional Foods, 130, p.106924.",
    "articleurl": "https://www.sciencedirect.com/science/article/pii/S175646462500266X"
  }
},
{
  "model": "main.articles",
  "pk": 393,
  "fields": {
    "articlename": "Lee, J., Kim, J.Y., Lee, J.H. and Lee, K.H., 2025. Protocatechuic acid modulates the circadian rhythm of keratinocytes and maintains skin barrier integrity. Molecular Biology Reports, 52(1), p.765.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/40721875/"
  }
},
{
  "model": "main.articles",
  "pk": 394,
  "fields": {
    "articlename": "Koo, J., Choe, H.K., Kim, H.D., Chun, S.K., Son, G.H. and Kim, K., 2015. Effect of mefloquine, a gap junction blocker, on circadian period2 gene oscillation in the mouse suprachiasmatic nucleus ex vivo. Endocrinology and Metabolism, 30(3), pp.361-370.",
    "articleurl": "https://pubmed.ncbi.nlm.nih.gov/25491783/"
  }
},
{
  "model": "main.articles",
  "pk": 395,
  "fields": {
    "articlename": "Gül, Z.M., Aydoğan, S., Sürme, S., Efendi, S.N.H., Özcan, O., Uyanık, E., Baris, I., Gül, S. and Kavakli, I.H., 2025. M54 selectively stabilizes the circadian clock component of CRY1 and enhances the period of circadian rhythm at cellular level. Journal of Biological Chemistry, 301(7).",
    "articleurl": "https://www.sciencedirect.com/science/article/pii/S0021925825021830?via%3Dihub"
  }
},
{
  "model": "main.targets",
  "pk": 7,
  "fields": {
    "targetsname": "T60529",
    "targetsfullname": "Prostaglandin G/H synthase 1 (COX-1)",
    "targeturl": "https://idrblab.net/ttd/data/target/details/t60529"
  }
},
{
  "model": "main.targets",
  "pk": 8,
  "fields": {
    "targetsname": "T58921 Peroxisome proliferator-activated receptor gamma (PPAR-gamma)",
    "targetsfullname": "Peroxisome proliferator-activated receptor gamma (PPAR-gamma)",
    "targeturl": "https://idrblab.net/ttd/data/target/details/t58921"
  }
},
{
  "model": "main.targets",
  "pk": 9,
  "fields": {
    "targetsname": "Melatonin receptor",
    "targetsfullname": "Melatonin receptor",
    "targeturl": "https://www.uniprot.org/uniprotkb/P48039/entry"
  }
},
{
  "model": "main.targets",
  "pk": 10,
  "fields": {
    "targetsname": "MT3",
    "targetsfullname": "Melatonin receptor 3",
    "targeturl": "https://www.rcsb.org/structure/4gr9"
  }
},
{
  "model": "main.targets",
  "pk": 11,
  "fields": {
    "targetsname": "MT1",
    "targetsfullname": "Melatonin receptor 1",
    "targeturl": "https://www.rcsb.org/structure/7db6"
  }
},
{
  "model": "main.targets",
  "pk": 12,
  "fields": {
    "targetsname": "MT2",
    "targetsfullname": "melatonin receptor 2",
    "targeturl": "https://www.rcsb.org/structure/6me7"
  }
},
{
  "model": "main.targets",
  "pk": 13,
  "fields": {
    "targetsname": "JNK",
    "targetsfullname": "JNK",
    "targeturl": "https://www.rcsb.org/structure/1JNK"
  }
},
{
  "model": "main.targets",
  "pk": 14,
  "fields": {
    "targetsname": "RORA",
    "targetsfullname": "",
    "targeturl": "https://www.ncbi.nlm.nih.gov/gene/6095"
  }
},
{
  "model": "main.targets",
  "pk": 15,
  "fields": {
    "targetsname": "NR1D1",
    "targetsfullname": "Reverb alpha",
    "targeturl": "https://www.ncbi.nlm.nih.gov/gene/9572"
  }
},
{
  "model": "main.targets",
  "pk": 16,
  "fields": {
    "targetsname": "RORB",
    "targetsfullname": "",
    "targeturl": "https://www.ncbi.nlm.nih.gov/gene/6096"
  }
},
{
  "model": "main.targets",
  "pk": 17,
  "fields": {
    "targetsname": "Cannabinoid receptor",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/5TGZ"
  }
},
{
  "model": "main.targets",
  "pk": 18,
  "fields": {
    "targetsname": "CB2",
    "targetsfullname": "cannabinoid receptor 2",
    "targeturl": "https://www.rcsb.org/structure/6pt0"
  }
},
{
  "model": "main.targets",
  "pk": 19,
  "fields": {
    "targetsname": "Mu opioid receptor",
    "targetsfullname": "",
    "targeturl": "https://www.uniprot.org/uniprotkb/P35372/entry"
  }
},
{
  "model": "main.targets",
  "pk": 20,
  "fields": {
    "targetsname": "OPRK1",
    "targetsfullname": "Kappa opioid receptor",
    "targeturl": "https://www.uniprot.org/uniprotkb/P48039/entry"
  }
},
{
  "model": "main.targets",
  "pk": 21,
  "fields": {
    "targetsname": "OPRD1",
    "targetsfullname": "Delta opioid receptor",
    "targeturl": "https://www.uniprot.org/uniprotkb/P41143/entry"
  }
},
{
  "model": "main.targets",
  "pk": 22,
  "fields": {
    "targetsname": "NMDA receptor",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/4pe5"
  }
},
{
  "model": "main.targets",
  "pk": 23,
  "fields": {
    "targetsname": "iGluRs",
    "targetsfullname": "Ionotropic glutamate receptors",
    "targeturl": "https://www.rcsb.org/structure/5l1f"
  }
},
{
  "model": "main.targets",
  "pk": 25,
  "fields": {
    "targetsname": "mPer2",
    "targetsfullname": "PERIOD 2",
    "targeturl": "https://www.rcsb.org/structure/3GDI"
  }
},
{
  "model": "main.targets",
  "pk": 26,
  "fields": {
    "targetsname": "mPer1",
    "targetsfullname": "Period 1",
    "targeturl": "https://www.uniprot.org/uniprotkb/O15534/entry"
  }
},
{
  "model": "main.targets",
  "pk": 27,
  "fields": {
    "targetsname": "CRY1-PER2 complex",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/6of7"
  }
},
{
  "model": "main.targets",
  "pk": 28,
  "fields": {
    "targetsname": "CRY1",
    "targetsfullname": "CRYPTOCHROME 1",
    "targeturl": "https://www.rcsb.org/structure/4ct0"
  }
},
{
  "model": "main.targets",
  "pk": 29,
  "fields": {
    "targetsname": "CLOCK-BMAL1",
    "targetsfullname": "complex CLOCK-BMAL1",
    "targeturl": "https://www.rcsb.org/structure/4h10"
  }
},
{
  "model": "main.targets",
  "pk": 30,
  "fields": {
    "targetsname": "Arntl (gene)",
    "targetsfullname": "",
    "targeturl": "https://www.ncbi.nlm.nih.gov/gene/406"
  }
},
{
  "model": "main.targets",
  "pk": 31,
  "fields": {
    "targetsname": "Monoamine transporters",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/8thr"
  }
},
{
  "model": "main.targets",
  "pk": 32,
  "fields": {
    "targetsname": "SEROTONIN TRANSPORTER",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/6AWN"
  }
},
{
  "model": "main.targets",
  "pk": 33,
  "fields": {
    "targetsname": "PPAR gamma",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/2p4y"
  }
},
{
  "model": "main.targets",
  "pk": 34,
  "fields": {
    "targetsname": "D2R (dopamine receptor)",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/8IRS"
  }
},
{
  "model": "main.targets",
  "pk": 35,
  "fields": {
    "targetsname": "GABAA receptors",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/6d6t"
  }
},
{
  "model": "main.targets",
  "pk": 36,
  "fields": {
    "targetsname": "NMDA receptor",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/5IPQ"
  }
},
{
  "model": "main.targets",
  "pk": 37,
  "fields": {
    "targetsname": "Muscarinic acetilcholine receptror M1",
    "targetsfullname": "",
    "targeturl": "https://pubchem.ncbi.nlm.nih.gov/protein/P11229"
  }
},
{
  "model": "main.targets",
  "pk": 38,
  "fields": {
    "targetsname": "ADCY1",
    "targetsfullname": "Adenylat cyclase type 1",
    "targeturl": "https://www.uniprot.org/uniprotkb/Q08828/entry"
  }
},
{
  "model": "main.targets",
  "pk": 39,
  "fields": {
    "targetsname": "SIRT1",
    "targetsfullname": "",
    "targeturl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8650132/"
  }
},
{
  "model": "main.targets",
  "pk": 40,
  "fields": {
    "targetsname": "RORα",
    "targetsfullname": "",
    "targeturl": "https://www.genecards.org/cgi-bin/carddisp.pl?gene=RORA"
  }
},
{
  "model": "main.targets",
  "pk": 41,
  "fields": {
    "targetsname": "Liver X receptors",
    "targetsfullname": "",
    "targeturl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5419308/"
  }
},
{
  "model": "main.targets",
  "pk": 42,
  "fields": {
    "targetsname": "CRY1",
    "targetsfullname": "",
    "targeturl": "https://www.ncbi.nlm.nih.gov/gene/1407"
  }
},
{
  "model": "main.targets",
  "pk": 43,
  "fields": {
    "targetsname": "CK1δ",
    "targetsfullname": "",
    "targeturl": "https://en.wikipedia.org/wiki/CSNK1D"
  }
},
{
  "model": "main.targets",
  "pk": 44,
  "fields": {
    "targetsname": "Microbiota",
    "targetsfullname": "",
    "targeturl": "https://pubmed.ncbi.nlm.nih.gov/36189686/"
  }
},
{
  "model": "main.targets",
  "pk": 45,
  "fields": {
    "targetsname": "Fe deficiency",
    "targetsfullname": "",
    "targeturl": "https://pubmed.ncbi.nlm.nih.gov/23307650/"
  }
},
{
  "model": "main.targets",
  "pk": 46,
  "fields": {
    "targetsname": "LUX (GENE)",
    "targetsfullname": "",
    "targeturl": "https://pubmed.ncbi.nlm.nih.gov/21236673/"
  }
},
{
  "model": "main.targets",
  "pk": 47,
  "fields": {
    "targetsname": "REV-ERBα",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/4n73"
  }
},
{
  "model": "main.targets",
  "pk": 48,
  "fields": {
    "targetsname": "Unknown",
    "targetsfullname": "",
    "targeturl": "https://www.sciencedirect.com/science/article/pii/S0969996121002047"
  }
},
{
  "model": "main.targets",
  "pk": 49,
  "fields": {
    "targetsname": "organellar transcription",
    "targetsfullname": "",
    "targeturl": "https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2020.00429/full"
  }
},
{
  "model": "main.targets",
  "pk": 50,
  "fields": {
    "targetsname": "Mitochondrial translation machine",
    "targetsfullname": "",
    "targeturl": "https://academic.oup.com/plphys/article/58/4/592/6075206"
  }
},
{
  "model": "main.targets",
  "pk": 51,
  "fields": {
    "targetsname": "5-HT7",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/7XTC"
  }
},
{
  "model": "main.targets",
  "pk": 52,
  "fields": {
    "targetsname": "NPAS2",
    "targetsfullname": "",
    "targeturl": "https://www.genecards.org/cgi-bin/carddisp.pl?gene=NPAS2"
  }
},
{
  "model": "main.targets",
  "pk": 53,
  "fields": {
    "targetsname": "Unknown",
    "targetsfullname": "",
    "targeturl": "https://link.springer.com/content/pdf/10.1007/978-3-319-56015-1_421-1.pdf"
  }
},
{
  "model": "main.targets",
  "pk": 54,
  "fields": {
    "targetsname": "5-HT 2A R",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/7wc5"
  }
},
{
  "model": "main.targets",
  "pk": 55,
  "fields": {
    "targetsname": "Calmodulin",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/3cln"
  }
},
{
  "model": "main.targets",
  "pk": 56,
  "fields": {
    "targetsname": "Calmodulin",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/3cln"
  }
},
{
  "model": "main.targets",
  "pk": 57,
  "fields": {
    "targetsname": "5-HT1A",
    "targetsfullname": "Serotonin receptor 5-HT1A",
    "targeturl": "https://www.rcsb.org/structure/7e2y"
  }
},
{
  "model": "main.targets",
  "pk": 58,
  "fields": {
    "targetsname": "Histamine 1 receptor",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/3RZE"
  }
},
{
  "model": "main.targets",
  "pk": 59,
  "fields": {
    "targetsname": "Orexin Receptors OX1R and OX2R",
    "targetsfullname": "",
    "targeturl": "https://www.sciencedirect.com/topics/medicine-and-dentistry/orexin-receptor"
  }
},
{
  "model": "main.targets",
  "pk": 60,
  "fields": {
    "targetsname": "Adenosine A1, A2A, A2B, and A3 Receptors",
    "targetsfullname": "",
    "targeturl": "https://www.sciencedirect.com/topics/neuroscience/adenosine-receptor"
  }
},
{
  "model": "main.targets",
  "pk": 61,
  "fields": {
    "targetsname": "ADORA2B",
    "targetsfullname": "",
    "targeturl": "https://en.wikipedia.org/wiki/Adenosine_A2B_receptor"
  }
},
{
  "model": "main.targets",
  "pk": 62,
  "fields": {
    "targetsname": "Lanosterol 14-α-demethylase (fungal CYP51)",
    "targetsfullname": "",
    "targeturl": "https://en.wikipedia.org/wiki/Lanosterol_14_alpha-demethylase"
  }
},
{
  "model": "main.targets",
  "pk": 63,
  "fields": {
    "targetsname": "BMAL1 expression (induction)",
    "targetsfullname": "",
    "targeturl": "https://www.genecards.org/cgi-bin/carddisp.pl?gene=BMAL1"
  }
},
{
  "model": "main.targets",
  "pk": 64,
  "fields": {
    "targetsname": "Monoamine oxidase A",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/2z5x"
  }
},
{
  "model": "main.targets",
  "pk": 65,
  "fields": {
    "targetsname": "Glyceraldehyde-3-phosphate dehydrogenase",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/2PKQ"
  }
},
{
  "model": "main.targets",
  "pk": 66,
  "fields": {
    "targetsname": "JAK2",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/7F7W"
  }
},
{
  "model": "main.targets",
  "pk": 67,
  "fields": {
    "targetsname": "EGFR",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/1IVO"
  }
},
{
  "model": "main.targets",
  "pk": 68,
  "fields": {
    "targetsname": "Vitamin D3 receptor",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/1DB1"
  }
},
{
  "model": "main.targets",
  "pk": 69,
  "fields": {
    "targetsname": "Vitamin D binding protein",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/1KW2"
  }
},
{
  "model": "main.targets",
  "pk": 70,
  "fields": {
    "targetsname": "Progesterone receptor",
    "targetsfullname": "",
    "targeturl": "https://www.uniprot.org/uniprotkb/P06401/entry"
  }
},
{
  "model": "main.targets",
  "pk": 71,
  "fields": {
    "targetsname": "Estrogen receptor alpha",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/4J24"
  }
},
{
  "model": "main.targets",
  "pk": 72,
  "fields": {
    "targetsname": "Fe",
    "targetsfullname": "",
    "targeturl": "https://pubchem.ncbi.nlm.nih.gov/compound/23925"
  }
},
{
  "model": "main.targets",
  "pk": 73,
  "fields": {
    "targetsname": "Melanopsin (Opn4)",
    "targetsfullname": "",
    "targeturl": "https://en.wikipedia.org/wiki/Melanopsin"
  }
},
{
  "model": "main.targets",
  "pk": 74,
  "fields": {
    "targetsname": "p38 MAP kinase",
    "targetsfullname": "",
    "targeturl": "https://en.wikipedia.org/wiki/P38_mitogen-activated_protein_kinases"
  }
},
{
  "model": "main.targets",
  "pk": 75,
  "fields": {
    "targetsname": "c-Jun N-terminal kinase (JNK)",
    "targetsfullname": "",
    "targeturl": "https://en.wikipedia.org/wiki/C-Jun_N-terminal_kinases"
  }
},
{
  "model": "main.targets",
  "pk": 76,
  "fields": {
    "targetsname": "GSK-3α/β",
    "targetsfullname": "",
    "targeturl": "https://en.wikipedia.org/wiki/GSK-3"
  }
},
{
  "model": "main.targets",
  "pk": 77,
  "fields": {
    "targetsname": "Topoisomerase I",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/1T8I"
  }
},
{
  "model": "main.targets",
  "pk": 78,
  "fields": {
    "targetsname": "Retinoic acid receptor alpha",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/7B88"
  }
},
{
  "model": "main.targets",
  "pk": 79,
  "fields": {
    "targetsname": "Beta 1,2 adrenergic receptor",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/2YCY"
  }
},
{
  "model": "main.targets",
  "pk": 80,
  "fields": {
    "targetsname": "Tyrosine proteine kinase ABL1",
    "targetsfullname": "",
    "targeturl": "https://www.uniprot.org/uniprotkb/P00519/entry"
  }
},
{
  "model": "main.targets",
  "pk": 81,
  "fields": {
    "targetsname": "H+ K+ ATPase",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/3IXZ"
  }
},
{
  "model": "main.targets",
  "pk": 82,
  "fields": {
    "targetsname": "PER3",
    "targetsfullname": "",
    "targeturl": "https://www.ncbi.nlm.nih.gov/gene/8863"
  }
},
{
  "model": "main.targets",
  "pk": 83,
  "fields": {
    "targetsname": "CRY2",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/7V8Y"
  }
},
{
  "model": "main.targets",
  "pk": 84,
  "fields": {
    "targetsname": "Per2 expression",
    "targetsfullname": "",
    "targeturl": "https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=8864"
  }
},
{
  "model": "main.targets",
  "pk": 85,
  "fields": {
    "targetsname": "Neuropeptide Y Y1 receptor",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/7X9A"
  }
},
{
  "model": "main.targets",
  "pk": 86,
  "fields": {
    "targetsname": "NR1F1",
    "targetsfullname": "",
    "targeturl": "https://www.uniprot.org/uniprotkb/B6ZGS4/entry"
  }
},
{
  "model": "main.targets",
  "pk": 87,
  "fields": {
    "targetsname": "ROR gamma",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/5X8Q"
  }
},
{
  "model": "main.targets",
  "pk": 88,
  "fields": {
    "targetsname": "TRPV4 Channel",
    "targetsfullname": "",
    "targeturl": "https://en.wikipedia.org/wiki/TRPV4"
  }
},
{
  "model": "main.targets",
  "pk": 89,
  "fields": {
    "targetsname": "CKI delta",
    "targetsfullname": "Caseine kinase I delta",
    "targeturl": "https://www.rcsb.org/structure/1CKI"
  }
},
{
  "model": "main.targets",
  "pk": 90,
  "fields": {
    "targetsname": "Dec1 gene expression",
    "targetsfullname": "",
    "targeturl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2423136/"
  }
},
{
  "model": "main.targets",
  "pk": 91,
  "fields": {
    "targetsname": "GUT MICROBIOTA",
    "targetsfullname": "",
    "targeturl": "https://www.sciencedirect.com/science/article/pii/S2213453024001691"
  }
},
{
  "model": "main.targets",
  "pk": 92,
  "fields": {
    "targetsname": "TIMELESS",
    "targetsfullname": "",
    "targeturl": "https://www.ncbi.nlm.nih.gov/gene/8914"
  }
},
{
  "model": "main.targets",
  "pk": 93,
  "fields": {
    "targetsname": "CLOCK gene expression",
    "targetsfullname": "",
    "targeturl": "https://www.genecards.org/cgi-bin/carddisp.pl?gene=CLOCK"
  }
},
{
  "model": "main.targets",
  "pk": 94,
  "fields": {
    "targetsname": "Heme",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/1n45"
  }
},
{
  "model": "main.targets",
  "pk": 95,
  "fields": {
    "targetsname": "CCA1",
    "targetsfullname": "circadian clock associated 1 [ Arabidopsis thaliana (thale cress) ]",
    "targeturl": "https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=819296"
  }
},
{
  "model": "main.targets",
  "pk": 96,
  "fields": {
    "targetsname": "orexin receptor subtypes (OX1 and OX2)",
    "targetsfullname": "",
    "targeturl": "https://en.wikipedia.org/wiki/Orexin_receptor#:~:text=There%20are%20two%20variants%2C%20OX,gene%20(HCRTR1%2C%20HCRTR2).&text=Both%20orexin%20receptors%20exhibit%20a,increase%20in%20intracellular%20cal"
  }
},
{
  "model": "main.targets",
  "pk": 97,
  "fields": {
    "targetsname": "p38 kinase",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/5uoj"
  }
},
{
  "model": "main.targets",
  "pk": 98,
  "fields": {
    "targetsname": "Corticosteroid hormone receptor",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/4P6X"
  }
},
{
  "model": "main.targets",
  "pk": 99,
  "fields": {
    "targetsname": "Per 1 expression (gene)",
    "targetsfullname": "",
    "targeturl": "https://www.ncbi.nlm.nih.gov/gene/5187"
  }
},
{
  "model": "main.targets",
  "pk": 100,
  "fields": {
    "targetsname": "Per 1 (Rat gene)",
    "targetsfullname": "",
    "targeturl": "https://www.ncbi.nlm.nih.gov/gene/287422"
  }
},
{
  "model": "main.targets",
  "pk": 101,
  "fields": {
    "targetsname": "Per 2 (gene Rat)",
    "targetsfullname": "",
    "targeturl": "https://www.ncbi.nlm.nih.gov/gene/63840"
  }
},
{
  "model": "main.targets",
  "pk": 102,
  "fields": {
    "targetsname": "BMAL1",
    "targetsfullname": "",
    "targeturl": "https://www.uniprot.org/uniprotkb/O00327/entry"
  }
},
{
  "model": "main.targets",
  "pk": 103,
  "fields": {
    "targetsname": "Rev-erb expression",
    "targetsfullname": "",
    "targeturl": "https://www.ncbi.nlm.nih.gov/gene/217166"
  }
},
{
  "model": "main.targets",
  "pk": 104,
  "fields": {
    "targetsname": "NLRP3 inflammasome",
    "targetsfullname": "",
    "targeturl": "https://www.uniprot.org/uniprotkb/Q96P20/entry"
  }
},
{
  "model": "main.targets",
  "pk": 105,
  "fields": {
    "targetsname": "MTOR (Human)",
    "targetsfullname": "",
    "targeturl": "https://www.uniprot.org/uniprotkb/P42345/entry"
  }
},
{
  "model": "main.targets",
  "pk": 106,
  "fields": {
    "targetsname": "CLOCK-BMAL1 COMPLEX",
    "targetsfullname": "",
    "targeturl": "https://www.e-enm.org/journal/view.php?doi=10.3803/enm.2014.29.3.379"
  }
},
{
  "model": "main.targets",
  "pk": 107,
  "fields": {
    "targetsname": "5-HT 2A R",
    "targetsfullname": "",
    "targeturl": "https://en.wikipedia.org/wiki/5-HT2A_receptor"
  }
},
{
  "model": "main.targets",
  "pk": 108,
  "fields": {
    "targetsname": "CK1 epsilon",
    "targetsfullname": "",
    "targeturl": "https://www.uniprot.org/uniprotkb/P49674/entry"
  }
},
{
  "model": "main.targets",
  "pk": 109,
  "fields": {
    "targetsname": "Mouse CRY2 with shp656",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/7v8z"
  }
},
{
  "model": "main.targets",
  "pk": 110,
  "fields": {
    "targetsname": "DAT ( human Dopamine transporter)",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/9EO4"
  }
},
{
  "model": "main.targets",
  "pk": 111,
  "fields": {
    "targetsname": "HSP90",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/2XJX"
  }
},
{
  "model": "main.targets",
  "pk": 112,
  "fields": {
    "targetsname": "CK2 alpha",
    "targetsfullname": "Caseine kinase 2 alpha",
    "targeturl": "https://www.rcsb.org/structure/1LP4"
  }
},
{
  "model": "main.targets",
  "pk": 113,
  "fields": {
    "targetsname": "AMPK",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/4CFF"
  }
},
{
  "model": "main.targets",
  "pk": 114,
  "fields": {
    "targetsname": "JAC (Janus kinase)",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/7T6F"
  }
},
{
  "model": "main.targets",
  "pk": 115,
  "fields": {
    "targetsname": "TRPV1",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/3J9J"
  }
},
{
  "model": "main.targets",
  "pk": 116,
  "fields": {
    "targetsname": "Serotonin N-acetyltransferase",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/1KUY"
  }
},
{
  "model": "main.targets",
  "pk": 117,
  "fields": {
    "targetsname": "PI3K/Akt",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/4FHJ"
  }
},
{
  "model": "main.targets",
  "pk": 118,
  "fields": {
    "targetsname": "NF-kB",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/1NFK"
  }
},
{
  "model": "main.targets",
  "pk": 119,
  "fields": {
    "targetsname": "Mel1C",
    "targetsfullname": "",
    "targeturl": "https://www.uniprot.org/uniprotkb/I2E116/entry"
  }
},
{
  "model": "main.targets",
  "pk": 120,
  "fields": {
    "targetsname": "CAND2",
    "targetsfullname": "Cullin-associated NEDD8-dissociated protein 2",
    "targeturl": "https://www.rcsb.org/structure/8VVY"
  }
},
{
  "model": "main.targets",
  "pk": 121,
  "fields": {
    "targetsname": "VDR",
    "targetsfullname": "Vitamin D Receptor",
    "targeturl": "https://www.rcsb.org/structure/5E7V"
  }
},
{
  "model": "main.targets",
  "pk": 122,
  "fields": {
    "targetsname": "QR2",
    "targetsfullname": "NAD(P)H dehydrogenase, quinone 2, also known as QR2",
    "targeturl": "https://www.rcsb.org/structure/1SG0"
  }
},
{
  "model": "main.targets",
  "pk": 123,
  "fields": {
    "targetsname": "MMP9",
    "targetsfullname": "Gelatinase B",
    "targeturl": "https://www.rcsb.org/structure/1L6J"
  }
},
{
  "model": "main.targets",
  "pk": 124,
  "fields": {
    "targetsname": "PEPSIN",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/1PSO"
  }
},
{
  "model": "main.targets",
  "pk": 125,
  "fields": {
    "targetsname": "PP2A",
    "targetsfullname": "Protein phosphatase 2 (PP2), also known as PP2A",
    "targeturl": "https://www.rcsb.org/structure/2IAE"
  }
},
{
  "model": "main.targets",
  "pk": 126,
  "fields": {
    "targetsname": "mPTP",
    "targetsfullname": "Mitochondrial permeability transition pore",
    "targeturl": "https://www.rcsb.org/structure/5A0E"
  }
},
{
  "model": "main.targets",
  "pk": 127,
  "fields": {
    "targetsname": "PEPT1",
    "targetsfullname": "proton-coupled peptide transporter 1",
    "targeturl": "https://www.rcsb.org/structure/7S8U"
  }
},
{
  "model": "main.targets",
  "pk": 128,
  "fields": {
    "targetsname": "PEPT2",
    "targetsfullname": "proton-coupled peptide transporter 2",
    "targeturl": "https://www.rcsb.org/structure/7NQK"
  }
},
{
  "model": "main.targets",
  "pk": 129,
  "fields": {
    "targetsname": "GLUT1",
    "targetsfullname": "Glucose transporter 1",
    "targeturl": "https://www.rcsb.org/structure/4PYP"
  }
},
{
  "model": "main.targets",
  "pk": 130,
  "fields": {
    "targetsname": "HBS",
    "targetsfullname": "Sickle hemoglobin",
    "targeturl": "https://www.uniprot.org/citations/10791557"
  }
},
{
  "model": "main.targets",
  "pk": 131,
  "fields": {
    "targetsname": "CaM",
    "targetsfullname": "Calmodulin",
    "targeturl": "https://www.rcsb.org/structure/6HCS"
  }
},
{
  "model": "main.targets",
  "pk": 132,
  "fields": {
    "targetsname": "TUBULIN",
    "targetsfullname": "Tubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed of alpha- and beta-tubu",
    "targeturl": "https://www.rcsb.org/structure/1TUB"
  }
},
{
  "model": "main.targets",
  "pk": 133,
  "fields": {
    "targetsname": "Calreticulin",
    "targetsfullname": "a highly conserved chaperone protein which resides primarily in the endoplasmic reticulum, and is involved in a variety of cellular processes, among t",
    "targeturl": "https://www.rcsb.org/structure/3POW"
  }
},
{
  "model": "main.targets",
  "pk": 134,
  "fields": {
    "targetsname": "PGC-1α",
    "targetsfullname": "",
    "targeturl": "https://www.rcsb.org/structure/3CS8"
  }
},
{
  "model": "main.targets",
  "pk": 135,
  "fields": {
    "targetsname": "Unknown | Multiple plant targets",
    "targetsfullname": "",
    "targeturl": "https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2020.00429/full"
  }
},
{
  "model": "main.targets",
  "pk": 136,
  "fields": {
    "targetsname": "SLC6A2",
    "targetsfullname": "solute carrier family 6 member 2",
    "targeturl": "https://platform.opentargets.org/target/ENSG00000103546"
  }
},
{
  "model": "main.targets",
  "pk": 137,
  "fields": {
    "targetsname": "PER2 gene expression",
    "targetsfullname": "",
    "targeturl": "https://en.wikipedia.org/wiki/PER2"
  }
},
{
  "model": "main.targets",
  "pk": 138,
  "fields": {
    "targetsname": "HCN1",
    "targetsfullname": "hyperpolarization-activated cyclic nucleotide-gated ion channel",
    "targeturl": "https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=400"
  }
},
{
  "model": "main.targets",
  "pk": 139,
  "fields": {
    "targetsname": "CNGA3",
    "targetsfullname": "Cyclic nucleotide-gated channel alpha-3",
    "targeturl": "https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=396"
  }
},
{
  "model": "main.targets",
  "pk": 140,
  "fields": {
    "targetsname": "HCN2",
    "targetsfullname": "hyperpolarization-activated, cyclic nucleotide-gated K+ 2",
    "targeturl": "https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=401"
  }
},
{
  "model": "main.targets",
  "pk": 141,
  "fields": {
    "targetsname": "CNGA2",
    "targetsfullname": "",
    "targeturl": "https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=395"
  }
},
{
  "model": "main.targets",
  "pk": 142,
  "fields": {
    "targetsname": "FPR2",
    "targetsfullname": "",
    "targeturl": "https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=223"
  }
},
{
  "model": "main.targets",
  "pk": 143,
  "fields": {
    "targetsname": "FPR1",
    "targetsfullname": "",
    "targeturl": "https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=222"
  }
},
{
  "model": "main.targets",
  "pk": 144,
  "fields": {
    "targetsname": "SLC18A2",
    "targetsfullname": "Synaptic vesicular amine transporter",
    "targeturl": "https://go.drugbank.com/drugs/DB01454#:~:text=Uniprot%20ID-,Q05940,-Uniprot%20Name"
  }
},
{
  "model": "main.targets",
  "pk": 145,
  "fields": {
    "targetsname": "SLC6A2",
    "targetsfullname": "Sodium-dependent noradrenaline transporter",
    "targeturl": "http://www.uniprot.org/uniprot/P23975"
  }
},
{
  "model": "main.targets",
  "pk": 146,
  "fields": {
    "targetsname": "SLC6A4",
    "targetsfullname": "Sodium-dependent serotonin transporter",
    "targeturl": "http://www.uniprot.org/uniprot/P31645"
  }
},
{
  "model": "main.targets",
  "pk": 147,
  "fields": {
    "targetsname": "HTR2C",
    "targetsfullname": "5-hydroxytryptamine receptor 2C",
    "targeturl": "http://www.uniprot.org/uniprot/P28335"
  }
},
{
  "model": "main.targets",
  "pk": 148,
  "fields": {
    "targetsname": "HTR2A",
    "targetsfullname": "",
    "targeturl": "http://www.uniprot.org/uniprot/P28223"
  }
},
{
  "model": "main.targets",
  "pk": 149,
  "fields": {
    "targetsname": "HTR2B",
    "targetsfullname": "5-hydroxytryptamine receptor 2B",
    "targeturl": "http://www.uniprot.org/uniprot/P41595"
  }
},
{
  "model": "main.targets",
  "pk": 150,
  "fields": {
    "targetsname": "SLC6A3",
    "targetsfullname": "",
    "targeturl": "http://www.uniprot.org/uniprot/Q01959"
  }
},
{
  "model": "main.effect",
  "pk": 1,
  "fields": {
    "Effectname": "phase advance"
  }
},
{
  "model": "main.effect",
  "pk": 2,
  "fields": {
    "Effectname": "Modulates circadian entrainment in hypothalamus"
  }
},
{
  "model": "main.effect",
  "pk": 3,
  "fields": {
    "Effectname": "activated RORα1 luciferase reporter activity"
  }
},
{
  "model": "main.effect",
  "pk": 4,
  "fields": {
    "Effectname": "Dose causes a rhythmic pattern of mPER2 with an average period of 24.48 h for PER2"
  }
},
{
  "model": "main.effect",
  "pk": 5,
  "fields": {
    "Effectname": "restores normal circadian rhythms"
  }
},
{
  "model": "main.effect",
  "pk": 6,
  "fields": {
    "Effectname": "↑ RORα exprssion"
  }
},
{
  "model": "main.effect",
  "pk": 7,
  "fields": {
    "Effectname": "increased protein expression of the core clocks BMAL1 and CLOCK"
  }
},
{
  "model": "main.effect",
  "pk": 8,
  "fields": {
    "Effectname": "cause period lengthening in a concentration-dependent manner"
  }
},
{
  "model": "main.effect",
  "pk": 9,
  "fields": {
    "Effectname": "l-Theanine significantly enhanced the expression of BMAL1, a clock gene in melanoma cells."
  }
},
{
  "model": "main.effect",
  "pk": 10,
  "fields": {
    "Effectname": "Increases amplitude of circadian rhtyhms"
  }
},
{
  "model": "main.effect",
  "pk": 11,
  "fields": {
    "Effectname": "reverses phase delay"
  }
},
{
  "model": "main.effect",
  "pk": 12,
  "fields": {
    "Effectname": "increased the expression levels of REV-ERBα target genes Bhmt, Cbs and Cth"
  }
},
{
  "model": "main.effect",
  "pk": 13,
  "fields": {
    "Effectname": "Piceatannol advanced PER2::LUC luminescence rhythm in peripheral organs in vivo."
  }
},
{
  "model": "main.effect",
  "pk": 14,
  "fields": {
    "Effectname": "recovered phase change of PER2::LUC disturbed by high-fat diet intake."
  }
},
{
  "model": "main.effect",
  "pk": 15,
  "fields": {
    "Effectname": "affects Per2 expression and may prevent circadian disturbance."
  }
},
{
  "model": "main.effect",
  "pk": 16,
  "fields": {
    "Effectname": "upregulate core circadian genes and reverse circadian misalignment caused by ethanol in liver cells."
  }
},
{
  "model": "main.effect",
  "pk": 17,
  "fields": {
    "Effectname": "Night alertness"
  }
},
{
  "model": "main.effect",
  "pk": 18,
  "fields": {
    "Effectname": "Melatonin level reduction"
  }
},
{
  "model": "main.effect",
  "pk": 19,
  "fields": {
    "Effectname": "reduced weight gain induced by circadian rhythm disorder"
  }
},
{
  "model": "main.effect",
  "pk": 20,
  "fields": {
    "Effectname": "Decreases phase"
  }
},
{
  "model": "main.effect",
  "pk": 21,
  "fields": {
    "Effectname": "enhancing the expression of the core clock component BMAL1"
  }
},
{
  "model": "main.effect",
  "pk": 22,
  "fields": {
    "Effectname": "disrupts the circadian clock specifically in cancer cells"
  }
},
{
  "model": "main.effect",
  "pk": 23,
  "fields": {
    "Effectname": "via HSP90 affects the stability of BMAL1 and circadian gene expression."
  }
},
{
  "model": "main.effect",
  "pk": 24,
  "fields": {
    "Effectname": "showed stronger period effects (0.32 μM for 5 h period lengthening) in a cell-based circadian assay"
  }
},
{
  "model": "main.effect",
  "pk": 25,
  "fields": {
    "Effectname": "dose dependently increases wakefulness at the expense of slow-wave and paradoxical sleep with no increase in locomotor activity per unit of time awake"
  }
},
{
  "model": "main.effect",
  "pk": 26,
  "fields": {
    "Effectname": "disrupts glioblastoma clock"
  }
},
{
  "model": "main.effect",
  "pk": 27,
  "fields": {
    "Effectname": "can induce a phase delay in circadian rhythms"
  }
},
{
  "model": "main.effect",
  "pk": 28,
  "fields": {
    "Effectname": "can disrupt circadian rhythms, can influence various aspects of sleep and wakefulness, including sleep onset, delta sleep, an"
  }
},
{
  "model": "main.effect",
  "pk": 29,
  "fields": {
    "Effectname": "led to delayed REM sleep onset and reduced NREM sleep maintenance for up to approximately 3 h after dosing"
  }
},
{
  "model": "main.effect",
  "pk": 30,
  "fields": {
    "Effectname": "is a rapidly-emerging treatment for depression"
  }
},
{
  "model": "main.effect",
  "pk": 31,
  "fields": {
    "Effectname": "directly targets BMAL1, impacting its ability to regulate gene expression within the circadian clock and immune system"
  }
},
{
  "model": "main.effect",
  "pk": 32,
  "fields": {
    "Effectname": "Advances circadian rhtyhms"
  }
},
{
  "model": "main.effect",
  "pk": 33,
  "fields": {
    "Effectname": "was found to promote sleep, alter circadian gene expression in the heart, and show a slight trend of increasing free-running periods. Together, these"
  }
},
{
  "model": "main.effect",
  "pk": 34,
  "fields": {
    "Effectname": "lengthened the periods of BMAL1 and PER2"
  }
},
{
  "model": "main.effect",
  "pk": 35,
  "fields": {
    "Effectname": "significantly reduced NREM sleep onset latency and transiently increased the time spent in NREM sleep, but did not alter REM sleep latency or the amou"
  }
},
{
  "model": "main.effect",
  "pk": 36,
  "fields": {
    "Effectname": "acute sleep-promoting activity"
  }
},
{
  "model": "main.effect",
  "pk": 37,
  "fields": {
    "Effectname": "Aldosterone influences the expression of clock genes such as Per1, Per2, and Bmal1 in cardiomyoblasts"
  }
},
{
  "model": "main.effect",
  "pk": 38,
  "fields": {
    "Effectname": "Disrupts sleep"
  }
},
{
  "model": "main.effect",
  "pk": 39,
  "fields": {
    "Effectname": "Resetting of circadian time in peripheral tissues"
  }
},
{
  "model": "main.effect",
  "pk": 40,
  "fields": {
    "Effectname": "alters the circadian rhythm"
  }
},
{
  "model": "main.effect",
  "pk": 41,
  "fields": {
    "Effectname": "improve wakefulness in individuals with certain sleep disorders"
  }
},
{
  "model": "main.effect",
  "pk": 42,
  "fields": {
    "Effectname": "can attenuate the sleep-promoting effects of the OX2R antagonist"
  }
},
{
  "model": "main.effect",
  "pk": 43,
  "fields": {
    "Effectname": "sleep-promoting effects"
  }
},
{
  "model": "main.effect",
  "pk": 44,
  "fields": {
    "Effectname": "reduces the levels of PRR7 protein in Arabidopsis"
  }
},
{
  "model": "main.effect",
  "pk": 45,
  "fields": {
    "Effectname": "primarily affect circadian rhythms by promoting sleep, particularly reducing wakefulness after sleep onset and improving sleep maintenance"
  }
},
{
  "model": "main.effect",
  "pk": 46,
  "fields": {
    "Effectname": "~0.3 h shortening of the period of circadian T(b) rhythms in mice kept under conditions of constant darkness (P < 0.01)"
  }
},
{
  "model": "main.effect",
  "pk": 47,
  "fields": {
    "Effectname": "improves circadian rhythms in pigs"
  }
},
{
  "model": "main.effect",
  "pk": 48,
  "fields": {
    "Effectname": "Per2 disruption affected both GBM migration and cell cycle progression."
  }
},
{
  "model": "main.effect",
  "pk": 49,
  "fields": {
    "Effectname": "period shortening of the mammalian circadian clock by specific inhibition of GSK-3β"
  }
},
{
  "model": "main.effect",
  "pk": 50,
  "fields": {
    "Effectname": "Affects melatonin synthsis"
  }
},
{
  "model": "main.effect",
  "pk": 51,
  "fields": {
    "Effectname": "prolonged period, increased amplitude, and phase modulation"
  }
},
{
  "model": "main.effect",
  "pk": 52,
  "fields": {
    "Effectname": "increases melatonin synthesis"
  }
},
{
  "model": "main.effect",
  "pk": 53,
  "fields": {
    "Effectname": "helps with sleep, it doesn't necessarily reset or re-establish the body's internal clock"
  }
},
{
  "model": "main.effect",
  "pk": 54,
  "fields": {
    "Effectname": "Modulates insulin release rhtyhms"
  }
},
{
  "model": "main.effect",
  "pk": 55,
  "fields": {
    "Effectname": "Induces resless legs syndrome"
  }
},
{
  "model": "main.effect",
  "pk": 56,
  "fields": {
    "Effectname": "affect expression of PER1 and CRY1 genes in human glioblastoma cell line"
  }
},
{
  "model": "main.effect",
  "pk": 57,
  "fields": {
    "Effectname": "improves sleep in insomnia"
  }
},
{
  "model": "main.effect",
  "pk": 58,
  "fields": {
    "Effectname": "Disrupts cellular synchrony in suprachiasmatic nucleus"
  }
},
{
  "model": "main.effect",
  "pk": 59,
  "fields": {
    "Effectname": "shortened the period length of the circadian rhythm by 2 hours"
  }
},
{
  "model": "main.effect",
  "pk": 60,
  "fields": {
    "Effectname": "Rifampicin lengthened the circadian period under darkness in plants."
  }
},
{
  "model": "main.effect",
  "pk": 61,
  "fields": {
    "Effectname": "Salicylic acid (SA) increased oscillatory robustness and shortened the period in plants"
  }
},
{
  "model": "main.effect",
  "pk": 62,
  "fields": {
    "Effectname": "Application Can Entrain the Clock"
  }
},
{
  "model": "main.effect",
  "pk": 63,
  "fields": {
    "Effectname": "may cause daytime sleepiness"
  }
},
{
  "model": "main.effect",
  "pk": 64,
  "fields": {
    "Effectname": "rescues recognition memory and circadian motor rhythmicity but does not prevent terminal disease in fatal familial insomnia mice"
  }
},
{
  "model": "main.effect",
  "pk": 65,
  "fields": {
    "Effectname": "circadian clock mediated antitumor effect"
  }
},
{
  "model": "main.effect",
  "pk": 66,
  "fields": {
    "Effectname": "Regulates Flowering Time through Expression of the Circadian Clock Gene LUX"
  }
},
{
  "model": "main.effect",
  "pk": 67,
  "fields": {
    "Effectname": "Improvement in daytime sleepiness in patients with GABA-related hypersomnia"
  }
},
{
  "model": "main.effect",
  "pk": 68,
  "fields": {
    "Effectname": "alone caused a long circadian period. However, the degree of lengthening was less than with Fe deficiency alone"
  }
},
{
  "model": "main.effect",
  "pk": 69,
  "fields": {
    "Effectname": "protective effects against cognitive impairment caused by circadian rhythm disruption"
  }
},
{
  "model": "main.effect",
  "pk": 70,
  "fields": {
    "Effectname": "heat shock protein 90 binding affinity affectin circadian clock (indirect effects"
  }
},
{
  "model": "main.effect",
  "pk": 71,
  "fields": {
    "Effectname": "lengthen circadian rhtyhms"
  }
},
{
  "model": "main.effect",
  "pk": 72,
  "fields": {
    "Effectname": "Disrupts cellular circadian system"
  }
},
{
  "model": "main.effect",
  "pk": 73,
  "fields": {
    "Effectname": "Resveratrol can influence the expression of key clock genes like CLOCK, BMAL1, PER, and CRY, which are involved in establishing and maintaining the 24"
  }
},
{
  "model": "main.effect",
  "pk": 74,
  "fields": {
    "Effectname": "shifted the phases"
  }
},
{
  "model": "main.effect",
  "pk": 75,
  "fields": {
    "Effectname": "inhibited the transcriptional activity of RORγt"
  }
},
{
  "model": "main.effect",
  "pk": 76,
  "fields": {
    "Effectname": "Suppresses TH17 cells and Stimulates T Regulatory Cells"
  }
},
{
  "model": "main.effect",
  "pk": 77,
  "fields": {
    "Effectname": "It reduces food intake, fat mass, and improves insulin sensitivity in obese diabetic mice, indicating potential as an anti-diabetic and anti-obesity"
  }
},
{
  "model": "main.effect",
  "pk": 78,
  "fields": {
    "Effectname": "SR2211 acts as an inverse agonist of RORγ, meaning it blocks the activity of the receptor. This can have implications for circadian rhythms, as RORγ's"
  }
},
{
  "model": "main.effect",
  "pk": 79,
  "fields": {
    "Effectname": "resets the molecular circadian clock in eosinophils"
  }
},
{
  "model": "main.effect",
  "pk": 80,
  "fields": {
    "Effectname": "leading to a decrease in the expression of core clock genes, which are essential for maintaining circadian rhythms. This can affect various aspects of"
  }
},
{
  "model": "main.effect",
  "pk": 81,
  "fields": {
    "Effectname": "It affects circadian rhythms by activating RORα/γ, which in turn regulates the transcription of target genes, including the core clock component BMAL1"
  }
},
{
  "model": "main.effect",
  "pk": 82,
  "fields": {
    "Effectname": "shortens the circadian period in a dose-dependent manner in cultured human cells"
  }
},
{
  "model": "main.effect",
  "pk": 84,
  "fields": {
    "Effectname": "Recent reports, however, have shown that high doses of DHEA (e.g., 100 μM) lengthen circadian period and decrease amplitude"
  }
},
{
  "model": "main.effect",
  "pk": 85,
  "fields": {
    "Effectname": "lengthen the circadian period, meaning the time it takes for the clock to complete one cycle"
  }
},
{
  "model": "main.effect",
  "pk": 86,
  "fields": {
    "Effectname": "Specifically, it can increase the stability of PER2 protein, a key player in the molecular clock, and enhance the function of RORα, another protein in"
  }
},
{
  "model": "main.effect",
  "pk": 87,
  "fields": {
    "Effectname": "lengthening of the circadian period, as Bmal1 is involved in determining the length of the clock's oscillation."
  }
},
{
  "model": "main.effect",
  "pk": 88,
  "fields": {
    "Effectname": "Studies using SRT1720 have demonstrated that it can alter the expression of genes involved in the circadian clock."
  }
},
{
  "model": "main.effect",
  "pk": 89,
  "fields": {
    "Effectname": "RT2183, a SIRT1 activator, affects circadian rhythms by reducing the expression of circadian genes, achieved by decreasing the hidstone acetylation"
  }
},
{
  "model": "main.effect",
  "pk": 90,
  "fields": {
    "Effectname": "non-psychoactive cannabinoid, can influence circadian rhythms through its interaction with the endocannabinoid system (ECS) and potentially by modulat"
  }
},
{
  "model": "main.effect",
  "pk": 91,
  "fields": {
    "Effectname": "Oxycodone, like other opioids, can disrupt circadian rhythms, the body's natural 24-hour cycle."
  }
},
{
  "model": "main.effect",
  "pk": 92,
  "fields": {
    "Effectname": "shortens the circadian period in a dose-dependent manner. However, high doses can also lengthen the circadian period and decrease its amplitude."
  }
},
{
  "model": "main.effect",
  "pk": 93,
  "fields": {
    "Effectname": "Period shortening in plants"
  }
},
{
  "model": "main.effect",
  "pk": 94,
  "fields": {
    "Effectname": "Period lengthening in fungi"
  }
},
{
  "model": "main.effect",
  "pk": 95,
  "fields": {
    "Effectname": "Phase shift and PER1 suppression in mammals"
  }
},
{
  "model": "main.effect",
  "pk": 96,
  "fields": {
    "Effectname": "Amplitude enhancement in human cells"
  }
},
{
  "model": "main.effect",
  "pk": 97,
  "fields": {
    "Effectname": "Phase-dependent cell death modulation"
  }
},
{
  "model": "main.effect",
  "pk": 98,
  "fields": {
    "Effectname": "BMAL1 amplitude enhancement via RORα-dependent pathway."
  }
},
{
  "model": "main.effect",
  "pk": 99,
  "fields": {
    "Effectname": "Period lengthening in Aplysia."
  }
},
{
  "model": "main.effect",
  "pk": 100,
  "fields": {
    "Effectname": "blocks melatonin-induced phase shifts"
  }
},
{
  "model": "main.effect",
  "pk": 101,
  "fields": {
    "Effectname": "Inhibition of light-induced phase shifts via melanopsin antagonism"
  }
},
{
  "model": "main.effect",
  "pk": 102,
  "fields": {
    "Effectname": "Melatonin receptor agonism"
  }
},
{
  "model": "main.effect",
  "pk": 103,
  "fields": {
    "Effectname": "Circadian phase entrainment via MT1/MT2 receptor agonism"
  }
},
{
  "model": "main.effect",
  "pk": 104,
  "fields": {
    "Effectname": "Period lengthening in human U2OS cells"
  }
},
{
  "model": "main.effect",
  "pk": 105,
  "fields": {
    "Effectname": "Circadian rhythm synchronization via melatonin receptor agonism"
  }
},
{
  "model": "main.effect",
  "pk": 106,
  "fields": {
    "Effectname": "Circadian modulation via Bmal1 activation (U2OS cells)"
  }
},
{
  "model": "main.effect",
  "pk": 107,
  "fields": {
    "Effectname": "Circadian phase modulation via MT1/MT2 agonism"
  }
},
{
  "model": "main.effect",
  "pk": 108,
  "fields": {
    "Effectname": "Circadian modulation detected in Bmal1-reporter assay"
  }
},
{
  "model": "main.effect",
  "pk": 109,
  "fields": {
    "Effectname": "Circadian modulator activity"
  }
},
{
  "model": "main.effect",
  "pk": 110,
  "fields": {
    "Effectname": "Period lengthening"
  }
},
{
  "model": "main.effect",
  "pk": 111,
  "fields": {
    "Effectname": "Circadian rhythm induction"
  }
},
{
  "model": "main.effect",
  "pk": 112,
  "fields": {
    "Effectname": "Circadian gene modulation"
  }
},
{
  "model": "main.effect",
  "pk": 113,
  "fields": {
    "Effectname": "Sleep improvement; potential indirect circadian stabilization via CB1 activation"
  }
},
{
  "model": "main.effect",
  "pk": 114,
  "fields": {
    "Effectname": "potential period alteration via EGFR/JAK2 inhibition"
  }
},
{
  "model": "main.effect",
  "pk": 115,
  "fields": {
    "Effectname": "Circadian rhythm disruption"
  }
},
{
  "model": "main.effect",
  "pk": 116,
  "fields": {
    "Effectname": "Circadian entrainment of activity episodes"
  }
},
{
  "model": "main.effect",
  "pk": 117,
  "fields": {
    "Effectname": "Period lengthening in human cells"
  }
},
{
  "model": "main.effect",
  "pk": 118,
  "fields": {
    "Effectname": "Phase advance"
  }
},
{
  "model": "main.effect",
  "pk": 119,
  "fields": {
    "Effectname": "Circadian gene modulation in human U2OS cells"
  }
},
{
  "model": "main.effect",
  "pk": 120,
  "fields": {
    "Effectname": "Modulation of circadian gene expression and CLOCK:BMAL1 transcriptional activity in neuronal cells and rats"
  }
},
{
  "model": "main.effect",
  "pk": 121,
  "fields": {
    "Effectname": "Modulation of circadian gene expression in human U2OS cells"
  }
},
{
  "model": "main.effect",
  "pk": 122,
  "fields": {
    "Effectname": "REM sleep suppression in humans"
  }
},
{
  "model": "main.effect",
  "pk": 123,
  "fields": {
    "Effectname": "NREM sleep promotion in humans"
  }
},
{
  "model": "main.effect",
  "pk": 124,
  "fields": {
    "Effectname": "Period shortening in mammalian cells"
  }
},
{
  "model": "main.effect",
  "pk": 125,
  "fields": {
    "Effectname": "Sleep induction and jet lag symptom relief in humans"
  }
},
{
  "model": "main.effect",
  "pk": 126,
  "fields": {
    "Effectname": "Phase shift via Dec1 induction in mammalian cells"
  }
},
{
  "model": "main.effect",
  "pk": 127,
  "fields": {
    "Effectname": "Circadian disruption in skeletal muscle and pineal gland (in animals)"
  }
},
{
  "model": "main.effect",
  "pk": 128,
  "fields": {
    "Effectname": "Period shortening in mammalian cells"
  }
},
{
  "model": "main.effect",
  "pk": 129,
  "fields": {
    "Effectname": "sleep modulation in humans"
  }
},
{
  "model": "main.effect",
  "pk": 130,
  "fields": {
    "Effectname": "potential circadian entrainment via TRPV4 in eye (mammals)"
  }
},
{
  "model": "main.effect",
  "pk": 131,
  "fields": {
    "Effectname": "Indirect circadian disruption via altered sleep–wake timing (in humans)"
  }
},
{
  "model": "main.effect",
  "pk": 132,
  "fields": {
    "Effectname": "Circadian modulation via RORγ activation in human immune cells"
  }
},
{
  "model": "main.effect",
  "pk": 133,
  "fields": {
    "Effectname": "Phase shift modulation and period regulation via adenosine receptor signaling (in mice and mammals)"
  }
},
{
  "model": "main.effect",
  "pk": 134,
  "fields": {
    "Effectname": "Modulation of clock gene expression and metabolic rhythm regulation in liver (in mammals)"
  }
},
{
  "model": "main.effect",
  "pk": 135,
  "fields": {
    "Effectname": "Circadian phase shift and dysrhythmia in eclosion rhythm in Drosophila melanogaster"
  }
},
{
  "model": "main.effect",
  "pk": 136,
  "fields": {
    "Effectname": "Phase shift via Y1 receptor antagonism in rodents"
  }
},
{
  "model": "main.effect",
  "pk": 137,
  "fields": {
    "Effectname": "Altered expression of clock genes in mice"
  }
},
{
  "model": "main.effect",
  "pk": 138,
  "fields": {
    "Effectname": "Phase stabilization and circadian gene modulation in mice"
  }
},
{
  "model": "main.effect",
  "pk": 139,
  "fields": {
    "Effectname": "Phase advance and reduced amplitude in mice and hamsters"
  }
},
{
  "model": "main.effect",
  "pk": 140,
  "fields": {
    "Effectname": "Circadian rhythm disruption in mammals"
  }
},
{
  "model": "main.effect",
  "pk": 141,
  "fields": {
    "Effectname": "Phase shift in fungi (Neurospora)"
  }
},
{
  "model": "main.effect",
  "pk": 142,
  "fields": {
    "Effectname": "Amplitude enhancement and phase shift in human cells"
  }
},
{
  "model": "main.effect",
  "pk": 143,
  "fields": {
    "Effectname": "Circadian rhythm disruption in mammals"
  }
},
{
  "model": "main.effect",
  "pk": 144,
  "fields": {
    "Effectname": "Circadian rhythm disruption in humans"
  }
},
{
  "model": "main.effect",
  "pk": 145,
  "fields": {
    "Effectname": "Period lengthening in human cells (U2OS)"
  }
},
{
  "model": "main.effect",
  "pk": 146,
  "fields": {
    "Effectname": "Circadian disruption via core clock interference (in mammals)"
  }
},
{
  "model": "main.effect",
  "pk": 147,
  "fields": {
    "Effectname": "Phase-dependent modulation of activity amplitude and onset (in rodents)"
  }
},
{
  "model": "main.effect",
  "pk": 148,
  "fields": {
    "Effectname": "Period lengthening and phase delay in rodents and SCN slices"
  }
},
{
  "model": "main.effect",
  "pk": 149,
  "fields": {
    "Effectname": "Circadian disruption via core clock targeting in mammals"
  }
},
{
  "model": "main.effect",
  "pk": 150,
  "fields": {
    "Effectname": "Clock gene normalization and potential phase shift in rats"
  }
},
{
  "model": "main.effect",
  "pk": 151,
  "fields": {
    "Effectname": "Modulation of circadian gene expression via RORγt inhibition in mice/human immune cells"
  }
},
{
  "model": "main.effect",
  "pk": 152,
  "fields": {
    "Effectname": "Circadian disruption via core clock gene targeting in animals (PAH exposure model)"
  }
},
{
  "model": "main.effect",
  "pk": 153,
  "fields": {
    "Effectname": "Circadian disruption in humans (rest-activity rhythm disturbance with flupentixol)"
  }
},
{
  "model": "main.effect",
  "pk": 155,
  "fields": {
    "Effectname": "Circadian modulation potential via CB2 in mammals (indirect, immune-related pathways)"
  }
},
{
  "model": "main.effect",
  "pk": 156,
  "fields": {
    "Effectname": "Period lengthening in human cells (U2OS)"
  }
},
{
  "model": "main.effect",
  "pk": 157,
  "fields": {
    "Effectname": "Phase shifting in humans (via MT1/MT2 receptor activation)"
  }
},
{
  "model": "main.effect",
  "pk": 158,
  "fields": {
    "Effectname": "Transcriptional inhibition of BMAL1–CLOCK complex in human cells"
  }
},
{
  "model": "main.effect",
  "pk": 159,
  "fields": {
    "Effectname": "CRY1/2 inhibition"
  }
},
{
  "model": "main.effect",
  "pk": 160,
  "fields": {
    "Effectname": "inhibition of photic phase shifts in mice (SCN-dependent)"
  }
},
{
  "model": "main.effect",
  "pk": 161,
  "fields": {
    "Effectname": "Circadian modulation in human U2OS cells"
  }
},
{
  "model": "main.effect",
  "pk": 162,
  "fields": {
    "Effectname": "Circadian modulation in human U2OS cells"
  }
},
{
  "model": "main.effect",
  "pk": 163,
  "fields": {
    "Effectname": "Circadian modulation via nuclear receptor pathways (LXRα/β) in mammalian cells"
  }
},
{
  "model": "main.effect",
  "pk": 164,
  "fields": {
    "Effectname": "Circadian gene expression modulation in human cells (U2OS)"
  }
},
{
  "model": "main.effect",
  "pk": 165,
  "fields": {
    "Effectname": "Phase shift disruption in animals"
  }
},
{
  "model": "main.effect",
  "pk": 166,
  "fields": {
    "Effectname": "Circadian modulation in human cells"
  }
},
{
  "model": "main.effect",
  "pk": 167,
  "fields": {
    "Effectname": "Phase shifting in mammals"
  }
},
{
  "model": "main.effect",
  "pk": 168,
  "fields": {
    "Effectname": "Phase advance in humans"
  }
},
{
  "model": "main.effect",
  "pk": 169,
  "fields": {
    "Effectname": "Circadian disruption via melatonin receptor antagonism"
  }
},
{
  "model": "main.effect",
  "pk": 170,
  "fields": {
    "Effectname": "Phase shift in humans via MT1/MT2 receptor agonism"
  }
},
{
  "model": "main.effect",
  "pk": 171,
  "fields": {
    "Effectname": "Phase shift disruption in mammals"
  }
},
{
  "model": "main.effect",
  "pk": 172,
  "fields": {
    "Effectname": "Phase shift disruption in mammals via MT1/MT2 receptor antagonism"
  }
},
{
  "model": "main.effect",
  "pk": 173,
  "fields": {
    "Effectname": "Phase shift induction in mammals via MT1/MT2 receptor agonism"
  }
},
{
  "model": "main.effect",
  "pk": 174,
  "fields": {
    "Effectname": "Phase shift induction in mammals via MT1/MT2 receptor agonism"
  }
},
{
  "model": "main.effect",
  "pk": 175,
  "fields": {
    "Effectname": "Phase shift modulation in mammals via selective MT2 receptor agonism"
  }
},
{
  "model": "main.effect",
  "pk": 176,
  "fields": {
    "Effectname": "Circadian rhythm entrainment in diet-induced obese rats via MT1/MT2 agonism"
  }
},
{
  "model": "main.effect",
  "pk": 177,
  "fields": {
    "Effectname": "MT1/MT2 receptor agonist; potential circadian phase modulation in mammals"
  }
},
{
  "model": "main.effect",
  "pk": 178,
  "fields": {
    "Effectname": "Partial MT2 receptor agonist; modulates circadian signaling in retina (mammals)"
  }
},
{
  "model": "main.effect",
  "pk": 179,
  "fields": {
    "Effectname": "improves sleep (cats)"
  }
},
{
  "model": "main.effect",
  "pk": 180,
  "fields": {
    "Effectname": "Weak MT1/MT2 agonist"
  }
},
{
  "model": "main.effect",
  "pk": 181,
  "fields": {
    "Effectname": "derivative of chronobiotic agomelatine (MT1/MT2)"
  }
},
{
  "model": "main.effect",
  "pk": 182,
  "fields": {
    "Effectname": "MT1/MT2 receptor agonist"
  }
},
{
  "model": "main.effect",
  "pk": 183,
  "fields": {
    "Effectname": "MT1/MT2 receptor agonist"
  }
},
{
  "model": "main.effect",
  "pk": 184,
  "fields": {
    "Effectname": "MT1/MT2 partial agonist"
  }
},
{
  "model": "main.effect",
  "pk": 185,
  "fields": {
    "Effectname": "MT2 antagonist; disrupts melatonin signaling (in human receptor models)"
  }
},
{
  "model": "main.effect",
  "pk": 186,
  "fields": {
    "Effectname": "Sleep-promoting and circadian phase-altering effects in mice"
  }
},
{
  "model": "main.effect",
  "pk": 187,
  "fields": {
    "Effectname": "Phase-shift"
  }
},
{
  "model": "main.effect",
  "pk": 188,
  "fields": {
    "Effectname": "Ultradian oscillations induction in Per1/2/3knockout mice"
  }
},
{
  "model": "main.effect",
  "pk": 189,
  "fields": {
    "Effectname": "exposure induces atime-varying circadian rhythm"
  }
},
{
  "model": "main.effect",
  "pk": 190,
  "fields": {
    "Effectname": "induced a  very long free-running period (~27 h) in heterozygous Gsk3β mutant mice in DD"
  }
},
{
  "model": "main.effect",
  "pk": 191,
  "fields": {
    "Effectname": "5-h phase advance in the sleep-wake cycle"
  }
},
{
  "model": "main.effect",
  "pk": 192,
  "fields": {
    "Effectname": "Agomelatine has been shown to induce robust circadian phase shifts"
  }
},
{
  "model": "main.effect",
  "pk": 193,
  "fields": {
    "Effectname": "can improve sleep continuity and quality, shorten sleep latency (time it takes to fall asleep"
  }
},
{
  "model": "main.effect",
  "pk": 194,
  "fields": {
    "Effectname": "advance the timing of sleep onset and other circadian rhythms like core body temperature and heart rate."
  }
},
{
  "model": "main.effect",
  "pk": 195,
  "fields": {
    "Effectname": "Lengthen perion of circadian rhythm"
  }
},
{
  "model": "main.effect",
  "pk": 196,
  "fields": {
    "Effectname": "Period shortening of the circadian rhythm in the uterus"
  }
},
{
  "model": "main.effect",
  "pk": 197,
  "fields": {
    "Effectname": "Shortening of circadian period"
  }
},
{
  "model": "main.effect",
  "pk": 198,
  "fields": {
    "Effectname": "sleep architecture modulation"
  }
},
{
  "model": "main.effect",
  "pk": 199,
  "fields": {
    "Effectname": "Increases expression of circadian rhythm genes (Bmal1, Per1, Per2) in a brain-region-specific"
  }
},
{
  "model": "main.effect",
  "pk": 200,
  "fields": {
    "Effectname": "Progesterone regulates the expression of clock genes like PER1, which is crucial for circadian timing."
  }
},
{
  "model": "main.effect",
  "pk": 201,
  "fields": {
    "Effectname": "delaying melatonin secretion, particularly when consumed in the evening, and potentially disrupting sleep patterns. It can shift the CCGs rhtyhms"
  }
},
{
  "model": "main.effect",
  "pk": 202,
  "fields": {
    "Effectname": "Nefazodone decreased both sleep latency and stage 1 sleep and increased sleep efficiency."
  }
},
{
  "model": "main.effect",
  "pk": 203,
  "fields": {
    "Effectname": "efficacy in readjusting phase shifts in all physiological systems. Reduces sleep latancy."
  }
},
{
  "model": "main.effect",
  "pk": 204,
  "fields": {
    "Effectname": "AA41612 alters the body's response to light, potentially influencing the timing and duration of circadian rhythms, such as sleep-wake cycles,"
  }
},
{
  "model": "main.effect",
  "pk": 205,
  "fields": {
    "Effectname": "effects on the circadian rhythm, also known as the body's natural sleep-wake cycle, are primarily related to its drowsiness and sedation properties"
  }
},
{
  "model": "main.effect",
  "pk": 206,
  "fields": {
    "Effectname": "Discrupts temporal organization in Candida albicans"
  }
},
{
  "model": "main.effect",
  "pk": 207,
  "fields": {
    "Effectname": "decreased the amplitude of circadian rhythm significantly while having no effect on the period"
  }
},
{
  "model": "main.effect",
  "pk": 208,
  "fields": {
    "Effectname": "Resynchronization of the circadian clock, potentially improving sleep quality and alleviating symptoms associated with sleep disturbances."
  }
},
{
  "model": "main.effect",
  "pk": 209,
  "fields": {
    "Effectname": "UNKNOWN"
  }
},
{
  "model": "main.effect",
  "pk": 210,
  "fields": {
    "Effectname": "possesses very different efficacies at the two melatonin receptors, beha full melatonin receptor agonist mt1, as an antagonist MT2 effect not studied"
  }
},
{
  "model": "main.effect",
  "pk": 211,
  "fields": {
    "Effectname": "suggests it could potentially interact with the circadian system, which involves processes like sleep-wake cycles and hormone production"
  }
},
{
  "model": "main.effect",
  "pk": 212,
  "fields": {
    "Effectname": "MT1 agonist with poorly described"
  }
},
{
  "model": "main.effect",
  "pk": 213,
  "fields": {
    "Effectname": "Partial agonist MT2 and associated effects"
  }
},
{
  "model": "main.effect",
  "pk": 214,
  "fields": {
    "Effectname": "Full mt2 rexeptor agonist"
  }
},
{
  "model": "main.effect",
  "pk": 215,
  "fields": {
    "Effectname": "influencing the expression and stability of key circadian clock genes"
  }
},
{
  "model": "main.effect",
  "pk": 216,
  "fields": {
    "Effectname": "increases the amplitude of circadian rhythm activity in mice with corticosterone-induced depression/anxiety"
  }
},
{
  "model": "main.effect",
  "pk": 217,
  "fields": {
    "Effectname": "sleep-promoting action in freely moving cats"
  }
},
{
  "model": "main.effect",
  "pk": 218,
  "fields": {
    "Effectname": "neutrophil activation"
  }
},
{
  "model": "main.effect",
  "pk": 219,
  "fields": {
    "Effectname": "chemotaxis stimulation"
  }
},
{
  "model": "main.effect",
  "pk": 220,
  "fields": {
    "Effectname": "activates G protein-coupled receptors, specifically FPR1"
  }
},
{
  "model": "main.effect",
  "pk": 221,
  "fields": {
    "Effectname": "actin polymerization"
  }
},
{
  "model": "main.effect",
  "pk": 222,
  "fields": {
    "Effectname": "oxidative burst"
  }
},
{
  "model": "main.effect",
  "pk": 223,
  "fields": {
    "Effectname": "Affects circadia nchemotaxis and phagocytosis"
  }
},
{
  "model": "main.effect",
  "pk": 224,
  "fields": {
    "Effectname": "fMLP-mediated activation of human eosinophils is influenced by the circadian clock"
  }
},
{
  "model": "main.effect",
  "pk": 225,
  "fields": {
    "Effectname": "Normalization of circadian rhythms in elderly, blind and people with social jet lag."
  }
},
{
  "model": "main.effect",
  "pk": 226,
  "fields": {
    "Effectname": "Circadian rhythm modulation"
  }
},
{
  "model": "main.effect",
  "pk": 227,
  "fields": {
    "Effectname": "Circadian rhythm modulation"
  }
},
{
  "model": "main.effect",
  "pk": 228,
  "fields": {
    "Effectname": "alters the response of the circadian clock to a photic and non-photic stimulus"
  }
},
{
  "model": "main.effect",
  "pk": 229,
  "fields": {
    "Effectname": "Disrupts circadian rhtyhms, depressant"
  }
},
{
  "model": "main.effect",
  "pk": 230,
  "fields": {
    "Effectname": "restored the circadian oscillations of differentiation-related genes and core clock genes that were reduced by D-galactose"
  }
},
{
  "model": "main.effect",
  "pk": 231,
  "fields": {
    "Effectname": "reduced reactive oxygen species (ROS) levels and upregulated antioxidant enzymes"
  }
},
{
  "model": "main.effect",
  "pk": 232,
  "fields": {
    "Effectname": "promoted skin barrier integrity by increasing structural protein and ceramide-related gene expression"
  }
},
{
  "model": "main.effect",
  "pk": 233,
  "fields": {
    "Effectname": "enhanced cellular longevity markers, such as cyclin-dependent kinase inhibitor 1B (CDKN1B) and telomerase reverse transcriptase (TERT)"
  }
},
{
  "model": "main.effect",
  "pk": 234,
  "fields": {
    "Effectname": "causes instability in the pulse period and a slight reduction of amplitude in cyclic PER2::LUC expression"
  }
},
{
  "model": "main.effect",
  "pk": 235,
  "fields": {
    "Effectname": "Blockade of gap junctions uncouples PER2::LUC-expressing cells, in terms of phase transition, which weakens synchrony among individual cellular rhythm"
  }
},
{
  "model": "main.effect",
  "pk": 236,
  "fields": {
    "Effectname": "lengthens the period of the U2-OS circadian rhythm"
  }
},
{
  "model": "main.effect",
  "pk": 237,
  "fields": {
    "Effectname": "decreases the transcription of clock-controlled genes in a concentration-dependent manner"
  }
},
{
  "model": "main.mechanism",
  "pk": 3,
  "fields": {
    "mechanismname": "protect"
  }
},
{
  "model": "main.mechanism",
  "pk": 4,
  "fields": {
    "mechanismname": "SIRT1"
  }
},
{
  "model": "main.mechanism",
  "pk": 5,
  "fields": {
    "mechanismname": "Melatonin receptor binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 6,
  "fields": {
    "mechanismname": "antagonist of melatonin receptors"
  }
},
{
  "model": "main.mechanism",
  "pk": 7,
  "fields": {
    "mechanismname": "MT2 receptor antagonist"
  }
},
{
  "model": "main.mechanism",
  "pk": 8,
  "fields": {
    "mechanismname": "MT3 receptor ligand"
  }
},
{
  "model": "main.mechanism",
  "pk": 9,
  "fields": {
    "mechanismname": "MT1 receptor binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 10,
  "fields": {
    "mechanismname": "MT2 receptor ligand"
  }
},
{
  "model": "main.mechanism",
  "pk": 11,
  "fields": {
    "mechanismname": "Melatonin agonist"
  }
},
{
  "model": "main.mechanism",
  "pk": 12,
  "fields": {
    "mechanismname": "Melatonin receptor antagonist"
  }
},
{
  "model": "main.mechanism",
  "pk": 13,
  "fields": {
    "mechanismname": "JNK kinase mediated circadian rhythm modulation"
  }
},
{
  "model": "main.mechanism",
  "pk": 14,
  "fields": {
    "mechanismname": "Disruption of circadian clock"
  }
},
{
  "model": "main.mechanism",
  "pk": 15,
  "fields": {
    "mechanismname": "Core clock modulation"
  }
},
{
  "model": "main.mechanism",
  "pk": 16,
  "fields": {
    "mechanismname": "Unknown"
  }
},
{
  "model": "main.mechanism",
  "pk": 17,
  "fields": {
    "mechanismname": "Cannabinoid receptor stimulation"
  }
},
{
  "model": "main.mechanism",
  "pk": 18,
  "fields": {
    "mechanismname": "Mu opioid receptor binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 19,
  "fields": {
    "mechanismname": "Kappa opioid receptor binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 20,
  "fields": {
    "mechanismname": "delta opioid receptor binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 21,
  "fields": {
    "mechanismname": "opioid receptors binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 22,
  "fields": {
    "mechanismname": "Dopamine receptor binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 23,
  "fields": {
    "mechanismname": "GABA A receptor binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 24,
  "fields": {
    "mechanismname": "NMDA receptor antagonist"
  }
},
{
  "model": "main.mechanism",
  "pk": 25,
  "fields": {
    "mechanismname": "Affects melatonin synthesis"
  }
},
{
  "model": "main.mechanism",
  "pk": 26,
  "fields": {
    "mechanismname": "Core clock suppression"
  }
},
{
  "model": "main.mechanism",
  "pk": 27,
  "fields": {
    "mechanismname": "Adenylate cyclase binding activity affects circadian clock"
  }
},
{
  "model": "main.mechanism",
  "pk": 28,
  "fields": {
    "mechanismname": "Bmal1"
  }
},
{
  "model": "main.mechanism",
  "pk": 29,
  "fields": {
    "mechanismname": "modulation of nuclear receptor signaling pathways"
  }
},
{
  "model": "main.mechanism",
  "pk": 30,
  "fields": {
    "mechanismname": "LXRα"
  }
},
{
  "model": "main.mechanism",
  "pk": 31,
  "fields": {
    "mechanismname": "LXRβ"
  }
},
{
  "model": "main.mechanism",
  "pk": 32,
  "fields": {
    "mechanismname": "ROR"
  }
},
{
  "model": "main.mechanism",
  "pk": 33,
  "fields": {
    "mechanismname": "Selective stabilizer of CRY1"
  }
},
{
  "model": "main.mechanism",
  "pk": 34,
  "fields": {
    "mechanismname": "Selectively stabilizes CRY2"
  }
},
{
  "model": "main.mechanism",
  "pk": 35,
  "fields": {
    "mechanismname": "Inhibits CK1δ"
  }
},
{
  "model": "main.mechanism",
  "pk": 36,
  "fields": {
    "mechanismname": "Binds CRY1 FAD-binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 37,
  "fields": {
    "mechanismname": "Antagonist of Rev-Erb nuclear receptors"
  }
},
{
  "model": "main.mechanism",
  "pk": 38,
  "fields": {
    "mechanismname": "de-repressing BMAL1"
  }
},
{
  "model": "main.mechanism",
  "pk": 39,
  "fields": {
    "mechanismname": "Muscarinic receptor binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 40,
  "fields": {
    "mechanismname": "HSP90 binding (in Arabidopsis)"
  }
},
{
  "model": "main.mechanism",
  "pk": 41,
  "fields": {
    "mechanismname": "Unknown"
  }
},
{
  "model": "main.mechanism",
  "pk": 42,
  "fields": {
    "mechanismname": "Affects flowering rhythms (LUX)"
  }
},
{
  "model": "main.mechanism",
  "pk": 43,
  "fields": {
    "mechanismname": "Lenghthen the circadian period"
  }
},
{
  "model": "main.mechanism",
  "pk": 44,
  "fields": {
    "mechanismname": "Chloramphenicol can inhibit both bacterial and mitochondrial protein synthesis"
  }
},
{
  "model": "main.mechanism",
  "pk": 45,
  "fields": {
    "mechanismname": "Melatonin synthesis alteration"
  }
},
{
  "model": "main.mechanism",
  "pk": 46,
  "fields": {
    "mechanismname": "Dopamine receptor binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 47,
  "fields": {
    "mechanismname": "PER gene exspression modulation"
  }
},
{
  "model": "main.mechanism",
  "pk": 48,
  "fields": {
    "mechanismname": "CRY gene expression modulation"
  }
},
{
  "model": "main.mechanism",
  "pk": 49,
  "fields": {
    "mechanismname": "5-HT7 binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 50,
  "fields": {
    "mechanismname": "Dopamine receptor agonist"
  }
},
{
  "model": "main.mechanism",
  "pk": 51,
  "fields": {
    "mechanismname": "BMAL1 expression modulation"
  }
},
{
  "model": "main.mechanism",
  "pk": 52,
  "fields": {
    "mechanismname": "Binding to rat brainα- andβ-adrenergic, muscarinic cholinergic, dopamine and opiate receptors"
  }
},
{
  "model": "main.mechanism",
  "pk": 53,
  "fields": {
    "mechanismname": "Hypnotic effect"
  }
},
{
  "model": "main.mechanism",
  "pk": 54,
  "fields": {
    "mechanismname": "Sleep promotion"
  }
},
{
  "model": "main.mechanism",
  "pk": 55,
  "fields": {
    "mechanismname": "Calmodulin inhibition"
  }
},
{
  "model": "main.mechanism",
  "pk": 56,
  "fields": {
    "mechanismname": "Calmodulin binding (Neurospora)"
  }
},
{
  "model": "main.mechanism",
  "pk": 57,
  "fields": {
    "mechanismname": "GABAergic system influence"
  }
},
{
  "model": "main.mechanism",
  "pk": 58,
  "fields": {
    "mechanismname": "Dopamine receptor antagonist"
  }
},
{
  "model": "main.mechanism",
  "pk": 59,
  "fields": {
    "mechanismname": "Serotoninergic signaling"
  }
},
{
  "model": "main.mechanism",
  "pk": 60,
  "fields": {
    "mechanismname": "Histamine 1 blocker"
  }
},
{
  "model": "main.mechanism",
  "pk": 61,
  "fields": {
    "mechanismname": "Orexin Receptor Antagonism"
  }
},
{
  "model": "main.mechanism",
  "pk": 62,
  "fields": {
    "mechanismname": "Activation of Adenosine Receptors"
  }
},
{
  "model": "main.mechanism",
  "pk": 63,
  "fields": {
    "mechanismname": "A2B receptor agonist."
  }
},
{
  "model": "main.mechanism",
  "pk": 64,
  "fields": {
    "mechanismname": "Inhibits the fungal enzyme lanosterol 14-α-demethylase (CYP51)"
  }
},
{
  "model": "main.mechanism",
  "pk": 65,
  "fields": {
    "mechanismname": "E3 ubiquitin-protein ligase XIAP"
  }
},
{
  "model": "main.mechanism",
  "pk": 66,
  "fields": {
    "mechanismname": "cGMP-gated cation channel alpha-1 binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 67,
  "fields": {
    "mechanismname": "Calcium-activated potassium channel subunit alpha-1\""
  }
},
{
  "model": "main.mechanism",
  "pk": 68,
  "fields": {
    "mechanismname": "BMAL1 expression modulation"
  }
},
{
  "model": "main.mechanism",
  "pk": 69,
  "fields": {
    "mechanismname": "Monoamine oxidase A binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 70,
  "fields": {
    "mechanismname": "\"Peptidyl-prolyl cis-trans isomerase A  Peroxiredoxin-1  60S ribosomal protein L10, L14, L18, L23a, L35, L4  40S ribosomal prote"
  }
},
{
  "model": "main.mechanism",
  "pk": 71,
  "fields": {
    "mechanismname": "Glyceraldehyde-3-phosphate dehydrogenase"
  }
},
{
  "model": "main.mechanism",
  "pk": 72,
  "fields": {
    "mechanismname": "mTOR signaling inhibition"
  }
},
{
  "model": "main.mechanism",
  "pk": 73,
  "fields": {
    "mechanismname": "Myosin-9 binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 74,
  "fields": {
    "mechanismname": "inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase"
  }
},
{
  "model": "main.mechanism",
  "pk": 75,
  "fields": {
    "mechanismname": "1,4-dihydropyridine calcium channel blocker"
  }
},
{
  "model": "main.mechanism",
  "pk": 76,
  "fields": {
    "mechanismname": "Vitamin D3 receptor,  Homeobox protein Hox-A10,  Vitamin D-binding protein"
  }
},
{
  "model": "main.mechanism",
  "pk": 77,
  "fields": {
    "mechanismname": "Binding Androgen receptor,  17-hydroxylase,  Steroid 21-hydroxylase,  11-hydroxylase,  Cytochrome P450 19A1,  Potassium voltage-"
  }
},
{
  "model": "main.mechanism",
  "pk": 78,
  "fields": {
    "mechanismname": "DNA  DNA topoisomerase 2-alpha, beta binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 79,
  "fields": {
    "mechanismname": "Retinoic acid receptor RXR-alpha, beta, gamma binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 80,
  "fields": {
    "mechanismname": "Tubulin alpha-1A, beta, delta, gamma-1, epsilon chain  Transcription factor AP-1 binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 81,
  "fields": {
    "mechanismname": "DNA alkylation"
  }
},
{
  "model": "main.mechanism",
  "pk": 82,
  "fields": {
    "mechanismname": "targeting DNA and DNA topoisomerase 2-alpha."
  }
},
{
  "model": "main.mechanism",
  "pk": 83,
  "fields": {
    "mechanismname": "Apoptosis regulator Bcl-2,  Tubulin beta-1 chain, Nuclear receptor subfamily 1 group I member 2  Microtubule-associated protein"
  }
},
{
  "model": "main.mechanism",
  "pk": 84,
  "fields": {
    "mechanismname": "Nuclear receptor subfamily 1 group I member 2 binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 85,
  "fields": {
    "mechanismname": "Progesterone receptor,  Estrogen receptor alpha, Mineralocorticoid receptor, Steroid 17-alpha-hydroxylase/17,20 lyase  Kappa-typ"
  }
},
{
  "model": "main.mechanism",
  "pk": 86,
  "fields": {
    "mechanismname": "HIV-1 protease binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 87,
  "fields": {
    "mechanismname": "DNA polymerase/reverse transcriptase (HBV-D) binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 88,
  "fields": {
    "mechanismname": "\"Inhibitor of nuclear factor kappa-B kinase subunit beta  Thioredoxin reductase 1, cytoplasmic  Transcription factor AP-1  G1/S-"
  }
},
{
  "model": "main.mechanism",
  "pk": 89,
  "fields": {
    "mechanismname": "calcimimetic and a P450 inhibitor"
  }
},
{
  "model": "main.mechanism",
  "pk": 90,
  "fields": {
    "mechanismname": "Intermediate conductance calcium-activated potassium channel, protein 4  Nuclear receptor subfamily 1 group I member 2, 3"
  }
},
{
  "model": "main.mechanism",
  "pk": 91,
  "fields": {
    "mechanismname": "\"Tyrosine-protein kinase ABL1, Lck, Yes, Fyn, BTK, CSK, Fgr, FRK, Lyn  Proto-oncogene tyrosine-protein kinase Src  Ephrin type-A"
  }
},
{
  "model": "main.mechanism",
  "pk": 92,
  "fields": {
    "mechanismname": "Competitive blockade of melanopsin’s retinal-binding site"
  }
},
{
  "model": "main.mechanism",
  "pk": 93,
  "fields": {
    "mechanismname": "Competitive binding at melanopsin’s retinal-binding site"
  }
},
{
  "model": "main.mechanism",
  "pk": 94,
  "fields": {
    "mechanismname": "Inhibits p38 MAPK α/β isoforms"
  }
},
{
  "model": "main.mechanism",
  "pk": 95,
  "fields": {
    "mechanismname": "Primarily a potent inhibitor of c-Jun N-terminal kinase (JNK)"
  }
},
{
  "model": "main.mechanism",
  "pk": 96,
  "fields": {
    "mechanismname": "Highly selective, ATP-competitive inhibition of GSK-3 (both α and β isoforms)"
  }
},
{
  "model": "main.mechanism",
  "pk": 97,
  "fields": {
    "mechanismname": "progesteron receptor binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 98,
  "fields": {
    "mechanismname": "Mineral corticoid receptor binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 99,
  "fields": {
    "mechanismname": "Serine/threonine-protein kinase mTOR"
  }
},
{
  "model": "main.mechanism",
  "pk": 100,
  "fields": {
    "mechanismname": "inhibits topoisomerase I"
  }
},
{
  "model": "main.mechanism",
  "pk": 101,
  "fields": {
    "mechanismname": "Binding retinoic acid receptor alpha"
  }
},
{
  "model": "main.mechanism",
  "pk": 102,
  "fields": {
    "mechanismname": "Histamine H1 receptor,  Nuclear receptor subfamily 1 group I member 3"
  }
},
{
  "model": "main.mechanism",
  "pk": 103,
  "fields": {
    "mechanismname": "Beta-1, 2 adrenergic receptor binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 104,
  "fields": {
    "mechanismname": "\"Tyrosine-protein kinase ABL1  Mast/stem cell growth factor receptor binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 105,
  "fields": {
    "mechanismname": "Vascular endothelial growth factor receptor 1, 2, 3"
  }
},
{
  "model": "main.mechanism",
  "pk": 106,
  "fields": {
    "mechanismname": "Platelet-derived growth factor receptor alpha, beta"
  }
},
{
  "model": "main.mechanism",
  "pk": 107,
  "fields": {
    "mechanismname": "Mast/stem cell growth factor receptor Kit"
  }
},
{
  "model": "main.mechanism",
  "pk": 108,
  "fields": {
    "mechanismname": "Fibroblast growth factor receptor 3"
  }
},
{
  "model": "main.mechanism",
  "pk": 109,
  "fields": {
    "mechanismname": "Tyrosine-protein kinase ITK/TSK"
  }
},
{
  "model": "main.mechanism",
  "pk": 110,
  "fields": {
    "mechanismname": "Fibroblast growth factor 1"
  }
},
{
  "model": "main.mechanism",
  "pk": 111,
  "fields": {
    "mechanismname": "SH2B adapter protein 3"
  }
},
{
  "model": "main.mechanism",
  "pk": 112,
  "fields": {
    "mechanismname": "Calcineurin Inhibitor Immunosuppressant"
  }
},
{
  "model": "main.mechanism",
  "pk": 113,
  "fields": {
    "mechanismname": "Tubulin alpha-4A, beta chain binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 114,
  "fields": {
    "mechanismname": "Potassium-transporting ATPase alpha chain 1 binding activity"
  }
},
{
  "model": "main.mechanism",
  "pk": 115,
  "fields": {
    "mechanismname": "Angiotensin receptor binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 116,
  "fields": {
    "mechanismname": "PER3"
  }
},
{
  "model": "main.mechanism",
  "pk": 117,
  "fields": {
    "mechanismname": "CRY1/2 inhibitor"
  }
},
{
  "model": "main.mechanism",
  "pk": 118,
  "fields": {
    "mechanismname": "Activation of CLOCK/Bmal1 mediated transcription"
  }
},
{
  "model": "main.mechanism",
  "pk": 119,
  "fields": {
    "mechanismname": "CRY 2 Stabilizer"
  }
},
{
  "model": "main.mechanism",
  "pk": 120,
  "fields": {
    "mechanismname": "Dual inhibitor of Cyclin-dependent kinases (CDK) and Glycogen Synthase Kinase-3 (GSK-3)"
  }
},
{
  "model": "main.mechanism",
  "pk": 121,
  "fields": {
    "mechanismname": "GSK‑3 Inhibition"
  }
},
{
  "model": "main.mechanism",
  "pk": 122,
  "fields": {
    "mechanismname": "Interferes with CLOCK–BMAL1"
  }
},
{
  "model": "main.mechanism",
  "pk": 123,
  "fields": {
    "mechanismname": "Targets BMAL1–CLOCK DNA-binding activity"
  }
},
{
  "model": "main.mechanism",
  "pk": 124,
  "fields": {
    "mechanismname": "Serves as a cofactor in various hemoproteins (e.g., hemoglobin, cytochromes) and can modulate transcription factors (e.g., REV-E"
  }
},
{
  "model": "main.mechanism",
  "pk": 125,
  "fields": {
    "mechanismname": "Inhibits casein kinase 1 delta (CKIδ) activity"
  }
},
{
  "model": "main.mechanism",
  "pk": 126,
  "fields": {
    "mechanismname": "aryl hydrocarbon receptor (AhR) binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 127,
  "fields": {
    "mechanismname": "Agonist REV-ERB alpha"
  }
},
{
  "model": "main.mechanism",
  "pk": 128,
  "fields": {
    "mechanismname": "SIRT1-mediated peroxisome proliferator-activated receptor coactivator 1α (PGC-1α) deacetylation in sleep-restricted mice"
  }
},
{
  "model": "main.mechanism",
  "pk": 129,
  "fields": {
    "mechanismname": "Neuropeptide Y1 receptor binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 130,
  "fields": {
    "mechanismname": "RORγ binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 131,
  "fields": {
    "mechanismname": "PTEN"
  }
},
{
  "model": "main.mechanism",
  "pk": 132,
  "fields": {
    "mechanismname": "ROCK"
  }
},
{
  "model": "main.mechanism",
  "pk": 133,
  "fields": {
    "mechanismname": "p53"
  }
},
{
  "model": "main.mechanism",
  "pk": 134,
  "fields": {
    "mechanismname": "RORyt/RORc inhibitor"
  }
},
{
  "model": "main.mechanism",
  "pk": 135,
  "fields": {
    "mechanismname": "This inhibition of TRPV4-mediated signaling can affect downstream pathways involved in the regulation of the circadian clock."
  }
},
{
  "model": "main.mechanism",
  "pk": 136,
  "fields": {
    "mechanismname": "Inhibits CKIδ"
  }
},
{
  "model": "main.mechanism",
  "pk": 137,
  "fields": {
    "mechanismname": "Stabilizes PER Proteins"
  }
},
{
  "model": "main.mechanism",
  "pk": 138,
  "fields": {
    "mechanismname": "Selective GSK-3β Inhibition:"
  }
},
{
  "model": "main.mechanism",
  "pk": 139,
  "fields": {
    "mechanismname": "Circadian Clock Impact"
  }
},
{
  "model": "main.mechanism",
  "pk": 140,
  "fields": {
    "mechanismname": "CK1 Inhibition"
  }
},
{
  "model": "main.mechanism",
  "pk": 141,
  "fields": {
    "mechanismname": "Binds to the ATP‑binding site of CK2"
  }
},
{
  "model": "main.mechanism",
  "pk": 142,
  "fields": {
    "mechanismname": "Activation of activin receptor-like kinase (ALK)"
  }
},
{
  "model": "main.mechanism",
  "pk": 143,
  "fields": {
    "mechanismname": "by an immediate-early induction of Dec1"
  }
},
{
  "model": "main.mechanism",
  "pk": 144,
  "fields": {
    "mechanismname": "inhibits glycogen synthase kinase-3β (GSK-3β)"
  }
},
{
  "model": "main.mechanism",
  "pk": 145,
  "fields": {
    "mechanismname": "Non-specific kinase inhibitor"
  }
},
{
  "model": "main.mechanism",
  "pk": 146,
  "fields": {
    "mechanismname": "Unknown metabolites"
  }
},
{
  "model": "main.mechanism",
  "pk": 147,
  "fields": {
    "mechanismname": "TIMELESS"
  }
},
{
  "model": "main.mechanism",
  "pk": 148,
  "fields": {
    "mechanismname": "Affects heme"
  }
},
{
  "model": "main.mechanism",
  "pk": 149,
  "fields": {
    "mechanismname": "Affects heme biosynthesis"
  }
},
{
  "model": "main.mechanism",
  "pk": 150,
  "fields": {
    "mechanismname": "Orexin Receptor Antagonism"
  }
},
{
  "model": "main.mechanism",
  "pk": 151,
  "fields": {
    "mechanismname": "PRR"
  }
},
{
  "model": "main.mechanism",
  "pk": 152,
  "fields": {
    "mechanismname": "p38 signaling"
  }
},
{
  "model": "main.mechanism",
  "pk": 153,
  "fields": {
    "mechanismname": "Orexin Receptor Blockade"
  }
},
{
  "model": "main.mechanism",
  "pk": 154,
  "fields": {
    "mechanismname": "OX₁ Receptor Blockade"
  }
},
{
  "model": "main.mechanism",
  "pk": 155,
  "fields": {
    "mechanismname": "OX₁R Antagonism"
  }
},
{
  "model": "main.mechanism",
  "pk": 156,
  "fields": {
    "mechanismname": "OX₂R Activation"
  }
},
{
  "model": "main.mechanism",
  "pk": 157,
  "fields": {
    "mechanismname": "Affects \"Circadian rhtyhm signaling\""
  }
},
{
  "model": "main.mechanism",
  "pk": 158,
  "fields": {
    "mechanismname": "Calcium signaling"
  }
},
{
  "model": "main.mechanism",
  "pk": 159,
  "fields": {
    "mechanismname": "Glutamat receptor signaling"
  }
},
{
  "model": "main.mechanism",
  "pk": 160,
  "fields": {
    "mechanismname": "Corticosteroid Hormone Receptor Agonist"
  }
},
{
  "model": "main.mechanism",
  "pk": 161,
  "fields": {
    "mechanismname": "Glucocorticoid Signaling"
  }
},
{
  "model": "main.mechanism",
  "pk": 162,
  "fields": {
    "mechanismname": "influences HPA axis"
  }
},
{
  "model": "main.mechanism",
  "pk": 163,
  "fields": {
    "mechanismname": "Glucocorticoid receptors"
  }
},
{
  "model": "main.mechanism",
  "pk": 164,
  "fields": {
    "mechanismname": "Binding with factors affine to Period2 gene promoter"
  }
},
{
  "model": "main.mechanism",
  "pk": 165,
  "fields": {
    "mechanismname": "Rev-erb expression modulation"
  }
},
{
  "model": "main.mechanism",
  "pk": 166,
  "fields": {
    "mechanismname": "NLRP3 inflammasome binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 167,
  "fields": {
    "mechanismname": "Altering Circadian Metabolism via the SIRT1-AMPK-PP2A Axis"
  }
},
{
  "model": "main.mechanism",
  "pk": 168,
  "fields": {
    "mechanismname": "Repression of PER/CRY feedback loops via deacetylation."
  }
},
{
  "model": "main.mechanism",
  "pk": 169,
  "fields": {
    "mechanismname": "AMPK-PP2A axis suppresses mTOR, advancing circadian phase in muscle."
  }
},
{
  "model": "main.mechanism",
  "pk": 170,
  "fields": {
    "mechanismname": "Dopamine receptor binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 171,
  "fields": {
    "mechanismname": "Targets CK1 epsilon"
  }
},
{
  "model": "main.mechanism",
  "pk": 172,
  "fields": {
    "mechanismname": "DAT interaction (human dopamine transporter)"
  }
},
{
  "model": "main.mechanism",
  "pk": 173,
  "fields": {
    "mechanismname": "Chk1/2 inhibition"
  }
},
{
  "model": "main.mechanism",
  "pk": 174,
  "fields": {
    "mechanismname": "PER2 phosphorylation"
  }
},
{
  "model": "main.mechanism",
  "pk": 175,
  "fields": {
    "mechanismname": "HSP90 Binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 176,
  "fields": {
    "mechanismname": "HSP90-mediated  BMAL1 modulation"
  }
},
{
  "model": "main.mechanism",
  "pk": 177,
  "fields": {
    "mechanismname": "CK2 inhibition"
  }
},
{
  "model": "main.mechanism",
  "pk": 178,
  "fields": {
    "mechanismname": "p53 stabilization and apoptosis induction"
  }
},
{
  "model": "main.mechanism",
  "pk": 179,
  "fields": {
    "mechanismname": "Adenosine Monophosphate-Activated Protein Kinase (AMPK)"
  }
},
{
  "model": "main.mechanism",
  "pk": 180,
  "fields": {
    "mechanismname": "Nuclear Factor Kappa B (NF- κB)"
  }
},
{
  "model": "main.mechanism",
  "pk": 181,
  "fields": {
    "mechanismname": "Janus kinase (JAK)/signal transducer and activator of transcription (STAT)"
  }
},
{
  "model": "main.mechanism",
  "pk": 182,
  "fields": {
    "mechanismname": "Nod-like receptor family protein (NLRP)"
  }
},
{
  "model": "main.mechanism",
  "pk": 183,
  "fields": {
    "mechanismname": "Toll-like receptors (TLRs)"
  }
},
{
  "model": "main.mechanism",
  "pk": 184,
  "fields": {
    "mechanismname": "Mitogen-Activated Signaling Proteins (MAPK)"
  }
},
{
  "model": "main.mechanism",
  "pk": 185,
  "fields": {
    "mechanismname": "Mammalian Target of Rapamycin (mTOR) signaling pathway"
  }
},
{
  "model": "main.mechanism",
  "pk": 186,
  "fields": {
    "mechanismname": "TRPV1 capsaicin site binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 187,
  "fields": {
    "mechanismname": "adenosine receptor binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 188,
  "fields": {
    "mechanismname": "inhibition of serotonin N-acetyltransferase"
  }
},
{
  "model": "main.mechanism",
  "pk": 189,
  "fields": {
    "mechanismname": "caspase, Bax, TNF-α, and NF-MB"
  }
},
{
  "model": "main.mechanism",
  "pk": 190,
  "fields": {
    "mechanismname": "Antioxidant"
  }
},
{
  "model": "main.mechanism",
  "pk": 191,
  "fields": {
    "mechanismname": "cAMP signaling cascade"
  }
},
{
  "model": "main.mechanism",
  "pk": 192,
  "fields": {
    "mechanismname": "Modulation of PI3K/Akt"
  }
},
{
  "model": "main.mechanism",
  "pk": 193,
  "fields": {
    "mechanismname": "Per2 expression induction"
  }
},
{
  "model": "main.mechanism",
  "pk": 194,
  "fields": {
    "mechanismname": "Melatonin receptor agonist"
  }
},
{
  "model": "main.mechanism",
  "pk": 195,
  "fields": {
    "mechanismname": "Antioxidant"
  }
},
{
  "model": "main.mechanism",
  "pk": 196,
  "fields": {
    "mechanismname": "PGC-1α interaction"
  }
},
{
  "model": "main.mechanism",
  "pk": 197,
  "fields": {
    "mechanismname": "canonical PDE-cAMP-PKA signaling axis"
  }
},
{
  "model": "main.mechanism",
  "pk": 198,
  "fields": {
    "mechanismname": "cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A"
  }
},
{
  "model": "main.mechanism",
  "pk": 199,
  "fields": {
    "mechanismname": "cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Inhibitor"
  }
},
{
  "model": "main.mechanism",
  "pk": 200,
  "fields": {
    "mechanismname": "Adenosine receptor A1Antagonist"
  }
},
{
  "model": "main.mechanism",
  "pk": 201,
  "fields": {
    "mechanismname": "Adenosine receptor A3Antagonist"
  }
},
{
  "model": "main.mechanism",
  "pk": 202,
  "fields": {
    "mechanismname": "CHK1 inhibitor crosstalk with caseine kinase 1"
  }
},
{
  "model": "main.mechanism",
  "pk": 203,
  "fields": {
    "mechanismname": "Photoreception inhibition"
  }
},
{
  "model": "main.mechanism",
  "pk": 204,
  "fields": {
    "mechanismname": "Plastoquinone interaction"
  }
},
{
  "model": "main.mechanism",
  "pk": 205,
  "fields": {
    "mechanismname": "Central clock rescue via microbial community alteration"
  }
},
{
  "model": "main.mechanism",
  "pk": 206,
  "fields": {
    "mechanismname": "Monoamine transporter inhibitor"
  }
},
{
  "model": "main.mechanism",
  "pk": 207,
  "fields": {
    "mechanismname": "Non-canonical circadian genes"
  }
},
{
  "model": "main.mechanism",
  "pk": 208,
  "fields": {
    "mechanismname": "methamphetamine-sensitive circadian oscillator (MASCO)"
  }
},
{
  "model": "main.mechanism",
  "pk": 209,
  "fields": {
    "mechanismname": "increase dopamine signalling"
  }
},
{
  "model": "main.mechanism",
  "pk": 210,
  "fields": {
    "mechanismname": "CRY1 stabilizer"
  }
},
{
  "model": "main.mechanism",
  "pk": 211,
  "fields": {
    "mechanismname": "BMAL1 expression modulation"
  }
},
{
  "model": "main.mechanism",
  "pk": 212,
  "fields": {
    "mechanismname": "Modulates sleep architecture via H1-histamine receptor antagonism"
  }
},
{
  "model": "main.mechanism",
  "pk": 213,
  "fields": {
    "mechanismname": "MT2 receptor agonist"
  }
},
{
  "model": "main.mechanism",
  "pk": 214,
  "fields": {
    "mechanismname": "HCN1 activator"
  }
},
{
  "model": "main.mechanism",
  "pk": 215,
  "fields": {
    "mechanismname": "CNGA3 activation"
  }
},
{
  "model": "main.mechanism",
  "pk": 216,
  "fields": {
    "mechanismname": "HCN2 activation"
  }
},
{
  "model": "main.mechanism",
  "pk": 217,
  "fields": {
    "mechanismname": "CNGA2 activation"
  }
},
{
  "model": "main.mechanism",
  "pk": 218,
  "fields": {
    "mechanismname": "OATP4C1 transportation"
  }
},
{
  "model": "main.mechanism",
  "pk": 219,
  "fields": {
    "mechanismname": "selective MT1A receptor agonist"
  }
},
{
  "model": "main.mechanism",
  "pk": 220,
  "fields": {
    "mechanismname": "FPR2 full agonist"
  }
},
{
  "model": "main.mechanism",
  "pk": 221,
  "fields": {
    "mechanismname": "FPR1 full agonist"
  }
},
{
  "model": "main.mechanism",
  "pk": 222,
  "fields": {
    "mechanismname": "MT1 antagonist"
  }
},
{
  "model": "main.mechanism",
  "pk": 223,
  "fields": {
    "mechanismname": "Melatonin receptor binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 224,
  "fields": {
    "mechanismname": "Synaptic vesicular amine transporter interaction"
  }
},
{
  "model": "main.mechanism",
  "pk": 225,
  "fields": {
    "mechanismname": "Sodium-dependent noradrenaline transporter"
  }
},
{
  "model": "main.mechanism",
  "pk": 226,
  "fields": {
    "mechanismname": "Sodium-dependent serotonin transporter"
  }
},
{
  "model": "main.mechanism",
  "pk": 227,
  "fields": {
    "mechanismname": "5-hydroxytryptamine receptor 2C binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 228,
  "fields": {
    "mechanismname": "5-hydroxytryptamine receptor 2A binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 229,
  "fields": {
    "mechanismname": "5-hydroxytryptamine receptor 2B binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 230,
  "fields": {
    "mechanismname": "Sodium-dependent dopamine transporter binding"
  }
},
{
  "model": "main.mechanism",
  "pk": 231,
  "fields": {
    "mechanismname": "Glutamate receptor ionotropic, NMDA 3A antagonist"
  }
},
{
  "model": "main.mechanism",
  "pk": 232,
  "fields": {
    "mechanismname": "Glutamate receptor ionotropic, NMDA 2A"
  }
},
{
  "model": "main.mechanism",
  "pk": 233,
  "fields": {
    "mechanismname": "Glutamate receptor ionotropic, NMDA 2B"
  }
},
{
  "model": "main.mechanism",
  "pk": 234,
  "fields": {
    "mechanismname": "Glutamate receptor ionotropic, NMDA 1"
  }
},
{
  "model": "main.mechanism",
  "pk": 235,
  "fields": {
    "mechanismname": "USigma non-opioid intracellular receptor 1"
  }
},
{
  "model": "main.mechanism",
  "pk": 236,
  "fields": {
    "mechanismname": "Restores oscillations of circadian genes"
  }
},
{
  "model": "main.mechanism",
  "pk": 237,
  "fields": {
    "mechanismname": "Per2 expression alteration"
  }
},
{
  "model": "main.mechanism",
  "pk": 238,
  "fields": {
    "mechanismname": "binds CRY1 ubiquitination site"
  }
},
{
  "model": "main.bioclass",
  "pk": 3,
  "fields": {
    "nameclass": "radioprotector"
  }
},
{
  "model": "main.bioclass",
  "pk": 4,
  "fields": {
    "nameclass": "chronobiotic"
  }
},
{
  "model": "main.bioclass",
  "pk": 5,
  "fields": {
    "nameclass": "circadian rhythm modulator"
  }
},
{
  "model": "main.bioclass",
  "pk": 6,
  "fields": {
    "nameclass": "Chronodisruptor"
  }
},
{
  "model": "main.bioclass",
  "pk": 7,
  "fields": {
    "nameclass": "Potential chronodisruptor"
  }
},
{
  "model": "main.bioclass",
  "pk": 8,
  "fields": {
    "nameclass": "Chronomodulator"
  }
},
{
  "model": "main.bioclass",
  "pk": 9,
  "fields": {
    "nameclass": "Potential modulator of circdain rhtyhms"
  }
},
{
  "model": "main.bioclass",
  "pk": 10,
  "fields": {
    "nameclass": "hypnotic"
  }
},
{
  "model": "main.bioclass",
  "pk": 11,
  "fields": {
    "nameclass": "Probiotic"
  }
},
{
  "model": "main.bioclass",
  "pk": 12,
  "fields": {
    "nameclass": "prebiotic"
  }
},
{
  "model": "main.bioclass",
  "pk": 13,
  "fields": {
    "nameclass": "Dopamine receptor binding"
  }
},
{
  "model": "main.bioclass",
  "pk": 14,
  "fields": {
    "nameclass": "Sedative drug"
  }
},
{
  "model": "main.chronobiotic",
  "pk": 6,
  "fields": {
    "gname": "Resveratrol",
    "smiles": "C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O",
    "linkname": "resveratrol",
    "molecula": "C14H12O3",
    "iupacname": "5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol",
    "updphoto": "media/Resveratrol.png",
    "description": "Resveratrol, a naturally occurring polyphenol predominantly found in grapes, red wine, and certain berries, has been extensively studied for its antioxidant, anti-inflammatory, and cardioprotective properties. Recent investigations have expanded its potential therapeutic applications to include its role as a chronobiotic agent—a compound capable of modulating circadian rhythms. Circadian rhythms, governed by the suprachiasmatic nucleus (SCN) and peripheral clocks, regulate critical physiological processes, including sleep-wake cycles, metabolism, and cellular homeostasis. Dysregulation of these rhythms is associated with various pathologies, including metabolic syndrome, neurodegenerative disorders, and age-related decline. Resveratrol has been shown to influence circadian clock mechanisms through its interaction with sirtuin 1 (SIRT1), a NAD+-dependent deacetylase that plays a pivotal role in circadian gene expression and metabolic regulation.\r\n\r\nKey Mechanisms:\r\n\r\nSIRT1 activation alters CLOCK/BMAL1 transcriptional activity.\r\n\r\nAMPK-PP2A axis suppresses mTOR, advancing circadian phase in muscle.\r\n\r\nRestoration of metabolic rhythms in high-fat diet models.\r\n\r\nRepression of PER/CRY feedback loops via deacetylation.\r\n\r\nAvital-Cohen, N., Chapnik, N. and Froy, O., 2024. Resveratrol Induces Myotube Development by Altering Circadian Metabolism via the SIRT1-AMPK-PP2A Axis. Cells, 13(12), p.1069.\r\n\r\nSun, L., Wang, Y., Song, Y., Cheng, X.R., Xia, S., Rahman, M.R.T., Shi, Y. and Le, G., 2015. Resveratrol restores the circadian rhythmic disorder of lipid metabolism induced by high-fat diet in mice. Biochemical and Biophysical Research Communications, 458(1), pp.86-91.\r\nSpaleniak, W. and Cuendet, M., 2023. Resveratrol as a circadian clock modulator: mechanisms of action and therapeutic applications. Molecular Biology Reports, 50(7), pp.6159-6170.",
    "fdastatus": "Approved",
    "linkslists": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10289927/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/Resveratrol",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.392875.html",
    "drugbank": "https://www.drugbank.ca/drugs/DB02709",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:27881",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/C03582",
    "selleckchem": "https://www.selleckchem.com/datasheet/Resveratrol-S139609-DataSheet.html",
    "articles": [
      176,
      177,
      178
    ],
    "classf": [
      3,
      4
    ],
    "mechanisms": [
      4,
      99,
      167,
      72,
      169,
      168
    ],
    "target": [
      7,
      105,
      106
    ],
    "effect": [
      73
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 7,
  "fields": {
    "gname": "Rosiglitazone",
    "smiles": "CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3",
    "linkname": "rosiglitazone",
    "molecula": "C18H19N3O3S",
    "iupacname": "5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione",
    "updphoto": "media/Rosiglitazone_1.png",
    "description": "Rosiglitazone, a PPARγ agonist, has been shown to affect circadian rhythms, particularly in the context of vascular diseases and metabolic regulation. Regulation of Clock Genes: Rosiglitazone administration can alter the expression of core clock genes such as BMAL1 and CLOCK. In a study, rosiglitazone treatment at different Zeitgeber times (ZT) shifted the phases of these genes, indicating its role in modulating circadian gene rhythms.\r\nInfluence on Lipid Metabolism: The drug promotes triglyceride (TG) accumulation in macrophages, which in turn affects the expression of clock genes like BMAL1 and CLOCK. This suggests that rosiglitazone's impact on lipid metabolism is linked to its effects on circadian rhythms.\r\nCircadian Rhythm Synchronization: The synchronization of circadian rhythms in cells is crucial for studying the effects of rosiglitazone. This synchronization is achieved through serum shock, which induces stable circadian oscillations in cells.\r\n\r\nTian, Y., Luan, X. and Yang, K., 2024. Chronotherapy involving rosiglitazone regulates the phenotypic switch of vascular smooth muscle cells by shifting the phase of TNF-α rhythm through triglyceride accumulation in macrophages. Heliyon, 10(10).",
    "fdastatus": "Approved",
    "linkslists": "https://pubmed.ncbi.nlm.nih.gov/39884973/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/Rosiglitazone",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.70383.html",
    "drugbank": "https://www.drugbank.ca/drugs/DB00412",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50122",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D08491",
    "selleckchem": "https://www.selleckchem.com/products/Rosiglitazone-Avandia.html",
    "articles": [
      179,
      180
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      3
    ],
    "target": [
      8,
      93,
      63
    ],
    "effect": [
      5,
      74
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 8,
  "fields": {
    "gname": "Melatonin",
    "smiles": "CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC",
    "linkname": "melatonin",
    "molecula": "C13H16N2O2",
    "iupacname": "N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide",
    "updphoto": "media/imgsrv.png",
    "description": "Melatonin is a naturally occurring hormone primarily produced by the pineal gland, playing a crucial role in regulating circadian rhythms and sleep-wake cycles. As a chronobiotic, it helps synchronize the body's internal clock with external environmental cues, such as light and darkness. Melatonin supplementation has gained popularity for its ability to alleviate sleep disorders, particularly in cases of jet lag, shift work, or delayed sleep phase syndrome. Its chronobiotic properties make it effective in resetting disrupted circadian rhythms, promoting faster adaptation to new time zones or schedules. Research suggests melatonin is most beneficial when taken at specific times, as it can phase-shift the circadian clock forward or backward depending on the timing of administration. It is generally well-tolerated, with minimal side effects, making it a safe option for short-term use. However, its efficacy varies among individuals, and long-term effects require further study.\r\n\r\nMelatonin primarily acts through two high-affinity G protein-coupled receptors: MT1 and MT2, which are densely expressed in the SCN but also found throughout the brain and peripheral tissues 26. These receptors have different functions:\r\nMT1 receptors are associated with sleep onset and acute suppression of neuronal activity in the SCN.\r\nMT2 receptors mediate phase-shifting effects on circadian rhythms.\r\nActivation of these receptors in the SCN attenuates the wake-promoting signal of the circadian clock, thereby facilitating sleep in diurnal species like humans.\r\n\r\n2. Direct Antioxidant Effects\r\nBeyond receptor-mediated actions, melatonin is a potent free radical scavenger and antioxidant that can directly neutralize reactive oxygen and nitrogen species 6. This property may contribute to its neuroprotective effects and role in healthy aging .\r\n\r\n3. Regulation of Clock Genes\r\nMelatonin influences the expression of core clock genes (CLOCK, BMAL1, PER, CRY) that generate circadian rhythms at the molecular level 68. By synchronizing peripheral oscillators with the central clock in the SCN, melatonin helps maintain temporal organization across tissues and systems. Effects. \r\nPhase-Shifting Capacity.\r\nOne of melatonin's most significant roles is its ability to phase-shift circadian rhythms—advancing or delaying the timing of the internal clock depending on when it is administered:\r\nEvening administration (typically 2-4 hours before habitual bedtime) produces phase advances\r\nMorning administration (around wake time) causes phase delays. \r\nThis phase-response curve (PRC) to melatonin is approximately opposite to that of light, making it particularly valuable for treating circadian rhythm disorders . However, some studies suggest melatonin's primary effect may be sleep promotion rather than clock resetting.\r\nMelatonin facilitates sleep initiation and maintenance through multiple pathways:\r\nReduces wake-promoting signals from the SCN.\r\nAttenuates activation in the default mode network (DMN), particularly the precuneus, promoting fatigue and sleep-like brain states .\r\nMore than 15 targets, including receptors (MT1, MT2, Mel1c, CAND2, ROR, VDR), enzymes (QR2, MMP-9, pepsin, PP2A, PR-10 proteins), pores (mtPTP), transporters (PEPT1/2, Glut1), and other proteins (HBS, CaM, tubulin, calreticuline), have been suggested to interact with melatonin at sub-nanomolar to millimolar conc\r\nNotably, melatonin does not appear to increase slow-wave sleep (SWS) or alter sleep architecture significantly, suggesting its effects are primarily circadian rather than homeostatic .\r\n\r\nIn totally blind individuals with non-24-hour sleep-wake disorder (N24HSWD), melatonin administration at a consistent time each day can entrain free-running circadian rhythms to the 24-hour day. This is particularly important as light, the primary zeitgeber (time cue), cannot synchronize their clocks.\r\n\r\nRowe, S.A. and Kennaway, D.J., 2002. Melatonin in rat milk and the likelihood of its role in postnatal maternal entrainment of rhythms. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 282(3), pp.R797-R804.\r\nCardinali, D.P., 2024. Melatonin as a chronobiotic/cytoprotective agent in bone. Doses involved. Journal of Pineal Research, 76(1), p.e12931.\r\nMinich, D.M., Henning, M., Darley, C., Fahoum, M., Schuler, C.B. and Frame, J., 2022. Is melatonin the “next vitamin D”?: a review of emerging science, clinical uses, safety, and dietary supplements. Nutrients, 14(19), p.3934.\r\nPevet, P., Bothorel, B., Slotten, H. and Saboureau, M., 2002. The chronobiotic properties of melatonin. Cell and tissue research, 309, pp.183-191.\r\nArendt, J. and Skene, D.J., 2005. Melatonin as a chronobiotic. Sleep medicine reviews, 9(1), pp.25-39.\r\nLiu, L., Labani, N., Cecon, E. and Jockers, R., 2019. Melatonin target proteins: too many or not enough?. Frontiers in endocrinology, 10, p.791.",
    "fdastatus": "Approved",
    "linkslists": "https://onlinelibrary.wiley.com/doi/full/10.1111/jpi.12931",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/Melatonin",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.872.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01065",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:16796",
    "uniprot": "https://www.uniprot.org/uniprotkb/P48039/entry",
    "kegg": "https://www.kegg.jp/entry/D08170",
    "selleckchem": "https://www.selleckchem.com/products/Melatonin.html",
    "articles": [
      181,
      182,
      183
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      4,
      32,
      194,
      130,
      195,
      5,
      134
    ],
    "target": [
      8,
      9,
      128,
      129,
      130,
      131,
      132,
      133,
      10,
      11,
      12,
      40,
      119,
      120,
      121,
      122,
      123,
      124,
      125,
      126,
      127
    ],
    "effect": [
      5
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 9,
  "fields": {
    "gname": "Indole",
    "smiles": "C1=CC=C2C(=C1)C=CN2",
    "linkname": "indole",
    "molecula": "C8H7N",
    "iupacname": "1H-indole",
    "updphoto": "media/1.png",
    "description": "Indole, a heterocyclic organic compound, has emerged as a potential chronobiotic agent due to its influence on circadian rhythms. Structurally related to melatonin, indole derivatives exhibit modulatory effects on the circadian clock by interacting with key regulatory proteins, such as CLOCK and BMAL1. Research indicates that indole compounds can phase-shift circadian oscillations in vitro and in vivo, suggesting their ability to resynchronize disrupted biological rhythms. These effects are mediated through interactions with nuclear receptors and epigenetic mechanisms, which alter the expression of clock-controlled genes. Indole’s chronobiotic properties are further supported by its role in gut microbiota-host interactions, where microbial indole metabolites influence systemic circadian regulation. While promising, further studies are needed to elucidate its precise mechanisms and therapeutic potential in circadian rhythm disorders.",
    "fdastatus": "not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/Indole#section=Information-Sources",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/798",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.776.html",
    "drugbank": "https://go.drugbank.com/drugs/DB04532",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      356
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      5
    ],
    "target": [
      9
    ],
    "effect": [
      187
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 10,
  "fields": {
    "gname": "Ramelteon",
    "smiles": "CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3",
    "linkname": "ramelteon",
    "molecula": "C16H21NO2",
    "iupacname": "N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]propanamide",
    "updphoto": "media/3.png",
    "description": "Ramelteon, a melatonin receptor agonist, demonstrates circadian phase-shifting effects, primarily by influencing the body's natural sleep-wake cycle. It can shift the phase of the circadian rhythm, effectively advancing it, especially when facing disturbances like eastward jet lag. This effect is thought to be achieved by modulating melatonin receptors in the suprachiasmatic nucleus, which regulates the circadian rhythm. \r\nElaboration:\r\nPhase Shifting:\r\nRamelteon can advance the circadian phase, meaning it can help shift the sleep-wake cycle forward, potentially useful in cases of delayed sleep phase disorder or jet lag. \r\nMechanism of Action:\r\nRamelteon works by selectively binding to melatonin receptors (MT1 and MT2) in the suprachiasmatic nucleus, a region of the brain that controls the body's internal clock.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/Ramelteon#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/Ramelteon",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.181000.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00980",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      184,
      185,
      186
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      5
    ],
    "target": [
      9
    ],
    "effect": [
      168,
      191
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 11,
  "fields": {
    "gname": "Luzindole",
    "smiles": "CC(=O)NCCC1=C(NC2=CC=CC=C21)CC3=CC=CC=C3",
    "linkname": "luzindole",
    "molecula": "C19H20N2O",
    "iupacname": "N-[2-(2-benzyl-1H-indol-3-yl)ethyl]acetamide",
    "updphoto": "media/4.png",
    "description": "Luzindole acts as a selective melatonin receptor antagonist, with approximately 11- to 25-fold greater affinity for the MT2 over the MT1 receptor. In animal studies, it has been observed to disrupt the circadian rhythm as well as produce antidepressant effects.",
    "fdastatus": "not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/122162#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/122162",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.108959.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      304,
      305
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      5,
      6
    ],
    "target": [
      9
    ],
    "effect": [
      165
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 12,
  "fields": {
    "gname": "4-P-PDOT (N-(4-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide)",
    "smiles": "CCC(=O)NC1CC(C2=CC=CC=C2C1)C3=CC=CC=C3",
    "linkname": "4-p-pdot-n-4-phenyl-1234-tetrahydronaphthalen-2-ylpropanamide",
    "molecula": "C19H21NO",
    "iupacname": "N-(4-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide",
    "updphoto": "media/i5.png",
    "description": "4-P-PDOT is primarily known as a melatonin receptor antagonist, with a high selectivity for the MT2 receptor subtype over the MT1 subtype7. While melatonin itself is a chronobiotic, meaning it influences biological rhythms and has sleep-promoting properties3, 4-P-PDOT's role as an antagonist suggests it may interfere with melatonin's chronobiotic effects rather than acting as a chronobiotic itself. In studies, 4-P-PDOT has been used to block the effects of melatonin in various contexts, such as in granulosa cells and in neurons.",
    "fdastatus": "not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/3976006#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/3976006",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      187
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      6
    ],
    "target": [
      9
    ],
    "effect": [
      100
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 13,
  "fields": {
    "gname": "Agomelatine",
    "smiles": "CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC",
    "linkname": "agomelatine",
    "molecula": "C15H17NO2",
    "iupacname": "N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide",
    "updphoto": "media/7.png",
    "description": "Agomelatine is recognized as a chronobiotic, it has the ability to influence and regulate the body's internal biological clock. This property is primarily attributed to its agonistic action on melatonin MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN), which is the part of the brain responsible for controlling circadian rhythms.\r\nKey Chronobiotic Features of Agomelatine:\r\nCircadian Rhythm Regulation: Agomelatine can reset and resynchronize disrupted circadian rhythms, which is beneficial in treating conditions like depression where circadian disturbances are common.\r\nMelatonin Receptor Interaction: It acts as a melatonergic agonist, binding to MT1 and MT2 receptors with high affinity, which helps in modulating the circadian system.",
    "fdastatus": "Aapproved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/82148#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/82148",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.74141.html",
    "drugbank": "https://go.drugbank.com/drugs/DB06594",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:134990",
    "uniprot": "https://www.uniprot.org/uniprotkb/P49286/entry",
    "kegg": "https://www.kegg.jp/entry/D02578",
    "selleckchem": "https://www.selleckchem.com/products/Agomelatine.html",
    "articles": [
      188,
      189,
      360
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      6
    ],
    "target": [
      9
    ],
    "effect": [
      170,
      192,
      193,
      194
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 14,
  "fields": {
    "gname": "N-[(6-Methoxy-9-tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaenyl)methyl]acetamide (UCM 549)",
    "smiles": "CC(=O)NCC1CC2=CC=CC=C2CC3=C1C=C(C=C3)OC",
    "linkname": "n-6-methoxy-9-tricyclo940038pentadeca-11538461113-hexaenylmethylacetamide-ucm-549",
    "molecula": "C19H21NO2",
    "iupacname": "N-[(6-Methoxy-9-tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaenyl)methyl]acetamide",
    "updphoto": "media/imgsrv_8.png",
    "description": "UCM549 is an antagonist of melatonin MT2 receptors",
    "fdastatus": "not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/11185529#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/11185529",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      190,
      191
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      6
    ],
    "target": [
      9
    ],
    "effect": [
      171
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 15,
  "fields": {
    "gname": "5-MCA-NAT",
    "smiles": "CC(=O)NCCC1=CNC2=C1C=C(C=C2)NC(=O)OC",
    "linkname": "5-mca-nat",
    "molecula": "C14H17N3O3",
    "iupacname": "methyl N-[3-(2-acetamidoethyl)-1H-indol-5-yl]carbamate",
    "updphoto": "media/imgsrv_9.png",
    "description": "5-MCA-NAT (5-methoxycarbonylamino-N-acetyltryptamine) is a melatonin analog with several pharmacological properties, but there is no direct evidence in the provided sources to classify it explicitly as a \"chronobiotic.\" A chronobiotic is a substance that can modify the timing of biological rhythms, such as the sleep-wake cycle.\r\nKey Properties of 5-MCA-NAT:\r\nMelatonin Receptor Activity:\r\n5-MCA-NAT acts as a ligand for melatonin receptors, particularly MT3, and exhibits partial agonist activity at MT1 and MT2 receptors in the sub-micromolar range.\r\nIt has been studied for its effects on intraocular pressure (IOP) reduction in animal models, suggesting potential therapeutic applications for glaucoma.\r\nEffects on Dopamine Levels:\r\nIt increases endogenous dopamine levels in the developing chick retina by binding to NRH:quinone reductase (QR2), which may influence retinal development and dopamine-related processes.\r\nHypotensive Effects:\r\n5-MCA-NAT reduces carbonic anhydrase expression.",
    "fdastatus": "not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/4284525#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/4284525",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.3491018.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      192,
      193
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      8
    ],
    "target": [
      10
    ],
    "effect": [
      102
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 16,
  "fields": {
    "gname": "S26131",
    "smiles": "CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OCCCOC3=CC4=C(C=CC=C4CCNC(=O)C)C=C3",
    "linkname": "s26131",
    "molecula": "C31H34N2O4",
    "iupacname": "N-[2-[7-[3-[8-(2-acetamidoethyl)naphthalen-2-yl]oxypropoxy]naphthalen-1-yl]ethyl]acetamide",
    "updphoto": "media/imgsrv_10.png",
    "description": "S26131 (two molecules of agomelatine) is a melatonin receptor ligand that acts as an antagonist on both MT1 and MT2 receptors. It is particularly noted for its selectivity towards the MT1 receptor, with a Ki value of 0.5 nM for MT1 and 112 nM for MT245. This makes it a useful tool in pharmacological studies involving melatonin receptors, which are crucial for regulating circadian rhythms and are targets for treating sleep disorders, mood disorders, and other conditions.\r\nKey Characteristics of S26131:\r\nReceptor Selectivity: S26131 is more selective for the MT1 receptor than the MT2 receptor.\r\nKi Values:\r\nMT1: 0.5 nM\r\nMT2: 112 nM\r\nFunction: Acts as an antagonist on both MT1 and MT2 receptors.",
    "fdastatus": "not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/9870523#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/9870523",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.8046214.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      194,
      195
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      9,
      5,
      7
    ],
    "target": [
      9,
      11,
      12
    ],
    "effect": [
      172
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 17,
  "fields": {
    "gname": "Melatonin-d4",
    "smiles": "CC(NC([2H])([2H])C([2H])([2H])C1=CNC2=C1C=C(OC)C=C2)=O",
    "linkname": "melatonin-d4",
    "molecula": "C13H12D4N2O2",
    "iupacname": "N-[1,1,2,2-tetradeuterio-2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide",
    "updphoto": "media/imgsrv_11.png",
    "description": "Melatonin-d4 is deuterium labeled Melatonin. Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Antioxidative and anti-inflammatory properties. Melatonin is a selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/Melatonin-d4#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/Melatonin-d4",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.23630278.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      196
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      5
    ],
    "target": [
      11,
      12
    ],
    "effect": [
      173
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 18,
  "fields": {
    "gname": "2-Iodomelatonin",
    "smiles": "CC(=O)NCCC1=C(NC2=C1C=C(C=C2)OC)I",
    "linkname": "2-iodomelatonin",
    "molecula": "C13H15IN2O2",
    "iupacname": "N-[2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl]acetamide",
    "updphoto": "media/imgsrv_12.png",
    "description": "2-Iodomelatonin is a melatonin analog used as a radiolabelled ligand for the melatonin receptors, MT1, MT2, and MT3. It acts as a full agonist at both MT1 and MT2 receptors.",
    "fdastatus": "not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/115348#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/115348",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.103191.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      197,
      198
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      9,
      4,
      5,
      7
    ],
    "target": [
      11,
      12
    ],
    "effect": [
      174
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 19,
  "fields": {
    "gname": "8-M-PDOT",
    "smiles": "CCC(=O)NC1CCC2=C(C1)C(=CC=C2)OC",
    "linkname": "8-m-pdot",
    "molecula": "C14H19NO2",
    "iupacname": "N-(8-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide",
    "updphoto": "media/imgsrv_13.png",
    "description": "8-M-PDOT (AH-002) is a selective melatonin MT2 receptor agonist. 8-M-PDOT is 5.2-fold selective for MT2 over MT1 receptors. 8-M-PDOT binds human recombinant MT2 and MT2 receptors with pKi values of 8.23 and 8.95 respectively. 8-M-PDOT has anxiolytic-like activity. Experimental drug.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/5170952#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5170952",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4343440.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      199,
      200
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      10
    ],
    "target": [
      12
    ],
    "effect": [
      175
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 20,
  "fields": {
    "gname": "Tasimelteon",
    "smiles": "CCC(=O)NCC1CC1C2=C3CCOC3=CC=C2",
    "linkname": "tasimelteon",
    "molecula": "C15H19NO2",
    "iupacname": "N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide",
    "updphoto": "media/imgsrv_14.png",
    "description": "Tasimelteon is considered a chronobiotic due to its ability to regulate circadian rhythms. It is a selective dual agonist of the melatonin receptors MT1 and MT2, which are key in controlling the body's internal clock. By activating these receptors in the suprachiasmatic nucleus of the brain, tasimelteon helps resynchronize disrupted circadian rhythms, especially in individuals with Non-24-Hour Sleep-Wake Disorder (N24HSWD) or Smith-Magenis Syndrome.\r\nIts mechanism mimics melatonin's natural role in regulating sleep-wake cycles, making it effective for conditions where the circadian rhythm is misaligned, such as in blind individuals without light perception.\r\n\r\nTorres, R., Kramer, W.G. and Baroldi, P., 2015. Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects with hepatic or renal impairment. The Journal of Clinical Pharmacology, 55(5), pp.525-533.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/10220503#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/10220503",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.8395995.html",
    "drugbank": "https://go.drugbank.com/drugs/DB09071",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:79042",
    "uniprot": "https://www.uniprot.org/uniprotkb/P49286/entry",
    "kegg": "https://www.kegg.jp/entry/D09388",
    "selleckchem": "https://www.selleckchem.com/products/tasimelteon.html",
    "articles": [
      201,
      202
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      9,
      10,
      5
    ],
    "target": [
      9,
      11,
      12
    ],
    "effect": [
      103
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 21,
  "fields": {
    "gname": "Agomelatine hydrochloride",
    "smiles": "CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC.Cl",
    "linkname": "agomelatine-hydrochloride",
    "molecula": "C15H18ClNO2",
    "iupacname": "N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide;hydrochloride",
    "updphoto": "media/imgsrv_15.png",
    "description": "Salt of agomelatine. Agomelatine hydrochloride, a novel antidepressant, has a significant impact on circadian rhythms. It works by acting on melatonin receptors, particularly MT1 and MT2, which play a crucial role in regulating the circadian cycle. This action leads to resynchronization of the circadian clock, potentially improving sleep quality and alleviating symptoms associated with sleep disturbances.",
    "fdastatus": "approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/66980040#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/66980040",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.35308334.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      203,
      204
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      5
    ],
    "target": [
      9
    ],
    "effect": [
      208,
      5
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 22,
  "fields": {
    "gname": "ACH-000143",
    "smiles": "CC(NCCN1C2=CC(OC)=C(Cl)C=C2N=C1OC)=O",
    "linkname": "ach-000143",
    "molecula": "C13H16ClN3O3",
    "iupacname": "N-[2-(5-chloro-2,6-dimethoxybenzimidazol-1-yl)ethyl]acetamide",
    "updphoto": "media/imgsrv_16.png",
    "description": "ACH-000143 is a potent and orally active melatonin receptor agonist, with EC50 values of 0.06 nM and 0.32 nM for MT1 and MT2, respectively. ACH-000143 reduces liver triglycerides and steatosis in diet-Induced obese rats.\r\nACH-000143 is devoid of hERG binding, genotoxicity, and behavioral alterations at doses up to 100 mg/kg p.o., supporting further investigation of this compound as a drug candidate.\r\nACH-000143 significantly reduces plasma glucose at 10 mg/kg (−16.4%, p < 0.05) and 30 mg/kg (−16.9%, p < 0.01)",
    "fdastatus": "not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/139451790#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/139451790",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.114641972.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      205
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      9,
      10
    ],
    "target": [
      9,
      11,
      12
    ],
    "effect": [
      176
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 23,
  "fields": {
    "gname": "Piromelatine",
    "smiles": "COC1=CC2=C(C=C1)NC=C2CCNC(=O)C3=CC(=O)C=CO3",
    "linkname": "piromelatine",
    "molecula": "C17H16N2O4",
    "iupacname": "N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-4-oxopyran-2-carboxamide",
    "updphoto": "media/imgsrv_17.png",
    "description": "Piromelatine is indeed considered a chronobiotic agent. Chronobiotics are substances that help regulate the body's internal clock and synchronize circadian rhythms. Piromelatine acts primarily as an agonist of melatonin receptors (MT1, MT2, and MT3), which are crucial for regulating the sleep-wake cycle and other circadian processes. By stimulating these receptors, piromelatine can promote sleep and improve the synchronization of daily rhythms, thus exerting a chronobiotic effect. In addition to its effects on sleep and circadian rhythms, piromelatine also interacts with serotonin receptors (5-HT1A and 5-HT1D), which can contribute to its anxiolytic and analgesic properties. Its potential benefits extend beyond sleep regulation, including metabolic improvements and cognitive effects, although these are still under investigation.\r\nTchekalarova, J., Kortenska, L., Marinov, P. and Ivanova, N., 2022. Sex-dependent effects of piromelatine treatment on sleep-wake cycle and sleep structure of prenatally stressed rats. International Journal of Molecular Sciences, 23(18), p.10349.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/24815904#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/24815904",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.32700981.html",
    "drugbank": "https://go.drugbank.com/drugs/DB12288",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      206,
      207
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      8,
      9,
      10
    ],
    "target": [
      9,
      10,
      11,
      12
    ],
    "effect": [
      105
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 24,
  "fields": {
    "gname": "UCM 608 (N-[2-(5-methoxy-2-phenyl-1H-indol-3-yl)ethyl]acetamide)",
    "smiles": "CC(=O)NCCC1=C(NC2=C1C=C(C=C2)OC)C3=CC=CC=C3",
    "linkname": "ucm-608-n-2-5-methoxy-2-phenyl-1h-indol-3-ylethylacetamide",
    "molecula": "C19H20N2O2",
    "iupacname": "N-[2-(5-methoxy-2-phenyl-1H-indol-3-yl)ethyl]acetamide",
    "updphoto": "media/imgsrv_19.png",
    "description": "UCM 608 is a high affinity melatonin (MT) membrane receptor agonist. The pKi values for MT1 and MT2 are 10.7 and 10.",
    "fdastatus": "not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/4018512#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/4018512",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.22547268.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      208,
      209
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      9,
      10,
      11
    ],
    "target": [
      9,
      11,
      12
    ],
    "effect": [
      177
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 25,
  "fields": {
    "gname": "Ramelteon metabolite M-II-d3",
    "smiles": "CC(C(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3)O",
    "linkname": "ramelteon-metabolite-m-ii-d3",
    "molecula": "C16H21NO3",
    "iupacname": "3,3,3-trideuterio-2-hydroxy-N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]propanamide",
    "updphoto": "media/imgsrv_20.png",
    "description": "The duration of action of melatonin may be important for improvements in sleep efficiency in insomniacs. Ramelteon, a selective melatonin agonist, is primarily metabolized to the active metabolite M-II, which has a longer half-life and greater systemic exposure than ramelteon. Hence, M-II may contribute significantly to the hypnotic benefits of ramelteon. We assessed the ramelteon-like activity of M-II in vitro and in vivo using cats. Binding and functional studies in Chinese hamster ovary cells expressing human melatonin receptors (MT1 or MT2) revealed that M-II binds melatonin receptors with lower affinity (Ki: 114 and 566 pmol/l for MT1 and MT2, respectively) and has lower potency (IC50: 208 and 1,470 pmol/l for MT1 and MT2, respectively) compared with ramelteon. However, higher M-II doses significantly improved sleep in cats. Thus, M-II may contribute to the clinical efficacy of ramelteon.",
    "fdastatus": "Not approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/71751961",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      210,
      211
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      9,
      10,
      5
    ],
    "target": [
      9,
      11,
      12
    ],
    "effect": [
      179
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 26,
  "fields": {
    "gname": "N-Acetyltryptamine",
    "smiles": "CC(=O)NCCC1=CNC2=CC=CC=C21",
    "linkname": "n-acetyltryptamine",
    "molecula": "C12H14N2O",
    "iupacname": "N-[2-(1H-indol-3-yl)ethyl]acetamide",
    "updphoto": "media/imgsrv_21.png",
    "description": "N-Acetyltryptamine is a partial agonist for melatonin receptors in the retina. N-Acetyltryptamine is also used for determination of serotonin N-acetyl transferase activity. Precursor of melatonin, N-acetyl-5-methoxytryptamine, is a hormone primarily synthesized by the pineal gland and plays a crucial role in regulating circadian rhythms and sleep-wake cycles. N-Acetyltryptamine is a partial agonist of melatonin receptors, particularly the MT2 receptor, with a binding affinity ( Ki​) of 41 nM. It can act as both an antagonist and a partial agonist depending on the biological context. It is also a reaction product in serotonin N-acetyltransferase assays, an enzyme involved in the biosynthesis of melatonin.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/70547#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/70547",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.63717.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      212,
      214
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      5,
      9
    ],
    "target": [
      9,
      11
    ],
    "effect": [
      178
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 27,
  "fields": {
    "gname": "Ramelteon metabolite M-II (DES(1-oxopropyl)-2-hydroxy-1-oxopropyl-ramelteon)",
    "smiles": "CC(C(=O)NCC[C@@H]1CCC2=C1C3=C(C=C2)OCC3)O",
    "linkname": "ramelteon-metabolite-m-ii-des1-oxopropyl-2-hydroxy-1-oxopropyl-ramelteon",
    "molecula": "C16H21NO 3",
    "iupacname": "2-hydroxy-N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]propanamide",
    "updphoto": "media/imgsrv_22.png",
    "description": "Ramelteon's major metabolite M-II contributes to its chronobiotic effects through its pharmacological profile and receptor interactions. While less potent than the parent compound, M-II's pharmacokinetic properties and receptor activity support its role in modulating circadian rhythms.\r\nKey Mechanisms\r\nReceptor Binding and Selectivity\r\nM-II binds to MT₁ and MT₂ melatonin receptors with lower affinity compared to ramelteon (Ki: ~114 pmol/L for MT₁ and ~566 pmol/L for MT₂). However, its 20–100-fold higher systemic exposure compensates for reduced potency, enabling sustained receptor activation14.\r\nChronobiotic Potential\r\nRamelteon itself has demonstrated phase-shifting effects in preclinical studies by acting on MT₂ receptors in the suprachiasmatic nucleus (SCN), the body’s circadian pacemaker68. While direct evidence for M-II’s chronobiotic activity is limited, its prolonged half-life (2–5 hours vs. ramelteon’s 1–2.6 hours) and receptor selectivity suggest it may contribute to c.rhythm",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/46783414#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/46783414",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      311
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      11
    ],
    "target": [
      9
    ],
    "effect": [
      184
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 28,
  "fields": {
    "gname": "Melatonin-d3",
    "smiles": "[2H]C([2H])([2H])C(=O)NCCC1=CNC2=C1C=C(C=C2)OC",
    "linkname": "melatonin-d3",
    "molecula": "C13H16N2O 2",
    "iupacname": "2,2,2-trideuterio-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide",
    "updphoto": "media/imgsrv_1.png",
    "description": "3 Deuterium radiopreparation of melatonin.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/91235750#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/91235750",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      216
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      5
    ],
    "target": [
      11
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 29,
  "fields": {
    "gname": "Agomelatine-d4",
    "smiles": "[2H]C([2H])(C1=CC=CC2=C1C=C(C=C2)OC)C([2H])([2H])NC(=O)C",
    "linkname": "agomelatine-d4",
    "molecula": "C15H17NO 2",
    "iupacname": "N-[1,1,2,2-tetradeuterio-2-(7-methoxynaphthalen-1-yl)ethyl]acetamide",
    "updphoto": "media/imgsrv_23.png",
    "description": "Agomelatine-d4 is a deuterated form of agomelatine, an atypical antidepressant primarily used to treat major depressive disorder and generalized anxiety disorder. Agomelatine itself acts as a melatonin receptor agonist and a serotonin receptor antagonist, which distinguishes it from other antidepressants.\r\nKey Points About Agomelatine-d4:\r\nChemical Properties: Agomelatine-d4 has a molecular formula of C15H13D4NO2 and a molecular weight of approximately 247.33 g/mol6.\r\nUse: Deuterated compounds like agomelatine-d4 are often used in research, particularly for pharmacokinetic studies, where the deuterium isotopes help track the compound's metabolism and distribution in the body.\r\nAvailability: Agomelatine-d4 is available from various suppliers as a reference material for research purposes.",
    "fdastatus": "Not approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/25174420",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.74141.html",
    "drugbank": "https://go.drugbank.com/drugs/DB06594",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      306
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      5
    ],
    "target": [
      9
    ],
    "effect": [
      181
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 30,
  "fields": {
    "gname": "Melatonin receptor agonist 1",
    "smiles": "CCCC(=O)NCCC1=C2C=C(C=CC2=CN=N1)OC",
    "linkname": "melatonin-receptor-agonist-1",
    "molecula": "C15H19N3O2",
    "iupacname": "N-[2-(7-methoxyphthalazin-1-yl)ethyl]butanamide",
    "updphoto": "media/imgsrv_24.png",
    "description": "Melatonin receptor agonist 1 (compound 20c) is a potent melatonin receptor (MT) agonist, with Ki values of 108 nM (MT2) and 1140 nM (MT1).",
    "fdastatus": "Not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/162661094#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/162661094",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      217
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      5
    ],
    "target": [
      11,
      12
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 31,
  "fields": {
    "gname": "Melatonin-d7",
    "smiles": "[2H]C([2H])([2H])C(NC([2H])([2H])C([2H])([2H])C(C1=C2)=CNC1=CC=C2OC)=O",
    "linkname": "melatonin-d7",
    "molecula": "C13H9D7N2O 2",
    "iupacname": "2,2,2-trideuterio-N-[1,1,2,2-tetradeuterio-2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide",
    "updphoto": "media/hy-b0075s2.gif",
    "description": "Melatonin-d7 is the deuterium labeled Melatonin (HY-B0075). Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress.",
    "fdastatus": "not approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/Melatonin-D7",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      307
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      9,
      10,
      5
    ],
    "target": [
      11,
      12
    ],
    "effect": [
      182
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 32,
  "fields": {
    "gname": "Ramelteon-d5",
    "smiles": "[2H]C([2H])([2H])C([2H])([2H])C(=O)NCC[C@@H]1CCC2=C1C3=C(C=C2)OCC3",
    "linkname": "ramelteon-d5",
    "molecula": "C16H21NO 2",
    "iupacname": "2,2,3,3,3-pentadeuterio-N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]propanamide",
    "updphoto": "media/imgsrv_2.png",
    "description": "Ramelteon-d5 is deuterium labeled Ramelteon. Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation",
    "fdastatus": "Approved",
    "linkslists": "https://www.medchemexpress.com/ramelteon-d5.html",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/25231404",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.68003920.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      308
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      5
    ],
    "target": [
      9
    ],
    "effect": [
      183
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 33,
  "fields": {
    "gname": "7-Desmethyl-3-hydroxyagomelatine",
    "smiles": "CC(=O)NCCC1=C2C=C(C=CC2=CC(=C1)O)O",
    "linkname": "7-desmethyl-3-hydroxyagomelatine",
    "molecula": "C14H15NO3",
    "iupacname": "N-[2-(3,7-dihydroxynaphthalen-1-yl)ethyl]acetamide",
    "updphoto": "media/imgsrv_29.png",
    "description": "7-Desmethyl-3-hydroxyagomelatine (3-Hydroxy-7-desmethyl agomelatine), a metabolite of Agomelatine, has less activity than Agomelatine. Agomelatine is a melatonergic (MT1 and MT2) agonist and serotonergic (5HT2C) antagonist.",
    "fdastatus": null,
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/23360888",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      218
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      9,
      10,
      5
    ],
    "target": [
      11,
      12
    ],
    "effect": [
      180
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 34,
  "fields": {
    "gname": "Agomelatin-d3",
    "smiles": "[2H]C([2H])([2H])C(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC",
    "linkname": "agomelatin-d3",
    "molecula": "C15H17NOO",
    "iupacname": "2,2,2-trideuterio-N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide",
    "updphoto": "media/hy-17038s2.gif",
    "description": "Agomelatine-d3 is the deuterium labeled Agomelatine. Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively. \r\n[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. \r\n\r\n[2]. Audinot V, et al. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367(6):553-61.  \r\n\r\n[3]. Millan MJ, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003 Sep;306(3):954-64.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/Agomelatine-d3-_acetamide-2_2_2-d3#section=Information-Sources&fullscreen=true",
    "pubchem": "null",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.52082565.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      309,
      310
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      5
    ],
    "target": [
      9
    ],
    "effect": [
      157
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 35,
  "fields": {
    "gname": "TIK-301",
    "smiles": "CC(CNC(=O)C)C1=CNC2=CC(=C(C=C21)OC)Cl",
    "linkname": "tik-301",
    "molecula": "C14H17ClN2O2",
    "iupacname": "N-[(2R)-2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide",
    "updphoto": "media/imgsrv_30.png",
    "description": "TIK-301 (LY-156735) is an agonist for the melatonin receptors MT1 and MT2 that is under development for the treatment of insomnia and other sleep disorders. Its agonist action on MT1 and MT2 receptors in the suprachiasmatic nucleus in the brain enables its action as a chronobiotic. It is in the same class of melatonin receptor agonists as ramelteon and tasimelteon.\r\n\r\nSzabadi, E., 2014. Neuronal networks regulating sleep and arousal: effect of drugs. In Drug Treatment of Sleep Disorders (pp. 25-70). Cham: Springer International Publishing.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/219018#section=Springer-Nature-References&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/219018",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.189853.html",
    "drugbank": "https://go.drugbank.com/drugs/DB16909",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      219,
      220
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      9,
      10,
      5
    ],
    "target": [
      9,
      11,
      12
    ],
    "effect": [
      203
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 36,
  "fields": {
    "gname": "S-20928",
    "smiles": "C1CC(C1)C(=O)NCCC2=CC=CC3=CC=CC=C32",
    "linkname": "s-20928",
    "molecula": "C17H19NO",
    "iupacname": "N-(2-naphthalen-1-ylethyl)cyclobutanecarboxamide",
    "updphoto": "media/imgsrv_31.png",
    "description": "S-20928 is an antagonist for melatonin receptor through inhibition of binding of melatonin to its receptors. S-20928 enhances the 2-Deoxy-D-glucose (2DG) (HY-13966)-induced increase in blood glucose and glucagon levels in rats brain.\r\n\r\nMasson‐Pévet, M., Recio, J., Guerrero, H.Y., Mocaer, E., Delagrange, P., Guardiola‐Lemaitre, B. and Pevet, P., 1998. Effects of two melatonin analogues, S‐20098 and S‐20928, on melatonin receptors in the pars tuberalis of the rat. Journal of pineal research, 25(3), pp.172-176.\r\n\r\nWillis, G.L. and Robertson, A.D., 2004. Recovery of experimental Parkinson's disease with the melatonin analogues ML-23 and S-20928 in a chronic, bilateral 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor. Pharmacology Biochemistry and Behavior, 79(3), pp.413-429.",
    "fdastatus": "Not approved",
    "linkslists": "https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-079X.1998.tb00556.x",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/127856",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.113400.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      221,
      222
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      6
    ],
    "target": [
      9
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 37,
  "fields": {
    "gname": "DH97",
    "smiles": "CCCCC(=O)NCCC1=C(NC2=CC=CC=C21)CC3=CC=CC=C3",
    "linkname": "dh97",
    "molecula": "C22H26N2O",
    "iupacname": "N-[2-(2-benzyl-1H-indol-3-yl)ethyl]pentanamide",
    "updphoto": "media/imgsrv_32.png",
    "description": "N-Pentanoyl 2-benzyltryptamine is a potent and selective antagonist of MT2 melatonin receptor, with a pKi of 8.03 for human MT2. N-Pentanoyl 2-benzyltryptamine shows 89- and 229-fold selectivity for human MT2 over human mt1 and Xenopus mel1c receptor subtypes. N-Pentanoyl 2-benzyltryptamine can inhibit melatonin-induced enhancement of electrically-evoked responses.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/3467177#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/3467177",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.2708767.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      223
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      5
    ],
    "target": [
      9
    ],
    "effect": [
      185
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 38,
  "fields": {
    "gname": "Ramelteon-d3",
    "smiles": "[2H]C([2H])([2H])CC(=O)NCC[C@@H]1CCC2=C1C3=C(C=C2)OCC3",
    "linkname": "ramelteon-d3",
    "molecula": "C16 H21 NO2",
    "iupacname": "3,3,3-trideuterio-N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]propanamide",
    "updphoto": "media/imgsrv_33.png",
    "description": "Ramelteon-d3 is a deuterium-labelled Ramelteon (HY-A0014). For research use only.",
    "fdastatus": "Approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/165437284",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.123963127.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      312
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      5
    ],
    "target": [
      9
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 39,
  "fields": {
    "gname": "6-Chloromelatonin",
    "smiles": "CC(=O)NCCC1=CNC2=CC(=C(C=C21)OC)Cl",
    "linkname": "6-chloromelatonin",
    "molecula": "C13H15ClN2O2",
    "iupacname": "N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)ethyl]acetamide",
    "updphoto": "media/imgsrv_34.png",
    "description": "6-Chloromelatonin is a potent melatonin receptor agonist with greater metabolic stability than melatonin. 6-Chloromelatonin compete for [3H]-melatonin and 2-[125I]-iodomelatonin binding to MT1 receptors (pKi=8.9 and 9.1, respectively). 6-Chloromelatonin compete for [3H]-melatonin binding to MT2 receptors (pKi=9.77).",
    "fdastatus": "Not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/1858#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/1858",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.1790.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      313
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      5
    ],
    "target": [
      9
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 40,
  "fields": {
    "gname": "GR 196429",
    "smiles": "CC(=O)NCCN1CCC2=C1C3=C(C=C2)OCC3",
    "linkname": "gr-196429",
    "molecula": "C14H18N2O2",
    "iupacname": "N-[2-(2,3,7,8-tetrahydrofuro[2,3-g]indol-1-yl)ethyl]acetamide",
    "updphoto": "media/imgsrv_35.png",
    "description": "GR-196429 is a melatonin receptor agonist with some selectivity for the MT1 subtype. It was one of the first synthetic melatonin agonists developed and continues to be used in scientific research, though it has never been developed for medical use. Studies in mice have shown GR-196429 to produce both sleep-promoting effects and alterations of circadian rhythm, as well as stimulating melatonin release. For research use only.\r\n\r\nBeresford, I.J., Harvey, F.J., Hall, D.A. and Giles, H., 1998. Pharmacological characterisation of melatonin mt1 receptor-mediated stimulation of [35S]-GTPγs binding. Biochemical pharmacology, 56(9), pp.1167-1174.\r\n\r\nChan, K.H., Cheung, A.S.T., Ho, M.K.C. and Wong, Y.H., 2013. Development of Novel Melatoninergics as Circadian Rhythm Sleep Disorder Therapeutics. New Developments in Melatonin Research, p.53.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/5311134#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5311134",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4470661.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      224,
      225
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      9
    ],
    "target": [
      9,
      11
    ],
    "effect": [
      186
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 41,
  "fields": {
    "gname": "Agomelatine (L(+)-Tartaric acid)",
    "smiles": "CC(NCCC1=C2C=C(OC)C=CC2=CC=C1)=O.O=C(O)[C@H](O)[C@@H](O)C(O)=O",
    "linkname": "agomelatine-l-tartaric-acid",
    "molecula": "C19H23NO8",
    "iupacname": "(2R,3R)-2,3-dihydroxybutanedioic acid;N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide",
    "updphoto": "media/imgsrv_36.png",
    "description": "Agomelatine L(+)-Tartaric acid (S-20098 L(+)-Tartaric acid) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively. Agomelatine L(+)-Tartaric acid is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively. For research use only.\r\n[1]. Audinot V, et al. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367(6):553-61.\r\n[2]. Millan MJ, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003 Sep;306(3):954-64.  \r\n[3]. Aguiar CC, et al. Effects of agomelatine on oxidative stress in the brain of mice after chemically induced seizures. Cell Mol Neurobiol.",
    "fdastatus": "Not approved",
    "linkslists": null,
    "pubchem": null,
    "chemspider": "https://www.chemspider.com/Chemical-Structure.35308335.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      226,
      227,
      228
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      5
    ],
    "target": [
      9
    ],
    "effect": [
      107
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 42,
  "fields": {
    "gname": "Tasimelteon-d5",
    "smiles": "[2H]C([2H])([2H])C([2H])([2H])C(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2",
    "linkname": "tasimelteon-d5",
    "molecula": "C15 H19 NO2",
    "iupacname": "2,2,3,3,3-pentadeuterio-N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide",
    "updphoto": "media/imgsrv_37.png",
    "description": "Tasimelteon-d5 is the deuterium labeled Tasimelteon. Tasimelteon (BMS-214778) is an orally active and selective dual melatonin receptor agonist (DMRA). Tasimelteon has 2.1-4.4 times greater affinity for the MT2 receptor than for the MT1 receptor. Tasimelteon is a circadian regulator and has the potential for Non-24-Hour Sleep-Wake Disorder (Non-24)[1][2].\r\n[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.\r\n\r\n[2]. Christian Lavedan, et al. Tasimelteon: a selective and unique receptor binding profile. Neuropharmacology. 2015 Apr;91:142-7.  \r\n\r\n[3]. Keating GM, et al. Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals. CNS Drugs. 2016 Mar 22.",
    "fdastatus": "not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/156588908#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/156588908",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.8395995.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      314,
      315
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      5
    ],
    "target": [
      9
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 43,
  "fields": {
    "gname": "GR 128107",
    "smiles": "CC(=O)N1CCCC(C1)C2=CNC3=C2C=C(C=C3)OC",
    "linkname": "gr-128107",
    "molecula": "C16H20N2O2",
    "iupacname": "1-[3-(5-methoxy-1H-indol-3-yl)piperidin-1-yl]ethanone",
    "updphoto": "media/imgsrv_38.png",
    "description": "GR 128107 is a competitive melatonin receptor antagonist (pKi: 9.6).",
    "fdastatus": "Not approved",
    "linkslists": "https://link.springer.com/article/10.1007/PL00004956",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/44208891",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.34250082.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      229,
      230
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      12
    ],
    "target": [
      9
    ],
    "effect": [
      169
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 44,
  "fields": {
    "gname": "ACH 000143",
    "smiles": "CC(=O)NCCN1C2=CC(=C(C=C2N=C1OC)Cl)OC",
    "linkname": "ach-000143",
    "molecula": "C13 H16ClN3O3",
    "iupacname": "N- [2-(5-chloro-2,6-dimethoxybenzimidazol-1-yl)ethyl]acetamide",
    "updphoto": "media/imgsrv_39.png",
    "description": "An early toxicological assessment indicated that 10b (also codified as ACH-000143) was devoid of hERG binding, genotoxicity, and behavioral alterations at doses up to 100 mg/kg p.o., supporting further investigation of this compound as a drug candidate. ACH-000143 is a novel, potent, and orally active melatonin receptor agonist. It exhibits high affinity for both MT1 and MT2 receptors, with EC50 values of 0.06 nM and 0.32 nM, respectively. This compound is particularly noted for its peripheral preference, meaning it has a higher effect on peripheral tissues compared to the central nervous system. ACH-000143 has been shown to reduce liver triglycerides and steatosis in diet-induced obese rats, suggesting potential therapeutic applications in managing liver-related conditions",
    "fdastatus": "not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/139451790#section=Biological-Test-Results&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/139451790",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      231
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      5
    ],
    "target": [
      9
    ],
    "effect": [
      102
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 45,
  "fields": {
    "gname": "S24014",
    "smiles": "CC(=O)NCCC1=C(OC2=C1C=C(C=C2)OC)CC3=CC(=CC=C3)OC",
    "linkname": "s24014",
    "molecula": "C21H23NO4",
    "iupacname": "N-[2-[5-methoxy-2-[(3-methoxyphenyl)methyl]-1-benzofuran-3-yl]ethyl]acetamide",
    "updphoto": "media/imgsrv_3.png",
    "description": "S24014 acts as an agonist against melatonin receptors, indicating its potential use in conditions related to melatonin regulation. However, specific therapeutic applications or diseases targeted by S24014 are not widely detailed in the available literature.\r\n\r\nS24014 is classified as an investigative drug, meaning it is under research and not yet approved for clinical use. It is available for research purposes only, not for human or veterinary use.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubmed.ncbi.nlm.nih.gov/12061881/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/9998187",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.8173768.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      232,
      233,
      367
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      5
    ],
    "target": [
      9
    ],
    "effect": [
      209
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 46,
  "fields": {
    "gname": "SP600125",
    "smiles": "C1=CC=C2C(=C1)C3=NN(C4=CC=CC(=C43)C2=O)CCO",
    "linkname": "sp600125",
    "molecula": "C16H12N2O2",
    "iupacname": "14-(2-hydroxyethyl)-14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2,4,6,9(16),10,12-heptaen-8-one",
    "updphoto": "media/imgsrv_4.png",
    "description": "The JNK inhibitor SP600125 has been shown to significantly impact mammalian circadian rhythms by modulating the phosphorylation of c-Jun N-terminal kinase (JNK), a key regulator of the circadian molecular machinery. Below is a summary of its effects:\r\nKey Findings on SP600125 and Circadian Rhythms\r\nDose-Dependent Period Lengthening:\r\nSP600125 dose-dependently extended the period of Period1-luciferase rhythms in rat-1 fibroblasts from approximately 24.23 hours to 31.48 hours.\r\nThis effect was reversible and accompanied by a delay in the onset of bioluminescence rhythms\r\nTissue-Specific Effects:\r\nIn explant cultures from Period1-luciferase transgenic mice and Period2-luciferase knockin mice, SP600125 lengthened the circadian period in tissues such as the suprachiasmatic nucleus (SCN), pineal gland, and lung.\r\nHowever, in kidney explants, circadian rhythms were abolished in Period1-luciferase models but remained unaffected in Period2-luciferase models.",
    "fdastatus": null,
    "linkslists": null,
    "pubchem": null,
    "chemspider": "https://www.chemspider.com/Chemical-Structure.8201.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01782",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      234,
      235
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      13
    ],
    "target": [
      13
    ],
    "effect": [
      110
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 47,
  "fields": {
    "gname": "Cannabidiol",
    "smiles": "CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O",
    "linkname": "cannabidiol",
    "molecula": "C21H30O2",
    "iupacname": "2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol",
    "updphoto": "media/imgsrv_43.png",
    "description": "Cannabidiol (CBD) is the second major cannabinoid which is often said to improve anxiety and sleep with no\r\npsychoactive effect.  then PER2 gene expression in the liver, kidney, and submandibular gland is observed by\r\nin-vivo imaging. Affects core circadian complex. \r\nNuclear molecules show a deregulation of circadian rhythm in microglial cells by CBD, such as RORA, RevErbα, RORB, CREBBP, AFT4, AFT5 and NFIL3.\r\n\r\nLafaye, G., Desterke, C., Marulaz, L. and Benyamina, A., 2019. Cannabidiol affects circadian clock core complex and its regulation in microglia cells. Addiction Biology, 24(5), pp.921-934.",
    "fdastatus": "Not approved",
    "linkslists": "https://onlinelibrary.wiley.com/doi/abs/10.1111/adb.12660?casa_token=4N833iaQoSsAAAAA%3A-MfmP1CQ-PQ5EL1ZRO26wQ2wPRkTPjdJsKXo5KqdIQddTApIvdBqei_3UT1yfx4U5b6USCSuHxNfH3F-",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/644019#section=3D-Conformer",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.454786.html",
    "drugbank": "https://go.drugbank.com/drugs/DB09061",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      236,
      237
    ],
    "classf": [
      5,
      6
    ],
    "mechanisms": [
      14,
      15
    ],
    "target": [
      16,
      14,
      15
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 48,
  "fields": {
    "gname": "Cannabigerol",
    "smiles": "CCCCCC1=CC(=C(C(=C1)O)CC=C(C)CCC=C(C)C)O",
    "linkname": "cannabigerols-cbg",
    "molecula": "C21H32O2",
    "iupacname": "2-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-pentylbenzene-1,3-diol",
    "updphoto": "media/imgsrv_44.png",
    "description": "Cannabigerol (CBG) has not been explicitly identified as a circadian clock modulator in the available research. However, its pharmacological profile suggests potential indirect effects on physiological processes that could influence circadian rhythms.\r\nCBG is a non-psychoactive cannabinoid that interacts weakly with cannabinoid receptors CB1 and CB2, acting as a partial agonist. It also strongly activates α2-adrenoceptors and antagonizes serotonin 5-HT1A receptors, which are involved in neurophysiological processes like mood regulation and anxiety",
    "fdastatus": "Not approved",
    "linkslists": "https://www.google.com/search?q=Cannabigerols+affect+circadian+clock&num=10&newwindow=1&sca_esv=415f77fc59cb58c0&rlz=1C1DVJR_enRU881RU881&sxsrf=AHTn8zpoWUTE2B3uJGbrtt0WWaMjTfiKNw%3A1742037539716&ei=I2",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5315659",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4474921.html",
    "drugbank": "https://go.drugbank.com/drugs/DB14734",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      319
    ],
    "classf": [
      6
    ],
    "mechanisms": [
      15,
      16
    ],
    "target": [
      17
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 49,
  "fields": {
    "gname": "Cannabichromenes",
    "smiles": "CCCCCC1=CC(=C2C=CC(OC2=C1)(C)CCC=C(C)C)O",
    "linkname": "cannabichromenes",
    "molecula": "C21 H30 O2",
    "iupacname": "2-methyl-2-(4-methylpent-3-enyl)-7-pentylchromen-5-ol",
    "updphoto": "media/imgsrv_45.png",
    "description": "Cannabichromene (CBC) is one of four major cannabinoids in Cannabis sativa L. and is the second most abundant cannabinoid in drug-type cannabis. Cannabichromene and some of its homologs, analogs, and isomers were evaluated for antiinflammatory, antibacterial, and antifungal activity.\r\nPotential chronodisruptor. There is no data on circadian effects.",
    "fdastatus": "Not approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/30219",
    "chemspider": null,
    "drugbank": "https://go.drugbank.com/drugs/DB14735",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      355
    ],
    "classf": [
      7
    ],
    "mechanisms": [
      16
    ],
    "target": [
      17
    ],
    "effect": [
      90
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 50,
  "fields": {
    "gname": "Dronabinol",
    "smiles": "CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O",
    "linkname": "dronabinol",
    "molecula": "C21H30OO",
    "iupacname": "(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol",
    "updphoto": "media/imgsrv_46.png",
    "description": "Tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis, has several effects on the circadian rhythm and sleep patterns:\r\nCircadian Effects\r\nDisruption of Circadian Signaling: Chronic THC administration can disrupt circadian signaling at the molecular level, affecting the body's internal clock.\r\nImpact on Zeitgebers: THC can alter the body's response to environmental cues (zeitgebers) like light, potentially disrupting the synchronization of the internal clock with external rhythms.\r\nPhase Shifts: THC can inhibit light-induced phase shifts in the circadian rhythm, which means it can affect the timing of sleep and wakefulness by altering how the body responds to light cues.",
    "fdastatus": "Not approved",
    "linkslists": "https://www.jneurosci.org/content/30/30/10061.short",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/16078",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.15266.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00470",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      238
    ],
    "classf": [
      6
    ],
    "mechanisms": [
      15
    ],
    "target": [
      17
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 51,
  "fields": {
    "gname": "6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol",
    "smiles": "CCCCCC1=CC(=C2C(=C1)OC(C3=C2C=C(C=C3)C)(C)C)O",
    "linkname": "cannabinol-cbn",
    "molecula": "C21H26O 2",
    "iupacname": "6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol",
    "updphoto": "media/imgsrv_47.png",
    "description": "A cannabinoid isolated from the plant Cannabis that is a metabolite of tetrahydrocannabinol (THC), with potential immunosuppressive and anti-inflammatory activities. Cannabinol preferentially binds to the cannabinoid G-protein coupled receptor CB2, which is mainly expressed on a variety of immune cells, such as T cells, B cells, macrophages and dendritic cells. Stimulation of CB2 receptors by cannabinol may both trigger apoptosis in these cells and inhibit the production of a variety of cytokines. Cannabinol exerts minimal affinity for CB1 and has a weak effect on the central nervous system.",
    "fdastatus": "Not approved",
    "linkslists": "https://link.springer.com/chapter/10.1007/978-3-030-61663-2_6",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/2543",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      302
    ],
    "classf": [
      7
    ],
    "mechanisms": [
      16,
      17,
      14,
      15
    ],
    "target": [
      17,
      18
    ],
    "effect": [
      155
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 52,
  "fields": {
    "gname": "Cannabinodiol",
    "smiles": "CCCCCC1=CC(=C(C(=C1)O)C2=C(C=CC(=C2)C)C(=C)C)O",
    "linkname": "cannabinodiol",
    "molecula": "C21H26O2",
    "iupacname": "2-(5-methyl-2-prop-1-en-2-ylphenyl)-5-pentylbenzene-1,3-diol",
    "updphoto": "media/imgsrv_48.png",
    "description": "Cannabis sativa metabolite with potential of chronodisruptor. 1. Lafaye G, Desterke C, Marulaz L, Benyamina A. Cannabidiol affects circadian clock core complex and its regulation in microglia cells. Addiction Biology. 2018.\r\n\r\n2Pisanti S, Malfitano AM, Ciaglia E, et al. Cannabidiol: state of the art and new challenges for therapeutic applications. Pharmacology & Therapeutics. 2017; 175: 133-150.\r\n\r\n3. de Assis LMV, Kinker GS, Moraes MN, Markus RP, Fernandes PA, Castrucci AML. Expression of the circadian clock gene BMAL1 positively correlates with antitumor immunity and patient survival in metastatic melanoma front. Oncology. 2018; 8: 185.\r\n\r\n4. Juknat A, Pietr M, Kozela E, et al. Microarray and pathway analysis reveal distinct mechanisms underlying cannabinoid-mediated modulation of LPS-induced activation of BV-2 microglial cells. PLoS One. 2013; 8(4):e61462.\r\n\r\n5. Nakazato R, Hotta S, Yamada D, et al.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/11551346#section=Information-Sources&fullscreen=true",
    "pubchem": null,
    "chemspider": "https://www.chemspider.com/Chemical-Structure.9726124.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      302
    ],
    "classf": [
      7
    ],
    "mechanisms": [
      16,
      17,
      14,
      15
    ],
    "target": [
      17,
      18
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 53,
  "fields": {
    "gname": "Nabilone",
    "smiles": "CCCCCCC(C)(C)C1=CC(=C2C3CC(=O)CCC3C(OC2=C1)(C)C)O",
    "linkname": "nabilone",
    "molecula": "C24 H36O3",
    "iupacname": "(6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-9-one",
    "updphoto": "media/imgsrv_49.png",
    "description": "Nabilone, a synthetic cannabinoid agonist, primarily interacts with the CB1 receptor, which is implicated in circadian rhythm regulation through its role in the endocannabinoid system (ECS). While direct studies on nabilone’s circadian effects are limited, evidence from related research provides insights into potential mechanisms/\r\nClinical Implications for Nabilone\r\nSleep Outcomes: Nabilone improves sleep in Parkinson’s disease (PD) patients, which may indirectly stabilize circadian rhythms disrupted by neurodegenerative pathology.\r\nStress and HPA Axis: Chronic stress disrupts circadian gene expression (e.g., PER1/2) via glucocorticoid signaling. Nabilone’s anxiolytic effects could mitigate stress-induced circadian dysregulation.\r\n\r\nPeball, M., et al., 2024. Long-term safety and efficacy of open-label nabilone on sleep and pain in Parkinson´ s Disease. npj Parkinson's Disease, 10(1), p.61.",
    "fdastatus": "Approved",
    "linkslists": "https://www.proquest.com/openview/f923d4ac8de328e184732bcdf986253f/1?cbl=18750&diss=y&pq-origsite=gscholar",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5284592",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4447641.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00486",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      239
    ],
    "classf": [
      5,
      7
    ],
    "mechanisms": [
      17
    ],
    "target": [
      17
    ],
    "effect": [
      113
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 54,
  "fields": {
    "gname": "Nabiximols",
    "smiles": "CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O",
    "linkname": "nabiximols",
    "molecula": "C42H60O4",
    "iupacname": "(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol;2-[(6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol",
    "updphoto": "media/imgsrv_50.png",
    "description": "Potential chronodisruptor",
    "fdastatus": "Not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/44148067#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/44148067",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.65321667.html",
    "drugbank": "https://go.drugbank.com/drugs/DB14011",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      321
    ],
    "classf": [
      7
    ],
    "mechanisms": [
      16,
      17,
      14,
      15
    ],
    "target": [
      17,
      18
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 55,
  "fields": {
    "gname": "Oxycodone",
    "smiles": "CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O",
    "linkname": "oxycodone",
    "molecula": "C18H21NO4",
    "iupacname": "(4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one",
    "updphoto": "media/imgsrv_51.png",
    "description": "Oxycodone, like other opioids, can disrupt circadian rhythms, which are closely linked to sleep patterns and overall physiological function. Here's how oxycodone affects circadian rhythms:\r\nImpact of Opioids on Circadian Rhythms\r\nSleep Disruption: Opioids, including oxycodone, can negatively affect sleep quality by altering the sleep-wake cycle, leading to insomnia or excessive sleepiness. Disrupted sleep patterns are a significant factor in circadian rhythm disturbances.\r\nCircadian System Interference: The circadian system regulates various physiological processes, including pain perception and opioid processing. Disruptions in this system can exacerbate pain and modulate opioid effects, creating a feedback loop where opioids further disrupt circadian rhythms.\r\nNeurobiological Effects: Opioid use disorder (OUD) is associated with molecular rhythm disruptions in the brain, particularly in regions involved in reward and cognition, such as the nucleus accumbens (NAc) and DPC",
    "fdastatus": "Approved",
    "linkslists": "https://www.proquest.com/openview/a4a9816d198cea92203d24d296c2bc8a/1?cbl=18750&diss=y&pq-origsite=gscholar",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5284603",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4447649.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00497",
    "chebi": null,
    "uniprot": "https://www.uniprot.org/uniprotkb/P35372/entry",
    "kegg": null,
    "selleckchem": null,
    "articles": [
      240,
      241
    ],
    "classf": [
      6
    ],
    "mechanisms": [
      18
    ],
    "target": [
      19,
      20
    ],
    "effect": [
      91
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 56,
  "fields": {
    "gname": "Oxymorphone",
    "smiles": "CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O",
    "linkname": "oxymorphone",
    "molecula": "C17H19NO4",
    "iupacname": "(4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one",
    "updphoto": "media/imgsrv_52.png",
    "description": "There is limited specific information available on the circadian effects of oxymorphone. However, we can infer potential impacts based on the broader context of opioids and circadian rhythms.\r\nOpioids and Circadian Disruption: Opioids, including morphine, can disrupt circadian rhythms. This disruption can affect various bodily functions, including sleep-wake cycles and pain perception. Oxymorphone, being an opioid, might similarly influence circadian rhythms.\r\nGeneral Opioid Effects on Circadian Genes: Morphine has been shown to alter the expression of circadian clock genes, such as mPer1, in various tissues1. While specific data on oxymorphone is lacking, it is plausible that oxymorphone could have similar effects on circadian gene expression.\r\nEffectiveness of Oximorphone is depending on circadian time.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/5284604#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5284604",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4447650.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01192",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [],
    "classf": [
      7
    ],
    "mechanisms": [
      16,
      19,
      20
    ],
    "target": [
      19,
      20,
      21
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 57,
  "fields": {
    "gname": "Hydrocodone",
    "smiles": "Hydrocodone",
    "linkname": "hydrocodone",
    "molecula": "C18H21NO3",
    "iupacname": "(4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one",
    "updphoto": "media/imgsrv_53.png",
    "description": "Potential chronodisruptor much alike Oxycodone",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/5284569#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5284569",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4447623.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00956",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [],
    "classf": [
      7
    ],
    "mechanisms": [
      18,
      19,
      20
    ],
    "target": [
      19,
      20,
      21
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 58,
  "fields": {
    "gname": "Hydromorphone",
    "smiles": "CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4",
    "linkname": "hydromorphone",
    "molecula": "C17H19NO3",
    "iupacname": "(4R,4aR,7aR,12bS)-9-hydroxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one",
    "updphoto": "media/imgsrv_54.png",
    "description": "Chronodisruptor much alike Oxymorphone.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/5284570#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5284570",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4447624.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00327",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      324
    ],
    "classf": [
      7
    ],
    "mechanisms": [
      18,
      19,
      20
    ],
    "target": [
      19,
      20,
      21
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 59,
  "fields": {
    "gname": "N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide",
    "smiles": "CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3",
    "linkname": "fentanyl",
    "molecula": "C22H28N2O",
    "iupacname": "N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide",
    "updphoto": "media/imgsrv_55.png",
    "description": "Adult female Sprague–Dawley rats housed under constant light in cages with attached running wheels received repeated low, medium, or high doses of either fentanyl or haloperidol on a 24-h administration schedule followed by a 31-h schedule (Experiment 1) or solely on a 31-h schedule . The results showed that all three doses of fentanyl entrained both pre-drug and post-drug episodes of wheel running when administered every 24 h, and the combined pre- and post-fentanyl activity episodes persisted for at least 3 days when the drug was withheld during test days. On the 31-h schedule, fentanyl produced an “ensuing” activity episode approximately 24 h post-administration, but failed to produce an anticipatory episode 29–31 h post-administration. \r\nGillman, A.G., Leffel II, J.K., Kosobud, A.E. and Timberlake, W., 2009. Fentanyl, but not haloperidol, entrains persisting circadian activity episodes when administered at 24-and 31-h intervals. Behavioural brain research, 205(1), pp.102-114.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/3345#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/3345#section=MolGenie-Organic-Chemistry-Ontology",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.3228.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00813",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      242,
      243
    ],
    "classf": [
      5,
      6
    ],
    "mechanisms": [
      18,
      19,
      20
    ],
    "target": [
      19,
      20,
      21
    ],
    "effect": [
      116
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 60,
  "fields": {
    "gname": "(4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol",
    "smiles": "CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O",
    "linkname": "codeine",
    "molecula": "C18H21NO 3",
    "iupacname": "(4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol",
    "updphoto": "media/imgsrv_56.png",
    "description": "Potential chronodisruptor like other opioids.\r\nYoung, A.M., Thompson, T., Jensen, M.A. and Muchow, L.R., 1979. Effects of response-contingent clock stimuli on behavior maintained by intravenous codeine in the rhesus monkey. Pharmacology Biochemistry and Behavior, 11(1), pp.43-49.\r\nWarfield, A.E., Prather, J.F. and Todd, W.D., 2021. Systems and circuits linking chronic pain and circadian rhythms. Frontiers in neuroscience, 15, p.705173.\r\nSharma, P. and Nelson, R.J., 2024. Disrupted Circadian Rhythms and Substance Use Disorders: A Narrative Review. Clocks & Sleep, 6(3), pp.446-467.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4447447.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00318",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      244,
      245
    ],
    "classf": [
      5,
      6
    ],
    "mechanisms": [
      21
    ],
    "target": [
      19
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 61,
  "fields": {
    "gname": "6-(dimethylamino)-4,4-diphenylheptan-3-one",
    "smiles": "CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2",
    "linkname": "methadone",
    "molecula": "C21H27NO",
    "iupacname": "6-(dimethylamino)-4,4-diphenylheptan-3-one",
    "updphoto": "media/imgsrv_57.png",
    "description": "Methadone acts by binding to the μ-opioid receptor, but also has some affinity for the NMDA receptor, an ionotropic glutamate receptor. Methadone is metabolized by CYP3A4, CYP2B6, CYP2D6, and is a substrate, or in this case target, for the P-glycoprotein efflux protein.\r\n10-day administration and withdrawal of both these drugs failed to affect clock genes and Avp expression in the SCN. Our results indicate that opioid-induced changes in behavioral and physiological rhythms originate in brain structures downstream of the suprachiasmatic nucleus regulatory output pathway. Furthermore, we observed that acute withdrawal from methadone markedly extended the period of high night AA-NAT activity in the pineal gland. Affects melatonin synthesis.\r\n\r\nPačesová, D., Novotný, J. and Bendová, Z., 2016. The effect of chronic morphine or methadone exposure and withdrawal on clock gene expression in the rat suprachiasmatic nucleus and AA-NAT activity in the pineal gland. Physiol Res, 65(3), pp.517-525.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/4095#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/4095",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.3953.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00333",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      247,
      248
    ],
    "classf": [
      5,
      6
    ],
    "mechanisms": [
      18,
      19,
      20,
      21
    ],
    "target": [
      19,
      20,
      21,
      22,
      23
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 62,
  "fields": {
    "gname": "Tramadol",
    "smiles": "CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O",
    "linkname": "tramadol",
    "molecula": "C16H25NO2",
    "iupacname": "(1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol",
    "updphoto": "media/imgsrv_58.png",
    "description": "A potential chronodisruptor like other opioids.\r\n\r\nMelatonin is responsible for regulating the sleep-wake cycle and circadian rhythms in mammals. Tramadol, a synthetic opioid analgesic, is used to manage moderate to severe pain but has a high potential for abuse and dependence. Studies have shown that melatonin could be a potential modulator to reduce tramadol addiction.\r\n\r\nHakami, A.Y., Alghamdi, B.S. and Alshehri, F.S., 2024. Exploring the potential use of melatonin as a modulator of tramadol-induced rewarding effects in rats. Frontiers in Pharmacology, 15, p.1373746.\r\nSalamatova, Y. and Packard, A., 2021. Effects of Circadian Rhythm on Migraine Therapy. OBM Neurobiology, 5(4), pp.1-12.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/33741#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/33741",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.31105.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00193",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      249,
      250
    ],
    "classf": [
      6
    ],
    "mechanisms": [
      18,
      19,
      20,
      21
    ],
    "target": [
      19,
      20,
      21
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 63,
  "fields": {
    "gname": "Buprenorphine",
    "smiles": "CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O",
    "linkname": "buprenorphine",
    "molecula": "C29H41NO4",
    "iupacname": "(1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol",
    "updphoto": "media/imgsrv_59.png",
    "description": "Buprenorphine, an opioid used for pain relief and opioid addiction treatment, can have significant effects on the circadian clock and sleep patterns. Here are some key points regarding its impact:\r\nEffects on Sleep and Circadian Rhythm\r\n•\tSleep Disruption: Buprenorphine significantly disrupts sleep architecture by increasing wakefulness, decreasing non-rapid eye movement (NREM) and rapid eye movement (REM) sleep, and delaying sleep onset\r\nThis disruption can affect the normal circadian rhythm.\r\n•\tCircadian Rhythm Disturbance: Studies in mice have shown that buprenorphine can disturb the circadian rhythm, leading to increased activity and behavioral abnormalities\r\nThis disturbance can persist for up to 24 hours after administration.\r\n•\tIncreased Activity: Buprenorphine can cause increased locomotor activity, which may disrupt the natural rest-activity cycle, further impacting the circadian rhythm",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/644073#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/644073",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.559124.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00921",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      251,
      252
    ],
    "classf": [
      6
    ],
    "mechanisms": [
      21
    ],
    "target": [
      19,
      20,
      21
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 64,
  "fields": {
    "gname": "(4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol",
    "smiles": "CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O",
    "linkname": "morphin",
    "molecula": "C17H19NO  3",
    "iupacname": "(4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol",
    "updphoto": "media/imgsrv_60.png",
    "description": "The effect of morphine on circadial wheel-running rhythms of C57BL/6j mice was examined. Mice received morphine (25 mg kg−1, i.p.) or saline at eight different circadian phases in constant dark. Morphine injections in the middle of the inactive period induced significant advance phase shifts, whereas injections at other times induced small delay shifts or no responses. This phase–response relationship was not altered by optic enucleation. Morphine also induced hyperactivity. Restriction of activity prevented phase shifts. The results indicate that morphine shifts circadian rhythms by its effects on behaviour, rather than by a direct action on the circadian pacemaker. Morphine may represent a useful tool for further study of behaviourally induced phase-resetting in this species.\r\n\r\nMarchant, E.G. and Mistlberger, R.E., 1995. Morphine phase-shifts circadian rhythms in mice: role of behavioural activation. Neuroreport, 7(1), pp.209-212.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/5288826#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5288826",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4450907.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00295",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      328
    ],
    "classf": [
      5,
      6
    ],
    "mechanisms": [
      16,
      21
    ],
    "target": [
      19,
      20,
      21
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 65,
  "fields": {
    "gname": "[(4R,4aR,7S,7aR,12bS)-9-acetyloxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl] acetate",
    "smiles": "CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C",
    "linkname": "heroin",
    "molecula": "C21H23NO5",
    "iupacname": "[(4R,4aR,7S,7aR,12bS)-9-acetyloxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl] acetate",
    "updphoto": "media/imgsrv_6.png",
    "description": "Heroin self-administration during the light cycle reverses the rat sleep–wake cycle.\r\nReversal does not depend on the amount of drug taken.\r\nWake and NREM sleep patterns recover immediately in abstinence.\r\nREM sleep patterns remain reversed into early abstinence (3–6 days).\r\n\r\nCoffey, A.A., Guan, Z., Grigson, P.S. and Fang, J., 2016. Reversal of the sleep–wake cycle by heroin self-administration in rats. Brain research bulletin, 123, pp.33-46.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/5462328#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5462328",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4575379.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01452",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      330
    ],
    "classf": [
      5,
      6
    ],
    "mechanisms": [
      21
    ],
    "target": [
      19,
      20,
      21
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 66,
  "fields": {
    "gname": "1-phenylpropan-2-amine",
    "smiles": "CC(CC1=CC=CC=C1)N",
    "linkname": "amphetamine",
    "molecula": "C9H13N",
    "iupacname": "1-phenylpropan-2-amine",
    "updphoto": "media/imgsrv_61.png",
    "description": "In the striatum, acute injection of d-amphetamine did not alter Per1, Per2 and Reverse erythroblastosis virus α (Rev-erbα) expressions. Chronic administration shifted the phase of Per1 and Per2 expressions from a nocturnal to diurnal pattern and advance shifted the peak of Rev-erbα in d-amphetamine-treated animals. In contrast, the rhythm of Brain and muscle Arnt-like protein-1 (Bmal1) was shifted from a diurnal to a nocturnal pattern by both acute and chronic treatments. These results demonstrated that chronic d-amphetamine treatment altered the expression of clock genes in the striatum. \r\nWongchitrat, P., Mukda, S., Phansuwan-Pujito, P. and Govitrapong, P., 2013. Effect of amphetamine on the clock gene expression in rat striatum. Neuroscience letters, 542, pp.126-130.\r\nKhazaie, H., Ahmadi, H.R., Kiani, A. and Ghadami, M.R., 2019. Circadian melatonin profile in opium and amphetamine dependent patients: a preliminary study. Neurobiology of sleep and circadian rhythms, 7, p.1000",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/3007#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/3007",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.13852819.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00182",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      331,
      332
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      15
    ],
    "target": [
      25,
      26,
      29,
      30
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 67,
  "fields": {
    "gname": "methyl (1R,2R,3S,5S)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate",
    "smiles": "CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC",
    "linkname": "cocaine",
    "molecula": "C17H21NO4",
    "iupacname": "methyl (1R,2R,3S,5S)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate",
    "updphoto": "media/imgsrv_62.png",
    "description": "Cocaine administration to mice disrupts nocturnal photic phase resetting of the suprachiasmatic (SCN) circadian clock, whereas administration during the day induces non-photic phase shifts. Importantly, the same effects are seen when cocaine is applied to the SCN in vitro, where it blocks photic-like (glutamate-induced) phase shifts at night and induces phase advances during the day.\r\n\r\nProsser, R.A., Stowie, A., Amicarelli, M., Nackenoff, A.G., Blakely, R.D. and Glass, J.D., 2014. Cocaine modulates mammalian circadian clock timing by decreasing serotonin transport in the SCN. Neuroscience, 275, pp.184-193.\r\nWang, D.Q., Wang, X.L., Wang, C.Y., Wang, Y., Li, S.X. and Liu, K.Z., 2019. Effects of chronic cocaine exposure on the circadian rhythmic expression of the clock genes in reward-related brain areas in rats. Behavioural Brain Research, 363, pp.61-69.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/446220#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/446220",
    "chemspider": "https://go.drugbank.com/drugs/DB00907",
    "drugbank": "https://www.chemspider.com/Chemical-Structure.10194104.html",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      333,
      336
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      16,
      22,
      15
    ],
    "target": [
      32,
      33,
      34
    ],
    "effect": [
      160
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 68,
  "fields": {
    "gname": "Propofol",
    "smiles": "CC(C)C1=C(C(=CC=C1)C(C)C)O",
    "linkname": "propofol",
    "molecula": "C12H18O",
    "iupacname": "2,6-di(propan-2-yl)phenol",
    "updphoto": "media/imgsrv_63.png",
    "description": "Chronodisruptor. When administered around (±2 h) the daily rest/activity transition point, a 30-min propofol anesthesia induced a 1-h phase advance in the free-running rest-activity rhythm, while anesthesia had no significant resetting effect at other times of the day. \r\nChallet, E., Gourmelen, S., Pevet, P., Oberling, P. and Pain, L., 2007. Reciprocal relationships between general (Propofol) anesthesia and circadian time in rats. Neuropsychopharmacology, 32(3), pp.728-735. \r\n\r\nBienert, A., et al., 2010. Assessing circadian rhythms in propofol PK and PD during prolonged infusion in ICU patients. Journal of Pharmacokinetics and Pharmacodynamics, 37, pp.289-304. \r\n\r\nTouitou, Y., Mauvieux, B., Reinberg, A. and Dispersyn, G., 2016. Disruption of the circadian period of body temperature by the anesthetic propofol. Chronobiology international, 33(9), pp.1247-1254.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/4943#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/4943",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4774.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00818",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      253,
      254,
      255
    ],
    "classf": [
      5,
      6
    ],
    "mechanisms": [
      23
    ],
    "target": [
      35
    ],
    "effect": [
      118
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 69,
  "fields": {
    "gname": "2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one",
    "smiles": "CNC1(CCCCC1=O)C2=CC=CC=C2Cl",
    "linkname": "ketamine",
    "molecula": "C13H16ClNO",
    "iupacname": "2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one",
    "updphoto": "media/imgsrv_64.png",
    "description": "Ketamine modulates CLOCK:BMAL1-mediated transcriptional activation when these regulators are ectopically expressed in NG108-15 neuronal cells. \r\nBellet, M.M., Vawter, M.P., Bunney, B.G., Bunney, W.E. and Sassone-Corsi, P., 2011. Ketamine influences CLOCK: BMAL1 function leading to altered circadian gene expression. PLoS One, 6(8), p.e23982.\r\nZhuo, C., Tian, H., Li, G., Chen, M., Jiang, D., Lin, X., Xu, Y. and Wang, W., 2019. Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment‐resistant depression: A protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans. Brain and Behavior, 9(11), p.e01423.\r\nMihara, T., Kikuchi, T., Kamiya, Y., Koga, M., Uchimoto, K., Kurahashi, K. and Goto, T., 2012. Day or night administration of ketamine and pentobarbital differentially affect circadian rhythms of pineal melatonin secretion and locomotor activity in rats. Anesthesia & Analgesia, 115(4), pp.805-813.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/3821#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/3821",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.3689.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01221",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      256,
      257,
      258
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      15
    ],
    "target": [
      29
    ],
    "effect": [
      120
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 70,
  "fields": {
    "gname": "Glycopyrrolate",
    "smiles": "C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-]",
    "linkname": "glycopyrrolate",
    "molecula": "C19H28BrNO3",
    "iupacname": "(1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide",
    "updphoto": "media/imgsrv_65.png",
    "description": "Glycopyrrolate affects melatonin synthsis. Melatonin secretion evaluated from the saliva samples was significantly diminished during the first postoperative evening as compared with that during the preoperative evening (P<0.001). There was also a significant decline of 26% (P<0.05) in postoperative 6-hydroxymelatonin sulphate excretion. There was no significant difference in melatonin secretion between the spinal and general anaesthesia groups.\r\n\r\nKärkelä, J., Vakkuri, O., Kaukinen, S., Huang, W.Q. and Pasanen, M., 2002. The influence of anaesthesia and surgery on the circadian rhythm of melatonin. Acta anaesthesiologica scandinavica, 46(1), pp.30-36.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/11693#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/11693",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.3374.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00986",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      259,
      260
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      25
    ],
    "target": [
      37
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 71,
  "fields": {
    "gname": "methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate",
    "smiles": "CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC",
    "linkname": "remifentanil",
    "molecula": "C20H28N2O5",
    "iupacname": "methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate",
    "updphoto": "media/imgsrv_66.png",
    "description": "Remifentanil inhibited rapid eye movement sleep (14.1 +/- 7.2% to 3.9 +/- 6.9%). The amount of slow wave sleep decreased from 6.8 +/- 7.6% to 3.2 +/- 6.1%, but this decrease was not statistically significant. Remifentanil did not decrease melatonin concentration. Melatonin administration did not prevent remifentanil-induced sleep disturbance.\r\nBonafide, C.P., Aucutt-Walter, N., Divittore, N., King, T., Bixler, E.O. and Cronin, A.J., 2008. Remifentanil inhibits rapid eye movement sleep but not the nocturnal melatonin surge in humans. Anesthesiology, 108(4), pp.627-633.\r\n\r\nWenk, M., Pöpping, D.M., Chapman, G., Grenda, H. and Ledowski, T., 2013. Long-term quality of sleep after remifentanil-based anaesthesia: a randomized controlled trial. British journal of anaesthesia, 110(2), pp.250-257.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/60815#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/60815",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.54803.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00899",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      261,
      262
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      16,
      18,
      19,
      20
    ],
    "target": [
      19,
      20,
      21
    ],
    "effect": [
      122
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 72,
  "fields": {
    "gname": "Sevoflurane",
    "smiles": "C(OC(C(F)(F)F)C(F)(F)F)F",
    "linkname": "sevoflurane",
    "molecula": "C4H3F7O",
    "iupacname": "1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane",
    "updphoto": "media/imgsrv_7.png",
    "description": "Expression of the genes encoding Per2, Dbp, Arc, Egr1, Krox20 and NGFI-B was suppressed during inhalation of sevoflurane for 2 h and 6 h. Although the suppression tended to be alleviated after awakening from anesthesia, the expression levels after a recovery period of 24 h remained significantly lower than the control levels of these genes, except for Krox20. We demonstrated that circadian gene expression is suppressed in whole brain during sevoflurane anesthesia, and the suppression continues for at least 24 h after termination of sevoflurane treatment. This suggests that sevoflurane anesthesia may have effects at the molecular level and that these effects are long lasting.\r\n\r\nKobayashi, K., Takemori, K. and Sakamoto, A., 2007. Circadian gene expression is suppressed during sevoflurane anesthesia and the suppression persists after awakening. Brain research, 1185, pp.1-7.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/5206#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5206",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.5017.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01236",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      263,
      264
    ],
    "classf": [
      5,
      6
    ],
    "mechanisms": [
      15,
      16
    ],
    "target": [
      25,
      26,
      27
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 73,
  "fields": {
    "gname": "Desflurane",
    "smiles": "C(C(F)(F)F)(OC(F)F)F",
    "linkname": "desflurane",
    "molecula": "C3H2F6O",
    "iupacname": "2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane",
    "updphoto": "media/imgsrv_68.png",
    "description": "Effects are like those observed in sevoflurane, the closest alike compound.\r\nCircadian gene expression is suppressed during sevoflurane anesthesia and the suppression persists after awakening.\r\nKobayashi, K., Takemori, K. and Sakamoto, A., 2007. Circadian gene expression is suppressed during sevoflurane anesthesia and the suppression persists after awakening. Brain research, 1185, pp.1-7.\r\nSugimura, S., et al., 2024. Effects of volatile anesthetics on circadian rhythm in mice: a comparative study of sevoflurane, desflurane, and isoflurane. Journal of Anesthesia, 38(1), pp.10-18.\r\nAnzai, M., Iijima, N., Higo, S., Takumi, K., Matsuo, I., Mori, K., Ohe, Y., Kadota, K., Akimoto, T., Sakamoto, A. and Ozawa, H., 2013. Direct and specific effect of sevoflurane anesthesia on rat Per2 expression in the suprachiasmatic nucleus. PLoS One, 8(3), p.e59454.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/42113#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/42113",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.38403.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01189",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      265,
      266
    ],
    "classf": [
      5,
      6,
      7
    ],
    "mechanisms": [
      15
    ],
    "target": [
      27
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 74,
  "fields": {
    "gname": "Isoflurane",
    "smiles": "C(C(F)(F)F)(OC(F)F)Cl",
    "linkname": "isoflurane",
    "molecula": "C3H2ClF5O",
    "iupacname": "2-chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane",
    "updphoto": "media/imgsrv_69.png",
    "description": "Supressor of core clock.\r\nKobayashi, K., Takemori, K. and Sakamoto, A., 2007. Circadian gene expression is suppressed during sevoflurane anesthesia and the suppression persists after awakening. Brain research, 1185, pp.1-7.\r\nWren-Dail, M.A., Dauchy, R.T., Blask, D.E., Hill, S.M., Ooms, T.G., Dupepe, L.M. and Bohm Jr, R.P., 2017. Effect of isoflurane anesthesia on circadian metabolism and physiology in rats. Comparative Medicine, 67(2), pp.138-146.\r\nCui, Y., Zheng, Z., Zhou, Q., Han, X., Liu, S., Xia, T., Gu, X. and Zhang, Y., 2025. The role of clock control of DRP1 activity involved in postoperative cognitive dysfunction. Experimental Neurology, 385, p.115140.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/3763#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/3763",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.3631.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00753",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      337,
      338
    ],
    "classf": [
      5,
      6
    ],
    "mechanisms": [
      15,
      26
    ],
    "target": [
      25,
      26,
      27
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 75,
  "fields": {
    "gname": "Hyoscyamine",
    "smiles": "CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3",
    "linkname": "hyoscyamine",
    "molecula": "C17H23NO3",
    "iupacname": "[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2S)-3-hydroxy-2-phenylpropanoate",
    "updphoto": "media/imgsrv_70.png",
    "description": "Affects adenylate cyclase type 1, which catalyzes the formation of the signaling molecule cAMP in response to G-protein signaling. Mediates responses to increased cellular Ca(2+)/calmodulin levels (By similarity). May be involved in regulatory processes in the central nervous system. May play a role in memory and learning. Plays a role in the regulation of the circadian rhythm of daytime contrast sensitivity probably by modulating the rhythmic synthesis of cyclic AMP in the retina.\r\nPérez-Llorca, M. and Müller, M., 2024. Unlocking Nature’s Rhythms: Insights into Secondary Metabolite Modulation by the Circadian Clock. International Journal of Molecular Sciences, 25(13), p.7308.\r\nNilsen, N.G., Gilson, S.J., Pedersen, H.R., Hagen, L.A., Wildsoet, C.F. and Baraas, R.C., 2024. The effect of topical 1% atropine on ocular dimensions and diurnal rhythms of the human eye. Vision Research, 214, p.108341.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/154417#section=Information-Sources&fullscreen=true",
    "pubchem": null,
    "chemspider": "https://www.chemspider.com/Chemical-Structure.10246417.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00424",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      339,
      340
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      27
    ],
    "target": [
      38
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 76,
  "fields": {
    "gname": "SRT2183",
    "smiles": "C1CN(CC1O)CC2=CSC3=NC(=CN23)C4=CC=CC=C4NC(=O)C5=CC6=CC=CC=C6C=C5",
    "linkname": "SRT2183",
    "molecula": "C27H24N4O2S",
    "iupacname": "(R)-N-(2-(3-((3-hydroxypyrrolidin-1-yl)methyl)imidazo[2,1-b]thiazol-6-yl)phenyl)-2-naphthamide",
    "updphoto": "media/imgsrv_MTO02pj.png",
    "description": "SRT2183 is a synthetic chronobiotic compound and a direct activator of SIRT1. It modulates circadian rhythms by enhancing SIRT1 deacetylase activity, leading to suppression of CLOCK:BMAL1-mediated transcription. This results in decreased expression and amplitude of key circadian genes such as Per2, Cry1, and Dbp. The mechanism involves epigenetic regulation through reduced histone H3 acetylation at K9/K14. SRT2183 acts on the SIRT1-CLOCK-BMAL1 axis, functioning as a fine-tuner of the core clock machinery.\r\n\r\nSultan, A., Ali, R., Sultan, T., Ali, S., Khan, N.J. and Parganiha, A., 2021. Circadian clock modulating small molecules repurposing as inhibitors of SARS-CoV-2 Mpro for pharmacological interventions in COVID-19 pandemic. Chronobiology international, 38(7), pp.971-985.",
    "fdastatus": "Not approved",
    "linkslists": "https://www.tandfonline.com/doi/abs/10.1080/07420528.2021.1903027",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/24180126#section=Chemical-Gene-Co-Occurrences-in-Literature",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.23315224.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      341,
      354
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      4
    ],
    "target": [
      29,
      39
    ],
    "effect": [
      89
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 77,
  "fields": {
    "gname": "SRT 1720 Hydrochloride",
    "smiles": "C1CN(CCN1)CC2=CSC3=NC(=CN23)C4=CC=CC=C4NC(=O)C5=NC6=CC=CC=C6N=C5.Cl",
    "linkname": "srt-1720-hydrochloride",
    "molecula": "C25H24ClN7OS",
    "iupacname": "N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide;hydrochloride",
    "updphoto": "media/imgsrv_1_02HtVWm.png",
    "description": "SRT1720 Hydrochloride is a potent synthetic activator of SIRT1, functioning as a chronobiotic by modulating circadian rhythms. It acts through deacetylation of core circadian transcription factors, specifically inhibiting CLOCK:BMAL1-driven transcription. Its administration leads to decreased expression of circadian genes Per2, Cry1, and Dbp, and reduces H3K9/K14 acetylation at their promoters, suppressing circadian oscillation amplitudes. This makes SRT1720 an effective modulator of circadian gene expression and a potential tool in managing circadian rhythm disruptions.",
    "fdastatus": "Not approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/25232708",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.24747359.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      344,
      352
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      15
    ],
    "target": [
      29,
      39
    ],
    "effect": [
      88
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 78,
  "fields": {
    "gname": "Camptothecin",
    "smiles": "CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O",
    "linkname": "camptothecin",
    "molecula": "C₂₀H₁₆N₂O₄",
    "iupacname": "(19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo 11.8.0.0 2 , 11 .0 4 , 9 .0 15 , 20 11.8.0.0  2  ,  11  .0  4  ,  9  .0  15  ,  20  henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione",
    "updphoto": "media/imgsrv_2_QYNKkp4.png",
    "description": "Camptothecin is a naturally occurring pyranoindolizinoquinoline alkaloid, originally isolated from the Chinese tree Camptotheca acuminata. Known primarily as a potent DNA Topoisomerase I inhibitor with strong antineoplastic activity, camptothecin also exerts an effect on circadian rhythms by modulating Bmal1 gene transcription. Experimental data show that it can lengthen the circadian period and alter clock-gene dynamics, making it a candidate “chronodisruptor” in circadian biology research. Its poor water solubility and lactone instability have prompted the development of more soluble analogs (e.g., topotecan, irinotecan).",
    "fdastatus": "Not approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/24360#section=InChI",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.22775.html",
    "drugbank": "https://go.drugbank.com/drugs/DB04690",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      349
    ],
    "classf": [
      7
    ],
    "mechanisms": [
      28
    ],
    "target": [
      29
    ],
    "effect": [
      87
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 79,
  "fields": {
    "gname": "Harmine",
    "smiles": "CC1=NC=CC2=C1NC3=C2C=CC(=C3)OC",
    "linkname": "harmine",
    "molecula": "C₁₃H₁₂N₂O",
    "iupacname": "7-methoxy-1-methyl-9H-pyrido 3 , 4 − 𝑏 3,4−bindole",
    "updphoto": "media/imgsrv_3_pNLgSG7.png",
    "description": "Harmine is a naturally occurring β-carboline alkaloid, traditionally isolated from Peganum harmala (Syrian rue) and found in other plants like Banisteriopsis caapi. Known for its monoamine oxidase inhibiting (MAOI) activity and potential psychoactive effects, harmine also modulates circadian rhythms by influencing Bmal1 gene expression. Experimental data show it lengthens the circadian period, indicating a chronobiotic effect through partial inhibition of Topoisomerase I and enhancement of RORα-mediated transcriptional regulation.",
    "fdastatus": "Not approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5280953",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4444445.html",
    "drugbank": "https://go.drugbank.com/drugs/DB07919",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      345,
      347
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      28
    ],
    "target": [
      29,
      40
    ],
    "effect": [
      85,
      86
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 80,
  "fields": {
    "gname": "Prasterone (DHEA)",
    "smiles": "CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)O)C",
    "linkname": "prasterone-dhea",
    "molecula": "C₁₉H₂₈O₂",
    "iupacname": "(3S,8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one",
    "updphoto": "media/imgsrv_4_BHYsDHe.png",
    "description": "Prasterone (commonly known as dehydroepiandrosterone or DHEA) is an endogenous steroid hormone produced predominantly by the adrenal glands in humans and is available as an over-the-counter dietary supplement in some regions. Acting as a prohormone for testosterone and estradiol, it exerts diverse endocrine effects and has shown promise in modulating circadian rhythms. Experimental data demonstrate that DHEA can shorten the intrinsic period (τ) of clock gene expression in cell cultures (e.g., U2OS cells and mouse embryonic fibroblasts) as well as in tissue explants (SCN, lung). In vivo, dietary administration of DHEA accelerates re-entrainment to advanced light–dark cycles, thereby reducing the effects of jet-lag. Its mechanism likely involves modulation of nuclear receptor pathways and interactions with circadian proteins, making prasterone a promising candidate chronobiotic for managing circadian misalignment.",
    "fdastatus": "Approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5881#section=Crystal-Structures",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.5670.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01708",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117,
      342,
      343,
      348
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      29
    ],
    "target": [
      36
    ],
    "effect": [
      84
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 81,
  "fields": {
    "gname": "T0901317",
    "smiles": "C1=CC=C(C=C1)S(=O)(=O)N(CC(F)(F)F)C2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O",
    "linkname": "t0901317",
    "molecula": "C₁₇H₁₂F₉NO₃S",
    "iupacname": "N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-N-(2,2,2-trifluoroethyl)benzenesulfonamide",
    "updphoto": "media/imgsrv_5.png",
    "description": "T0901317 is a potent synthetic agonist of the liver X receptors LXRα and LXRβ. LXRs are nuclear receptors that regulate the transcription of genes involved in cholesterol homeostasis, lipid metabolism, and inflammatory responses. By activating these receptors, T0901317 alters metabolic pathways and has been widely used as a tool compound to study LXR-mediated effects. Recent research suggests that modulation of nuclear receptor activity can impact circadian gene expression, positioning T0901317 as a potential chronotherapeutic agent that may indirectly influence circadian rhythms. Ribeiro, R.F., Cavadas, C. and Silva, M.M.C., 2021. Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases. Drug Discovery Today, 26(7), pp.1620-1641.",
    "fdastatus": "Not approved",
    "linkslists": "https://www.sciencedirect.com/science/article/abs/pii/S1359644621001525#b0330",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/447912",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.394870.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      80,
      334,
      335,
      350
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      30,
      31
    ],
    "target": [
      41
    ],
    "effect": [
      163
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 82,
  "fields": {
    "gname": "SR  1078",
    "smiles": "C1=CC(=CC=C1C(=O)NC2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O)C(F)(F)F",
    "linkname": "sr-1078",
    "molecula": "C₁₇H₁₀F₉NO₂",
    "iupacname": "N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide",
    "updphoto": "media/imgsrv_6_3YBLQSv.png",
    "description": "SR 1078 is a synthetic agonist of the retinoic acid receptor-related orphan receptors RORα and RORγ, key regulators of genes involved in circadian rhythm and metabolic processes. By binding to these nuclear receptors, SR 1078 influences the expression of various circadian and metabolic target genes, positioning it as a potential chronomodulator with applications in studying circadian mechanisms and possibly correcting circadian rhythm disruptions.\r\n\r\nWang, Y., Kumar, N., Nuhant, P., Cameron, M.D., Istrate, M.A., Roush, W.R., Griffin, P.R. and Burris, T.P., 2010. Identification of SR1078, a synthetic agonist for the orphan nuclear receptors RORα and RORγ. ACS chemical biology, 5(11), pp.1029-1034.\r\n\r\nRibeiro, R.F., Cavadas, C. and Silva, M.M.C., 2021. Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases. Drug Discovery Today, 26(7), pp.1620-1641.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubs.acs.org/doi/abs/10.1021/cb100223d",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/17980288",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.16472645.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      329,
      351
    ],
    "classf": [
      8
    ],
    "mechanisms": [
      32
    ],
    "target": [
      40
    ],
    "effect": [
      81
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 83,
  "fields": {
    "gname": "SR3335 (ML-176)",
    "smiles": "C1=CSC(=C1)S(=O)(=O)NC2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O",
    "linkname": "SR3335-ML-176",
    "molecula": "C₁₃H₉F₆NO₃S₂",
    "iupacname": "N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]thiophene-2-sulfonamide",
    "updphoto": "media/imgsrv_7_m9KVdQl.png",
    "description": "SR 3335 is a synthetic compound acting as an inverse agonist of RORα, a nuclear receptor critically involved in controlling circadian and metabolic genes. By inhibiting RORα activity, SR 3335 modulates the expression of various clock‐controlled genes, making it a valuable tool both for probing circadian mechanisms in research and for potential therapeutic strategies in disorders where RORα regulation is dysregulated.\r\n\r\nKumar, N., Kojetin, D.J., Solt, L.A., Kumar, K.G., Nuhant, P., Duckett, D.R., Cameron, M.D., Butler, A.A., Roush, W.R., Griffin, P.R. and Burris, T.P., 2011. Identification of SR3335 (ML-176): a synthetic RORα selective inverse agonist. ACS chemical biology, 6(3), pp.218-222.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubs.acs.org/doi/abs/10.1021/cb1002762",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/2360837",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.1763470.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      326
    ],
    "classf": [
      8
    ],
    "mechanisms": [
      32
    ],
    "target": [
      40
    ],
    "effect": [
      80
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 84,
  "fields": {
    "gname": "SR1001",
    "smiles": "CC1=C(SC(=N1)NC(=O)C)S(=O)(=O)NC2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O",
    "linkname": "sr1001",
    "molecula": "C₁₅H₁₃F₆N₃O₄S₂",
    "iupacname": "N-[5-[[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]sulfamoyl]-4-methyl-1,3-thiazol-2-yl]acetamide",
    "updphoto": "media/imgsrv_8_IqQ3KzL.png",
    "description": "SR1001 is a synthetic molecule acting as an inverse agonist of both RORα and RORγ. By blocking the transcriptional activities of these nuclear receptors, SR1001 reduces expression of genes governed by RORα/γ, thereby modulating multiple circadian and immune/metabolic processes. It has been studied to clarify ROR-mediated regulation in the clock and holds potential for treating clock-linked inflammatory and metabolic disorders. Ribeiro, R.F., Cavadas, C. and Silva, M.M.C., 2021. Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases. Drug Discovery Today, 26(7), pp.1620-1641.",
    "fdastatus": "Not approved",
    "linkslists": "https://www.sciencedirect.com/science/article/abs/pii/S1359644621001525#b0365",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/44241473",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.29342145.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      323,
      325
    ],
    "classf": [
      8
    ],
    "mechanisms": [
      32
    ],
    "target": [
      40
    ],
    "effect": [
      79
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 85,
  "fields": {
    "gname": "SR2211",
    "smiles": "C1CN(CCN1CC2=CC=C(C=C2)C3=C(C=C(C=C3)C(C(F)(F)F)(C(F)(F)F)O)F)CC4=CC=NC=C4",
    "linkname": "sr2211",
    "molecula": "C₂₆H₂₄F₇N₃O",
    "iupacname": "1,1,1,3,3,3-hexafluoro-2-[3-fluoro-4-[4-[[4-(pyridin-4-ylmethyl)piperazin-1-yl]methyl]phenyl]phenyl]propan-2-ol",
    "updphoto": "media/imgsrv_9_3XPoAIa.png",
    "description": "SR2211 is a synthetic small molecule acting primarily as an inverse agonist of RORγt (the thymus-specific isoform of RORγ). By inhibiting RORγt’s transcriptional activity, SR2211 suppresses genes under RORγt control, impacting T-helper 17 (Th17) cell differentiation and function (and thereby influencing inflammatory/circadian/metabolic pathways). It has been used extensively as a research tool to examine RORγ biology and as a lead compound for potential treatments of inflammatory and immune-related disorders (e.g., autoimmune diseases). \r\n\r\nKumar, N., Lyda, B., Chang, M.R., Lauer, J.L., Solt, L.A., Burris, T.P., Kamenecka, T.M. and Griffin, P.R., 2012. Identification of SR2211: a potent synthetic RORγ-selective modulator. ACS chemical biology, 7(4), pp.672-677.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubmed.ncbi.nlm.nih.gov/22292739/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/51035449",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.28660681.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      322
    ],
    "classf": [
      8
    ],
    "mechanisms": [
      32
    ],
    "target": [
      40
    ],
    "effect": [
      78
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 86,
  "fields": {
    "gname": "SR1555",
    "smiles": "CC(=O)N1CCN(CC1)CC2=CC=C(C=C2)C3=CC=C(C=C3)C(C(F)(F)F)(C(F)(F)F)O",
    "linkname": "sr1555",
    "molecula": "C₂₂H₂₂F₆N₂O₂",
    "iupacname": "1-[4-[[4-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]phenyl]methyl]piperazin-1-yl]ethanone",
    "updphoto": "media/imgsrv_10_uBDshN8.png",
    "description": "SR1555 is a synthetic small molecule acting as a modulator of ROR nuclear receptors. By targeting these transcription factors (especially RORγ), SR1555 influences the expression of ROR-controlled genes affecting circadian rhythms, immune/inflammatory responses, and metabolic homeostasis. It is commonly used as a research probe to interrogate ROR function and is under exploration for potential use in inflammatory, metabolic, and circadian-related disorders.\r\n\r\nXiang, K., Xu, Z., Hu, Y.Q., He, Y.S., Wu, G.C., Li, T.Y., Wang, X.R., Ding, L.H., Zhang, Q., Tao, S.S. and Ye, D.Q., 2021. Circadian clock genes as promising therapeutic targets for autoimmune diseases. Autoimmunity Reviews, 20(8), p.102866.\r\n\r\nSolt, L.A., Kumar, N., He, Y., Kamenecka, T.M., Griffin, P.R. and Burris, T.P., 2012. Identification of a selective RORγ ligand that suppresses TH17 cells and stimulates T regulatory cells. ACS chemical biology, 7(9), pp.1515-1519.\r\n\r\nChang, M.R., He, Y., Khan, T.M., Kuruvilla, D.S., Garcia-Ordonez, R., Corzo, C.A., Unger, T.J., White, D.W., Khan, S., Lin, L. and Cameron, M.D., 2015. Antiobesity effect of a small molecule repressor of RORγ. Molecular Pharmacology, 88(1), pp.48-56.",
    "fdastatus": "Not approved",
    "linkslists": "https://faseb.onlinelibrary.wiley.com/doi/10.1096/fasebj.29.1_supplement.lb479",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/71470549",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.34227648.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      317,
      318,
      320
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      32
    ],
    "target": [
      40
    ],
    "effect": [
      76,
      77
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 87,
  "fields": {
    "gname": "ML209",
    "smiles": "CC1CC(CN(C1)C(=O)CC(C2=CC3=C(C=C2)OCO3)C4=C(C=C(C=C4OC)OC)O)C",
    "linkname": "ml-209",
    "molecula": "C₂₅H₃₁NO₆",
    "iupacname": "3-(1,3-benzodioxol-5-yl)-1-[(3S,5R)-3,5-dimethylpiperidin-1-yl]-3-(2-hydroxy-4,6-dimethoxyphenyl)propan-1-one",
    "updphoto": "media/imgsrv_11_32S0Ibe.png",
    "description": "ML 209 is a synthetic small‐molecule antagonist of RORγt, discovered through a cell-based high-throughput screen targeting RORγt transcriptional activity. It potently blocks RORγt function at submicromolar concentrations, suppressing Th17 (interleukin 17–producing T-helper) cell differentiation. In contrast, it shows little effect on RORα- or VP16-driven gene expression, indicating good selectivity for the RORγt isoform. By reducing Th17 cell polarization, (±)-ML 209 serves as a valuable research probe for immunological disorders wherein IL-17 or Th17 cells play a pathogenic role.\r\nHuang, W., Wang, H., Johnson, R.L., Huang, R., Englund, E.E., Huh, J. and Littman, D.R., 2013. Identification of potent and selective RORγ antagonists. Probe Reports from the NIH Molecular Libraries Program",
    "fdastatus": "Not approved",
    "linkslists": "https://www.ncbi.nlm.nih.gov/books/NBK133441/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/53385590",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      316
    ],
    "classf": [
      8
    ],
    "mechanisms": [
      32
    ],
    "target": [
      40
    ],
    "effect": [
      75
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 88,
  "fields": {
    "gname": "TMP778",
    "smiles": "CC1=CC(=C(C=C1)C(C2=CC=CC=C2)NC(=O)CC3=CC4=C(C=C3)OC(=C4)C(C5=C(ON=C5C)C)O)C",
    "linkname": "tmp778",
    "molecula": "C₃₁H₃₀N₂O₄",
    "iupacname": "2-[2-[(S)-(3,5-dimethyl-1,2-oxazol-4-yl)-hydroxymethyl]-1-benzofuran-5-yl]-N-[(S)-(2,4-dimethylphenyl)-phenylmethyl]acetamide",
    "updphoto": "media/imgsrv_12_DT84Mo7.png",
    "description": "TMP778 is a small-molecule inverse agonist that potently and selectively binds the ligand-binding domain of RORγt, blocking this nuclear receptor’s ability to promote transcription of Th17-associated genes (e.g., IL-17A, IL-17F, IL-22). In contrast to many broad-spectrum immunosuppressants, TMP778 specifically antagonizes RORγt, thus reducing pathogenic Th17 (CD4⁺) and Tc17 (CD8⁺) cells and diminishing production of IL-17–related cytokines. It has shown efficacy in preclinical models of cutaneous inflammation such as imiquimod‑induced (IMQ‑induced) psoriasis-like skin disease, and it inhibits IL-17 secretion in patient-derived psoriatic T cells ex vivo. \r\nLyu, C., Bing, S.J., Wandu, W.S., Xu, B., Shi, G., Hinshaw, S.J., Lobera, M., Caspi, R.R., Lu, L., Yang, J. and Gery, I., 2018. TMP778, a selective inhibitor of RORγt, suppresses experimental autoimmune uveitis development, but affects both Th17 and Th1 cell populations. European journal of immunology, 48(11), pp.1810-1816.\r\n\r\nVenken, K., Jacques, P., Mortier, C., Labadia, M.E., Decruy, T., Coudenys, J., Hoyt, K., Wayne, A.L., Hughes, R., Turner, M. and Van Gassen, S., 2019. RORγt inhibition selectively targets IL-17 producing iNKT and γδ-T cells enriched in Spondyloarthritis patients. Nature communications, 10(1), p.9.",
    "fdastatus": "Not approved",
    "linkslists": "https://onlinelibrary.wiley.com/doi/full/10.1002/eji.201747029",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/71247311",
    "chemspider": null,
    "drugbank": null,
    "chebi": "https://thesaurus.cancer.gov/ncitbrowser/ConceptReport.jsp?dictionary=ChEBI&code=CHEBI:230502&ns=chebi_ontology",
    "uniprot": null,
    "kegg": null,
    "selleckchem": "https://www.selleckchem.com/products/tmp778.html",
    "articles": [
      300,
      301
    ],
    "classf": [
      8
    ],
    "mechanisms": [
      32
    ],
    "target": [
      40
    ],
    "effect": [
      151
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 89,
  "fields": {
    "gname": "GSK805",
    "smiles": "CCS(=O)(=O)C1=CC=C(C=C1)CC(=O)NC2=CC(=C(C(=C2)Cl)C3=CC=CC=C3OC(F)(F)F)Cl",
    "linkname": "gsk805",
    "molecula": "C₂₃H₁₈Cl₂F₃NO₄S",
    "iupacname": "N-[3,5-dichloro-4-[2-(trifluoromethoxy)phenyl]phenyl]-2-(4-ethylsulfonylphenyl)acetamide",
    "updphoto": "media/imgsrv_13_lcc3gM4.png",
    "description": "GSK805 is a potent, orally active small molecule that acts primarily as an inverse agonist of RORγt. By binding to the RORγ ligand-binding domain, GSK805 inhibits Th17 cell differentiation and suppresses IL-17 production in both in vitro and in vivo models. Its oral bioavailability and effectiveness in reducing Th17-mediated inflammatory responses make it a strong candidate for therapeutic applications in immune-mediated conditions (e.g., multiple sclerosis, psoriasis).",
    "fdastatus": "Not approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/71285927",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.35308218.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      299
    ],
    "classf": [
      8,
      6
    ],
    "mechanisms": [
      32
    ],
    "target": [
      40
    ],
    "effect": [
      72
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 90,
  "fields": {
    "gname": "KL101",
    "smiles": "CC1=CC(=C(C=C1)N2C(=C3CSCC3=N2)NC(=O)C4=CC(=C(C=C4)C)C)C",
    "linkname": "kl101",
    "molecula": "C₂₂H₂₃N₃OS",
    "iupacname": "N-[2-(2,4-dimethylphenyl)-4,6-dihydrothieno[3,4-c]pyrazol-3-yl]-3,4-dimethylbenzamide",
    "updphoto": "media/imgsrv_14_94ermo9.png",
    "description": "KL101 is a small-molecule modulator that selectively stabilizes CRY1, a key component of the circadian clock. Unlike KL001, which stabilizes both CRY1 and CRY2, KL101 is highly selective for CRY1 and requires its C-terminal region for its effects. By enhancing CRY1 stability, KL101 lengthens the circadian period and disrupts CLOCK:BMAL1-driven transcription, leading to phase shifts in cellular rhythms. It is a valuable tool for studying cryptochrome function and circadian regulation in mammals.\r\n\r\nMiller, S., Son, Y.L., Aikawa, Y., Makino, E., Nagai, Y., Srivastava, A., Oshima, T., Sugiyama, A., Hara, A., Abe, K. and Hirata, K., 2020. Isoform-selective regulation of mammalian cryptochromes. Nature chemical biology, 16(6), pp.676-685.",
    "fdastatus": "Not approved",
    "linkslists": "https://academic.oup.com/jb/article-abstract/171/5/501/6370884",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/4626654#section=2D-Structure",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.3817268.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      298
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      33
    ],
    "target": [
      42
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 91,
  "fields": {
    "gname": "KL201",
    "smiles": "C1CCC2=C(C1)C3=C(N=CN=C3S2)NC(=O)C4=CC=CC=C4Br",
    "linkname": "kl201",
    "molecula": "C₁₇H₁₄BrN₃OS",
    "iupacname": "2-bromo-N-(5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-yl)benzamide",
    "updphoto": "media/imgsrv_15_crtl1SW.png",
    "description": "KL201 is a thienopyrimidine-based small molecule that selectively stabilizes CRY1, a key component of the circadian clock, while showing minimal effects on CRY2. KL201 achieves its effects by interfering with FBXL3, a subunit of the E3 ubiquitin ligase complex that targets CRY1 for degradation. By prolonging CRY1 stability, KL201 lengthens the circadian period in mammalian cells and tissues.",
    "fdastatus": "Not approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/1330855#section=2D-Structure",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.1115283.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      297
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      33
    ],
    "target": [
      42
    ],
    "effect": [
      71
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 92,
  "fields": {
    "gname": "TH301",
    "smiles": "TH301",
    "linkname": "th301",
    "molecula": "C₂₄H₂₄ClN₃O₄S",
    "iupacname": "1-(4-chlorophenyl)-N-[2-(4-methoxyphenyl)-5,5-dioxo-4,6-dihydrothieno[3,4-c]pyrazol-3-yl]cyclopentane-1-carboxamide",
    "updphoto": "media/imgsrv_16_R4bCXtJ.png",
    "description": "TH301 is a thienopyrazole-based small molecule that selectively stabilizes CRY2, a key component of the mammalian circadian clock. Unlike KL201 and KL101 (which target CRY1), TH301 acts specifically on CRY2, preventing its degradation and influencing circadian rhythm regulation. This isoform selectivity provides a unique tool for studying differential roles of CRY1 and CRY2.",
    "fdastatus": "Not approved",
    "linkslists": "https://www.nature.com/articles/s41589-020-0505-1",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/4653191#section=2D-Structure",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      296
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      34
    ],
    "target": [
      27
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 93,
  "fields": {
    "gname": "PF-670462",
    "smiles": "C1CCC(CC1)N2C=NC(=C2C3=NC(=NC=C3)N)C4=CC=C(C=C4)F.Cl.Cl",
    "linkname": "pf-670462",
    "molecula": "C₁₉H₂₂Cl₂FN₅",
    "iupacname": "4-[3-cyclohexyl-5-(4-fluorophenyl)imidazol-4-yl]pyrimidin-2-amine; dihydrochloride",
    "updphoto": "media/imgsrv_17_VSmfLoV.png",
    "description": "PF-670462 (commonly referred to as PF-670462 dihydrochloride) is a selective CK1δ inhibitor with modest activity against CK1ε at higher doses. By inhibiting CK1δ-mediated phosphorylation of PER proteins, PF-670462 stabilizes nuclear PER, prolongs negative feedback in the molecular clock, and lengthens the circadian period in various model systems (e.g., SCN slices, fibroblasts). It has been shown to phase-delay or entrain locomotor activity rhythms in rodents and can rescue or enhance damped/arrhythmic circadian states, making it a potent tool compound for circadian research and a candidate for chronotherapeutic applications.\r\n\r\nMeng, Q.J., Maywood, E.S., Bechtold, D.A., Lu, W.Q., Li, J., Gibbs, J.E., Dupré, S.M., Chesham, J.E., Rajamohan, F., Knafels, J. and Sneed, B., 2010. Entrainment of disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymes. Proceedings of the National Academy of Sciences, 107(34), pp.15240-15245.",
    "fdastatus": "Not approved",
    "linkslists": "https://www.pnas.org/doi/abs/10.1073/pnas.1005101107",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/51049607#section=2D-Structure",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.24606003.html",
    "drugbank": null,
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:87284",
    "uniprot": null,
    "kegg": null,
    "selleckchem": "https://www.selleckchem.com/products/pf-670462.html",
    "articles": [
      295
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      35
    ],
    "target": [
      43
    ],
    "effect": [
      148
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 94,
  "fields": {
    "gname": "M47",
    "smiles": "CC1=C(OC2=C1C3=C(C=C2)OC(CC3=O)(C)C4=CC=C(C=C4)Cl)C(=O)N5CCC6=CC=CC=C65",
    "linkname": "m47",
    "molecula": "C₂₈H₂₂ClNO₄",
    "iupacname": "11-(4-chlorophenyl)-4-(2,3-dihydro-1H-indole-1-carbonyl)-3,11-dimethyl-5,10-dioxatricyclo(7.4.0.0,2,6)trideca-1,3,6,8-tetraen-13-one",
    "updphoto": "media/imgsrv_18.png",
    "description": "M47 was discovered via structure-based virtual screening for compounds that bind the “FAD-binding” pocket of CRY1. Experimental analyses show that it selectively decreases CRY1 half-life (via increased polyubiquitination and proteasomal degradation) while sparing CRY2. By reducing nuclear CRY1, M47 lengthens the cellular circadian period in U2OS reporter cells, increases Per2 expression, and amplifies apoptosis in p53-null fibroblasts when combined with oxaliplatin. Systemic administration of M47 to p53−/− mice extends their median survival by ~25%, suggesting M47’s potential utility as a clock-manipulating adjuvant in certain cancer contexts where CRY1 modulation can enhance therapeutic efficacy.\r\n\r\nGul, S., Akyel, Y.K., Gul, Z.M., Isin, S., Ozcan, O., Korkmaz, T., Selvi, S., Danis, I., Ipek, O.S., Aygenli, F. and Taskin, A.C., 2022. Discovery of a small molecule that selectively destabilizes Cryptochrome 1 and enhances life span in p53 knockout mice. Nature Communications, 13(1), p.6742.",
    "fdastatus": "Not approved",
    "linkslists": "https://www.nature.com/articles/s41467-022-34582-1",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/23601714",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      294
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      36
    ],
    "target": [
      28
    ],
    "effect": [
      145
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 95,
  "fields": {
    "gname": "SR8278",
    "smiles": "CCOC(=O)C1CC2=CC=CC=C2CN1C(=O)C3=CC=C(S3)SC",
    "linkname": "sr8278",
    "molecula": "C₁₈H₁₉NO₃S₂",
    "iupacname": "ethyl 2-(5-methylsulfanylthiophene-2-carbonyl)-3,4-dihydro-1H-isoquinoline-3-carboxylate",
    "updphoto": "media/imgsrv_19_BBN2Sux.png",
    "description": "SR8278 is a synthetic small molecule discovered as an antagonist of REV-ERB. By inhibiting REV-ERB’s repressive function on BMAL1 transcription, SR8278 upregulates clock-control gene (CCG) expression and enhances CLOCK–BMAL1–driven transcription. It has been applied in various studies to probe the circadian clock’s physiology and has demonstrated protective or modulatory roles in contexts of DNA damage repair, cellular metabolism, and proliferation.\r\n\r\nKojetin, D., Wang, Y., Kamenecka, T.M. and Burris, T.P., 2011. Identification of SR8278, a synthetic antagonist of the nuclear heme receptor REV-ERB. ACS chemical biology, 6(2), pp.131-134.\r\n\r\nAnabtawi, N., Cvammen, W. and Kemp, M.G., 2021. Pharmacological inhibition of cryptochrome and REV-ERB promotes DNA repair and cell cycle arrest in cisplatin-treated human cells. Scientific Reports, 11(1), p.17997.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubs.acs.org/doi/abs/10.1021/cb1002575",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/53393127#section=2D-Structure",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.28189717.html",
    "drugbank": "https://go.drugbank.com/unearth/q?searcher=drugs&query=SR8278&button=",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": "https://www.selleckchem.com/products/sr-8278.html",
    "articles": [
      292,
      293
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      37,
      38
    ],
    "target": [
      29
    ],
    "effect": [
      142
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 96,
  "fields": {
    "gname": "Methohexital",
    "smiles": "CCC#CC(C)C1(C(=O)NC(=O)N(C1=O)C)CC=C",
    "linkname": "methohexital",
    "molecula": "C17H21NO 4",
    "iupacname": "[(1R,2S,4S,5S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate",
    "updphoto": "media/imgsrv_71.png",
    "description": "While specific circadian effects of methohexital are not well-documented, its use as an anesthetic can indirectly affect circadian rhythms by altering sleep patterns. Methohexital is known for its rapid onset and short duration of action, which might minimize long-term disruptions to the circadian cycle compared to longer-acting anesthetics",
    "fdastatus": "Approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/9034",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.8683.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00474",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:102216",
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      291
    ],
    "classf": [
      7
    ],
    "mechanisms": [
      16,
      39,
      23
    ],
    "target": [
      35
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 97,
  "fields": {
    "gname": "Geldanamycin",
    "smiles": "CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)OC)C)OC)OC(=O)N)C)C)O)OC",
    "linkname": "geldanamycin",
    "molecula": "C29H40N2O9",
    "iupacname": "[(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate",
    "updphoto": "media/imgsrv_72.png",
    "description": "Geldanamycin is a 1,4-benzoquinone ansamycin antitumor antibiotic that inhibits the function of Hsp90 (Heat Shock Protein 90) by binding to the unusual ADP/ATP-binding pocket of the protein. HSP90 client proteins play important roles in the regulation of the cell cycle, cell growth, cell survival, apoptosis, angiogenesis and oncogenesis. Geldanamycin, an HSP90 inhibitor, has been shown to affect circadian rhythms, particularly in plant systems like *Arabidopsis thaliana*. Research indicates that geldanamycin treatment can disrupt the normal functioning of the circadian clock by lengthening the circadian period. This effect is linked to the role of HSP90 in stabilizing key proteins involved in the circadian system, such as the F-box protein ZEITLUPE (ZTL) and the transcription factor BMAL1 in mammals.\r\n\r\nDavis, A.M., et al. 2018. HSP90 contributes to entrainment of the Arabidopsis circadian clock via  the Morning Loop Genetics, 210(4), pp.1383-1390.",
    "fdastatus": "Not approved",
    "linkslists": "https://www.pnas.org/doi/abs/10.1073/pnas.1110406108",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5288382",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.10272739.html",
    "drugbank": "https://go.drugbank.com/drugs/DB02424",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5292",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/C11222",
    "selleckchem": "https://www.selleckchem.com/products/geldanamycin.html",
    "articles": [
      289
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      40
    ],
    "target": [
      29
    ],
    "effect": [
      70
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 98,
  "fields": {
    "gname": "Herbimycin",
    "smiles": "CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C=C(C1OC)C2=O)C)OC)OC(=O)N)C)C)OC)OC",
    "linkname": "herbimycin",
    "molecula": "C30H42N2O9",
    "iupacname": "[(4E,6Z,8S,9S,10E,12S,13R,14S,16S,17R)-8,13,14,17-tetramethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate",
    "updphoto": "media/imgsrv_73.png",
    "description": "Herbimycin A (PLANT CHRONOBIOTIC)_, a benzoquinone ansamycin antibiotic, has been identified as a modulator of cellular circadian rhythms through its dual inhibitory effects on Src family kinases and heat shock protein 90 (Hsp90). This compound disrupts the molecular clock machinery by interfering with key signaling pathways that regulate circadian oscillations, including the destabilization of client proteins dependent on Hsp90 chaperone activity 12. Studies demonstrate that Herbimycin A alters circadian parameters such as rhythm amplitude and dampening in fibroblast cells, with time- and dose-dependent effects observed across different cell types 11. In the context of the retina, circadian autophagy—a process critical for photoreceptor and retinal pigment epithelium (RPE) homeostasis—exhibits bimodal activation patterns influenced by light-dark cycles and phagocytosis of shed outer segments. While Herbimycin A was used experimentally to investigate autophagy regulation in RPE cells, its broader impact on circadian-driven cellular processes suggests potential cross-talk between stress-response pathways and the circadian clock.\r\n\r\nFurther research highlights Herbimycin A’s role in modulating redox-sensitive pathways, which are intrinsically linked to circadian clock function. For instance, oxidative stress responses, governed by reactive oxygen species (ROS) and antioxidant enzymes, exhibit diurnal variations under clock gene regulation. By inhibiting Hsp90, Herbimycin A impairs the stability of client proteins involved in ROS homeostasis, thereby indirectly influencing circadian outputs. Lichen-derived secondary metabolites, such as usnic acid, share similar mechanistic profiles with Herbimycin A, underscoring the broader relevance of natural compounds in circadian modulation.\r\n\r\nThese findings position Herbimycin A as a valuable tool for dissecting the interplay between cellular stress responses and circadian timing. Future studies could explore its therapeutic potential in circadian-related disorders, such as metabolic syndromes or neurodegenerative diseases, where clock dysregulation is implicated. However, challenges such as hepatotoxicity (associated with its quinone moiety) and off-target effects necessitate the development of derivatives with improved specificity.\r\n\r\nDavis, M.A. and Carbott, D.E., 1999. Herbimycin A and geldanamycin inhibit okadaic acid-induced apoptosis and p38 activation in NRK-52E renal epithelial cells. Toxicology and applied pharmacology, 161(1), pp.59-74.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/5311102#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5311102",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4470632.html",
    "drugbank": null,
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5674",
    "uniprot": null,
    "kegg": "https://www.genome.jp/dbget-bin/www_bget?C11225",
    "selleckchem": null,
    "articles": [
      289,
      290
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      15
    ],
    "target": [
      29
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 99,
  "fields": {
    "gname": "Rifaximin",
    "smiles": "CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C",
    "linkname": "Rifaximin",
    "molecula": "C43H51N3O11",
    "iupacname": "[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,36-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22,30-octamethyl-6,23-dioxo-8,37-dioxa-24,27,33-triazahexacyclo[23.10.1.14,7.05,35.026,34.027,32]heptatriaconta-1(35),2,4,9,19,21,25(36),26(34),28,30,32-und",
    "updphoto": "media/imgsrv_74.png",
    "description": "Rifaximin has been shown to have protective effects against disruptions in circadian rhythms, particularly in relation to cognitive impairment and gut health. Research indicates that rifaximin can mitigate the negative impacts of circadian rhythm disruption (CRD) by preventing gut barrier damage and reducing systemic inflammation. This is particularly relevant as circadian disruptions can lead to cognitive deficits and alterations in gut microbiota composition /In studies involving animal models, rifaximin has been observed to protect against cognitive impairment induced by CRD, suggesting its potential role in maintaining cognitive function during periods of circadian disruption. \r\n\r\nMeng, D., Yang, M., Hu, L., Liu, T., Zhang, H., Sun, X., Wang, X., Chen, Y.U., Jin, Y.U. and Liu, R., 2022. Rifaximin protects against circadian rhythm disruption–induced cognitive impairment through preventing gut barrier damage and neuroinflammation. Journal of neurochemistry, 163(5), pp.406-418.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/6436173#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/6436173",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.10482302.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01220",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:75246",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D02554",
    "selleckchem": "https://www.selleckchem.com/products/Rifaximin(Xifaxan).html",
    "articles": [
      288
    ],
    "classf": [
      8,
      4,
      5
    ],
    "mechanisms": [
      3
    ],
    "target": [
      44
    ],
    "effect": [
      69
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 100,
  "fields": {
    "gname": "Lincomycin",
    "smiles": "CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)O",
    "linkname": "lincomycin",
    "molecula": "C18H34N2O6S",
    "iupacname": "(2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide",
    "updphoto": "media/imgsrv_75.png",
    "description": "Lincomycin, an antibiotic that inhibits protein synthesis in chloroplasts, has been shown to affect circadian rhythms, particularly in plants. Research indicates that lincomycin has a dose-dependent effect on the amplitude of circadian rhythms related to photosynthesis in species like *Marchantia polymorpha and Arabidopsis.\r\n1. Amplitude Reduction: Lincomycin treatment leads to a reduction in the amplitude of circadian rhythms associated with photosynthetic processes. Specifically, higher concentrations of lincomycin resulted in decreased circadian amplitude of the estimated rate of photosynthetic electron transport (ETR) and non-photochemical quenching (NPQ) in M. polymorpha .\r\n2. Circadian Period Length: In Arabidopsis, lincomycin has been shown to influence circadian period length, particularly under conditions of iron deficiency. The treatment appears to interact with the plant's circadian mechanisms, potentially altering the synchronization of biological clocks.\r\n\r\nNorflurazon or lincomycin alone caused in arabidopsis a long circadian period. However, the degree of lengthening was less than with Fe deficiency alone",
    "fdastatus": "not approved",
    "linkslists": "https://www.google.com/search?q=Lincomycin+affects+circadian+clock&rlz=1C1DVJR_enRU881RU881&oq=Lincomycin+affects+circadian+clock&gs_lcrp=EgZjaHJvbWUyCwgAEEUYChg5GKABMgkIARAhGAoYoAEyBwgCECEYjwIyBwgDEC",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/3000540",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.2272112.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01627",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6472",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D00223",
    "selleckchem": "https://www.selleckchem.com/products/Lincomycin-hydrochloride(Lincocin).html",
    "articles": [
      287
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      16
    ],
    "target": [
      45
    ],
    "effect": [
      68
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 101,
  "fields": {
    "gname": "Clarithromycin",
    "smiles": "CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)O)(C)O",
    "linkname": "clarithromycin",
    "molecula": "C38H69NO13",
    "iupacname": "(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione",
    "updphoto": "media/imgsrv_76.png",
    "description": "Clarithromycin, a macrolide antibiotic, can have circadian effects, impacting sleep and alertness. It has been shown to reduce sleepiness in some individuals, particularly those with hypersomnolence related to GABA-A receptors, possibly by altering gastrointestinal microbiota. This improvement could be related to its potential effects on central nervous system excitability or alterations in the gut microbiome, which might indirectly influence circadian rhythms.\r\nMechanism of Action: Clarithromycin primarily acts as an antibiotic by inhibiting bacterial protein synthesis. It does not have a known direct mechanism of action on the circadian clock.\r\nTrotti, L.M., Saini, P., Freeman, A.A., Bliwise, D.L., García, P.S., Jenkins, A. and Rye, D.B., 2014. Improvement in daytime sleepiness with clarithromycin in patients with GABA-related hypersomnia: clinical experience. Journal of psychopharmacology, 28(7), pp.697-702.",
    "fdastatus": "Approved",
    "linkslists": "https://journals.sagepub.com/doi/10.1177/0269881113515062",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/84029",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.10342604.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01211",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      286
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      41
    ],
    "target": [
      44
    ],
    "effect": [
      67
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 102,
  "fields": {
    "gname": "Sulfamethoxazole",
    "smiles": "CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N",
    "linkname": "sulfamethoxazole",
    "molecula": "C10H11N3O3S",
    "iupacname": "4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide",
    "updphoto": "media/imgsrv_77.png",
    "description": "Sulfamethoxazole (SMZ or SMX) is an antibiotic. It is used for bacterial infections such as urinary tract infections, bronchitis, and prostatitis and is effective against both gram negative and positive bacteria such as Escherichia coli and Listeria monocytogenes.\r\nAntibiotics have recently gained attention because they are emerging environmental pollutants with obesogenic properties. Drosophila melanogaster were exposed to sulfamethoxazole (SMX), a sulfonamide antibiotic, and the effects were measured on circadian rhythm (represented by the eclosion rhythm), lipid metabolism, and microbiota. Circadian rhythm disorder was considered due to its connection with lipid metabolism and microbiota in association with obesity. SMX decreased the proportion of adult flies that eclosed in the morning (AM adults) and increased the proportion of PM adults. Moreover, SMX increased the body weight of PM adults, indicating that SMX exposure caused dysrhythmia in eclosion together with obesity.",
    "fdastatus": "Approved",
    "linkslists": "https://pubs.acs.org/doi/abs/10.1021/acs.est.9b07889",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5329",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.5138.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01015",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=9332",
    "uniprot": null,
    "kegg": "https://www.genome.jp/dbget-bin/www_bget?dr:D00447",
    "selleckchem": "https://www.selleckchem.com/products/Sulfamethoxazole.html",
    "articles": [
      285
    ],
    "classf": [
      6
    ],
    "mechanisms": [
      26
    ],
    "target": [
      25,
      26,
      27,
      28,
      29
    ],
    "effect": [
      135
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 103,
  "fields": {
    "gname": "Sulfanilamide",
    "smiles": "C1=CC(=CC=C1N)S(=O)(=O)N",
    "linkname": "sulfanilamide",
    "molecula": "C6H8N2O2S",
    "iupacname": "4-aminobenzenesulfonamide",
    "updphoto": "media/imgsrv_18_fW3UCND.png",
    "description": "PLANT CHRONOBIOTIC. Sulfanilamide, an inhibitor of folate biosynthesis, delays flowering by repressing the expression of florigen FLOWERING LOCUS T (FT) in Arabidopsis thaliana. Transcriptome deep sequencing and quantitative polymerase chain reaction analyses showed that the expression of the circadian clock gene LUX ARRYTHMO/PHYTOCLOCK1 (LUX/PCL1) is altered by sulfanilamide treatment. Furthermore, in the lux nox mutant harboring loss of function in both LUX and its homolog BROTHER OF LUX ARRHYTHMO (BOA, also named NOX), the inhibitory effect of sulfanilamide treatment on FT expression was weak and the flowering time was similar to that of the wild type, suggesting that the circadian clock may contribute to the FT-mediated regulation of flowering by sulfanilamide. Sulfanilamide also delayed flowering time in arugula (Eruca sativa), suggesting that it is involved in the regulation of flowering across Brassicaceae. We propose that sulfanilamide is a novel modulator of flowering.",
    "fdastatus": "not approved",
    "linkslists": "https://academic.oup.com/pcp/article/63/5/649/6541824",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5333",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      284
    ],
    "classf": [
      6
    ],
    "mechanisms": [
      42
    ],
    "target": [
      46
    ],
    "effect": [
      66
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 104,
  "fields": {
    "gname": "Sulfasalazine",
    "smiles": "C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O",
    "linkname": "sulfasalazine",
    "molecula": "C18H14N4O5S",
    "iupacname": "2-hydroxy-5-[[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl]benzoic acid",
    "updphoto": "media/imgsrv_25.png",
    "description": "Regulation of BCRP expression by REV-ERBα was assessed using Rev-erbα-/- mice and AML12 and CT26 cells. Pharmacokinetic analysis was performed with Rev-erbα-/- and wild-type mice after sulfasalazine administration.\r\n\r\nit was found that the expression levels of BCRP mRNA and protein were downregulated in the liver and small intestine of Rev-erbα-dificient mice. In line with this, Rev-erbα ablation increased the systemic exposures of oral sulfasalazine.\r\n\r\nPositive regulation of BCRP expression and function by REV-ERBα was furtherly confirmed in AML12 and CT26 cells. Moreover, indirect regulation of Bcrp expression by REV-ERBα was potentially mediated by a negative transcription factor DEC2, which is a downstream target of REV-ERBα.\r\n\r\nIn conclusion, REV-ERBα positively regulates BCRP expression in mice, thereby affecting sulfasalazine pharmacokinetics.",
    "fdastatus": "Approved",
    "linkslists": "https://www.tandfonline.com/doi/abs/10.1080/00498254.2023.2200839",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5339",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.10481900.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00795",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      283
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      26
    ],
    "target": [
      47
    ],
    "effect": [
      65
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 105,
  "fields": {
    "gname": "Doxycycline",
    "smiles": "CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O",
    "linkname": "doxycycline",
    "molecula": "C22H24N2O8",
    "iupacname": "(4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide",
    "updphoto": "media/imgsrv_27.png",
    "description": "Early doxycycline treatment improves memory in fatal familial insomnia mice.\r\nDoxycycline restores normal circadian motor rhythmicity.\r\nDoxycycline reduces microglial activation in the hippocampus.\r\nDoxycycline does not reduce mutant prion protein aggregation or protease resistance.\r\nDoxycycline does not delay disease onset or prolong survival of the mice.\r\n\r\nLavigna, G., Masone, A., Bouybayoune, I., Bertani, I., Lucchetti, J., Gobbi, M., Porcu, L., Zordan, S., Rigamonti, M., Imeri, L. and Restelli, E., 2021. Doxycycline rescues recognition memory and circadian motor rhythmicity but does not prevent terminal disease in fatal familial insomnia mice. Neurobiology of Disease, 158, p.105455.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/54671203#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/54671203",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.10469369.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00254",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      282
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      205
    ],
    "target": [
      48
    ],
    "effect": [
      5,
      63,
      64
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 106,
  "fields": {
    "gname": "Rifampin",
    "smiles": "C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C",
    "linkname": "rifampin",
    "molecula": "C43H58N4O12",
    "iupacname": "[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-oc",
    "updphoto": "media/imgsrv_28.png",
    "description": "Rifampicin lengthened the circadian period under darkness in plants. Salicylic acid (SA) increased oscillatory robustness and shortened the period. The latter was attenuated by sucrose addition and was also gated, taking place during the first 3 h of the subjective day. Furthermore, the effect of SA on period length was dependent on light quality and genotype. Period lengthening or shortening by these chemicals was correlated to their inferred impact on photosynthetic electron transport activity and the redox state of plastoquinone (PQ). Based on these data and on previous publications on circadian effects that alter the redox state of PQ, we propose that the photosynthetic electron transport and the redox state of PQ participate in circadian periodicity. Moreover, coupling between chloroplast-derived signals and nuclear oscillations, as observed in our chemical and genetic assays, produces traits that are predicted by previous models.",
    "fdastatus": "Approved",
    "linkslists": "https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2020.00429/full",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/135398735",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.10468813.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01045",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      281
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      43
    ],
    "target": [
      49
    ],
    "effect": [
      60
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 107,
  "fields": {
    "gname": "Chloramphenicol",
    "smiles": "C1=CC(=CC=C1C(C(CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-]",
    "linkname": "chloramphenicol",
    "molecula": "C11H12Cl2N2O5",
    "iupacname": "2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide",
    "updphoto": "media/imgsrv_80.png",
    "description": "Chloramphenicol, an inhibitor of mitochondrial protein synthesis, shortened the period length of the circadian rhythm in the Timex strain of Neurospora crassa by 2 hours. Both the l(+) threo and d(−) threo optical isomers had the same effect on the period of the rhythm, whereas only the d(−) threo isomer significantly inhibited mitochondrial protein synthesis. Tetracycline, another inhibitor of mitochondrial protein synthesis, did not change the period of the circadian rhythm. The effect of chloramphenicol on the circadian rhythm is, therefore, presumably not directly related to inhibition of mitochondrial protein synthesis, suggesting that chloramphenicol has other effects.\r\n\r\nFrelinger, J.G., Motulsky, H. and Woodward, D.O., 1976. Effects of chloramphenicol on the circadian rhythm of Neurospora crassa. Plant Physiology, 58(4), pp.592-594.",
    "fdastatus": "Approved",
    "linkslists": "https://academic.oup.com/plphys/article/58/4/592/6075206",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5959",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.2625.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00477",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      280
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      44
    ],
    "target": [
      50
    ],
    "effect": [
      59
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 108,
  "fields": {
    "gname": "Metronidazole",
    "smiles": "CC1=NC=C(N1CCO)[N+](=O)[O-]",
    "linkname": "metronidazole",
    "molecula": "C6H9N3O3",
    "iupacname": "2-(2-methyl-5-nitroimidazol-1-yl)ethanol",
    "updphoto": "media/imgsrv_26.png",
    "description": "Metronidazole, an antibiotic, can influence circadian rhythms by affecting skeletal muscle metabolism and disrupting pineal gland function. It can lead to skeletal muscle atrophy and alter the expression of genes involved in the muscle's circadian clock and metabolism. Additionally, metronidazole can impair pineal photoreceptor cells, disrupting melatonin production and affecting retinal rod and cone sensitivity\r\n\r\nManickam, R., Oh, H.Y.P., Tan, C.K., Paramalingam, E. and Wahli, W., 2018. Metronidazole causes skeletal muscle atrophy and modulates muscle chronometabolism. International journal of molecular sciences, 19(8), p.2418.",
    "fdastatus": null,
    "linkslists": "https://www.researchgate.net/publication/378211528_Gut_microbiota_regulates_host_melatonin_production_through_epithelial_cell_MyD88",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/4173",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4029.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00916",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      279
    ],
    "classf": [
      5,
      7
    ],
    "mechanisms": [
      45
    ],
    "target": [
      44
    ],
    "effect": [
      127
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 109,
  "fields": {
    "gname": "Aripiprazole",
    "smiles": "C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl",
    "linkname": "aripiprazole",
    "molecula": "C23H27Cl2N3O2",
    "iupacname": "7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one",
    "updphoto": "media/imgsrv_81.png",
    "description": "Many patients with psychiatric conditions, such as bipolar disorder and major depressive disorder, frequently experience disruptions in their sleep–wake cycles. Several case studies and clinical trials have shown that the administration of aripiprazole, a commonly prescribed antipsychotic drug, alleviates the symptoms of circadian sleep disorders in these patients. This improvement may be attributed to the effects of aripiprazole on the circadian central clock, specifically the hypothalamic suprachiasmatic nucleus (SCN), which regulates various circadian physiological rhythms, including the sleep–wake cycle, in mammals. \r\n\r\nLi, R., Masuda, K., Ono, D., Kanbayashi, T., Hirano, A. and Sakurai, T., 2023. Aripiprazole disrupts cellular synchrony in the suprachiasmatic nucleus and enhances entrainment to environmental light–dark cycles in mice. Frontiers in Neuroscience, 17, p.1201137.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/60795#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/60795",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.54790.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01238",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      278
    ],
    "classf": [
      6
    ],
    "mechanisms": [
      46
    ],
    "target": [
      34
    ],
    "effect": [
      58
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 110,
  "fields": {
    "gname": "Quetiapine",
    "smiles": "C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42",
    "linkname": "quetiapine",
    "molecula": "C21H25N3O2S",
    "iupacname": "2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol",
    "updphoto": "media/imgsrv_40.png",
    "description": "Quetiapine has been shown to improve sleep quality and duration in both healthy volunteers and patients with bipolar depression. It increases sleep efficiency and can delay the final wake time.\r\nCircadian Rhythm: While quetiapine does not significantly delay the circadian rhythm like lithium, it can advance the acrophase (the peak time of a circadian rhythm) compared to lithium in bipolar depression patients2. However, it does not seem to disrupt the circadian rhythm in the same way as some other antipsychotics.\r\nCircadian Gene Expression: There is evidence suggesting that quetiapine may affect the expression of clock genes (e.g., Per1, Per2, Bmal1), which are crucial for maintaining the circadian rhythm. \r\n\r\nCaruso, V., Geoffroy, P.A., Alfì, G. et al. Effects of Mood Stabilizers on Sleep and Circadian Rhythms: A Systematic Review. Curr Sleep Medicine Rep 10, 329–357 (2024). https://doi.org/10.1007/s40675-024-00298-52. doi: 10.1177/0269881115626336.",
    "fdastatus": "Approved",
    "linkslists": "https://pubmed.ncbi.nlm.nih.gov/26869012/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5002",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4827.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01224",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      276,
      277
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      15,
      28
    ],
    "target": [
      25,
      26,
      29
    ],
    "effect": [
      57
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 111,
  "fields": {
    "gname": "Haloperidol",
    "smiles": "C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F",
    "linkname": "haloperidol",
    "molecula": "C21H23ClFNO2",
    "iupacname": "4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one",
    "updphoto": "media/imgsrv_41.png",
    "description": "Circadian changes in behavioral responses to haloperidol were evaluated in rats under normal and altered lighting cycles. There was a 5.5-fold change in ED50 between the maximum (4 PM) and minimum (4 AM) cataleptic response to the drug under normal lighting (lights on 7 AM-7 PM). The rhythm was present whether the same rats were tested repeatedly, or fresh rats were used at each time to avoid drug effects which persist for at least several days. Under normal lighting, the maximum cataleptic effect of haloperidol corresponded closely to the light-phase minimum of spontaneous motor activity in untreated rats. Measures of sedation (ptosis and motor inhibition) induced by haloperidol yielded small circadian rhythms under normal lighting and were highly dependent on the baseline level of arousal. A month of constant light or dark, or reversed dark-light cycles had small effects on the sedative actions of haloperidol, although inhibition of locomotion tended to phase-shift.\r\nMokros, Ł., Karbownik, M.S., Nowakowska-Domagała, K., Szemraj, J., Wieteska, Ł., Woźniak, K., Witusik, A., Antczak, A. and Pietras, T., 2016. Haloperidol, but not olanzapine, may affect expression of PER1 and CRY1 genes in human glioblastoma cell line. Biological Rhythm Research, 47(6), pp.865-871.",
    "fdastatus": "Approved",
    "linkslists": "https://www.tandfonline.com/doi/full/10.1080/09291016.2016.1202379",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/3559",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.3438.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00502",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      275
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      47,
      48
    ],
    "target": [
      26,
      27,
      28,
      42
    ],
    "effect": [
      56
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 112,
  "fields": {
    "gname": "Asenapine",
    "smiles": "CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24",
    "linkname": "asenapine",
    "molecula": "C17H16ClNO",
    "iupacname": "(2R,6R)-9-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),7(12),8,10,14,16-hexaene",
    "updphoto": "media/imgsrv_67.png",
    "description": "Asenapine, an atypical antipsychotic used primarily for treating schizophrenia and bipolar disorder, has a complex interaction with circadian rhythms. While there is no direct evidence that asenapine significantly alters circadian rhythms, its effects on serotonin receptors, particularly the 5-HT7 receptor, are noteworthy. The 5-HT7 receptor is involved in regulating circadian rhythms, as it is located in the supra-chiasmatic nucleus of the hypothalamus, a key area for circadian rhythm regulation.\r\n\r\nDelcourte, S., Abrial, E., Etiévant, A., Rovera, R., Arnt, J., Didriksen, M. and Haddjeri, N., 2017. Asenapine modulates mood‐related behaviors and 5‐HT 1A/7 receptors‐mediated neurotransmission. CNS Neuroscience & Therapeutics, 23(6), pp.518-525.\r\n\r\nAssociated with incidence of restless legs syndrome. McCall, W.V., Riley, M.A., Hodges, C., McCloud, L., Phillips, M. and Rosenquist, P.B., 2014. Asenapine-induced restless legs syndrome: differentiation from akathisia. Journal of Clinical Sleep Medicine, 10(12), pp.1341-1342.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/3036780#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/3036780",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.143157.html",
    "drugbank": "https://go.drugbank.com/drugs/DB06216",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      272,
      273,
      274
    ],
    "classf": [
      6
    ],
    "mechanisms": [
      49
    ],
    "target": [
      51
    ],
    "effect": [
      55
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 113,
  "fields": {
    "gname": "Benperidol",
    "smiles": "C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F",
    "linkname": "benperidol",
    "molecula": "C22H24FN3O2",
    "iupacname": "3-[1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl]-1H-benzimidazol-2-one",
    "updphoto": "media/imgsrv_78.png",
    "description": "D2 receptor antagonists, such as benperidol and droperidol, increase wakefulness as well as rest in Zebrafish.\r\nAltenhofen, S. and Bonan, C.D., 2022. Zebrafish as a Tool in the Study of Sleep and Memory-related Disorders. Current neuropharmacology, 20(3), pp.540-549.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/16363#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/16363",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.15521.html",
    "drugbank": "https://go.drugbank.com/drugs/DB12867",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      271
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      22,
      50
    ],
    "target": [
      34
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 114,
  "fields": {
    "gname": "Cariprazine",
    "smiles": "CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl",
    "linkname": "cariprazine",
    "molecula": "C21H32Cl2N4O",
    "iupacname": "3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea",
    "updphoto": "media/imgsrv_79.png",
    "description": "Cariprazine (0.3 mg/kg i.p.) reduced the time spent in rapid eye movement (REM) sleep and increased REM latency. This dose of cariprazine decreased the gamma (40–80 Hz) band frequency oscillations and increased the theta (4–9 Hz) and alpha (9–15 Hz) frequencies during the wake periods but not during slow-wave sleep. The 0.03 mg/kg dose of cariprazine only increased the alpha power during the wake periods, while the 0.003 mg/kg dose was without any effect.\r\nCircadian Rhythm Disorders: While cariprazine is associated with sleep disorders such as insomnia and circadian rhythm sleep disorders, there is limited direct evidence on how it affects the body's natural circadian rhythms.\r\n\r\nNyitrai, G., et al. 2021. Cariprazine modulates sleep architecture in rats. Journal of Psychopharmacology, 35(3), pp.303-310.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/11154555#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/11154555",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.25999972.html",
    "drugbank": "https://go.drugbank.com/drugs/DB06016",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      270
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      22
    ],
    "target": [
      34
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 115,
  "fields": {
    "gname": "Chlorpromazine",
    "smiles": "CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl",
    "linkname": "chlorpromazine",
    "molecula": "C17H19ClN2S",
    "iupacname": "3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine",
    "updphoto": "media/imgsrv_82.png",
    "description": "Chlorpromazine, a phenothiazine antipsychotic, has been studied for its effects on circadian rhythms, although its primary use is not related to circadian rhythm regulation. It is known to modulate the circadian rhythm of contrast sensitivity by influencing the rhythmic expression of NPAS2 in retinal ganglion cells, though this is based on similarity rather than direct evidence.\r\n\r\nNagayama, H., Takagi, A., Sakurai, Y., Nishiwaki, K. and Takahashi, R., 1978. Chronopharmacological study of neuroleptics: II. Circadian susceptibility rhythm to chlorpromazine. Psychopharmacology, 58, pp.49-53.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/2726#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/2726",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      269
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      16
    ],
    "target": [
      52
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 116,
  "fields": {
    "gname": "Zuclopentixol",
    "smiles": "C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO",
    "linkname": "zuclopentixol",
    "molecula": "C22H25ClN2OS",
    "iupacname": "2-[4-[(3Z)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethanol",
    "updphoto": "media/imgsrv_83.png",
    "description": "Antipsychotics, particularly atypical ones, have been shown to dampen the morning cortisol peak and flatten the body temperature curve, which are important components of the circadian rhythm.\r\nMelatonin: There is limited evidence that antipsychotics significantly affect melatonin levels.\r\n\r\nWhile zuclopentixol doesn't directly affect circadian rhythms, it can indirectly influence sleep patterns and the timing of activity. This can lead to disruptions in the sleep-wake cycle, potentially impacting the overall circadian rhythm\r\nBehavioral Effects: Some atypical antipsychotics can improve sleep quality, but typical antipsychotics may disrupt daily activity pattern.\r\nHerberger, S., Ruether, E. and Hajak, G., 2021. Somnologics: Medicines for the Treatment of Sleep Disorders. In NeuroPsychopharmacotherapy (pp. 1-39). Cham: Springer International Publishing.\r\nhttps://link.springer.com/content/pdf/10.1007/978-3-319-56015-1_421-1.pdf",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/5311507#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5311507",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4470984.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01624",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      268
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      41
    ],
    "target": [
      53
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 117,
  "fields": {
    "gname": "Clozapine",
    "smiles": "CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42",
    "linkname": "clozapine",
    "molecula": "C18H19ClN4",
    "iupacname": "3-chloro-6-(4-methylpiperazin-1-yl)-11H-benzo[b][1,4]benzodiazepine",
    "updphoto": "media/imgsrv_84.png",
    "description": "Clozapine, an atypical antipsychotic, has been observed to affect circadian rhythms, particularly in patients with psychiatric disorders such as schizophrenia and Alzheimer's disease. Clozapine has been shown to improve the rest-activity cycle in patients, which is often disrupted in psychiatric conditions. For example, in a case study involving a patient with early-onset Alzheimer's disease, switching from haloperidol to clozapine led to a rapid normalization of the rest-activity cycle.Clozapine may enhance the body's sensitivity to light, which can help synchronize the circadian rhythm. This is attributed to its action on serotonin receptors, particularly the 5HT7 receptor, which is involved in regulating light sensitivity in the SCN, the body's master clock.\r\nAlzheimer Disease and Associated Disorders 14(4):p 212-215, October 2000.\r\nWirz-Justice, A., Werth, E., Savaskan, E., Knoblauch, V., Gasio, P.F. and Müller-Spahn, F., 2000. Haloperidol disrupts, clozapine reinstates the circadian rest–activity cycle in a patient with early-onset Alzheimer disease. Alzheimer Disease & Associated Disorders, 14(4), pp.212-215.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/135398737#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/135398737",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.10442628.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00363",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      267
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      49
    ],
    "target": [
      51
    ],
    "effect": [
      5
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 118,
  "fields": {
    "gname": "Flupentixol",
    "smiles": "C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO",
    "linkname": "flupentixol",
    "molecula": "C23H25F3N2OS",
    "iupacname": "2-[4-[(3Z)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol",
    "updphoto": "media/imgsrv_85.png",
    "description": "Typical antipsychotics like flupentixol have been associated with disruptions in daily rhythms, including irregular sleep-wake cycles. This is evident in case series and case reports where patients treated with flupentixol or similar drugs experienced disturbances in their rest-activity patterns, such as delayed circadian phase syndrome or irregular sleep-wake patterns.\r\nDagan, Y. and Borodkin, K., 2005. Behavioral and psychiatric consequences of sleep-wake schedule disorders. Dialogues in clinical neuroscience, 7(4), pp.357-365.\r\nhttps://www.thecarlatreport.com/blogs/2-the-carlat-psychiatry-podcast/post/3338-bad-news-for-antipsychotics-and-circadian-rhythms-60-sec-psych-",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/5281881#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5281881",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      173,
      174
    ],
    "classf": [
      7
    ],
    "mechanisms": [
      41,
      49
    ],
    "target": [
      53
    ],
    "effect": [
      153
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 119,
  "fields": {
    "gname": "Risperidon",
    "smiles": "CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4C5=C(C=C(C=C5)F)ON4",
    "linkname": "risperidon",
    "molecula": "C23H29FN4O2",
    "iupacname": "3-[2-[4-(6-fluoro-2,3-dihydro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one",
    "updphoto": "media/imgsrv_86.png",
    "description": "Risperidone, an atypical antipsychotic, has been shown to affect circadian rhythms in both animal models and humans. Here are some key points regarding its impact.\r\nRisperidone alters the expression of circadian genes such as Per1, Per2, Cry1, Cry2, Bmal1, and Rev-erbα in tissues like the liver and gonadal white adipose tissue (gWAT). These changes are time-dependent, with dosing in the morning (AM) versus evening (PM) affecting gene expression differently.\r\n\r\nZapata, R.C., Silver, A., Yoon, D., Chaudry, B., Libster, A., McCarthy, M.J. and Osborn, O., 2022. Adverse effects of antipsychotic drugs on metabolism depend on drug dosing and feeding times. medRxiv, pp.2022-02.\r\nCherukalady, R., Kumar, D., Basu, P. and Singaravel, M., 2017. Risperidone resets the circadian clock in mice. Biological Rhythm Research, 48(4), pp.583-591.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/44402564#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/44402564",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      171,
      172
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      48,
      51,
      15,
      47
    ],
    "target": [
      42,
      47,
      25,
      26,
      27,
      28
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 120,
  "fields": {
    "gname": "Sulpiride",
    "smiles": "CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC",
    "linkname": "sulpiride",
    "molecula": "C15H23N3O4S",
    "iupacname": "N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide",
    "updphoto": "media/imgsrv_87.png",
    "description": "Sulpiride, an antipsychotic drug, primarily acts as a selective antagonist of the dopamine D2 receptor. Research indicates that sulpiride can affect circadian rhythms, particularly in relation to metabolic outcomes. Here are some key points about how sulpiride impacts circadian rhythms. Sulpiride's action on dopamine D2 receptors can alter the interaction between dopamine and the circadian system, affecting metabolic functions. Dopamine signaling modulates pancreatic beta-cell function, and this interaction is influenced by circadian rhythms.\r\nWhile specific studies on sulpiride's direct impact on circadian gene expression are limited, antipsychotic drugs in general can alter circadian gene expression and metabolic hormones, which are crucial for maintaining circadian rhythms. It is plausible that sulpiride, as an antipsychotic, may have similar effects.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/5355#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5355",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.5162.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00391",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      170
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      22
    ],
    "target": [
      34
    ],
    "effect": [
      54
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 121,
  "fields": {
    "gname": "Fluphenazine decanoate",
    "smiles": "CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F",
    "linkname": "fluphenazine-decanoate",
    "molecula": "C32H44F3N3O2S",
    "iupacname": "2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl decanoate",
    "updphoto": "media/imgsrv_88.png",
    "description": "Antipsychotics like fluphenazine decanoate may perturb circadian gene expression in tissues such as the liver and gonadal white adipose tissue (gWAT), as observed in studies with risperidone. These changes could disrupt metabolic hormones and inflammatory pathways, though direct evidence for fluphenazine decanoate remains limited.\r\nNaber, D., Wirz-Justice, A. and Kafka, M.S., 1982. Chronic fluphenazine treatment modifies circadian rhythms of neurotransmitter receptor binding in rat brain. Journal of Neural Transmission, 55, pp.277-288.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/3388#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/3388",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.3271.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00623",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      169
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      52
    ],
    "target": [
      53
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 122,
  "fields": {
    "gname": "Lurasidone",
    "smiles": "C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O",
    "linkname": "lurasidone",
    "molecula": "C28H36N4O2S",
    "iupacname": "(1S,2R,6S,7R)-4-[[(1R,2R)-2-[[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]cyclohexyl]methyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione",
    "updphoto": "media/imgsrv_89.png",
    "description": "Studies in animal models have demonstrated that lurasidone can reverse the abnormalities in CLOCK genes (such as Per1, Per2, and Cry2) caused by chronic stress in the prefrontal cortex. This normalization is associated with improved depression-like behaviors in rats12.\r\nSerotonin Receptor Antagonism: Lurasidone acts as a potent antagonist of the 5-HT7 serotonin receptor, which is linked to its antidepressant effects and may also contribute to its ability to modulate circadian rhythms.\r\n\r\n\r\nCalabrese, F., Savino, E., Papp, M., Molteni, R. and Riva, M.A., 2016. Chronic mild stress-induced alterations of clock gene expression in rat prefrontal cortex: modulatory effects of prolonged lurasidone treatment. Pharmacological research, 104, pp.140-150.\r\n\r\nKrystal, A.D. and Zammit, G., 2016. The sleep effects of lurasidone: a placebo‐controlled cross‐over study using a 4‐h phase‐advance model of transient insomnia. Human Psychopharmacology: Clinical and Experimental, 31(3), pp.206-216.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/213046#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/213046",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.184739.html",
    "drugbank": "https://go.drugbank.com/drugs/DB08815",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      167,
      168
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      15
    ],
    "target": [
      25,
      26,
      27,
      28,
      29,
      30
    ],
    "effect": [
      150
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 123,
  "fields": {
    "gname": "Olanzapine",
    "smiles": "CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C",
    "linkname": "olanzapine",
    "molecula": "C17H20N4S",
    "iupacname": "2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine",
    "updphoto": "media/imgsrv_90.png",
    "description": "Olanzapine alters the temporal relationship between serum prolactin and cortisol rhythms in healthy individuals, shifting their daily acrophase (peak timing)4. While cortisol rhythms in schizophrenia patients remain relatively intact compared to healthy controls1, olanzapine-induced prolactin elevation6 may indirectly affect circadian entrainment through neuroendocrine pathways.\r\nOlanzapine, an atypical antipsychotic, can disrupt the circadian clock through several mechanisms, although direct evidence of circadian disruption by olanzapine is limited.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/135398745#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/135398745",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.10442212.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00334",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      165,
      166
    ],
    "classf": [
      6
    ],
    "mechanisms": [
      14,
      16
    ],
    "target": [
      53
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 124,
  "fields": {
    "gname": "Pimozidine",
    "smiles": "C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F",
    "linkname": "pimozidine",
    "molecula": "C28H29F2N3O",
    "iupacname": "3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one",
    "updphoto": "media/imgsrv_91.png",
    "description": "When GBL was given intra-peritoneally during the light phase of the lighting cycle the onset of inactivity occurred rapidly (4m), while when GBL was given during the dark phase of the cycle the onset was delayed (16m). Duration of the inactive phase also varied with time of administration. GBL was also administered in the drinking water and total activity over 24 hours was recorded. Results showed that the amplitude of the activity patterns during the dark phase of the lighting cycle was greatly increased. The results of both the temperature and activity experiments are discussed in terms of a change in the sensitivity of dopaminergic receptors.\r\n\r\nDavies, J.A., 1979. The Influence of Dopaminergic Mechanism on 24-Hour Temperature and Activity Rhythms in Rodents. In Neuro-Psychopharmacology (pp. 611-620). Pergamon.",
    "fdastatus": "Approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/16362",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      164
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      46
    ],
    "target": [
      34
    ],
    "effect": [
      147
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 125,
  "fields": {
    "gname": "Promazine",
    "smiles": "CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31",
    "linkname": "promazine",
    "molecula": "C17H20N2S",
    "iupacname": "N,N-dimethyl-3-phenothiazin-10-ylpropan-1-amine",
    "updphoto": "media/imgsrv_92.png",
    "description": "Circadian Disruption: Antipsychotics can impact circadian rhythms indirectly by affecting neurotransmitter systems that regulate sleep and wakefulness. For example, serotonin and dopamine play roles in modulating circadian rhythms.\r\nSleep-Wake Cycle: Some antipsychotics, like chlorpromazine (a related phenothiazine), can influence sleep patterns due to their sedative effects, potentially impacting the sleep-wake cycle and, by extension, circadian rhythms",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/4926#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/4926",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4757.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00420",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      163
    ],
    "classf": [
      9,
      6
    ],
    "mechanisms": [
      53,
      54
    ],
    "target": [
      34
    ],
    "effect": [
      144
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 126,
  "fields": {
    "gname": "Trifluoperazine",
    "smiles": "CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F",
    "linkname": "trifluoperazine",
    "molecula": "C21H24F3N3S",
    "iupacname": "10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine",
    "updphoto": "media/imgsrv_94.png",
    "description": "Trifluoperazine has been shown to cause phase shifts in circadian rhythms. In Neurospora, it effectively shifts the phase of the conidiation rhythm, leading to a maximum phase delay at certain concentrations, such as 30 μM24. This indicates that TFP can influence the timing of biological processes regulated by the circadian clock.\r\nAs a calmodulin antagonist, TFP's effects on circadian rhythms are likely mediated through its inhibition of calmodulin activity. Calmodulin plays a role in various cellular processes, including signaling pathways that can influence circadian clock function\r\n\r\nSuzuki, S., Katagiri, S. and Nakashima, H., 1996. Mutants with altered sensitivity to a calmodulin antagonist affect the circadian clock in Neurospora crassa. Genetics, 143(3), pp.1175-1180.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/5566#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5566",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.5365.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00831",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      162
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      56
    ],
    "target": [
      56
    ],
    "effect": [
      141
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 127,
  "fields": {
    "gname": "Eszopiclone",
    "smiles": "CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl",
    "linkname": "eszopiclone",
    "molecula": "C17H17ClN6O3",
    "iupacname": "[(7S)-6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate",
    "updphoto": "media/imgsrv_95.png",
    "description": "A sedative-hypnotic used in the treatment of insomnia, improving both the latency phase and the maintenance phase of sleep.\r\n\r\nKrystal, A.D., Walsh, J.K., Laska, E., Caron, J., Amato, D.A., Wessel, T.C. and Roth, T., 2003. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep, 26(7), pp.793-799.",
    "fdastatus": "Approved",
    "linkslists": null,
    "pubchem": null,
    "chemspider": "https://www.chemspider.com/Chemical-Structure.839530.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00402",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      161
    ],
    "classf": [
      10
    ],
    "mechanisms": [
      54
    ],
    "target": [
      53
    ],
    "effect": [
      53
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 128,
  "fields": {
    "gname": "Zolpidem",
    "smiles": "CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C",
    "linkname": "zolpidem",
    "molecula": "C19H21N3O",
    "iupacname": "N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide",
    "updphoto": "media/imgsrv_96.png",
    "description": "The abrupt and frequent changes in a rotating work-shift schedule can lead to dysregulation of the circadian sleep/wake cycle.\r\nKeuroghlian, A.S., Barry, A.S. and Weiss, R.D., 2012. Circadian dysregulation, zolpidem dependence, and withdrawal seizure in a resident physician performing shift work. The American Journal on Addictions/American Academy of Psychiatrists in Alcoholism and Addictions, 21(6), p.576.\r\nHarrison, T.S. and Keating, G.M., 2005. Zolpidem: a review of its use in the management of insomnia. CNS drugs, 19, pp.65-89.\r\nCopinschi, G., Akseki, E., Moreno-Reyes, R., Leproult, R., L'Hermite-Balériaux, M., Caufriez, A., Vertongen, F. and Cauter, E.V., 1995. Effects of Bedtime Administration of Zolpidem on Orcadian and Sleep-Related Hormonal Profiles in Normal Women. Sleep, 18(6), pp.417-424.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/5732#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5732",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.5530.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00425",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      158,
      159,
      160
    ],
    "classf": [
      9,
      10
    ],
    "mechanisms": [
      53,
      57
    ],
    "target": [
      35
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 129,
  "fields": {
    "gname": "Droperidol",
    "smiles": "C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F",
    "linkname": "droperidol",
    "molecula": "C22H22FN3O2",
    "iupacname": "3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-3,6-dihydro-2H-pyridin-4-yl]-1H-benzimidazol-2-one",
    "updphoto": "media/imgsrv_97.png",
    "description": "A butyrophenone derivative and dopamine antagonist used to prevent and treat postoperative nausea and vomiting.\r\n\r\nCugini, P., Delogu, G., Casula, M.A., Gatta, L., Cascioli, C. and Di Palma, L., 1991. Anaesthesia‐induced dissociation between the circadian rhythms of blood pressure and heart rate. Biological Rhythm Research, 22(4), pp.333-340.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/3168#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/3168",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.3056.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00450",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      157
    ],
    "classf": [
      9,
      10
    ],
    "mechanisms": [
      58,
      46,
      22
    ],
    "target": [
      34
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 130,
  "fields": {
    "gname": "Buspirone",
    "smiles": "C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4",
    "linkname": "buspirone",
    "molecula": "C21H31N5O2",
    "iupacname": "8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione",
    "updphoto": "media/imgsrv_98.png",
    "description": "Buspirone, a serotonin 1A receptor partial agonist, is known to affect circadian rhythms. Here are some key points regarding its impact:\r\nBuspirone attenuates phase advances to late subjective night light pulses in hamsters and wild-type mice. This suggests that it can modify how the circadian system responds to light, which is crucial for maintaining the body's internal clock.\r\nEffects on Wheel-Running Rhythms: Chronic buspirone treatment decreases the amplitude of wheel-running rhythms, lengthens the duration of the active phase, and advances the phase angle of entrainment. These changes indicate that buspirone can alter the natural activity patterns of animals. Buspirone administration at midday can produce non-photic phase advances in wild-type mice but not in 5-HT1A receptor knockout mice. This shows that its effects on the circadian system are primarily mediated through the 5-HT1A receptor13.\r\nPotential chronobiotic.\r\nSmith, V.M., Iannatonne, S., Achal, S., Jeffers, R.T. and Antle, M.C., 2014. The serotonergic anxiolytic buspirone attenuates circadian responses to light. European Journal of Neuroscience, 40(10), pp.3512-3525.",
    "fdastatus": "Approved",
    "linkslists": "https://onlinelibrary.wiley.com/doi/full/10.1111/ejn.12712?casa_token=zhyyM6J4AGQAAAAA%3ASnIQdHScG2sveYeexATyMfq5kG5pca0KP8TzW2f_3QQMfVoixp_m-7MZZ7dc5kt7SYPMfCl1KTyYuvf2",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/2477",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.2383.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00490",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      156
    ],
    "classf": [
      4,
      5
    ],
    "mechanisms": [
      59
    ],
    "target": [
      57
    ],
    "effect": [
      139
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 131,
  "fields": {
    "gname": "Hydroxyzine",
    "smiles": "C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl",
    "linkname": "hydroxyzine",
    "molecula": "C21H27ClN2O2",
    "iupacname": "2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethanol",
    "updphoto": "media/imgsrv_99.png",
    "description": "Histamine H1 Blocker Hydroxyzine Improves Sleep in Patients With Cirrhosis and Minimal Hepatic Encephalopathy. Subjective improvement in sleep was observed in 40% of hydroxyzine-treated patients but in none receiving placebo (P < 0.04). Objectively, 65% of hydroxyzine-treated patients versus 25% of patients under placebo had a ≥30% increase in sleep efficiency as measured by wrist actigraphy (P < 0.04). Neuropsychological tests (Z scores) and protein s100β levels remained statistically unchanged in both groups. One patient developed an acute episode of encephalopathy reversible upon cessation of hydroxyzine.",
    "fdastatus": "Approved",
    "linkslists": "https://journals.lww.com/ajg/abstract/2007/04000/histamine_h1_blocker_hydroxyzine_improves_sleep_in.9.aspx",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/3658",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.3531.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00557",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      155
    ],
    "classf": [
      4,
      5
    ],
    "mechanisms": [
      60
    ],
    "target": [
      58
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 132,
  "fields": {
    "gname": "Lemborexant",
    "smiles": "CC1=NC(=NC=C1OC[C@]2(C[C@H]2C(=O)NC3=NC=C(C=C3)F)C4=CC(=CC=C4)F",
    "linkname": "lemborexant",
    "molecula": "C₂₂H₂₀F₂N₄O₂",
    "iupacname": "(1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide",
    "updphoto": "media/imgsrv_20_wP1ln8L.png",
    "description": "Lemborexant is a novel dual orexin receptor antagonist approved for the treatment of insomnia in adults, particularly those experiencing difficulties in sleep onset and/or sleep maintenance. Unlike traditional hypnotics that work by enhancing sleep drive via GABA and melatonin receptors, lemborexant works by counteracting inappropriate wakefulness. This mechanism offers potential advantages such as a favorable side effect profile and minimal next-day residual effects.",
    "fdastatus": "Approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/56944144",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.34500836.html",
    "drugbank": "https://go.drugbank.com/drugs/DB11951",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      154
    ],
    "classf": [
      8
    ],
    "mechanisms": [
      61
    ],
    "target": [
      59
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 133,
  "fields": {
    "gname": "Dexmedetomidine",
    "smiles": "CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C",
    "linkname": "dexmedetomidine",
    "molecula": "C13H16N2",
    "iupacname": "5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole",
    "updphoto": "media/imgsrv_100.png",
    "description": "An alpha-2 agonist used for sedation during various procedures, positively affects sleep quality.\r\n\r\n In the D6H group, the whole expression of seven genes was changed significantly compared with the N group. In the P6H group, all gene expressions except for Tef (thyrotroph embryonic factor) were changed significantly compared with the L group. In this group, the expression of Dbp (D site albumin promoter binding protein) was increased, and the others were decreased. In the D6H group, all gene expressions except for Dbp and Tef were decreased significantly compared with the N group. For the two anesthetics, the expression patterns were different only in Dbp.\r\n\r\nHuang, X., Lin, D., Sun, Y., Wu, A. and Wei, C., 2021. Effect of dexmedetomidine on postoperative sleep quality: a systematic review. Drug design, development and therapy, pp.2161-2170.",
    "fdastatus": "Approved",
    "linkslists": "https://www.sciencedirect.com/science/article/abs/pii/S0361923009001294",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5311068",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4470605.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00633",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      153
    ],
    "classf": [
      4,
      5
    ],
    "mechanisms": [
      15
    ],
    "target": [
      25,
      26,
      27
    ],
    "effect": [
      137
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 134,
  "fields": {
    "gname": "Daridorexant",
    "smiles": "CC1=C(C=CC2=C1N=C(N2)[C@@]3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl",
    "linkname": "daridorexant",
    "molecula": "C₂₃H₂₃ClN₆O₂",
    "iupacname": "[(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone",
    "updphoto": "media/imgsrv_21_r8uMWPd.png",
    "description": "Daridorexant is an FDA- and EU-approved dual orexin receptor antagonist specifically developed for the treatment of insomnia. It shortens the latency to persistent sleep and reduces wake time after sleep onset, improving both subjective and objective sleep parameters and, at higher doses (50 mg), daytime functioning. Its relatively short half-life (~8 hours) and targeted mechanism of action minimize next-day residual effects often associated with traditional hypnotics, offering a more favorable safety and tolerability profile for chronic insomnia management.",
    "fdastatus": "Approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/91801202",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.64854514.html",
    "drugbank": "https://go.drugbank.com/drugs/DB15031",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      152
    ],
    "classf": [
      8
    ],
    "mechanisms": [
      61
    ],
    "target": [
      59
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 135,
  "fields": {
    "gname": "Zaleplon",
    "smiles": "CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C",
    "linkname": "zaleplon",
    "molecula": "C17H15N5O",
    "iupacname": "N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide",
    "updphoto": "media/imgsrv_-_2025-03-19T102536.927.png",
    "description": "Zaleplon has been shown to increase nocturnal melatonin secretion in humans without affecting daytime melatonin levels. This increase in melatonin can influence the circadian rhythm, as melatonin plays a crucial role in regulating sleep-wake cycles.\r\nCircadian Rhythm Influence: While zaleplon's direct impact on the circadian clock is not as well-documented as its effect on melatonin, its ability to enhance nocturnal melatonin levels suggests it could indirectly influence circadian rhythms. Melatonin itself is known to affect the circadian rhythm by promoting sleep onset and helping regulate the sleep-wake cycle.\r\nChronobiological Effects: Studies in rabbits indicate that zaleplon can increase plasma melatonin levels, which may suggest an influence on chronobiology, or the study of biological rhythms.\r\n\r\nMorera, A.L., Abreu-Gonzalez, P. and Henry, M., 2009. Zaleplon increases nocturnal melatonin secretion in humans. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 33(6), pp.1013-1016.",
    "fdastatus": "Approved",
    "linkslists": "https://www.sciencedirect.com/science/article/pii/S0378517318301601",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5719",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.5517.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00962",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      151
    ],
    "classf": [
      4,
      5
    ],
    "mechanisms": [
      23,
      57
    ],
    "target": [
      35
    ],
    "effect": [
      50,
      52
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 136,
  "fields": {
    "gname": "Filorexant",
    "smiles": "CC1CCC(CN1C(=O)C2=C(C=CC(=C2)C)C3=NC=CC=N3)COC4=NC=C(C=C4)F",
    "linkname": "filorexant",
    "molecula": "C₂₄H₂₅FN₄O₂",
    "iupacname": "[(2R,5R)-5-((5-fluoropyridin-2-yl)oxymethyl)-2-methylpiperidin-1-yl]-(5-methyl-2-(pyrimidin-2-yl)phenyl)methanone",
    "updphoto": "media/imgsrv_22_3TBr6sf.png",
    "description": "Filorexant (MK-6096) is an investigational dual orexin receptor antagonist that was clinically studied for insomnia and other potential indications, such as migraine prophylaxis and major depressive disorder. By reducing orexin-mediated arousal signaling, filorexant promotes sleep and alters sleep architecture, though clinical development is not currently ongoing for mainstream approval. Its wake-suppressing effects position it alongside other DORAs as a possible treatment for sleep disorders. However, while showing efficacy in sleep induction, issues including safety and potential side effects have been part of its clinical evaluations.",
    "fdastatus": "Not approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/25128145",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.28528372.html",
    "drugbank": "https://go.drugbank.com/drugs/DB12158",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      150
    ],
    "classf": [
      8
    ],
    "mechanisms": [
      61
    ],
    "target": [
      59
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 137,
  "fields": {
    "gname": "Promethazine",
    "smiles": "CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C",
    "linkname": "promethazine",
    "molecula": "C17 H20N2S",
    "iupacname": "N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine",
    "updphoto": "media/imgsrv_-_2025-03-19T103211.198.png",
    "description": "Promethazine, a phenothiazine derivative, acts as an anti-emetic, sedative, and hypnotic. It is primarily used for its antihistamine properties, which help in treating allergic reactions, inducing sedation, and reducing pain23. Promethazine can influence circadian rhythms indirectly by affecting sleep patterns. It helps regulate the body's sleep-wake cycle and can improve sleep quality by acting as a hypnotic45.\r\nPromethazine's sedative effects can help individuals fall asleep and maintain sleep, thereby influencing the sleep-wake cycle, which is a key component of the circadian rhythm. While promethazine does not directly regulate circadian rhythms, its ability to induce sleep can indirectly affect the body's natural circadian rhythm by promoting a consistent sleep schedule.\r\nThere was a significant increase in the percentage of epochs staged as ‘sleep’ during the day (F(5,75) = 4.46; P < 0.002) with promethazine.",
    "fdastatus": "Approved",
    "linkslists": "https://www.mdpi.com/2227-9032/10/1/147",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/4927",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4758.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01069",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      147,
      149
    ],
    "classf": [
      10,
      6,
      14
    ],
    "mechanisms": [
      60
    ],
    "target": [
      58
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 138,
  "fields": {
    "gname": "Adenosine",
    "smiles": "C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N",
    "linkname": "adenosine",
    "molecula": "C₁₀H₁₃N₅O₄",
    "iupacname": "(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol",
    "updphoto": "media/imgsrv_24_ezXrRDw.png",
    "description": "Adenosine, a ubiquitous nucleoside, plays a critical role in modulating circadian rhythms, the endogenous ~24-hour cycles that regulate physiological and behavioral processes in organisms. Emerging research highlights adenosine as a key mediator linking metabolic state with circadian timing, primarily through its interaction with G protein-coupled adenosine receptors (A₁, A₂A, A₂B, and A₃). Adenosine levels fluctuate in a circadian manner, influenced by sleep-wake cycles, neuronal activity, and energy metabolism, particularly via ATP breakdown. The sleep-promoting effects of adenosine, mediated through A₁ and A₂A receptors in the brain, directly interact with the suprachiasmatic nucleus (SCN), the master circadian pacemaker. Adenosine receptor signaling influences clock gene expression (e.g., Per1, Per2, Bmal1) and alters neuronal firing rates in the SCN, thereby fine-tuning circadian phase and period.\r\n\r\nCaffeine, a well-known adenosine receptor antagonist, disrupts circadian rhythms by blocking adenosine’s sleep-inducing effects, further underscoring adenosine’s regulatory role. Additionally, adenosine modulates light-induced phase shifts in the SCN, affecting entrainment to external cues. Beyond the central clock, adenosine impacts peripheral oscillators in the liver, heart, and immune system, linking cellular energy status with circadian function. Dysregulation of adenosine signaling is implicated in sleep disorders, metabolic syndrome, and neurodegenerative diseases, where circadian disruption is a common feature.\r\n\r\nJagannath, A., Varga, N., Dallmann, R., Rando, G., Gosselin, P., Ebrahimjee, F., Taylor, L., Mosneagu, D., Stefaniak, J., Walsh, S. and Palumaa, T., 2021. Adenosine integrates light and sleep signalling for the regulation of circadian timing in mice. Nature communications, 12(1), p.2113.",
    "fdastatus": "Approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/60961",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.54923.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00640",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      148
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      62
    ],
    "target": [
      60
    ],
    "effect": [
      133
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 139,
  "fields": {
    "gname": "Zopiclone",
    "smiles": "CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4) Cl",
    "linkname": "zopiclone",
    "molecula": "C17 H17 ClN6O3",
    "iupacname": "[6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate",
    "updphoto": "media/imgsrv_-_2025-03-19T103959.606.png",
    "description": "A nonbenzodiazepine hypnotic used for the short-term management of insomnia. Zopiclone has been shown to accelerate the readjustment of the rest/activity rhythm after a westward flight, helping to normalize the phase relationship between sleep and the temperature rhythm. This effect is primarily due to its ability to facilitate sleep induction rather than a direct chronobiotic action, which means it doesn't inherently reset the body's internal clock but helps align sleep patterns with the new environment. In studies involving aircrew, zopiclone was effective in facilitating early circadian sleep, similar to melatonin. It helped subjects fall asleep more quickly and improved sleep quality without impacting psychomotor performance after waking.\r\nMasse, M., et al., 2022, January. Sleep medication in older adults: identifying the need for support by a community pharmacist. In Healthcare (Vol. 10, No. 1, p. 147). MDPI.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/5735#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5735",
    "chemspider": "https://www.chemspider.com/search",
    "drugbank": "https://go.drugbank.com/drugs/DB01198",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      147
    ],
    "classf": [
      10,
      4,
      5
    ],
    "mechanisms": [
      23,
      57
    ],
    "target": [
      35
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 140,
  "fields": {
    "gname": "BAY 60-6583",
    "smiles": "C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N",
    "linkname": "bay-60-6583",
    "molecula": "C₁₉H₁₇N₅O₂S",
    "iupacname": "2-[6-amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-yl]sulfanylacetamide",
    "updphoto": "media/imgsrv_25_a7E6xoM.png",
    "description": "BAY 60-6583 is a selective adenosine A₂B receptor (ADORA2B) agonist. Adenosine receptors are G-protein-coupled receptors (GPCRs) that modulate intracellular cyclic AMP (cAMP) levels, especially in hypoxic or ischemic tissues.\r\n\r\nHinz, S., Lacher, S.K., Seibt, B.F. and Müller, C.E., 2014. BAY60-6583 acts as a partial agonist at adenosine A2B receptors. The Journal of pharmacology and experimental therapeutics, 349(3), pp.427-436.",
    "fdastatus": "Not approved",
    "linkslists": "https://www.sciencedirect.com/science/article/abs/pii/S0022356524186867?via%3Dihub",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/11717831",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.9892551.html",
    "drugbank": "https://go.drugbank.com/unearth/q?searcher=drugs&query=BAY+60-6583&button=",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      146
    ],
    "classf": [
      8
    ],
    "mechanisms": [
      63
    ],
    "target": [
      61
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 141,
  "fields": {
    "gname": "Chloral hydrate",
    "smiles": "C(C(Cl)(Cl)Cl)(O)O",
    "linkname": "chloral-hydrate",
    "molecula": "C2H3Cl3O2",
    "iupacname": "2,2,2-trichloroethane-1,1-diol",
    "updphoto": "media/imgsrv_-_2025-03-19T104213.841.png",
    "description": "A mild hypnotic used for experimental purposes that was previously used for the treatment of insomnia.  A study found that the success rate of chloral hydrate sedation was higher in the afternoon compared to the morning, suggesting that circadian rhythms may influence its efficacy. This indicates that while chloral hydrate itself does not directly regulate the circadian clock, its effectiveness can be influenced by natural circadian variations. Chloral hydrate acts primarily by enhancing GABA-A receptor function and suppressing the central nervous system. Its active metabolite, trichloroethanol, is responsible for its sedative effects, which could indirectly affect sleep patterns but not directly alter the circadian clock. \r\n\r\nAshrafi, M.R., Mohammadi, M., Tafarroji, J., Shabanian, R., Salamati, P. and Zamani, G.R., 2010. Melatonin versus chloral hydrate for recording sleep EEG. european journal of paediatric neurology, 14(3), pp.235-238.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/2707#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/2707",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.2606.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01563",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      145
    ],
    "classf": [
      10,
      5
    ],
    "mechanisms": [
      57
    ],
    "target": [
      35
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 142,
  "fields": {
    "gname": "Butisol (butabarbital)",
    "smiles": "CCC(C)C1(C(=O)NC(=O)NC1=O)CC",
    "linkname": "butisol-butabarbital",
    "molecula": "C10H16N2O3",
    "iupacname": "5-butan-2-yl-5-ethyl-1,3-diazinane-2,4,6-trione",
    "updphoto": "media/imgsrv_-_2025-03-19T105959.629.png",
    "description": "Butabarbital, known by the brand name Butisol, is a barbiturate with a fast onset and short duration of action. It acts by enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) in the brain, leading to sedation and sleep induction. While barbiturates like butabarbital can help induce sleep, they do not specifically target or regulate the body's natural circadian rhythms. Instead, they can potentially disrupt these rhythms by altering sleep patterns and affecting the timing of sleep-wake cycles.\r\nPrinz, P.N., Vitiello, M.V., Raskind, M.A. and Thorpy, M.J., 1990. Sleep disorders and aging. New England Journal of Medicine, 323(8), pp.520-526.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/2479#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/2479",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.2385.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00237",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      144
    ],
    "classf": [
      10
    ],
    "mechanisms": [
      57
    ],
    "target": [
      35
    ],
    "effect": [
      131
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 143,
  "fields": {
    "gname": "Doral (quazepam)",
    "smiles": "C1C(=S)N(C2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3F)CC(F)(F)F",
    "linkname": "doral-quazepam",
    "molecula": "C17H11ClF4N2S",
    "iupacname": "7-chloro-5-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepine-2-thione",
    "updphoto": "media/imgsrv_-_2025-03-19T110538.240.png",
    "description": "Doral, also known as quazepam, is a benzodiazepine used primarily for the short-term treatment of insomnia, particularly for sleep-maintenance insomnia. While quazepam is effective in promoting sleep by enhancing the effects of the neurotransmitter GABA, its impact on circadian rhythms is not explicitly detailed in the available literature.\r\nHowever, quazepam's long half-life (ranging from 27 to 41 hours) and its active metabolites could potentially influence circadian rhythms indirectly by affecting sleep patterns over extended periods\r\n\r\nHilbert, J.M., Chung, M., Maier, G., Gural, R., Symchowicz, S. and Zampaglione, N., 1984. Effect of sleep on quazepam kinetics. Clinical Pharmacology & Therapeutics, 36(1), pp.99-104.",
    "fdastatus": "Approved",
    "linkslists": "https://pubmed.ncbi.nlm.nih.gov/8428895/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/4999",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4825.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01589",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      143
    ],
    "classf": [
      10
    ],
    "mechanisms": [
      57
    ],
    "target": [
      35
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 144,
  "fields": {
    "gname": "Estazolam",
    "smiles": "C1C2=NN=CN2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4",
    "linkname": "estazolam",
    "molecula": "C16H11ClN4",
    "iupacname": "8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine",
    "updphoto": "media/imgsrv_-_2025-03-19T111250.362.png",
    "description": "Estazolam, a benzodiazepine derivative, is primarily used for the short-term management of insomnia. While there is no direct evidence that estazolam specifically affects the circadian clock, benzodiazepines in general can influence the body's natural rhythms due to their effects on sleep and wakefulness.\r\nBenzodiazepines, including estazolam, act by enhancing the effects of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA_A receptor, which can lead to sedative and hypnotic effects.\r\nVogel, G.W. and Morris, D., 1992. The effects of estazolam on sleep, performance, and memory: a long‐term sleep laboratory study of elderly insomniacs. The Journal of Clinical Pharmacology, 32(7), pp.647-651.",
    "fdastatus": "Approved",
    "linkslists": "https://onlinelibrary.wiley.com/doi/abs/10.1002/hup.470060204?casa_token=6MylTocqQ6EAAAAA:m-8AA3dPy04NuMvhGvqFx8w2ADTtAoFZTRBJxQMmAOW3Ox-R39-T_nFi3Ts9zmoe8WVDd6mugjH_n2qK",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/3261",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.3146.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01215",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      142
    ],
    "classf": [
      10
    ],
    "mechanisms": [
      57
    ],
    "target": [
      35
    ],
    "effect": [
      129
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 145,
  "fields": {
    "gname": "Fluconazole",
    "smiles": "C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O",
    "linkname": "fluconazole",
    "molecula": "C₁₃H₁₂F₂N₆O",
    "iupacname": "2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol",
    "updphoto": "media/imgsrv_26_LPCCQ6P.png",
    "description": "Fluconazole is a well-known triazole antifungal agent widely used in treating both superficial and systemic mycoses, especially infections caused by Candida albicans. It exerts a mainly fungistatic effect by disrupting the conversion of lanosterol into ergosterol, an essential component of the fungal cell membrane. Fluconazole is characterized by high oral bioavailability, a relatively long plasma half-life (~30 hours), and good penetration into various tissues, including cerebrospinal fluid—making it effective for cryptococcal meningitis.\r\n\r\nDisrupts temporal organization of candida albicans.\r\n\r\nNikolenko, M.V., TKh, T. and Paromova, Y.I., 2015. EFFECT OF FLUCONAZOLE ON TEMPORAL ORGANIZATION OF BIOLOGICAL PROPERTIES OF CANDIDA ALBICANS. Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii, (4), pp.30-35.",
    "fdastatus": "Approved",
    "linkslists": "https://microbiol.crie.ru/jour/article/view/14063",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/3365",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.3248.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00196",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      141
    ],
    "classf": [
      8
    ],
    "mechanisms": [
      64
    ],
    "target": [
      62
    ],
    "effect": [
      206
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 146,
  "fields": {
    "gname": "Flurazepam",
    "smiles": "CCN(CC)CCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F",
    "linkname": "flurazepam",
    "molecula": "C21H23ClFN3O",
    "iupacname": "7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one",
    "updphoto": "media/imgsrv_-_2025-03-19T111333.160.png",
    "description": "Treatments in parallel groups were administered before shifted sleeps. Sleep disturbance was greatest in the last quarter of shifted nights (6.5 to 8.5 hours after medication). Subjects taking placebo showed significant sleep loss on shifted nights and increased sleepiness the next day. Triazolam, 0.5 mg, reversed the sleep loss and consequent daytime sleepiness associated with the shifted sleep schedule. Triazolam, 0.25 mg, was not significantly better than placebo. In a dose-related manner, flurazepam mitigated the insomnia, but carryover effects left both dose groups more sleepy than were the placebo control subjects.\r\nSeidel, W.F., Cohen, S.A., Bliwise, N.G., Roth, T. and Dement, W.C., 1986. Dose‐related effects of triazolam and flurazepam on a circadian rhythm insomnia. Clinical Pharmacology & Therapeutics, 40(3), pp.314-320\r\nCrowley, T.J. and Hydinger-Macdonald, M., 1979. Bedtime flurazepam and the human circadian rhythm of spontaneous motility. Psychopharmacology, 62, pp.157-161",
    "fdastatus": "Approved",
    "linkslists": "https://link.springer.com/article/10.1007/BF00427130",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/3393",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.3276.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00690",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      138,
      140
    ],
    "classf": [
      10
    ],
    "mechanisms": [
      57
    ],
    "target": [
      35
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 147,
  "fields": {
    "gname": "Halcion (triazolam)",
    "smiles": "CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4Cl",
    "linkname": "halcion-triazolam",
    "molecula": "C17H12Cl2N4",
    "iupacname": "8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine",
    "updphoto": "media/imgsrv_-_2025-03-19T111810.310.png",
    "description": "Seidel, W.F., Cohen, S.A., Bliwise, N.G., Roth, T. and Dement, W.C., 1986. Dose‐related effects of triazolam and flurazepam on a circadian rhythm insomnia. Clinical Pharmacology & Therapeutics, 40(3), pp.314-320.\r\nTurek, F.W. and Losee-Olson, S.H., 1987. Dose response curve for the phase-shifting effect of triazolam on the mammalian circadian clock. Life sciences, 40(11), pp.1033-1038.",
    "fdastatus": "Approved",
    "linkslists": "https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1038/clpt.1986.182?casa_token=yL4E8oFS5qkAAAAA:8My_ERSmZuX7iUk4joGZt8kEOdTq4eNSbNKU0MIzZ9EhH5bVMlERjLXA41bUp53jGTXyabsruoH4LCDV",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5556",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.5355.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00897",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      138,
      139
    ],
    "classf": [
      10,
      5
    ],
    "mechanisms": [
      23,
      57
    ],
    "target": [
      35
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 148,
  "fields": {
    "gname": "Restoril (temazepam)",
    "smiles": "CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)O)C3=CC=CC=C3",
    "linkname": "restoril-temazepam",
    "molecula": "C16H13ClN2O2",
    "iupacname": "7-chloro-3-hydroxy-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one",
    "updphoto": "media/imgsrv_-_2025-03-19T112118.322.png",
    "description": "Temazepam has been shown to help induce sleep during periods of circadian rhythm desynchronization, such as during transmeridian flights. It aids in resetting the sleep-wake cycle to align with the new time zone, which can help mitigate jet lag symptoms. Studies indicate that temazepam improves sleep quality and alertness following transmeridian travel without impairing performance. However, it does not significantly alter the rate of adjustment of physiological rhythms like the pineal, adrenal, and temperature rhythms to the new environment. While temazepam helps with sleep induction and improves subjective sleep characteristics, it does not affect the rate of entrainment of physiological rhythms to new environments. \r\nHeel, C., Brogden, R.N., Speight, T.M. and Avery, G.S., 1981. Temazepam: a review of its pharmacological properties and therapeutic efficacy as an hypnotic. Drugs, 21, pp.321-340.",
    "fdastatus": "Approved",
    "linkslists": "https://onlinelibrary.wiley.com/doi/full/10.1046/j.1365-2869.2003.00360.x?casa_token=CWvmta64s8QAAAAA%3Azh2-necPlLH__WRm6ZcNd_B138wXZ-kyTa9fZCM5r-J4m4t_iVkg0410TM0Kmh93BQTgYIn40oJE0X0n",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5391",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.5198.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00231",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      137
    ],
    "classf": [
      10
    ],
    "mechanisms": [
      57
    ],
    "target": [
      35
    ],
    "effect": [
      125
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 149,
  "fields": {
    "gname": "Seconal (secobarbital)",
    "smiles": "CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C",
    "linkname": "seconal-secobarbital",
    "molecula": "C12H18N2O3",
    "iupacname": "5-pentan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione",
    "updphoto": "media/imgsrv_-_2025-03-19T112325.687.png",
    "description": "Secobarbital is a member of the class of barbiturates that is barbituric acid in which the hydrogens at position 5 are substituted by prop-2-en-1-yl and pentan-2-yl groups. It has a role as an anaesthesia adjuvant, a GABA modulator and a sedative. It is functionally related to a barbituric acid. \r\nBrunet, R., Caza, N. and Cyr, A., 1996. Food intake and circadian rhythms of activity of red-winged blackbirds (Agelaius phoeniceus). A time-course study on the effects of alpha-chloralose and secobarbital. Biological Rhythm Research, 27(2), pp.227-240.",
    "fdastatus": null,
    "linkslists": "https://www.tandfonline.com/doi/abs/10.1076/brhm.27.2.227.12943",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5193",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.5005.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00418",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      136
    ],
    "classf": [
      10
    ],
    "mechanisms": [
      23,
      57
    ],
    "target": [
      35
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 150,
  "fields": {
    "gname": "Silenor (doxepin)",
    "smiles": "CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31.Cl",
    "linkname": "silenor-doxepin",
    "molecula": "C19H22ClNO",
    "iupacname": "(3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine;hydrochloride",
    "updphoto": "media/imgsrv_-_2025-03-19T112834.407.png",
    "description": "Six studies were on doxepin 1–6 mg/d, two on doxepin 25–300 mg/d, and one on ramelteon 8 mg and doxepin 3 mg combined. All low-dose studies were industry-sponsored. We found that low-dose doxepin had a small to medium effect size against placebo for sleep maintenance and sleep duration but not for sleep initiation at both immediate and short-term posttreatment. There was no significant next-day residual effect with low-dose doxepin. Headache and somnolence were the most common side effect. Low-dose doxepin for 1–2 nights appeared to be safe and effective in improving sleep.\r\nYeung, W.F., Chung, K.F., Yung, K.P. and Ng, T.H.Y., 2015. Doxepin for insomnia: a systematic review of randomized placebo-controlled trials. Sleep medicine reviews, 19, pp.75-83.",
    "fdastatus": "Approved",
    "linkslists": "https://www.sciencedirect.com/science/article/pii/S1087079214000653",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/6419921",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4925526.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01142",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      135
    ],
    "classf": [
      10
    ],
    "mechanisms": [
      23,
      57
    ],
    "target": [
      35
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 151,
  "fields": {
    "gname": "Benadryl (diphenhydramine)",
    "smiles": "CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2",
    "linkname": "benadryl-diphenhydramine",
    "molecula": "C17H21NO",
    "iupacname": "2-benzhydryloxy-N,N-dimethylethanamine",
    "updphoto": "media/imgsrv_-_2025-03-19T113103.065.png",
    "description": "Histamine, which diphenhydramine antagonizes, plays a role in modulating circadian rhythms through pathways involving nuclear factors like NF-κB2. However, diphenhydramine's effect on histamine receptors does not directly imply an impact on the circadian clock itself.\r\nIndirect Effects: While diphenhydramine can induce sleepiness, its use as a sleep aid is not recommended due to potential side effects and lack of efficacy in long-term sleep management.\r\n\r\nWang, Y.Q., Takata, Y., Li, R., Zhang, Z., Zhang, M.Q., Urade, Y., Qu, W.M. and Huang, Z.L., 2015. Doxepin and diphenhydramine increased non-rapid eye movement sleep through blockade of histamine H1 receptors. Pharmacology Biochemistry and Behavior, 129, pp.56-64.\r\n\r\nMorioka, E., Kanda, Y., Koizumi, H., Miyamoto, T. and Ikeda, M., 2018. Histamine regulates molecular clock oscillations in human retinal pigment epithelial cells via H1 receptors. Frontiers in endocrinology, 9, p.108.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/3100#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/3100",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      133,
      134
    ],
    "classf": [
      10,
      5
    ],
    "mechanisms": [
      60
    ],
    "target": [
      58
    ],
    "effect": [
      123
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 152,
  "fields": {
    "gname": "Unisom (doxylamine)",
    "smiles": "CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C.C(CC(=O)O)C(=O)O",
    "linkname": "unisom-doxylamine",
    "molecula": "C17H22N2O.C4H6O4 C21H28N2O5",
    "iupacname": "butanedioic acid;N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine",
    "updphoto": "media/imgsrv_-_2025-03-19T113720.925.png",
    "description": "Doxylamine is a medication used to manage and treat nausea and vomiting of pregnancy (NVP), allergic rhinitis, and insomnia. It is in the first-generation histamine receptor H1 antagonist class of medications. In the USA, it is available as an over-the-counter medication.\r\n\r\nWard, L.G., Bourjeily, G., Guthrie, K., Salmoirago-Blotcher, E., Sharp, M., Desmarattes, A. and Bublitz, M., 2024. Sleep Quality in High-Risk Pregnancies: Mixed Methods Results from a Randomized Controlled Trial of a Mindfulness Training Intervention. Journal of Integrative and Complementary Medicine, 30(10), pp.953-960.",
    "fdastatus": "Approved",
    "linkslists": "https://books.google.ru/books?hl=en&lr=&id=ojP_EAAAQBAJ&oi=fnd&pg=PA60&dq=doxylamine+circadian&ots=zVNQC2zgeU&sig=qnFzYNd5efLps8S0uN8FFE1Li0c&redir_esc=y#v=onepage&q=doxylamine%20circadian&f=false",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/11224",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      132
    ],
    "classf": [
      10
    ],
    "mechanisms": [
      60
    ],
    "target": [
      58
    ],
    "effect": [
      205
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 153,
  "fields": {
    "gname": "Lormetazepam",
    "smiles": "CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)O)C3=CC=CC=C3Cl",
    "linkname": "lormetazepam",
    "molecula": "C16H12Cl2N2O2",
    "iupacname": "7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-3H-1,4-benzodiazepin-2-one",
    "updphoto": "media/imgsrv_-_2025-03-19T113915.655.png",
    "description": "Lormetazepam is a benzodiazepine used primarily for its hypnotic effects, particularly in treating insomnia. While it has been studied for its effects on sleep architecture, such as reducing REM sleep and increasing sleep spindles and K-complexes, there is limited direct evidence regarding its impact on circadian rhythms1.\r\nHowever, one study suggests that the timing of lormetazepam administration can influence sleep patterns in patients with depressive insomnia. The study found that the timing of treatment affected changes in sleep onset and morning awakening, indicating that lormetazepam's effects may depend on the timing of administration relative to the individual's circadian cycle.\r\nMasse, M., Henry, H., Cuvelier, E., Pinçon, C., Pavy, M., Beeuwsaert, A., Barthélémy, C., Cuny, D., Gautier, S., Kambia, N. and Lefebvre, J.M., 2022, January. Sleep medication in older adults: identifying the need for support by a community pharmacist. In Healthcare (Vol. 10, No. 1, p. 147). MDPI.",
    "fdastatus": "Not approved",
    "linkslists": "https://onlinelibrary.wiley.com/doi/abs/10.1002/hup.470040406",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/13314",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.12750.html",
    "drugbank": "https://go.drugbank.com/drugs/DB13872",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:52993",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D01657",
    "selleckchem": null,
    "articles": [
      131
    ],
    "classf": [
      10
    ],
    "mechanisms": [
      23,
      57
    ],
    "target": [
      35
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 154,
  "fields": {
    "gname": "Nitrazepam",
    "smiles": "C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3",
    "linkname": "nitrazepam",
    "molecula": "C15H11N3O3",
    "iupacname": "7-nitro-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one",
    "updphoto": "media/imgsrv_-_2025-03-19T114338.415.png",
    "description": "Nitrazepam, a long-acting benzodiazepine, is primarily prescribed for the treatment of insomnia and certain seizure disorders. While its sedative and anxiolytic properties are well-documented, its influence on circadian rhythms—the endogenous ~24-hour cycles regulating sleep-wake patterns, hormone secretion, and other physiological processes—remains a subject of significant research interest. This abstract synthesizes current findings on how nitrazepam interacts with circadian regulation, drawing from pharmacological, clinical, and experimental studies.\r\n\r\n1. Disruption of Sleep Architecture and Circadian Stability\r\nNitrazepam alters sleep architecture by increasing Stage 2 non-rapid eye movement (NREM) sleep while suppressing deep slow-wave sleep (SWS) and rapid eye movement (REM) sleep. Such modifications can destabilize circadian rhythms, as SWS and REM sleep are critical for restorative sleep and neurophysiological synchronization. Studies indicate that benzodiazepines, including nitrazepam, may impair the natural progression of sleep stages, leading to fragmented sleep patterns that misalign with endogenous circadian timing.\r\n\r\n2. Impact on Circadian Phase and Entrainment\r\nBenzodiazepines like triazolam have been shown to induce phase shifts in circadian rhythms in animal models, suggesting a potential role in modulating the suprachiasmatic nucleus (SCN), the brain's central circadian pacemaker. While direct evidence for nitrazepam’s phase-shifting effects is limited, its long half-life (16–38 hours) and sustained GABAergic activity may interfere with normal circadian entrainment, particularly in vulnerable populations such as the elderly.\r\n\r\n3. Interactions with Melatonin and Light-Dark Cycles\r\nMelatonin, a key circadian regulator, is suppressed by benzodiazepines, potentially exacerbating circadian misalignment in patients with insomnia. Nitrazepam’s prolonged suppression of GABAergic activity may further disrupt melatonin secretion, impairing the body's ability to synchronize with environmental light-dark cycles. Conversely, some research suggests that melatonin supplementation during benzodiazepine withdrawal (including nitrazepam) can help restore circadian stability, indicating a bidirectional relationship between benzodiazepines and circadian regulation.\r\n\r\n4. Clinical Implications and Long-Term Effects\r\nChronic nitrazepam use is associated with tolerance, dependence, and withdrawal-related circadian disturbances, including rebound insomnia and heightened sleep fragmentation. Elderly patients are particularly susceptible to prolonged sedation and next-day impairments, which may exacerbate age-related circadian decline. Additionally, nitrazepam’s suppression of deep sleep may contribute to long-term cognitive and metabolic dysregulation, further destabilizing circadian homeostasis.",
    "fdastatus": "Not approved",
    "linkslists": "https://karger.com/hrp/article-abstract/31/1-2/59/365242",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/4506",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4350.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01595",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7581",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D00531",
    "selleckchem": null,
    "articles": [
      130
    ],
    "classf": [
      10,
      5
    ],
    "mechanisms": [
      23,
      57
    ],
    "target": [
      35
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 155,
  "fields": {
    "gname": "Loprazolam",
    "smiles": "CN1CCN(CC1)/C=C\\2/C(=O)N3C(=N2)CN=C(C4=C3C=CC(=C4)[N+](=O)[O-])C5=CC=CC=C5Cl",
    "linkname": "Loprazolam",
    "molecula": "C23H21ClN6O3",
    "iupacname": "(2Z)-6-(2-chlorophenyl)-2-[(4-methylpiperazin-1-yl)methylidene]-8-nitro-4H-imidazo[1,2-a][1,4]benzodiazepin-1-one",
    "updphoto": "media/imgsrv_-_2025-03-19T114723.032.png",
    "description": "There is limited specific information available on how loprazolam affects circadian rhythms. However, benzodiazepines, the class of drugs to which loprazolam belongs, can influence sleep patterns and potentially impact circadian rhythms indirectly.\r\nSome benzodiazepines, like triazolam, have been shown to affect circadian rhythms in animal studies. For example, triazolam can induce phase shifts in the circadian clock of golden hamsters, especially in the absence of a light-dark cycle. However, this specific effect has not been documented for loprazolam.\r\nGeneral Effects of Benzodiazepines: Benzodiazepines are used for their sedative and hypnotic properties, which can alter sleep patterns. Disruptions in sleep can indirectly affect circadian rhythms, as regular sleep-wake cycles are crucial for maintaining a stable circadian rhythm.\r\nDe Crescenzo, F., D'Alò, G.L., Ostinelli, E.G., Ciabattini, M., Di Franco, V., Watanabe, N., Kurtulmus, A., Tomlinson, A., Mitrova, Z., Foti, F. and Del Giovane, C., 2022. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. The Lancet, 400(10347), pp.170-184.",
    "fdastatus": "Not approved",
    "linkslists": "https://www.thelancet.com/article/S0140-6736(22)00878-9/fulltext",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/4506",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.2298440.html",
    "drugbank": "https://go.drugbank.com/drugs/DB13643",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:135754",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D07326",
    "selleckchem": null,
    "articles": [
      129
    ],
    "classf": [
      10,
      5
    ],
    "mechanisms": [
      23,
      57
    ],
    "target": [
      35
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 156,
  "fields": {
    "gname": "DEQUALINIUM CHLORIDE",
    "smiles": "CC1=[N+](C2=CC=CC=C2C(=C1)N)CCCCCCCCCC[N+]3=C(C=C(C4=CC=CC=C43)N)C.[Cl-].[Cl-]",
    "linkname": "dequalinium-chloride",
    "molecula": "C30H40Cl2N4",
    "iupacname": "1-[10-(4-amino-2-methylquinolin-1-ium-1-yl)decyl]-2-methylquinolin-1-ium-4-amine;dichloride",
    "updphoto": "media/imgsrv_-_2025-03-19T115553.631.png",
    "description": "Dequalinium chloride is an organic chloride salt derived from dequalinium, a quaternary ammonium compound. It acts as an antiseptic, antifungal, antibacterial, and antineoplastic agent. It is commonly used in wound dressings, mouth infections, and vaginal tablets for bacterial vaginosis. Dequalinium chloride has rapid bactericidal and fungicidal effects, primarily targeting gram-positive bacteria. However, it may cause skin irritation or ulceration in some cases. Binds E3 ubiquitin-protein ligase XIAP, cGMP-gated cation channel alpha-1, Calcium-activated potassium channel subunit alpha-1.\r\nTamai detected activity on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/10649#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/10649",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.10201.html",
    "drugbank": "https://go.drugbank.com/drugs/DB04209",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31466",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D01575",
    "selleckchem": "https://www.selleckchem.com/products/dequalinium-chloride.html",
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      28,
      51
    ],
    "target": [
      29
    ],
    "effect": [
      121
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 157,
  "fields": {
    "gname": "Berberine Chloride",
    "smiles": "COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC.[Cl-]",
    "linkname": "berberine-chloride",
    "molecula": "C20H18NO4.Cl C20H18ClNO4",
    "iupacname": "16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene;chloride",
    "updphoto": "media/imgsrv_-_2025-03-19T115902.318.png",
    "description": "GASTROINTESTINAL drug. Binds Baculoviral IAP repeat-containing protein 5. Tamai  et al. 2018. detected activity on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10\r\n\r\nThe anti-inflammatory effects of berberine were lost in BMDMs derived from Rev-erbα-deficient mice. Furthermore, chronic colitis displayed a diurnal rhythmicity in disease severity and its diurnal pattern was in an opposite phase to that of Rev-erbα expression, supporting a direct control of colitis by Rev-erbα. Moreover, berberine effects on chronic colitis were dosing time-dependent. ZT10 dosing generated a better treatment outcome compared to ZT2. This was because colitis was less severe and Rev-erbα expression was much higher at ZT10 than at ZT2. In conclusion, circadian pharmacological effects of berberine on chronic colitis were mainly contributed by diurnal rhythms of both disease severity and Rev-erbα (as a drug target). The findings may have implications for chronotherapeutic practice on colitis or related diseases.\r\n\r\nZhou, Z., Lin, Y., Gao, L., Yang, Z., Wang, S. and Wu, B., 2020. Circadian pharmacological effects of berberine on chronic colitis in mice: role of the clock component Rev-erbα. Biochemical pharmacology, 172, p.113773.\r\n\r\nThe chronopharmacological effect is attributed to the alignment of berberine’s action with the circadian regulation of NF-κB/NLRP3 inflammasome pathways . Furthermore, berberine ameliorates metabolic-associated fatty liver disease (MAFLD) by upregulating Clock and Bmal1, thereby restoring redox homeostasis and insulin sensitivity.\r\n\r\nYe, C., Zhang, Y., Lin, S., Chen, Y., Wang, Z., Feng, H., Fang, G. and Quan, S., 2023. Berberine ameliorates metabolic-associated fatty liver disease mediated metabolism disorder and redox homeostasis by upregulating clock genes: Clock and Bmal1 expressions. Molecules, 28(4), p.1874.",
    "fdastatus": "Not approved",
    "linkslists": "https://www.sciencedirect.com/science/article/pii/S0006295219304721",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/12456",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.11947.html",
    "drugbank": "https://go.drugbank.com/drugs/DB04115",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31271",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D01147",
    "selleckchem": "https://www.selleckchem.com/products/Berberine-Hydrochloride.html",
    "articles": [
      117,
      127,
      128
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      51,
      165,
      166
    ],
    "target": [
      29,
      104,
      103,
      47
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 158,
  "fields": {
    "gname": "Protoporphyrin IX",
    "smiles": "CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C=C)C)C(=C4CCC(=O)O)C)C(=C3C)CCC(=O)O)C=C",
    "linkname": "protoporphyrin-ix",
    "molecula": "C34H34N4O4",
    "iupacname": "3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid",
    "updphoto": "media/imgsrv_-_2025-03-19T120232.983.png",
    "description": "ANTI-CANCER, IMMUNOSUPPRESSIVES agent. Binds Ferritin light chain. Tamai detected activity on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": null,
    "linkslists": null,
    "pubchem": null,
    "chemspider": "https://www.chemspider.com/Chemical-Structure.10469486.html",
    "drugbank": "https://go.drugbank.com/drugs/DB02285",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      15,
      68
    ],
    "target": [
      29
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 159,
  "fields": {
    "gname": "Nadifloxacin",
    "smiles": "CC1CCC2=C3N1C=C(C(=O)C3=CC(=C2N4CCC(CC4)O)F)C(=O)O",
    "linkname": "Nadifloxacin",
    "molecula": "C19H21FN2O4",
    "iupacname": "7-fluoro-8-(4-hydroxypiperidin-1-yl)-12-methyl-4-oxo-1-azatricyclo[7.3.1.05,13]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid",
    "updphoto": "media/imgsrv_-_2025-03-19T120537.824.png",
    "description": "DISINFECTANT, ANTISEPTIC. DNA gyrase subunit A*, B* binding is observed.  Tamai et al detected activity of Nadifloxacin on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10\r\n\r\n\r\nAdditionally, nadifloxacin’s antibacterial action could reduce infection-induced inflammation, potentially stabilizing circadian rhythms disrupted by systemic inflammation. Inflammatory cytokines (e.g., IL-6, TNF-α) are known to perturb clock function, and their suppression might restore rhythmicity in peripheral tissues . However, fluoroquinolones may also induce oxidative stress, which can impair clock gene expression by destabilizing redox-sensitive transcription factors like BMAL1\r\n\r\nJacob, H., Curtis, A.M. and Kearney, C.J., 2020. Therapeutics on the clock: circadian medicine in the treatment of chronic inflammatory diseases. Biochemical pharmacology, 182, p.114254.",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/4410",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4257.html",
    "drugbank": "https://go.drugbank.com/drugs/DB12447",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31889",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D01147",
    "selleckchem": "https://www.selleckchem.com/products/nadifloxacin.html",
    "articles": [
      117,
      126
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      51,
      28,
      38,
      68
    ],
    "target": [
      29
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 160,
  "fields": {
    "gname": "Metergoline",
    "smiles": "CN1CC(CC2C1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5",
    "linkname": "metergoline",
    "molecula": "C25H29N3O2",
    "iupacname": "benzyl N-[[(6aR,9S,10aR)-4,7-dimethyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinolin-9-yl]methyl]carbamate",
    "updphoto": "media/imgsrv_-_2025-03-19T121149.901.png",
    "description": "Tamai et al detected activity of Metergoline on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/28693",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.26687.html",
    "drugbank": "https://go.drugbank.com/drugs/DB13520",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      51,
      68,
      38
    ],
    "target": [
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 161,
  "fields": {
    "gname": "Cyproterone",
    "smiles": "CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)[C@@H]5C[C@@H]5[C@]34C)Cl)C)O",
    "linkname": "cyproterone",
    "molecula": "C22H27ClO3",
    "iupacname": "(1S,2S,3S,5R,11R,12S,15R,16S)-15-acetyl-9-chloro-15-hydroxy-2,16-dimethylpentacyclo[9.7.0.02,8.03,5.012,16]octadeca-7,9-dien-6-one",
    "updphoto": "media/imgsrv_-_2025-03-19T121350.745.png",
    "description": "Cyproterone is a synthetic steroidal antiandrogen that was studied in the 1960s and 1970s but was never introduced for medical use. It is a precursor to cyproterone acetate (CPA), which is widely used as a medication. Cyproterone acts as a potent antiandrogen, though it has about three-fold lower potency compared to CPA. Unlike CPA, cyproterone lacks progestogenic activity and does not suppress gonadotropin secretion, making it progonadotropic in males. Tamai detected activity of Cyproterone on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5284537",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4447594.html",
    "drugbank": "https://go.drugbank.com/drugs/DB04839",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50742",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D07766",
    "selleckchem": "https://www.selleckchem.com/products/cyproterone-acetate.html",
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      51,
      28,
      38,
      68
    ],
    "target": [
      29,
      30,
      63
    ],
    "effect": [
      119
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 162,
  "fields": {
    "gname": "Clorgyline hydrochloride",
    "smiles": "CN(CCCOC1=C(C=C(C=C1)Cl)Cl)CC#C.Cl",
    "linkname": "clorgyline-hydrochloride",
    "molecula": "C13H16Cl3NO",
    "iupacname": "3-(2,4-dichlorophenoxy)-N-methyl-N-prop-2-ynylpropan-1-amine;hydrochloride",
    "updphoto": "media/imgsrv_-_2025-03-19T121617.527.png",
    "description": "CENTRAL NERVOUS SYSTEM\tdrug affects Monoamine oxidase A.\r\nTamai detected activity of Clorgyline hydrochloride on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/28767",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.26759.html",
    "drugbank": "https://go.drugbank.com/drugs/DB04017",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      68,
      69,
      38,
      51,
      28
    ],
    "target": [
      64,
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 163,
  "fields": {
    "gname": "Nitroxoline",
    "smiles": "C1=CC2=C(C=CC(=C2N=C1)O)[N+](=O)[O-]",
    "linkname": "nitroxoline",
    "molecula": "C9H6N2O3",
    "iupacname": "5-nitroquinolin-8-ol",
    "updphoto": "media/imgsrv_-_2025-03-19T122541.278.png",
    "description": "Nitroxoline is a urinary antibacterial agent used primarily to treat urinary tract infections (UTIs). It is effective against both gram-positive and gram-negative bacteria, as well as mycoplasmas and certain fungi like Candida spp. Nitroxoline works by chelating metallic ions essential for microbial survival, and it is also known for its ability to combat biofilm infections. It has been used in Europe for decades and is gaining renewed interest due to its safety profile and effectiveness in an era of increasing antibiotic resistance.\r\nTamai detected activity of Nitroxoline on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/19910",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.18756.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01422",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      68
    ],
    "target": [
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 164,
  "fields": {
    "gname": "Artenimol (DHA, Dihydroartemisinin)",
    "smiles": "C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)O)C",
    "linkname": "artenimol",
    "molecula": "C15H24O5",
    "iupacname": "(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol",
    "updphoto": "media/imgsrv_-_2025-03-19T122807.263.png",
    "description": "Artenimol, also known as dihydroartemisinin (DHA), is an artemisinin derivative used as an antimalarial agent. It is the active metabolite of all artemisinin compounds and is effective against uncomplicated Plasmodium falciparum infections. Artenimol works by producing free radicals that damage the malaria parasite's biological macromolecules, leading to oxidative stress and parasite death. It is often used in combination with other drugs, such as piperaquine, and is approved by the European Medicines Agency for use in treating malaria.\r\nTamai et al. 2018 detected activity of Artenimol on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/3000518#section=Names-and-Identifiers",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.2272104.html",
    "drugbank": "https://go.drugbank.com/drugs/DB11638",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:135921",
    "uniprot": null,
    "kegg": null,
    "selleckchem": "https://www.selleckchem.com/products/Dihydroartemisinin(DHA).html",
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      68,
      70
    ],
    "target": [
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 165,
  "fields": {
    "gname": "Hydroxyprogesterone",
    "smiles": "CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O",
    "linkname": "hydroxyprogesterone",
    "molecula": "C21H30O3",
    "iupacname": "(8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one",
    "updphoto": "media/imgsrv_-_2025-03-19T123150.880.png",
    "description": "Tamai detected activity of Hydroxyprogesterone on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/Hydroxyprogesterone",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.6002.html",
    "drugbank": "https://go.drugbank.com/drugs/DB14570",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:197158",
    "uniprot": "https://www.uniprot.org/uniprotkb/P05093/entry",
    "kegg": "https://www.kegg.jp/entry/D08053",
    "selleckchem": "https://www.selleckchem.com/products/17-hydroxyprogesterone.html",
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      71
    ],
    "target": [
      65,
      29,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 166,
  "fields": {
    "gname": "Rapamycin (Sirolimus)",
    "smiles": "CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC",
    "linkname": "rapamycin",
    "molecula": "C51H79NO13",
    "iupacname": "(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetrae",
    "updphoto": "media/imgsrv_-_2025-03-19T123544.746.png",
    "description": "Rapamycin, also known as sirolimus, is a macrolide compound produced by the bacterium Streptomyces hygroscopicus. It is primarily used as an immunosuppressant to prevent organ transplant rejection and in drug-eluting stents to inhibit restenosis. Rapamycin acts by inhibiting the mammalian target of rapamycin (mTOR), affecting cell growth and metabolism. It has potential applications in anti-aging research and cancer treatment due to its ability to extend lifespan in various animal models and inhibit cell proliferation. ANTI-CANCER, IMMUNOSUPPRESSIVE drug.\r\nTamai detected activity of  RAPAMYCIN on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5284616",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.10482078.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00877",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9168",
    "uniprot": "https://www.uniprot.org/uniprotkb/P42345/entry",
    "kegg": "https://www.kegg.jp/entry/D00753",
    "selleckchem": "https://www.selleckchem.com/products/Rapamycin.html",
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      72,
      51,
      68,
      38
    ],
    "target": [
      29
    ],
    "effect": [
      117
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 167,
  "fields": {
    "gname": "SERTACONAZOLE",
    "smiles": "C1=CC2=C(C(=C1)Cl)SC=C2COC(CN3C=CN=C3)C4=C(C=C(C=C4)Cl)Cl",
    "linkname": "SERTACONAZOLE",
    "molecula": "C20H15Cl3N2OS",
    "iupacname": "1-[2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole",
    "updphoto": "media/imgsrv_-_2025-03-19T140326.468.png",
    "description": "Tamai detected activity of SERTACONAZOLE on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/65863",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.59273.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01153",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:82866",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D06883",
    "selleckchem": "https://www.selleckchem.com/products/sertaconazole.html",
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      68,
      73
    ],
    "target": [
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 168,
  "fields": {
    "gname": "BLEOMYCIN SULFATE",
    "smiles": "CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@H](C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O",
    "linkname": "bleomycin-sulfate",
    "molecula": "C55H84N17O21S3+",
    "iupacname": "3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydrox",
    "updphoto": "media/imgsrv_-_2025-03-19T140858.187.png",
    "description": "ANTI-CANCER, IMMUNOSUPPRESSIVE drug. Protein disulfide-isomerase binding.\r\nTamai detected activity of BLEOMYCIN  on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10\r\n\r\n\r\nBleomycin disrupted the circadian rhythm and increased DEC1 which promoted p21 expression, increased p21 mediated AT2 senescence and pulmonary fibrosis.\r\n\r\nChen, S.J., Yu, F., Feng, X., Li, Q., Jiang, Y.H., Zhao, L.Q., Cheng, P.P., Wang, M., Song, L.J., Liang, L.M. and He, X.L., 2024. DEC1 is involved in circadian rhythm disruption-exacerbated pulmonary fibrosis. Cell Communication and Signaling, 22(1), p.245.",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5360373",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4574226.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00290",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:34582",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D02177",
    "selleckchem": "https://www.selleckchem.com/search.html",
    "articles": [
      117,
      125
    ],
    "classf": [
      5,
      7
    ],
    "mechanisms": [
      51,
      28,
      38,
      68,
      143
    ],
    "target": [
      29,
      63,
      90
    ],
    "effect": [
      115
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 169,
  "fields": {
    "gname": "Erlotinib",
    "smiles": "COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC",
    "linkname": "erlotinib",
    "molecula": "C22H23N3O4",
    "iupacname": "N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine",
    "updphoto": "media/imgsrv_-_2025-03-19T141027.758.png",
    "description": "Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.\r\nTamai detected activity of on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, et al, 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/176870",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.154044.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00530",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      74
    ],
    "target": [
      66,
      67,
      29,
      63
    ],
    "effect": [
      114
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 170,
  "fields": {
    "gname": "Felodipine",
    "smiles": "CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C",
    "linkname": "felodipine",
    "molecula": "C18H19Cl2NO4",
    "iupacname": "5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate",
    "updphoto": "media/imgsrv_-_2025-03-19T142215.869.png",
    "description": "CARDIOVASCULAR DRUG. Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction. Felodipine is the most potent CCB in use and is unique in that it exhibits fluorescent activity.\r\nTamai detected activity of Felodipine on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/3333",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.3216.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01023",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:585948",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D00319",
    "selleckchem": "https://www.selleckchem.com/products/Felodipine(Plendil).html",
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      68,
      38,
      75,
      51,
      28
    ],
    "target": [
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 171,
  "fields": {
    "gname": "Bromocriptine",
    "smiles": "CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O",
    "linkname": "bromocriptine",
    "molecula": "C32H40BrN5O5",
    "iupacname": "CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O",
    "updphoto": "media/imgsrv_-_2025-03-19T142645.681.png",
    "description": "CENTRAL NERVOUS SYSTEM DRUG. \"D1A, D1B, D2, D3, D4 dopamine receptor, 5-hydroxytryptamine receptor 1A, 1B, 1D, 2A, 2B, 2C, 7\r\n Alpha-1A, 1B, 1D, 2A, 2B, 2C adrenergic receptor binding activity.\r\n\r\nTamai detected activity of BROMOCRIPTINE on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/31101",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.28858.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01200",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3181",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D03165",
    "selleckchem": "https://www.selleckchem.com/products/bromocriptine-mesylate.html",
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      68,
      38,
      46,
      50,
      51,
      22,
      28
    ],
    "target": [
      34,
      29,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 172,
  "fields": {
    "gname": "Acitretin",
    "smiles": "CC1=CC(=C(C(=C1/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C)C)C)OC",
    "linkname": "acitretin",
    "molecula": "C21H26O3",
    "iupacname": "(2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid",
    "updphoto": "media/imgsrv_-_2025-03-19T142809.889.png",
    "description": "DERMATOLOGICAL DRUG. An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate. Tamai detected activity of Acitretin on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5284513",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4447573.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00459",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50172",
    "uniprot": null,
    "kegg": null,
    "selleckchem": "https://www.selleckchem.com/products/Acitretin.html",
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      51,
      28,
      68
    ],
    "target": [
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 173,
  "fields": {
    "gname": "CALCITRIOL",
    "smiles": "C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C",
    "linkname": "calcitriol",
    "molecula": "C27H44O3",
    "iupacname": "(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol",
    "updphoto": "media/imgsrv_-_2025-03-19T143039.718.png",
    "description": "VITAMIN.  Calcitriol is an active metabolite of vitamin D with 3 hydroxyl (OH) groups and is commonly referred to as 1,25-dihydroxycholecalciferol, or 1alpha,25-dihydroxyvitamin D3, 1,25-dihydroxyvitamin D3. It is produced in the body after series of conversion steps of 7-dehydrocholesterol from exposure to UV light. 7-dehydrocholesterol is converted to [DB00169] (vitamin D3) in the skin, which is then converted to [DB00146] in the liver and kidneys. Binds Vitamin D3 receptor,  Homeobox protein Hox-A10,  Vitamin D-binding protein.\r\nTamai detected activity of Calcitriol  on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5280453",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4444108.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00136",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:17823",
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      51,
      28,
      68,
      76
    ],
    "target": [
      69,
      68,
      29,
      63
    ],
    "effect": [
      112
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 174,
  "fields": {
    "gname": "KETOCONAZOLE",
    "smiles": "CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl",
    "linkname": "ketoconazole",
    "molecula": "C26H28Cl2N4O4",
    "iupacname": "1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone",
    "updphoto": "media/imgsrv_-_2025-03-19T143752.269.png",
    "description": "DISINFECTANT, ANTISEPTIC. Binding Androgen receptor,  17-hydroxylase,  Steroid 21-hydroxylase,  11-hydroxylase,  Cytochrome P450 19A1,  Potassium voltage-gated channel subfamily H member 2,  Nuclear receptor subfamily 2, 3. Tamai detected activity of KETOCONAZOLE on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/456201",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.3691.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01026",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:47519",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D00351",
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      51,
      68,
      77
    ],
    "target": [
      29,
      63
    ],
    "effect": [
      109
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 175,
  "fields": {
    "gname": "DAUNORUBICIN HCL",
    "smiles": "CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O.Cl",
    "linkname": "daunorubicin-hcl",
    "molecula": "C27H29NO10.HCl C27H30ClNO10",
    "iupacname": "(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride",
    "updphoto": "media/imgsrv_-_2025-03-19T144156.777.png",
    "description": "ANTI-CANCER drug, IMMUNOSUPPRESSANT. Tamai  et al. 2018 detected activity of DAUNORUBICIN on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/62770",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.56512.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00694",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:41977",
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [],
    "classf": [
      5
    ],
    "mechanisms": [
      68,
      38,
      78,
      51,
      28
    ],
    "target": [
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 176,
  "fields": {
    "gname": "Bexarotene",
    "smiles": "CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C",
    "linkname": "bexarotene",
    "molecula": "C24H28O2",
    "iupacname": "4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid",
    "updphoto": "media/imgsrv_-_2025-03-19T144804.884.png",
    "description": "ANTI-CANCER drug, IMMUNOSUPPRESSANT. Tamai et al. 2018 detected activity of bexarotene on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/82146",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.74139.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00307",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50859",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D03106",
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      51,
      28,
      38,
      68
    ],
    "target": [
      29,
      63
    ],
    "effect": [
      108
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 177,
  "fields": {
    "gname": "CLOFARABINE",
    "smiles": "C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)F)Cl)N",
    "linkname": "clofarabine",
    "molecula": "C10H11ClFN5O3",
    "iupacname": "(2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol",
    "updphoto": "media/imgsrv_-_2025-03-19T151110.094.png",
    "description": "Clofarabine is a purine nucleoside analogue consisting of a 6-amino-2-chloropurin-9-yl group attached to the 1beta position of 2'-deoxy-2'-fluoro-D-arabinofuranose. It is metabolized intracellularly to the active 5'-triphosphate metabolite, which inhibits DNA synthesisis and so stops the growth of cancer cells. Clofarabine is used as an antimetabolite antineoplastic agent in the treatment of relapsed or refractory acute lymphoblastic leukaemia. It has a role as an antineoplastic agent and an antimetabolite. It is an organofluorine compound and a member of adenosines. Tamai et al detected activity of CLOFARABINE on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/119182",
    "chemspider": null,
    "drugbank": "https://go.drugbank.com/drugs/DB00631",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:681569",
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      51,
      28,
      68
    ],
    "target": [
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 178,
  "fields": {
    "gname": "VINBLASTINE SULFATE",
    "smiles": "CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O",
    "linkname": "vinblastine-sulfate",
    "molecula": "C46H58N4O9.H2O4S C46H60N4O13S",
    "iupacname": "methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016",
    "updphoto": "media/imgsrv_-_2025-03-19T151243.550.png",
    "description": "Methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate;sulfuric acid is an ANTI-CANCER drug, IMMUNOSUPPRESSANT.\r\nTamai detected activity of VINBLASTINE  on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5388983",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4535008.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00570",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:27375",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D01068",
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      80,
      51,
      28,
      68
    ],
    "target": [
      29,
      30,
      63
    ],
    "effect": [
      106
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 179,
  "fields": {
    "gname": "CHLORAMBUCIL",
    "smiles": "C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl",
    "linkname": "chlorambucil",
    "molecula": "C14H19Cl2NO2",
    "iupacname": "4-[4-[bis(2-chloroethyl)amino]phenyl]butanoic acid",
    "updphoto": "media/imgsrv_-_2025-03-19T151720.991.png",
    "description": "ANTI-CANCER, IMMUNOSUPPRESSIVE drug. Chlorambucil is a monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia. It has a role as an alkylating agent, a carcinogenic agent, an antineoplastic agent, an immunosuppressive agent and a drug allergen. It is a nitrogen mustard, an organochlorine compound, an aromatic amine, a tertiary amino compound and a monocarboxylic acid.\r\nTamai detected activity of chlorambucil on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/2708",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.2607.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00291",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      51,
      28,
      68
    ],
    "target": [
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 180,
  "fields": {
    "gname": "MITOXANTRONE HCL",
    "smiles": "C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl",
    "linkname": "mitoxantrone-hcl",
    "molecula": "C22H30Cl2N4O6",
    "iupacname": "1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione;dihydrochloride",
    "updphoto": "media/imgsrv_-_2025-03-19T152132.804.png",
    "description": "ANTI-CANCER, IMMUNOSUPPRESSIVE drug, targeting DNA and DNA topoisomerase 2-alpha.\r\nTamai detected activity of MITOXANTRONE on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/51082",
    "chemspider": null,
    "drugbank": "https://go.drugbank.com/drugs/DB01204",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=50729",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D02166",
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      68
    ],
    "target": [
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 181,
  "fields": {
    "gname": "Paclitaxel (TAXOL)",
    "smiles": "CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C",
    "linkname": "paclitaxel-taxol",
    "molecula": "C47H51NO14",
    "iupacname": "[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate",
    "updphoto": "media/imgsrv_-_2025-03-19T152301.931.png",
    "description": "Paclitaxel injections delayed voluntary wheel running activity onset in a light-dark cycle (LD) and lengthened the free-running period of locomotion in constant darkness (DD), indicating an effect on inherent suprachiasmatic nucleus (SCN) pacemaker activity. Paclitaxel attenuated clock gene rhythms in multiple brain regions in LD and DD. Furthermore, paclitaxel disrupted circulating corticosterone rhythms in DD by elevating its levels across a 24-hour cycle, which correlated with blunted amplitudes of Arntl, Nr1d1, Per1, and Star rhythms in the adrenal glands. Paclitaxel also shortened SCN slice rhythms, increased the amplitude of adrenal gland oscillations in PER2::luciferase cultures, and increased the concentration of pro-inflammatory cytokines and chemokines released from the SCN. These findings indicate that paclitaxel disrupts clock genes and behavior driven by the SCN, other brain regions, and adrenal glands, which were associated with chemotherapy-induced inflammation. \r\nSullivan, K.A., Grant, C.V., Jordan, K.R., Obrietan, K. and Pyter, L.M., 2022. Paclitaxel chemotherapy disrupts behavioral and molecular circadian clocks in mice. Brain, behavior, and immunity, 99, pp.106-118.",
    "fdastatus": "Approved",
    "linkslists": null,
    "pubchem": "https://www.chemspider.com/Chemical-Structure.10368587.html",
    "chemspider": "https://go.drugbank.com/drugs/DB01229",
    "drugbank": "https://go.drugbank.com/drugs/DB01229",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=45863",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D00491",
    "selleckchem": null,
    "articles": [
      124
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      51,
      28,
      38,
      68
    ],
    "target": [
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 182,
  "fields": {
    "gname": "NEFAZODONE HCL",
    "smiles": "CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl.Cl",
    "linkname": "nefazodone-hcl",
    "molecula": "C25H33Cl2N5O2",
    "iupacname": "2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one;hydrochloride",
    "updphoto": "media/imgsrv_-_2025-03-19T152744.922.png",
    "description": "Nefazodone Hydrochloride is a synthetic derivative of phenylpiperazine and chemically unrelated to selective serotonin reuptake inhibitors, tricyclics, tetracyclics, or monoamine oxidase inhibitors (MAOI), antidepressant Nefazadone Hydrochloride antagonizes central 5-HT2 receptors and inhibits reuptake of serotonin and norepinephrine.\r\nTamai detected activity of  Nefazodone  on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://www.chemspider.com/Chemical-Structure.49584.html",
    "chemspider": "https://go.drugbank.com/drugs/DB01149",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      51,
      68,
      38
    ],
    "target": [
      29,
      30,
      63
    ],
    "effect": [
      202
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 183,
  "fields": {
    "gname": "Oxiconazole Nitrate",
    "smiles": "C1=CC(=C(C=C1Cl)Cl)CO/N=C(\\CN2C=CN=C2)/C3=C(C=C(C=C3)Cl)Cl.[N+](=O)(O)[O-]",
    "linkname": "oxiconazole-nitrate",
    "molecula": "C18H14Cl4N4O4",
    "iupacname": "Z)-1-(2,4-dichlorophenyl)-N-[(2,4-dichlorophenyl)methoxy]-2-imidazol-1-ylethanimine;nitric acid",
    "updphoto": "media/imgsrv_-_2025-03-19T153055.653.png",
    "description": "Oxiconazole Nitrate is the nitrate salt form of oxiconazole, a broad spectrum imidazole derivative with antifungal activity. Although the exact mechanism of action has yet to be fully elucidated, oxiconazole, like other azole antifungals, most likely inhibits the cytochrome P450-dependent demethylation of lanosterol. This prevents the synthesis of ergosterol which is a crucial component of fungal cell membrane. By disrupting fungal cell membrane synthesis and integrity, oxiconazole alters fungal cell membrane permeability, promotes loss of essential intracellular components and eventually inhibits fungal cell growth. Tamai detected activity  of Oxiconazole using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMB",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/9556529",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.7834530.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00239",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      51,
      28,
      38,
      68
    ],
    "target": [
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 184,
  "fields": {
    "gname": "PROGESTERONE",
    "smiles": "CC(=O)C1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C",
    "linkname": "progesterone",
    "molecula": "C21_ H30_ O2",
    "iupacname": "(8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one",
    "updphoto": "media/imgsrv_-_2025-03-19T153414.573.png",
    "description": "Progesterone is a C21-steroid hormone in which a pregnane skeleton carries oxo substituents at positions 3 and 20 and is unsaturated at C(4)-C(5). As a hormone, it is involved in the female menstrual cycle, pregnancy and embryogenesis of humans and other species. It has a role as a contraceptive drug, a progestin, a progesterone receptor agonist, a human metabolite and a mouse metabolite. It is a 20-oxo steroid, a 3-oxo-Delta(4) steroid and a C21-steroid hormone. It derives from a hydride of a pregnane.Tamai detected activity of PROGESTERONE on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5994",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.5773.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00396",
    "chebi": null,
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D00066",
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      51,
      28,
      85,
      68
    ],
    "target": [
      70,
      71,
      29,
      30,
      63
    ],
    "effect": [
      200
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 185,
  "fields": {
    "gname": "Nelfinavir mesylate",
    "smiles": "CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O.CS(=O)(=O)O",
    "linkname": "nelfinavir-mesylate",
    "molecula": "C33H49N3O7S2",
    "iupacname": "(3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide;methanesulfonic acid",
    "updphoto": "media/imgsrv_-_2025-03-19T153929.608.png",
    "description": "Nelfinavir mesylate is a methanesulfonate (mesylate) salt prepared from equimolar amounts of nelfinavir and methanesulfonic acid. It is used for treatment of HIV and also exhibits some anticancer properties. It has a role as a HIV protease inhibitor and an antineoplastic agent. It contains a nelfinavir(1+). Tamai detected activity of  Nelfinavir on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/64142",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.57717.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00220",
    "chebi": null,
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D00899",
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      68,
      38,
      51,
      86,
      28
    ],
    "target": [
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 186,
  "fields": {
    "gname": "Adefovir Dipivoxil",
    "smiles": "CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N=CN=C21)N)OCOC(=O)C(C)(C)C",
    "linkname": "adefovir-dipivoxil",
    "molecula": "C20H32N5O8P",
    "iupacname": "[2-(6-aminopurin-9-yl)ethoxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate",
    "updphoto": "media/imgsrv_-_2025-03-19T154535.660.png",
    "description": "Adefovir pivoxil is an organic phosphonate that is the dipivoxil ester of adefovir. A prodrug for adefovir, an HIV-1 reverse transcriptase inhibitor, adefovir pivoxil is used to treat chronic hepatitis B viral infection. It has a role as a prodrug, an antiviral drug, a DNA synthesis inhibitor, a HIV-1 reverse transcriptase inhibitor and a nephrotoxic agent. It is an organic phosphonate, a member of 6-aminopurines, an ether and a carbonate ester. It is functionally related to an adefovir. Tamai detected Adefovir activity on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/60871",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.54855.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00718",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      68,
      38,
      51,
      87,
      28
    ],
    "target": [
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 187,
  "fields": {
    "gname": "ARSENIC TRIOXIDE",
    "smiles": "[O-2].[O-2].[O-2].[As+3].[As+3]",
    "linkname": "arsenic-trioxide",
    "molecula": "As2O3",
    "iupacname": "arsenic(3+);oxygen(2-)",
    "updphoto": "media/imgsrv_-_2025-03-19T155136.214.png",
    "description": "ANTI-CANCER, IMMUNOSUPPRESSIVE Inhibitor of nuclear factor kappa-B kinase subunit beta, Thioredoxin reductase 1, cytoplasmic,  Transcription factor AP-1,  G1/S-specific cyclin-D1 , Mitogen-activated protein kinase 1, 3,  RAC-alpha serine/threonine-protein kinase,  Cyclin-dependent kinase inhibitor 1,  Histone deacetylase 1,  Protein PML.\r\nTamai detected activity of ARSENIC TRIOXIDE on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": null,
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/14888",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.229103.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01169",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      68,
      38,
      51,
      88,
      28
    ],
    "target": [
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 188,
  "fields": {
    "gname": "CIDOFOVIR",
    "smiles": "C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O",
    "linkname": "cidofovir",
    "molecula": "C8H14N3O6P",
    "iupacname": "[(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid",
    "updphoto": "media/imgsrv_-_2025-03-19T155443.173.png",
    "description": "Cidofovir is an injectable antiviral medication employed in the treatment of cytomegalovirus (CMV) retinitis in patients diagnosed with AIDS. It suppresses CMV replication through selective inhibition of viral DNA synthesis. It was manufactured by Gilead and initially approved by the FDA in 1996, but has since been discontinued. Tamai detected activity of Cidofovir on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Not approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/60613",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.54636.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00369",
    "chebi": null,
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D10547",
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      51,
      28,
      68
    ],
    "target": [
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 189,
  "fields": {
    "gname": "CINACALCET HCL",
    "smiles": "CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F.Cl",
    "linkname": "cinacalcet-hcl",
    "molecula": "C22H23ClF3N",
    "iupacname": "N-[(1R)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine;hydrochloride",
    "updphoto": "media/imgsrv_-_2025-03-19T155721.693.png",
    "description": "Cinacalcet Hydrochloride is the orally bioavailable hydrochloride salt of the calcimimetic cinacalcet. Cinacalcet increases the sensitivity of calcium-sensing receptors on chief cells in the parathyroid gland to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion. A reduction in PTH levels inhibits osteoclast activity, which may result in a decrease in cortical bone turnover and bone fibrosis, and normalization of serum calcium and phosphorus levels. In addition, by reducing PTH levels, cinacalcet may reduce PSA levels.\r\nTamai detected activity of CINACALCET on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/156418",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.137742.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01012",
    "chebi": null,
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D03505",
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      68,
      38,
      51,
      89,
      28
    ],
    "target": [
      29,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 190,
  "fields": {
    "gname": "Cladribine",
    "smiles": "C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O",
    "linkname": "cladribine",
    "molecula": "C10H12ClN5O3",
    "iupacname": "(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol",
    "updphoto": "media/imgsrv_-_2025-03-19T155935.572.png",
    "description": "Cladribine is a purine analogue or a chlorinated derivative of adenine that causes apoptosis of B and T lymphocytes. Cladribine was first approved in the United States in 1993 initially as a treatment for a number of hematological malignancies; currently, it is approved for the treatment of hairy cell leukemia. In 2017 in Europe and in 2019 in the United States, cladribine was also approved for the treatment multiple sclerosis.Tamai detected activity of Cladribine  on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/20279#section=2D-Structure",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.19105.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00242",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      51,
      28,
      38,
      68
    ],
    "target": [
      29,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 191,
  "fields": {
    "gname": "Clotrimazole",
    "smiles": "C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4",
    "linkname": "clotrimazole",
    "molecula": "C22H17ClN2",
    "iupacname": "1-[(2-chlorophenyl)-diphenylmethyl]imidazole",
    "updphoto": "media/imgsrv_-_2025-03-19T160442.508.png",
    "description": "Clotrimazole is a member of the class of imidazoles that is 1H-imidazole in which the hydrogen attached to a nitrogen is replaced by a monochlorotrityl group. It has a role as an antiinfective agent, an environmental contaminant and a xenobiotic. It is a member of imidazoles, a member of monochlorobenzenes, a conazole antifungal drug and an imidazole antifungal drug.\r\nTamai detected activity of on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/2812#section=2D-Structure",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.2710.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00257",
    "chebi": null,
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D00282",
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      90,
      51,
      28,
      68
    ],
    "target": [
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 192,
  "fields": {
    "gname": "Dasatinib",
    "smiles": "CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO",
    "linkname": "dasatinib",
    "molecula": "C22H26ClN7O2S",
    "iupacname": "N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide",
    "updphoto": "media/imgsrv_-_2025-03-19T160642.723.png",
    "description": "Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases. Dasatinib also inhibits a spectrum of kinases involved in cancer.\r\nTamai detected activity of on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/3062316",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.2323020.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01254",
    "chebi": null,
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D03658",
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      51,
      91,
      28,
      68
    ],
    "target": [
      29,
      63
    ],
    "effect": [
      104
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 193,
  "fields": {
    "gname": "Deferasirox",
    "smiles": "C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O",
    "linkname": "deferasirox",
    "molecula": "C21H15N3O4",
    "iupacname": "4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid",
    "updphoto": "media/imgsrv_-_2025-03-19T161345.957.png",
    "description": "Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions. Tamai detected activity of Deferasirox  on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc.\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/214348",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.10770206.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01609",
    "chebi": null,
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D03669",
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      51,
      28,
      68
    ],
    "target": [
      72,
      29,
      63
    ],
    "effect": [
      104
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 194,
  "fields": {
    "gname": "AA92593",
    "smiles": "CC1=C(C=CC(=C1)S(=O)(=O)N2CCCCC2)OC",
    "linkname": "aa92593",
    "molecula": "C₁₃H₁₉NO₃S",
    "iupacname": "1-(4-methoxy-3-methylphenyl)sulfonylpiperidine",
    "updphoto": "media/imgsrv_27_UYYJuBL.png",
    "description": "AA92593 is a piperidine-based sulfonamide first identified through a small-molecule screening campaign for inhibitors of melanopsin-mediated Ca²⁺ mobilization. Together with similar molecules (collectively termed “opsinamides”), AA92593 demonstrates the capacity to displace retinal from melanopsin apoprotein, thereby dampening melanopsin-dependent light responses (e.g., light-evoked Ca²⁺ signals in cells expressing melanopsin).\r\n\r\nObayashi, K., Zou, R., Kawaguchi, T., Mori, T. and Tsukamoto, H., 2025. Molecular basis underlying the specificity of an antagonist AA92593 for mammalian melanopsins. Journal of Biological Chemistry, 301(5), p.108461.\r\n\r\nMoraes, M.N., De Assis, L.V.M., Magalhães-Marques, K.K., Poletini, M.O., De Lima, L.H.R.G. and Castrucci, A.M.D.L., 2017. Melanopsin, a canonical light receptor, mediates thermal activation of clock genes. Scientific Reports, 7(1), p.13977.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubmed.ncbi.nlm.nih.gov/29070825/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/847007",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.740058.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": "https://www.selleckchem.com/products/aa92593.html",
    "articles": [
      122,
      123
    ],
    "classf": [
      8
    ],
    "mechanisms": [
      92
    ],
    "target": [
      73
    ],
    "effect": [
      101
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 195,
  "fields": {
    "gname": "AA41612",
    "smiles": "COC1=CC(=C(C=C1Cl)S(=O)(=O)N2CCCCC2)Cl",
    "linkname": "aa41612",
    "molecula": "C₁₂H₁₅Cl₂NO₃S",
    "iupacname": "1-(2,5-dichloro-4-methoxyphenyl)sulfonylpiperidine",
    "updphoto": "media/imgsrv_28_YXsya47.png",
    "description": "AA41612 is a dichlorophenyl sulfonamide identified through high-throughput screening for inhibitors of melanopsin-mediated Ca²⁺ signaling. Along with AA92593 and other “opsinamides,” AA41612 competes with cis-retinal or 9-cis retinal for binding to melanopsin, thus preventing photoactivation in cell-based assays.\r\n\r\nJones, K.A., Hatori, M., Mure, L.S., Bramley, J.R., Artymyshyn, R., Hong, S.P., Marzabadi, M., Zhong, H., Sprouse, J., Zhu, Q. and Hartwick, A.T., 2013. Small-molecule antagonists of melanopsin-mediated phototransduction. Nature chemical biology, 9(10), pp.630-635.",
    "fdastatus": "Not approved",
    "linkslists": null,
    "pubchem": null,
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      121
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      93,
      203
    ],
    "target": [
      73
    ],
    "effect": [
      204
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 196,
  "fields": {
    "gname": "SB-202190",
    "smiles": "C1=CC(=CC=C1C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F)O",
    "linkname": "sb-202190",
    "molecula": "C₂₀H₁₄FN₃O",
    "iupacname": "4-[4-(4-fluorophenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]phenol",
    "updphoto": "media/imgsrv_29_AT6kU3b.png",
    "description": "SB-202190 is an imidazole-based compound best known as a selective inhibitor of the α and β isoforms of p38 mitogen-activated protein kinase (MAPK). Because p38 MAPKs are key regulators of inflammatory and stress-related signaling pathways, SB-202190 is widely employed in cell biology to dissect MAPK-mediated processes such as apoptosis, cytokine production, and circadian clock regulation.\r\n\r\nShanware, N.P., Williams, L.M., Bowler, M.J. and Tibbetts, R.S., 2009. Non-specific in vivo inhibition of CK1 by the pyridinyl imidazole p38 inhibitors SB 203580 and SB 202190. BMB reports, 42(3), p.142.\r\n\r\nHirota, T., Lewis, W.G., Liu, A.C., Lee, J.W., Schultz, P.G. and Kay, S.A., 2008. A chemical biology approach reveals period shortening of the mammalian circadian clock by specific inhibition of GSK-3β. Proceedings of the National Academy of Sciences, 105(52), pp.20746-20751.\r\n\r\n\r\nCause period lengthening in cultured Aplysia eye.\r\nSankrithi, N. and Eskin, A., 1999. Effects of Cyclin‐Dependent Kinase Inhibitors on Transcription and Ocular Circadian Rhythm of Aplysia. Journal of neurochemistry, 72(2), pp.605-613.",
    "fdastatus": "Not approved",
    "linkslists": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4412876/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5169",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.10739553.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      118,
      119,
      120
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      94
    ],
    "target": [
      74
    ],
    "effect": [
      99
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 197,
  "fields": {
    "gname": "Laduviglusib (CHIR-99021)",
    "smiles": "CC1=CN=C(N1)C2=CN=C(N=C2C3=C(C=C(C=C3)Cl)Cl)NCCNC4=NC=C(C=C4)C#N",
    "linkname": "laduviglusib",
    "molecula": "C₂₂H₁₈Cl₂N₈",
    "iupacname": "6-[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)pyrimidin-2-yl]amino]ethylamino]pyridine-3-carbonitrile",
    "updphoto": "media/imgsrv_31_qUb1AJ0.png",
    "description": "CHIR-99021 (also called laduviglusib) is regarded as one of the most potent and specific GSK-3 inhibitors. It has found utility in stem cell biology (promoting self-renewal of embryonic stem cells) and in circadian biology, where inhibiting GSK-3 shortens the circadian period in mammalian cells. This runs counter to lithium’s period-lengthening effect—highlighting GSK-3’s multifaceted roles in clock protein phosphorylation.\r\n\r\n\r\nHirota, T., Lewis, W.G., Liu, A.C., Lee, J.W., Schultz, P.G. and Kay, S.A., 2008. A chemical biology approach reveals period shortening of the mammalian circadian clock by specific inhibition of GSK-3β. Proceedings of the National Academy of Sciences, 105(52), pp.20746-20751.",
    "fdastatus": "Not approved",
    "linkslists": "https://www.pnas.org/doi/abs/10.1073/pnas.0811410106",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/9956119",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.8131728.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      118
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      96
    ],
    "target": [
      76
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 198,
  "fields": {
    "gname": "DROSPIRENONE",
    "smiles": "CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C",
    "linkname": "drospirenone",
    "molecula": "C24H30O3",
    "iupacname": "(1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.02,4.05,10.014,19.016,18]nonadec-5-ene-15,5'-oxolane]-2',7-dione",
    "updphoto": "media/imgsrv_-_2025-03-20T095838.313.png",
    "description": "Drospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with [Ethinyl estradiol]. Most recently, it was approved by both Health Canada and the FDA in combination with [Estetrol] as an oral contraceptive therapy. Aside from its contraceptive effects, drospirenone is used with estrogens to control acne and premenstrual dysphoric disorder (PMDD). Drospirenone has been the subject of widespread safety concern due to the possibility of an increased risk of venous thromboembolism associated with its use.\r\nTamai detected activity of drospirenone on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc. Tamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/68873",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.62105.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01395",
    "chebi": null,
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D03917",
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      98,
      68,
      38,
      51,
      28
    ],
    "target": [
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 199,
  "fields": {
    "gname": "EPIRUBICIN HCL",
    "smiles": "C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl",
    "linkname": "epirubicin-hcl",
    "molecula": "C27H30ClNO11",
    "iupacname": "(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride",
    "updphoto": "media/imgsrv_-_2025-03-20T100306.526.png",
    "description": "Epirubicin Hydrochloride is the hydrochloride salt of the 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin. Epirubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. Tamai et al. 2018 detected activity of EPIRUBICIN on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc. Tamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/65348",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.58827.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00445",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      68,
      38,
      78,
      82,
      51,
      28
    ],
    "target": [
      29,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 200,
  "fields": {
    "gname": "EVEROLIMUS",
    "smiles": "CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC",
    "linkname": "everolimus",
    "molecula": "C53H83NO14",
    "iupacname": "(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26",
    "updphoto": "media/imgsrv_-_2025-03-20T100825.063.png",
    "description": "ANTI-CANCER, IMMUNOSUPPRESSIVE drug. Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein. Tamai detected activity of EVEROLIMUS on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc. Tamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/6442177",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.21106307.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01590",
    "chebi": null,
    "uniprot": "https://www.uniprot.org/uniprotkb/P42345/entry",
    "kegg": "https://www.kegg.jp/entry/D02714",
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      99,
      68,
      38,
      72,
      51,
      28
    ],
    "target": [
      29,
      63
    ],
    "effect": [
      166
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 201,
  "fields": {
    "gname": "Irinotecan Hydrochloride",
    "smiles": "CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl",
    "linkname": "irinotecan-hydrochloride",
    "molecula": "C33H39ClN4O6",
    "iupacname": "[(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate;hydrochloride",
    "updphoto": "media/imgsrv_-_2025-03-20T101131.425.png",
    "description": "Irinotecan HCl is the hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic alkaloid extracted from Camptotheca acuminata. Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death. Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent. Tamai detected activity of Cidofovir on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc. Tamai, T.K., et al. 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/74990",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.67545.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00762",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      100,
      68,
      38,
      51,
      28
    ],
    "target": [
      77,
      29,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 202,
  "fields": {
    "gname": "ISOTRETINOIN (13-CIS-RETINOIC ACID)",
    "smiles": "CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C",
    "linkname": "isotretinoin-13-cis-retinoic-acid",
    "molecula": "C20H28O2",
    "iupacname": "(2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid",
    "updphoto": "media/imgsrv_-_2025-03-20T101557.461.png",
    "description": "DERMATOLOGICAL drug affecting retinoic acid receptor alpha. Isotretinoin can cause developmental toxicity according to an independent committee of scientific and health experts.  Tamai detected activity of ISOTRETINOIN on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc. Tamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5282379",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4445539.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00982",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      68,
      101,
      38,
      51,
      28
    ],
    "target": [
      78,
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 203,
  "fields": {
    "gname": "MECLIZINE DIHYDROCHLORIDE",
    "smiles": "CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl.Cl.Cl",
    "linkname": "meclizine-dihydrochloride",
    "molecula": "C25H29Cl3N2",
    "iupacname": "1-[(4-chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine;dihydrochloride",
    "updphoto": "media/imgsrv_-_2025-03-20T101958.626.png",
    "description": "Meclizine Hydrochloride is the hydrochloride salt form of meclizine, a synthetic piperazine with anti-emetic, sedative and histamine H1 antagonistic properties. Meclizine hydrochloride blocks the H1 histamine receptor and prevents the symptoms that are caused by histamine activity on capillaries, bronchial and gastrointestinal smooth muscles, including vasodilation, increased capillary permeability, bronchoconstriction, and spasmodic contraction of gastrointestinal smooth muscles. Meclizine hydrochloride may exert its antiemetic effects by its anticholinergic actions or due to a direct effect on the medullary chemoreceptive trigger zone.  Tamai detected activity of Meclizine on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc. Tamai, T.K.,et al., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/64713",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.58260.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      68,
      102,
      38,
      28,
      51,
      60
    ],
    "target": [
      58,
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 204,
  "fields": {
    "gname": "NEBIVOLOL HCL",
    "smiles": "C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O.Cl",
    "linkname": "nebivolol-hcl",
    "molecula": "C22H26ClF2NO4",
    "iupacname": "1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol;hydrochloride",
    "updphoto": "media/imgsrv_-_2025-03-20T102340.447.png",
    "description": "NEBIVOLOL HYDROCHLORIDE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for hypertension and stroke. Tamai detected activity of NEBIVOLOL HYDROCHLORIDE  on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc. Tamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/9933004",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.9801131.html",
    "drugbank": "https://go.drugbank.com/drugs/DB04861",
    "chebi": null,
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D05127",
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      68,
      38,
      103,
      51,
      28
    ],
    "target": [
      79,
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 205,
  "fields": {
    "gname": "NILOTINIB",
    "smiles": "CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5",
    "linkname": "nilotinib",
    "molecula": "C28H22F3N7O",
    "iupacname": "4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide",
    "updphoto": "media/imgsrv_-_2025-03-20T103000.746.png",
    "description": "Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML. Tamai detected activity of Nilotinib on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc. Tamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/644241",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.559260.html",
    "drugbank": "https://go.drugbank.com/drugs/DB04868",
    "chebi": null,
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D08953",
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      68,
      38,
      104,
      51,
      28
    ],
    "target": [
      80,
      29,
      30,
      63
    ],
    "effect": [
      164
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 206,
  "fields": {
    "gname": "PAZOPANIB HCL",
    "smiles": "CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N.Cl",
    "linkname": "pazopanib-hcl",
    "molecula": "C21H24ClN7O2S",
    "iupacname": "5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide;hydrochloride",
    "updphoto": "media/imgsrv_-_2025-03-20T103415.128.png",
    "description": "Pazopanib Hydrochloride is the hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated. Tamai detected activity of Pazopanib Hydrochloride on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc. Tamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/11525740",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.9700526.html",
    "drugbank": "https://go.drugbank.com/drugs/DB06589",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      68,
      38,
      105,
      106,
      107,
      108,
      109,
      110,
      111,
      51,
      28
    ],
    "target": [
      29,
      30,
      63
    ],
    "effect": [
      162
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 207,
  "fields": {
    "gname": "PIMECROLIMUS",
    "smiles": "CC[C@@H]1/C=C(/C[C@@H](C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC1=O)O)C)/C(=C/[C@@H]4CC[C@@H]([C@@H](C4)OC)Cl)/C)O)C)OC)OC)C)\\C",
    "linkname": "pimecrolimus",
    "molecula": "C43H68ClNO11",
    "iupacname": "(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-12-[(E)-1-[(1R,3R,4S)-4-chloro-3-methoxycyclohexyl]prop-1-en-2-yl]-17-ethyl-1,14-dihydroxy-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone",
    "updphoto": "media/imgsrv_-_2025-03-20T103822.521.png",
    "description": "Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007. It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema).\r\nPimecrolimus is a Calcineurin Inhibitor Immunosuppressant. The mechanism of action of pimecrolimus is as a Calcineurin Inhibitor. Tamai detected activity of Pimecrolimus on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc. Tamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/6509979",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.21111755.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00337",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      112,
      51,
      68
    ],
    "target": [
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 208,
  "fields": {
    "gname": "PODOFILOX",
    "smiles": "COC1=CC(=CC(=C1OC)OC)C2C3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)O",
    "linkname": "podofilox",
    "molecula": "C22H22O8",
    "iupacname": "(5R,5aR,8aR,9R)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one",
    "updphoto": "media/imgsrv_-_2025-03-20T104058.174.png",
    "description": "Podophyllotoxin is an organic heterotetracyclic compound that has a furonaphthodioxole skeleton bearing a 3,4,5-trimethoxyphenyl substituent. It is found in the roots and rhizomes of Podophyllum species and is used for the topical treatment of genital warts. It has a role as an antineoplastic agent, a keratolytic drug, a tubulin modulator, a microtubule-destabilising agent, an antimitotic and a plant metabolite. It is a furonaphthodioxole, a lignan and an organic heterotetracyclic compound. Tamai detected activity of Podophyllotoxin on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc. Tamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/10607",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.10162.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01179",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      68,
      38,
      78,
      113,
      51,
      28
    ],
    "target": [
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 209,
  "fields": {
    "gname": "Rabeprazole Sodium",
    "smiles": "CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3[N-]2)OCCCOC.[Na+]",
    "linkname": "rabeprazole-sodium",
    "molecula": "C18H20N3NaO3S",
    "iupacname": "sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]benzimidazol-1-ide",
    "updphoto": "media/imgsrv_-_2025-03-20T104731.757.png",
    "description": "Rabeprazole Sodium is the sodium salt of the prodrug rabeprazole, a substituted benzimidazole proton pump inhibitor, with potential anti-ulcer activity. After protonation, accumulation, and transformation to the active sulfenamide within the acidic environment of gastric parietal cells, rabeprazole selectively and irreversibly binds to and inhibits the H+, K+ATPase (hydrogen-potassium adenosine triphosphatase) enzyme system located on the parietal cell secretory surface, inhibiting gastric acid secretion.",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/14720269",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.54689.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01129",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      68,
      38,
      114,
      51,
      28
    ],
    "target": [
      81,
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 210,
  "fields": {
    "gname": "Tazarotene",
    "smiles": "CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C",
    "linkname": "tazarotene",
    "molecula": "C21H21NO2S",
    "iupacname": "ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate",
    "updphoto": "media/imgsrv_-_2025-03-20T105259.005.png",
    "description": "Tazarotene, commonly marketed as Tazorac®, Avage®, and Zorac®, is member of the acetylenic class of retinoids. It is a prodrug that is found in topical formulations used in the treatment of various conditons, such as psoriasis, acne, and sun damaged skin (photodamage). Tamai detected activity of Tazarotene on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc. \r\n\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5381",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.5188.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00799",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      51,
      28,
      38,
      68
    ],
    "target": [
      78,
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 211,
  "fields": {
    "gname": "THIOTEPA",
    "smiles": "C1CN1P(=S)(N2CC2)N3CC3",
    "linkname": "thiotepa",
    "molecula": "C6H12N3PS",
    "iupacname": "tris(aziridin-1-yl)-sulfanylidene-λ5-phosphane",
    "updphoto": "media/imgsrv_-_2025-03-20T105713.524.png",
    "description": "Tris(1-aziridinyl)phosphine Sulfide (Thiotepa) can cause cancer according to an independent committee of scientific and health experts.\r\nCalifornia Office of Environmental Health Hazard Assessment (OEHHA)\r\nTris(aziridinyl)phosphine sulfide is an odorless white crystalline solid. (NTP, 1992)\r\nThiotepa is a member of aziridines.\r\nTamai detected activity of THIOTEPA on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc. Tamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10",
    "fdastatus": "Not approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5453",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.5254.html",
    "drugbank": "https://go.drugbank.com/drugs/DB04572",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      68,
      38,
      81,
      51,
      28
    ],
    "target": [
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 212,
  "fields": {
    "gname": "TRETINOIN",
    "smiles": "CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C",
    "linkname": "tretinoin",
    "molecula": "C 20 H 28O2",
    "iupacname": "(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid",
    "updphoto": "media/imgsrv_-_2025-03-20T105815.120.png",
    "description": "DERMATOLOGICAL drug affecting Retinoic acid receptor RXR-alpha, beta, gamma,  Retinoic acid receptor alpha, beta, gamma, Retinal dehydrogenase 1,  Retinoic acid-induced protein 3,  Nuclear receptor subfamily 0 group B member 1,  Retinal dehydrogenase 2,  Retinoic acid receptor responder protein 1,  Lipocalin-1,  Odorant-binding protein 2a,  Retinol-binding protein 4,  [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 4, mitochondrial,  Cytochrome P450 26A1, 26B1, 26C1,  Hematopoietic prostaglandin D synthase. Tamai detected activity of TRETINOIN on circadian gene expression using a human osteosarcoma U2OS cell line stably expressing the clock reporter Bmal1‐dLuc. \r\n\r\nTamai, T.K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M. and Nishiwaki‐Ohkawa, T., 2018. Identification of circadian clock modulators from existing drugs. EMBO molecular medicine, 10(5), p.e8724.",
    "fdastatus": "Approved",
    "linkslists": "https://www.embopress.org/doi/full/10.15252/emmm.201708724",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/444795",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.392618.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00755",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      117
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      68,
      101,
      38,
      79,
      51,
      28
    ],
    "target": [
      29,
      30,
      63
    ],
    "effect": [
      161
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 213,
  "fields": {
    "gname": "Irbesartan",
    "smiles": "CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C#N",
    "linkname": "irbesartan",
    "molecula": "C25H28N6O",
    "iupacname": "2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one",
    "updphoto": "media/imgsrv_-_2025-03-20T110339.690.png",
    "description": "Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy. It can also be used as part of a combination product with [hydrochlorothiazide] for patients not well controlled or not expected to be well controlled on monotherapy. Unlike angiotensin converting enzyme inhibitors. Irbesartan may affect the expression of numerous kidney genes involved in circadian rhythm, cell cycle, micoRNAs in cancer, and PI3K–AKT signaling pathway. In the miRNA-DEGs network, miR-1970, miR-703, miR-466f, miR-5135, and miR-132-3p were the potential targets for irbesartan treatment. The validation test confirmed that key genes regulating circadian rhythm (Arntl, Per3, and Dbp) and cell cycle (Prc1, Ccna2, and Ccnb2)\r\n\r\nZhao, et al., 2024. Irbesartan ameliorates diabetic kidney injury in db/db mice by restoring circadian rhythm and cell cycle. Journal of translational internal medicine, 12(2), pp.157-169.",
    "fdastatus": "Approved",
    "linkslists": "https://www.degruyter.com/document/doi/10.2478/jtim-2022-0049/html",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/3749",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.3618.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01029",
    "chebi": null,
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D00523",
    "selleckchem": null,
    "articles": [
      116
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      115,
      116
    ],
    "target": [
      30,
      82
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 214,
  "fields": {
    "gname": "KL001",
    "smiles": "CS(=O)(=O)N(CC1=CC=CO1)CC(CN2C3=CC=CC=C3C4=CC=CC=C42)O",
    "linkname": "kl001",
    "molecula": "C21H22N2O4S",
    "iupacname": "N-(3-carbazol-9-yl-2-hydroxypropyl)-N-(furan-2-ylmethyl)methanesulfonamide",
    "updphoto": "media/imgsrv_-_2025-03-20T111503.569.png",
    "description": "KL001 is a small molecule identified as a modulator of the circadian clock through its specific interaction with cryptochrome proteins (CRY1 and CRY2). It stabilizes these proteins by preventing their ubiquitin-dependent degradation, thereby lengthening the circadian period. KL001 achieves this by competing with flavin adenine dinucleotide (FAD) for binding to CRY, which inhibits FBXL3-mediated ubiquitination of CRY proteins.\r\n\r\nHirota, T., et al. 2012. Identification of small molecule activators of cryptochrome. Science, 337(6098), pp.1094-1097.\r\n\r\nIida, M., Nakane, Y., Yoshimura, T. and Hirota, T., 2022. Effects of cryptochrome-modulating compounds on circadian behavioural rhythms in zebrafish. Journal of Biochemistry, 171(5), pp.501-507.",
    "fdastatus": "Not approved",
    "linkslists": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3589997/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/kl001",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.2162737.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": "https://www.selleckchem.com/products/kl001.html",
    "articles": [
      113,
      114
    ],
    "classf": [
      4,
      5
    ],
    "mechanisms": [
      33,
      34,
      36
    ],
    "target": [
      42,
      27,
      28
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 215,
  "fields": {
    "gname": "KS15",
    "smiles": "CCOC(CC1=CC(=CC=C1)C(=NOCC2=CC=C(C=C2)Br)C)C(=O)O",
    "linkname": "ks15",
    "molecula": "C20H22BrNO4",
    "iupacname": "(2R)-3-[3-[(E)-N-[(4-bromophenyl)methoxy]-C-methylcarbonimidoyl]phenyl]-2-ethoxypropanoic acid",
    "updphoto": "media/imgsrv_-_2025-03-20T111751.759.png",
    "description": "KS15 can functionally inhibit the effects of CRY1/2 in the molecular circadian clockwork. In conclusion, the present study describes the first novel chemical inhibitor of CRY1/2 that inhibits the repressive function of CRY1/2, thereby activating CLOCK-BMAL1-evoked E-box-mediated transcription.\r\n\r\nChun, S.K., Jang, J., Chung, S., Yun, H., Kim, N.J., Jung, J.W., Son, G.H., Suh, Y.G. and Kim, K., 2014. Identification and validation of cryptochrome inhibitors that modulate the molecular circadian clock. ACS chemical biology, 9(3), pp.703-710.\r\n\r\n전승국, 2014. Development of circadian clock modulator and its application (Doctoral dissertation, 서울대학교 대학원).\r\n\r\nJang, J., Chung, S., Choi, Y., Lim, H.Y., Son, Y., Chun, S.K., Son, G.H., Kim, K., Suh, Y.G. and Jung, J.W., 2018. The cryptochrome inhibitor KS15 enhances E-box-mediated transcription by disrupting the feedback action of a circadian transcription-repressor complex. Life sciences, 200, pp.49-55.\r\n\r\nSolovev, I.A., Shaposhnikov, M.V. and Moskalev, A.A., 2021. Chronobiotics KL001 and KS15 extend lifespan and modify circadian rhythms of Drosophila melanogaster. Clocks & Sleep, 3(3), pp.429-441.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubs.acs.org/doi/10.1021/cb400752k",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/25114872",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.88297860.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      109,
      110,
      111,
      112
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      36,
      117,
      118
    ],
    "target": [
      83,
      27,
      28
    ],
    "effect": [
      159,
      207
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 216,
  "fields": {
    "gname": "Azakenpaullone",
    "smiles": "C1C2=C(C3=C(C=CC=N3)NC1=O)NC4=C2C=C(C=C4)Br",
    "linkname": "azakenpaullone",
    "molecula": "C₁₅H₁₀BrN₃O",
    "iupacname": "14-bromo-3,8,18-triazatetracyclo[9.7.0.0^2,7^.0^12,17^]octadeca-1(11),2(7),3,5,12(17),13,15-heptaen-9-one",
    "updphoto": "media/imgsrv_32_C3Yoqr8.png",
    "description": "1-Azakenpaullone (sometimes referred to as 1-AKP or simply “azakenpaullone”) is a brominated derivative in the paullone family, showing potent inhibition of GSK-3. In circadian studies, GSK-3 blockade by 1-azakenpaullone and related molecules has been linked to period shortening of mammalian cellular rhythms, opposite to the period-lengthening seen with lithium (another GSK-3 modulator). Beyond its effects on GSK-3, azakenpaullone also inhibits certain CDKs, offering a tool for dissecting overlapping kinase pathways in both circadian biology and cell-cycle regulation.",
    "fdastatus": "Not approved",
    "linkslists": "https://www.pnas.org/doi/abs/10.1073/pnas.0811410106",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/6538897#section=2D-Structure",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.5021365.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      108
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      120
    ],
    "target": [
      76
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 217,
  "fields": {
    "gname": "CLK8",
    "smiles": "CC1(CCC2=C3C(=C(C=C2O1)OCC(=O)NC4=CC=CC=C4C(=O)N)C(=CC(=O)O3)C5=CC=CC=C5)C",
    "linkname": "clk8",
    "molecula": "C₂₉H₂₆N₂O₆",
    "iupacname": "2-[[2-[(8,8-dimethyl-2-oxo-4-phenyl-9,10-dihydropyrano[2,3-h]chromen-5-yl)oxy]acetyl]amino]benzamide",
    "updphoto": "media/imgsrv_34_PpVqL1F.png",
    "description": "CLK8 emerged from a structure-based virtual screen designed to identify small molecules that disrupt the CLOCK–BMAL1 interface. Experimental validation in cell-based assays indicated that CLK8 decreases CLOCK–BMAL1 binding, thereby diminishing CLOCK nuclear entry. This selective inhibition leads to enhanced amplitude of the circadian rhythm, presumably by stabilizing the negative arm (CRY/PER) of the circadian feedback loop and reducing positive-arm (CLOCK/BMAL1) activity. As such, CLK8 is a unique probe for exploring CLOCK function in transcriptional regulation and circadian rhythm amplitude modulation. \r\n\r\nDoruk, et al. 2020. A CLOCK-binding small molecule disrupts the interaction between CLOCK and BMAL1 and enhances circadian rhythm amplitude. Journal of Biological Chemistry, 295(11), pp.3518-3531.",
    "fdastatus": "Not approved",
    "linkslists": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7076206/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/4869040",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4053676.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      107
    ],
    "classf": [
      9,
      5
    ],
    "mechanisms": [
      122
    ],
    "target": [
      29
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 218,
  "fields": {
    "gname": "5,8-Quinoxalinedione",
    "smiles": "C1=CC(=O)C2=NC=CN=C2C1=O",
    "linkname": "58-quinoxalinedione",
    "molecula": "C₈H₄N₂O₂",
    "iupacname": "quinoxaline-5,8-dione",
    "updphoto": "media/imgsrv_35_eQ3sTTb.png",
    "description": "5,8-Quinoxalinedione was identified via a screening approach to find chemical inhibitors of the BMAL1–CLOCK transcriptional complex. This small molecule impairs the ability of BMAL1/CLOCK to bind E-box sequences, a central step in the circadian positive feedback loop. By decreasing E-box occupancy, 5,8-quinoxalinedione provides a useful chemical probe for dissecting circadian gene regulation and may offer a strategic lead for developing circadian-targeting therapeutics.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubs.rsc.org/en/content/articlelanding/2020/cc/d0cc04861e",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/11355645#section=2D-Structure",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.9530572.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      106
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      123
    ],
    "target": [
      29
    ],
    "effect": [
      158
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 219,
  "fields": {
    "gname": "Protoheme",
    "smiles": "CC1=C(C2=CC3=C(C(=C([N-]3)C=C4C(=C(C(=N4)C=C5C(=C(C(=N5)C=C1[N-]2)C)C=C)C)C=C)C)CCC(=O)O)CCC(=O)O.[Fe+2]",
    "linkname": "protoheme",
    "molecula": "C₃₄H₃₂FeN₄O₄",
    "iupacname": "3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid;iron(2+)",
    "updphoto": "media/imgsrv_36_xoJWNSX.png",
    "description": "Protoheme (also called heme b or ferroprotoporphyrin IX) is the most abundant heme type in animal cells. It integrates an iron(II)/(III) center into a protoporphyrin IX ring. This arrangement underpins oxygen transport (hemoglobin, myoglobin), electron transfer (respiratory chain cytochromes), and regulatory roles in circadian transcription factors. In circadian biology, protoheme binding can impact CLOCK–BMAL1 or NPAS2–BMAL1 complexes, modulating their DNA-binding ability and thus influencing circadian gene expression.",
    "fdastatus": "Not approved",
    "linkslists": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6778266/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/26945#section=2D-Structure",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.16739950.html",
    "drugbank": "https://go.drugbank.com/drugs/DB18267",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      105
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      124
    ],
    "target": [
      29
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 220,
  "fields": {
    "gname": "LH-846",
    "smiles": "CC1=CC2=C(C=C1Cl)N=C(S2)NC(=O)CC3=CC=CC=C3",
    "linkname": "lh-846",
    "molecula": "C₁₆H₁₃ClN₂OS",
    "iupacname": "N-(5-chloro-6-methyl-1,3-benzothiazol-2-yl)-2-phenylacetamide",
    "updphoto": "media/imgsrv_37_fkr7irt.png",
    "description": "LH-846 emerged from a high-throughput cell-based screen for compounds that alter circadian rhythms. It prominently lengthens the cellular circadian period (by approximately 10 hours) in U2OS reporter cells. Mechanistically, LH-846 blocks phosphorylation of the PER1 protein by CKIδ, hindering PER1 degradation and thereby extending the period of the clock. LH-846 is a synthetic compound that has gained attention for its potential effects on circadian biology. Research suggests that it may influence the timing and stability of circadian rhythms by interacting with key molecular pathways.\r\n\r\nLee, J.W., Hirota, T., Peters, E.C., Garcia, M., Gonzalez, R., Cho, C.Y., Wu, X., Schultz, P.G. and Kay, S.A., 2011. A small molecule modulates circadian rhythms through phosphorylation of the period protein. Angewandte Chemie (International ed. in English), 50(45), p.10608.\r\nRay, S., Lach, R., Heesom, K.J., Valekunja, U.K., Encheva, V., Snijders, A.P. and Reddy, A.B., 2019. Phenotypic proteomic profiling identifies a landscape of targets for circadian clock–modulating compounds. Life Science Alliance, 2(6).",
    "fdastatus": "Not approved",
    "linkslists": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3755734/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/851474#section=2D-Structure",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.744168.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": "https://www.selleckchem.com/products/lh846.html",
    "articles": [
      103,
      104
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      125
    ],
    "target": [
      43
    ],
    "effect": [
      156
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 221,
  "fields": {
    "gname": "naphthalene",
    "smiles": "C1=CC=C2C=CC=CC2=C1",
    "linkname": "naphthalene",
    "molecula": "C10H8",
    "iupacname": "naphthalene",
    "updphoto": "media/imgsrv2354653748.png",
    "description": "Chronotoxicant. Naphthalene, methylnaphthalenes appears as a black liquid with the odor of coal tar. Negligibly soluble in water. Slightly denser than water. Vapors, fumes or direct contact may irritate the eyes. Direct skin contact may produce severe burns. Inhalation may produce mucous irritation, dizziness, loss of coordination, cardiovascular collapse and death. Disrupts circadian rhtyhms targeting core clock. Koh, Y.C. and Pan, M.H., 2024. Food-Borne Polycyclic Aromatic Hydrocarbons and Circadian Disruption. ACS omega, 9(29), pp.31298-31312.",
    "fdastatus": "none",
    "linkslists": "https://pubs.acs.org/doi/full/10.1021/acsomega.4c04120",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/931",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.906.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      102
    ],
    "classf": [
      6
    ],
    "mechanisms": [
      26,
      51,
      28,
      15
    ],
    "target": [
      29
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 222,
  "fields": {
    "gname": "anthracene",
    "smiles": "C1=CC=C2C=C3C=CC=CC3=CC2=C1",
    "linkname": "anthracene",
    "molecula": "C14H10",
    "iupacname": "anthracene",
    "updphoto": "media/imgsrv_-_2025-03-20T155815.130.png",
    "description": "Chronodisruptor from food, a solid polycyclic aromatic hydrocarbon (PAH) consisting of three benzene rings derived from coal-tar, is the simplest tricyclic aromatic hydrocarbon. It is on the EPA's priority pollutant list. It is primarily used as an intermediate in the production of dyes, smoke screens, scintillation counter crystals, and in organic semiconductor research. Although a large body of literature exists on the toxicity of PAHs, data for anthracene are limited. Prolonged exposure causes variety of topical and systemic adverse reactions. Carcinogenicity bioassays with anthracene generally gave negative results. Disrupts circadian rhtyhms targeting core clock. Koh, Y.C. and Pan, M.H., 2024. Food-Borne Polycyclic Aromatic Hydrocarbons and Circadian Disruption. ACS omega, 9(29), pp.31298-31312.",
    "fdastatus": "none",
    "linkslists": "https://pubs.acs.org/doi/full/10.1021/acsomega.4c04120",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/8418",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.8111.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      102
    ],
    "classf": [
      6
    ],
    "mechanisms": [
      26,
      122,
      126,
      14
    ],
    "target": [
      27,
      29
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 223,
  "fields": {
    "gname": "Benz[a]anthracene",
    "smiles": "C1=CC=C2C(=C1)C=CC3=CC4=CC=CC=C4C=C32",
    "linkname": "benzaanthracene",
    "molecula": "C18H12",
    "iupacname": "benzo[a]anthracene",
    "updphoto": "media/imgsrv_-_2025-03-20T155856.638.png",
    "description": "Benz[a]anthracene is a crystalline, aromatic hydrocarbon consisting of four fused benzene rings, produced by incomplete combustion of organic matter. Benz(a)anthracene is primarily found in gasoline and diesel exhaust, tobacco and cigarette smoke, coal tar and coal tar pitch, coal combustion emissions, charcoal-broiled foods, amino acids, fatty acids and carbohydrate pyrolysis products, wood and soot smoke, and creosote, asphalt and mineral oils. This substance is used only for research purposes. Benz(a)anthracene is reasonably anticipated to be a human carcinogen. Disrupts circadian rhtyhms targeting core clock. Koh, Y.C. and Pan, M.H., 2024. Food-Borne Polycyclic Aromatic Hydrocarbons and Circadian Disruption. ACS omega, 9(29), pp.31298-31312.",
    "fdastatus": null,
    "linkslists": "https://pubs.acs.org/doi/full/10.1021/acsomega.4c04120",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5954",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.5739.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [],
    "classf": [
      6
    ],
    "mechanisms": [
      122,
      126,
      14
    ],
    "target": [
      27,
      29,
      30
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 224,
  "fields": {
    "gname": "Dibenzopyrene",
    "smiles": "C1=CC=C2C(=C1)C=C3C=CC4=C5C3=C2C6=CC=CC=C6C5=CC=C4",
    "linkname": "dibenzopyrene",
    "molecula": "C24H14",
    "iupacname": "hexacyclo[10.10.2.02,7.08,24.015,23.017,22]tetracosa-1(23),2,4,6,8,10,12(24),13,15,17,19,21-dodecaene",
    "updphoto": "media/imgsrv_-_2025-03-20T160236.110.png",
    "description": "Dibenzo (a,l) pyrene is a yellowish-reddish, carcinogenic aromatic hydrocarbon consisting of six fused rings and produced by the incomplete combustion of organic matter. Dibenzo[a,e]pyrene is primarily found in coal gasification products, cigarette smoke and fossil fuels. This substance is used only for research purposes to induce tumorigenesis. Dibenzo[a,e]pyrene is a mutagen and is reasonably anticipated to be a human carcinogen. Chronodisruptor targeting core clock according to Koh, Y.C. and Pan, M.H., 2024. Food-Borne Polycyclic Aromatic Hydrocarbons and Circadian Disruption. ACS omega, 9(29), pp.31298-31312.",
    "fdastatus": "none",
    "linkslists": "https://pubs.acs.org/doi/full/10.1021/acsomega.4c04120",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/#query=Dibenzopyrene",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.8765.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      102
    ],
    "classf": [
      6
    ],
    "mechanisms": [
      26,
      14,
      122,
      123,
      126
    ],
    "target": [
      25,
      26,
      27,
      28,
      29,
      30
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 225,
  "fields": {
    "gname": "Benzo[k]fluoranthene",
    "smiles": "C1=CC=C2C=C3C4=CC=CC5=C4C(=CC=C5)C3=CC2=C1",
    "linkname": "benzokfluoranthene",
    "molecula": "C20H12",
    "iupacname": "benzo[k]fluoranthene",
    "updphoto": "media/imgsrv_-_2025-03-20T160632.375.png",
    "description": "Benzo[k]fluoranthene is a pale yellow aromatic hydrocarbon consisting of five fused rings and is produced by the incomplete combustion of organic matter. Benzo(k)fluoranthene is primarily found in gasoline exhaust, cigarette smoke, coal tar, coal and oil combustion emissions, lubricating oils, used motor oils and crude oils. This substance is used only for research purposes. Benzo(k)fluoranthene is reasonably anticipated to be a human carcinogen. Disrupts circadian rhtyhms targeting core clock. Koh, Y.C. and Pan, M.H., 2024. Food-Borne Polycyclic Aromatic Hydrocarbons and Circadian Disruption. ACS omega, 9(29), pp.31298-31312.",
    "fdastatus": "none",
    "linkslists": "https://pubs.acs.org/doi/full/10.1021/acsomega.4c04120",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/9158",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.8804.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      102
    ],
    "classf": [
      6
    ],
    "mechanisms": [
      14,
      122,
      123,
      28,
      126
    ],
    "target": [
      25,
      26,
      27,
      28,
      29
    ],
    "effect": [
      152
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 226,
  "fields": {
    "gname": "Chrysene",
    "smiles": "C1=CC=C2C(=C1)C=CC3=C2C=CC4=CC=CC=C43",
    "linkname": "chrysene",
    "molecula": "C18 H12",
    "iupacname": "chrysene",
    "updphoto": "media/imgsrv_-_2025-03-20T161252.181.png",
    "description": "Chrysene can cause cancer according to The Environmental Protection Agency (EPA).\r\nChrysene appears as a crystalline solid. Denser than water and insoluble in water. The primary hazard is the threat to the environment. Immediate steps should be taken to limit spread to the environment. Toxic by ingestion. Used to make other chemicals.\r\nDisrupts circadian rhtyhms targeting core clock. Koh, Y.C. and Pan, M.H., 2024. Food-Borne Polycyclic Aromatic Hydrocarbons and Circadian Disruption. ACS omega, 9(29), pp.31298-31312.",
    "fdastatus": "none",
    "linkslists": "https://pubs.acs.org/doi/full/10.1021/acsomega.4c04120",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/9171",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.8817.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      102
    ],
    "classf": [
      6
    ],
    "mechanisms": [
      14,
      122,
      123,
      28,
      29
    ],
    "target": [
      25,
      26,
      27,
      28,
      29
    ],
    "effect": [
      149
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 227,
  "fields": {
    "gname": "Benzo[b]fluoranthene",
    "smiles": "C1=CC=C2C3=C4C(=CC=C3)C5=CC=CC=C5C4=CC2=C1",
    "linkname": "benzobfluoranthene",
    "molecula": "C20 H12",
    "iupacname": "pentacyclo[10.7.1.02,7.08,20.013,18]icosa-1(19),2(7),3,5,8(20),9,11,13,15,17-decaene",
    "updphoto": "media/imgsrv_-_2025-03-20T161933.441.png",
    "description": "",
    "fdastatus": null,
    "linkslists": "https://pubs.acs.org/doi/full/10.1021/acsomega.4c04120",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/9153",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.8799.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      353
    ],
    "classf": [
      6
    ],
    "mechanisms": [
      14,
      122,
      123,
      28,
      126
    ],
    "target": [
      25,
      26,
      27,
      28,
      29
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 228,
  "fields": {
    "gname": "Dibenzo[a,h]anthracene",
    "smiles": "C1=CC=C2C(=C1)C=CC3=CC4=C(C=CC5=CC=CC=C54)C=C32",
    "linkname": "dibenzoahanthracene",
    "molecula": "C22H14",
    "iupacname": "naphtho[1,2-b]phenanthrene",
    "updphoto": "media/imgsrv_-_2025-03-20T162510.732.png",
    "description": "Dibenz[a,h]anthracene can cause cancer according to an independent committee of scientific and health experts.\r\nDisrupts circadian rhtyhms targeting core clock. Koh, Y.C. and Pan, M.H., 2024. Food-Borne Polycyclic Aromatic Hydrocarbons and Circadian Disruption. ACS omega, 9(29), pp.31298-31312.",
    "fdastatus": "none",
    "linkslists": "https://pubs.acs.org/doi/full/10.1021/acsomega.4c04120",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5889",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.5678.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      102
    ],
    "classf": [
      6
    ],
    "mechanisms": [
      122,
      28,
      126,
      14
    ],
    "target": [
      25,
      26,
      27,
      29
    ],
    "effect": [
      146
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 229,
  "fields": {
    "gname": "BENZO(ghi)PERYLENE",
    "smiles": "C1=CC2=C3C(=C1)C4=CC=CC5=C4C6=C(C=C5)C=CC(=C36)C=C2",
    "linkname": "benzoghiperylene",
    "molecula": "C22 H12",
    "iupacname": "hexacyclo[12.8.0.02,11.03,8.04,21.017,22]docosa-1(14),2(11),3(8),4,6,9,12,15,17(22),18,20-undecaene",
    "updphoto": "media/imgsrv_-_2025-03-20T162628.873.png",
    "description": "Disrupts circadian rhtyhms targeting core clock. Koh, Y.C. and Pan, M.H., 2024. Food-Borne Polycyclic Aromatic Hydrocarbons and Circadian Disruption. ACS omega, 9(29), pp.31298-31312.",
    "fdastatus": null,
    "linkslists": "https://pubs.acs.org/doi/full/10.1021/acsomega.4c04120",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/9117",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.8763.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      102
    ],
    "classf": [
      6
    ],
    "mechanisms": [
      14,
      122,
      126
    ],
    "target": [
      25,
      26,
      27,
      29
    ],
    "effect": [
      143
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 230,
  "fields": {
    "gname": "Indeno[1,2,3-c,d]pyrene",
    "smiles": "C1=CC=C2C(=C1)C3=C4C2=CC5=CC=CC6=C5C4=C(C=C6)C=C3",
    "linkname": "indeno123-cdpyrene",
    "molecula": "C22 H 12",
    "iupacname": "hexacyclo[16.3.1.02,7.08,21.011,20.014,19]docosa-1(22),2,4,6,8(21),9,11(20),12,14(19),15,17-undecaene",
    "updphoto": "media/imgsrv_-_2025-03-20T162941.253.png",
    "description": "Indeno[1,2,3-cd]pyrene can cause cancer according to an independent committee of scientific and health experts. Disrupts circadian rhtyhms targeting core clock. Koh, Y.C. and Pan, M.H., 2024. Food-Borne Polycyclic Aromatic Hydrocarbons and Circadian Disruption. ACS omega, 9(29), pp.31298-31312.",
    "fdastatus": "none",
    "linkslists": "https://pubs.acs.org/doi/full/10.1021/acsomega.4c04120",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/9131",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.8777.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      102
    ],
    "classf": [
      6
    ],
    "mechanisms": [
      14,
      126
    ],
    "target": [
      29
    ],
    "effect": [
      140
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 231,
  "fields": {
    "gname": "KK-S6",
    "smiles": "CC(C1=CC(=C(C=C1)OC)OC)C(=O)C2=C(C=C(C=C2)C(C)(C)C#C)OC",
    "linkname": "kk-s6",
    "molecula": "C23H26O4",
    "iupacname": "2-(3,4-dimethoxyphenyl)-1-[2-methoxy-4-(2-methylbut-3-yn-2-yl)phenyl]propan-1-one",
    "updphoto": "media/imgsrv_-_2025-03-20T163424.472.png",
    "description": "Poorly studied core clock modulator. KK-S6 works by targeting specific molecular components of the circadian clock. It is believed to interact with key proteins involved in the regulation of circadian rhythms, such as CLOCK, BMAL1, PER, and CRY. By modulating the expression and activity of these proteins, KK-S6 can phase-shift the circadian clock, either advancing or delaying it to align with desired sleep-wake patterns.\r\n\r\nHuang, S., Jiao, X., Lu, D., Pei, X., Qi, D. and Li, Z., 2020. Recent advances in modulators of circadian rhythms: an update and perspective. Journal of Enzyme Inhibition and Medicinal Chemistry, 35(1), pp.1267-1286.",
    "fdastatus": "none",
    "linkslists": "https://www.tandfonline.com/doi/full/10.1080/14756366.2020.1772249#d1e446",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/171378887",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.88296328.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      101
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      15,
      28,
      51
    ],
    "target": [
      29
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 232,
  "fields": {
    "gname": "GSK4112",
    "smiles": "CC(C)(C)OC(=O)CN(CC1=CC=C(C=C1)Cl)CC2=CC=C(S2)[N+](=O)[O-]",
    "linkname": "gsk4112",
    "molecula": "C18H21ClN2O4S",
    "iupacname": "tert-butyl 2-[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]acetate",
    "updphoto": "media/imgsrv_-_2025-03-20T164433.974.png",
    "description": "GSK4112 is a Small Molecule Chemical Probe for the Cell Biology of the Nuclear Heme Receptor Rev-erbα. \r\n\r\nGrant, D., Yin, L., Collins, J.L., Parks, D.J., Orband-Miller, L.A., Wisely, G.B., Joshi, S., Lazar, M.A., Willson, T.M. and Zuercher, W.J., 2010. GSK4112, a small molecule chemical probe for the cell biology of the nuclear heme receptor Rev-erbα. ACS chemical biology, 5(10), pp.925-932.",
    "fdastatus": "none",
    "linkslists": "https://pubs.acs.org/doi/abs/10.1021/cb100141y",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/50905018#section=Structures",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.24606038.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      100
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      37
    ],
    "target": [
      47
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 233,
  "fields": {
    "gname": "SR9009",
    "smiles": "CCOC(=O)N1CCC(C1)CN(CC2=CC=C(C=C2)Cl)CC3=CC=C(S3)[N+](=O)[O-]",
    "linkname": "sr9009",
    "molecula": "C20H24ClN3O4S",
    "iupacname": "ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate",
    "updphoto": "media/imgsrv_-_2025-03-20T164614.601.png",
    "description": "SR9009 is known as a synthetic agonist for the REV-ERB nuclear receptors, which play a crucial role in regulating the circadian clock. The circadian clock is a biological system that controls various physiological processes, including sleep-wake cycles, metabolism, and hormone secretion. SR9009 has been shown to modulate the expression of key circadian genes such as Rev-erbα, Bmal1, Clock, and Per1. In models of ischemic stroke, SR9009 attenuated the decline in these genes' expression levels, suggesting its potential in maintaining circadian rhythm integrity under pathological conditions. Circadian rhythm disruptions are associated with increased susceptibility to various diseases, including ischemic stroke. SR9009's ability to stabilize circadian gene expression may help mitigate these risks by maintaining a more stable circadian rhythm. \r\n\r\nChronic low-dose SR9009 reduced LL-induced weight gain and insulin resistance.\r\nSR9009 restored Bmal1 upregulation and Rev-erbs downregulation caused by LL.\r\nSR9009 inhibited adipogenesis in vitro and in vivo.\r\nSR9009 may prevent weight gain and insulin resistance caused by circadian disruption.\r\n\r\nSolt, L.A., et al, 2012. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature, 485(7396), pp.62-68.\r\n\r\nYang, M.Y., Lin, H.Y.H., Chen, Y.Y.M., Hu, M.L., Chen, I.Y. and Yang, C.H., 2025. Chronic low-dose REV-ERBs agonist SR9009 mitigates constant light-induced weight gain and insulin resistance via adipogenesis modulation. Biomedical Journal, p.100830.",
    "fdastatus": "not approved",
    "linkslists": "https://www.nature.com/articles/nature11030",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/57394020",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.28487410.html",
    "drugbank": "https://go.drugbank.com/drugs/DB14013",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      98,
      99
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      127
    ],
    "target": [
      25,
      84,
      47
    ],
    "effect": [
      138
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 234,
  "fields": {
    "gname": "SR9011",
    "smiles": "CCCCCNC(=O)N1CCC(C1)CN(CC2=CC=C(C=C2)Cl)CC3=CC=C(S3)[N+](=O)[O-]",
    "linkname": "sr9011",
    "molecula": "C23H31ClN4O3S",
    "iupacname": "3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]-N-pentylpyrrolidine-1-carboxamide",
    "updphoto": "media/imgsrv_-_2025-03-20T165329.675.png",
    "description": "SR9011 is a research compound developed by Professor Thomas Burris of Scripps as an agonist of the Rev-ErbAα receptor, with a focus on regulating circadian rhythms and metabolic processes5. It is often used in sports and fitness for its potential to enhance metabolic rates, aid in fat loss, and improve muscle energy reserves without interfering with the endocrine system. \r\n\r\nSolt, L.A., et al, 2012. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature, 485(7396), pp.62-68.",
    "fdastatus": "none",
    "linkslists": "https://www.nature.com/articles/nature11030",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/57394021",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.28487552.html",
    "drugbank": "https://go.drugbank.com/drugs/DB14014",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      98
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      127
    ],
    "target": [
      25,
      84,
      63,
      47
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 235,
  "fields": {
    "gname": "Pterostilbene",
    "smiles": "COC1=CC(=CC(=C1)/C=C/C2=CC=C(C=C2)O)OC",
    "linkname": "pterostilbene",
    "molecula": "C16H16O3",
    "iupacname": "4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol",
    "updphoto": "media/imgsrv_-_2025-03-20T165808.093.png",
    "description": "Pterostilbene (PTE) can affect the circadian clock by ameliorating circadian misalignment and mitochondrial dysfunction12. Studies show PTE can restore rhythms of AMP-activated protein kinase (AMPK) phosphorylation activity, silent information regulator 1 (SIRT1) deacetylation activity, and SIRT1-mediated peroxisome proliferator-activated receptor coactivator 1α (PGC-1α) deacetylation in sleep-restricted mice. Liu, Y., \r\nmarkedly regulating the expression of skeletal muscle clock genes, circadian locomotor output cycles kaput, and brain and muscle arnt-like. Lang, H., Zhou, M., Huang, L., Hui, S., Wang, X., Chen, K. and Mi, M., 2020. The preventive effects of pterostilbene on the exercise intolerance and circadian misalignment of mice subjected to sleep restriction. Molecular Nutrition & Food Research, 64(11), p.1900991.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubmed.ncbi.nlm.nih.gov/32277569/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5281727",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4445042.html",
    "drugbank": "https://go.drugbank.com/drugs/DB17939",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      96,
      97
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      128,
      68,
      38,
      15,
      51,
      118,
      28
    ],
    "target": [
      25,
      26,
      27,
      28,
      29,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 236,
  "fields": {
    "gname": "BIBO 3304 trifluoroacetate",
    "smiles": "C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC3=CC=C(C=C3)CNC(=O)N.C(=O)(C(F)(F)F)O",
    "linkname": "bibo-3304-trifluoroacetate",
    "molecula": "C31H36F3N7O5",
    "iupacname": "(2R)-N-[[4-[(carbamoylamino)methyl]phenyl]methyl]-5-(diaminomethylideneamino)-2-[(2,2-diphenylacetyl)amino]pentanamide;2,2,2-trifluoroacetic acid",
    "updphoto": "media/imgsrv_-_2025-03-20T170516.999.png",
    "description": "BIBO 3304 trifluoroacetate functions as a selective antagonist of the Y1 receptor, which is one of the receptor subtypes for neuropeptide Y (NPY). NPY is a neurotransmitter involved in various physiological processes, including the regulation of circadian rhythms. By blocking the Y1 receptor, BIBO 3304 trifluoroacetate can potentially alter the timing of circadian rhythms, making it a valuable tool for studying and treating circadian-related disorders.\r\n\r\nCohen, S., Vainer, E., Matar, M.A., Kozlovsky, N., Kaplan, Z., Zohar, J., Mathé, A.A. and Cohen, H., 2015. Diurnal fluctuations in HPA and neuropeptide Y-ergic systems underlie differences in vulnerability to traumatic stress responses at different zeitgeber times. Neuropsychopharmacology, 40(3), pp.774-790.",
    "fdastatus": "none",
    "linkslists": "https://pubmed.ncbi.nlm.nih.gov/25241802/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5311021",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4470559.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      95
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      129
    ],
    "target": [
      85
    ],
    "effect": [
      136
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 237,
  "fields": {
    "gname": "BIBP3226",
    "smiles": "C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)NC(CCCN=C(N)N)C(=O)NCC3=CC=C(C=C3)O",
    "linkname": "bibp3226",
    "molecula": "C27H31N5O3",
    "iupacname": "(2R)-5-(diaminomethylideneamino)-2-[(2,2-diphenylacetyl)amino]-N-[(4-hydroxyphenyl)methyl]pentanamide",
    "updphoto": "media/D0V2GT.png",
    "description": "BIBP-3226 acts as a competitive antagonist at NPY Y1 receptors, blocking the effects of NPY, a neuropeptide involved in stress responses, appetite regulation, and circadian rhythm modulation. NPY is known to interact with the suprachiasmatic nucleus (SCN), the brain's master circadian clock, and can influence the timing of circadian rhythms. By inhibiting Y1 receptors, BIBP-3226 may alter the phase and amplitude of circadian rhythms, potentially resetting or stabilizing disrupted sleep-wake cycles.  BIBP-3226 could be investigated for its ability to treat disorders such as delayed sleep phase syndrome (DSPS) or advanced sleep phase syndrome (ASPS) by modulating the SCN's activity.\r\nNeuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor. Mol Pharmacol. 1996 Aug;50(2):285-92.",
    "fdastatus": "Not approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5311023",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4470561.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      94
    ],
    "classf": [
      9,
      5
    ],
    "mechanisms": [
      129
    ],
    "target": [
      85
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 238,
  "fields": {
    "gname": "Nobiletin",
    "smiles": "COC1=C(C=C(C=C1)C2=CC(=O)C3=C(O2)C(=C(C(=C3OC)OC)OC)OC)OC",
    "linkname": "nobiletin",
    "molecula": "C21H22O8",
    "iupacname": "2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxychromen-4-one",
    "updphoto": "media/imgsrv_-_2025-03-21T101730.272.png",
    "description": "Nobiletin, a natural small molecule, has emerged as a modulator of circadian rhythms with therapeutic implications across various biological systems. Its effects on circadian rhythms are mediated through the enhancement of clock machinery, particularly via activation of Retinoid Acid-related Orphan Receptor (ROR), which binds to the Bmal1 promoter and activates transcription of core clock genes like PER and CRY.\r\nNobiletin enhances circadian oscillations by increasing the amplitude of clock gene expression, such as Bmal1 and Per2. It also induces subtle changes in the period and phase of circadian rhythms in various models, including mouse fibroblasts and liver slices.\r\nIn arrhythmic cancer cell lines (e.g., MDA-MB-231), nobiletin restores rhythmicity while subtly altering circadian features in rhythmic cell lines (e.g., U2OS and MCF7) . Cell metabolism, 2016 23(4), pp.610-621.",
    "fdastatus": "Not approved",
    "linkslists": "https://www.cell.com/cell-metabolism/fulltext/S1550-4131(16)30110-3",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/72344",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.65283.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      89,
      90,
      91,
      92,
      93
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      32,
      15,
      118,
      47
    ],
    "target": [
      14
    ],
    "effect": [
      51
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 239,
  "fields": {
    "gname": "Neoruscogenin",
    "smiles": "C[C@H]1[C@H]2[C@H](C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4([C@@H](C[C@@H](C5)O)O)C)C)O[C@]16CCC(=C)CO6",
    "linkname": "neoruscogenin",
    "molecula": "C27H40O4",
    "iupacname": "(1S,2S,4S,6R,7S,8R,9S,12S,13R,14R,16R)-7,9,13-trimethyl-5'-methylidenespiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-14,16-diol",
    "updphoto": "media/imgsrv_-_2025-03-21T102434.308.png",
    "description": "Neoruscogenin, a member of the steroidal sapogenin family, has been identified as a potent and high-affinity agonist for the nuclear receptor RORα (retinoic acid receptor-related orphan receptor alpha). RORα is a critical regulator of the circadian clock, as it modulates the expression of genes involved in circadian rhythms. Neoruscogenin's activity has been demonstrated in both in vitro and in vivo studies, where it influences RORα target gene expression, suggesting its potential role in regulating circadian mechanisms.\r\n\r\n Helleboid, S., Haug, C., Lamottke, K., Zhou, Y., Wei, J., Daix, S., Cambula, L., Rigou, G., Hum, D.W. and Walczak, R., 2014. The identification of naturally occurring neoruscogenin as a bioavailable, potent, and high-affinity agonist of the nuclear receptor RORα (NR1F1). Journal of biomolecular screening, 19(3), pp.399-406.",
    "fdastatus": "none",
    "linkslists": "https://www.slas-discovery.org/article/S2472-5552(22)07333-6/fulltext",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/9910474",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.8086125.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      88
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      32
    ],
    "target": [
      40,
      86,
      14
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 240,
  "fields": {
    "gname": "Compound 1a",
    "smiles": "CC1=CC=C(C=C1)N2C(=O)N(C(=O)S2)CC3=CC=C(C=C3)F",
    "linkname": "compound-1a",
    "molecula": "C16H13FN2O2S",
    "iupacname": "4-[(4-fluorophenyl)methyl]-2-(4-methylphenyl)-1,2,4-thiadiazolidine-3,5-dione",
    "updphoto": "media/imgsrv_-_2025-03-21T103735.319.png",
    "description": "Zhang, W., Zhang, J., Fang, L., Zhou, L., Wang, S., Xiang, Z., Li, Y., Wisely, B., Zhang, G., An, G. and Wang, Y., 2012. Increasing human Th17 differentiation through activation of orphan nuclear receptor retinoid acid-related orphan receptor γ (RORγ) by a class of aryl amide compounds. Molecular pharmacology, 82(4), pp.583-590.",
    "fdastatus": "none",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/2733079",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      86,
      87
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      32,
      130
    ],
    "target": [
      87
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 241,
  "fields": {
    "gname": "Digoxin",
    "smiles": "C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O",
    "linkname": "digoxin",
    "molecula": "C41H64O14",
    "iupacname": "12beta-Hydroxydigitoxin",
    "updphoto": "media/imgsrv_-_2025-03-21T112549.258.png",
    "description": "3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one - A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small. It has a role as an epitope, an anti-arrhythmia drug, a cardiotonic drug and an EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor. It is a cardenolide glycoside and a steroid saponin.",
    "fdastatus": "Approved",
    "linkslists": "https://pubmed.ncbi.nlm.nih.gov/21441909/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/2724385",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.2006532.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00390",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4551",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D00298",
    "selleckchem": "https://www.selleckchem.com/products/digoxin.html",
    "articles": [
      85
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      32,
      130
    ],
    "target": [
      87
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 242,
  "fields": {
    "gname": "Ursolic acid",
    "smiles": "C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O",
    "linkname": "ursolic-acid",
    "molecula": "C30H48O3",
    "iupacname": "(1S,2R,4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid",
    "updphoto": "media/imgsrv_-_2025-03-21T113232.507.png",
    "description": "Ursolic Acid is a pentacyclic triterpenoid found in various fruits, vegetables and medicinal herbs, with a variety of potential pharmacologic activities including anti-inflammatory, antioxidative, antiviral, serum lipid-lowering, and antineoplastic activities. Upon administration, ursolic acid may promote apoptosis and inhibit cancer cell proliferation through multiple mechanisms. This may include the regulation of mitochondrial function through various pathways including the ROCK/PTEN and p53 pathways, the suppression of the nuclear factor-kappa B (NF-kB) pathways, and the increase in caspase-3, caspase-8 and caspase-9 activities. Ursolic acid alters the expression of clock and clock-controlled genes (CCGs), which are essential for the regulation of circadian rhythms. This modulation helps in improving lipid metabolism and detoxification processes in the liver",
    "fdastatus": "Not approved",
    "linkslists": "https://www.nature.com/articles/nrd4100",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/64945",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.58472.html",
    "drugbank": "https://go.drugbank.com/drugs/DB15588",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      82,
      83,
      84
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      131,
      132,
      133
    ],
    "target": [
      87
    ],
    "effect": [
      134
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 243,
  "fields": {
    "gname": "Vtp-43742",
    "smiles": "CCS(=O)(=O)C1=CN=C(C=C1)CNC(=O)C2=CC3=C([C@H](N(C3)CC4CCC(CC4)C(F)(F)F)C(C)C)N=C2",
    "linkname": "vtp-43742",
    "molecula": "C27H35F3N4O3S",
    "iupacname": "(7R)-N-[(5-ethylsulfonylpyridin-2-yl)methyl]-7-propan-2-yl-6-[[4-(trifluoromethyl)cyclohexyl]methyl]-5,7-dihydropyrrolo[3,4-b]pyridine-3-carboxamide",
    "updphoto": "media/imgsrv_-_2025-03-21T115948.869.png",
    "description": "Vitae Pharmaceuticals against Psoriasis\tPhase I; 40 healthy subjects and 34 patients with psoriasis\tEvaluate safety, tolerability, PK, and PD effects of oral VTP-4374. NCT03724292\r\nPhase I/Phase II; 48 healthy adults and 60 patients with psoriasis\tNCT02555709\t\t\t\t\r\nRibeiro, R.F., Cavadas, C. and Silva, M.M.C., 2021. Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases. Drug Discovery Today, 26(7), pp.1620-1641.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/118282339#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/118282339#section=Information-Sources",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      80,
      81
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      134
    ],
    "target": [
      87
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 244,
  "fields": {
    "gname": "ARN-6039",
    "smiles": "COC1=C(C=C2CC(C(=O)C2=C1)CC3=C(C=CC=N3)C(F)(F)F)N4CCOCC4",
    "linkname": "arn-6039",
    "molecula": "C21H21F3N2O3",
    "iupacname": "6-methoxy-5-morpholin-4-yl-2-[[3-(trifluoromethyl)pyridin-2-yl]methyl]-2,3-dihydroinden-1-one",
    "updphoto": "media/imgsrv_-_2025-03-21T120341.720.png",
    "description": "ARN-6039 is known as an inverse agonist of RORγ, primarily used for autoimmune demyelinating diseases45. RORγ is not directly mentioned in the context of circadian clock modulation in the provided search results, but RORα is discussed as part of the accessory loop in the circadian clock system, influencing Bmal1 transcription. Ribeiro, R.F., Cavadas, C. and Silva, M.M.C., 2021. Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases. Drug Discovery Today, 26(7), pp.1620-1641.",
    "fdastatus": null,
    "linkslists": "https://www.sciencedirect.com/science/article/abs/pii/S1359644621001525#b0265",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/117940165",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.88295832.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      80
    ],
    "classf": [
      9,
      5
    ],
    "mechanisms": [
      32
    ],
    "target": [
      87
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 245,
  "fields": {
    "gname": "AZD-0284e",
    "smiles": "CC(=O)N1CC2=C([C@@H]1C(=O)NC3=CC=C(C=C3)C(C(F)(F)F)(C(F)(F)F)O)C=CC(=C2)S(=O)(=O)C",
    "linkname": "azd-0284e",
    "molecula": "C21H18F6N2O5S",
    "iupacname": "(1R)-2-acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide",
    "updphoto": "media/imgsrv_-_2025-03-21T120554.205.png",
    "description": "AZD0284 is a small molecule modulator targeting RORγ, a nuclear receptor involved in circadian rhythm regulation and immune responses. While primarily studied for its immunomodulatory effects, its role in circadian biology emerges through RORγ’s function in the clock system.\r\nMechanism of Action\r\nAZD0284 acts as an inverse agonist of RORγ, suppressing its transcriptional activity. RORγ regulates Bmal1 expression via ROR-responsive elements (RREs), influencing the core circadian feedback loop23. By inhibiting RORγ, AZD0284 disrupts this regulatory pathway, potentially altering circadian gene expression rhythms.",
    "fdastatus": null,
    "linkslists": "https://www.sciencedirect.com/science/article/abs/pii/S1359644621001525#b0265",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/129205086#section=Information-Sources&fullscreen=true",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      80
    ],
    "classf": [
      9,
      5
    ],
    "mechanisms": [
      32,
      130
    ],
    "target": [
      87
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 246,
  "fields": {
    "gname": "Cintirorgon",
    "smiles": "CC(C)(C[C@H]1CN(C2=C(O1)C=CC(=C2)C3=CC(=CC(=C3)F)OC(F)F)S(=O)(=O)C4=CC=CC(=C4)C(F)(F)F)C(=O)O",
    "linkname": "cintirorgon",
    "molecula": "C27H23F6NO6S",
    "iupacname": "3-[(2S)-6-[3-(difluoromethoxy)-5-fluorophenyl]-4-[3-(trifluoromethyl)phenyl]sulfonyl-2,3-dihydro-1,4-benzoxazin-2-yl]-2,2-dimethylpropanoic acid",
    "updphoto": "media/imgsrv_-_2025-03-21T142828.736.png",
    "description": "Cintirorgon is an orally bioavailable agonist of retinoic acid-related orphan receptor gamma (RORg), with potential immunomodulatory and antineoplastic activities. Upon oral administration of cintirorgon, this agent selectively binds to the nuclear receptor transcription factor RORg, forming a receptor complex that translocates to the nucleus, and binds to ROR response elements (ROREs), enhancing the function, proliferation and survival of type 17 T-cells, including Th17 (helper T-cells) and Tc17 (cytotoxic T-cells). Cancer (solid tumors)\tPhase I/II; 105 participants\tEvaluate safety and tolerability of increased repeated doses of LYC-55716 in patients with locally advanced or metastatic solid tumors\tNCT02929862 \tPhase Ib; 18 participants\tAssess safety and tolerability of LYC-55716 in combination with pembrolizumab in patients with metastatic NSCLC, and to assess combination for biological and clinical activity in NSCLC\tNCT03396497",
    "fdastatus": "Not approved",
    "linkslists": "https://www.sciencedirect.com/science/article/abs/pii/S0960894X19303014",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/#query=LYC-55716",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.67896554.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      79
    ],
    "classf": [
      9,
      5
    ],
    "mechanisms": [
      32,
      130
    ],
    "target": [
      16,
      87
    ],
    "effect": [
      132
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 247,
  "fields": {
    "gname": "Gsk2981278",
    "smiles": "CCC1=CC=C(C=C1)N(CC(C)C)S(=O)(=O)C2=CC(=C(C=C2)OCC3CCOCC3)CO",
    "linkname": "gsk2981278",
    "molecula": "C25H35NO5S",
    "iupacname": "N-(4-ethylphenyl)-3-(hydroxymethyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzenesulfonamide",
    "updphoto": "media/imgsrv_-_2025-03-21T143541.487.png",
    "description": "GSK-2981278 is under investigation in clinical trial NCT03004846 (A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis).\r\nGSK2981278 is a small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication. \r\nAmaudrut, J., Argiriadi, M.A., Barth, M., Breinlinger, E.C., Bressac, D., Broqua, P., Calderwood, D.J., Chatar, M., Cusack, K.P., Gauld, S.B. and Jacquet, S., 2019. Discovery of novel quinoline sulphonamide derivatives as potent, selective and orally active RORγ inverse agonists. Bioorganic & Medicinal Chemistry Letters, 29(14), pp.1799-1806.",
    "fdastatus": "none",
    "linkslists": "https://www.sciencedirect.com/science/article/abs/pii/S0960894X19303014",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/89875987",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.39625826.html",
    "drugbank": "https://go.drugbank.com/drugs/DB16319",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      78
    ],
    "classf": [
      9,
      5
    ],
    "mechanisms": [
      32,
      130
    ],
    "target": [
      87
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 248,
  "fields": {
    "gname": "RN-1734",
    "smiles": "CC(C)NCCN(C(C)C)S(=O)(=O)C1=C(C=C(C=C1)Cl)Cl",
    "linkname": "rn-1734",
    "molecula": "C₁₄H₂₂Cl₂N₂O₂S",
    "iupacname": "2,4-dichloro-N-propan-2-yl-N-[2-(propan-2-ylamino)ethyl]benzenesulfonamide",
    "updphoto": "media/imgsrv_2J4TjRW.png",
    "description": "RN‑1734 is a benzothiazole-derived compound best known as a selective antagonist of the TRPV4 channel. By inhibiting TRPV4, RN‑1734 reduces Ca²⁺ influx, which in turn can alter the activity of signaling cascades that control the expression of AANAT. Since AANAT is pivotal for melatonin production—a key hormone regulating the circadian rhythm—RN‑1734 provides a valuable tool for exploring how TRPV4-mediated pathways contribute to circadian clock modulation.\r\n\r\nAlkozi, H.A., de Lara, M.J.P. and Pintor, J., 2017. Melatonin synthesis in the human ciliary body triggered by TRPV4 activation: Involvement of AANAT phosphorylation. Experimental eye research, 162, pp.1-8.",
    "fdastatus": "Not approved",
    "linkslists": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5412331/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/3601086",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.2836900.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      77
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      135
    ],
    "target": [
      88
    ],
    "effect": [
      50
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 249,
  "fields": {
    "gname": "HC067047",
    "smiles": "CC1=C(C=C(N1CCCN2CCOCC2)C3=CC=CC=C3)C(=O)NC4=CC=CC(=C4)C(F)(F)F",
    "linkname": "hc067047",
    "molecula": "C₂₆H₂₈F₃N₃O₂",
    "iupacname": "2-methyl-1-(3-morpholin-4-ylpropyl)-5-phenyl-N-[3-(trifluoromethyl)phenyl]pyrrole-3-carboxamide",
    "updphoto": "media/imgsrv_1_okQoyz2.png",
    "description": "HC067047 is a potent and selective antagonist of the transient receptor potential vanilloid 4 (TRPV4) channel. TRPV4 plays a crucial role in mediating Ca²⁺ entry in response to mechanical, osmotic, and thermal stimuli. In the eye, activation of TRPV4 in ciliary body epithelial cells triggers the upregulation of AANAT—the rate‑limiting enzyme in melatonin synthesis—thereby enhancing melatonin production and influencing circadian rhythms.",
    "fdastatus": "Not approved",
    "linkslists": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4448752/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/2742550#section=2D-Structure",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.2024081.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      76
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      135
    ],
    "target": [
      88
    ],
    "effect": [
      130
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 250,
  "fields": {
    "gname": "Longdaysin",
    "smiles": "CC(C)N1C=NC2=C(N=CN=C21)NCC3=CC(=CC=C3)C(F)(F)F",
    "linkname": "longdaysin",
    "molecula": "C16H16F3N5",
    "iupacname": "9-propan-2-yl-N-[[3-(trifluoromethyl)phenyl]methyl]purin-6-amine",
    "updphoto": "media/imgsrv_-_2025-03-21T145000.905.png",
    "description": "It significantly lengthens the circadian period by inhibiting three key protein kinases: Casein Kinase I delta (CKIδ), Casein Kinase I alpha (CKIα), and ERK2. These kinases are critical in regulating the phosphorylation and degradation of the circadian clock protein PER1, which plays a central role in maintaining the circadian cycle. By inhibiting these kinases, longdaysin prevents PER1 degradation, thereby slowing the circadian clock.\r\nKolarski, D., Sugiyama, A., Breton, G., Rakers, C., Ono, D., Schulte, A., Tama, F., Itami, K., Szymanski, W., Hirota, T. and Feringa, B.L., 2019. Controlling the circadian clock with high temporal resolution through photodosing. Journal of the American Chemical Society, 141(40), pp.15784-15791.",
    "fdastatus": "none",
    "linkslists": "https://pubs.acs.org/doi/10.1021/jacs.9b05445?src=getftr",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/49830252",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.24751747.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      75
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      125
    ],
    "target": [
      89
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 251,
  "fields": {
    "gname": "BRD1652",
    "smiles": "C[C@]1(C2=C(CC(CC2=O)(C)C)NC3=NNC(=C31)C(F)(F)F)C4=CC=CC=C4",
    "linkname": "brd1652",
    "molecula": "C₂₀H₂₀F₃N₃O",
    "iupacname": "(4S)-4,7,7-trimethyl-4-phenyl-3-(trifluoromethyl)-2,6,8,9-tetrahydropyrazolo[3,4-b]quinolin-5-one",
    "updphoto": "media/imgsrv_3_Rz5Gbjw.png",
    "description": "BRD1652 is a chiral pyrrolidine-based compound that exhibits high potency and exceptional selectivity for GSK-3β. Unlike broader inhibitors such as CHIR99021, BRD1652 minimizes off-target kinase inhibition, making it a valuable tool for dissecting GSK-3β’s specific role in circadian regulation. By modulating GSK-3β activity, BRD1652 is poised to affect the degradation dynamics of clock proteins and thereby shorten the circadian period. Its refined selectivity also underpins its potential therapeutic utility in treating mood disorders and other conditions linked to circadian dysfunction.\r\n\r\nWagner, F.F., Bishop, J.A., Gale, J.P., Shi, X., Walk, M., Ketterman, J., Patnaik, D., Barker, D., Walpita, D., Campbell, A.J. and Nguyen, S., 2016. Inhibitors of glycogen synthase kinase 3 with exquisite kinome-wide selectivity and their functional effects. ACS Chemical Biology, 11(7), pp.1952-1963.",
    "fdastatus": "Not approved",
    "linkslists": "https://www.sciencedirect.com/science/article/pii/S002228362030019X",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/136237017#section=2D-Structure",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.88297338.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      74
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      138,
      139
    ],
    "target": [
      76
    ],
    "effect": [
      128
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 252,
  "fields": {
    "gname": "DK325",
    "smiles": "CC(C)N1C=NC2=C1N=CN=C2N(CC3=CC(=CC=C3)C(F)(F)F)CC4=C(C=CC=C4)[N+](=O)[O-]",
    "linkname": "dk325",
    "molecula": "9-isopropyl-N-(2-nitrobenzyl)-N-(3-(trifluoromethyl)benzyl)-9H-purin-6-amine",
    "iupacname": "9-isopropyl-N-(2-nitrobenzyl)-N-(3-(trifluoromethyl)benzyl)-9H-purin-6-amine",
    "updphoto": "media/Снимок_экрана_2025-03-21_144036.jpg",
    "description": "DK325 is a photocleavable derivative designed to modulate the circadian clock by controlling the activity of Casein Kinase I (CKI), a key regulator of the circadian rhythm. It is based on longdaysin, a potent CKI inhibitor, but its activity is suppressed until it is exposed to light, allowing for precise temporal control over the biological timing of circadian rhythms",
    "fdastatus": null,
    "linkslists": "https://pubs.acs.org/doi/10.1021/jacs.9b05445?src=getftr",
    "pubchem": null,
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [],
    "classf": [
      5
    ],
    "mechanisms": [
      136
    ],
    "target": [
      89
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 253,
  "fields": {
    "gname": "PF-4800567",
    "smiles": "C1COCCC1N2C3=NC=NC(=C3C(=N2)COC4=CC(=CC=C4)Cl)N",
    "linkname": "pf-4800567",
    "molecula": "C₁₇H₁₈ClN₅O₂",
    "iupacname": "3-[(3-chlorophenoxy)methyl]-1-(tetrahydropyran-4-yl)pyrazolo[3,4-d]pyrimidin-4-amine",
    "updphoto": "media/imgsrv_5_BxAnEIj.png",
    "description": "PF-4800567 is a pyrazolopyrimidine-based compound that selectively inhibits CK1ε. It is used primarily in circadian rhythm studies to dissect the individual roles of CK1 isoforms. Although inhibition of CK1ε has only a slight effect on the circadian period in wild-type cells, it has a pronounced effect in CK1ε gain-of-function mutant models. PF-4800567 serves as a valuable chemical tool for understanding the molecular mechanisms of circadian clock regulation.",
    "fdastatus": "Not approved",
    "linkslists": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2930590/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/53472153#section=2D-Structure",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.26325201.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [],
    "classf": [
      9
    ],
    "mechanisms": [
      140
    ],
    "target": [
      43
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 254,
  "fields": {
    "gname": "DK359",
    "smiles": "COC1=CC(=C(CN(C2=C3N=CN(C3=NC=N2)C(C)C)CC2=CC(=CC=C2)C(F)(F)F)C=C1OC)[N+](=O)[O-]",
    "linkname": "dk359",
    "molecula": "C25H25N6F3O4H",
    "iupacname": "N-(4,5-dimethoxy-2-nitrobenzyl)-9-isopropyl-N-(3-(trifluoromethyl)benzyl)-9H-purin-6-amine",
    "updphoto": "media/Снимок_экрана_2025-03-21_151527.jpg",
    "description": "DK359 is a photocaged derivative of longdaysin, a purine-based inhibitor of CKIα and CKIδ, which are enzymes involved in the regulation of the circadian clock. DK359 is designed to have no effect on the circadian period in the dark, but upon exposure to light, it releases longdaysin, leading to a lengthening of the circadian period. Human U2OS cells: Light-induced period lengthening (up to ~30 hours) via CKI inhibition.\r\nMouse spleen/SCN explants: Concentration- and irradiation-duration-dependent period modulation.",
    "fdastatus": "none",
    "linkslists": "https://pubs.acs.org/doi/10.1021/jacs.9b05445?src=getftr",
    "pubchem": null,
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      73
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      125,
      136
    ],
    "target": [
      89
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 255,
  "fields": {
    "gname": "CX-4945",
    "smiles": "C1=CC(=CC(=C1)Cl)NC2=NC3=C(C=CC(=C3)C(=O)O)C4=C2C=CN=C4",
    "linkname": "cx-4945",
    "molecula": "C₁₉H₁₂ClN₃O₂",
    "iupacname": "5‑(3‑chlorophenylamino)benzo[c][2,6]naphthyridine‑8‑carboxylic acid",
    "updphoto": "media/imgsrv_6_SLSesXK.png",
    "description": "PF‑4800567 is a selective, ATP‑competitive inhibitor of the epsilon isoform of casein kinase 1 (CK1ε). Belonging to the pyrazolopyrimidine family, this compound has been developed as a research tool for dissecting CK1ε‑dependent pathways, particularly in studies of circadian rhythm regulation.\r\n\r\nSiddiqui-Jain, A., Drygin, D., Streiner, N., Chua, P., Pierre, F., O'Brien, S.E., Bliesath, J., Omori, M., Huser, N., Ho, C. and Proffitt, C., 2010. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer research, 70(24), pp.10288-10298.",
    "fdastatus": "Not approved",
    "linkslists": "https://aacrjournals.org/cancerres/article/70/24/10288/561243/CX-4945-an-Orally-Bioavailable-Selective-Inhibitor",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/24748573#section=2D-Structure",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.25057795.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      72
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      141
    ],
    "target": [
      43
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 256,
  "fields": {
    "gname": "LH846",
    "smiles": "CC1=CC2=C(C=C1Cl)N=C(S2)NC(=O)CC3=CC=CC=C 3",
    "linkname": "lh846",
    "molecula": "C16H13ClN2OS",
    "iupacname": "N-(5-chloro-6-methyl-1,3-benzothiazol-2-yl)-2- phenylacetamide",
    "updphoto": "media/imgsrv_-_2025-03-21T151654.331.png",
    "description": "A high-throughput cell-based screen identified a benzothiazole analogue, LH846, which induces period lengthening of the circadian rhythm. Affinity chromatography coupled with mass spectrometry and genomic analysis identified protein kinase CKIδ as the biological target of LH846.\r\n\r\nLee, J.W., Hirota, T., Peters, E.C., Garcia, M., Gonzalez, R., Cho, C.Y., Wu, X., Schultz, P.G. and Kay, S.A., 2011. A small molecule modulates circadian rhythms through phosphorylation of the period protein. Angewandte Chemie (International ed. in English), 50(45), p.10608.",
    "fdastatus": null,
    "linkslists": "https://onlinelibrary.wiley.com/doi/10.1002/anie.201103915",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/851474",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.744168.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      71
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      125,
      136
    ],
    "target": [
      89
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 257,
  "fields": {
    "gname": "4-(4-(benzo[d][1,3]dioxol-5-yl)-5-(pyridin-2-yl)-1H-imidazol-2-yl)benzamide",
    "smiles": "C1OC2=C(O1)C=C(C=C2)C3=C(NC(=N3)C4=CC=C(C=C4)C(=O)N)C5=CC=CC=N5",
    "linkname": "4-4-benzod13dioxol-5-yl-5-pyridin-2-yl-1h-imidazol-2-ylbenzamide",
    "molecula": "C22H16N4O3",
    "iupacname": "4-[4-(1,3-benzodioxol-5-yl)-5-pyridin-2-yl-1H-imidazol-2-yl]benzamide",
    "updphoto": "media/imgsrv_-_2025-03-21T152223.701.png",
    "description": "Activation of TGF-β/activin signalling resets the circadian clock through rapid induction of Dec1 transcripts. These results indicate that ALK–SMAD3–Dec1 signalling provides an input pathway in the mammalian molecular clock. Activation of activin receptor-like kinase (ALK), triggered by TGF-β, activin or alkali signals, evoked resetting of the cellular clock independently of Per induction. The resetting was mediated by an immediate-early induction of Dec1, a gene whose physiological role in the function of the circadian clock has been unclear.  \r\nKon, N., Hirota, T., Kawamoto, T., Kato, Y., Tsubota, T. and Fukada, Y., 2008. Activation of TGF-β/activin signalling resets the circadian clock through rapid induction of Dec1 transcripts. Nature cell biology, 10(12), pp.1463-1469.",
    "fdastatus": "none",
    "linkslists": "https://www.nature.com/articles/ncb1806",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/4521392",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      70
    ],
    "classf": [
      5,
      7
    ],
    "mechanisms": [
      142,
      143
    ],
    "target": [
      90
    ],
    "effect": [
      126
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 258,
  "fields": {
    "gname": "Li (Lithium Carbonate)",
    "smiles": "[Li+].[Li+].C(=O)([O-])[O-]",
    "linkname": "li",
    "molecula": "Li2CO3",
    "iupacname": "Lithium",
    "updphoto": "media/imgsrv_-_2025-04-02T115830.561.png",
    "description": "Lithium is known to affect circadian rhythms across various organisms, including humans and animals. Here's a summary of its effects:\r\nLithium has been shown to lengthen the circadian period in several organisms, including humans, under certain conditions. This effect is observed in both constant light and darkness, though it is more pronounced in constant light conditions. Inhibits glycogen synthase kinase-3β (GSK-3β).\r\nLithium can increase the amplitude of circadian rhythms, which means it can enhance the intensity or robustness of the circadian cycle. This is observed in various organisms from plants to humans.\r\nRegulation of Activity: In bipolar disorder patients, lithium helps stabilize activity levels and promotes morningness behaviors, which can contribute to its therapeutic effects. It also suppresses elevated activity in models like honey bees, particularly under constant light conditions.\r\nRohr, K.E. and McCarthy, M.J., 2022. The impact of lithium on circadian rhythms and implications for bipolar disorder pharmacotherapy. Neuroscience letters, 786, p.136772.",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/11125#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/11125",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.2293625.html",
    "drugbank": "https://go.drugbank.com/drugs/DB14509",
    "chebi": null,
    "uniprot": null,
    "kegg": "https://www.genome.jp/dbget-bin/www_bget?dr:D00801",
    "selleckchem": null,
    "articles": [
      69
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      144
    ],
    "target": [
      42,
      84,
      25,
      26,
      27,
      28
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 259,
  "fields": {
    "gname": "PF670462",
    "smiles": "C1CCC(CC1)N2C=NC(=C2C3=NC(=NC=C3)N)C4=CC=C(C=C4)F.Cl. Cl",
    "linkname": "pf-670462",
    "molecula": "C19H22Cl2FN5",
    "iupacname": "4-[3-cyclohexyl-5-(4-fluorophenyl)imidazol-4-yl]pyrimidin-2-amine;dihydrochloride",
    "updphoto": "media/imgsrv_-_2025-03-21T153645.925.png",
    "description": "PF-670462 is a hydrochloride salt resulting from the formal reaction of 3-[(3-chlorophenoxy)methyl]-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine with 2 mol eq. of hydrogen chloride. It is a selective inhibitor of the delta- and epsilon-isoforms of casein kinase 1 (CK1delta and CK1epsilon). It has a role as an EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor. It contains a PF-670462 free base(2+).",
    "fdastatus": null,
    "linkslists": "https://link.springer.com/article/10.1007/s10571-024-01485-2",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/51049607",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.24606003.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      66
    ],
    "classf": [
      9,
      5
    ],
    "mechanisms": [
      35,
      125,
      145
    ],
    "target": [
      89
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 260,
  "fields": {
    "gname": "1-Azakenpaullone",
    "smiles": "C1C2=C(C3=C(C=CC=N3)NC1=O)NC4=C2C=C(C=C4) Br",
    "linkname": "azakenpaullone",
    "molecula": "C15H10BrN3O",
    "iupacname": "14-bromo-3,8,18-triazatetracyclo[9.7.0.02,7.012,17]octadeca-1(11),2(7),3,5,12(17),13,15-heptaen-9-one",
    "updphoto": "media/imgsrv_-_2025-03-21T154302.244.png",
    "description": "1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase 3β (GSK3β), which plays a role in modulating the circadian clock. GSK3β can phosphorylate key circadian proteins such as CLOCK, PER, REV-ERB, and CRY, influencing their activity and stability. By inhibiting GSK3β, 1-azakenpaullone has been shown to shorten the circadian period in mammalian cells45. This effect is consistent with other GSK3β inhibitors like Chir99021, which also shorten the circadian period, indicating that GSK3β activity is crucial for maintaining the normal duration of the circadian cycle. \r\nMiller, S. and Hirota, T., 2020. Pharmacological interventions to circadian clocks and their molecular bases. Journal of molecular biology, 432(12), pp.3498-3514.",
    "fdastatus": "none",
    "linkslists": "https://www.sciencedirect.com/science/article/pii/S002228362030019X",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/6538897",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.5021365.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      68
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      96,
      121,
      138,
      144
    ],
    "target": [
      76
    ],
    "effect": [
      124
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 261,
  "fields": {
    "gname": "Indirubin (Couroupitine B)",
    "smiles": "C1=CC=C2C(=C1)C(=C(N2)O)C3=NC4=CC=CC=C4C3=O",
    "linkname": "indirubin-couroupitine-b",
    "molecula": "C16H10N2O2",
    "iupacname": "2-(2-hydroxy-1H-indol-3-yl)indol-3-one",
    "updphoto": "media/imgsrv_-_2025-03-21T154913.181.png",
    "description": "Indirubin derivatives have been shown to alter the circadian period in cell cultures. These compounds can modulate the expression of circadian genes, potentially affecting the timing and amplitude of circadian oscillations. Indirubins are known to inhibit glycogen synthase kinase-3 (GSK-3), an enzyme involved in various physiological processes. GSK-3 inhibition can influence circadian rhythm regulation indirectly by affecting signaling pathways that interact with the circadian clock machinery. Studies using luminescent reporters have demonstrated that indirubin derivatives can modify the oscillations of core circadian elements like Bmal1 and Per2. These modifications suggest that indirubins could be used as tools to investigate circadian rhythm regulation",
    "fdastatus": "none",
    "linkslists": "https://www.pnas.org/doi/abs/10.1073/pnas.0811410106",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/10177",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4477010.html",
    "drugbank": "https://go.drugbank.com/drugs/DB12379",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      67
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      96,
      138,
      144,
      120,
      121
    ],
    "target": [
      76
    ],
    "effect": [
      49
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 262,
  "fields": {
    "gname": "CHIR99021 (Laduviglusib)",
    "smiles": "CC1=CN=C(N1)C2=CN=C(N=C2C3=C(C=C(C=C3)Cl)Cl)NCCNC4=NC=C(C=C4)C# N",
    "linkname": "chir99021-laduviglusib",
    "molecula": "C22H18Cl2N8",
    "iupacname": "6 -[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)pyrimidin-2-yl]amino]ethylamino]pyridine-3-carbonitrile",
    "updphoto": "media/imgsrv_-_2025-03-21T155326.564.png",
    "description": "CHIR99021, also known as laduviglusib or CT99021, is a potent and selective inhibitor of glycogen synthase kinase-3 (GSK3), targeting both GSK3α and GSK3β isoforms. It has IC50 values of 10 nM for GSK3α and 6.7 nM for GSK3β, making it highly effective in modulating pathways regulated by these enzymes. Mechanism of Action: CHIR99021 acts as an ATP-competitive inhibitor of GSK3, which is involved in several cellular pathways, including insulin signaling, Wnt signaling, neurotrophic factor signaling, and neurotransmitter regulation. Shortening of Circadian Period: CHIR-99021 has been demonstrated to shorten the circadian period in various cell models. It achieves this by preventing the phosphorylation of key clock proteins such as PER2, CRY2, CLOCK, BMAL1, and REV-ERBα, which are involved in the transcriptional-translational feedback loops (TTFLs) that govern circadian rhythms.",
    "fdastatus": "none",
    "linkslists": "https://link.springer.com/article/10.1007/s10571-024-01485-2",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/9956119",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      66
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      96,
      121,
      138,
      144
    ],
    "target": [
      76
    ],
    "effect": [
      26,
      48
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 263,
  "fields": {
    "gname": "Bifidobacterium breve CCFM1025",
    "smiles": "Unknown",
    "linkname": "bifidobacterium-breve-ccfm1025",
    "molecula": "Unknown",
    "iupacname": "Unknown",
    "updphoto": "media/images_30.jpg",
    "description": "Bifidobacterium breve CCFM1025 has been shown to improve circadian rhythms, particularly in the context of sleep deprivation. Studies indicate that this probiotic strain modulates the gut microbiota, which in turn influences the production of key metabolites involved in regulating sleep function. For instance, CCFM1025 mitigated circadian rhythm disturbances induced by sleep deprivation in mice by altering the gut microbiome and its associated metabolites. Tian, P., Hou, Y., Wang, Z., Jiang, J., Qian, X., Qu, Z., Zhao, J., Wang, G. and Chen, W., 2024. Probiotics administration alleviates cognitive impairment and circadian rhythm disturbance induced by sleep deprivation. Food Science and Human Wellness, 13(4), pp.1951-1961.",
    "fdastatus": null,
    "linkslists": "https://www.sciencedirect.com/science/article/pii/S2213453024001691",
    "pubchem": null,
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [],
    "classf": [
      11
    ],
    "mechanisms": [
      146
    ],
    "target": [
      91
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 264,
  "fields": {
    "gname": "OMNi-BiOTiC® Stress Repair",
    "smiles": "(B. bifidum W23, B. lactis W51, B. lactis W52) and lactobacilli (L. acidophilus W22, L. casei W56, L. paracasei W20, L. plantarum W62, L. salivarius W24, L. lactis W19)",
    "linkname": "omni-biotic-stress-repair",
    "molecula": "(B. bifidum W23, B. lactis W51, B. lactis W52) and lactobacilli (L. acidophilus W22, L. casei W56, L. paracasei W20, L. plantarum W62, L. salivarius W24, L. lactis W19)",
    "iupacname": "(B. bifidum W23, B. lactis W51, B. lactis W52) and lactobacilli (L. acidophilus W22, L. casei W56, L. paracasei W20, L. plantarum W62, L. salivarius W24, L. lactis W19)",
    "updphoto": "media/omni-biotic-stress-repair-pulver-7-stk_763_692_900x900_0.jpg",
    "description": "The composition of B. bifidum W23, B. lactis W51, B. lactis W52) and lactobacilli (L. acidophilus W22, L. casei W56, L. paracasei W20, L. plantarum W62, L. salivarius W24, L. lactis W19)  The gene expression levels of the clock gene CLOCK were significantly altered only in individuals receiving probiotic add-on treatment. TIMELESS and ARNTL gene expression changed significantly over the 4-week intervention period in both groups. Various positive and negative correlations between metabolites in serum/stool and core clock gene expression levels were observed. Changing the gut microbiome by probiotic treatment potentially influences CLOCK gene expression.\r\n\r\n\r\nKreuzer, K.,et al. 2024. PROVIT-CLOCK: A Potential Influence of Probiotics and Vitamin B7 Add-On Treatment and Metabolites on Clock Gene Expression in Major Depression. Neuropsychobiology, 83(3-4), pp.135-151.",
    "fdastatus": "Not approved",
    "linkslists": "https://karger.com/nps/article/83/3-4/135/907513/PROVIT-CLOCK-A-Potential-Influence-of-Probiotics",
    "pubchem": null,
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      65
    ],
    "classf": [
      11,
      4
    ],
    "mechanisms": [
      139,
      15,
      147,
      118,
      28
    ],
    "target": [
      52,
      92,
      29,
      30,
      63
    ],
    "effect": [
      5
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 265,
  "fields": {
    "gname": "Lactobacillus delbrueckii",
    "smiles": "Lactobacillus delbrueckii",
    "linkname": "lactobacillus-delbrueckii",
    "molecula": "Lactobacillus delbrueckii",
    "iupacname": "Lactobacillus delbrueckii",
    "updphoto": "media/images_31.jpg",
    "description": "Dietary L. delbrueckii affected ileal bacterial composition at the genus level, including Lactobacillus, Enterococcus, Leptotrichia, Pediococcus, Bifidobacte, Cel-lulosilyticum, Desulfomicrobium, Sharpea, Eubacterium, Propionivibrio, and Aerococcus, which were associated with membrane transport, metabolism of cofactors and vitamins, cell motility, the endocrine system, signaling molecules and interaction, and the nervous system. Bacteria were sequenced at 6 Zeitgeber times (ZT), and the results showed that Lactobacillus, Terrisporobacter, and Weissella exhibited significant rhythmic fluctuation in the control pigs, which was disturbed by probiotic exposure. In addition, dietary L. delbrueckii shaped circadian rhythms in ileal Romboutsia, Erysipelatoclostridium, Celllosilyticum, and Eubacterium abundances. \r\n\r\nLuo, W., Yin, Z., Zhang, M., Huang, X. and Yin, J., 2024. Dietary Lactobacillus delbrueckii Affects Ileal Bacterial Composition and Circadian Rhythms in Pigs. Animals, 14(3), p.412.",
    "fdastatus": "none",
    "linkslists": "https://www.mdpi.com/2076-2615/14/3/412",
    "pubchem": null,
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      64
    ],
    "classf": [
      11,
      4
    ],
    "mechanisms": [
      3,
      139,
      146
    ],
    "target": [
      91
    ],
    "effect": [
      5,
      47
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 266,
  "fields": {
    "gname": "Urolithin A",
    "smiles": "C1=CC2=C(C=C1O)C(=O)OC3=C2C=CC(=C3)O",
    "linkname": "urolithin-a",
    "molecula": "C13H8O4",
    "iupacname": "3,8-dihydroxybenzo[c]chromen-6-one",
    "updphoto": "media/imgsrv_-_2025-03-22T105945.373.png",
    "description": "Urolithin A (UA), a kind of intestinal microbial metabolite, was selected in this study. Results showed UA influenced on the expression rhythm of the clock genes BMAL1 and PER2 in intestinal epithelial cells. Furthermore, the study investigated the effects of UA on the expression rhythms of clock genes (BMAL1 and PER2) and tight junctions (OCLN, TJP1, and CLND1), all of which were dysregulated by inflammation. In addition, UA pre-treatment by oral administration to female C57BL/6 mice showed the improvement in the fecal IgA concentrations, tight junction expression (Clnd1 and Clnd4), and clock gene expression (Bmal1 and Per2) in a DSS-induced colitis model induced using DSS treatment. Finally, the Nrf2-SIRT1 signaling pathway was confirmed to be involved in UA’s effect on the circadian rhythm of intestinal epithelial cells by antagonist treatment. doi:10.3390/nu16142263",
    "fdastatus": "Not approved",
    "linkslists": "https://www.mdpi.com/2072-6643/16/14/2263",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5488186",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4589709.html",
    "drugbank": "https://go.drugbank.com/drugs/DB15464",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      63
    ],
    "classf": [
      4,
      12
    ],
    "mechanisms": [
      68,
      38,
      51,
      118,
      28
    ],
    "target": [
      91,
      84,
      30,
      63
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 267,
  "fields": {
    "gname": "Griseofulvin",
    "smiles": "C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC",
    "linkname": "griseofulvin",
    "molecula": "C17H17ClO6",
    "iupacname": "(2S,5'R)-7-chloro-3',4,6-trimethoxy-5'-methylspiro[1-benzofuran-2,4'-cyclohex-2-ene]-1',3-dione",
    "updphoto": "media/imgsrv_-_2025-03-22T110822.092.png",
    "description": "Griseofulvin, a compound historically used as an antifungal agent, has been shown to influence circadian rhythms in animal models, particularly in mice. Studies indicate that griseofulvin induces impairments in heme biosynthesis, leading to alterations in circadian rhythms. Specifically, mice fed a diet containing griseofulvin exhibited phase advances in diurnal rhythms and a shortening of the circadian period in core body temperature rhythms under constant darkness conditions13. These effects were transient, lasting between 1 to 3 weeks, and correlated with the extent of heme biosynthesis impairment. \r\n\r\nIwadate, R., Satoh, Y., Watanabe, Y., Kawai, H., Kudo, N., Kawashima, Y., Mashino, T. and Mitsumoto, A., 2012. Impairment of heme biosynthesis induces short circadian period in body temperature rhythms in mice. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 303(1), pp.R8-R18.",
    "fdastatus": "Approved",
    "linkslists": "https://pubmed.ncbi.nlm.nih.gov/22552790/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/441140",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.389934.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00400",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      62
    ],
    "classf": [
      9,
      5
    ],
    "mechanisms": [
      15,
      148,
      149
    ],
    "target": [
      29,
      94
    ],
    "effect": [
      46
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 268,
  "fields": {
    "gname": "HTL‑6641",
    "smiles": "COC1=C(N=CC(=C1OC)N2C(=O)N(C3=C(S2(=O)=O)C=CC=N3)CC4=C(C=C(C=C4F)F)F",
    "linkname": "htl6641",
    "molecula": "C₂₀H₁₅F₃N₄O₅S",
    "iupacname": "2-(5,6-dimethoxypyridin-3-yl)-1,1-dioxo-4-[[2,4,6-tris(fluoranyl)phenyl]methyl]pyrido[2,3-e][1,2,4]thiadiazin-3-one",
    "updphoto": "media/imgsrv_39_bPZSMen.png",
    "description": "HTL‑6641 is a pyrazolothiadiazinone‑based compound featuring a unique central thiadiazin-3-one 1,1‑dioxide core. It is decorated with a 5,6‑dimethoxypyridin‑3‑yl group and a (2,4,6‑trifluorophenyl)methyl substituent. HTL‑6641 acts as a dual orexin receptor antagonist (DORA) and has been instrumental in structural studies that reveal how diverse ligands interact with the orexin receptors. Its binding mode, which has been elucidated via co‑crystallization with OX2, highlights its role in targeting key lipophilic hotspots within the receptor binding pocket. As such, HTL‑6641 is an important chemical probe for dissecting the molecular mechanisms underlying orexin receptor function and may provide a foundation for developing novel therapeutics for sleep‑related disorders.\r\n\r\nChristopher, J.A., Aves, S.J., Brown, J., Errey, J.C., Klair, S.S., Langmead, C.J., Mace, O.J., Mould, R., Patel, J.C., Tehan, B.G. and Zhukov, A., 2015. Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties. MedChemComm, 6(5), pp.947-955.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01787",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/72707143#section=2D-Structure",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      61
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      58,
      150
    ],
    "target": [
      96
    ],
    "effect": [
      45
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 269,
  "fields": {
    "gname": "TU-892 (5-(3,4-dichlorophenyl)-1-phenyl-1,7-dihydro-4H-pyrazolo[3,4-d] pyrimidine-4,6(5H)-dione)",
    "smiles": "ClC=1C=C(C=CC1Cl)N1C(NC2=C(C1=O)C=NN2C2=CC=CC=C2)=O",
    "linkname": "tu-892",
    "molecula": "______",
    "iupacname": "5-(3,4-dichlorophenyl)-1-phenyl-1,7-dihydro-4H-pyrazolo[3,4-d] pyrimidine-4,6(5H)-dione",
    "updphoto": "media/download_5.png",
    "description": "TU-892 as a period-lengthening molecule. Gene expression analyses showed that TU-892 treatment upregulates CIRCADIAN CLOCK–ASSOCIATED 1 (CCA1) mRNA expression. TU-892 treatment reduced the amount of PRR7 protein, a transcriptional repressor of CCA1. Other PRR proteins including TIMING OF CAB EXPRESSION 1 were altered less by TU-892 treatment. TU-892-dependent CCA1 upregulation was attenuated in mutants impaired in PRR7. Collectively, TU-892 is a novel type of clock modulator that reduces the levels of PRR7 protein.\r\n Uehara, T.N., Takao, S., Matsuo, H., Saito, A.N., Ota, E., Ono, A., Itami, K., Kinoshita, T., Yamashino, T., Yamaguchi, J. and Nakamichi, N., 2023. A Small-Molecule Modulator Affecting the Clock-Associated PSEUDO-RESPONSE REGULATOR 7 Amount. Plant And Cell Physiology, 64(11), pp.1397-1406.",
    "fdastatus": "none",
    "linkslists": "https://academic.oup.com/pcp/article/64/11/1397/7273486",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/135444961",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      60
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      151
    ],
    "target": [
      95
    ],
    "effect": [
      44
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 270,
  "fields": {
    "gname": "SB203580 (152121-47-6; SB 203580; SB-203580; SB203580; Adezmapimod)",
    "smiles": "CS(=O)C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F",
    "linkname": "sb203580-152121-47-6-sb-203580-sb-203580-sb203580-adezmapimod",
    "molecula": "C21H16FN3OS",
    "iupacname": "4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine",
    "updphoto": "media/imgsrv_-_2025-03-22T113640.407.png",
    "description": "4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole has been reported in Annulohypoxylon truncatum, Eleutherococcus divaricatus, and other organisms with data available.  SB203580, a potent p38 MAPK inhibitor, has been shown to affect circadian rhythms. Specifically, in chick pineal cells, chronic application of SB203580 lengthened the period of the circadian rhythm3. Additionally, in cell-based studies using Rat-1 fibroblasts, SB203580 treatment also lengthened the period of the cellular circadian rhythm6. These findings suggest that p38 MAPK plays a role in regulating circadian oscillations, and its inhibition by SB203580 can alter these rhythms. Proc Natl Acad Sci U S A\r\n. 2009 Sep 15;106(37):15744-9. doi: 10.1073/pnas.0908733106. Epub 2009 Sep 2.",
    "fdastatus": null,
    "linkslists": "https://pubmed.ncbi.nlm.nih.gov/19805222/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/176155",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [],
    "classf": [
      9,
      5
    ],
    "mechanisms": [
      15,
      152
    ],
    "target": [
      97
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 271,
  "fields": {
    "gname": "ACT‑462206",
    "smiles": "CC1=CC(=CC(=C1)NC(=O)[C@@H]2CCCN2S(=O)(=O)C3=CC=C(C=C3)OC",
    "linkname": "act462206",
    "molecula": "C₂₀H₂₄N₂O₄S",
    "iupacname": "(2S)-N-(3,5-dimethylphenyl)-1-(4-methoxyphenyl)sulfonylpyrrolidine-2-carboxamide",
    "updphoto": "media/imgsrv_39_KhsZsKU.png",
    "description": "ACT‑462206 is a proline sulfonamide-based, brain‑penetrant dual orexin receptor antagonist. It effectively blocks both OX₁ and OX₂ receptors to modulate the sleep–wake cycle. In preclinical studies, ACT‑462206 has shown the ability to decrease wakefulness and enhance sleep quality while preserving natural sleep architecture.",
    "fdastatus": "Not approved.",
    "linkslists": "https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cmdc.201402258",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/40924317#section=2D-Structure",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      327
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      153
    ],
    "target": [
      96
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 272,
  "fields": {
    "gname": "GSK1059865",
    "smiles": "C[C@H]1CC[C@H](N(C1)C(=O)C2=C(C(=CC=C2)F)OC)CNC3=NC=C(C=C3)Br",
    "linkname": "gsk1059865",
    "molecula": "C₂₀H₂₃BrFN₃O₂",
    "iupacname": "[(2S,5S)-2-[[(5‑bromopyridin‑2‑yl)amino]methyl]-5‑methylpiperidin‑1‑yl]-(3‑fluoro‑2‑methoxyphenyl)methanone",
    "updphoto": "media/imgsrv_41_qlEGZRa.png",
    "description": "GSK1059865 is a pyrazolopyrimidine-based small molecule that selectively inhibits the orexin 1 receptor. It is widely used in neuropharmacological research to dissect the specific functions of OX₁ in regulating arousal, stress, and glutamate neurotransmission. Due to its high selectivity, GSK1059865 serves as an excellent chemical probe for exploring the distinct contributions of the OX₁ receptor relative to OX₂, thereby enhancing our understanding of orexin signaling in neuropsychiatric conditions.",
    "fdastatus": "Not approved",
    "linkslists": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4033200/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/44463491#section=2D-Structure",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      59
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      154
    ],
    "target": [
      96
    ],
    "effect": [
      43
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 273,
  "fields": {
    "gname": "SB-334867",
    "smiles": "CC1=NC2=C(O1)C=C(C=C2)NC(=O)NC3=C4C(=NC=C3)C=CC=N4",
    "linkname": "sb-334867",
    "molecula": "C₁₇H₁₃N₅O₂",
    "iupacname": "1-(2‑methyl‑1,3‑benzoxazol-6‑yl)-3-(1,5‑naphthyridin-4‑yl)urea",
    "updphoto": "media/imgsrv_42.png",
    "description": "SB‑334867 is a naphthyridine derivative that acts as a selective antagonist of the orexin 1 receptor. It is widely used in neuropharmacological studies to investigate the role of OX₁R in modulating arousal, stress responses, and seizure activity. Preclinical research has demonstrated that SB‑334867 elevates seizure thresholds, suggesting its potential utility in exploring therapeutic strategies for seizure disorders and other conditions associated with dysregulated orexin signaling.",
    "fdastatus": "Not approved",
    "linkslists": "https://www.sciencedirect.com/science/article/abs/pii/S0024320516301254",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/6604926#section=2D-Structure",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.5037182.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      58
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      155
    ],
    "target": [
      96
    ],
    "effect": [
      42
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 274,
  "fields": {
    "gname": "SB-408124",
    "smiles": "CC1=CC(=C2C=C(C=C(C2=N1)F)F)NC(=O)NC3=CC=C(C=C3)N(C)C",
    "linkname": "sb-408124",
    "molecula": "C₁₉H₁₈F₂N₄O",
    "iupacname": "1-(6,8-difluoro-2-methylquinolin-4-yl)-3-[4-(dimethylamino)phenyl]urea",
    "updphoto": "media/imgsrv_43_ZJmPSgj.png",
    "description": "SB‑408124 is an organohalogen quinoline derivative that selectively antagonizes the orexin 1 receptor. Although it exhibits high in vitro affinity for OX₁R—with a Ki in the low nanomolar range—its in vivo utility is compromised by poor brain penetration. SB‑408124 is used in preclinical research to dissect the role of OX₁R in sleep, arousal, and seizure susceptibility.\r\n\r\nMorairty, S.R., Revel, F.G., Malherbe, P., Moreau, J.L., Valladao, D., Wettstein, J.G., Kilduff, T.S. and Borroni, E., 2012. Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PloS one, 7(7), p.e39131.",
    "fdastatus": "Not approved",
    "linkslists": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3388080/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/4331799",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.3536200.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      58
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      155
    ],
    "target": [
      96
    ],
    "effect": [
      42
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 275,
  "fields": {
    "gname": "TAK‑925 (Danavorexton)",
    "smiles": "COC(=O)N1CCC[C@@H]([C@@H]1COC2CCC(CC2)C3=CC=CC=C3)NS(=O)(=O)C",
    "linkname": "tak925",
    "molecula": "C₂₁H₃₂N₂O₅S",
    "iupacname": "methyl (2R,3S)-3-(methanesulfonamido)-2-[(4-phenylcyclohexyl)oxymethyl]piperidine-1-carboxylate",
    "updphoto": "media/imgsrv_44_GCAkZ3a.png",
    "description": "TAK‑925, also known as Danavorexton, is a non‑peptidic small‑molecule agonist of the OX₂ receptor. It has a molecular formula of C₂₁H₃₂N₂O₅S with a molecular weight of 424.6 g/mol. TAK‑925 binds within the same deep orthosteric pocket used by antagonists but stabilizes the receptor's active conformation to initiate Gq protein coupling and calcium release.\r\n\r\nYin, J., Kang, Y., McGrath, A.P., Chapman, K., Sjodt, M., Kimura, E., Okabe, A., Koike, T., Miyanohana, Y., Shimizu, Y. and Rallabandi, R., 2022. Molecular mechanism of the wake-promoting agent TAK-925. Nature communications, 13(1), p.2902.",
    "fdastatus": "Not approved",
    "linkslists": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9133036/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/130310079#section=2D-Structure",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      57
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      156
    ],
    "target": [
      96
    ],
    "effect": [
      41
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 276,
  "fields": {
    "gname": "Triamcinolone (acetonide)",
    "smiles": "CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O",
    "linkname": "triamcinolone",
    "molecula": "C21H27FO6",
    "iupacname": "(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one",
    "updphoto": "media/imgsrv_-_2025-03-22T131000.025.png",
    "description": "Both triamcinolone and dexamethasone caused differential activation of genes involved in “Circadian Rhythm Signaling” pathway at both time points tested. Triamcinolone (TAA) uniquely induced significant changes in gene expression in “Calcium Signaling” (1 week) and “Glutamate Receptor Signaling” pathways (1 month). In contrast, dexamethasone (Dex) affected the “GABA Receptor Signaling” (1 week) and “Serotonin Receptor Signaling” (1 month) pathways. Understanding how intraocular steroids affect the gene expression of RPE/choroid is clinically relevant. Several genes and pathways that are potentially altering the circadian rhythms and several other neurotransmitter pathways in RPE/choroid during intravitreal steroid injections. \r\n\r\nSmit-McBride, et al., 2016. Comparison of in vivo gene expression profiling of RPE/choroid following intravitreal injection of dexamethasone and triamcinolone acetonide. Journal of Ophthalmology, 2016(1), p.9856736.",
    "fdastatus": "Approved",
    "linkslists": "https://onlinelibrary.wiley.com/doi/10.1155/2016/9856736",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/31307",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.29046.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00620",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      56
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      160,
      15,
      157,
      158,
      159
    ],
    "target": [
      98
    ],
    "effect": [
      40
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 277,
  "fields": {
    "gname": "Dexamethasone",
    "smiles": "C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C",
    "linkname": "dexamethasone",
    "molecula": "C22H29FO5",
    "iupacname": "(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one",
    "updphoto": "media/imgsrv_-_2025-03-22T131000_YDUEy0E.025.png",
    "description": "In summary, dexamethasone affects circadian rhythms by altering clock gene expression in peripheral tissues, desynchronizing peripheral oscillators from the central clock, and suppressing endogenous cortisol rhythms. These effects can lead to disruptions in sleep, metabolism, and other physiological processes tied to circadian timing, highlighting the importance of considering timing and dosage when administering glucocorticoid therapies.\r\n\r\nBarnea, M., Madar, Z. and Froy, O., 2013. Dexamethasone induces high-amplitude rhythms in preadipocytes, but hinders circadian expression in differentiated adipocytes. Chronobiology International, 30(6), pp.837-842.\r\n\r\nBalsalobre, A., Brown, S.A., Marcacci, L., Tronche, F., Kellendonk, C., Reichardt, H.M., Schutz, G. and Schibler, U., 2000. Resetting of circadian time in peripheral tissues by glucocorticoid signaling. Science, 289(5488), pp.2344-2347.\r\nhttps://pmc.ncbi.nlm.nih.gov/articles/PMC7533542/",
    "fdastatus": "Approved",
    "linkslists": "https://www.science.org/doi/10.1126/science.289.5488.2344",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5743",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.5541.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01234",
    "chebi": null,
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D00292",
    "selleckchem": null,
    "articles": [
      54,
      55
    ],
    "classf": [
      5,
      7
    ],
    "mechanisms": [
      160,
      161
    ],
    "target": [
      98
    ],
    "effect": [
      39
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 278,
  "fields": {
    "gname": "Prednisolone",
    "smiles": "CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O",
    "linkname": "prednisolone",
    "molecula": "C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O",
    "iupacname": "(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one",
    "updphoto": "media/imgsrv_-_2025-03-22T133818.987.png",
    "description": "Glucocorticoid Receptor (GR) ligands like prednisone bind GRs in peripheral tissues (e.g., hippocampus, liver), altering circadian gene expression. For example, methylprednisolone upregulates Period1 (Per1) via glucocorticoid response elements (GREs), disrupting rhythmic transcription in hippocampal neurons. While the SCN remains unaffected due to lack of GR expression1, peripheral oscillators (e.g., liver, immune cells) are sensitive to corticosteroid-induced phase shifts. Chronic prednisolone represses circadian clock genes like Bmal1 and Clock.\r\nHPA Axis Suppression: Prednisone timing critically affects adrenal function. Morning administration minimizes suppression, whereas nighttime doses disrupt cortisol rhythms more profoundly.\r\n\r\nJiang, Y., Gen, N., Wang, P., Feng, N. and Lu, X., 2022. Prednisolone induces sleep disorders via inhibition of melatonin secretion by the circadian rhythm in zebrafish. Biomedicine & Pharmacotherapy, 147, p.112590.",
    "fdastatus": "Approved",
    "linkslists": "https://www.sciencedirect.com/science/article/pii/S0753332221013779",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5755#section=2D-Structure",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.5552.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00860",
    "chebi": null,
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D00472",
    "selleckchem": null,
    "articles": [
      53
    ],
    "classf": [
      9,
      6
    ],
    "mechanisms": [
      160,
      25,
      161,
      45
    ],
    "target": [
      98
    ],
    "effect": [
      38
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 279,
  "fields": {
    "gname": "Aldosterone",
    "smiles": "CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4C(=O)CO)C=O)O",
    "linkname": "aldosterone",
    "molecula": "C21H28O5",
    "iupacname": "(8S,9S,10R,11S,13R,14S,17S)-11-hydroxy-17-(2-hydroxyacetyl)-10-methyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-13-carbaldehyde",
    "updphoto": "media/imgsrv_-_2025-03-22T134930.946.png",
    "description": "Aldosterone influences the expression of clock genes such as Per1, Per2, and Bmal1 in cardiomyoblasts. It induces rhythmic expression of these genes, suggesting a role in modulating circadian rhythms at the cellular level. Aldosterone secretion exhibits a circadian pattern, with peaks often synchronized with cortisol during late sleep and early morning hours. This pattern is influenced by both the renin-angiotensin system (RAS) and the adrenocorticotropic system. Sleep Influence: Sleep processes significantly affect aldosterone release, with higher levels during sleep due to the influence of the RAS. This contrasts with cortisol, which is more influenced by circadian rhythms. The timing of aldosterone secretion relative to the circadian cycle can affect its potency on renal sodium and potassium excretion.",
    "fdastatus": "Approved",
    "linkslists": "https://pubmed.ncbi.nlm.nih.gov/17653520/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5839",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.5633.html",
    "drugbank": "https://go.drugbank.com/drugs/DB04630",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      52
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      162,
      68,
      47,
      51,
      118
    ],
    "target": [
      25,
      26,
      30,
      63
    ],
    "effect": [
      37
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 280,
  "fields": {
    "gname": "Hydrocortisone (Cortisole)",
    "smiles": "C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O",
    "linkname": "hydrocortisone-cortisole",
    "molecula": "C21H30O5",
    "iupacname": "(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one",
    "updphoto": "media/imgsrv_-_2025-03-22T140716.429.png",
    "description": "Cortisol exhibits a distinct circadian rhythm, with levels typically peaking in the early morning and reaching their lowest point at the onset of sleep135. This rhythm is essential for synchronizing peripheral clocks throughout the body, ensuring that physiological activities align with the light-dark cycle. Cortisol acts as a secondary messenger between the central clock and peripheral clocks, helping to coordinate the timing of biological processes such as metabolism, immune function, and stress responses. Disruptions in cortisol's circadian rhythm, such as those caused by chronic stress or shift work, can impair this synchronization, leading to adverse health outcomes. \r\n\r\nKanki, M. and Young, M.J., 2021. Corticosteroids and circadian rhythms in the cardiovascular system. Current Opinion in Pharmacology, 57, pp.21-27.",
    "fdastatus": "Approved",
    "linkslists": "https://www.binasss.sa.cr/farmacia/18.pdf",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5754",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.5551.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00741",
    "chebi": null,
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D00088",
    "selleckchem": null,
    "articles": [
      51
    ],
    "classf": [
      5,
      7
    ],
    "mechanisms": [
      161,
      163
    ],
    "target": [
      98
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 281,
  "fields": {
    "gname": "IIK7",
    "smiles": "CCCC(=O)NCCC1=C2C3=CC=CC=C3CN2C4=C1C=C(C=C4)OC",
    "linkname": "IIK7",
    "molecula": "C22H24N2O2",
    "iupacname": "N-[2-(2-methoxy-6H-isoindolo[2,1-a]indol-11-yl)ethyl]butanamide",
    "updphoto": "media/imgsrv_-_2025-03-24T135822.228.png",
    "description": "IIK7, a selective melatonin type 2 (MT2) receptor agonist, affects circadian rhythms by mimicking the phase-shifting effect of melatonin (MLT). Melatonin administration can entrain human circadian rhythms2. Studies show that treatment with IIK7 influences sleep patterns and the bioluminescence rhythm in the cornea.  IIK7 can significantly decrease NREM (non-rapid eye movement) sleep onset latency and increase NREM sleep duration shortly after administration, mirroring the effects of melatonin. However, it does not change REM (rapid eye movement) onset latency or duration, which is consistent with the effects of melatonin. \r\n\r\nFisher, S.P. and Sugden, D., 2009. Sleep-promoting action of IIK7, a selective MT2 melatonin receptor agonist in the rat. Neuroscience letters, 457(2), pp.93-96.",
    "fdastatus": "none",
    "linkslists": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2724036/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/4172142",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.3383538.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      50
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      5,
      10
    ],
    "target": [
      12
    ],
    "effect": [
      35,
      36
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 282,
  "fields": {
    "gname": "UCSF7447",
    "smiles": "Clc1ccc(c(c1)Br)CNc1cccc(c1)c1nnc[nH]1",
    "linkname": "ucsf7447",
    "molecula": "N-[(2-bromo-4-chlorophenyl)methyl]-3-(1H-1,2,4-triazol-5-yl)aniline",
    "iupacname": "N-[(2-bromo-4-chlorophenyl)methyl]-3-(1H-1,2,4-triazol-5-yl)aniline",
    "updphoto": "media/10666.gif",
    "description": "UCSF7447 was found to act as selective inverse agonist of the melatonin receptor 1A (MT1 receptor). It represents a novel chemotype for MT ligands, and was designed using structure-based optimisation of a lead molecule that was identified in a docking screen of 150 million virtual molecules against a MT1 crystal structure. Corroborating in vivo data, both melatonin and UCSF7447 lengthened the periods of BMAL1 and PER2, and while melatonin delayed circadian phases, UCSF7447 advanced them.",
    "fdastatus": null,
    "linkslists": "https://www.mdpi.com/1422-0067/25/24/13508",
    "pubchem": null,
    "chemspider": "https://www.chemspider.com/Chemical-Structure.77454736.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      49
    ],
    "classf": [
      4
    ],
    "mechanisms": [
      9
    ],
    "target": [
      11
    ],
    "effect": [
      1,
      34
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 283,
  "fields": {
    "gname": "MORICIZINE",
    "smiles": "CCOC(=O)NC1=CC2=C(C=C1)SC3=CC=CC=C3N2C(=O)CCN4CCOCC4",
    "linkname": "moricizine",
    "molecula": "C22H25N3O4S",
    "iupacname": "ethyl N-[10-(3-morpholin-4-ylpropanoyl)phenothiazin-2-yl]carbamate",
    "updphoto": "media/imgsrv_39KW3Cx.png",
    "description": "Using wild-type C57BL/6J mice, moricizine treatment was found to promote sleep as well as in Per2:LucSV reporter fibroblast cells, alter circadian gene expression in the heart, and show a slight trend of increasing free-running periods. Together, these observations demonstrate novel clock-modulating activities of moricizine, particularly the period-lengthening effects on cellular oscillators, which may have clinical relevance against heart diseases. \r\n\r\nHan, C., Wirianto, M., Kim, E., Burish, M.J., Yoo, S.H. and Chen, Z., 2021. Clock-modulating activities of the anti-arrhythmic drug moricizine. Clocks & sleep, 3(3), pp.351-365.",
    "fdastatus": "Not approved",
    "linkslists": "https://www.mdpi.com/2624-5175/3/3/22",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/34633",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.31872.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00680",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      48
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      43,
      47
    ],
    "target": [
      25,
      26,
      84
    ],
    "effect": [
      33
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 284,
  "fields": {
    "gname": "Forskolin (Colforsin)",
    "smiles": "CC(=O)O[C@H]1[C@H]([C@@H]2[C@]([C@H](CCC2(C)C)O)([C@@]3([C@@]1(O[C@@](CC3=O)(C)C=C)C)O)C)O",
    "linkname": "forskolin-colforsin",
    "molecula": "C22H34O7",
    "iupacname": "[(3R,4aR,5S,6S,6aS,10S,10aR,10bS)-3-ethenyl-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-5,6,6a,8,9,10-hexahydro-2H-benzo[f]chromen-5-yl] acetate",
    "updphoto": "media/imgsrv_-_2025-03-26T163231.754.png",
    "description": "Incubation of rat-1 cells with forskolin successfully induced the rhythmic expression of Per1, Per2 and dbp. In the initial step of the circadian gene expression, a marked transient induction of Per1 was observed accompanied with CREB phosphorylation. Thus the present study strongly suggests that CREB activation through the cAMP/PKA pathway is involved in the generation of circadian rhythm in rat-1 cells. \r\n\r\n\r\nYagita, K. and Okamura, H., 2000. Forskolin induces circadian gene expression of rPer1, rPer2 and dbp in mammalian rat-1 fibroblasts. FEBS letters, 465(1), pp.79-82.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubmed.ncbi.nlm.nih.gov/10620710/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/47936",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.43607.html",
    "drugbank": "https://go.drugbank.com/drugs/DB02587",
    "chebi": null,
    "uniprot": null,
    "kegg": "https://www.genome.jp/dbget-bin/www_bget?cpd:C09076",
    "selleckchem": null,
    "articles": [
      47
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      47
    ],
    "target": [
      99,
      100,
      101,
      84,
      25,
      26
    ],
    "effect": [
      111
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 285,
  "fields": {
    "gname": "Sudachitin",
    "smiles": "COC1=C(C=CC(=C1)C2=CC(=O)C3=C(C(=C(C(=C3O2)OC)O)OC)O)O",
    "linkname": "sudachitin",
    "molecula": "C18H16O8",
    "iupacname": "5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-6,8-dimethoxychromen-4-one",
    "updphoto": "media/imgsrv_-_2025-03-27T152113.752.png",
    "description": "Using circadian reporter cells, study shows that Sudachitin modulates circadian amplitude and period of Bmal1 promoter-driven reporter rhythms, and real-time qPCR analysis shows that Sudachitin alters expression of core clock genes, notably Bmal1, at both transcript and protein levels. Mass-spec analysis reveals systemic exposure in vivo. In mice fed with high-fat diet with or without Sudachitin, it observes increased nighttime activity and daytime sleep, accompanied by significant metabolic improvements in a circadian time-dependent manner, including respiratory quotient, blood lipid and glucose profiles, and liver physiology. \r\n\r\n\r\nMawatari, K., Koike, N., Nohara, K., Wirianto, M., Uebanso, T., Shimohata, T., Shikishima, Y., Miura, H., Nii, Y., Burish, M.J. and Yagita, K., 2023. The polymethoxyflavone sudachitin modulates the circadian clock and improves liver physiology. Molecular Nutrition & Food Research, 67(9), p.2200270.",
    "fdastatus": "none",
    "linkslists": "https://onlinelibrary.wiley.com/doi/10.1002/mnfr.202200270",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/12443122",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.10276573.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      46
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      68,
      38,
      15,
      51,
      118,
      28
    ],
    "target": [
      29,
      63
    ],
    "effect": [
      5
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 286,
  "fields": {
    "gname": "Cyclocybelide",
    "smiles": "CC1(C)CC2=C(CO)C3=C(COC3=O)C(=C2C1)O",
    "linkname": "cyclocybelide",
    "molecula": "C14H16O4",
    "iupacname": "8-hydroxy-4-(hydroxymethyl)-6,6-dimethyl-5,7-dihydro-1H-cyclopenta[f][2]benzofuran-3-one",
    "updphoto": "media/Снимок_экрана_2025-03-28_152849.jpg",
    "description": "The extract from the culture filtrate of Cyclocybe cf. erebia showed activity that advanced the circadian rhythm in a bioassay with mouse fibroblasts expressing the LUCIFERASE protein under the control of the Period2 promoter. Bioassay-guided fractionation of the extract resulted in the isolation of the compound. Spectroscopic analyses identified the compound as a phthalide derivative, and the compound was named cyclocybelide. Treatment of mouse fibroblasts with the compound shifted the circadian rhythm forward, irrespective of the timing of treatment. In addition, some phthalide derivatives with hydroxy and methoxy groups showed similar effects on circadian rhythms.\r\n\r\nKobayashi, Y., Lu, Y., Li, N., Endo, N., Sotome, K., Ueno, K., Tahara, Y. and Ishihara, A., 2024. A new phthalide derivative from the mushroom Cyclocybe cf. erebia culture filtrate affects the phase of circadian rhythms in mouse fibroblasts. Bioscience, Biotechnology, and Biochemistry, p.zbae187.",
    "fdastatus": null,
    "linkslists": "https://academic.oup.com/bbb/article-abstract/89/3/354/7917622",
    "pubchem": null,
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      45
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      15,
      164
    ],
    "target": [
      25,
      84
    ],
    "effect": [
      32
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 287,
  "fields": {
    "gname": "A190",
    "smiles": "C1=CC(=C2C(=C1)C=CO2)OCCCO",
    "linkname": "a190",
    "molecula": "C11H11O3",
    "iupacname": "7-(3-methoxypropoxy)-1-benzofuran",
    "updphoto": "media/Снимок_экрана_2025-03-28_154336.jpg",
    "description": "A190 is Core Circadian Modulator (CCM) precursor, that targets the cavity in the PASB domain of BMAL1, causing it to expand, leading to conformational changes in the PASB domain and altering the functions of BMAL1 as a transcription factor. Biochemical, structural and cellular investigations validate the high level of selectivity of CCM in engaging BMAL1, enabling direct access to BMAL1–CLOCK cellular activities. CCM induces dose-dependent alterations in PER2–Luc oscillations and orchestrates the downregulation of inflammatory and phagocytic pathways in macrophages. These findings collectively reveal that the BMAL1 protein architecture is inherently configured to enable the binding of chemical ligands for functional modulation.\r\n\r\nPu, H., Bailey, L.C., Bauer, L.G., Voronkov, M., Baxter, M., Huber, K.V., Khorasanizadeh, S., Ray, D. and Rastinejad, F., 2025. Pharmacological targeting of BMAL1 modulates circadian and immune pathways. Nature Chemical Biology, pp.1-10.",
    "fdastatus": "none",
    "linkslists": "https://www.nature.com/articles/s41589-025-01863-x",
    "pubchem": null,
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      44
    ],
    "classf": [
      9,
      5,
      7
    ],
    "mechanisms": [
      122,
      123,
      28,
      118
    ],
    "target": [
      29,
      102
    ],
    "effect": [
      31
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 288,
  "fields": {
    "gname": "A340",
    "smiles": "CCC1=C2C=COC2=C(OCCCO)C=C1",
    "linkname": "a340",
    "molecula": "C13H15O3",
    "iupacname": "3-[(4-ethyl-1-benzofuran-7-yl)oxy]propan-1-ol",
    "updphoto": "media/Снимок_экрана_2025-03-28_154631.jpg",
    "description": "A340 is Core Circadian Modulator (CCM) precursor, that targets the cavity in the PASB domain of BMAL1, causing it to expand, leading to conformational changes in the PASB domain and altering the functions of BMAL1 as a transcription factor. Biochemical, structural and cellular investigations validate the high level of selectivity of CCM in engaging BMAL1, enabling direct access to BMAL1–CLOCK cellular activities. CCM induces dose-dependent alterations in PER2–Luc oscillations and orchestrates the downregulation of inflammatory and phagocytic pathways in macrophages. These findings collectively reveal that the BMAL1 protein architecture is inherently configured to enable the binding of chemical ligands for functional modulation.\r\n\r\nPu, H., Bailey, L.C., Bauer, L.G., Voronkov, M., Baxter, M., Huber, K.V., Khorasanizadeh, S., Ray, D. and Rastinejad, F., 2025. Pharmacological targeting of BMAL1 modulates circadian and immune pathways. Nature Chemical Biology, pp.1-10.",
    "fdastatus": "none",
    "linkslists": "https://www.nature.com/articles/s41589-025-01863-x",
    "pubchem": null,
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      43,
      44
    ],
    "classf": [
      9,
      5,
      7
    ],
    "mechanisms": [
      15,
      28
    ],
    "target": [
      29,
      102
    ],
    "effect": [
      31
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 289,
  "fields": {
    "gname": "Core Circadian Modulator (CCM)",
    "smiles": "CCC1=C2C=COC2=C(OCC(F)CO)C=C1",
    "linkname": "core-circadian-modulator-ccm",
    "molecula": "C13H14O3F",
    "iupacname": "3-[(4-ethyl-1-benzofuran-7-yl)oxy]-2-fluoropropan-1-ol",
    "updphoto": "media/Снимок_экрана_2025-03-28_160020.jpg",
    "description": "Core Circadian Modulator (CCM) targets the cavity in the PASB domain of BMAL1, causing it to expand, leading to conformational changes in the PASB domain and altering the functions of BMAL1 as a transcription factor. Biochemical, structural and cellular investigations validate the high level of selectivity of CCM in engaging BMAL1, enabling direct access to BMAL1–CLOCK cellular activities. CCM induces dose-dependent alterations in PER2–Luc oscillations and orchestrates the downregulation of inflammatory and phagocytic pathways in macrophages. These findings collectively reveal that the BMAL1 protein architecture is inherently configured to enable the binding of chemical ligands for functional modulation. \r\n\r\nPu, H., Bailey, L.C., Bauer, L.G., Voronkov, M., Baxter, M., Huber, K.V., Khorasanizadeh, S., Ray, D. and Rastinejad, F., 2025. Pharmacological targeting of BMAL1 modulates circadian and immune pathways. Nature Chemical Biology, pp.1-10.",
    "fdastatus": "none",
    "linkslists": "https://www.nature.com/articles/s41589-025-01863-x",
    "pubchem": null,
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      43
    ],
    "classf": [
      9,
      5,
      7
    ],
    "mechanisms": [
      28,
      122,
      123
    ],
    "target": [
      29,
      102
    ],
    "effect": [
      31
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 290,
  "fields": {
    "gname": "Psilocin",
    "smiles": "CN(C)CCC1=CNC2=C1C(=CC=C2)O",
    "linkname": "psilocin",
    "molecula": "C₁₂H₁₆N₂O",
    "iupacname": "3-[2-(dimethylamino)ethyl]-1H-indol-4-ol",
    "updphoto": "media/imgsrv_7_VtZ1j6g.png",
    "description": "Psilocin, the active metabolite of the psychedelic compound psilocybin, has garnered increasing interest for its profound effects on consciousness, perception, and cognition. Recent research suggests that psilocin may also influence circadian rhythms—the endogenous ~24-hour cycles that regulate sleep-wake patterns, hormone secretion, metabolism, and other physiological processes. This review explores the mechanisms by which psilocin interacts with circadian biology, focusing on its effects on serotonin (5-HT) receptors, the suprachiasmatic nucleus (SCN), and molecular clock genes.\r\n\r\nPsilocin primarily exerts its psychedelic effects through agonism at the serotonin 5-HT2A receptor, which is densely expressed in brain regions involved in mood, perception, and circadian regulation. The SCN, the master circadian pacemaker in mammals, receives serotonergic input from the raphe nuclei, suggesting a potential pathway for psilocin to modulate circadian timing. Preclinical studies indicate that acute psilocin administration can alter locomotor activity patterns and phase-shift circadian rhythms in rodents, possibly by resetting SCN neuronal activity. Additionally, psilocin may affect the expression of core clock genes (e.g., Bmal1, Clock, Per1/2, Cry1/2) in peripheral tissues, indicating a broader role in circadian synchronization.\r\n\r\nBeyond direct effects on the SCN, psilocin’s impact on mood and neuroplasticity may indirectly influence circadian disruptions seen in psychiatric conditions such as depression, where circadian misalignment is common. Clinical studies report that psilocybin (rapidly converted to psilocin) can induce lasting improvements in mood and sleep quality, possibly by restoring circadian rhythmicity. Furthermore, psilocin’s ability to enhance synaptic plasticity and reduce inflammation could support circadian resilience, given the bidirectional relationship between circadian dysfunction and neuroinflammation.\r\n\r\nDespite promising findings, many questions remain regarding dose-dependent effects, long-term circadian adaptations, and individual variability in psilocin’s chronobiological actions. Future research should integrate behavioral, electrophysiological, and omics approaches to elucidate how psilocin modulates circadian pathways and whether it holds therapeutic potential for circadian rhythm disorders, such as delayed sleep-wake phase disorder or shift work maladaptation. Understanding these mechanisms could pave the way for novel treatments combining psychedelics and chronotherapy.\r\n\r\nThomas, C.W., Blanco-Duque, C., Bréant, B.J., Goodwin, G.M., Sharp, T., Bannerman, D.M. and Vyazovskiy, V.V., 2022. Psilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice. Translational psychiatry, 12(1), p.77.",
    "fdastatus": "Not approved",
    "linkslists": "https://www.nature.com/articles/s41398-022-01846-9",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/4980",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4807.html",
    "drugbank": "https://go.drugbank.com/indications/DBCOND0146606",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8613",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/C08312",
    "selleckchem": null,
    "articles": [
      41,
      42
    ],
    "classf": [
      9,
      7
    ],
    "mechanisms": [
      59,
      170
    ],
    "target": [
      107
    ],
    "effect": [
      29,
      30
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 291,
  "fields": {
    "gname": "Scopolamine",
    "smiles": "CN1[C@@H]2CC(C[C@H]1[C@H]3[C@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4",
    "linkname": "scopolamine",
    "molecula": "C17 H21 N O4",
    "iupacname": "[(1R,2S,4S,5S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoat e",
    "updphoto": "media/imgsrv_-_2025-04-07T111647.835.png",
    "description": "Levels of melatonin, acetylcholine (ACh), serotonin (5-HT), and norepinephrine (NE) were measured in four groups of aged rats (control group; light pulse group; scopolamine group, light pulse and scopolamine group). Aged rats exposed to light pulse exhibited a phase shift in the circadian rhythm of neurotransmitters and melatonin. 5-HT levels in the tested brain areas were highly elevated while serum melatonin level was decreased. In most time intervals scopolamine caused a decrease in neurotransmitters and melatonin levels. Exposure to light pulse with scopolamine injection caused an elevation of ACh and 5-HT. In conclusion: light exposure during late-night upsurge serotonin secretion and reduce melatonin levels. A light pulse may exert a protective effect on the progression of AD through enhancement of the neuronal pathway as well as the circadian system via the serotonergic system\r\n\r\nAbdel-Rahman, M., Abdel-Kader, S., El-Masry, H. and El-Hennamy, R.E., 2020. Light exposure during late night attenuates the risk of scopolamine-induced Alzheimer disease in aged rats. Egyptian journal of basic and applied sciences, 7(1), pp.126-140.",
    "fdastatus": "Approved",
    "linkslists": "https://www.researchsquare.com/article/rs-2819458/v1",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/11968014",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.19969292.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00747",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:16794",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D00138",
    "selleckchem": "https://www.selleckchem.com/products/scopolamine.html",
    "articles": [
      40
    ],
    "classf": [
      7
    ],
    "mechanisms": [
      25,
      39
    ],
    "target": [
      37
    ],
    "effect": [
      28
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 292,
  "fields": {
    "gname": "IC261",
    "smiles": "O=C1NC2=C(C=CC=C2)/C1=C\\C3=C(OC)C=C(OC)C=C3OC",
    "linkname": "ic261",
    "molecula": "C18H17NO4",
    "iupacname": "(E)-3-(2,4,6-trimethoxybenzylidene)indolin-2-one",
    "updphoto": "media/hy-12774.gif",
    "description": "IC261 is a selective, ATP-competitive CK1 inhibitor, with IC50s of 1 μM, 1 μM, 16 μM for Ckiδ, Ckiε and Ckiα1, respectively.\r\n\r\nPrevious studies have shown that thyroid malignancies can alter the transcriptional oscillations of circadian clock genes.  The expression of core circadian clock genes in thyroid neoplasms was screened, authors found that CSNK1E, NPAS2, and TIMELESS were upregulated, while ARNTL, CRY1, CRY2, PER2, and RORA were downregulated during the progression and dedifferentiation of thyroid cancer. Immunohistochemical analysis further confirmed an increase in CSNK1E expression parallel to the loss of tumor differentiation. To investigate the potential therapeutic implications, we treated thyroid cancer cell lines with two different CSNK1E inhibitors: PF670462 and IC261. Both inhibitors resulted in growth inhibition in monolayer and three-dimensional spheroid cultures. This growth inhibition was accompanied by G2/M cell cycle arrest and a decrease in CDK4 and cyclin D1 expression. Moreover, CSNK1E inhibitors suppressed cell migration and invasion and reduced the expression of epithelial–mesenchymal transition markers. In vivo experiments using xenograft models showed that the administration of IC261 significantly restrained tumor growth and decreased the Ki-67 index of the xenograft tumors. In conclusion, our study provides evidence of aberrant CSNK1E expression in thyroid cancer dedifferentiation and highlights the potential therapeutic value of targeting CSNK1E.",
    "fdastatus": null,
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/5288600#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5288600",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4450729.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      39
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      171
    ],
    "target": [
      108
    ],
    "effect": [
      27
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 293,
  "fields": {
    "gname": "SHP656",
    "smiles": "C1=CC2=C(C=C1F)C3=C(C=CC(=C3)F)N2CC(CN4CCNC4=O)O",
    "linkname": "shp656",
    "molecula": "C18H17F2N3O2",
    "iupacname": "4,10-difluoro-15-methoxyimino-1,14,16-triazatetracyclo[12.4.0.02,7.08,13]octadeca-2(7),3,5,8(13),9,11-hexaen-18-ol",
    "updphoto": "media/clipboard_1744015908_0.png",
    "description": "Synthtic CRY2 ligand. SHP656 lengthens circadian period. Effects on circadian rhythms registered in Bmal1-dLuc and Per2-dLuc U2OS cells. SHP656 is an orally available KL001 derivative.\r\n\r\nMiller, S., Kesherwani, M., Chan, P., Nagai, Y., Yagi, M., Cope, J., Tama, F., Kay, S.A. and Hirota, T., 2022. CRY2 isoform selectivity of a circadian clock modulator with antiglioblastoma efficacy. Proceedings of the National Academy of Sciences, 119(40), p.e2203936119.",
    "fdastatus": null,
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/91938072#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/91938072",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      38
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      34
    ],
    "target": [
      83,
      109
    ],
    "effect": [
      26
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 294,
  "fields": {
    "gname": "SHP1703 ( (R)-1-(3-(3,6-difluoro-9H-carbazol-9-yl)-2-hydroxypropyl)imid-azolidin-2-one )",
    "smiles": "C1=CC2=C(C=C1F)C3=C(C=CC(=C3)F)N2C[C@H](CN4CCNC4=O)O",
    "linkname": "shp1703-r-1-3-36-difluoro-9h-carbazol-9-yl-2-hydroxypropylimid-azolidin-2-one",
    "molecula": "C18 H17 F2N3O2",
    "iupacname": "1-[(2R)-3-(3,6-difluorocarbazol-9-yl)-2-hydroxypropyl]imidazolidin-2-one",
    "updphoto": "media/Снимок_экрана_2025-04-07_120719.jpg",
    "description": "Treatment with SHP1703 effectively reduced GSC viability targeting CRY2. SHP1703, which contained pure R form, showed higher activity than the S form of SHP656 in Per2 repression and a decrease in GSC viability in culture. Due to the selectivity of SHP656 and SHP1703 for CRY2,  results indicate CRY2 as a potential therapeutic target for the treatment of clock-related diseases such as glioblastoma.\r\n\r\nMiller, S., Kesherwani, M., Chan, P., Nagai, Y., Yagi, M., Cope, J., Tama, F., Kay, S.A. and Hirota, T., 2022. CRY2 isoform selectivity of a circadian clock modulator with antiglioblastoma efficacy. Proceedings of the National Academy of Sciences, 119(40), p.e2203936119.",
    "fdastatus": "none",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/118415358#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/118415358",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      38
    ],
    "classf": [
      6
    ],
    "mechanisms": [
      34
    ],
    "target": [
      83,
      109
    ],
    "effect": [
      22,
      26
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 295,
  "fields": {
    "gname": "Modafinil",
    "smiles": "C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N",
    "linkname": "modafinil",
    "molecula": "C15H15NO2S",
    "iupacname": "2-benzhydrylsulfinylacetamide",
    "updphoto": "media/modafinil.png",
    "description": "Effects of modafinil (2-[(diphenylmethyl)sulfinyl]acetamide), an atypical alerting compound, on circadian rhythms in male Syrian hamsters were detected. Electroencephalogram recordings and video observations confirmed that modafinil dose dependently increases wakefulness at the expense of slow-wave and paradoxical sleep with no increase in locomotor activity per unit of time awake. Despite inducing arousal, modafinil at these doses (150 or 300 mg/kg), administered in the subjective day or early or late in the subjective night, did not perturb circadian phase. Modafinil (300 mg/kg) also had no effect on phase shifts to light exposure either early or late in the night and did not alter the size of phase shifts induced by running in a novel wheel for 3 h during the mid-day. Modafinil (300 mg/kg) did, however, decrease by ∼50% the amount of novel wheel-stimulated running, moving leftward the dose-response relation between wheel revolutions and shift magnitude. These results indicate that, in Syrian hamsters, modafinil alone has no significant chronobiotic efficacy. Nevertheless, this agent may increase the sensitivity of the circadian pacemaker to nonphotic stimuli and may thus have some potential as a tool for promoting clock resetting in combination with behavioral strategies.\r\n\r\nModafinil is known to have less or no adverse effects than those found in traditional psychostimulants such as amphetamine, methylphenidate or cocaine. It can be applied as an anti-psychotic or anti-fatigue agent. However, the waking mechanism of modafinil is yet to be fully revealed. Recent studies reported that modafinil may be subject to abuse and addiction. In addition prolonged sleeplessness induces stress responses and impairs immune function.\r\n\r\nKim, D., 2012. Practical use and risk of modafinil, a novel waking drug. Environmental health and toxicology, 27, p.e2012007.\r\n\r\nWebb, I.C., Pollock, M.S. and Mistlberger, R.E., 2006. Modafinil [2-[(diphenylmethyl) sulfinyl] acetamide] and circadian rhythms in syrian hamsters: assessment of the chronobiotic potential of a novel alerting compound. The Journal of pharmacology and experimental therapeutics, 317(2), pp.882-889.\r\n\r\nLaunay, J.C., Savourey, G., Guinet, A., Lallement, G., Besnard, Y. and Bittel, J., 2002. Circadian rhythm of rectal temperature during sleep deprivation with modafinil. Aviation, space, and environmental medicine, 73(10), pp.985-990.\r\n\r\nUyhelji, H.A., Munster, S.K., White, V.L. and Nicholson, S.J., 2023. Gene expression biomarkers of the response to sleep loss with and without modafinil (No. DOT/FAA/AM-23/25). United States. Department of Transportation. Federal Aviation Administration. Office of Aviation. Civil Aerospace Medical Institute.",
    "fdastatus": "Approved",
    "linkslists": "https://www.sciencedirect.com/science/article/abs/pii/S0022356524326825",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/4236",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4088.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00745",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31859",
    "uniprot": null,
    "kegg": "https://www.genome.jp/dbget-bin/www_bget?drug:D01832",
    "selleckchem": null,
    "articles": [
      35,
      36,
      37
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      172
    ],
    "target": [
      110
    ],
    "effect": [
      25
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 296,
  "fields": {
    "gname": "NCC007",
    "smiles": "CC(C1CC1)N2C=NC3=C(N=C(N=C32)NCCN(C)C)NCC4=CC(=CC=C4)C(F)(F)F",
    "linkname": "ncc007",
    "molecula": "C22H28F3N7",
    "iupacname": "9-(1-cyclopropylethyl)-2-N-[2-(dimethylamino)ethyl]-6-N-[[3-(trifluoromethyl)phenyl]methyl]purine-2,6-diamine",
    "updphoto": "media/imgsrv_-_2025-04-15T105954.730.png",
    "description": "NCC007 (a derivative of longdaysin) showed stronger period effects (0.32 μM for 5 h period lengthening) in a cell-based circadian assay. The following in vitro kinase assay showed that NCC007 inhibited CKIα and CKIδ with an IC50 of 1.8 and 3.6 μM. We further demonstrated that NCC007 lengthened the period of mouse behavioral rhythms in vivo. Thus, NCC007 is a valuable tool compound to control circadian rhythms through CKI inhibition.\r\n\r\nLee, J.W., Hirota, T., Ono, D., Honma, S., Honma, K.I., Park, K. and Kay, S.A., 2019. Chemical control of mammalian circadian behavior through dual inhibition of casein kinase Iα and δ. Journal of medicinal chemistry, 62(4), pp.1989-1998.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01541",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/138403252",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.75534035.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": "https://divbio.eu/pl/dostawcy/target-mol/244691-ncc007",
    "articles": [
      34
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      125,
      136
    ],
    "target": [
      89
    ],
    "effect": [
      24
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 297,
  "fields": {
    "gname": "Prexasertib",
    "smiles": "COC1=C(C(=CC=C1)OCCCN)C2=CC(=NN2)NC3=NC=C(N=C3)C#N",
    "linkname": "prexasertib",
    "molecula": "C18H19N7O2",
    "iupacname": "5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile",
    "updphoto": "media/imgsrv_-_2025-04-15T111643.609.png",
    "description": "Prexasertib (LY2606368, Chk1/2 inhibitor) has been studied in cancer therapy but may also affect PER2 dynamics via its phosphorilation. GSK3 inhibitor\r\n\r\nCollis SJ, Boulton SJ. Emerging links between the biological clock and the DNA damage response. Chromosoma (2007) 116:331–9. doi: 10.1007/s00412-007-0108-6",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/Prexasertib#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/46700756",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      33
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      140,
      173,
      174,
      202
    ],
    "target": [
      89
    ],
    "effect": []
  }
},
{
  "model": "main.chronobiotic",
  "pk": 298,
  "fields": {
    "gname": "17-DMAG",
    "smiles": "C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\\C=C(\\C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCCN(C)C)/C)OC)OC(=O)N)\\C)C)O)OC",
    "linkname": "17-dmag",
    "molecula": "C32H48N4O8",
    "iupacname": "[(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[2-(dimethylamino)ethylamino]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate",
    "updphoto": "media/imgsrv_-_2025-04-15T114156.960.png",
    "description": "Drugs like 17-DMAG, a potent HSP90 inhibitor, exhibit time-of-day-specific action on melanoma tumors. Their rhythmic cytotoxicity is mediated by specific isoforms of HSP90 that are cyclically expressed and linked to the cell cycle. Clock-deficient tumors show reduced sensitivity to these drugs, highlighting the importance of circadian regulation in their efficacy.  HSP90 affects the stability of BMAL1 and circadian gene expression.\r\n\r\nLee, Y., Fong, S.Y., Shon, J., Zhang, S.L., Brooks, R., Lahens, N.F., Chen, D., Dang, C.V., Field, J.M. and Sehgal, A., 2021. Time-of-day specificity of anticancer drugs may be mediated by circadian regulation of the cell cycle. Science advances, 7(7), p.eabd2645.\r\n\r\nSchneider, R., Linka, R.M. and Reinke, H., 2014. HSP90 affects the stability of BMAL1 and circadian gene expression. Journal of Biological Rhythms, 29(2), pp.87-96.",
    "fdastatus": "none",
    "linkslists": "https://www.science.org/doi/abs/10.1126/sciadv.abd2645",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5288674",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      31,
      32
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      175,
      176
    ],
    "target": [
      111
    ],
    "effect": [
      23
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 299,
  "fields": {
    "gname": "GO289",
    "smiles": "COC1=C(C=C(C(=C1)/C=N\\N2C(=NN=C2SC)C3=CC=CC=C3)Br)O",
    "linkname": "go289",
    "molecula": "C17H15BrN4O2S",
    "iupacname": "5-bromo-2-methoxy-4-[(Z)-(3-methylsulfanyl-5-phenyl-1,2,4-triazol-4-yl)iminomethyl]phenol",
    "updphoto": "media/imgsrv_-_2025-04-15T114828.402.png",
    "description": "GO289 disrupts the circadian clock specifically in cancer cells by targeting casein kinase 2 (CK2), an essential regulator of circadian rhythm. This drug slows cancer cell cycles while sparing healthy cells, demonstrating a promising approach for targeting the biological clock of tumors.\r\n\r\nGO289, which strongly lengthened circadian period, is known as a potent and selective inhibitor of CK2. Phosphoproteomics identified multiple phosphorylation sites inhibited by GO289 on clock proteins, including PER2 S693. Furthermore, GO289 exhibited cell type–dependent inhibition of cancer cell growth that correlated with cellular clock function. The x-ray crystal structure of the CK2α-GO289 complex revealed critical interactions between GO289 and CK2-specific residues and no direct interaction of GO289 with the hinge region that is highly conserved among kinases. The discovery of GO289 provides a direct link between the circadian clock and cancer regulation and reveals unique design principles underlying kinase selectivity.\r\n\r\nOshima, T., Niwa, Y., Kuwata, K., Srivastava, A., Hyoda, T., Tsuchiya, Y., Kumagai, M., Tsuyuguchi, M., Tamaru, T., Sugiyama, A. and Ono, N., 2019. Cell-based screen identifies a new potent and highly selective CK2 inhibitor for modulation of circadian rhythms and cancer cell growth. Science advances, 5(1), p.eaau9060.",
    "fdastatus": "not approved",
    "linkslists": "https://www.science.org/doi/full/10.1126/sciadv.aau9060",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/136819792",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": "https://www.selleckchem.com/products/e-z-go289.html",
    "articles": [
      30
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      177
    ],
    "target": [
      112
    ],
    "effect": [
      22
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 300,
  "fields": {
    "gname": "SR1078",
    "smiles": "C1 =CC(=CC=C1C(=O)NC2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O)C(F)(F)F",
    "linkname": "sr1078",
    "molecula": "C17H10F9NO2",
    "iupacname": "N- [4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide",
    "updphoto": "media/imgsrv_-_2025-04-15T131752.263.png",
    "description": "SR1078 is a synthetic small molecule known as an agonist of the nuclear receptor ROR (retinoic acid receptor-related orphan receptor). RORs are key regulators of the circadian clock, influencing the transcription of the core clock gene BMAL1. By activating RORs, SR1078 can modulate circadian rhythms at the molecular level.\r\nHowever, its effects appear to be context-dependent. For instance, while SR1078 promotes BMAL1 expression, it has been shown to suppress both anabolic and catabolic processes in chondrocytes, limiting its therapeutic potential in certain conditions like osteoarthritis (OA). In contrast, other modulators like Nobiletin and SR8278 have demonstrated more favorable outcomes in enhancing clock function and protecting cartilage from degeneration.\r\nThis highlights SR1078's role as a circadian clock modulator but also underscores the need for further research to better understand its specific applications and limitations.\r\n\r\nRahman S, Wittine K, Sedic M, Markova-Car EP (2020) Small molecules Targeting Biological clock; a novel prospective for anti-cancer drugs. Molecules. ;25(21); doi: ARTN 493710.3390/molecules25214937.",
    "fdastatus": "none",
    "linkslists": "https://www.mdpi.com/1420-3049/25/21/4937",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/17980288",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.16472645.html",
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": "https://www.selleckchem.com/products/sr1078.html",
    "articles": [
      29
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      51,
      178
    ],
    "target": [
      63
    ],
    "effect": [
      21
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 301,
  "fields": {
    "gname": "Vanillic Acid",
    "smiles": "COC1=C(C=CC(=C1)C(=O)O)O",
    "linkname": "vanillic-acid",
    "molecula": "C8H8O4",
    "iupacname": "4-hydroxy-3-methoxybenzoic acid",
    "updphoto": "media/imgsrvpoiuyt.png",
    "description": "Chrononutrient. May be obtained from Angelica sinensis root, acai oil. Increases amplitude; delays phase. Normalizes circulating lipid peroxidation and antioxidant status. \r\n\r\nHuang, J.Q., Lu, M. and Ho, C.T., 2021. Health benefits of dietary chronobiotics: beyond resynchronizing internal clocks. Food & Function, 12(14), pp.6136-6156.\r\n\r\nBhavani, P., Subramanian, P. and Shanmugapriya, S., 2016. Modulating effects of vanillic acid on circadian pattern of indices of redox homeostasis in N-Methly-N′-Nitro-N-Nitrosoguanidine induced endometrial carcinoma in rats. Biological Rhythm Research, 47(4), pp.609-619.\r\n\r\nKiessig, R.S., Herz, J.M. and Sweeney, B.M., 1979. Shifting the phase of the circadian rhythm in bioluminescence in Gonyaulax with vanillic acid. Plant Physiology, 63(2), pp.324-327.\r\n\r\nLashgari, N.A., Roudsari, N.M., Momtaz, S., Abdolghaffari, A.H., Atkin, S.L. and Sahebkar, A., 2023. Regulatory mechanisms of vanillic acid in cardiovascular diseases: a review. Current Medicinal Chemistry, 30(22), pp.2562-2576.",
    "fdastatus": "Not approved",
    "linkslists": "https://www.tandfonline.com/doi/full/10.1080/09291016.2016.1173362",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/8468",
    "chemspider": null,
    "drugbank": "https://go.drugbank.com/drugs/DB02130",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:30816",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/C06672",
    "selleckchem": null,
    "articles": [
      22,
      26,
      27,
      28
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      99,
      72,
      169,
      179,
      180,
      181,
      182,
      183,
      184,
      185
    ],
    "target": [
      105,
      114,
      113
    ],
    "effect": [
      10,
      20
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 302,
  "fields": {
    "gname": "Capsaicin",
    "smiles": "CC(C)/C=C/CCCCC(=O)NCC1=CC(=C(C=C1)O)OC",
    "linkname": "capsaicin",
    "molecula": "C18H27NO3",
    "iupacname": "(E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide",
    "updphoto": "media/imgsrv_-_2025-05-05T165122.210.png",
    "description": "Found in Chili pepper . Regulates circadian clock disruption.Improves redox imbalance and glucose metabolism. Circadian disorder mouse model induced by constant darkness (CD) was constructed to investigate the regulating effects of capsaicin (CAP) on disturbances of metabolism homeostasis and gut microbiota in the respect of circadian rhythm-related mechanisms. Results indicated that CAP reduced weight gain induced by circadian rhythm disorder in mice by inhibiting fat accumulation in liver and adipose tissue. The rhythmic expressions of circadian clock genes and lipid-metabolism related genes in liver were also recovered by CAP. Microbial study using 16S rRNA sequencing revealed that CAP modulated the gut microbiota richness, diversity and composition, and restored diurnal oscillations of gut microbes at the phylum and family level. These results indicated that CAP could alleviate CD-induced hepatic clock gene disruption and gut microbiota dysbiosis in mice, providing theoretical basis for CAP to be used as a muti-functional ingredient with great health-promoting effects.\r\n\r\nLin, B., Ho, C.T., Wang, Y., Xiao, J. and Lu, M., 2024. Capsaicin alleviates the hepatic clock gene disruption and gut microbiota dysbiosis in circadian rhythm disorder mouse model. Food Science and Human Wellness, 13(5), pp.2947-2958.\r\n\r\nFDA APPROVED QUTENZA.\t022395.\tAVERITAS PHARMA INC.\tNov 16, 2009\r\n\r\nCapsaicin Changes the Pattern of Brain Rhythms in Sleeping Rats. Liu, L. and Tian, Y., 2023. Capsaicin changes the pattern of brain rhythms in sleeping rats. Molecules, 28(12), p.4736.",
    "fdastatus": "Approved",
    "linkslists": "https://www.sciencedirect.com/science/article/pii/S2213453024002246",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/1548943",
    "chemspider": null,
    "drugbank": "https://go.drugbank.com/drugs/DB06774",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3374",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/C06866",
    "selleckchem": null,
    "articles": [
      25
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      186
    ],
    "target": [
      115
    ],
    "effect": [
      5
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 303,
  "fields": {
    "gname": "Caffeine",
    "smiles": "CN1C=NC2=C1C(=O)N(C(=O)N2C)C",
    "linkname": "caffeine",
    "molecula": "C8H10N4O2",
    "iupacname": "1,3,7-trimethylpurine-2,6-dione",
    "updphoto": "media/imgsrv_-_2025-05-05T170001.539.png",
    "description": "Coffee, yerba mate leaves, guarana\tExtends period; increases amplitude; resets peripheral clocks; delays melatonin rhythm.\tPromotes wakefulness; reduces and fragments sleep; aids in weight loss; increases photosensitivity; regulates appetite; affects body temperature.\r\nCaffeine’s wakefulness-promoting and sleep-disrupting effects are well established, yet whether caffeine affects human circadian timing is unknown. Here we show that evening caffeine consumption delays the human circadian melatonin rhythm in vivo, and chronic application of caffeine lengthens the circadian period of molecular oscillations in vitro primarily via an adenosine receptor/cyclic AMP-dependent mechanism. In a double-blind, placebo controlled, ~49-day long within-subject study, we found the equivalent amount of caffeine as that in a double espresso 3 hours before habitual bedtime induced a phase delay of the circadian melatonin rhythm in humans by ~40 minutes. This magnitude of delay was nearly half of the magnitude of the phase-delaying response induced by exposure to 3-hours of evening bright-light (~3000 lux; ~7 Watts/m2) that began at habitual bedtime. Furthermore, using human osteosarcoma U2OS cells expressing clock gene luciferase reporters, we found a dose-dependent lengthening of circadian period by caffeine. By pharmacological dissection and siRNA knockdown we established that perturbation of adenosine receptor signaling, but not ryanodine receptor or phosphodiesterase activity, is sufficient to account for caffeine’s effects on cellular timekeeping. We also used a cyclic AMP biosensor to show that caffeine increased cyclic AMP levels, indicating that caffeine can influence a core component of the cellular circadian clock. Taken together, our findings demonstrate that caffeine influences human circadian timing and gives new insight into how the world’s most widely consumed psychoactive drug impacts upon human physiology\r\n\r\nBurke, T.M., Markwald, R.R., McHill, A.W., Chinoy, E.D., Snider, J.A., Bessman, S.C., Jung, C.M., O’Neill, J.S. and Wright Jr, K.P., 2015. Effects of caffeine on the human circadian clock in vivo and in vitro. Science translational medicine, 7(305), pp.305ra146-305ra146.",
    "fdastatus": "Approved as food (400 mg per day)",
    "linkslists": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4657156",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/2519",
    "chemspider": null,
    "drugbank": "https://go.drugbank.com/drugs/DB00201",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:27732",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/C07481",
    "selleckchem": null,
    "articles": [
      24
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      62,
      179,
      187
    ],
    "target": [
      60
    ],
    "effect": [
      201
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 304,
  "fields": {
    "gname": "Myricetin",
    "smiles": "C1=C(C=C(C(=C1O)O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O",
    "linkname": "myricetin",
    "molecula": "C15H10O8",
    "iupacname": "3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one",
    "updphoto": "media/imgsrv_-_2025-05-05T170415.422.png",
    "description": "Night alertness drug. The flavonoid myricetin reduces nocturnal melatonin levels in the blood through the inhibition of serotonin N-acetyltransferase. Myricae Cortex (Myrica rubra), Perillae Herba (Perilla sikokiana), and Eriobotryae Folium (Eriobotrya japonica) showed potent inhibition of AANAT activity. Myricetin (5,7,3',4',5'-pentahydroxyflavonol), a main component of the Myricae Cortex, strongly inhibited the activity of AANAT and probably block the access to the substrate by docking to the catalytic residues that are important for AANAT activity. Myricetin significantly decreased the nocturnal serum melatonin levels in rats. In addition, the locomotor activity of rats treated with myricetin decreased during the nighttime and slightly increased throughout the day. These results suggest that myricetin could be used as a therapy to increase nighttime alertness by changing the circadian rhythm of serum melatonin and locomotor activity.\r\n\r\nShin, J.C., Jung, H.Y., Harikishore, A., Kwon, O.D., Yoon, H.S., Kim, K.T. and Choi, B.H., 2013. The flavonoid myricetin reduces nocturnal melatonin levels in the blood through the inhibition of serotonin N-acetyltransferase. Biochemical and biophysical research communications, 440(2), pp.312-316.",
    "fdastatus": "none",
    "linkslists": "https://pubmed.ncbi.nlm.nih.gov/24076393/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5281672",
    "chemspider": null,
    "drugbank": "https://go.drugbank.com/drugs/DB02375",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:18152",
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      23
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      188
    ],
    "target": [
      116
    ],
    "effect": [
      17,
      18
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 305,
  "fields": {
    "gname": "Physcione",
    "smiles": "CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)OC",
    "linkname": "physcione",
    "molecula": "C16H12O5",
    "iupacname": "1,8-dihydroxy-3-methoxy-6-methylanthracene-9,10-dione",
    "updphoto": "media/imgsrv_-_2025-05-06T110030.647.png",
    "description": "Obtained from Rheum palmatum root (traditional Chinese medicine), lettuce, beans.\tExhibits secondary bioactivity in free circadian rhythms\tDemonstrates hepatoprotective, anti-inflammatory, antimicrobial, and antiproliferative effects; protects the liver; reduces lipogenesis. Physcion affects circadian rhythms by modulating core circadian clock genes, particularly BMAL1. Research shows that physcion can upregulate core circadian genes and reverse circadian misalignment caused by ethanol in liver cells. It binds to the active pocket of BMAL1 and promotes its expression, which contributes to its protective effects against alcohol-induced liver injury. Suppression of BMAL1 abolishes physcion's protective effects, indicating that physcion's action is closely tied to the circadian clock mechanism. This modulation of the circadian clock by physcion also leads to reduced lipogenesis and inflammation in alcoholic liver disease models, suggesting that targeting circadian machinery like BMAL1 may be a beneficial therapeutic strategy.\r\nYao, Y., Zuo, A., Deng, Q., Liu, S., Zhan, T., Wang, M., Xu, H., Ma, J. and Zhao, Y., 2020. Physcion protects against ethanol-induced liver injury by reprogramming of circadian clock. Frontiers in Pharmacology, 11, p.573074.\r\nHuang, J.Q., Lu, M. and Ho, C.T., 2021. Health benefits of dietary chronobiotics: beyond resynchronizing internal clocks. Food & Function, 12(14), pp.6136-6156.",
    "fdastatus": "Not approved",
    "linkslists": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7768821/",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/Physcione",
    "chemspider": null,
    "drugbank": null,
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:38167",
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      21,
      22
    ],
    "classf": [
      4,
      5
    ],
    "mechanisms": [
      28,
      51,
      122
    ],
    "target": [
      29
    ],
    "effect": [
      5,
      16
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 306,
  "fields": {
    "gname": "Piceatannol",
    "smiles": "C1=CC(=C(C=C1/C=C/C2=CC(=CC(=C2)O)O)O)O",
    "linkname": "piceatannol",
    "molecula": "C14H12O4",
    "iupacname": "4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,2-diol",
    "updphoto": "media/imgsrv_-_2025-05-06T112308.373.png",
    "description": "Piceatannol could advance and delay the phase of PER2::LUC oscillation in vitro.\r\nPiceatannol advanced PER2::LUC luminescence rhythm in peripheral organs in vivo.\r\nPiceatannol recovered phase change of PER2::LUC disturbed by high-fat diet intake.\r\nPiceatannol affects Per2 expression and may prevent circadian disturbance.\r\n\r\nPassion fruit seeds extract (PFSE) contains a high concentration of piceatannol that exhibits many physiological activities; however, whether PFSE and piceatannol affect clock genes is not known with certainty. In this study, we evaluated the effects of PFSE and piceatannol on the rhythm of PER2 using bioluminescence in mPer2Luc knock-in mice and their embryonic fibroblasts. Piceatannol was demonstrated to advance and delay the phase of PER2::LUC oscillation owing to differences in timing of treatment in vitro. In the in vivo imaging system, oral administration of piceatannol significantly advanced the luminescence rhythm of PER2::LUC in peripheral organs. Furthermore, piceatannol recovered the phase change of PER2::LUC disturbed by high-fat diet intake. These findings indicate that piceatannol affects peripheral clock gene expression and may prevent circadian disturbance.",
    "fdastatus": "Not approved",
    "linkslists": "https://linkinghub.elsevier.com/retrieve/pii/S1756464619301045",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/667639",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      20
    ],
    "classf": [
      4,
      5
    ],
    "mechanisms": [
      47
    ],
    "target": [
      84,
      99
    ],
    "effect": [
      13,
      14,
      15
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 307,
  "fields": {
    "gname": "Puerarin",
    "smiles": "C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O",
    "linkname": "puerarin",
    "molecula": "C21H20O9",
    "iupacname": "7-hydroxy-3-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one",
    "updphoto": "media/imgsrv_-_2025-05-06T112845.972.png",
    "description": "Pathological detection demonstrated that sleep disturbances resulted in observable damage to the liver, lung, and kidney. Puerarin reversed multi-organ damage and inflammation. Further, puerarin activated paneth cells, resulting in increased lysozyme and TGF-β production, and stimulating intestinal stem cell proliferation. Puerarin also effectively inhibited the expression of F4/80, iNOS, TNF-α, and IL-1β in the small intestine, while it increased Chil3, CD206, and Arg-1 levels. Moreover, puerarin treatment significantly decreased P-P65, TLR4, Bcl-xl, and cleaved caspase-3 protein levels while increasing barrier protein levels, including ZO-1, Occludin, Claudin 1 and E-cadherin suggesting a reduction in inflammation and apoptosis in the gut. Overall, puerarin diminished systemic inflammation, particularly intestinal inflammation, and enhanced intestinal barrier integrity in mice with sleep disorders. Our findings suggest a potential new therapeutic pathway for sleep disorders. The pharmacological effect of PR on hyperhomocysteinemia in mice was evaluated by measuring total homocysteine, triglyceride levels and lipid accumulation. PR dosed at ZT10 generated a stronger effect on hyperhomocysteinemia than drug dosed at ZT2. Furthermore, PR increased the expression levels of REV-ERBα target genes Bhmt, Cbs and Cth (encoding three key enzymes responsible for homocysteine catabolism), thereby alleviating hyperhomocysteinemia in mice. Moreover, CR attenuated chronic colitis in mice in a dosing time-dependent manner based on measurements of disease activity index, colon length, malondialdehyde/myeloperoxidase activities and IL-1β/IL-6 levels. ZT10 dosing generated a stronger anti-colitis effect as compared to ZT2 dosing. This was accompanied by lower production of colonic inflammatory cytokines (i.e., Nlrp3, IL-1β, IL-6, Tnf-α and Ccl2, REV-ERBα target genes) in colitis mice dosed at ZT10. The diurnal patterns of PR and CR effects were respectively consistent with those of puerarin (a main active constituent of PR, a REV-ERBα antagonist) and berberine (a main active constituent of CR, a REV-ERBα agonist). In addition, loss of Rev-erbα in mice abolished the dosing time-dependency in PR and CR effects. In conclusion, the therapeutic effects of PR and CR depend on dosing time in mice, which are probably attributed to diurnal expression of REV-ERBα as the drug target. Our findings have implications for improving therapeutic outcomes of herbal medicines with a chronotherapeutic approach.\r\n\r\nChen, M., Zhou, C., Xu, H., Zhang, T. and Wu, B., 2020. Chronopharmacological targeting of Rev-erbα by puerarin alleviates hyperhomocysteinemia in mice. Biomedicine & pharmacotherapy, 125, p.109936.\r\n\r\nLiu, J., Xu, H., Zhang, L., Wang, S., Lu, D., Chen, M. and Wu, B., 2021. Chronoeffects of the herbal medicines Puerariae radix and Coptidis rhizoma in mice: A potential role of REV-ERBα. Frontiers in Pharmacology, 12, p.707844.",
    "fdastatus": "none",
    "linkslists": "https://www.sciencedirect.com/science/article/pii/S0753332220301268",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5281807",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4445119.html",
    "drugbank": "https://go.drugbank.com/drugs/DB12290",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8633",
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      18,
      19
    ],
    "classf": [
      4,
      5
    ],
    "mechanisms": [
      127
    ],
    "target": [
      47
    ],
    "effect": [
      5,
      12
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 308,
  "fields": {
    "gname": "Hesperidin",
    "smiles": "C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O",
    "linkname": "hesperidin",
    "molecula": "C28H34O15",
    "iupacname": "(2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one",
    "updphoto": "media/imgsrv_-_2025-05-06T113503.647.png",
    "description": "Hesperidin (Increases amplitude of circadian rhtyhms; reverses phase delay) acts by different mechanisms including reducing oxidative stress and lowering the apoptotic protein like caspase, Bax, TNF-α, and NF-MB as well as the inflammatory markers such as IL-6, and LOX-2 in preclinical studies. Clinical studies showed that its consumption can remarkably prevent these lifestyle disorders. Although it has poor bioavailability when administered orally, various novel drug delivery approaches are used nowadays to resolve shortcomings associated with hesperidin. Hesperidin acts as a potential bioactive molecule for the prevention and treatment of lifestyle problems due to its wide therapeutic applications. \r\nTreatment of hesperidin results in normalization of the altered rhythms of these indices plausibly by its cytoprotective and antioxidant effects. Impairment of 24 h rhythms in oxidative stress markers and antioxidants were observed during rotenone treatment and the impairment is severe in circadian clock mutant cry[b] flies. A reversibility of rhythms was prominent consequent to hesperidin treatment in wild-type flies than cry[b] flies. These findings revealed a role of circadian clock in redox homeostasis and the use of Drosophila model in screening putative antioxidative phytomedicines earlier to their use in mammalian systems.\r\n\r\n\r\nManjula, A., Subashini, R., Punitha, R. and Subramanian, P., 2017. Modulating effects of hesperidin on circadian pattern indices of rotenone induced redox homeostasis in clock mutant (cry b) of Drosophila melanogaster. Biological Rhythm Research, 48(6), pp.897-906.\r\n\r\nTayal, R., Munjal, K., Gauttam, V.K., Popli, P., Khurana, L. and Choudhary, N., 2023. Potential role of hesperidin in lifestyle disorders: A scoping review. South African Journal of Botany, 161, pp.542-554.\r\nJayapalan, J.J., Subramanian, P., Kani, A., Hiji, J., Najjar, S.G., Abdul‐Rahman, P.S. and Hashim, O.H., 2020. Hesperidin modulates the rhythmic proteomic profiling in Drosophila melanogaster under oxidative stress. Archives of Insect Biochemistry and Physiology, 105(3), p.e21738.",
    "fdastatus": "none",
    "linkslists": "https://onlinelibrary.wiley.com/doi/full/10.1002/arch.21738",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/10621",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      15,
      16,
      17
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      3,
      189,
      190,
      47
    ],
    "target": [
      84
    ],
    "effect": [
      10,
      11
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 309,
  "fields": {
    "gname": "Theanine",
    "smiles": "CCNC(=O)CC[C@@H](C(=O)O)N",
    "linkname": "theanine",
    "molecula": "C7H14N2O3",
    "iupacname": "(2S)-2-amino-5-(ethylamino)-5-oxopentanoic acid",
    "updphoto": "media/imgsrv_-_2025-05-06T145357.904.png",
    "description": "Non-proteinogenic amino acid. l-Theanine apparently reduced the viability of melanoma cells. Further experiments showed that l-theanine attenuated the proliferation and migration, and promoted apoptosis of melanoma cells. l-Theanine significantly enhanced the expression of BMAL1, a clock gene in melanoma cells. Down-regulation of BMAL1 suppressed the anti-cancer effects of l-theanine on melanoma cells. Further experiments indicated that the p53 transcriptional activity raised by l-theanine was dependent on BMAL1 expression in melanoma cells.\r\n\r\n\r\nWang, R., Xiao, M., Zhang, Y., Ho, C.T., Wan, X., Li, D. and Xie, Z., 2019. RNA-sequencing analysis reveals l-theanine regulating transcriptional rhythm alteration in vascular smooth muscle cells induced by dexamethasone. Journal of agricultural and food chemistry, 67(19), pp.5413-5422.\r\n\r\nZhang, R., Zheng, S., Guo, Z., Wang, Y., Yang, G., Yin, Z. and Luo, L., 2022. L-Theanine inhibits melanoma cell growth and migration via regulating expression of the clock gene BMAL1. European journal of nutrition, pp.1-15.",
    "fdastatus": "none",
    "linkslists": "https://link.springer.com/article/10.1007/s00394-021-02677-y",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/439378",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.388498.html",
    "drugbank": "https://go.drugbank.com/drugs/DB12444",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:17394",
    "uniprot": null,
    "kegg": "https://www.genome.jp/dbget-bin/www_bget?cpd:C01047",
    "selleckchem": null,
    "articles": [
      10
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      38,
      51,
      68
    ],
    "target": [
      63
    ],
    "effect": [
      9
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 310,
  "fields": {
    "gname": "Theophylline",
    "smiles": "CN1C2=C(C(=O)N(C1=O)C)NC=N2",
    "linkname": "theophylline",
    "molecula": "C7H8N4O2",
    "iupacname": "1,3-dimethyl-7H-purine-2,6-dione",
    "updphoto": "media/imgsrv_-_2025-05-06T150551.063.png",
    "description": "Direct Effects on the Circadian Clock: Theophylline, a methylxanthine compound similar to caffeine, has been shown to lengthen the circadian period in a concentration-dependent manner in model organisms such as the fungus Neurospora crassa. This effect is observed at the level of core-clock gene expression, indicating that theophylline can directly modulate the molecular mechanisms underlying circadian rhythms.\r\nNotably, the period-lengthening effect of theophylline and other methylxanthines appears to occur independently of the classical phosphodiesterase (PDE)-cAMP-PKA signaling pathway, which is a canonical target of these drugs. This suggests that theophylline influences the circadian clock through alternative, yet-to-be-fully-elucidated mechanisms6.\r\nDisruption of Diurnal Rhythms in Physiology.\r\nTheophylline has also been reported to disrupt diurnal rhythms of humoral factors (such as hormones or metabolites) and can lead to a loss of normal meal-related cyclicity, indicating broader effects on physiological circadian outputs beyond the core molecular clock.\r\nPharmacokinetics and Circadian Variation.\r\nThe pharmacokinetics of theophylline itself show circadian variation, with lower serum concentrations and area under the curve (AUC) during the night in healthy young adults. This is attributed to delayed absorption at night rather than changes in elimination kinetics.\r\nThe timing of theophylline administration can influence its serum levels and apparent circadian variation, which may be related to the sleep-wake cycle and gastrointestinal motility rather than direct effects on the core circadian clock.\r\nPhase Shifting Effects.\r\nAdministration of theophylline at specific times relative to the circadian cycle can shift the phase of circadian rhythms. When given immediately before or during the early active phase, theophylline can cause a phase delay (set back the clock), while administration later in the cycle may have different effects.\r\n\r\nTheophylline and related methylxanthines are potent modulators of the circadian clock, acting through mechanisms distinct from their well-known effects on cAMP signaling. Their ability to lengthen the circadian period is robust and conserved, but the detailed molecular pathways involved remain to be elucidated.\r\nTheophylline shows anti-inflammatory effects, mitochondrial support, and modulation of key pathways (e.g., PI3K/Akt, NF-κB). It demonstrates potential in COVID-19-related ARDS, promoting muscle regeneration, and treating infertility. However, its narrow therapeutic index and variability in pharmacokinetics remain significant challenges.\r\n\r\n\r\nEhret, C.F., Potter, V.R. and Dobra, K.W., 1975. Chronotypic action of theophylline and of pentobarbital as circadian zeitgebers in the rat. Science, 188(4194), pp.1212-1215.\r\n\r\nSakata, T., Fukushima, M., Tsutsui, K., Arase, K. and Fujimoto, K., 1982. Theophylline disrupts diurnal rhythms of humoral factors with loss of meal cyclicity. Physiology & Behavior, 28(4), pp.641-647.\r\n\r\nSzarłowicz, J., Mazur, M., Waz, D., Goliszek, Z., Sobek, K.Ł., Tabin-Barczak, W., Sokołowska, A., Fikas, K., Chwaliszewski, K. and Samuła, S., 2025. Theophylline Revisited. Mechanisms, Challenges, and New Horizons. Quality in Sport, 37, pp.57009-57009.\r\n\r\nOlivares-Yañez, C., Alessandri, M.P., Salas, L. and Larrondo, L.F., 2023. Methylxanthines modulate circadian period length independently of the action of phosphodiesterase. Microbiology Spectrum, 11(4), pp.e03727-22.",
    "fdastatus": "Approved",
    "linkslists": "https://apcz.umk.pl/QS/article/view/57009",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/2153#section=2D-Structure",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.2068.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00277",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28177",
    "uniprot": null,
    "kegg": "https://www.genome.jp/dbget-bin/www_bget?drug:D00371",
    "selleckchem": null,
    "articles": [
      11,
      12,
      13
    ],
    "classf": [
      9,
      7
    ],
    "mechanisms": [
      180,
      191,
      192
    ],
    "target": [
      117,
      118
    ],
    "effect": [
      8
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 311,
  "fields": {
    "gname": "Fisetin",
    "smiles": "C1=CC(=C(C=C1C2=C(C(=O)C3=C(O2)C=C(C=C3)O)O)O)O",
    "linkname": "fisetin",
    "molecula": "C15H10O6",
    "iupacname": "2-(3,4-dihydroxyphenyl)-3,7-dihydroxychromen-4-one",
    "updphoto": "media/imgsrv_-_2025-05-06T151904.778.png",
    "description": "FISETIN alleviates Lipid Droplet accumulation by inhibiting CIDEC-mediated fusion, resulting in smaller LDs that facilitated lipophagy. Additionally, studies indicated that the dysfunction of circadian rhythms is closely related to lipid metabolism. HFD and FFA disrupted circadian rhythm in C57BL/6 mouse hepatocytes and AML12 cells, while FIS modified the rhythm disturbances and increased protein expression of the core clocks BMAL1 and CLOCK. Authors silenced the BMAL1 protein and revealed that si-BMAL1 upregulated CIDEC proteins. These data suggested that FIS might inhibit CIDEC-mediated LD fusion and enhance hepatocyte lipophagy by promoting the expression of rhythm protein BMAL1, thereby alleviating LD accumulation in C57BL/6 and AML12 cells caused by the HFD and FFA. The present study provided novel insights and potential targets for utilizing functional food factors to mitigate the accumulation of LD in hepatocytes.\r\n\r\n\r\nZhang, R., Liu, M., Lu, J., Lu, S., Wang, Y. and Guan, S., 2024. Fisetin Ameliorates Hepatocyte Lipid Droplet Accumulation via Targeting the Rhythmic Protein BMAL1 to Regulate Cell Death-Inducing DNA Fragmentation Factor-α-like Effector C-Mediated Lipid Droplet Fusion. Journal of Agricultural and Food Chemistry, 72(48), pp.26884-26897.",
    "fdastatus": "none",
    "linkslists": "https://pubs.acs.org/doi/abs/10.1021/acs.jafc.4c06487",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5281614",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4444933.html",
    "drugbank": null,
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:42567",
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      4,
      10
    ],
    "classf": [
      9,
      5
    ],
    "mechanisms": [
      28,
      122
    ],
    "target": [
      106,
      29,
      102
    ],
    "effect": [
      5,
      7
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 312,
  "fields": {
    "gname": "Baicalein",
    "smiles": "C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O",
    "linkname": "baicalein",
    "molecula": "C15H10O5",
    "iupacname": "5,6,7-trihydroxy-2-phenylchromen-4-one",
    "updphoto": "media/imgsrv_-_2025-05-06T152755.120.png",
    "description": "Baicalein, a flavone present in various plants, has gained widespread recognition for its variety of health benefits. It exhibits promising therapeutic potential in conditions like microbial infection, cancer, neurodegenerative diseases, and cardiovascular diseases, acting through intricate pathways that modulate oxidative stress, inflammatory responses, cell cycle arrest, and cell death. Its impact extends to curtailing oxidative stress and activating specific molecular pathways, underscoring its strong neuroprotective effect. Additionally, it contributes to cardiovascular well-being by hindering inflammation, apoptosis, and fibrosis, the crucial factors in its cardioprotective effects. Furthermore, it showcases notable antibacterial prowess against several pathogens. This antimicrobial action is executed by disruption of bacterial cell membranes and interferes with essential cellular processes that curtail pathogen proliferation. Extensive scientific literature analysis supports the notion that baicalein is well-tolerated and exerts positive influences on certain health conditions. Consequently, it emerges as a potential nutritional supplement and adjunctive therapeutic agent, warranting consideration as a leading therapeutic candidate. The implications of this review are diverse, serving to deepen the understanding of the diverse applications of baicalein. It is poised to stimulate global researchers to explore baicalein as a viable pharmaceutical solution in the face of impending health crises involving various debilitating diseases. As time progresses, this article will serve as a foundational resource, chronicling the unfolding revelations surrounding the latent potential of baicalein as a preeminent nutraceutical and medicinal agent in the realm of healthcare.\r\n\r\nTreatment with baicalein/6 h. Control (0.1% DMSO).\tsiRNA-RORα.\t↑ RORα. ↓ RORα and BMAL1 in RORα-silenced cells.\tRegulate FGF21 expression in RORα dependent manner.\r\n\r\n\r\nSulaimani, N., Houghton, M.J., Bonham, M.P. and Williamson, G., 2024. Effects of (Poly) Phenols on Circadian Clock Gene–Mediated Metabolic Homeostasis in Cultured Mammalian Cells: A Scoping Review. Advances in Nutrition, 15(6), p.100232.\r\n\r\nPaul, A., Das, P., Gogoi, M., Islam, M.A., Das, S. and Zaman, M.K., 2024. Baicalein: multiple pharmacological activities, pharmacokinetics, and clinical trials. Revista Brasileira de Farmacognosia, pp.1-15.",
    "fdastatus": "none",
    "linkslists": "https://www.sciencedirect.com/science/article/pii/S2161831324000668",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5281605",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4444924.html",
    "drugbank": null,
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:2979",
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      4,
      9
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      32
    ],
    "target": [
      14,
      40
    ],
    "effect": [
      98
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 313,
  "fields": {
    "gname": "Chicoric acid",
    "smiles": "C1=CC(=C(C=C1/C=C/C(=O)O[C@@H](C(=O)O)[C@@H](OC(=O)/C=C/C2=CC(=C(C=C2)O)O)C(=O)O)O)O",
    "linkname": "chicoric-acid",
    "molecula": "C22H18O12",
    "iupacname": "(2R,3R)-2,3-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]butanedioic acid",
    "updphoto": "media/imgsrv_-_2025-05-06T153327.243.png",
    "description": "Cichoric Acid Prevents Free-Fatty-Acid-Induced Lipid Metabolism Disorders via Regulating Bmal1 in HepG2 Cells. Cichoric acid (CA), a polyphenol component from Echinacea purpurea, exhibits preventive effects on liver lipid-metabolism disorders in obesity. This research aimed to determine the role of circadian rhythm signaling during the process of CA-attenuated lipid accumulation in hepatocytes. In the current study, CA treatments improved cell morphology changes and hepatic lipid levels, which were triggered by free fatty acids (2:1, oleate: palmitate) in a dose-dependent way. Besides, CA (200 μM) regulated the circadian rhythm expressions of clock genes and the relatively shallow daily oscillations. Moreover, silencing Bmal1 significantly blocked the p-Akt/Akt pathway to 80.1% ± 1.5% and the p-GSK3β/GSK3β pathway to 64.7% ± 2.8% (p < 0.05). Furthermore, silencing Bmal1 elevated the expressions of FAS and ACC to 122.4% ± 5.6% and 114.9% ± 1.7% in protein levels (p < 0.05) and to 166.5% ± 18.5% and 131.4% ± 5.5% in mRNA levels (p < 0.05). Therefore, our results demonstrated that CA has a Bmal1 resistance to lipid accumulation by enhancing the Akt/GSK3β signaling pathways and modulating the downstream expressions related to lipid metabolism, which indicated that CA might be useful as a natural and promising nonalcoholic fatty liver diseases (NAFLD) modulator. ↑ SIRT1 and PGC-1α proteins, BMAL1- and CLOCK-dependent. ↓ Lipid metabolism disorders via ↓ FAS, ↑ p-AKT and p-GSK3β proteins and ↑ PPARα mRNA, BMAL1-dependent. ↓ Intracellular lipid accumulation, BMAL1 dependent.\r\n\r\nGuo, R., Zhao, B., Wang, Y., Wu, D., Wang, Y., Yu, Y., Yan, Y., Zhang, W., Liu, Z. and Liu, X., 2018. Cichoric acid prevents free-fatty-acid-induced lipid metabolism disorders via regulating Bmal1 in HepG2 cells. Journal of agricultural and food chemistry, 66(37), pp.9667-9678.",
    "fdastatus": "none",
    "linkslists": "https://pubs.acs.org/doi/abs/10.1021/acs.jafc.8b02147",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5281764",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4445078.html",
    "drugbank": "https://go.drugbank.com/drugs/DB12029",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3594",
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      8
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      138,
      139,
      15,
      144,
      118,
      122,
      196
    ],
    "target": [
      76,
      29,
      134
    ],
    "effect": [
      5
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 314,
  "fields": {
    "gname": "Curcumin",
    "smiles": "COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O",
    "linkname": "curcumin",
    "molecula": "C21H20O6",
    "iupacname": "(1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione",
    "updphoto": "media/imgsrv_-_2025-05-06T154301.312.png",
    "description": "Treatment with CUR/12 h. Control (DMSO). Affects expression of PER2:: mPER2::Luc.\t↓ Dose causes a rhythmic pattern of mPER2 with an average period of 24.48 h for PER2. Circadian rhythms in cell death were observed in response to low (5 μM) curcumin, reaching a peak several hours before the peak in rhythmic expression of mPER2 protein, a major circadian clock component. These results revealed a sensitive phase of the circadian cycle that could be effectively targeted in patient therapies based on curcumin or its analogs. Curcumin fluorescence was observed in cell compartments at least 24 h after treatment, and the two congeners displayed greater stability than curcumin in cell culture medium. Sarma, A., Sharma, V.P., Sarkar, A.B., Sekar, M.C., Samuel, K. and Geusz, M.E., 2016. The circadian clock modulates anti-cancer properties of curcumin. BMC cancer, 16, pp.1-13.",
    "fdastatus": "none",
    "linkslists": "https://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2789-9",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/969516",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.839564.html",
    "drugbank": "https://go.drugbank.com/drugs/DB11672",
    "chebi": "https://www.ebi.ac.uk/chebi/advancedSearchFT.do",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/C10443",
    "selleckchem": null,
    "articles": [
      7
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      193
    ],
    "target": [
      84
    ],
    "effect": [
      97
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 315,
  "fields": {
    "gname": "Bavachalcone",
    "smiles": "CC(=CCC1=CC(=C(C=C1O)O)C(=O)/C=C/C2=CC=C(C=C2)O)C",
    "linkname": "bavachalcone",
    "molecula": "C20H20O4",
    "iupacname": "(E)-1-[2,4-dihydroxy-5-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one",
    "updphoto": "media/imgsrv_-_2025-05-06T155147.787.png",
    "description": "Bavachalcone, a prenylchalcone, is a major bioactive chalcone isolated from Psoralea corylifolia. This natural ingredient activated RORα1 luciferase reporter activity on drug screening. RAR-related orphan receptor α (RORα), an orphan nuclear receptor, is involved in circadian rhythm regulation, including regulation of cardiovascular function.  In addition, bavachalcone induced RORα1 expression in mRNA and protein levels in a dose-dependent manner and enhanced the circadian amplitude of Bmal1 mRNA expression after serum shock. Moreover, bavachalcone suppressed senescence in human endothelial cells and mRNA expression of p16ink4a (a marker of replicative senescence) and IL-1α (a proinflammatory cytokine of the senescence-associated secretory phenotype). These inhibitory effects were partially reversed by the RORα inhibitor VPR-66. Our results demonstrate that bavachalcone, as a natural medicine ingredient, has a pharmacological function in regulating RORα1. Human HUVECs/2-h Serum shock (50% newborn bovine serum).\tTreatment with bavachalcone/24 h. Control\t↑ ROR-α1 mRNA and protein, dose-dependent (>2-fold and 6-fold at 20 μM, respectively). ↑ amplitude of BMAL1 at (28, 36, and 40 h)",
    "fdastatus": "none",
    "linkslists": "https://onlinelibrary.wiley.com/doi/full/10.1155/2015/920431",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/6450879",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4479431.html",
    "drugbank": null,
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:187324",
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      6
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      32
    ],
    "target": [
      14,
      40
    ],
    "effect": [
      96
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 316,
  "fields": {
    "gname": "Genistein",
    "smiles": "C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O",
    "linkname": "genistein",
    "molecula": "15H10O5",
    "iupacname": "5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one",
    "updphoto": "media/imgsrv_-_2025-05-06T155618.432.png",
    "description": "Dietary Genistein Could Modulate Hypothalamic Circadian Entrainment, Reduce Body Weight, and Improve Glucose and Lipid Metabolism in Female Mice \r\nRat C6.\tNoradrenaline (NA) or Fsk (10 μM, 1 h).\tPretreatment gen/1 h and then NA or Fsk/1 h. Control.↓ PER1 mRNA and protein.\r\n\r\nNoradrenaline induces clock gene Per1 mRNA expression in C6 glioma cells through β2-adrenergic receptor coupled with protein kinase A - cAMP response element binding protein (PKA-CREB) and Src-tyrosine kinase - glycogen synthase kinase-3β (Src-GSK-3β)\r\n\r\nSulaimani, N., Houghton, M.J., Bonham, M.P. and Williamson, G., 2024. Effects of (Poly) Phenols on Circadian Clock Gene–Mediated Metabolic Homeostasis in Cultured Mammalian Cells: A Scoping Review. Advances in Nutrition, 15(6), p.100232.\r\nZhou, L., Xiao, X., Zhang, Q., Zheng, J., Li, M., Yu, M., Wang, X., Deng, M., Zhai, X., Li, R. and Liu, J., 2019. Dietary genistein could modulate hypothalamic circadian entrainment, reduce body weight, and improve glucose and lipid metabolism in female mice. International Journal of Endocrinology, 2019(1), p.2163838.",
    "fdastatus": "none",
    "linkslists": "https://onlinelibrary.wiley.com/doi/full/10.1155/2019/2163838",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5280961",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      4,
      5
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      96,
      121,
      138,
      144
    ],
    "target": [
      76
    ],
    "effect": [
      1
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 317,
  "fields": {
    "gname": "Aminophylline",
    "smiles": "CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N",
    "linkname": "aminophylline",
    "molecula": "C16H24N10O4",
    "iupacname": "1,3-dimethyl-7H-purine-2,6-dione;ethane-1,2-diamine",
    "updphoto": "media/aminophylline.png",
    "description": "Likewise, methylxanthines still exert a period effect in several cAMP signaling pathway mutants, including adenylate cyclase (cr-1) and protein kinase A (PKA) (Δpkac-1) mutants, suggesting that these drugs lead to circadian phenotypes through mechanisms different from the canonical PDE-cAMP-PKA signaling axis. Thus, this study highlights the strong impact of methylxanthines on circadian period in Neurospora, albeit the exact mechanisms somehow remain elusive. IMPORTANCE Evidence from diverse organisms show that caffeine causes changes in the circadian clock, causing period lengthening. The fungus Neurospora crassa is no exception; here, several methylxanthines such as caffeine, theophylline, and aminophylline cause period lengthening in a concentration-dependent manner. Although methylxanthines are expected to inhibit phosphodiesterase activity, we were able to show by genetic and pharmacological means that these drugs exert their effects through a different mechanism. Moreover, our results indicate that increases in cAMP levels and changes in PKA activity do not impact the circadian period and therefore are not part of underlying effects of methylxanthine. These results set the stage for future analyses dissecting the molecular mechanisms by which these drugs dramatically modify the circadian period.\r\n\r\nAminophylline targets miR-128-3p/Slc7a11 axis to attenuate neuronal ferroptosis after traumatic brain injury",
    "fdastatus": "Approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/Aminophylline#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/Aminophylline",
    "chemspider": null,
    "drugbank": "https://go.drugbank.com/drugs/DB01223",
    "chebi": null,
    "uniprot": null,
    "kegg": "https://www.genome.jp/dbget-bin/www_bget?drug:D00227",
    "selleckchem": null,
    "articles": [
      13,
      14
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      200,
      201,
      198,
      199
    ],
    "target": [
      60
    ],
    "effect": [
      94
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 318,
  "fields": {
    "gname": "Salicilic acid",
    "smiles": "C1=CC=C(C(=C1)C(=O)O)O",
    "linkname": "salicilic-acid",
    "molecula": "C7H6O3",
    "iupacname": "2-hydroxybenzoic acid",
    "updphoto": "media/imgsrv_-_2025-05-25T231319.306.png",
    "description": "PLANT CHRONOBIOTIC. Salicylic acid (SA) increased oscillatory robustness and shortened the period. The latter was attenuated by sucrose addition and was also gated, taking place during the first 3 h of the subjective day. Furthermore, the effect of SA on period length was dependent on light quality and genotype. Period lengthening or shortening by these chemicals was correlated to their inferred impact on photosynthetic electron transport activity and the redox state of plastoquinone (PQ). Based on these data and on previous publications on circadian effects that alter the redox state of PQ, we propose that the photosynthetic electron transport and the redox state of PQ participate in circadian periodicity.",
    "fdastatus": "none",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/Salicylic-Acid#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/Salicylic-Acid",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      279
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      204
    ],
    "target": [
      135
    ],
    "effect": [
      93
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 319,
  "fields": {
    "gname": "(2S)-N-methyl-1-phenylpropan-2-amine",
    "smiles": "C[C@@H](CC1=CC=CC=C1)NC",
    "linkname": "2s-n-methyl-1-phenylpropan-2-amine",
    "molecula": "C10H15N",
    "iupacname": "(2S)-N-methyl-1-phenylpropan-2-amine",
    "updphoto": "media/imgsrv_-_2025-05-29T105411.470.png",
    "description": "methamphetamine exposure restores the circadian rhythm, although the frequency of the methamphetamine sensitive circadian oscillator (MASCO) varied considerably compared to the highly regular wild-type circadian rhythm. Additionally, methamphetamine increased multiscale activity and induced a circabidian oscillation in the Per1/2/3 KO mice. The information transfer between oscillatory modes, with frequencies around circadian, lowfrequency ultradian and high-frequency ultradian activity, due to their mutual couplings, was also investigated. For Per1/2/3 KO mice in constant darkness, the most prevalent coupling was between low and high-frequency ultradian activity. Following methamphetamine administration, the coupling between the circadian and high-frequency ultradian activity became dominant. In each case, the direction of information transfer was between the corresponding phases from the slower to faster oscillations. The time-varying nature of the circadian rhythm exhibited in the absence of Per1/2/3 genes and following methamphetamine administration may have profound implications for health and disease. The methamphetamine-sensitive circadian oscillator does not employ canonical clock genes.\r\n\r\nMethamphetamine-sensitive circadian oscillator (MASCO), which generates behavioral rhythms in the absence of the SCN, is based on an entirely different molecular mechanism.\r\n\r\n\r\n\r\nBarnes, S.J., Alanazi, M., Yamazaki, S. and Stefanovska, A., 2025. Methamphetamine alters the circadian oscillator and its couplings on multiple scales in Per1/2/3 knockout mice. PNAS nexus, 4(4), p.pgaf070.\r\n\r\nMohawk, J.A., Baer, M.L. and Menaker, M., 2009. The methamphetamine-sensitive circadian oscillator does not employ canonical clock genes. Proceedings of the National Academy of Sciences, 106(9), pp.3519-3524.",
    "fdastatus": "Approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/10836",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.10379.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01577",
    "chebi": "https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201201",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/C07164",
    "selleckchem": null,
    "articles": [
      357,
      358,
      359
    ],
    "classf": [
      4,
      5,
      6
    ],
    "mechanisms": [
      208,
      209,
      206,
      207
    ],
    "target": [
      136
    ],
    "effect": [
      188,
      189,
      190
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 320,
  "fields": {
    "gname": "TW68",
    "smiles": "CC1=CC=CC2=C1N=C(CN3C[C@H]4C[C@@H](C3)C5=CC=CC(=O)N5C4)N=C2NC6=CC=C7C(=C6)OCO7",
    "linkname": "tw68",
    "molecula": "C28H27N5O3",
    "iupacname": "(1S,9S)-11-[[4-(1,3-benzodioxol-5-ylamino)-8-methylquinazolin-2-yl]methyl]-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one",
    "updphoto": "media/imgsrvtw68.png",
    "description": "A new molecule called TW68 that interacts with the primary pockets of mammalian CRY1/2, leading to reduced ubiquitination levels and increased stability. In cell-based circadian rhythm assays using U2OS:Bmal1-dLuccells, TW68 extended the period length of the circadian rhythm. Additionally, TW68 decreased the transcriptional levels of two genes,Phosphoenolpyruvate carboxykinase 1(PCK1) andGlucose-6-phosphatase(G6PC), which play crucial roles in glucose biosynthesis during glucagon-induced gluconeogenesis in HepG2 cells. Oral administration of TW68 in mice showed good tolerance, a good pharmacokinetic profile, and remarkable bioavailability. Finally, when administered to fastingob/oband fat-induced diabetic animals, TW68 reduced blood glucose levels by enhancing CRY stabilization and subsequently decreasing the transcriptional levels ofPck1 and G6pc. These findings collectively demonstrate the antidiabetic efficacy of TW68in vivo, suggesting its therapeutic potential for controlling fasting glucose levels in the treatment of type 2 diabetes mellitus.\r\n\r\nSurme, S., Ergun, C., Gul, S., Akyel, Y.K., Gul, Z.M., Ozcan, O., Ipek, O.S., Akarlar, B.A., Ozlu, N., Taskin, A.C. and Turkay, M., 2023. TW68, Cryptochromes stabilizer, regulates fasting blood glucose level in ob/ob and fat-induced diabetic mice. bioRxiv, pp.2023-07.",
    "fdastatus": "none",
    "linkslists": "https://www.degruyterbrill.com/document/doi/10.1515/tjb-2023-48s104/html",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/175816612",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      362
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      33,
      34,
      119
    ],
    "target": [
      42,
      83
    ],
    "effect": [
      195
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 321,
  "fields": {
    "gname": "Raloxifene",
    "smiles": "C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O",
    "linkname": "raloxifene",
    "molecula": "C28H27NO4S",
    "iupacname": "[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone",
    "updphoto": "media/imgsrv_8_g0YDrwq.png",
    "description": "Raloxifene (RLX) is a selective estrogen receptor modulator (SERM) known for its ability to selectively bind to estrogen receptors. According to the article, raloxifene acts as an antiestrogen in uterine tissue, where it attenuates the effect of estrogen (17β-estradiol, E2) on the circadian rhythms of PER2 gene expression.",
    "fdastatus": null,
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5035",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.4859.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00481",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      363
    ],
    "classf": [
      8
    ],
    "mechanisms": [
      211
    ],
    "target": [
      137
    ],
    "effect": [
      196
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 322,
  "fields": {
    "gname": "verapamil",
    "smiles": "CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC",
    "linkname": "verapamil",
    "molecula": "C27H38N2O4",
    "iupacname": "2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile",
    "updphoto": "media/imgsrv_9_TVmHK8e.png",
    "description": "Verapamil, a first-line preventive medication for cluster headache, is primarily known as a canonical L-type calcium channel antagonist. However, this study reveals its potent role as a circadian modulator. In both cell-based (Per2::LucSV fibroblasts) and in vivo (C57BL6/J mice) models, verapamil shortens the circadian period at physiological doses. It alters the expression of key clock genes in a dose- and tissue-dependent manner, notably Bmal1, Per1, and Cry2.",
    "fdastatus": "Approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/2520",
    "chemspider": null,
    "drugbank": "https://go.drugbank.com/drugs/DB00661",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      364
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      51
    ],
    "target": [
      29
    ],
    "effect": [
      197
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 323,
  "fields": {
    "gname": "amitriptyline",
    "smiles": "CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31",
    "linkname": "amitriptyline",
    "molecula": "C20H23N",
    "iupacname": "N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine",
    "updphoto": "media/imgsrv_10_SFiqq3V.png",
    "description": "Amitriptyline is a tricyclic antidepressant widely used for depression, chronic pain, and sleep disorders. Its primary action is to inhibit the reuptake of serotonin and norepinephrine, boosting their levels in the synaptic cleft and improving mood.",
    "fdastatus": "approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/2160",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.2075.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00321",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      365
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      51
    ],
    "target": [
      29
    ],
    "effect": [
      198
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 324,
  "fields": {
    "gname": "Trazodon",
    "smiles": "C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl",
    "linkname": "trazodon",
    "molecula": "C19H22ClN5O",
    "iupacname": "2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one",
    "updphoto": "media/imgsrv_11_ZnDIx0d.png",
    "description": "Trazodone is an atypical antidepressant with dual actions: serotonin transporter inhibition and 5-HT2A/5-HT2C receptor antagonism. It also antagonizes H1-histaminergic and alpha1-adrenergic receptors, conferring significant sleep-promoting properties. Recent studies have demonstrated that chronic trazodone treatment increases expression of trophic factors (BDNF, TrkB) and key circadian genes (Bmal1, Per1, Per2)",
    "fdastatus": "approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5533",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.5332.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00656",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      366
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      212
    ],
    "target": [
      29
    ],
    "effect": [
      199
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 325,
  "fields": {
    "gname": "5‐HEAT",
    "smiles": "CC(=O)NCCC1=CNC2=C1C=C(C=C2)OCCO",
    "linkname": "5heat",
    "molecula": "C14H18N2O3",
    "iupacname": "N-[2-[5-(2-hydroxyethoxy)-1H-indol-3-yl]ethyl]acetamide",
    "updphoto": "media/imgsrv_-_2025-06-05T124645.969.png",
    "description": "5-HEAT was able to differentiate between the high- and the low-affinity receptor states in the mt1 but not in the MT2 receptor. 5-HEAT induced a high level of G protein activation when acting through the mt1 receptor, with a relative intrinsic activity of 0.92. On the contrary, it elicited only minimal MT2 receptor-mediated G protein activation, with a relative intrinsic activity of 0.16, and was also able to inhibit the melatonin-induced MT2 receptor-mediated G protein activation, with a pKB value of 7.4. In conclusion, it appears that 5-HEAT possesses very different efficacies at the two melatonin receptors, behaving as a full melatonin receptor agonist at the mt1 and as an antagonist/weak partial agonist at the MT2 receptor. Therefore, it is a promising ligand for use in functional studies aimed at distinguishing between the effects mediated by the different melatonin receptors in the human.",
    "fdastatus": "none",
    "linkslists": null,
    "pubchem": null,
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      368
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      7,
      9,
      10
    ],
    "target": [
      11,
      12
    ],
    "effect": [
      210
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 326,
  "fields": {
    "gname": "2‐(indolin‐1yl)‐melatonin",
    "smiles": "CC(=O)NCCC1=C(NC2=C1C=C(C=C2)OC)CN3CCC4=CC=CC=C43",
    "linkname": "2indolin1ylmelatonin",
    "molecula": "C22H25N3O2",
    "iupacname": "N-[2-[2-(2,3-dihydroindol-1-ylmethyl)-5-methoxy-1H-indol-3-yl]ethyl]acetamide",
    "updphoto": "media/imgsrv_-_2025-06-05T125942.604.png",
    "description": "The compound \"N-[2-[2-(2,3-dihydroindol-1-ylmethyl)-5-methoxy-1H-indol-3-yl]ethyl]acetamide\" is a chemical molecule that can be described as a melatonin derivative with modifications. Specifically, it has an acetamide group, a modified melatonin core structure (including a dihydroindol-1-ylmethyl and a methoxy group), and an ethyl linker connecting the acetamide and the modified melatonin structure. This molecule is related to melatonin, a hormone involved in regulating circadian rhythms, and could potentially interact with melatonin receptors or other components of the circadian system.",
    "fdastatus": "none",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/25210130",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      369
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      7
    ],
    "target": [
      12
    ],
    "effect": [
      211
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 327,
  "fields": {
    "gname": "2-methoxy-α,β-didehydro-agomelatine",
    "smiles": "CC(=O)N/C=C/C1=C(C=CC2=C1C=C(C=C2)OC)OC",
    "linkname": "2-methoxy-ab-didehydro-agomelatine",
    "molecula": "C16H17NO3",
    "iupacname": "N-[(E)-2-(2,7-dimethoxynaphthalen-1-yl)ethenyl]acetamide",
    "updphoto": "media/imgsrv_-_2025-06-05T130414.219.png",
    "description": "Derivative of agomelatine.",
    "fdastatus": "none",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/71533431#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/71533431",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      370
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      9
    ],
    "target": [
      11
    ],
    "effect": [
      212
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 328,
  "fields": {
    "gname": "5‐Methoxyluzindole",
    "smiles": "CC(=O)NCCC1=C(NC2=C1C=C(C=C2)OC)CC3=CC=CC=C3",
    "linkname": "5methoxyluzindole",
    "molecula": "C20H22N2O2",
    "iupacname": "N-[2-[5-methoxy-2-(phenylmethyl)-1H-indol-3-yl]ethyl]acetamide",
    "updphoto": "media/imgsrv_-_2025-06-05T134413.034.png",
    "description": "Luzindole, a melatonin receptor antagonist, disrupts circadian rhythms in animals. It blocks melatonin's effects by binding to melatonin receptors 1 (MT1) and 2 (MT2), particularly MT2 with higher affinity. This disruption can be seen in various animal studies, including those examining sleep patterns, mood, and other physiological functions.",
    "fdastatus": "none",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/5-Methoxyindole",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      371
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      10
    ],
    "target": [
      12
    ],
    "effect": [
      103
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 329,
  "fields": {
    "gname": "AAE‐M‐PBP amine (Isoamyl-agomelatine)",
    "smiles": "CC(C)CCC1=CC(=C2C=C(C=CC2=C1)OC)CCNC(=O)C",
    "linkname": "aaempbp-amine",
    "molecula": "C20H27NO2",
    "iupacname": "N-[2-[7-methoxy-3-(3-methylbutyl)naphthalen-1-yl]ethyl]acetamide",
    "updphoto": "media/imgsrv_-_2025-06-05T134733.378.png",
    "description": "Isoamyl-agomelatine is aderivative of egomelatine",
    "fdastatus": "none",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/57381997",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      372
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      213
    ],
    "target": [
      12
    ],
    "effect": [
      213,
      157
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 330,
  "fields": {
    "gname": "benzyloxy-methoxyphenyl-propylamide (Bomppa)",
    "smiles": "CCC(=O)NCCCC1=C(C=CC(=C1)OC)CC2=CC(=CC=C2)OC",
    "linkname": "benzyloxy-methoxyphenyl-propylamide-bomppa",
    "molecula": "C21H27NO3",
    "iupacname": "N-[3-[5-methoxy-2-[(3-methoxyphenyl)methyl]phenyl]propyl]propanamide",
    "updphoto": "media/imgsrv_-_2025-06-05T135857.290.png",
    "description": "",
    "fdastatus": "none",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/71508234",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      373
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      10
    ],
    "target": [
      12
    ],
    "effect": [
      214
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 331,
  "fields": {
    "gname": "Adenosine cyclic phosphate (cAMP)",
    "smiles": "C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)OP(=O)(O1)O",
    "linkname": "adenosine-cyclic-phosphate-camp",
    "molecula": "C10H12N5O6P",
    "iupacname": "(4aR,6R,7R,7aS)-6-(6-aminopurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol",
    "updphoto": "media/imgsrv_-_2025-06-05T140924.678.png",
    "description": "Metabolite. cAMP is not just a passively regulated molecule; it actively participates in the circadian oscillator. Studies have shown that manipulating cAMP levels, including elevating or reducing them, can affect the rhythmicity of circadian gene expression in the SCN.  Circadian rhythms can be reset or phase-shifted by external cues like light, and cAMP signaling may play a role in this process.  Beyond its role in the SCN, cAMP also influences other aspects of circadian rhythms, including melatonin production and retinomotor movements in the eye. Melatonin, a hormone that regulates sleep, is influenced by cAMP levels. Retinomotor movements, which involve changes in the position of photoreceptors in the eye, are also affected by cAMP signaling.",
    "fdastatus": "Approved",
    "linkslists": null,
    "pubchem": "http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6076",
    "chemspider": null,
    "drugbank": "http://www.drugbank.ca/drugs/DB02527",
    "chebi": "http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:17489",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/C00575",
    "selleckchem": null,
    "articles": [
      374,
      375,
      376
    ],
    "classf": [
      4,
      5
    ],
    "mechanisms": [
      214,
      215,
      216,
      217,
      218,
      25
    ],
    "target": [
      138,
      139,
      140,
      141
    ],
    "effect": [
      215
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 332,
  "fields": {
    "gname": "CBOBNEA",
    "smiles": "CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OCCCCOC3=CC=C(C=C3)C4=CC=C(C=C4)C(=O)O",
    "linkname": "cbobnea",
    "molecula": "C31H31NO5",
    "iupacname": "4-[4-[4-[8-(2-acetamidoethyl)naphthalen-2-yl]oxybutoxy]phenyl]benzoic acid",
    "updphoto": "media/imgsrv_-_2025-06-05T142331.666.png",
    "description": "CBOBNEA (carboxybiphenyloxy-butoxynaphthalene-ethylacetamide) is a compound that is a selective MT1 receptor ligand, meaning it binds to and activates the MT1 melatonin receptor. Melatonin, a hormone that regulates the sleep-wake cycle, acts through two receptor subtypes, MT1 and MT2. CBOBNEA's selective activity on MT1 receptors could have implications for understanding how melatonin affects circadian rhythms and sleep, as well as for developing new therapeutic interventions for sleep disorders and circadian rhythm disorders. \r\nUnderstanding how CBOBNEA interacts with the MT1 receptor can provide insights into the mechanisms by which melatonin regulates circadian rhythms and sleep. This knowledge could be used to develop drugs that specifically target the MT1 receptor for treating sleep disorders, circadian rhythm disorders, and other conditions where melatonin signaling is disrupted.",
    "fdastatus": "Not approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/9957516",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      232
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      219
    ],
    "target": [
      11
    ],
    "effect": [
      212,
      5
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 333,
  "fields": {
    "gname": "cyclohexylmethyl-indenofurane-ethylacetamide (CIFEA)",
    "smiles": "CC(=O)NCCC1=C(CC2=C1C3=C(C=C2)OCC3)CC4CCCCC4",
    "linkname": "cyclohexylmethyl-indenofurane-ethylacetamide-cifea",
    "molecula": "C22H29NO2",
    "iupacname": "N-[2-[7-(cyclohexylmethyl)-2,6-dihydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]acetamide",
    "updphoto": "media/imgsrv_-_2025-06-05T143052.442.png",
    "description": "A novel series of 1,6-dihydro-2H-indeno[5,4-b]furan derivatives were designed and synthesized as MT(2)-selective ligands. This scaffold was identified as a potent mimic of the 5-methoxy indole core of melatonin, and introduction of a cyclohexylmethyl group at the 7-position of this scaffold afforded an MT(2)-selective ligand 15 (K(i) = 0.012 nM) with high MT(1)/MT(2) selectivity (799). Compound 15 was identified as a potent full agonist for the MT(2) subtype and exhibited reentrainment effects to a new light/dark cycle in ICR mice at 3-30 mg/kg. This result demonstrated the involvement of the MT(2) receptors in chronobiotic activity.",
    "fdastatus": "Not approved",
    "linkslists": null,
    "pubchem": "http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=53238181",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      377
    ],
    "classf": [
      4,
      5
    ],
    "mechanisms": [
      10,
      213
    ],
    "target": [
      12
    ],
    "effect": [
      214,
      206
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 334,
  "fields": {
    "gname": "Difluoroagomelatine",
    "smiles": "COC1=CC2=C(C=CC=C2CCNC(=O)C(F)F)C=C1",
    "linkname": "difluoroagomelatine",
    "molecula": "C15H15F2NO2",
    "iupacname": "2,2-difluoro-N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide",
    "updphoto": "media/imgsrv_-_2025-06-05T144800.561.png",
    "description": "Difluoro-agomelatine displays high MT1 binding affinity (Ki = 0.03 nM), acting as a MT1 selective full agonist ([35S]GTPγS test).",
    "fdastatus": "Not approved",
    "linkslists": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=summary&ligandId=7776",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/57381112",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      378
    ],
    "classf": [
      4,
      5
    ],
    "mechanisms": [
      9
    ],
    "target": [
      11
    ],
    "effect": [
      216,
      212
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 335,
  "fields": {
    "gname": "(125I)Div880",
    "smiles": "CC(C)(C)OC(=O)CC1=CC(=C(C=C1CC2=CC(=C(C=C2[125I])OC)OC)OC)OC",
    "linkname": "125idiv880",
    "molecula": "C23H29IO6",
    "iupacname": "tert-butyl 2-[2-[(2-(125I)iodanyl-4,5-dimethoxyphenyl)methyl]-4,5-dimethoxyphenyl]acetate",
    "updphoto": "media/imgsrv_-_2025-06-05T145423.549.png",
    "description": "Radioligand of MT2.",
    "fdastatus": null,
    "linkslists": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=summary&ligandId=7771",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/86277837",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      379,
      380
    ],
    "classf": [
      4,
      5
    ],
    "mechanisms": [
      10
    ],
    "target": [
      12
    ],
    "effect": [
      185,
      213
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 336,
  "fields": {
    "gname": "EFPPEA",
    "smiles": "CCC1=NN2C=CC3=C(C2=C1CCNC(=O)C)CCO3",
    "linkname": "efppea",
    "molecula": "C15 H19 N3 O2",
    "iupacname": "N-[2-(4-ethyl-10-oxa-5,6-diazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,7-tetraen-3-yl)ethyl]acetamide",
    "updphoto": "media/7774.gif",
    "description": "EFPPEA (N-[2-(2-Ethyl-8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridin-1-yl)ethyl]acetamide) is a synthesized compound that belongs to a class of drugs known as acetyl-substituted pyrazolo[1,5-a]pyridine derivatives. It is not a widely recognized drug and is primarily used in research settings, according to the National Institutes of Health (NIH) PubChem database. \r\nNovel tricyclic dihydrofuran derivatives were designed, synthesized, and evaluated as melatonin receptor (MT(1)/MT(2)) ligands based on the previously reported 1,6-dihydro-2H-indeno[5,4-b]furan 1a. By screening the central tricyclic cores, we identified 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridine as a potent scaffold with a high ligand-lipophilicity efficiency (LLE) value. Subsequent optimization of the side chains led to identification of the potent MT(1)/MT(2) agonist 4d (MT(1), K(i) = 0.062 nM; MT(2), K(i) = 0.420 nM) with good oral absorption and blood-brain barrier (BBB) penetration in rats. The oral administration of compound 4d exhibited a sleep-promoting action in freely moving cats at 0.1 mg/kg.",
    "fdastatus": "none",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/24954989",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      381
    ],
    "classf": [
      10,
      4
    ],
    "mechanisms": [
      9,
      10
    ],
    "target": [
      11
    ],
    "effect": [
      103,
      107,
      174,
      217,
      157
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 337,
  "fields": {
    "gname": "fMet-Leu-Phe",
    "smiles": "CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCSC)NC=O",
    "linkname": "fmet-leu-phe",
    "molecula": "C21H31N3O5S",
    "iupacname": "IUPAC Name Click here for help (2S)-2-[[(2S)-2-[[(2S)-2-formamido-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoic acid",
    "updphoto": "media/imgsrv_-_2025-06-05T150534.220.png",
    "description": "Abbreviated name: fMLP\r\nSynonyms: fMetLeuPhe | fMLF | formyl-Met-Leu-Phe\r\nCompound class: Peptide\r\nComment: From the bacterium E.coli\r\n\r\nAdditional information and targets (data relate to human unless otherwise stated)\r\n\r\nPotency order of endogenous ligands at FPR1\tfMet-Leu-Phe > cathepsin G (CTSG, P08311) > annexin I (ANXA1, P04083).\r\nPotency order of endogenous and other ligands at FPR2\tLXA4 = aspirin triggered lipoxin A4 = ATLa2 = resolvin D1 > LTC4 = LTD4 >> 15-deoxy-LXA4 >> fMet-Leu-Phe.",
    "fdastatus": "Not approved",
    "linkslists": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1022",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/443295",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      382
    ],
    "classf": [
      9
    ],
    "mechanisms": [
      220,
      221
    ],
    "target": [
      142,
      143
    ],
    "effect": [
      224,
      219,
      220,
      221,
      222,
      223
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 338,
  "fields": {
    "gname": "K185 (K-185)",
    "smiles": "CCCC(=O)NCCC1=C2C3=CC=CC=C3CCCN2C4=C1C=C(C=C4)OC",
    "linkname": "k185-k-185",
    "molecula": "C24H28N2O2",
    "iupacname": "N-[2-(11-methoxy-6,7-dihydro-5H-indolo[2,1-a][2]benzazepin-13-yl)ethyl]butanamide",
    "updphoto": "media/1359.gif",
    "description": "K185, a melatonin receptor antagonist, is not a therapeutic drug but may be of interest in understanding circadian rhythm disorders and sleep-wake disturbances. Research suggests that melatonin receptor antagonists, in general, might be beneficial in treating circadian rhythm disorders in the elderly, blind, and in managing sleep-wake issues caused by shift work and jet lag. K185 specifically has been studied in relation to MT1 and MT2 receptors, and its effects are used to understand how melatonin influences these receptors. \r\nElaboration:\r\nK185 and Melatonin Receptors:\r\nK185 is a specific antagonist, meaning it blocks the effects of melatonin, a hormone that plays a crucial role in regulating circadian rhythms and sleep-wake cycles. \r\nTreating circadian rhythm disorders in specific populations, such as the elderly, blind, or individuals experiencing disruptions from shift work or jet lag.",
    "fdastatus": "none",
    "linkslists": null,
    "pubchem": "http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5311198",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      383,
      384
    ],
    "classf": [
      4,
      5,
      6
    ],
    "mechanisms": [
      5,
      6,
      7,
      9,
      10,
      222
    ],
    "target": [
      9,
      11,
      12
    ],
    "effect": [
      185,
      172,
      225
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 339,
  "fields": {
    "gname": "N‐acetyl‐serotonin",
    "smiles": "[2H]C([2H])(C1=CNC2=C1C=C(C=C2)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C(=O)OC)OC(=O)C)OC(=O)C)OC(=O)C)C([2H])([2H])NC(=O)C",
    "linkname": "nacetylserotonin",
    "molecula": "C25H30N2O11",
    "iupacname": "methyl (2S,3S,4S,5R,6S)-6-[[3-(2-acetamido-1,1,2,2-tetradeuterioethyl)-1H-indol-5-yl]oxy]-3,4,5-triacetyloxyoxane-2-carboxylate",
    "updphoto": "media/imgsrv_46_UqoAfij.png",
    "description": "This compound is primarily used in pharmacokinetic and metabolic studies, to track how N-acetyl serotonin is processed in the body. It is not a known selective ligand for the MT3/QR2 site like MCA-NAT, but rather a synthetic, tagged metabolite for research applications.",
    "fdastatus": "Not approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/171379315",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      387
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      223
    ],
    "target": [
      11,
      12
    ],
    "effect": [
      227
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 340,
  "fields": {
    "gname": "3,4-Methylenedioxymethamphetamine",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "linkname": "34-methylenedioxymethamphetamine",
    "molecula": "C11H15NO2",
    "iupacname": "1-(1,3-benzodioxol-5-yl)-N-methylpropan-2-amine",
    "updphoto": "media/imgsrv_SVwJ8CH.png",
    "description": "MDMA (ecstasy) is an illicit drug that stimulates monoamine neurotransmitter release and inhibits reuptake. MDMA’s acute cardiotoxicity includes tachycardia and arrhythmia which are associated with cardiomyopathy. MDMA acute cardiotoxicity has been explored, but neither long-term MDMA cardiac pathological changes nor epigenetic changes have been evaluated. Microarray analyses were employed to identify cardiac gene expression changes and epigenetic DNA methylation changes. To identify permanent MDMA-induced pathogenetic changes, mice received daily 10- or 35-day MDMA, or daily 10-day MDMA followed by 25-day saline washout (10 + 25 days). MDMA treatment caused differential gene expression (p < .05, fold change >1.5) in 752 genes following 10 days, 558 genes following 35 days, and 113 genes following 10-day MDMA + 25-day saline washout. Changes in MAPK and circadian rhythm gene expression were identified as early as 10 days. After 35 days, circadian rhythm genes (Per3, CLOCK, ARNTL, and NPAS2) persisted to be differentially expressed. MDMA caused DNA hypermethylation and hypomethylation that was independent of gene expression; hypermethylation of genes was found to be 71% at 10 days, 68% at 35 days, and 91% at 10 + 25 days washout. Differential gene expression paralleled DNA methylation in 22% of genes at 10-day treatment, 17% at 35 days, and 48% at 10 + 25 days washout. We show here that MDMA induced cardiac epigenetic changes in DNA methylation where hypermethylation predominated. Moreover, MDMA induced gene expression of key elements of circadian rhythm regulatory genes. This suggests a fundamental organism-level event to explain some of the etiologies of MDMA dysfunction in the heart.\r\nKoczor, C.A., Ludlow, I., Hight, R.S., Jiao, Z., Fields, E., Ludaway, T., Russ, R., Torres, R.A. and Lewis, W., 2015. Ecstasy (MDMA) alters cardiac gene expression and DNA methylation: implications for circadian rhythm dysfunction in the heart. Toxicological Sciences, 148(1), pp.183-191.",
    "fdastatus": "Not approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/3_4-Methylenedioxymethamphetamine",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.64409.html",
    "drugbank": "https://go.drugbank.com/drugs/DB01454",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      388,
      389,
      391
    ],
    "classf": [
      9,
      6
    ],
    "mechanisms": [
      224,
      225,
      226,
      227,
      228,
      229,
      230
    ],
    "target": [
      144,
      145,
      146,
      147,
      148,
      149,
      150
    ],
    "effect": [
      228,
      38
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 341,
  "fields": {
    "gname": "Phencyclidine (PCP)",
    "smiles": "C1CCC(CC1)(C2=CC=CC=C2)N3CCCCC3",
    "linkname": "phencyclidine",
    "molecula": "C17H25N",
    "iupacname": "1-(1-phenylcyclohexyl)piperidine",
    "updphoto": "media/imgsrv_-_2025-06-20T160501.613.png",
    "description": "PCP resulted in significantly increased distance travelled from 15 to 60 min post injection. Induced stereotyped behaviour and locomotor hyperactivity. Furthermore, PCP significantly enhanced time spent isolated from cage mates and this asociality occured from 60 to 105 min post treatment.\r\n\r\nPCP can disrupt the normal daily rhythms of activity in animals. For example, research indicates that PCP can reduce locomotor activity in rats during specific times of the day, particularly around the transition between the dark and light periods. \r\n\r\n\r\nUnlike conventional assays, in-cage monitoring captures the temporal duration of drug effects on multiple behaviours in the same group of animals. This approach could benefit psychiatric preclinical drug discovery through improved welfare and increased between-laboratory replicability.\r\n\r\nMitchell, E.J., Brett, R.R., Armstrong, J.D., Sillito, R.R. and Pratt, J.A., 2020. Temporal dissociation of phencyclidine: Induced locomotor and social alterations in rats using an automated homecage monitoring system–implications for the 3Rs and preclinical drug discovery. Journal of Psychopharmacology, 34(7), pp.709-715.",
    "fdastatus": "Not approved",
    "linkslists": "https://pubchem.ncbi.nlm.nih.gov/compound/6468#section=Information-Sources&fullscreen=true",
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/6468",
    "chemspider": null,
    "drugbank": "https://go.drugbank.com/drugs/DB03575",
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      390
    ],
    "classf": [
      6
    ],
    "mechanisms": [
      24,
      231,
      232,
      233,
      234,
      235
    ],
    "target": [
      22,
      36
    ],
    "effect": [
      229
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 342,
  "fields": {
    "gname": "Riboflavin",
    "smiles": "CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O",
    "linkname": "riboflavin",
    "molecula": "C17H20N4O6",
    "iupacname": "7,8-dimethyl-10-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]benzo[g]pteridine-2,4-dione",
    "updphoto": "media/imgsrv_-_2025-08-11T001355.786.png",
    "description": "Vitamin. Riboflavin restored the circadian oscillations of differentiation-related genes and core clock genes that were reduced by D-galactose. Ribo alleviated oxidative stress by regulating ROS, MDA, catalase, and GPx levels. Riboflavin improved mitochondrial function by increasing ATP production and mitochondrial membrane potential. Notably, Riboflavin restored ATP5A rhythmicity, highlighting its role in the circadian regulation of mitochondrial function. Riboflavin is a promising candidate for age-related muscle decline, as it restores myogenic differentiation, reduces oxidative stress, and supports mitochondrial function, preserving circadian homeostasis.\r\n\r\nLee, S., Sim, Y., Lee, M., Choi, Y., Lim, J.Y., Lee, J.H. and Kim, E., 2025. Riboflavin as a circadian modulator mitigates D-galactose-induced muscle senescence via oxidative stress and mitochondrial regulation in C2C12 cells. Journal of Functional Foods, 130, p.106924.",
    "fdastatus": "Approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/493570",
    "chemspider": null,
    "drugbank": "https://www.drugbank.ca/drugs/DB00140",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:17015",
    "uniprot": null,
    "kegg": "https://www.kegg.jp/entry/D08170",
    "selleckchem": null,
    "articles": [
      392
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      236
    ],
    "target": [
      137
    ],
    "effect": [
      230
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 343,
  "fields": {
    "gname": "Protocatechuic Acid",
    "smiles": "C1=CC(=C(C=C1C(=O)O)O)O",
    "linkname": "protocatechuic-acid",
    "molecula": "C7H6O4",
    "iupacname": "3,4-dihydroxybenzoic acid",
    "updphoto": "media/imgsrv_-_2025-08-27T234623.455.png",
    "description": "Protocatechuic acid (PCA) is a naturally occurring compound with antioxidant and anti-inflammatory properties; however, its role in regulating circadian rhythms has not been previously explored.  The potential of PCA as a circadian rhythm modulator in human epidermal keratinocytes was investigated only. PCA enhanced circadian activity in a dose-dependent manner, as evidenced by increased amplitude of basic helix-loop-helix ARNT like 1 (BMAL1)-driven bioluminescence. In silico docking revealed strong binding affinity of PCA to retinoic acid-related orphan receptor alpha (RORα), a core clock regulator, suggesting a molecular mechanism of action. PCA also modulated core clock gene expression. Under oxidative stress conditions, PCA reduced reactive oxygen species (ROS) levels and upregulated antioxidant enzymes, including catalase and superoxide dismutase 1. Additionally, PCA promoted skin barrier integrity by increasing structural protein and ceramide-related gene expression and enhanced cellular longevity markers, such as cyclin-dependent kinase inhibitor 1B (CDKN1B) and telomerase reverse transcriptase (TERT). PCA shows strong potential as a therapeutic candidate for treating skin disorders associated with circadian disruption and oxidative damage. Potential geroprotector. Lee, J., Kim, J.Y., Lee, J.H. and Lee, K.H., 2025. Protocatechuic acid modulates the circadian rhythm of keratinocytes and maintains skin barrier integrity. Molecular Biology Reports, 52(1), p.765.",
    "fdastatus": "none",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/72",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.71.html",
    "drugbank": "https://go.drugbank.com/drugs/DB03946",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:167537",
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      393
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      15,
      32
    ],
    "target": [
      14,
      40
    ],
    "effect": [
      232,
      233,
      231
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 344,
  "fields": {
    "gname": "Mefloquine",
    "smiles": "C1CCNC(C1)C(C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O",
    "linkname": "mefloquine",
    "molecula": "C17H16F6N2O",
    "iupacname": "[2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol",
    "updphoto": "media/imgsrv_-_2025-08-28T000222.596.png",
    "description": "Mefloquine is known as a neuronal gap junction blocker. Administration of mefloquine causes instability in the pulse period and a slight reduction of amplitude in cyclic PER2::LUC expression. Blockade of gap junctions uncouples PER2::LUC-expressing cells, in terms of phase transition, which weakens synchrony among individual cellular rhythms.\r\nKoo, J., Choe, H.K., Kim, H.D., Chun, S.K., Son, G.H. and Kim, K., 2015. Effect of mefloquine, a gap junction blocker, on circadian period2 gene oscillation in the mouse suprachiasmatic nucleus ex vivo. Endocrinology and Metabolism, 30(3), pp.361-370.",
    "fdastatus": "Approved",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/4046",
    "chemspider": "https://www.chemspider.com/Chemical-Structure.3906.html",
    "drugbank": "https://go.drugbank.com/drugs/DB00358",
    "chebi": "https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63609",
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      394
    ],
    "classf": [
      5,
      7
    ],
    "mechanisms": [
      237
    ],
    "target": [
      137
    ],
    "effect": [
      234,
      235
    ]
  }
},
{
  "model": "main.chronobiotic",
  "pk": 345,
  "fields": {
    "gname": "M54",
    "smiles": "CC1=CC(=C(C(=C1)C)N2CC(CC2=O)C(=O)N3CCC(CC3)(C4=CNC5=CC=CC=C45)C6=CNC7=CC=CC=C67)C",
    "linkname": "m54",
    "molecula": "C35H36N4O2",
    "iupacname": "4-[4,4-bis(1H-indol-3-yl)piperidine-1-carbonyl]-1-(2,4,6-trimethylphenyl)pyrrolidin-2-one",
    "updphoto": "media/ketcher_3.png",
    "description": "M54 is a modulator of circadian rhythm at the cellular level via CRY1. M54 specifically binds to CRY1, but not CRY2, reducing its ubiquitination and thereby enhancing its stability. Consequently, M54 lengthens the period of the U2-OS circadian rhythm and decreases the transcription of clock-controlled genes in a concentration-dependent manner. Thesefindings highlight the potential of M54 as a therapeuticcandidate for circadian disorders associated with reducedCRY1 levels. \r\nM54 selectively stabilizes the circadian clock component of CRY1 and enhances the period of circadian rhythm at cellular level. Available from:",
    "fdastatus": "none",
    "linkslists": null,
    "pubchem": "https://pubchem.ncbi.nlm.nih.gov/compound/71694853",
    "chemspider": null,
    "drugbank": null,
    "chebi": null,
    "uniprot": null,
    "kegg": null,
    "selleckchem": null,
    "articles": [
      395
    ],
    "classf": [
      5
    ],
    "mechanisms": [
      33,
      210,
      238
    ],
    "target": [
      42
    ],
    "effect": [
      236,
      237
    ]
  }
}
]
